0001140859-19-000040.txt : 20191119 0001140859-19-000040.hdr.sgml : 20191119 20191119171119 ACCESSION NUMBER: 0001140859-19-000040 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 103 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191119 DATE AS OF CHANGE: 20191119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMERISOURCEBERGEN CORP CENTRAL INDEX KEY: 0001140859 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 233079390 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16671 FILM NUMBER: 191232084 BUSINESS ADDRESS: STREET 1: 1300 MORRIS DRIVE CITY: CHESTERBROOK STATE: PA ZIP: 19087-5594 BUSINESS PHONE: 6107277000 MAIL ADDRESS: STREET 1: 1300 MORRIS DRIVE CITY: CHESTERBROOK STATE: PA ZIP: 19087-5594 10-K 1 a10-kx9302019.htm 10-K Document
103633300012229060000.001250.0005false--09-30FY201900011408591.461.521.600.016000000002835884632852951702132178822067606540.00650.001250.0112500.00700.00915000000005000000005000000007500000005000000005000000000.03500.0340.03250.03450.04250.0430471000000000.00090.75P3YP4YP3YP7Y07037058178534516 0001140859 2018-10-01 2019-09-30 0001140859 2019-03-31 0001140859 2019-10-31 0001140859 2018-09-30 0001140859 2019-09-30 0001140859 2017-10-01 2018-09-30 0001140859 2016-10-01 2017-09-30 0001140859 us-gaap:TreasuryStockMember 2016-09-30 0001140859 us-gaap:RetainedEarningsMember 2016-09-30 0001140859 us-gaap:AdditionalPaidInCapitalMember 2016-10-01 2017-09-30 0001140859 us-gaap:AdditionalPaidInCapitalMember 2017-10-01 2018-09-30 0001140859 us-gaap:CommonStockMember 2018-10-01 2019-09-30 0001140859 us-gaap:CommonStockMember 2019-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-10-01 2019-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-10-01 2018-09-30 0001140859 us-gaap:TreasuryStockMember 2019-09-30 0001140859 2016-10-01 0001140859 us-gaap:NoncontrollingInterestMember 2016-09-30 0001140859 us-gaap:RetainedEarningsMember 2016-10-01 2017-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2017-10-01 2018-09-30 0001140859 us-gaap:TreasuryStockMember 2016-10-01 2017-09-30 0001140859 us-gaap:CommonStockMember 2018-09-30 0001140859 us-gaap:CommonStockMember 2016-09-30 0001140859 2018-10-01 0001140859 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2019-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001140859 us-gaap:TreasuryStockMember 2017-10-01 2018-09-30 0001140859 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-10-01 2017-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001140859 us-gaap:CommonStockMember 2017-10-01 2018-09-30 0001140859 us-gaap:RetainedEarningsMember 2019-09-30 0001140859 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001140859 us-gaap:RetainedEarningsMember 2017-10-01 2018-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2019-09-30 0001140859 us-gaap:TreasuryStockMember 2018-10-01 2019-09-30 0001140859 2017-09-30 0001140859 2016-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2018-10-01 0001140859 us-gaap:TreasuryStockMember 2018-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-30 0001140859 us-gaap:TreasuryStockMember 2017-09-30 0001140859 us-gaap:CommonStockMember 2017-09-30 0001140859 us-gaap:RetainedEarningsMember 2017-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2018-09-30 0001140859 us-gaap:RetainedEarningsMember 2018-10-01 2019-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2018-10-01 2019-09-30 0001140859 us-gaap:CommonStockMember 2016-10-01 2017-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2017-09-30 0001140859 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0001140859 us-gaap:RetainedEarningsMember 2018-09-30 0001140859 us-gaap:RetainedEarningsMember 2016-10-01 0001140859 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001140859 us-gaap:RetainedEarningsMember 2018-10-01 0001140859 us-gaap:ShippingAndHandlingMember 2017-10-01 2018-09-30 0001140859 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2018-10-01 2019-09-30 0001140859 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-03-31 0001140859 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-10-01 2019-09-30 0001140859 abc:PharmediumHealthcareHoldingsIncMember 2019-03-31 0001140859 abc:ExpressScriptsMember 2018-10-01 2019-09-30 0001140859 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2018-10-01 2019-09-30 0001140859 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-10-01 2019-09-30 0001140859 2019-01-01 2019-03-31 0001140859 abc:ExpressScriptsMember 2019-09-30 0001140859 srt:ScenarioForecastMember us-gaap:SubsequentEventMember 2019-10-01 0001140859 us-gaap:TradeNamesMember 2019-01-01 2019-03-31 0001140859 abc:WalgreensBootsAllianceIncMember 2019-09-30 0001140859 us-gaap:AccountingStandardsUpdate201609Member us-gaap:RetainedEarningsMember 2016-10-01 0001140859 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-01-01 2019-03-31 0001140859 us-gaap:ShippingAndHandlingMember 2018-10-01 2019-09-30 0001140859 us-gaap:ShippingAndHandlingMember 2016-10-01 2017-09-30 0001140859 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2018-10-01 2019-09-30 0001140859 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2018-10-01 2019-09-30 0001140859 abc:WalgreensBootsAllianceIncMember 2018-10-01 2019-09-30 0001140859 us-gaap:AccountingStandardsUpdate201609Member 2016-10-01 0001140859 abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-01-31 0001140859 abc:ProfarmaJointVentureMember 2018-01-31 0001140859 abc:H.D.SmithMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-01-31 0001140859 abc:ProfarmaJointVentureMember 2018-09-01 2018-09-30 0001140859 abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member 2018-01-01 2018-01-31 0001140859 abc:H.D.SmithMember us-gaap:TradeNamesMember 2018-01-01 2018-01-31 0001140859 abc:NortheastVeterinarySupplyCompanyNEVSCOMember 2017-12-31 0001140859 abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member 2018-01-31 0001140859 abc:ProfarmaJointVentureMember 2017-10-01 2018-09-30 0001140859 abc:ProfarmaJointVentureMember 2018-01-01 2018-01-31 0001140859 abc:H.D.SmithMember 2018-01-31 0001140859 abc:NortheastVeterinarySupplyCompanyNEVSCOMember 2017-12-01 2017-12-31 0001140859 abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member us-gaap:TradeNamesMember 2018-01-31 0001140859 abc:NortheastVeterinarySupplyCompanyNEVSCOMember us-gaap:CustomerRelationshipsMember 2017-12-01 2017-12-31 0001140859 abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member us-gaap:CustomerRelationshipsMember 2018-01-31 0001140859 us-gaap:AccumulatedTranslationAdjustmentMember 2017-10-01 2018-09-30 0001140859 abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member 2018-03-31 0001140859 abc:H.D.SmithMember us-gaap:TradeNamesMember 2018-01-31 0001140859 abc:ProfarmaJointVentureMember 2018-03-31 0001140859 srt:MinimumMember abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member us-gaap:TradeNamesMember 2018-01-01 2018-01-31 0001140859 abc:ProfarmaJointVentureMember 2019-09-30 0001140859 srt:MaximumMember abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member us-gaap:TradeNamesMember 2018-01-01 2018-01-31 0001140859 abc:ProfarmaJointVentureMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-01-31 0001140859 abc:ProfarmaJointVentureMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-01-31 0001140859 abc:H.D.SmithMember 2018-01-01 2018-01-31 0001140859 abc:H.D.SmithMember us-gaap:CustomerRelationshipsMember 2018-01-31 0001140859 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2019-09-30 0001140859 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2018-09-30 0001140859 us-gaap:StateAndLocalJurisdictionMember 2019-09-30 0001140859 2018-10-01 2018-12-31 0001140859 abc:USAOEDNYMatterMember 2017-09-30 0001140859 srt:MaximumMember us-gaap:StateAndLocalJurisdictionMember 2019-09-30 2019-09-30 0001140859 us-gaap:DomesticCountryMember abc:AlternativeMinimumTaxMember 2019-09-30 0001140859 2019-07-01 2019-09-30 0001140859 us-gaap:ForeignCountryMember 2019-09-30 0001140859 us-gaap:DomesticCountryMember 2019-09-30 0001140859 srt:MinimumMember us-gaap:DomesticCountryMember 2019-09-30 2019-09-30 0001140859 srt:MinimumMember us-gaap:StateAndLocalJurisdictionMember 2019-09-30 2019-09-30 0001140859 srt:MaximumMember us-gaap:DomesticCountryMember 2019-09-30 2019-09-30 0001140859 us-gaap:ForeignCountryMember abc:AlternativeMinimumTaxMember 2019-09-30 0001140859 abc:USAOEDNYCivilClaimsMember 2016-10-01 2017-09-30 0001140859 abc:USAOEDNYCivilClaimsMember 2018-09-28 2018-09-28 0001140859 us-gaap:TradeNamesMember 2018-09-30 0001140859 abc:TradeNamesAndOtherMember 2019-09-30 0001140859 us-gaap:CustomerRelationshipsMember 2019-09-30 2019-09-30 0001140859 us-gaap:CustomerRelationshipsMember 2018-09-30 0001140859 abc:TradeNamesAndOtherMember 2018-09-30 0001140859 us-gaap:TradeNamesMember 2019-09-30 0001140859 us-gaap:CustomerRelationshipsMember 2019-09-30 0001140859 abc:TradeNamesAndOtherMember 2019-09-30 2019-09-30 0001140859 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2017-10-01 2018-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:PharmaceuticalDistributionMember 2018-10-01 2019-09-30 0001140859 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2018-09-30 0001140859 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2018-10-01 2019-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:PharmaceuticalDistributionMember 2017-10-01 2018-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:PharmaceuticalDistributionMember 2019-09-30 0001140859 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2019-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:PharmaceuticalDistributionMember 2018-09-30 0001140859 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2017-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:PharmaceuticalDistributionMember 2017-09-30 0001140859 abc:SeniorNotesDue2047Member 2019-09-30 0001140859 abc:SeniorNotesDue2027Member 2019-09-30 0001140859 abc:NonrecourseDebtMember 2019-09-30 0001140859 abc:NonrecourseDebtMember 2018-09-30 0001140859 abc:ReceivablesSecuritizationFacilityMember 2018-09-30 0001140859 abc:SeniorNotesDue2024Member 2018-09-30 0001140859 abc:TermLoanAgreementMember 2019-09-30 0001140859 abc:RevolvingCreditNoteMember 2019-09-30 0001140859 abc:SeniorNotesDue2021Member 2018-09-30 0001140859 abc:OverdraftFacilityMember 2019-09-30 0001140859 abc:ReceivablesSecuritizationFacilityMember 2019-09-30 0001140859 abc:SeniorNotesDue2045Member 2018-09-30 0001140859 abc:SeniorNotesDue2027Member 2018-09-30 0001140859 abc:MultiCurrencyRevolvingCreditFacilityMember 2019-09-30 0001140859 abc:TermLoanAgreementMember 2018-09-30 0001140859 abc:SeniorNotesDue2047Member 2018-09-30 0001140859 abc:SeniorNotesDue2024Member 2019-09-30 0001140859 abc:CorporationDebtMember 2018-09-30 0001140859 abc:SeniorNotesDue2021Member 2019-09-30 0001140859 abc:MultiCurrencyRevolvingCreditFacilityMember 2018-09-30 0001140859 abc:CorporationDebtMember 2019-09-30 0001140859 abc:SeniorNotesDue2025Member 2019-09-30 0001140859 abc:SeniorNotesDue2045Member 2019-09-30 0001140859 abc:RevolvingCreditNoteMember 2018-09-30 0001140859 abc:OverdraftFacilityMember 2018-09-30 0001140859 abc:SeniorNotesDue2025Member 2018-09-30 0001140859 abc:SeniorNotesDue2027Member 2017-12-31 0001140859 abc:SeniorNotesDue2047Member 2017-12-31 0001140859 2017-12-01 2017-12-31 0001140859 us-gaap:CommercialPaperMember 2019-09-30 0001140859 abc:SeniorNotesDue2019Member 2017-12-31 0001140859 2018-10-31 0001140859 abc:TermLoanAgreementOctober2018Member 2018-10-31 0001140859 abc:MultiCurrencyRevolvingCreditFacilityMember 2018-10-01 2019-09-30 0001140859 abc:MultiCurrencyRevolvingCreditFacilityMember abc:CdorLiborEuriborBankersAcceptanceStampingFeeMember 2018-10-01 2019-09-30 0001140859 srt:MaximumMember abc:MultiCurrencyRevolvingCreditFacilityMember abc:AlternateBaseRateAndCanadianPrimeRateCdorRateMember 2018-10-01 2019-09-30 0001140859 srt:MinimumMember abc:MultiCurrencyRevolvingCreditFacilityMember abc:AlternateBaseRateAndCanadianPrimeRateCdorRateMember 2018-10-01 2019-09-30 0001140859 us-gaap:CommercialPaperMember 2018-09-30 0001140859 abc:TermLoanAgreementOctober2018Member us-gaap:LondonInterbankOfferedRateLIBORMember 2018-10-01 2018-10-31 0001140859 srt:MaximumMember abc:MultiCurrencyRevolvingCreditFacilityMember abc:CdorLiborEuriborBankersAcceptanceStampingFeeMember 2018-10-01 2019-09-30 0001140859 srt:MinimumMember abc:MultiCurrencyRevolvingCreditFacilityMember abc:CdorLiborEuriborBankersAcceptanceStampingFeeMember 2018-10-01 2019-09-30 0001140859 abc:AccumulatedOtherAdjustmentsAttributabletoParentMember 2019-09-30 0001140859 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0001140859 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-09-30 0001140859 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-09-30 0001140859 abc:AccumulatedOtherAdjustmentsAttributabletoParentMember 2018-09-30 0001140859 us-gaap:AccumulatedTranslationAdjustmentMember 2018-09-30 0001140859 abc:November2016ShareRepurchaseProgramMember 2018-10-01 2019-09-30 0001140859 abc:October2018ShareRepurchaseProgramMember 2018-10-01 2019-09-30 0001140859 abc:May2016ShareRepurchaseProgramMember 2016-10-01 2017-09-30 0001140859 abc:May2016ShareRepurchaseProgramMember 2016-09-01 2016-09-30 0001140859 abc:November2016ShareRepurchaseProgramMember 2016-11-30 0001140859 abc:May2016ShareRepurchaseProgramMember 2016-11-01 2016-11-30 0001140859 abc:November2016ShareRepurchaseProgramMember 2016-10-01 2017-09-30 0001140859 abc:November2016ShareRepurchaseProgramMember 2017-10-01 2018-09-30 0001140859 abc:May2016ShareRepurchaseProgramMember 2016-09-30 0001140859 abc:October2018ShareRepurchaseProgramMember 2019-09-30 0001140859 abc:October2018ShareRepurchaseProgramMember 2018-10-31 0001140859 abc:WalgreensBootsAllianceIncMember us-gaap:InvestorMember 2018-09-30 0001140859 abc:WalgreensBootsAllianceIncMember us-gaap:InvestorMember 2019-09-30 0001140859 abc:WalgreensBootsAllianceIncMember us-gaap:InvestorMember 2018-10-01 2019-09-30 0001140859 abc:WalgreensBootsAllianceIncMember us-gaap:InvestorMember 2017-10-01 2018-09-30 0001140859 abc:WalgreensBootsAllianceIncMember us-gaap:InvestorMember 2016-10-01 2017-09-30 0001140859 abc:EmployeeContributionFirstThreePercentOfSalaryMember 2016-10-01 2016-12-31 0001140859 abc:EmployeeContributionAdditionalTwoPercentOfSalaryMember srt:ScenarioForecastMember 2019-01-01 2019-12-31 0001140859 2016-10-01 2016-12-31 0001140859 2017-01-01 2018-12-31 0001140859 abc:EmployeeContributionFirstThreePercentOfSalaryMember 2017-01-01 2018-12-31 0001140859 srt:ScenarioForecastMember 2019-01-01 2019-12-31 0001140859 abc:EmployeeContributionAdditionalTwoPercentOfSalaryMember 2016-10-01 2016-12-31 0001140859 abc:EmployeeContributionFirstThreePercentOfSalaryMember srt:ScenarioForecastMember 2019-01-01 2019-12-31 0001140859 2017-10-01 2017-12-31 0001140859 2019-09-30 2019-09-30 0001140859 2018-09-30 2018-09-30 0001140859 us-gaap:PerformanceSharesMember 2018-10-01 2019-09-30 0001140859 us-gaap:PerformanceSharesMember 2019-09-30 0001140859 us-gaap:PerformanceSharesMember 2018-09-30 0001140859 srt:MinimumMember us-gaap:PerformanceSharesMember 2017-10-01 2018-09-30 0001140859 srt:MinimumMember us-gaap:PerformanceSharesMember 2018-10-01 2019-09-30 0001140859 us-gaap:RestrictedStockUnitsRSUMember 2019-09-30 2019-09-30 0001140859 us-gaap:RestrictedStockUnitsRSUMember 2017-10-01 2018-09-30 0001140859 us-gaap:RestrictedStockUnitsRSUMember 2019-09-30 0001140859 srt:MaximumMember us-gaap:PerformanceSharesMember 2017-10-01 2018-09-30 0001140859 us-gaap:RestrictedStockUnitsRSUMember 2018-10-01 2019-09-30 0001140859 abc:NonEmployeeMember 2018-10-01 2019-09-30 0001140859 us-gaap:RestrictedStockUnitsRSUMember 2016-10-01 2017-09-30 0001140859 us-gaap:PerformanceSharesMember 2016-10-01 2017-09-30 0001140859 srt:MaximumMember us-gaap:PerformanceSharesMember 2018-10-01 2019-09-30 0001140859 us-gaap:PerformanceSharesMember 2017-10-01 2018-09-30 0001140859 us-gaap:RestrictedStockUnitsRSUMember 2018-09-30 0001140859 us-gaap:EmployeeStockOptionMember 2018-10-01 2019-09-30 0001140859 abc:OpioidLawsuitsandInvestigationsMember 2018-10-01 2019-09-30 0001140859 abc:OpioidLawsuitsandInvestigationsMember 2017-10-01 2018-09-30 0001140859 abc:USAOSDNYMatterMember 2016-10-01 2017-09-30 0001140859 2018-07-01 2018-09-30 0001140859 abc:WestVirginiaAGMatterMember 2016-10-01 2017-09-30 0001140859 abc:USAOEDNYMisdemeanorViolationMember 2016-10-01 2017-09-30 0001140859 abc:SettlementwithOhioCountiesMember 2018-10-01 2019-09-30 0001140859 abc:MDLandOtherRelatedStateCourtLitigationMember us-gaap:SubsequentEventMember 2019-10-21 2019-10-21 0001140859 abc:USAOSDNYMatterMember 2017-10-01 2018-09-30 0001140859 2018-07-01 0001140859 us-gaap:MaterialReconcilingItemsMember 2017-10-01 2018-09-30 0001140859 us-gaap:MaterialReconcilingItemsMember 2016-10-01 2017-09-30 0001140859 us-gaap:OperatingSegmentsMember 2018-10-01 2019-09-30 0001140859 us-gaap:OperatingSegmentsMember 2017-10-01 2018-09-30 0001140859 us-gaap:MaterialReconcilingItemsMember 2018-10-01 2019-09-30 0001140859 us-gaap:OperatingSegmentsMember 2016-10-01 2017-09-30 0001140859 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2016-10-01 2017-09-30 0001140859 us-gaap:IntersegmentEliminationMember 2016-10-01 2017-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:PharmaceuticalDistributionMember 2016-10-01 2017-09-30 0001140859 us-gaap:IntersegmentEliminationMember 2017-10-01 2018-09-30 0001140859 us-gaap:IntersegmentEliminationMember 2018-10-01 2019-09-30 0001140859 abc:PharmaceuticalDistributionMember 2017-10-01 2018-09-30 0001140859 abc:PharmaceuticalDistributionMember 2018-10-01 2019-09-30 0001140859 abc:PharmaceuticalDistributionMember 2016-10-01 2017-09-30 0001140859 us-gaap:AllOtherSegmentsMember 2016-10-01 2017-09-30 0001140859 us-gaap:AllOtherSegmentsMember 2017-10-01 2018-09-30 0001140859 us-gaap:AllOtherSegmentsMember 2018-10-01 2019-09-30 0001140859 us-gaap:AllOtherSegmentsMember abc:WorldCourierMember 2019-09-30 0001140859 us-gaap:OtherNonoperatingIncomeExpenseMember 2018-10-01 2019-09-30 0001140859 us-gaap:OtherNonoperatingIncomeExpenseMember 2017-10-01 2018-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:MWIAnimalHealthMember 2017-10-01 2018-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:GlobalCommercializationServicesMember 2016-10-01 2017-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:MWIAnimalHealthMember 2018-10-01 2019-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:MWIAnimalHealthMember 2016-10-01 2017-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:GlobalCommercializationServicesMember 2017-10-01 2018-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:GlobalCommercializationServicesMember 2018-10-01 2019-09-30 0001140859 us-gaap:AllOtherSegmentsMember 2018-09-30 0001140859 abc:PharmaceuticalDistributionMember 2019-09-30 0001140859 us-gaap:AllOtherSegmentsMember 2019-09-30 0001140859 us-gaap:AllOtherSegmentsMember 2017-09-30 0001140859 abc:PharmaceuticalDistributionMember 2017-09-30 0001140859 abc:PharmaceuticalDistributionMember 2018-09-30 0001140859 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-09-30 0001140859 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MoneyMarketFundsMember 2019-09-30 0001140859 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-09-30 0001140859 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-09-30 0001140859 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-09-30 0001140859 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MoneyMarketFundsMember 2018-09-30 0001140859 2018-04-01 2018-06-30 0001140859 2018-01-01 2018-03-31 0001140859 2019-04-01 2019-06-30 0001140859 us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-03-31 0001140859 us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-03-31 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsMember 2017-10-01 2018-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsMember 2019-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsMember 2018-10-01 2019-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsMember 2016-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsMember 2018-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsMember 2016-10-01 2017-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsMember 2017-09-30 0001140859 us-gaap:OtherNoncurrentAssetsMember abc:AllowanceForReturnsandDoubtfulAccountsNoncurrentMember 2018-09-30 0001140859 us-gaap:OtherNoncurrentAssetsMember abc:AllowanceForReturnsandDoubtfulAccountsNoncurrentMember 2019-09-30 0001140859 us-gaap:OtherNoncurrentAssetsMember abc:AllowanceForReturnsandDoubtfulAccountsNoncurrentMember 2017-09-30 iso4217:USD xbrli:pure xbrli:shares iso4217:USD xbrli:shares iso4217:GBP abc:country

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K

☑   ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED September 30, 2019

☐    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM ___________ TO___________

Commission file number 1-16671
AMERISOURCEBERGEN CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
 
23-3079390
(State or other jurisdiction of
 
(I.R.S. Employer
incorporation or organization)
 
Identification No.)
 
 
 
 
 
1300 Morris Drive
Chesterbrook,
PA
 
19087-5594
(Address of principal executive offices)
 
(Zip Code)
(610) 727-7000
(Registrant’s telephone number, including area code)
Securities Registered Pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of exchange on which registered
Common stock
ABC
New York Stock Exchange
(NYSE)
_________________________________________________
Indicate by check mark if the registrant is a well-known seasoned issuer (as defined in Rule 405 of the Securities Act). Yes þ No o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes o No þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:
Large accelerated filer þ  Accelerated filer o  Non-accelerated filer o  Smaller reporting company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act of 1934). Yes ☐ No þ
The aggregate market value of voting stock held by non-affiliates of the registrant on March 31, 2019 based upon the closing price of such stock on the New York Stock Exchange on March 31, 2019 was $9,817,515,026.
The number of shares of common stock of AmerisourceBergen Corporation outstanding as of October 31, 2019 was 205,922,186.
Documents Incorporated by Reference
Portions of the following document are incorporated by reference in the Part of this report indicated below:
Part III — Registrant's Proxy Statement for the 2020 Annual Meeting of Stockholders.
 


TABLE OF CONTENTS

Item
 
Page
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


PART I

ITEM 1.    BUSINESS
As used herein, the terms "Company," "AmerisourceBergen," "we," "us," or "our" refer to AmerisourceBergen Corporation, a Delaware corporation.
AmerisourceBergen is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health. More specifically, we distribute a comprehensive offering of brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers located in the United States and select global markets, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, physician practices, medical and dialysis clinics, veterinarians, and other customers. Additionally, we furnish healthcare providers and pharmaceutical manufacturers with an assortment of related services, including data analytics, outcomes research, reimbursement and pharmaceutical consulting services, niche premium logistics services, inventory management, pharmacy automation, pharmacy management, and packaging solutions.
Industry Overview
Pharmaceutical sales in the United States, as recently estimated by IQVIA, an independent third-party provider of information to the pharmaceutical and healthcare industry, are expected to grow at a compound annual growth rate of approximately 4.2% from 2018 through 2023, and the growth rate is dependent, in part, on pharmaceutical manufacturer price increases.
In addition to general economic conditions, factors that impact the growth of the pharmaceutical industry in the United States and other industry trends include:
Aging Population. The number of individuals age 65 and over in the United States is expected to exceed 61 million by 2023 and is the most rapidly growing segment of the population. This age group suffers from more chronic illnesses and disabilities than the rest of the population and accounts for a substantial portion of total healthcare expenditures in the United States.
Introduction of New Pharmaceuticals. Traditional research and development, as well as the advent of new research, production, and delivery methods, such as biotechnology and gene therapy, continue to generate new pharmaceuticals and delivery methods that are more effective in treating diseases. We believe ongoing research and development expenditures by the leading pharmaceutical manufacturers will contribute to continued growth of the industry. In particular, we believe ongoing research and development of biotechnology and other specialty pharmaceutical drugs will provide opportunities for the continued growth of our specialty pharmaceuticals business.
Increased Use of Generic Pharmaceuticals. A number of patents for widely used brand-name pharmaceutical products will continue to expire during the next several years. In addition, increased emphasis by managed care and other third-party payors on utilization of generics has accelerated their growth. We consider the increase in generic usage a favorable trend because generic pharmaceuticals have historically provided us with a greater gross profit margin opportunity than brand-name products, although their lower prices reduce revenue growth. Generic pharmaceuticals currently account for approximately 90% of the prescription volume in the United States.
Increased Use of Drug Therapies. In response to rising healthcare costs, governmental and private payors have adopted cost containment measures that encourage the use of efficient drug therapies to prevent or treat diseases. While national attention has been focused on the overall increase in aggregate healthcare costs, we believe drug therapy has had a beneficial impact on healthcare costs by reducing expensive surgeries and prolonged hospital stays. Pharmaceuticals currently account for approximately 11% of overall healthcare costs. Pharmaceutical manufacturers' continued emphasis on research and development is expected to result in the continuing introduction of cost-effective drug therapies and new uses for existing drug therapies.

1

Legislative Developments. In 2010, the federal government enacted major health reform legislation designed to expand access to health insurance, which increased the number of people in the United States who are eligible to be reimbursed for all or a portion of prescription drug costs. The health reform law provides for sweeping changes to Medicare and Medicaid policies (including drug reimbursement policies), expanded disclosure requirements regarding financial arrangements within the healthcare industry, enhanced enforcement authority to prevent fraud and abuse, and new taxes and fees on pharmaceutical and medical device manufacturers. These policies and other legislative developments (including potential revisions to or repeal of any portions of the health reform legislation) may affect our businesses directly and/or indirectly (see Government Regulation on page 6 for further details).
Other economic conditions and certain risk factors could adversely affect our business and prospects (see Item 1A. Risk Factors on page 8).
The Company
We serve our customers (healthcare providers and pharmaceutical and biotech manufacturers) through a geographically diverse network of distribution service centers and other operations in the United States and select global markets. In our pharmaceutical distribution business, we are typically the primary supplier of pharmaceutical and related products to our healthcare provider customers. We offer a broad range of services to our customers designed to enhance the efficiency and effectiveness of their operations, which allow them to improve the delivery of healthcare to patients and to lower overall costs in the pharmaceutical supply channel.
Strategy
Our business strategy is focused on the global pharmaceutical supply channel where we provide value-added distribution and global commercialization services to healthcare providers (primarily pharmacies, health systems, medical and dialysis clinics, physicians, and veterinarians) and pharmaceutical manufacturers that improve channel efficiencies and patient outcomes. Implementing this disciplined and focused strategy in a seamless and unified way has allowed us to significantly expand our business, and we believe we are well positioned to grow revenue and increase operating income through the execution of the following key elements of our business strategy:
•
Optimize and Grow Our Pharmaceutical Distribution and Strategic Global Sourcing Businesses.  We believe we are well positioned in size and market breadth to continue to grow our distribution businesses as we invest to improve our operating and capital efficiencies. Distribution, including specialty pharmaceuticals, anchors our growth and position in the pharmaceutical supply channel as we provide superior distribution services and deliver value-added solutions, which improve the efficiency and competitiveness of both healthcare providers and pharmaceutical manufacturers, thus allowing the pharmaceutical supply channel to better deliver healthcare to patients.

We are a leader in distribution and services to community oncologists and have leading positions in other physician-administered products. We distribute plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products. We are well positioned to service and support many of the new biotechnology therapies that are expected to be coming to market in the near future.
With the continued growth of generic pharmaceuticals in the U.S. market, we have introduced strategies to enhance our position in the generic marketplace, including our generic product private label program based in Ireland. We source generics globally, offer a value-added generic formulary program to our healthcare provider customers, and monitor our customers' compliance with our generics program. We also provide data and other valuable services to our manufacturer customers, which includes our international presence in Switzerland where we lead our global manufacturer relations and commercialization strategy.
We offer value-added services and solutions to assist healthcare providers and pharmaceutical manufacturers to improve their efficiency and their patient outcomes. Services for manufacturers include: assistance with rapid new product launches, promotional and marketing services to accelerate product sales, product data reporting, and logistical support.
Our provider solutions include: our Good Neighbor Pharmacy® program, which enables independent community pharmacies to compete more effectively through pharmaceutical benefit and merchandising programs; Elevate Provider Network®, our managed care network, which connects our retail pharmacy customers to payor plans throughout the country and is one of the largest in the United States; generic product purchasing and private label services; hospital pharmacy consulting designed to improve operational efficiencies; and packaging solutions for institutional and retail healthcare providers.
We believe we have one of the lowest operating cost structures among all pharmaceutical distributors. Our robust distribution facility network includes a national distribution center in Columbus, OH, which offers pharmaceutical

2

manufacturers a single shipping destination. We continue to seek opportunities to achieve increased productivity and operating income gains as we invest in and continue to implement warehouse automation technology, adopt "best practices" in warehousing activities, and increase operating leverage by increasing volume per full-service distribution facility. We continue to seek opportunities to expand our offerings in our Pharmaceutical Distribution and Strategic Global Sourcing businesses.

•
Optimize and Grow Our Global Commercialization Services and Animal Health Businesses.  Our consulting service businesses help global pharmaceutical and biotechnology manufacturers commercialize their products. We believe we are the largest provider of reimbursement services that assist pharmaceutical companies in supporting access to branded drugs. We also provide outcomes research, contract field staffing, patient assistance and copay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical companies. World Courier is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. World Courier further strengthens our service offerings to global pharmaceutical manufacturers and provides an established platform for the introduction of our specialty services outside North America. MWI Animal Health (“MWI”) sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. MWI also offers its customers a variety of value-added services, including its e-commerce platform, technology management systems, pharmacy fulfillment, inventory management system, equipment procurement consultation, special order fulfillment, and educational seminars, which we believe closely integrate MWI with its customers' day-to-day operations and provide them with meaningful incentives to continue doing business with MWI. We continue to seek opportunities to expand our offerings in our Global Commercialization Services and Animal Health businesses.

•
Acquisitions. In order to grow our core strategic offerings and to enter related markets, we have acquired and invested in businesses and will continue to consider additional acquisitions and investments.

•
Divestitures.  In order to allow us to concentrate on our strategic focus areas, we have divested certain non-core businesses and may, from time to time, consider additional divestitures.
Operations
Operating Structure. We are organized based upon the products and services we provide to our customers. Our operations as of September 30, 2019 are comprised of the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant enough to require separate reportable segment disclosure, and, therefore, have been included in Other for the purpose of reportable segment presentation.
Pharmaceutical Distribution Services Segment
Servicing healthcare providers in the pharmaceutical supply channel, the Pharmaceutical Distribution Services segment's operations provide drug distribution, strategic global sourcing, and related services designed to reduce healthcare costs and improve patient outcomes.
The Pharmaceutical Distribution Services reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. Through a number of operating businesses, the Pharmaceutical Distribution Services reportable segment provides pharmaceutical distribution (including plasma and other blood products, injectible pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. Additionally, the Pharmaceutical Distribution Services reportable segment provides data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The Pharmaceutical Distribution Services reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. Additionally, it delivers packaging solutions to institutional and retail healthcare providers.
Other
Other consists of operating segments that focus on global commercialization services and animal health and includes AmerisourceBergen Consulting Services ("ABCS"), World Courier, and MWI.
ABCS, through a number of operating businesses, provides a full suite of integrated manufacturer services that range from clinical trial support to product post-approval and commercialization support. World Courier, which operates in more than

3

50 countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. MWI is a leading animal health distribution company in the United States and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. Additionally, MWI offers demand-creating sales force services to manufacturers.
Sales and Marketing. The majority of Pharmaceutical Distribution Services’ sales force is led nationally, with geographic focus and specialized by either healthcare provider type or size. Customer service representatives are centralized in order to respond to customer needs in a timely and effective manner. Pharmaceutical Distribution Services also has support professionals focused on its various technologies and service offerings. Pharmaceutical Distribution Services’ sales teams also serve national account customers through close coordination with local distribution centers and ensure that our customers are receiving service offerings that meet their needs. Our other operating segments each have independent sales forces that specialize in their respective product and service offerings. In addition, we have an enterprise-wide marketing group that coordinates branding and all other marketing activities across the Company.
Customers. We have a diverse customer base that includes institutional and retail healthcare providers as well as pharmaceutical manufacturers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies, and providers of pharmacy services to such facilities, physicians, and physician group practices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies, pharmacy departments of supermarkets and mass merchandisers, and veterinarians. We are typically the primary source of supply for our healthcare provider customers. Our manufacturer customers include branded, generic, and biotechnology manufacturers of prescription pharmaceuticals, as well as over-the-counter product and health and beauty aid manufacturers. In addition, we offer a broad range of value-added solutions designed to enhance the operating efficiencies and competitive positions of our customers, thereby allowing them to improve the delivery of healthcare to patients and consumers.
Our two largest customers, Walgreens Boots Alliance, Inc. ("WBA") and Express Scripts, Inc. ("Express Scripts"), accounted for approximately 34% and approximately 13%, respectively, of revenue in the fiscal year ended September 30, 2019. Our top 10 customers, including governmental agencies and group purchasing organizations ("GPO"), represented approximately 64% of revenue in the fiscal year ended September 30, 2019. The loss of any major customer or GPO relationship could adversely affect future revenue and results of operations. Additionally, from time to time, significant contracts may be terminated in accordance with their terms or extended, renewed, or replaced prior to their expiration dates. If those contracts are not renewed or are extended, renewed, or replaced at less favorable terms, they may negatively impact our revenue, results of operations, and cash flows.
Suppliers. We obtain pharmaceutical and other products from manufacturers, none of which accounted for 10% or more of our purchases in the fiscal year ended September 30, 2019. The loss of a supplier could adversely affect our business if alternate sources of supply are unavailable since we are committed to be the primary source of pharmaceutical products for a majority of our customers. We believe that our relationships with our suppliers are strong. The 10 largest suppliers in fiscal year ended September 30, 2019 accounted for approximately 45% of our purchases.
Information Systems. The Pharmaceutical Distribution Services operating segment operates its full-service wholesale pharmaceutical distribution facilities in the United States on two primary enterprise resource planning ("ERP") systems. We are currently working to transition all of these facilities to a single primary ERP system. Pharmaceutical Distribution Services’ ERP systems provide for, among other things, electronic order entry by customers, invoice preparation and purchasing, and inventory tracking. All of our other operating segments operate the majority of their businesses on their own common operating systems resulting in the ability to rapidly deploy new capabilities. We are currently making significant investments to enhance and upgrade the operating systems utilized by our other operating segments.
Additionally, we are improving our entity-wide infrastructure environment to drive efficiency, capabilities, and speed to market.
We will continue to invest in advanced information systems and automated warehouse technology. For example, in an effort to comply with future pedigree and other supply chain custody requirements (see Risk Factor - Increasing governmental efforts to regulate the pharmaceutical supply channel and pharmaceutical compounding may increase our costs and reduce our profitability), we expect to continue to make significant investments in our secure supply chain information systems.
Pharmaceutical Distribution Services has made significant investments in its electronic ordering systems. Pharmaceutical Distribution Services’ systems are intended to strengthen customer relationships by helping customers to reduce operating costs and by providing a platform for a number of the basic and value-added services offered to our customers, including product demand data, inventory replenishment, single-source billing, third-party claims processing, real-time price and incentive updates, and price labels.

4

Pharmaceutical Distribution Services processes a substantial portion of its purchase orders, invoices, and payments electronically, and it continues to make substantial investments to expand its electronic interface with its suppliers. Pharmaceutical Distribution Services has warehouse operating systems, which are used to manage the majority of Pharmaceutical Distribution Services’ transactional volume. The warehouse operating systems have improved Pharmaceutical Distribution Services’ productivity and operating leverage.
A significant portion of our data center operations, which were previously outsourced to third-party providers, is now insourced.
Competition
We face a highly competitive global environment in the distribution of pharmaceuticals and related healthcare services. Our largest competitors are McKesson Corporation ("McKesson"), Cardinal Health, Inc. ("Cardinal"), FFF Enterprises, Henry Schein, Inc., and UPS Logistics, among others. Pharmaceutical Distribution Services competes with both McKesson and Cardinal, as well as national generic distributors and regional distributors within pharmaceutical distribution. In addition, we compete with manufacturers who sell directly to customers, chain drugstores who manage their own warehousing, specialty distributors, and packaging and healthcare technology companies. ABCS, World Courier, and MWI also face competition from a variety of businesses. In all areas, competitive factors include price, product offerings, value-added service programs, service and delivery, credit terms, and customer support.
Intellectual Property
We use a number of trademarks and service marks. All of the principal trademarks and service marks used in the course of our business have been registered in the United States and, in some cases, in foreign jurisdictions or are the subject of pending applications for registration.
We have developed or acquired various proprietary products, processes, software, and other intellectual property that are used either to facilitate the conduct of our business or that are made available as products or services to customers. We generally seek to protect such intellectual property through a combination of trade secret, patent and copyright laws, and through confidentiality and other contractually imposed protections.
We hold patents and have patent applications pending that relate to certain of our products, particularly our automated pharmacy dispensing equipment, our medication and supply dispensing equipment, certain warehousing equipment, and some of our proprietary packaging solutions. We seek patent protection for our proprietary intellectual property from time to time as appropriate.
Although we believe that our patents or other proprietary products and processes do not infringe upon the intellectual property rights of any third parties, third parties may assert infringement claims against us from time to time.
Employees
As of September 30, 2019, we had approximately 22,000 employees, of which approximately 21,000 were full-time employees. Approximately 2% of our employees are covered by collective bargaining agreements. We believe that our relationship with our employees is good. If any of our employees in locations that are unionized should engage in strikes or other such bargaining tactics in connection with the negotiation of new collective bargaining agreements upon the expiration of any existing collective bargaining agreements, such tactics could be disruptive to our operations and adversely affect our results of operations. However, we believe we have adequate contingency plans in place to assure delivery of pharmaceuticals to our customers in the event of any such disruptions.

5

Government Regulation
We are subject to extensive oversight by various federal and state governmental entities and we are subject to, and affected by, a variety of federal and state laws, regulations, and policies.
The U.S. Drug Enforcement Administration ("DEA"), the U.S. Food and Drug Administration ("FDA"), the U.S. Department of Justice ("DOJ"), and various other federal and state authorities regulate the compounding, purchase, storage, and/or distribution of pharmaceutical products, including controlled substances. Wholesale distributors of controlled substances and entities that compound pharmaceuticals that contain controlled substances must hold valid DEA licenses, meet various security and operating standards, and comply with regulations governing the sale, marketing, compounding, packaging, holding, and distribution of controlled substances. Our Section 503B outsourcing facilities must comply with current Good Manufacturing Practices ("cGMPs") and are inspected by the FDA periodically to determine that we are complying with such cGMPs. DEA, FDA, DOJ, and state authorities have broad enforcement powers, including the ability to suspend our distribution centers or Section 503B outsourcing facilities from distributing pharmaceutical products (including controlled substances), seize or recall products, and impose significant criminal, civil, and administrative sanctions. On May 17, 2019, PharMEDium Healthcare Holdings, Inc. ("PharMEDium") reached an agreement on the terms of a consent decree (the "Consent Decree") with the FDA and the Consumer Protection Branch of the Civil Division of the DOJ that was entered by the United States District Court for the Northern District of Illinois on May 22, 2019. The Consent Decree permits commercial operations to continue at PharMEDium’s Dayton, New Jersey and Sugar Land, Texas compounding facilities and administrative operations to continue at its Lake Forest, Illinois headquarters subject to compliance with the requirements of the Consent Decree. As required by the Consent Decree, we have completed audit inspections by an independent cGMP expert at the Dayton and Sugar Land facilities to confirm that the facilities are being operated in conformity with cGMP. Additional audit inspections by the independent cGMP expert of the Sugar Land and Dayton facilities are also required at least annually for four years. The Consent Decree also establishes requirements that must be satisfied prior to the resumption of commercial operations at the Memphis, Tennessee facility, where we voluntarily suspended production activities in December 2017. We continue the ongoing compliance efforts of our subsidiary PharMEDium, including efforts to resume commercial distribution at the Memphis, Tennessee facility.
We and our customers are subject to fraud and abuse laws, including the federal anti-kickback statute and False Claims Act. The anti-kickback statute prohibits persons from soliciting, offering, receiving, or paying any remuneration in order to induce the purchasing, leasing, or ordering, induce a referral to purchase, lease, or order, or arrange for or recommend purchasing, leasing, or ordering items or services that are in any way paid for by Medicare, Medicaid, or other federal healthcare programs. The False Claims Act prohibits knowingly submitting, or causing the submission, of false or fraudulent claims for payment to the government, and authorizes treble damages and substantial civil penalties in the case of violations. The fraud and abuse laws and regulations are broad in scope and are subject to frequent and varied interpretation.
In recent years, some states have passed or proposed laws and regulations that are intended to protect the safety of the pharmaceutical supply channel. These laws and regulations are designed to prevent the introduction of counterfeit, diverted, adulterated, or mislabeled pharmaceuticals into the distribution system. At the federal level, the supply chain security legislation known as the Drug Quality and Security Act (“DQSA”) became law in 2013. The DQSA establishes federal traceability standards requiring drugs to be labeled and tracked at the lot level, preempts state drug pedigree requirements, and will eventually require all supply-chain stakeholders to participate in an electronic, interoperable prescription drug traceability system. The DQSA also establishes new requirements for drug wholesale distributors and third-party logistics providers, including licensing requirements applicable in states that had not previously licensed third-party logistics providers. We expect that the FDA, and eventually comparable state agencies, will promulgate implementing regulations governing wholesale distributor and third-party logistics providers. In addition, the DQSA created 503B outsourcing facilities as a new category for providers of compounded sterile preparations ("CSPs"), allowing such facilities to voluntarily register with the FDA. Our CSP business locations have registered with the FDA as Section 503B outsourcing facilities and have implemented policies and procedures to achieve compliance with current federal and state requirements for such facilities. There can be no assurance that we are fully compliant with the new DQSA requirements, or with additional related state regulatory and licensing requirements, and any failure to comply may result in suspension or delay of certain operations and additional costs to bring our operations into compliance. These and other requirements will continue to increase the cost of our operations.
The regulation of public and private health insurance and benefit programs can also affect our business and scrutiny of the healthcare delivery and reimbursement systems in the United States can be expected to continue at both the state and federal levels. This process may result in additional legislation and/or regulation governing the production, delivery, or pricing of pharmaceutical products and other healthcare services. In addition, changes in the interpretations of existing regulations may result in significant additional compliance costs or the discontinuation of our ability to continue to operate our distribution centers or Section 503B outsourcing facilities, which may have a material adverse effect on our financial condition and results of operations.

6

Any future reductions in Medicare or Medicaid reimbursement rates could negatively impact our customers' businesses and their ability to continue to purchase drugs from us. We cannot predict what additional initiatives, if any, will be adopted, when they may be adopted, or what impact they may have on us.
We are subject to various federal, state, and local environmental laws, including with respect to the sale, transportation, storage, handling, and disposal of hazardous or potentially hazardous substances, as well as laws relating to safe working conditions and laboratory practices.
The costs, burdens, and/or impacts of complying with federal and state regulations could be significant and the failure to comply with any such legal requirements could have a significant impact on our results of operations and financial condition.
See "Risk Factors" beginning on page 8 for a discussion of additional legal and regulatory developments, as well as enforcement actions or other litigation that may arise out of our failure to adequately comply with applicable laws and regulations that may negatively affect our results of operations and financial condition.
Health Information and Privacy Practices
The Health Information Portability and Accountability Act of 1996 ("HIPAA") and its implementing regulations set forth privacy and security standards designed to protect the privacy of and provide for the security of protected health information, as defined under the HIPAA regulations. Some of our businesses collect, maintain, and/or access protected health information and are subject to the HIPAA regulations. Our operations, depending on their location, may also be subject to state or foreign regulations affecting personal data protection and the manner in which information services or products are provided. Significant criminal and civil penalties may be imposed for violation of HIPAA standards and other such laws. We have a HIPAA compliance program to facilitate our ongoing efforts to comply with the HIPAA regulations.
The Health Information Technology for Economic and Clinical Health Act ("HITECH Act"), enacted as part of the 2009 American Recovery and Reinvestment Act ("ARRA"), strengthened federal privacy and security provisions governing protected health information. Among other things, the HITECH Act expanded certain aspects of the HIPAA privacy and security rules, imposed new notification requirements related to health data security breaches, broadened the rights of the U.S. Department of Health and Human Services ("HHS") to enforce HIPAA, and directed HHS to publish more specific security standards. On January 25, 2013, the Office for Civil Rights of HHS published the HIPAA omnibus final rule ("HIPAA Final Rule"), which amended certain aspects of the HIPAA privacy, security, and enforcement rules pursuant to the HITECH Act, extending certain HIPAA obligations to business associates and their subcontractors. Certain components of our business act as "business associates" within the meaning of HIPAA and are subject to these additional obligations under the HIPAA Final Rule.
Some of our businesses collect, maintain, and/or access other personal information (including sensitive personal information) that is subject to federal and state laws protecting such information, in addition to the requirements of HIPAA, the HITECH Act, and the implementing regulations. Personally identifiable information is also highly regulated in many other countries in which we operate. As such regulations continue to evolve, we must comply with applicable privacy and security requirements of these countries, including but not limited to those in the European Union. Most notably certain aspects of our business are subject to the European Union's General Data Protection Regulation ("GDPR") which became effective on May 25, 2018, and the recently enacted California Consumer Protection Act ("CCPA") which becomes effective on January 1, 2020 (with the promulgation of regulations due to be released on July 1, 2020). We have implemented a privacy and information security compliance program to facilitate our ongoing efforts to comply with GDPR, CCPA and other applicable privacy regulations. There can be no assurances that compliance with these requirements will not impose new costs on our business.
Available Information
For more information about us, visit our website at www.amerisourcebergen.com. The contents of the website are not part of this Form 10-K. Our electronic filings with the Securities and Exchange Commission (including all Forms 10-K, 10-Q, and 8-K, and any amendments to these reports) are available free of charge through our website at investor.amerisourcebergen.com immediately after we electronically file with or furnish them to the Securities and Exchange Commission and may also be viewed using their website at www.sec.gov.

7

ITEM 1A.    RISK FACTORS
The following discussion describes certain risk factors that we believe could affect our business and prospects. These risk factors are in addition to those set forth elsewhere in this report. Our business operations could also be affected by additional factors that are not presently known to us or that we currently consider not to be material. The reader should not consider this list to be a complete statement of all risks and uncertainties.
Our results of operations could be adversely impacted by manufacturer pricing changes.
In fiscal 2019, we continued to experience unfavorable brand and generic pharmaceutical pricing trends, which negatively impacted our Pharmaceutical Distribution Services reportable segment profit and our consolidated operating earnings. We expect these trends to continue in fiscal 2020, which could have an adverse effect on our results of operations.

Our contractual arrangements with pharmaceutical manufacturers for the purchase of brand pharmaceutical products generally use wholesale acquisition cost ("WAC") as the reference price. We sell brand pharmaceutical products to many of our customers using WAC as the reference price and to other customers based on their negotiated contract price. If manufacturers change their pricing policies or practices with regard to WAC or if prices charged by manufacturers do not align with prices negotiated to be paid by our customers, and we are unable to negotiate alternative ways to be compensated by manufacturers or customers for the value of our services, our results of operations could be adversely affected. Additionally, there are a number of policy initiatives being considered which, if enacted, could directly or indirectly regulate or impact WAC list prices. If such initiatives are passed and we are unable to negotiate equitable changes with our suppliers and/or customers, our results of operations could be adversely impacted.

The pharmaceutical products that we purchase are also subject to price inflation and deflation. Additionally, certain distribution service agreements that we have entered into with brand and generic pharmaceutical manufacturers have a price appreciation component to them. As a result, our gross profit from brand-name and generic pharmaceuticals continues to be subject to fluctuation based upon the timing and extent of manufacturer price increases, which we do not control. If the frequency or rate of brand and generic pharmaceutical price increases slows, whether due to regulatory mandates, the implementation of legislative proposals, policy initiatives or voluntary manufacturer actions, our results of operations could be adversely affected. In addition, generic pharmaceuticals are also subject to price deflation. If the frequency or rate of generic pharmaceutical price deflation accelerates, the negative impact on our results of operations will be greater.

Competition and industry consolidation may erode our profit.
As described in greater detail in the "Competition" section beginning on page 5, the industries in which we operate are highly competitive. In addition, in recent years the healthcare industry has been subject to increasing consolidation, including among pharmaceutical manufacturers, retail pharmacies, and health insurers, which may create further competitive pressures on our pharmaceutical distribution business. If we do not compete successfully, it could have a material and adverse effect on our business and results of operations. The impact on us will be greater if consolidation among our customers, suppliers, and competitors gives the resulting enterprises greater bargaining power, which could lead to greater pressure on us to reduce prices for our products and services.
Increasing governmental efforts to regulate the pharmaceutical supply channel and pharmaceutical compounding may increase our costs and reduce our profitability.
The healthcare industry in the United States is highly regulated at the federal and state levels. There have been increasing efforts by Congress and state and federal agencies, including state boards of pharmacy, departments of health, and the FDA, to regulate the pharmaceutical distribution system and pharmacy compounding activities. Regulation of pharmaceutical distribution is intended to prevent diversion and the introduction of counterfeit, adulterated, and/or mislabeled drugs into the pharmaceutical distribution system. Consequently, we are subject to the risk of changes in various federal and state laws, which include operating and security standards of the DEA, the FDA, various state boards of pharmacy and comparable agencies. In recent years, some states have passed or proposed laws and regulations that are intended to protect the safety and security of the supply channel but that also may substantially increase the costs and burden of pharmaceutical distribution and pharmaceutical compounding.
At the federal level, the DQSA establishes federal traceability standards requiring drugs to be labeled and tracked at the bottle level, preempts state drug pedigree requirements, and will require all supply-chain stakeholders to participate in an electronic, interoperable prescription drug traceability system by November 2023. The DQSA also established requirements for drug wholesale distributors and third-party logistics providers, including licensing requirements applicable in states that had not previously licensed third-party logistics providers. In addition, the DQSA established 503B outsourcing facilities as a category for providers of CSPs, allowing such facilities to voluntarily register with the FDA. Our CSP business locations have registered with the FDA as 503B

8

outsourcing facilities and have implemented policies and procedures to achieve compliance with current federal and state requirements for such facilities.
There can be no assurance that we are fully compliant with the DQSA requirements, or with additional related state regulatory and licensing requirements, and any failure to comply may result in suspension or delay of certain operations and additional costs to bring our facilities into compliance. Moreover, we expect that the FDA will continue to issue draft and final guidance and to promulgate regulations in its efforts to implement the requirements in the DQSA, including those relating to current good manufacturing practices ("cGMPs") and other matters related to 503B outsourcing facilities, which may require changes to our business, some of which may be significant. Additional details on risks related to our 503B outsourcing facilities and implementation of cGMPs are described below.
As discussed in the risk factor below about public concern over the abuse of opioid medications, certain governmental and regulatory agencies, as well as state and local jurisdictions, are focused on the abuse of opioid medications in the United States. In addition to conducting investigations and participating in litigation related to the misuse of prescription opioid medications, federal, state and local governmental and regulatory agencies are considering legislation and regulatory measures to limit opioid prescriptions and more closely monitor product distribution, prescribing, and dispensing of these drugs.
Complying with the DQSA requirements and other chain of custody and pharmaceutical distribution and compounding requirements, including follow-on actions related to current public concern over the abuse of opioid medications, could result in suspension or delays in our production and distribution activities which may increase our costs and could otherwise adversely affect our results of operations.
Legal, regulatory, and legislative changes with respect to reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining reimbursement rates.
Both our business and our customers' businesses may be adversely affected by laws and regulations reducing reimbursement rates for pharmaceuticals and/or medical treatments or services, changing the methodology by which reimbursement levels are determined, or regulating pricing, contracting, and discounting practices with respect to medical products and services. Additionally, on occasion, price increases and pricing practices with respect to certain brand and generic pharmaceuticals have been the subject of U.S. Congressional inquiries, federal and state investigations and private litigation. Any law or regulation impacting pharmaceutical pricing or reimbursement, such as pricing controls or indexing models at the federal or state level, could adversely affect our operations.
Federal insurance and healthcare reform legislation known as the Affordable Care Act ("ACA") became law in March 2010, and included numerous reforms broadening healthcare access and affecting Medicare and Medicaid reimbursement, pricing, and contracting for prescription drugs, including changes to the Medicaid rebate statute. Given the scope of the changes made by the ACA and continuing implementation controversies, we cannot predict the impact of every aspect of the law on our operations. Likewise, we cannot predict the impact of any efforts to change or repeal any provisions of the ACA may have on the ACA or other healthcare legislation and regulation.
Subsequent legislation has made additional changes to federal drug payment policies, including the Bipartisan Budget Act of 2018, which increased the Medicaid rebate due with respect to line extensions of single source or innovator multiple source oral solid dosage form drugs. The federal government and state governments could take other actions in the future that impact Medicaid reimbursement and rebate amounts or the cost of drugs. Any reduction in the Medicaid reimbursement rates to our customers may indirectly impact the prices that we can charge our customers for multiple source pharmaceuticals and cause corresponding declines in our profitability.
There can be no assurance that recent or future changes in Medicaid prescription drug reimbursement policies will not have an adverse impact on our business. Unless we are able to successfully advocate to prevent or mitigate the impact of these legislative and regulatory changes, these changes in reimbursement and related reporting requirements could adversely affect our results of operations.
Our businesses also sell specialty and other drugs to physicians, hospitals, community oncology practices and other providers that are reimbursed under Part B of the Medicare program. The Centers of Medicare & Medicaid Services ("CMS") published a final rule on November 13, 2017 that reduces Medicare outpatient hospital reimbursement for separately payable drugs (other than vaccines) purchased through the 340B drug discount program from average sales price ("ASP") plus 6% to ASP minus 22.5% (with certain exceptions), effective January 1, 2018. On December 27, 2018, the United States District Court for the District of Columbia concluded that this policy exceeded CMS statutory authority (with regard to 2018 payments). While the appeals process is still underway, CMS solicited comments in the proposed calendar year 2020 Medicare outpatient prospective payment system rule on appropriate payment for such 340B-acquired drugs, potentially including a reduced rate of ASP plus 3%

9

for calendar years 2018 through 2020. Separately, on November 21, 2018, CMS published a final rule that reduces from 6% to 3% the “add-on” payment for new, separately-payable Part B drugs and biologicals that are paid based on WAC when ASP data during first quarter or sales is unavailable.
The federal government may adopt measures in the future that would further reduce Medicare and/or Medicaid spending or impose additional requirements on healthcare entities. Notably, the Trump Administration and members of Congress proposed numerous amendments to Part B drug distribution and payment models during 2018 and have continued to do so throughout 2019. Some of these proposals could have significant effects on our business, including a potential proposal to create an “International Pricing Index” payment model that would modify distribution methods for Part B drugs and tie reimbursement rates to international drug pricing metrics. Any future reductions in Medicare reimbursement rates or modifications to Medicare drug pricing regulations such as ASP calculations could negatively impact our customers' businesses and their ability to continue to purchase such drugs from us, or could indirectly affect the structure of our relationships with manufacturers and our customers. At this time, we can provide no assurances that future Medicare and/or Medicaid payment or policy changes, if adopted, would not have a material adverse effect on our business.
Finally, federal and state governments may adopt policies affecting drug pricing and contracting practices outside of the context of federal programs such as Medicare and Medicaid, which may adversely affect our business. For example, several states have adopted laws that require drug manufacturers to provide advance notice of certain price increases and to report information relating to those price increases, while others have taken legislative or administrative action to establish prescription drug affordability boards or multi-payer purchasing pools to reduce the cost of prescription drugs. On July 31, 2019, the Department of Health and Human Services announced a “Safe Importation Action Plan” that outlines two potential pathways to allow importation of certain drugs from foreign markets. There can be no assurances that future changes to drug reimbursement policies, drug pricing and contracting practices outside of federal healthcare programs, or to government drug price regulation programs such as the Medicaid rebate, ASP, or 340B program will not have an adverse impact on our business.

If we fail to comply with laws and regulations in respect of healthcare fraud and abuse, we could suffer penalties or be required to make significant changes to our operations.

We are subject to extensive and frequently changing federal and state laws and regulations relating to healthcare fraud and abuse. The federal government continues to strengthen its scrutiny of practices potentially involving healthcare fraud affecting Medicare, Medicaid and other government healthcare programs. Our relationships with healthcare providers and pharmaceutical manufacturers subject our business to laws and regulations on fraud and abuse which, among other things, (i) prohibit persons from soliciting, offering, receiving or paying any remuneration in order to induce the referral of a patient for treatment or the ordering or purchasing of items or services that are in any way paid for by Medicare, Medicaid or other government-sponsored healthcare programs and (ii) impose a number of restrictions upon referring physicians and providers of designated health services under Medicare and Medicaid programs. Legislative provisions relating to healthcare fraud and abuse give federal enforcement personnel substantially increased funding, powers and remedies to pursue suspected fraud and abuse, and these enforcement authorities were further expanded by the ACA. While we believe that we are in compliance with applicable laws and regulations, many of the regulations applicable to us, including those relating to marketing incentives offered in connection with pharmaceutical sales, are vague or indefinite, and have not been interpreted by the courts. They may be interpreted or applied by a prosecutorial, regulatory or judicial authority in a manner that could require us to make changes in our operations. If we fail to comply with applicable laws and regulations, we could be subject to civil and criminal penalties, including the loss of licenses or our ability to participate in Medicare, Medicaid, and other federal and state healthcare programs.
Public concern over the abuse of opioid medications, including increased legal and regulatory action, could negatively affect our business.

Certain governmental and regulatory agencies, as well as state and local jurisdictions, are focused on the abuse of opioid medications in the United States. Federal, state and local governmental and regulatory agencies are conducting investigations of us and others in the supply chain, including pharmaceutical manufacturers and other pharmaceutical wholesale distributors, regarding the distribution of opioid medications. In addition, a significant number of lawsuits have been filed against us, other pharmaceutical wholesale distributors, and others in the supply chain. The lawsuits against us and other pharmaceutical wholesale distributors allege, among other claims, that we failed to provide effective controls and procedures to guard against the diversion of controlled substances, acted negligently by distributing controlled substances to pharmacies that serve individuals who abuse controlled substances, and failed to report suspicious orders of controlled substances in accordance with regulations. Additional governmental and regulatory entities have indicated an intent to sue and may conduct investigations of us in the future. We are deeply committed to diversion control efforts, have sophisticated systems in place to identify orders placed warranting further review to determine if they are suspicious (including through the use of data analytics), and engage in significant due diligence

10

and ongoing monitoring of customers. While we are vigorously defending ourselves in these lawsuits, the allegations may negatively affect our business in various ways, including through increased costs and harm to our reputation.

We are currently engaged in discussions with the objective of reaching potential terms for a global resolution of the multi-district opioid litigation and other related state court litigation described in Note 13 of the Notes to Consolidated Financial Statements. Given the large number of parties involved, the complexity and difficulty of the underlying issues, and the resulting uncertainty of achieving a potential global resolution, we continue to litigate and prepare for trial in the cases pending in the multi-district opioid litigation as well as in state courts where lawsuits have been filed, and intend to continue to vigorously defend ourselves in all such cases. Since these matters are still developing, we are unable to predict the outcome, but the result of these lawsuits could include excessive monetary verdicts and/or injunctive relief that may affect how we operate our business, or we may enter into settlements of claims that may also include monetary payments and/or injunctive relief. The adverse resolution of any of these lawsuits or investigations could have a material adverse effect on our business, results of operations, and cash flows and could result in a lower than historical level of capital available for deployment, including a lower level of capital returned to stockholders.

Legislative, regulatory or industry measures to address the misuse of prescription opioid medications may also affect our business in ways that we are not be able to predict. For example, New York has instituted an opioid excise tax, which went into effect on July 1, 2019, and taxes entities that make the initial sale or distribution of opioid medications into the state. In addition, Rhode Island and Delaware have enacted opioid taxes, Minnesota has enacted increased licensure fees, and other states are considering legislation that could require entities to pay an assessment or tax on the sale or distribution of opioid medications in those states. If additional state or local jurisdictions enact legislation that taxes or assesses the sale or distribution of opioid medications and we are not able to mitigate the impact on our business through operational changes or commercial arrangements where permitted, such legislation in the aggregate may have a material adverse effect on the Company's results of operations, cash flows, or financial condition.

Our business, results of operations, and cash flows could be adversely affected by legal proceedings.
We conduct our operations through a variety of businesses, including the distribution of pharmaceuticals, the dispensing of healthcare products, and the provision of services to the pharmaceutical industry. Each of our businesses may cause us to become involved in legal disputes or proceedings involving healthcare fraud and abuse, the False Claims Act, antitrust, class action, commercial, employment, environmental, intellectual property, licensing, and various other claims, including claims related to opioid medications as discussed in the above risk factor. Litigation is costly, time-consuming, and disruptive to ordinary business operations. The defense and resolution of these current and future proceedings could have a material adverse effect on our results of operations and financial condition. Violations of various federal and state laws, including with respect to the marketing, sale, purchase, and dispensing of pharmaceutical products and the provision of services to the pharmaceutical industry, can result in criminal, civil, and administrative liability for which there can be significant financial damages, criminal and civil penalties, and possible exclusion from participation in federal and state health programs. Any settlement, judgment or fine could materially adversely affect our results of operations.
Statutory and/or regulatory violations could also form the basis for qui tam complaints. The qui tam provisions of the federal and various state civil False Claims Acts authorize a private person, known as a relator, to file civil actions under these statutes on behalf of the federal and state governments. Under False Claims Acts, the filing of a qui tam complaint by a relator imposes obligations on government authorities to investigate the allegations and determine whether or not to intervene in the action. Such cases may involve allegations around the marketing, sale, purchase, and/or dispensing of brand and/or generic pharmaceutical products or the provision of services to the pharmaceutical industry. Such complaints are filed under seal and remain sealed until the applicable court orders otherwise. Our business and results of operations could be adversely affected if qui tam complaints are filed against us for alleged violations of any health laws and regulations and damages arising from resultant false claims, if the litigation proceeds whether or not government authorities decide to intervene in any such matters, and/or if we are found liable for all or any portion of violations alleged in any such matters.
In fiscal 2018, we resolved potential civil claims and administrative action by entering into, among other things, a Corporate Integrity Agreement (see Note 13 of the Notes to Consolidated Financial Statements). The Corporate Integrity Agreement has a five-year term. Failure to comply with obligations under the Corporate Integrity Agreement could lead to monetary or other penalties.

11

Our revenue, results of operations, and cash flows may suffer upon the loss, or renewal at less favorable terms, of a significant customer or group purchasing organization.
WBA accounted for approximately 34% of our revenue in the fiscal year ended September 30, 2019. Express Scripts accounted for approximately 13% of our revenue in the fiscal year ended September 30, 2019. Our top ten customers, including governmental agencies and GPOs, represented approximately 64% of revenue in the fiscal year ended September 30, 2019. We may lose a significant customer or GPO relationship if any existing contract with such customer or GPO expires without being extended, renewed, renegotiated or replaced or is terminated by the customer or GPO prior to expiration, to the extent such early termination is permitted by the contract. A number of our contracts with significant customers or GPOs are typically subject to expiration each year and we may lose any of these customers or GPO relationships if we are unable to extend, renew, renegotiate or replace the contracts. The loss of any significant customer or GPO relationship could adversely affect our revenue, results of operations, and cash flows. Additionally, from time to time, significant contracts may be renewed prior to their expiration date. If those contracts are renewed at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.
The anticipated ongoing strategic and financial benefits of our relationship with WBA may not be realized.
In May 2016, we extended to 2026 our strategic arrangement with WBA - specifically, our distribution agreement under which we distribute drugs to Walgreens pharmacies and our generics purchasing services arrangement under which Walgreens Boots Alliance Development GmbH ("WBAD") provides a variety of services, including negotiating acquisition pricing with generic manufacturers on our behalf. This reflected our expectation that partnering strategically with WBA would result in various benefits including, among other things, continued cost savings as a result of our generics purchasing services arrangement with WBAD, as well as the potential for exploring innovation together and sharing best practices. The processes and initiatives needed to achieve and maintain these benefits are complex, costly, and time-consuming. Achieving the anticipated benefits from the arrangement on an ongoing basis is subject to a number of significant challenges and uncertainties, including: the potential inability to realize and/or delays in realizing potential benefits resulting from participation in our generics purchasing services arrangement with WBAD, including improved generic drug pricing and terms, improved service fees from generic manufacturers, cost savings, innovations, or other benefits due to its inability to negotiate successfully with generic manufacturers or otherwise to perform as expected; the potential disruption of our plans and operations as a result of the terms under which we extended the duration of the distribution agreement and generics purchasing services agreement, including any disruption of our cash flow and ability to return value to our stockholders in accordance with our past practices and any reduction in our operational, strategic or financial flexibility; potential changes in supplier relationships and terms; unexpected or unforeseen costs, fees, expenses and charges incurred by us related to the transaction or the overall strategic relationship; unforeseen changes in the economic terms under which we distribute pharmaceuticals to WBA; and any potential issues that could impede our ability to continue to work collaboratively with WBA in an efficient and effective manner in furtherance of the anticipated strategic and financial benefits of the relationship.
In addition, WBA has the right, but not the obligation, under the transactions contemplated by the Framework and Shareholder Agreements dated March 18, 2013 to make certain additional investments in our common stock. WBA also has the right to sell any of the shares of our common stock that it has acquired so long as WBA has held the shares beyond the requisite dates specified in the Shareholder Agreement. Any sales in the public market of common stock currently held by WBA or acquired by WBA pursuant to open market purchases could adversely affect prevailing market prices of our common stock. We could also encounter unforeseen costs, circumstances, or issues with respect to the transactions and collaboration we anticipate pursuing with WBA. Many of these potential circumstances are outside of our control and any of them could result in increased costs, decreased revenue, decreased benefits and the diversion of management time and attention. If we are unable to achieve our objectives within the anticipated time frame, or at all, the expected future benefits may not be realized fully or at all, or may take longer to realize than expected, which could have a material adverse impact on our business, financial condition, and results of operations.
A disruption in our distribution or generic purchasing services arrangements with WBA could adversely affect our business and financial results.
We are the primary distributor of pharmaceutical products for WBA. Our generic pharmaceutical program has also benefited from the generics purchasing services arrangement with WBA. If the operations of WBA are seriously disrupted for any reason, whether by natural disaster, labor disruption, regulatory or governmental action, or otherwise, it could adversely affect our business and our sales and profitability. If the generics purchasing services arrangement does not continue to be successful, our margins and results of operations could also be adversely affected.
If our operations are seriously disrupted for any reason, we may have an obligation to pay or credit WBA for failure to supply products. In addition, upon the expiration or termination of the distribution agreement or generics purchasing services arrangement, there can be no assurance that we or WBA will be willing to renew, on terms favorable to us or at all.

12

In addition, our business may be adversely affected by any operational, financial, or regulatory difficulties that WBA experiences, including any disruptions of certain of its existing distribution facilities or retail pharmacies resulting from ongoing inspections by the DEA and/or state regulatory agencies and possible revocation of the controlled substance registrations for those facilities and pharmacies.
Tax legislation or challenges to our tax positions could adversely affect our results of operations and financial condition.
We are a large corporation with operations in the United States and select global markets. As such, we are subject to tax laws and regulations of the U.S. federal, state and local governments, and of various foreign jurisdictions. From time to time, various legislative initiatives, such as the repeal of last-in, first-out ("LIFO") treatment or the promulgation of state opioid taxes and fees, may be proposed that could adversely affect our tax positions and/or our tax liabilities. There can be no assurance that our effective tax rate or tax payments will not be adversely affected by legislation resulting from these initiatives. We believe that our historical tax positions are consistent with applicable laws, regulations, and existing precedent. In addition, U.S. federal, state and local, as well as foreign, tax laws and regulations, are extremely complex and subject to varying interpretations. There can be no assurance that our tax positions will not be challenged by relevant tax authorities or that we would be successful in any such challenge.
On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the "2017 Tax Act") was enacted and contains significant changes to U.S. income tax law. Due to the potential for changes to tax laws and regulations or changes to the interpretation thereof (including regulations and interpretations pertaining to the 2017 Tax Act), the ambiguity of tax laws and regulations, the subjectivity of factual interpretations, the complexity of our business and intercompany arrangements, uncertainties regarding the geographic mix of earnings in any particular period, and other factors, material adjustments to our tax estimates may impact our provision for income taxes and our earnings per share, as well as our cash flows, in the period in which any such adjustments would be made.
The suspension or revocation by federal or state authorities of any of the registrations that must be in effect for our distribution and 503B outsourcing facilities to purchase, compound, store, and/or distribute pharmaceuticals and controlled substances, the refusal by such authorities to issue a registration to any such facility, or any enforcement action or other litigation that arises out of our failure to comply with applicable laws and regulations governing distribution and 503B outsourcing facilities may adversely affect our reputation, our business, and our results of operations.
The DEA, FDA, DOJ, and various other federal and state authorities regulate the distribution of pharmaceuticals and controlled substances and the compounding of pharmaceuticals that contain controlled substances. We are required to hold valid DEA and state-level licenses, meet various security and operating standards, and comply with the Controlled Substances Act and its implementing regulations governing the sale, marketing, packaging, compounding, holding and distribution of controlled substances. Government authorities may from time to time investigate whether we are in compliance with various security and operating standards applicable to the distribution of controlled substances including whether we are adequately detecting and preventing the illegal diversion of controlled substances. Although we have procedures in place that are intended to ensure compliance with such laws and regulations, there can be no assurance that a regulatory agency or tribunal would conclude that our operations are compliant with applicable laws and regulations. If we were found to be non-compliant with such laws and regulations, federal and state authorities have broad enforcement powers, including (i) the ability to suspend our distribution centers' and 503B outsourcing facilities' licenses to distribute and compound pharmaceutical products (including controlled substances), (ii) seize or recall products, and (iii) impose significant criminal, civil and administrative sanctions for violations of these laws and regulations, each of which could have a material adverse effect on our reputation, business, and results of operations.
We have received, and may in the future receive, requests for information, letters, and subpoenas from the DEA, FDA, various U.S. Attorneys' Offices of the DOJ, and/or state attorneys general and state regulatory authorities and agencies related to our distribution of controlled substances and our order monitoring program, which is designed to prevent and detect the illegal diversion of controlled substances, or other matters. We generally respond to subpoenas, requests, letters, and other authority and/or agency correspondence in a thorough and timely manner. These responses require time and effort and can result in considerable costs being incurred by us, such as costs related to addressing the observations listed on FDA Form 483 reports. Such subpoenas, requests and letters can also lead to the assertion of claims or the commencement of civil, criminal, or regulatory legal proceedings against us, as well as to settlements and the suspension or revocation of registrations required by our distribution and 503B outsourcing facilities, each of which could have a material adverse effect on our reputation, business and results of operations.
In December 2017, following FDA inspections of our 503B outsourcing facilities, we voluntarily suspended production activities at our largest 503B outsourcing facility located in Memphis, Tennessee. In May 2019, PharMEDium reached an agreement on the terms of a consent decree (the “Consent Decree”) with the FDA and the Consumer Protection Branch of the Civil Division of the DOJ. The Consent Decree permits commercial operations to continue at PharMEDium’s Dayton, New Jersey, and Sugar Land, Texas compounding facilities and administrative operations to continue at its Lake Forest, Illinois headquarters subject to

13

compliance with the requirements set forth therein. As required by the Consent Decree, we have completed audit inspections by an independent cGMP expert at the Dayton and Sugar Land facilities to determine that the facilities are being operated in conformity with cGMP. Additional audit inspections by the independent cGMP expert of the Sugar Land and Dayton facilities are also required at least annually for a period of four years.

The Consent Decree also establishes requirements that must be satisfied prior to the resumption of commercial operations at the Memphis, Tennessee facility. Through fiscal 2019, our results of operations were adversely impacted by the Memphis suspension. Our results of operations will continue to be adversely impacted until the Memphis facility resumes commercial distribution and we cannot predict if or when the FDA will permit PharMEDium to resume commercial distribution at the Memphis facility.

Separately, we have agreed in several state regulatory matters to consent orders or temporary licensing suspensions regarding certain of our 503B outsourcing facilities. Certain other states have requested information concerning the status of operations at some or all of our 503B outsourcing facilities. These state regulatory matters preclude us from commercially distributing into certain states, which could have an adverse impact on our results of operations.

Additionally, the FDA may from time to time issue Form 483 reports and warning letters in connection with their oversight of 503B outsourcing facilities. Prior to our acquisition of the business, PharMEDium received a warning letter from the FDA in 2014 and a series of Form 483 reports were issued in 2015 and 2016 following up on the 2014 letter. We cannot be assured that the FDA and DOJ will be satisfied with the sufficiency or timing of PharMEDium’s corrective actions in response to this warning letter or the Form 483 reports. A failure to comply with the Consent Decree or to address observations identified by the FDA in Form 483 reports or any warning letters issued by the FDA or observations identified by any other federal and state regulatory authority, including a failure to resolve the observations identified by the 2014 warning letter and subsequent Form 483 reports, could lead to the suspension of facilities currently in operation, an enforcement action, monetary penalties, and/or license revocation, each of which could have an adverse effect on our reputation, business and results of operations.

The products compounded by our CSP business are administered by our customers to patients intravenously, and failures or errors in production, labeling, or packaging could contribute to patient harm or death, which may subject us to significant liabilities and reputational harm.
The production, labeling, and packaging of CSPs is inherently risky. Our CSP business sells CSPs to acute care hospitals, freestanding hospital outpatient departments, and ambulatory surgery centers, who then administer the CSPs to patients intravenously or through other injectable routes of administration. There are a number of factors that could result in the injury or death of a patient who receives one of our CSPs, including quality issues, manufacturing or labeling flaws, improper packaging, or unanticipated or improper uses of the products, any of which could result from human or other error. Any of these situations could lead to a recall of, or safety alert relating to, one or more of our products. In addition, in the ordinary course of business, we may voluntarily recall or retrieve products. Any recall or retrieval, whether voluntary or requested by the FDA or state regulatory authorities, could result in significant costs and negative publicity. Negative publicity, including regarding a quality or safety issue, whether accurate or inaccurate, could reduce market acceptance of our products, harm our reputation, decrease demand for our products, result in the loss of customers, lead to product withdrawals, and harm our ability to successfully launch new products and services. These problems could also result in enforcement actions by state and federal authorities or other healthcare self-regulatory bodies, or product liability claims or lawsuits, including those brought by individuals or groups seeking to represent a class or establish multidistrict litigation proceedings. Any such action, litigation, recall, or reputational harm resulting from patient harm or death caused by CSPs prepared by a competitor or a hospital pharmacy could result in a material adverse effect on our business, results of operations, financial condition, and liquidity. Our current or future insurance coverage may prove insufficient to cover any liability claims brought against us. Changes in the commercial insurance market may impair or prohibit our ability to obtain insurance coverage that will be adequate to satisfy any liability that may arise.
Our results of operations and financial condition may be adversely affected if we undertake acquisitions of or investments in businesses that do not perform as we expect or that are difficult for us to integrate.
As part of our strategy we seek to pursue acquisitions of and investments in other companies. At any particular time, we may be in various stages of assessment, discussion, and negotiation with regard to one or more potential acquisitions or investments, not all of which will be consummated. We make public disclosure of pending and completed acquisitions when appropriate and required by applicable securities laws and regulations.
Acquisitions involve numerous risks and uncertainties and may be of businesses in which we lack operational or market experience. If we complete one or more acquisitions, our results of operations and financial condition may be adversely affected by a number of factors, including: regulatory or compliance issues that could arise; changes in regulations and laws; the failure

14

of the acquired businesses to achieve the results we have projected in either the near or long term; the assumption of unknown liabilities, including litigation risks; the fair value of assets acquired and liabilities assumed not being properly estimated; the difficulties of imposing adequate financial and operating controls on the acquired companies and their management and the potential liabilities that might arise pending the imposition of adequate controls; the difficulties in the integration of the operations, technologies, services and products of the acquired companies; and the failure to achieve the strategic objectives of these acquisitions.
As previously disclosed, we have commenced a comprehensive strategic and financial review of PharMEDium, which remains ongoing. The review includes consideration of the ongoing regulatory, operational, and financial challenges that face PharMEDium as a result of the Consent Decree, state regulatory actions, and related matters. While we are unable to predict the outcome of the review, if we are unable to achieve our objectives within the anticipated time frame, or at all, it could have a material adverse effect on our reputation, results of operations, or financial condition.
Our business and results of operations may be adversely affected if we fail to manage and complete divestitures.

We regularly evaluate our portfolio in order to determine whether an asset or business may no longer help us meet our objectives. When we decide to sell assets or a business, we may encounter difficulty finding buyers or alternative exit strategies, which could delay the achievement of our strategic objectives. The impact of a divestiture on our results of operations could also be greater than anticipated.

Violations of anti-bribery, anti-corruption, and/or international trade laws to which we are subject could have a material adverse effect on our business, financial position, and results of operations.
We are subject to laws concerning our business operations and marketing activities in foreign countries where we conduct business. For example, we are subject to the U.S. Foreign Corrupt Practices Act (the "FCPA"), U.S. export control and trade sanction laws, and similar anti-corruption and international trade laws in certain foreign countries, such as the U.K. Bribery Act, any violation of which could create substantial liability for us and also cause a loss of reputation in the market. The FCPA generally prohibits U.S. companies and their officers, directors, employees, and intermediaries from making improper payments to foreign officials for the purpose of obtaining or retaining business abroad or otherwise obtaining favorable treatment. The FCPA also requires that U.S. public companies maintain books and records that fairly and accurately reflect transactions and maintain an adequate system of internal accounting controls. If we are found to have violated the FCPA, we may face sanctions including civil and criminal fines, disgorgement of profits, and suspension or debarment of our ability to contract with government agencies or receive export licenses. From time to time, we may face audits or investigations by one or more domestic or foreign government agencies relating to our international business activities, compliance with which could be costly and time-consuming, and could divert our management and key personnel from our business operations. An adverse outcome under any such investigation or audit could subject us to fines or other penalties, which could adversely affect our business, financial position, and results of operations.
Our results of operations and our financial condition may be adversely affected by our global operations.
Our operations in jurisdictions outside of the United States are subject to various risks inherent in global operations. We currently have operations in over 50 countries. We may conduct business in additional foreign jurisdictions in the future, which may carry operational risks in addition to the risks of acquisition described above. At any particular time, our global operations may be affected by local changes in laws, regulations, and the political and economic environments, including inflation, recession, currency volatility, and competition. Changes or uncertainty in U.S. or foreign policy, including any changes or uncertainty with respect to U.S. or international trade policies or tariffs, also can disrupt our global operations, as well as our customers and suppliers, in a particular location and may require us to spend more money to source certain products or materials that we purchase. Any of these factors could adversely affect our business, financial position, and results of operations.
Our stock price and our ability to access credit markets may be adversely affected by financial market volatility and disruption or a downgrade in our credit ratings.
If the capital and credit markets experience significant disruption and volatility in the future, there can be no assurance that we will not experience downward movement in our stock price without regard to our financial condition or results of operations or an adverse effect, which may be material, on our ability to access credit. Although we believe that our operating cash flow and existing credit arrangements give us the ability to meet our financing needs, there can be no assurance that disruption and volatility will not increase our costs of borrowing, impair our liquidity, or adversely impact our business.
Additionally, rating agencies continually review the ratings they have assigned to us and our outstanding debt securities. To maintain our ratings, we are required to meet certain financial performance ratios. Liabilities related to litigation or any significant related settlements, an increase in our debt or a decline in our earnings could result in downgrades in our credit ratings. Actual or

15

anticipated changes or downgrades in our credit ratings, including any announcement that our ratings are under review for a downgrade or have been assigned a negative outlook, could limit our access to public debt markets, limit the institutions willing to provide credit to us, result in more restrictive financial and other covenants in our public and private debt, and would likely increase our overall borrowing costs and adversely affect our earnings.
Our results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant supplier.
Our relationships with pharmaceutical suppliers give rise to substantial amounts that are due to us from the suppliers, including amounts owed to us for returned goods or defective goods, chargebacks, and amounts due to us for services provided to the suppliers. Volatility of the capital and credit markets, general economic conditions, pending litigation, and regulatory changes may adversely affect the solvency or creditworthiness of our suppliers. The bankruptcy, insolvency, or other credit failure of any supplier at a time when the supplier has a substantial account payable balance due to us could have a material adverse effect on our results of operations.
Our revenue and results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant customer.
Most of our customers buy pharmaceuticals and other products and services from us on credit. Credit is made available to customers based upon our assessment and analysis of creditworthiness. Although we often try to obtain a security interest in assets and other arrangements intended to protect our credit exposure, we generally are either subordinated to the position of the primary lenders to our customers or substantially unsecured. Volatility of the capital and credit markets, general economic conditions, and regulatory changes, including changes in reimbursement, may adversely affect the solvency or creditworthiness of our customers. The bankruptcy, insolvency, or other credit failure of any customer that has a substantial amount owed to us could have a material adverse effect on our operating revenue and results of operations. As of September 30, 2019, our two largest trade receivable balances due from customers represented approximately 49% and 8% of accounts receivable, net.
Recently, one of our customers, Diplomat Pharmacy, Inc. ("Diplomat"), indicated in a public filing that it believes it is probable it will need to obtain waivers as of December 31, 2019 for breach of certain financial debt covenants in its credit agreement. Diplomat's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 (the "Diplomat 10-Q") also reflected management's assessment that there is uncertainty regarding its ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to Diplomat’s ability to continue as a going concern.

The Diplomat 10-Q stated that if Diplomat violates its covenants and access to its credit facility is terminated or its indebtedness thereunder is accelerated, it may be unable to repay its obligations due under the credit agreement, which would have a material adverse impact on its liquidity and business. As a result of the foregoing, including the consequences of the going concern assessment of Diplomat's management, we may be unable to recover amounts owed to us and to continue the relationship on our current terms. As of November 15, 2019, our trade receivable balance due from this customer was approximately $109.6 million, none of which was past due as of such date.
Risks generally associated with our sophisticated information systems may adversely affect our business and results of operations.
Our businesses rely on sophisticated information systems to obtain, rapidly process, analyze, and manage data to facilitate the purchase and distribution of thousands of inventory items from numerous distribution centers; to receive, process, and ship orders on a timely basis; to account for other product and service transactions with customers; to manage the accurate billing and collections for thousands of customers; and to process payments to suppliers. We continue to make substantial investments in data centers and information systems, including, but not limited to, a program to enhance and upgrade our information technology systems. Third-party service providers are also responsible for managing a portion of our information systems. To the extent our information systems are not successfully implemented or fail, or to the extent there are data center interruptions, our business and results of operations may be adversely affected. Our business and results of operations may also be adversely affected if a third-party service provider does not perform satisfactorily, or if the information systems are interrupted or damaged by unforeseen events, including due to the actions of third parties.
Information security risks have generally increased in recent years because of the proliferation of cloud-based infrastructure and other services, new technologies, and the increased sophistication and activities of perpetrators of cyber attacks. A failure, interruption, or breach of our operational or information security systems, or those of our third-party service providers, as a result of cyber attacks or information security breaches could disrupt our business, result in the disclosure or misuse of confidential or proprietary information or personal data, damage our reputation, increase our costs, and/or cause losses. As a result, cyber security and the continued development and enhancement of the controls and processes designed to protect our systems, computers, software, data, and networks from attack, damage, or unauthorized access remain a priority for us. Although we believe

16

that we have robust information security procedures and other safeguards in place, as cyber threats continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures and/or to investigate and remediate any information security vulnerabilities.
Risks generally associated with data privacy regulation and the international transfer of personal data.
We are required to comply with increasingly complex and changing data privacy regulations both in the United States and beyond that regulate the collection, use, security, processing, and transfer of personal data, including particularly the transfer of personal data between or among countries. Many of these regulations also grant rights to individuals. Many foreign data privacy regulations (including GDPR in the European Union and the Personal Information Protection and Electronic Documents Act in Canada) and certain state regulations (including California's CCPA) are more stringent than those enacted under United States federal law. We may also face audits or investigations by one or more domestic or foreign government agencies relating to our compliance with these regulations. An adverse outcome under any such investigation or audit could subject us to fines or other penalties. That or other circumstances related to our collection, use, and transfer of personal data could cause a loss of reputation in the market and/or adversely affect our business and financial position.
Our goodwill, indefinite-lived intangible assets, or long-lived assets may become impaired, which may require us to record a further significant charge to earnings in accordance with generally accepted accounting principles.
U.S. generally accepted accounting principles ("GAAP") require us to test our goodwill and indefinite-lived intangible assets for impairment on an annual basis, or more frequently if indicators for potential impairment exist. Indicators that are considered include significant changes in performance relative to expected operating results, significant negative industry or economic trends, or a significant decline in our stock price and/or market capitalization for a sustained period of time. In addition, we periodically review our intangible assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable. Factors that may be considered a change in circumstances indicating that the carrying value of our long-lived assets may not be recoverable include slower growth rates, the loss of a significant customer, or divestiture of a business or asset for below its carrying value. The testing required by GAAP involves estimates and judgments by management.
As a result of the suspension of production activities at PharMEDium's compounding facility located in Memphis, Tennessee and the entry into the Consent Decree, the Company performed a recoverability assessment of PharMEDium's long-lived assets and recorded an impairment loss in fiscal year 2019 for the amount that the carrying value of the PharMEDium asset group exceeded its fair value. Although we believe our assumptions and estimates are reasonable and appropriate, any changes in key assumptions, including a failure to meet business plans or other unanticipated events and circumstances such as a rise in interest rates, may affect the accuracy or validity of such estimates. We may be required to record a further significant charge to earnings in our consolidated financial statements during the period in which any impairment of our goodwill, indefinite-lived intangible assets, or long-lived assets is determined. Any such charge could have a material adverse impact on our results of operations.
Natural disasters or other unexpected events may disrupt our operations, adversely affect our results of operations and financial condition, and may not be covered by insurance.
The occurrence of one or more unexpected events, including fires, tornadoes, tsunamis, hurricanes, earthquakes, floods, and other severe hazards or accidents in the United States or in other countries in which we operate or are located could adversely affect our operations and financial performance. Extreme weather, natural disasters, power outages, or other unexpected events could result in physical damage to and complete or partial closure of one or more of distribution centers or outsourcing facilities, temporary or long-term disruption in the supply of products, delay in the delivery of products to our distribution centers, and/or disruption of our ability to deliver products to customers. Current or future insurance arrangements may not provide protection for costs that may arise from such events, particularly if such events are catastrophic in nature or occur in combination. Further, the long-term effects of climate change on general economic conditions and the pharmaceutical distribution industry in particular are unclear, and changes in the supply, demand, or available sources of energy and the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including natural resources, necessary to run our businesses. Any long-term disruption in our ability to service our customers from one or more distribution centers or outsourcing facilities could have a material adverse effect on our operations.

Declining economic conditions could adversely affect our results of operations and financial condition.
Our operations and performance depend on economic conditions in the United States and other countries where we do business. Deterioration in general economic conditions could adversely affect the amount of prescriptions that are filled and the amount of pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers, which would negatively affect our revenue growth and cause a decrease in our profitability. Negative trends in the general economy,

17

including interest rate fluctuations, financial market volatility, or credit market disruptions, may also affect our customers' ability to obtain credit to finance their businesses on acceptable terms and reduce discretionary spending on health products. Reduced purchases by our customers or changes in payment terms could adversely affect our revenue growth and cause a decrease in our cash flow from operations. Bankruptcies or similar events affecting our customers may cause us to incur bad debt expense at levels higher than historically experienced. Declining economic conditions may also increase our costs. If the economic conditions in the United States or in the countries where we do business do not improve or deteriorate, our results of operations or financial condition could be adversely affected.
ITEM 1B.    UNRESOLVED STAFF COMMENTS
None.
ITEM 2.    PROPERTIES
As of September 30, 2019, we conducted our business from office and operating facilities at owned and leased locations throughout the United States (including Puerto Rico) and select global markets. We lease facilities in Chesterbrook, Pennsylvania and in Conshohocken, Pennsylvania for our corporate headquarters.
Pharmaceutical Distribution Services has a robust distribution facility network in the United States. Significant leased facilities are located in Puerto Rico plus the following states: Arizona, Colorado, Florida, Georgia, Hawaii, Indiana, Kentucky, Minnesota, Mississippi, New York, North Carolina, Utah, and Washington. Owned facilities are located in the following states: Alabama, California, Illinois, Massachusetts, Michigan, Missouri, Ohio, Pennsylvania, Texas, and Virginia.
As of September 30, 2019, the Consulting Group's operations were conducted in leased locations. Its headquarters are located in South Carolina and internationally in Canada.
As of September 30, 2019, World Courier's office and operating facilities are located in over 50 countries. Its headquarters are located in London, England. Most of the facilities are leased.
As of September 30, 2019, MWI's operations were conducted in the United States and in the United Kingdom. Leased facilities are located in California, Colorado, Florida, Idaho, Indiana, Kansas, Massachusetts, Minnesota, North Carolina, Pennsylvania, Texas, Washington, and internationally in the United Kingdom. Significant owned facilities are located in Alabama, Idaho, Texas, and Virginia and internationally in the United Kingdom. Its headquarters are located in Idaho.
We consider all of our operating and office properties to be in satisfactory condition.
ITEM 3.    LEGAL PROCEEDINGS
Legal proceedings in which we are involved are discussed in Note 13 (Legal Matters and Contingencies) of the Notes to Consolidated Financial Statements appearing in this Annual Report on Form 10-K.
ITEM 4.    MINE SAFETY DISCLOSURES
Not applicable.

18

INFORMATION ABOUT OUR EXECUTIVE OFFICERS
The following is a list of our executive officers and their ages and positions as of November 15, 2019.
Name
 
Age
 
Current Position with the Company
Steven H. Collis
 
58
 
Chairman, President, and Chief Executive Officer
Silvana Battaglia
 
52
 
Executive Vice President and Chief Human Resources Officer
John G. Chou
 
63
 
Executive Vice President, Chief Legal Officer and Secretary
Gina K. Clark
 
62
 
Executive Vice President and Chief Communications & Administration Officer
James F. Cleary
 
56
 
Executive Vice President and Chief Financial Officer
Leslie E. Donato
 
50
 
Executive Vice President and Chief Strategy Officer
Kathy H. Gaddes
 
56
 
Executive Vice President and Chief Compliance Officer
Robert P. Mauch
 
52
 
Executive Vice President and Group President
Unless indicated to the contrary, the business experience summaries provided below for our executive officers describe positions held by the named individuals during the last five years.
Mr. Collis has been President and Chief Executive Officer of the Company since July 2011 and Chairman since March 2016. From November 2010 to July 2011, he served as President and Chief Operating Officer. He served as Executive Vice President and President of AmerisourceBergen Drug Corporation from September 2009 to November 2010. He was Executive Vice President and President of AmerisourceBergen Specialty Group from September 2007 to September 2009 and was Senior Vice President of the Company and President of AmerisourceBergen Specialty Group from August 2001 to September 2007. Mr. Collis has been employed by the Company or one of its predecessors for 25 years.
Ms. Battaglia has been Executive Vice President and Chief Human Resources Officer since January 2019. Prior to joining the Company, she worked at Aramark as Senior Vice President of Global Compensation, Benefits, and Labor Relations from August 2017 to December 2018 and as Senior Vice President, Global Field Human Resources from May 2011 to August 2017. She also previously worked for Day & Zimmerman and Merck Corporation.
Mr. Chou has been Executive Vice President since August 2011 and became the Chief Legal Officer and Secretary in September 2019. He served as Chief Legal & Business Officer of the Company from May 2017 to September 2019. He served as General Counsel of the Company from January 2007 to June 2017. From January 2007 to August 2011, Mr. Chou was a Senior Vice President. He served as Secretary of the Company from February 2006 to May 2012. He was Vice President and Deputy General Counsel from November 2004 to January 2007 and Associate General Counsel from July 2002 to November 2004. Mr. Chou has been employed by the Company for 17 years.
Ms. Clark has been Executive Vice President since November 2014 and became Chief Communication & Administration Officer in June 2017. She served as Chief Marketing Officer from November 2014 to June 2017. Ms. Clark was named Senior Vice President and Chief Marketing Officer in June 2011. She previously served as Senior Vice President of Marketing and Business Development for AmerisourceBergen Specialty Group from January 2007 to June 2011. Prior to joining the Company, she worked in executive leadership roles at Premier Inc. and HealthSouth, including Senior Vice President of Marketing and Alliance Relations, Group Vice President of Relationship Management, and Senior Vice President of Managed Care and National Contracting.
Mr. Cleary has been Executive Vice President since March 2015 and became Chief Financial Officer in November 2018. He served as Group President, Global Commercialization Services & Animal Health from June 2017 to November 2018. He previously served as President, MWI Animal Health from March 2015 to June 2017. Prior to joining the Company, he was President and Chief Executive Officer of MWI Veterinary Supply, Inc. from June 2002.
Ms. Donato has been Executive Vice President and Chief Strategy Officer since July 2019. Prior to joining the Company, she held various leadership roles at Bayer from May 2009 to May 2019, including Vice President of Strategy, Pharmaceuticals Division, Vice President of Strategy, Bayer Healthcare US, and Vice President & General Manager of Neurology & Hematology. She also worked for McKinsey & Company where she was a Partner in the Healthcare Practice.
Ms. Gaddes became Executive Vice President and Chief Compliance Officer in October 2018. She served as Executive Vice President and Chief Human Resources Officer from April 2016 to January 2019. She served as Vice President, Group General Counsel and Secretary from May 2012 to April 2016. She served as Assistant General Counsel, Corporate and Securities from October 2011 to May 2012. Prior to joining the Company, Ms. Gaddes was Associate Corporate Secretary at ARCO Chemical Company.

19

Mr. Mauch has been Executive Vice President since February 2015 and became Group President in February 2019. He served as Group President, Pharmaceutical Distribution & Strategic Global Sourcing from June 2017 to February 2019. He served as President, AmerisourceBergen Drug Corporation from February 2015 to June 2017. Mr. Mauch previously served as Senior Vice President Chief Operating Officer, AmerisourceBergen Drug Corporation from March 2014 to February 2015. He was Senior Vice President, Operations, AmerisourceBergen Drug Corporation from April 2012 to March 2014. He was Senior Vice President of Sales and Marketing, AmerisourceBergen Drug Corporation from April 2011 to April 2012. He was Senior Vice President, Alternate Care Sales and Marketing, AmerisourceBergen Drug Corporation from May 2010 to April 2011. Mr. Mauch has been employed by the Company or one of its predecessors for 25 years.

20

PART II
ITEM 5.    MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
The Company's common stock is traded on the New York Stock Exchange under the trading symbol "ABC." As of October 31, 2019, there were 2,459 record holders of the Company's common stock.
In November 2017, our board of directors increased the quarterly dividend by 4% from $0.365 per share to $0.380 per share. In November 2018, our board of directors increased the quarterly dividend by 5% from $0.380 per share to $0.400 per share. The Company anticipates that it will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Company's board of directors and will depend upon the Company's future earnings, financial condition, capital requirements, and other factors.
Computershare is the Company's transfer agent. Computershare can be reached at (mail) AmerisourceBergen Corporation c/o Computershare, P.O. Box 50500, Louisville, KY 40233-500; (telephone): Domestic 1-800-522-6645, International 1-201-680-6578, and (internet) www.computershare.com/investor.

21

ISSUER PURCHASES OF EQUITY SECURITIES
The following sets forth the total number of shares purchased, the average price paid per share, the total number of shares purchased as part of publicly announced programs, and the approximate dollar value of shares that may yet be purchased under the programs during each month in the fiscal year ended September 30, 2019.
Period
 
Total Number
of Shares
Purchased
 
Average
Price
Paid Per
Share
 
Total Number of
Shares Purchased
as Part of Publicly
Announced
Programs
 
Approximate
Dollar Value of
Shares that May
Yet Be Purchased
Under the
Programs
October 1 to October 31
 
1,386,835

 
$
90.72

 
1,386,835

 
$
1,000,000,000

November 1 to November 30
 
62,923

 
$
89.85

 
—

 
$
1,000,000,000

December 1 to December 31
 
1,319,378

 
$
75.79

 
1,319,378

 
$
900,000,064

January 1 to January 31
 
—

 
$
—

 
—

 
$
900,000,064

February 1 to February 28
 
157

 
$
82.79

 
—

 
$
900,000,064

March 1 to March 31
 
1,252,495

 
$
78.33

 
1,252,495

 
$
801,896,921

April 1 to April 30
 
116

 
$
75.35

 
—

 
$
801,896,921

May 1 to May 31
 
1,038,138

 
$
79.56

 
1,034,499

 
$
719,581,614

June 1 to June 30
 
1,111,252

 
$
83.29

 
1,111,252

 
$
627,021,288

July 1 to July 31
 
139,217

 
$
84.95

 
139,217

 
$
615,195,472

August 1 to August 31
 
752,384

 
$
82.85

 
752,048

 
$
552,888,358

September 1 to September 30
 
1,101,040

 
$
83.33

 
1,101,040

 
$
461,135,868

Total
 
8,163,935

 
$
82.15

 
8,096,764

 
 

________________________________________________
(a)
In November 2016, the Company's board of directors authorized a share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2019, the Company purchased 1.4 million shares of its common stock for a total of $125.8 million, which excluded $24.0 million of September 2018 purchases that cash settled in October 2018, to complete its authorization under this program.
(b)
In October 2018, the Company's board of directors authorized a new share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2019, the Company purchased 6.7 million shares of its common stock for a total of $538.9 million under this program, which included $14.8 million of September 2019 purchases that cash settled in October 2019. As of September 30, 2019, the Company had $461.1 million of availability under this program.
(c)
Employees surrendered 67,171 shares during the fiscal year ended September 30, 2019 to meet minimum tax-withholding obligations upon vesting of restricted stock.

22

STOCK PERFORMANCE GRAPH
This graph depicts the Company's five year cumulative total stockholder returns relative to the performance of the Standard and Poor's 500 Composite Stock Index, the S&P Health Care Index, and an index of peer companies selected by the Company from the market close on September 30, 2014 to September 30, 2019. The graph assumes $100 invested at the closing price of the common stock of the Company and of each of the other indices on the New York Stock Exchange on September 30, 2014. The points on the graph represent fiscal year-end index levels based upon the last trading day in each fiscal quarter. The Peer Group index (which is weighted on the basis of market capitalization) consists of the following companies engaged primarily in wholesale pharmaceutical distribution and related services: McKesson Corporation and Cardinal Health, Inc.

performancegraphfy2019a02.jpg
         
* $100 invested on September 30, 2014 in stock or index, including reinvestment of dividends.








23

ITEM 6.    SELECTED FINANCIAL DATA
The following should be read in conjunction with the consolidated financial statements, including the notes thereto, and Management's Discussion and Analysis of Financial Condition and Results of Operations beginning on page 25.
 
 
As of or for the Fiscal Year Ended September 30,
(Amounts in thousands, except per share amounts)
 
2019(a)
 
2018(b)
 
2017(c)
 
2016(d)
 
2015(e)
Statement of Operations Data:
 
 

 
 

 
 

 
 

 
 

Revenue
 
$
179,589,121

 
$
167,939,635

 
$
153,143,826

 
$
146,849,686

 
$
135,961,803

Gross profit
 
5,138,312

 
4,612,317

 
4,546,002

 
4,272,606

 
3,529,313

Operating expenses
 
4,026,389

 
3,168,632

 
3,485,660

 
2,746,832

 
3,107,093

Operating income
 
1,111,923

 
1,443,685

 
1,060,342

 
1,525,774

 
422,220

Interest expense, net
 
157,769

 
174,699

 
145,185

 
139,912

 
109,036

Net income (loss)
 
854,135

 
1,615,892

 
364,484

 
1,427,929

 
(138,165
)
Net income (loss) attributable to AmerisourceBergen Corporation
 
$
855,365

 
$
1,658,405

 
$
364,484

 
$
1,427,929

 
$
(138,165
)
Earnings per share — diluted
 
$
4.04

 
$
7.53

 
$
1.64

 
$
6.32

 
$
(0.63
)
Cash dividends declared per common share
 
$
1.60

 
$
1.52

 
$
1.46

 
$
1.36

 
$
1.16

Weighted average common shares outstanding — diluted
 
211,840

 
220,336

 
221,602

 
225,959

 
217,786

Balance Sheet Data:
 
 

 
 

 
 

 
 

 
 

Cash and cash equivalents
 
$
3,374,194

 
$
2,492,516

 
$
2,435,115

 
$
2,741,832

 
$
2,167,442

Accounts receivable, net
 
12,386,879

 
11,314,226

 
10,303,324

 
9,175,876

 
8,222,951

Inventories
 
11,060,254

 
11,918,508

 
11,461,428

 
10,723,920

 
9,755,094

Property and equipment, net
 
1,770,516

 
1,892,424

 
1,797,945

 
1,530,682

 
1,192,510

Total assets
 
39,171,980

 
37,669,838

 
35,316,470

 
33,637,501

 
27,962,982

Accounts payable
 
28,385,074

 
26,836,873

 
25,404,042

 
23,926,320

 
20,886,439

Total debt
 
4,172,892

 
4,310,189

 
3,442,055

 
4,186,703

 
3,493,048

Total equity
 
2,993,206

 
3,049,961

 
2,064,461

 
2,129,404

 
616,386

Total liabilities and stockholders' equity
 
$
39,171,980

 
$
37,669,838

 
$
35,316,470

 
$
33,637,501

 
$
27,962,982

_________________________________
(a)
Includes a $421.3 million impairment of PharMEDium's long-lived assets, net of income tax benefit of $148.7 million; $245.8 million of employee severance, litigation, and other costs, net of income tax benefit of $84.6 million; a $107.8 million gain from antitrust litigation settlements, net of income tax expense of $38.1 million; $51.3 million of PharMEDium remediation costs, net of income tax benefit of $18.1 million; $16.7 million of LIFO credit, net of income tax expense of $5.9 million; a $16.3 million reversal of an estimated assessment related to the New York State Opioid Stewardship Act, net of income tax expense of $5.7 million; and a $10.1 million gain on the sale of an equity investment, net of income tax expense of $3.6 million.
(b)
Includes $61.3 million of employee severance, litigation, and other costs, net of income tax benefit of $122.2 million; a $59.7 million goodwill impairment with no income tax benefit; $48.6 million of LIFO expense, net of income tax benefit of $18.7 million; $47.8 million of PharMEDium remediation costs, net of income tax benefit of $18.4 million; a $42.3 million loss on consolidation of equity investments with no income tax benefit; a $30.0 million impairment on a non-customer note receivable with no income tax benefit; a $25.9 million gain from antitrust litigation settlements, net of income tax expense of $10.0 million; a $17.2 million loss on early retirement of debt, net of income tax benefit of $6.6 million; and $15.9 million of expense for an estimated assessment related to the New York State Opioid Stewardship Act, net of income tax benefit of $6.1 million.
(c)
Includes $101.1 million of LIFO credit, net of income tax expense of $56.7 million; a $0.9 million gain from antitrust litigation settlements, net of income tax expense of $0.5 million; and $937.4 million of employee severance, litigation, and other costs, net of income tax benefit of $21.9 million.
(d)
Includes $367.2 million of Warrants income, net of income tax benefit of $507.5 million; $120.9 million of LIFO expense, net of income tax benefit of $79.3 million; an $80.8 million gain from antitrust litigation settlements, net of income tax expense of $53.0 million; $62.1 million of employee severance, litigation, and other costs, net of income tax benefit of $40.8 million; and a $28.7 million pension settlement charge, net of income tax benefit of $18.9 million.
(e)
Includes $887.5 million of Warrants expense, net of income tax benefit of $25.3 million; $336.2 million of LIFO expense, net of income tax benefit of $206.6 million; a $40.6 million gain from antitrust litigation settlements, net of income tax expense of$24.9 million; a $30.6 million impairment charge on an equity investment, with no income tax benefit; and $23.5 million of employee severance, litigation, and other costs, net of income tax benefit of $14.4 million.

24

ITEM 7.    MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
The following discussion should be read in conjunction with the Consolidated Financial Statements and notes thereto contained herein.
We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health. We are organized based upon the products and services we provide to our customers. Our operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in Other for the purpose of our reportable segment presentation.
Pharmaceutical Distribution Services Segment
The Pharmaceutical Distribution Services reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. Through a number of operating businesses, the Pharmaceutical Distribution Services reportable segment provides pharmaceutical distribution (including plasma and other blood products, injectible pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. Additionally, the Pharmaceutical Distribution Services reportable segment provides data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The Pharmaceutical Distribution Services reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. Additionally, it delivers packaging solutions to institutional and retail healthcare providers.
Other
Other consists of operating segments that focus on global commercialization services and animal health (MWI Animal Health). The operating segments that focus on global commercialization services include ABCS and World Courier.
MWI is a leading animal health distribution company in the United States and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. Additionally, MWI offers demand-creating sales force services to manufacturers. ABCS, through a number of operating businesses, provides a full suite of integrated manufacturer services that range from clinical trial support to product post-approval and commercialization support. World Courier, which operates in over 50 countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry.







25

Executive Summary
This executive summary provides highlights from the results of operations that follow:
•
Revenue increased 6.9% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment;
•
Pharmaceutical Distribution Services' gross profit increased 6.2% from the prior fiscal year primarily due to the increase in revenue largely due to strong specialty product sales, the January 2018 consolidation of Profarma, and the January 2018 acquisition of H.D. Smith and was negatively impacted by our pharmaceutical compounding operations as production at our Memphis facility has been suspended since December 2017. Gross profit in Other increased 4.3% from the prior fiscal year primarily due to growth at World Courier and MWI, the January 2018 consolidation of the specialty joint venture in Brazil, and ABCS's growth in its Canadian operations. Total gross profit in the current fiscal year was favorably impacted primarily by increases in gains from antitrust litigation settlements, a last-in, first-out ("LIFO") credit in the current year in comparison to a LIFO expense in the prior year, and the reversal of a previously-estimated assessment related to the New York State Opioid Stewardship Act;
•
Distribution, selling, and administrative expenses increased 8.3% from the prior fiscal year as the Pharmaceutical Distribution Services' segment expenses increased by 10.2% from the prior fiscal year primarily due to an increase in costs to support the increase in revenue, the January 2018 consolidation of Profarma, and the January 2018 acquisition of H.D. Smith;
•
Operating income decreased 23.0% in the current fiscal year primarily due to a $570.0 million impairment of PharMEDium's long-lived assets (see Note 1 of the Notes to Consolidated Financial Statements), and an increase in employee severance, litigation, and other costs, offset in part by increases in gains from antitrust litigation settlements, a LIFO credit in the current fiscal year, and an increase in total operating segment income;
•
Our effective tax rates were 11.7% and (37.2)% in the fiscal years ended September 30, 2019 and 2018, respectively. Our effective tax rate in the fiscal year ended September 30, 2019 was primarily impacted by the $570.0 million impairment of long-lived assets (see Note 1 of the Notes to Consolidated Financial Statements) and legal settlements, which changed the mix of domestic and international income. The effective tax rate in the fiscal year ended September 30, 2019 was also impacted by a $37.0 million decrease to the Company's transition tax related to the Tax Cuts and Jobs Act (the "2017 Tax Act"). Our effective tax rate in the fiscal year ended September 30, 2018 was primarily impacted by the effect of 2017 Tax Act. Our total income tax benefit in the fiscal year ended September 30, 2018 of $438.5 million reflects $612.6 million of tax benefits recognized and a reduction in the U.S. federal income tax rate from 35% to 21%, both resulting from the 2017 Tax Act. Additionally, during the fourth quarter of fiscal 2018, a portion of a 2017 legal settlement charge was determined to be deductible, which favorably impacted our effective tax rate for the fiscal year ended September 30, 2018. Our effective tax rates for the fiscal years ended September 30, 2019 and 2018 were favorably impacted by the Company's international businesses in Switzerland and Ireland, which have lower income tax rates, and the benefit from stock option exercises and restricted stock vesting; and
•
Net income and earnings per share were significantly lower in the current fiscal year primarily due to the $570.0 million impairment of long-lived assets and the significant income tax benefit recognized in the prior fiscal year as a result of the 2017 Tax Act.

26

Results of Operations
Year ended September 30, 2019 compared to the Year ended September 30, 2018
Revenue
 
 
Fiscal Year Ended
September 30,
 
 
(dollars in thousands)
 
2019
 
2018
 
Change
Pharmaceutical Distribution Services
 
$
172,813,537

 
$
161,699,343

 
6.9%
Other:
 
 
 
 
 
 
MWI Animal Health
 
3,975,232

 
3,789,759

 
4.9%
Global Commercialization Services
 
2,893,109

 
2,542,971

 
13.8%
Total Other
 
6,868,341

 
6,332,730

 
8.5%
Intersegment eliminations
 
(92,757
)
 
(92,438
)
 

Revenue
 
$
179,589,121

 
$
167,939,635

 
6.9%
We currently expect our revenue growth percentage to be in the mid to high-single digits in fiscal 2020. Our future revenue growth will continue to be affected by various factors, such as industry growth trends, including drug utilization, the introduction of new, innovative brand therapies (including biosimilars), the likely increase in the number of generic drugs that will be available over the next few years as a result of the expiration of certain drug patents held by brand-name pharmaceutical manufacturers and the rate of conversion from brand products to those generic drugs, price inflation and price deflation, general economic conditions in the United States, competition within the industry, customer consolidation, changes in pharmaceutical manufacturer pricing and distribution policies and practices, increased downward pressure on government and other third-party reimbursement rates to our customers, and changes in federal government rules and regulations.
Revenue increased by 6.9% from the prior fiscal year primarily due to the revenue growth of our Pharmaceutical Distribution Services segment.
The Pharmaceutical Distribution Services segment grew its revenue by 6.9% from the prior fiscal year, primarily due to the growth of some of its largest customers, continued strong specialty product sales, and overall market growth. In addition, revenue increased in the current fiscal year due to the January 2018 consolidation of Profarma and the January 2018 acquisition of H.D. Smith.
Revenue in Other increased 8.5% from the prior fiscal year, primarily due to ABCS's growth in its Canadian operations, growth at MWI, growth at World Courier, and the January 2018 consolidation of the specialty joint venture in Brazil.
A number of our contracts with customers, including group purchasing organizations, are typically subject to expiration each year. We may lose a significant customer if an existing contract with such customer expires without being extended, renewed, or replaced. During the fiscal year ended September 30, 2019, no significant contracts expired. Over the next twelve months, there are no significant contracts scheduled to expire. Additionally, from time to time, significant contracts may be terminated in accordance with their terms or extended, renewed, or replaced prior to their expiration dates. If those contracts are extended, renewed, or replaced at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.
Gross Profit
 
 
Fiscal Year Ended
September 30,
 
 
(dollars in thousands)
 
2019
 
2018
 
Change
Pharmaceutical Distribution Services
 
$
3,682,986

 
$
3,466,956

 
6.2%
Other
 
1,314,172

 
1,260,485

 
4.3%
Intersegment eliminations
 
(659
)
 
(609
)
 
 
Gain from antitrust litigation settlements
 
145,872

 
35,938

 
 
LIFO credit (expense)
 
22,544

 
(67,324
)
 
 
PharMEDium remediation costs
 
(48,603
)
 
(61,129
)
 
 
New York State Opioid Stewardship Act
 
22,000

 
(22,000
)
 
 
Gross profit
 
$
5,138,312

 
$
4,612,317

 
11.4%
Gross profit increased 11.4%, or $526.0 million, from the prior fiscal year. Gross profit in the current fiscal year was favorably impacted primarily by the increase in gross profit in Pharmaceutical Distribution Services, the increase in gross profit

27

in Other, an increase in gains from antitrust litigation settlements, the LIFO credit in the current year in comparison to a LIFO expense in the prior year, and the reversal of a previously-estimated assessment related to the New York State Opioid Stewardship Act.
Our cost of goods sold includes a LIFO provision that is affected by manufacturer pricing practices, which may be impacted by market and other external influences, changes in inventory quantities, and product mix, many of which are difficult to predict. Changes to any of the above factors may have a material impact to our annual LIFO provision. The LIFO credit in the current fiscal year was primarily driven by lower brand inflation, offset in part by lower generic deflation in comparison to the prior fiscal year.

After FDA inspections of our compounding facilities, we voluntarily suspended production activities in December 2017 at our largest compounding facility located in Memphis pending execution of certain remedial measures (see Notes 1 and 13 of the Notes to Consolidated Financial Statements). We continue to incur remediation costs in connection with our compounding operations. Additionally, in April 2019, we ceased production at our compounding facility in Cleveland, Mississippi.

New York State ("NYS") enacted the Opioid Stewardship Act ("OSA"), which went into effect on July 1, 2018. The OSA established an annual $100 million Opioid Stewardship Fund (the "Fund") and required manufacturers, distributors, and importers licensed in NYS to ratably source the Fund. The ratable share of the assessment for each licensee was to be based upon opioids sold or distributed to or within NYS. In September 2018, we accrued $22.0 million as an estimate of our liability under the OSA for the period from January 1, 2017 through September 30, 2018. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York, and, as a result, we reversed the $22.0 million accrual in the quarter ended December 31, 2018. NYS filed an appeal of the court decision on January 17, 2019; however, we do not believe a loss contingency is probable.
Pharmaceutical Distribution Services gross profit increased 6.2%, or $216.0 million, from the prior fiscal year primarily due to the increase in revenue largely due to strong specialty product sales, the January 2018 consolidation of Profarma, and the January 2018 acquisition of H.D. Smith and was negatively impacted by our pharmaceutical compounding operations as production at our Memphis facility has been suspended since December 2017. As a percentage of revenue, Pharmaceutical Distribution Services gross profit margin of 2.13% in the current fiscal year remained relatively flat compared to the prior fiscal year.
Gross profit in Other increased 4.3%, or $53.7 million, from the prior fiscal year primarily due to growth at World Courier and MWI, the January 2018 consolidation of the specialty joint venture in Brazil, and ABCS's growth in its Canadian operations. As a percentage of revenue, gross profit margin in Other of 19.13% in the current fiscal year decreased from 19.90% in the prior fiscal year.
We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $145.9 million and $35.9 million during the fiscal years ended September 30, 2019 and 2018, respectively. The gains were recorded as reductions to cost of goods sold (see Note 14 of the Notes to Consolidated Financial Statements).
Operating Expenses
 
 
Fiscal Year Ended
September 30,
 
 
(dollars in thousands)
 
2019
 
2018
 
Change
Distribution, selling, and administrative
 
$
2,663,508

 
$
2,460,301

 
8.3%
Depreciation and amortization
 
462,407

 
465,127

 
(0.6)%
Employee severance, litigation, and other
 
330,474

 
183,520

 
 
Goodwill impairment
 
—

 
59,684

 
 
Impairment of long-lived assets
 
570,000

 
—

 
 
Total operating expenses
 
$
4,026,389

 
$
3,168,632

 
27.1%
Distribution, selling, and administrative expenses increased 8.3%, or $203.2 million, from the prior fiscal year. As a percentage of revenue, distribution, selling, and administrative expenses were 1.48% in the current fiscal year, and represents a 2 basis point increase compared to the prior fiscal year. Pharmaceutical Distribution Services' segment expenses increased by 10.2% from the prior fiscal year primarily due to an increase in costs to support revenue growth, the January 2018 consolidation of Profarma, and the January 2018 acquisition of H.D. Smith. Distribution, selling, and administrative expenses in Other increased by 2.7% in the current fiscal year due to an increase in costs to support revenue growth at MWI, and the January 2018 consolidation of the specialty joint venture in Brazil, offset in part by a reduction in distribution, selling, and administrative expenses at ABCS.

28

Depreciation expense increased 3.9% from the prior fiscal year primarily due to the January 2018 acquisition of H.D. Smith and the January 2018 consolidation of Profarma. Amortization expense decreased 7.6% from the prior fiscal year primarily due to the impairment of PharMEDium intangible assets recorded in March 2019, offset in part by the amortization of intangible assets originating from our January 2018 acquisition of H.D. Smith and the January 2018 consolidation of Profarma.
Employee severance, litigation, and other in the fiscal year ended September 30, 2019 included $34.1 million of severance costs primarily related to PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D. Smith, and restructuring activities related to our consulting business, $185.1 million of litigation costs that consisted of legal settlements totaling $116.7 million and legal fees in connection with opioid lawsuits and investigations, $55.4 million related to our business transformation efforts, $43.2 million of acquisition-related deal and integration costs (primarily related to the integration of H.D. Smith), and $12.6 million of other restructuring initiatives.
Employee severance, litigation, and other in the fiscal year ended September 30, 2018 included $36.7 million of severance costs primarily related to position eliminations resulting from our business transformation efforts and restructuring activities related to our consulting business, $61.5 million of litigation costs primarily related to legal fees in connection with opioid lawsuits and investigations, and related initiatives, $33.9 million of acquisition-related deal and integration costs (primarily related to H.D. Smith), $33.0 million related to our business transformation efforts, and $18.4 million of other restructuring initiatives.
We recorded a $570.0 million impairment of PharMEDium's long-lived assets in the fiscal year ended September 30, 2019 (see Note 1 of the Notes to Consolidated Financial Statements).
We recorded a $59.7 million goodwill impairment charge at our Profarma reporting unit in the fiscal year September 30, 2018 in connection with our annual goodwill impairment assessment.
Operating Income
 
 
Fiscal Year Ended
September 30,
 
 
(dollars in thousands)
 
2019
 
2018
 
Change
Pharmaceutical Distribution Services
 
$
1,671,251

 
$
1,626,748

 
2.7%
Other
 
380,660

 
355,091

 
7.2%
Intersegment eliminations
 
(659
)
 
(609
)
 

Total segment operating income
 
2,051,252

 
1,981,230

 
3.5%
 
 
 
 
 
 
 
Gain from antitrust litigation settlements
 
145,872

 
35,938

 
 
LIFO credit (expense)
 
22,544

 
(67,324
)
 
 
PharMEDium remediation costs
 
(69,423
)
 
(66,204
)
 
 
New York State Opioid Stewardship Act
 
22,000

 
(22,000
)
 
 
Acquisition-related intangibles amortization
 
(159,848
)
 
(174,751
)
 
 
Employee severance, litigation, and other
 
(330,474
)
 
(183,520
)
 
 
Goodwill impairment
 
—

 
(59,684
)
 
 
Impairment of long-lived assets
 
(570,000
)
 
—

 
 
Operating income
 
$
1,111,923

 
$
1,443,685

 
(23.0)%
Segment operating income is evaluated excluding gain from antitrust litigation settlements; LIFO credit (expense); PharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation, and other; goodwill impairment; and impairment of long-lived assets.
Pharmaceutical Distribution Services operating income increased 2.7%, or $44.5 million, from the prior fiscal year primarily due to the increase in gross profit, offset in part by an increase in operating expenses. As a percentage of revenue, Pharmaceutical Distribution Services operating income margin decreased 4 basis points from the prior fiscal year primarily due to a lower contribution from our pharmaceutical compounding operations.
Operating income in Other increased 7.2%, or $25.6 million, from the prior fiscal year primarily due to the increase in gross profit, offset in part by an increase in operating expenses.
We recorded a $13.7 million gain on the sale of an equity investment in Other (Income) Loss in the fiscal year ended September 30, 2019.

29

We recorded a $30.0 million impairment on a non-customer note receivable related to a start-up venture in Other (Income ) Loss in the fiscal year ended September 30, 2018.
Interest expense, net and the respective weighted average interest rates were as follows:
 
 
Fiscal Year Ended September 30,
 
 
2019
 
2018
(dollars in thousands)
 
Amount
 
Weighted Average
Interest Rate
 
Amount
 
Weighted Average
Interest Rate
Interest expense
 
$
195,474

 
3.73%
 
$
189,640

 
3.59%
Interest income
 
(37,705
)
 
1.87%
 
(14,941
)
 
1.18%
Interest expense, net
 
$
157,769

 
 
 
$
174,699

 
 
Interest expense, net decreased 9.7%, or $16.9 million, from the prior fiscal year. The decrease in interest expense, net from the prior fiscal year was due to an increase in interest income due to a $752 million increase in our average invested cash balance during the current fiscal year and an increase in investment interest rates, offset in part by an increase in interest expense due to the December 2017 issuance of senior notes to finance our January 2018 acquisition of H.D. Smith and the January 2018 consolidation of Profarma's debt and related interest expense.
Our interest expense in future periods may vary significantly depending upon changes in net borrowings, interest rates, amendments to our current borrowing facilities, and strategic decisions to deploy our invested cash.
For the fiscal year ended September 30, 2018, we recorded a $42.3 million loss in connection with the January 2018 consolidations of Profarma and the specialty joint venture in Brazil and a $23.8 million loss on the early retirement of our $400 million of 4.875% senior notes that were due in 2019. The loss on the early retirement of the debt included a $22.3 million prepayment premium and $1.5 million of an unamortized debt discount and unamortized debt issuance costs.
Our effective tax rates were 11.7% and (37.2)% in the fiscal years ended September 30, 2019 and 2018, respectively. Our effective tax rate in the fiscal year ended September 30, 2019 was primarily impacted by the $570.0 million impairment of long-lived assets (see Note 1 of the Notes to Consolidated Financial Statements) and legal settlements, which changed the mix of domestic and international income. The effective tax rate in the fiscal year ended September 30, 2019 was also impacted by a $37.0 million decrease to the Company's transition tax related to the 2017 Tax Act. Our effective tax rate in the fiscal year ended September 30, 2018 was primarily impacted by the effect of 2017 Tax Act. Our total income tax benefit in the fiscal year ended September 30, 2018 of $438.5 million reflects $612.6 million of tax benefits recognized and a reduction in the U.S. federal income tax rate from 35% to 21%, both resulting from the 2017 Tax Act. Additionally, during the fourth quarter of fiscal 2018, a portion of a 2017 legal settlement charge was determined to be deductible, which favorably impacted our effective tax rate for the fiscal year ended September 30, 2018. Our effective tax rates for the fiscal years ended September 30, 2019 and 2018 were also favorably impacted by the Company's international businesses in Switzerland and Ireland, which have lower income tax rates, and the benefit from stock option exercises and restricted stock vesting.
Net income and earnings per share were significantly lower in the current fiscal year primarily due to the $570.0 million impairment of long-lived assets and the significant income tax benefit recognized in the prior fiscal year as a result of the 2017 Tax Act.
Year ended September 30, 2018 compared to the Year ended September 30, 2017
Revenue
 
 
Fiscal Year Ended
September 30,
 
 
(dollars in thousands)
 
2018
 
2017
 
Change
Pharmaceutical Distribution Services
 
$
161,699,343

 
$
147,453,495

 
9.7%
Other:
 
 
 
 
 
 
MWI Animal Health
 
3,789,759

 
3,636,305

 
4.2%
Global Commercialization Services
 
2,542,971

 
2,111,558

 
20.4%
Total Other
 
6,332,730

 
5,747,863

 
10.2%
Intersegment eliminations
 
(92,438
)
 
(57,532
)
 
 
Revenue
 
$
167,939,635

 
$
153,143,826

 
9.7%

30

Revenue increased by 9.7% from the prior fiscal year primary due to the revenue growth of our Pharmaceutical Distribution Services segment.
The Pharmaceutical Distribution Services segment grew its revenue by 9.7% from the prior fiscal year primarily due to the growth of some of its largest customers, overall market growth, and especially strong oncology product sales. In addition, revenue increased in the prior fiscal year due to the January 2018 acquisition of H.D. Smith and the January 2018 consolidation of Profarma.
Revenue in Other increased 10.2% from the prior fiscal year, primarily due to the January 2018 consolidation of the specialty joint venture in Brazil, ABCS's growth in its Canadian operations, and increased revenue from MWI and World Courier, offset in part by a decrease in revenue at ABCS's Lash consulting group.
Gross Profit
 
 
Fiscal Year Ended
September 30,
 
 
(dollars in thousands)
 
2018
 
2017
 
Change
Pharmaceutical Distribution Services
 
$
3,466,956

 
$
3,182,836

 
8.9%
Other
 
1,260,485

 
1,204,545

 
4.6%
Intersegment eliminations
 
(609
)
 
(556
)
 
 
Gain from antitrust litigation settlements
 
35,938

 
1,395

 
 
LIFO (expense) credit
 
(67,324
)
 
157,782

 
 
PharMEDium remediation costs
 
(61,129
)
 
—

 
 
New York State Opioid Stewardship Act
 
(22,000
)
 
—

 
 
Gross profit
 
$
4,612,317

 
$
4,546,002

 
1.5%
Gross profit increased 1.5%, or $66.3 million, from the prior fiscal year. Gross profit in the fiscal year ended September 30, 2018 was favorably impacted by increases in gross profit in Pharmaceutical Distribution Services and Other and an increase in gains from antitrust litigation settlements. Gross profit was negatively impacted by an increase in LIFO expense in comparison to the prior fiscal year, PharMEDium remediation costs, and an estimated assessment related to the New York State Opioid Stewardship Act.
Pharmaceutical Distribution Services gross profit increased 8.9%, or $284.1 million, from the prior fiscal year primarily due to the increase in revenue, the January 2018 consolidation of Profarma, and the January 2018 acquisition of H.D. Smith, offset in part by a lower contribution from our pharmaceutical compounding operations as it shipped fewer units as we voluntarily suspended production in December 2017 at our Memphis facility. As a percentage of revenue, Pharmaceutical Distribution Services gross profit margin of 2.14% in the fiscal year ended September 30, 2018 decreased 2 basis points from the prior fiscal year. The decrease in gross profit margin from the prior fiscal year was primarily due to a lower contribution from our pharmaceutical compounding operations and due to increased sales to our larger customers, which typically have lower gross profit margins, offset in part by the January 2018 consolidation of Profarma and the January 2018 acquisition of H.D. Smith.
Gross profit in Other increased 4.6%, or $55.9 million, from the prior fiscal year primarily due to World Courier and the January 2018 consolidation of the specialty joint venture in Brazil, offset in part by lower gross profit at ABCS, specifically the Lash consulting group. As a percentage of revenue, gross profit margin in Other of 19.90% in the fiscal year ended September 30, 2018 decreased from 20.96% in the prior fiscal year. The decline in gross profit margin from the prior fiscal year was primarily due to the decrease in gross profit margin at ABCS, specifically the Lash consulting group.
We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $35.9 million and $1.4 million during the fiscal years ended September 30, 2018 and 2017, respectively. The gains were recorded as reductions to cost of goods sold (see Note 14 of the Notes to Consolidated Financial Statements).

31

Operating Expenses
 
 
Fiscal Year Ended
September 30,
 
 
(dollars in thousands)
 
2018
 
2017
 
Change
Distribution, selling, and administrative
 
$
2,460,301

 
$
2,128,730

 
15.6%
Depreciation and amortization
 
465,127

 
397,603

 
17.0%
Employee severance, litigation, and other
 
183,520

 
959,327

 
 
Goodwill impairment
 
59,684

 
—

 
 
Total operating expenses
 
$
3,168,632

 
$
3,485,660

 
(9.1)%
Distribution, selling, and administrative expenses decreased 15.6%, or $331.6 million, from the prior fiscal year as the Pharmaceutical Distribution Services' segment expenses increased by 19.4% from the prior fiscal year primarily due to the January 2018 consolidation of Profarma, the January 2018 acquisition of H.D. Smith, and the duplicate costs resulting from the implementation of new information technology systems. Distribution, selling, and administrative expenses in Other increased by 8.2% in the fiscal year ended September 30, 2018 primarily to support its revenue growth, the January 2018 consolidation of the specialty joint venture in Brazil, and due to duplicate costs resulting from the implementation of new information technology systems. As a percentage of revenue, distribution, selling, and administrative expenses were 1.46% in the fiscal year ended September 30, 2018, and represents a 7 basis point increase compared to the prior fiscal year. The increase in expense as a percentage of revenue in comparison to the prior fiscal year was primarily due to the January 2018 consolidation of Profarma and the specialty joint venture in Brazil.
Depreciation expense increased 19.8% from the prior fiscal year due to an increase in the amount of property and equipment placed into service relating to our distribution infrastructure and various technology assets. Amortization expense increased 12.9% from the prior fiscal year primarily due to the amortization of intangible assets originating from our January 2018 acquisition of H.D. Smith and the January 2018 consolidation of Profarma.
Employee severance, litigation, and other in the fiscal year ended September 30, 2018 included $36.7 million of severance costs primarily related to position eliminations resulting from our business transformation efforts and restructuring activities related to our consulting business, $61.5 million of litigation costs primarily related to legal fees in connection with opioid lawsuits and investigations, and related initiatives, $33.9 million of acquisition-related deal and integration costs (primarily related to H.D. Smith), $33.0 million related to our business transformation efforts, and $18.4 million of other restructuring initiatives.
Employee severance, litigation, and other in the fiscal year ended September 30, 2017 included $7.8 million of employee severance costs primarily related to position eliminations as we began to reorganize to further align our organization to our customers' needs, $917.6 million of litigation costs primarily related to litigation settlements and accruals, $17.0 million of acquisition-related deal and integration costs, $13.3 million of other restructuring initiatives, and $3.7 million related to our business transformation efforts.
Operating Income
 
 
Fiscal Year Ended
September 30,
 
 
(dollars in thousands)
 
2018
 
2017
 
Change
Pharmaceutical Distribution Services
 
$
1,626,748

 
$
1,643,629

 
(1.0)%
Other
 
355,091

 
373,797

 
(5.0)%
Intersegment eliminations
 
(609
)
 
(556
)
 
 
Total segment operating income
 
1,981,230

 
2,016,870

 
(1.8)%
 
 
 
 
 
 
 
Gain from antitrust litigation settlements
 
35,938

 
1,395

 
 
LIFO (expense) credit
 
(67,324
)
 
157,782

 
 
PharMEDium remediation costs
 
(66,204
)
 
—

 
 
New York State Opioid Stewardship Act
 
(22,000
)
 
—

 
 
Acquisition-related intangibles amortization
 
(174,751
)
 
(156,378
)
 
 
Employee severance, litigation, and other
 
(183,520
)
 
(959,327
)
 
 
Goodwill impairment
 
(59,684
)
 
—

 
 
Operating income
 
$
1,443,685

 
$
1,060,342

 
36.2%

32

Segment operating income is evaluated excluding gain from antitrust litigation settlements; LIFO (expense) credit; PharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation, and other; and goodwill impairment.
Pharmaceutical Distribution Services operating income decreased 1.0%, or $16.9 million, from the prior fiscal year primarily due to an increase in operating expenses, offset in part by an increase in gross profit. As a percentage of revenue, Pharmaceutical Distribution Services operating income margin decreased 10 basis points from the prior fiscal year primarily due to a lower contribution from our pharmaceutical compounding operations as it shipped fewer units as we voluntarily suspended production in December 2017 at our Memphis facility.
Operating income in Other decreased 5.0%, or $18.7 million, from the prior fiscal year primarily due to a decrease in operating income at ABCS, specifically the Lash consulting group, offset in part by the operating income increase at World Courier.
We recorded a $59.7 million goodwill impairment charge at our Profarma reporting unit in connection with our annual goodwill impairment assessment.
We recorded a $30.0 million impairment on a non-customer note receivable related to a start-up venture in Other (Income) Loss in the fiscal year ended September 30, 2018.
Interest expense, net and the respective weighted average interest rates were as follows:
 
 
Fiscal Year Ended September 30,
 
 
2018
 
2017
(dollars in thousands)
 
Amount
 
Weighted Average
Interest Rate
 
Amount
 
Weighted Average
Interest Rate
Interest expense
 
$
189,640

 
3.59%
 
$
149,042

 
2.99%
Interest income
 
(14,941
)
 
1.18%
 
(3,857
)
 
0.52%
Interest expense, net
 
$
174,699

 
 
 
$
145,185

 
 
Interest expense, net increased 20.3%, or $29.5 million, from the prior fiscal year. The increase in interest expense, net from the prior fiscal year was primarily due to the December 2017 issuance of senior notes to finance our January 2018 acquisition of H.D. Smith and the January 2018 consolidation of Profarma's debt and related interest expense. Average borrowings increased by $519.8 million in the current fiscal year in comparison to the prior fiscal year.
In connection with our incremental Brazil investments, we adjusted the carrying values of our previously held equity interests in Profarma and the specialty joint venture to equal their fair values. The adjustments resulted in a loss of $42.3 million, which was comprised of foreign currency translation adjustments from Accumulated Other Comprehensive Loss of $45.9 million, a $12.4 million gain on the remeasurement of Profarma's previously held interest, and an $8.8 million loss on the remeasurement of the specialty joint venture's previously held equity interest (see Note 2 of the Notes to Consolidated Financial Statements).
For the fiscal year ended September 30, 2018, we recorded a $23.8 million loss on the early retirement of our $400 million of 4.875% senior notes that were due in 2019 (see Note 6 of the Notes to Consolidated Financial Statements). The loss on the early retirement of the debt included a $22.3 million prepayment premium and $1.5 million of an unamortized debt discount and unamortized debt issuance costs.
Our effective tax rates were (37.2)% and 60.3% in the fiscal years ended September 30, 2018 and 2017, respectively. Our effective tax rate in the fiscal year ended September 30, 2018 was primarily impacted by the effect of the 2017 Tax Act. Our total income tax benefit in the fiscal year ended September 30, 2018 of $438.5 million reflects $612.6 million of tax benefits recognized and a reduction in the U.S. federal income tax rate from 35% to 21%, both resulting from the 2017 Tax Act. Additionally, during the fourth quarter of fiscal 2018, a portion of a 2017 legal settlement charge was determined to be deductible, which favorably impacted our effective tax rate for the fiscal year ended September 30, 2018. The effective tax rate for the fiscal year ended September 30, 2017 was negatively impacted by non-deductible legal settlement charges. Our effective tax rates for the fiscal years ended September 30, 2018 and 2017 were favorably impacted by our international businesses in Switzerland and Ireland, which have lower income tax rates, and the benefit from stock option exercises and restricted stock vesting.
Net income attributable to AmerisourceBergen Corporation was significantly higher in the fiscal year ended September 30, 2018 primarily due to the 2017 Tax Act and legal settlement charges that were incurred in the prior fiscal year.

33

Critical Accounting Policies and Estimates
Critical accounting policies are those policies that involve accounting estimates and assumptions that can have a material impact on our financial position and results of operations and require the use of complex and subjective estimates based upon past experience and management's judgment. Actual results may differ from these estimates due to uncertainties inherent in such estimates. Below are those policies applied in preparing our financial statements that management believes are the most dependent upon the application of estimates and assumptions. For a complete list of significant accounting policies, see Note 1 of the Notes to Consolidated Financial Statements.
Allowances for Returns and Doubtful Accounts
Trade receivables are primarily comprised of amounts owed to us for our pharmaceutical distribution and services activities and are presented net of an allowance for customer sales returns and an allowance for doubtful accounts. Our customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. We record an accrual for estimated customer sales returns at the time of sale to the customer based upon historical customer return trends. The allowance for returns as of September 30, 2019 and 2018 was $1,147.5 million and $988.8 million, respectively.
In determining the appropriate allowance for doubtful accounts, we consider a combination of factors, such as the aging of trade receivables, industry trends, and our customers' financial strength, credit standing, and payment and default history. Changes in the aforementioned factors, among others, may lead to adjustments in our allowance for doubtful accounts. The calculation of the required allowance requires judgment by our management as to the impact of these and other factors on the ultimate realization of our trade receivables. Each of our business units performs ongoing credit evaluations of its customers' financial condition and maintains reserves for probable bad debt losses based upon historical experience and for specific credit problems when they arise. We write off balances against the reserves when collectability is deemed remote. Each business unit performs formal, documented reviews of the allowance at least quarterly, and our largest business units perform such reviews monthly. There were no significant changes to this process during the fiscal years ended September 30, 2019, 2018, and 2017, and bad debt expense was computed in a consistent manner during these periods. The bad debt expense for any period presented is equal to the changes in the period end allowance for doubtful accounts, net of write-offs, recoveries, and other adjustments.
Bad debt expense for the fiscal years ended September 30, 2019, 2018, and 2017 was $25.2 million, $16.7 million, and $8.9 million, respectively. An increase or decrease of 0.1% in the 2019 allowance as a percentage of trade receivables would result in an increase or decrease in the provision on accounts receivable of approximately $12.5 million. The allowance for doubtful accounts was $76.4 million and $61.1 million as of September 30, 2019 and 2018, respectively.
Schedule II of this Form 10-K sets forth a rollforward of allowances for returns and doubtful accounts.
Business Combinations
The assets acquired and liabilities assumed upon the acquisition or consolidation of a business are recorded at fair value, with the residual of the purchase price allocated to goodwill. We engage third-party appraisal firms to assist management in determining the fair values of certain assets acquired and liabilities assumed. Such valuations require management to make significant judgments, estimates, and assumptions, especially with respect to intangible assets. Management makes estimates of fair value based upon assumptions it believes to be reasonable. These estimates are based upon historical experience and information obtained from the management of the acquired companies and are inherently uncertain. Critical estimates in valuing certain of the intangible assets include, but are not limited to: discount rates and expected future cash flows from and economic lives of customer relationships, trade names, existing technology, and other intangible assets. Unanticipated events and circumstances may occur, which may affect the accuracy or validity of such assumptions or estimates.
Goodwill and Other Intangible Assets
Goodwill arises from acquisitions or consolidations of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. We identify our reporting units based upon our management reporting structure, beginning with our operating segments. We aggregate two or more components within an operating segment that have similar economic characteristics. We evaluate whether the components within our operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment. Our reporting units include Pharmaceutical Distribution Services, Profarma, ABCS, World Courier, and MWI.

34

Goodwill and other intangible assets with indefinite lives, such as certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, we can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite-lived intangible assets, respectively. Such qualitative factors can include, among other, industry and market conditions, overall financial performance, and relevant entity-specific events. If we conclude based on our qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we perform a quantitative analysis. We elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2019, with the exception of our testing in the Profarma reporting unit. In the fourth quarter of fiscal 2018 and 2017, we elected to bypass performing the qualitative assessment and went directly to performing our annual quantitative assessments of the goodwill and indefinite-lived intangible assets.
The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized. If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.
When performing a quantitative impairment assessment, we utilize an income-based approach to value our reporting units, with the exception of the Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium. The income-based approach relies on a discounted cash flow analysis, which considers forecasted cash flows discounted at an appropriate discount rate, to determine the fair value of each reporting unit. We generally believe that market participants would use a discounted cash flow analysis to determine the fair value of our reporting units in a sale transaction. The annual goodwill impairment test requires us to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon our long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While we use the best available information to prepare our cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, our overall methodology and the population of assumptions used have remained unchanged.
The quantitative impairment test for indefinite-lived intangibles other than goodwill (certain trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. We estimate the fair value of our indefinite-lived intangibles using the relief from royalty method. We believe the relief from royalty method is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.
We completed our required annual impairment tests of goodwill and indefinite-lived intangible assets in the fourth quarter of the fiscal years ended September 30, 2019, 2018, and 2017. We recorded a goodwill impairment of $59.7 million in our Profarma reporting unit in connection with our fiscal 2018 annual impairment test (see Note 5 of the Notes to Consolidated Financial Statements). No goodwill impairments were recorded in the fiscal years ended September 30, 2019 and 2017. No indefinite-lived intangible impairments were recorded in the fiscal years ended September 30, 2019, 2018, and 2017.
We perform a recoverability assessment of our long-lived assets when impairment indicators are present.
PharMEDium's long-lived assets were tested for recoverability in fiscal 2019 and 2018 due to the existence of impairment indicators. After U.S. Food and Drug Administration ("FDA") inspections of PharMEDium compounding facilities, we voluntarily suspended production activities in December 2017 at our largest compounding facility located in Memphis, Tennessee pending execution of certain remedial measures. On May 17, 2019, PharMEDium reached an agreement on the terms of a consent decree (the "Consent Decree") with the FDA and the Consumer Protection Branch of the Civil Division of the Department of Justice ("DOJ") that was entered by the United States District Court for the Northern District of Illinois on May 22, 2019. The Consent Decree permits commercial operations to continue at PharMEDium’s Dayton, New Jersey and Sugar Land, Texas compounding facilities and administrative operations to continue at its Lake Forest, Illinois headquarters subject to compliance with requirements set forth therein. As required by the Consent Decree, initial audit inspections were conducted by an independent cGMP expert of the Dayton and Sugar Land facilities. The cGMP expert has notified the FDA that all of the short-term corrective actions taken are acceptable. PharMEDium has submitted to the FDA several additional longer-term corrective actions, and the independent cGMP expert will assess the effectiveness of the implementation of these items in future audits. Additional audit inspections by the independent cGMP expert of the Sugar Land and Dayton facilities are also required at least annually for a period of four years.

35

The Consent Decree also establishes requirements that must be satisfied prior to the resumption of commercial operations at the Memphis, Tennessee facility. The requirements include a work plan approved by the FDA and an audit inspection and certification by an independent cGMP expert that the facilities, methods and controls at the Memphis facility and PharMEDium’s Lake Forest, Illinois headquarters comply with the Consent Decree. If PharMEDium receives written notification from the FDA of compliance with the requirements to resume operations at the Memphis facility, additional audit inspections are required for five years, during which time PharMEDium must correct any deviations from the Consent Decree observed by the independent cGMP expert.
After five years, PharMEDium may petition the district court for full relief from the Consent Decree, or for specific relief with regard to one or more facilities. If, at the time of such petition, all obligations under the Consent Decree with respect to the specific facilities for which PharMEDium is seeking relief have been satisfied, and there has been continuous compliance with the Consent Decree for at least five years, the federal government will not oppose the petition, and PharMEDium may request that the district court grant such relief.
As a result of the suspension of production activities at PharMEDium's compounding facility located in Memphis, Tennessee and the aforementioned regulatory matters, we performed a recoverability assessment of PharMEDium's long-lived assets and recorded a $570.0 million impairment loss in the quarter ended March 31, 2019 for the amount that the carrying value of the PharMEDium asset group exceeded its fair value. Prior to the impairment, the carrying value of the asset group was $792 million. The fair value of the asset group was $222 million as of March 31, 2019. The PharMEDium asset group is included in the Pharmaceutical Distribution Services reportable segment. Significant assumptions used in estimating the fair value of PharMEDium's asset group included (i) a 15% discount rate, which contemplated a higher risk at PharMEDium; (ii) the period in which PharMEDium will resume production at or near capacity; and (iii) the estimated EBITDA (earnings before interest, taxes, depreciation, and amortization) margins when considering the likelihood of higher operating and compliance costs. We believe that our fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment are inherently uncertain and include assumptions that could differ from actual results in future periods. This represents a Level 3 nonrecurring fair value measurement. We allocated $522.1 million of the impairment to finite-lived intangibles ($420.8 million of customer relationships, $79.9 million of a trade name, and $21.4 million of software technology) and $47.9 million of the impairment to property and equipment.
We updated our recoverability assessment of PharMEDium’s long-lived assets as of September 30, 2019. We concluded that PharMEDium’s long-lived assets were recoverable as of September 30, 2019.
Income Taxes
Our income tax expense, deferred tax assets and liabilities, and uncertain tax positions reflect management's assessment of estimated future taxes to be paid on items in the financial statements. Deferred income taxes arise from temporary differences between financial reporting and tax reporting bases of assets and liabilities, as well as net operating loss and tax credit carryforwards for tax purposes.
We have established a valuation allowance against certain deferred tax assets for which the ultimate realization of future benefits is uncertain. Expiring carryforwards and the required valuation allowances are adjusted annually. After application of the valuation allowances described above, we anticipate that no limitations will apply with respect to utilization of any of the other deferred income tax assets described above.
We prepare and file tax returns based upon our interpretation of tax laws and regulations and record estimates based upon these judgments and interpretations. In the normal course of business, our tax returns are subject to examination by various taxing authorities. Such examinations may result in future tax and interest assessments by these taxing authorities. Inherent uncertainties exist in estimates of tax contingencies due to changes in tax law resulting from legislation, regulation, and/or as concluded through the various jurisdictions' tax court systems. Significant judgment is exercised in applying complex tax laws and regulations across multiple global jurisdictions where we conduct our operations. We recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based upon the technical merits of the position.
We believe that our estimates for the valuation allowances against deferred tax assets and the amount of benefits recognized in our financial statements for uncertain tax positions are appropriate based upon current facts and circumstances. However, others applying reasonable judgment to the same facts and circumstances could develop a different estimate and the amount ultimately paid upon resolution of issues raised may differ from the amounts accrued.
The significant assumptions and estimates described in the preceding paragraphs are important contributors to the ultimate effective tax rate in each year. If any of our assumptions or estimates were to change, an increase or decrease in our effective tax rate by 1% on income before income taxes would have caused income tax expense to change by $9.7 million in the fiscal year ended September 30, 2019.

36

For a complete discussion on the impact of the 2017 Tax Act, refer to Note 4 of the Notes to Consolidated Financial Statements.
Inventories
Inventories are stated at the lower of cost or market. Cost for approximately 75% of our inventories as of September 30, 2019 and 2018 has been determined using the LIFO method. If we had used the first-in, first-out method of inventory valuation, which approximates current replacement cost, inventories would have been approximately $1,511.8 million and $1,534.4 million higher than the amounts reported as of September 30, 2019 and 2018, respectively. We recorded LIFO credits of $22.5 million and $157.8 million in the fiscal years ended September 30, 2019 and 2017, respectively. We recorded LIFO expense of $67.3 million in the fiscal year ended September 30, 2018. The annual LIFO provision is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences, many of which are difficult to predict. Changes to any of the above factors can have a material impact to our annual LIFO provision.
Loss Contingencies
In the ordinary course of business, we become involved in lawsuits, administrative proceedings, government subpoenas, government investigations, and other disputes, including antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought in some matters, and some matters may require years to resolve. We record a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. We also perform an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, we provide disclosure of the loss contingency in the footnotes to our financial statements. We review all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made. Among the loss contingencies we considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 13 of the Notes to Consolidated Financial Statements. Although we are not able to predict the outcome or reasonably estimate a range of possible losses in these matters, an adverse judgment or negotiated resolution in any of these matters could have a material adverse effect on our results of operations, consolidated financial position, cash flows or liquidity.
Liquidity and Capital Resources
The following illustrates our debt structure as of September 30, 2019, including availability under the multi-currency revolving credit facility, the receivables securitization facility, the revolving credit note, and the overdraft facility:
(in thousands)
 
Outstanding
Balance
 
Additional
Availability
Fixed-Rate Debt:
 
 

 
 

$500,000, 3.50% senior notes due 2021
 
$
498,908

 
$
—

$500,000, 3.40% senior notes due 2024
 
497,744

 
—

$500,000, 3.25% senior notes due 2025
 
496,311

 
—

$750,000, 3.45% senior notes due 2027
 
743,099

 
—

$500,000, 4.25% senior notes due 2045
 
494,514

 
—

$500,000, 4.30% senior notes due 2047
 
492,488

 
—

Nonrecourse debt
 
75,196

 
—

Total fixed-rate debt
 
3,298,260

 
—

 
 
 
 
 
Variable-Rate Debt:
 
 

 
 

Revolving credit note
 
—

 
75,000

Term loan due 2020
 
399,778

 
—

Overdraft facility due 2021 (£30,000)
 
32,573

 
4,314

Receivables securitization facility due 2022
 
350,000

 
1,100,000

Multi-currency revolving credit facility due 2024
 
—

 
1,400,000

Nonrecourse debt
 
92,281

 
—

Total variable-rate debt
 
874,632

 
2,579,314

Total debt
 
$
4,172,892

 
$
2,579,314


37

Our operating results have generated cash flows, which, together with availability under our debt agreements and credit terms from suppliers, have provided sufficient capital resources to finance working capital and cash operating requirements, and to fund capital expenditures, acquisitions, repayment of debt, the payment of interest on outstanding debt, dividends, and repurchases of shares of our common stock.
 Our primary ongoing cash requirements will be to finance working capital, fund the repayment of debt, fund the payment of interest on debt, fund repurchases of our common stock, fund the payment of dividends, finance acquisitions, and fund capital expenditures and routine growth and expansion through new business opportunities. Future cash flows from operations and borrowings are expected to be sufficient to fund our ongoing cash requirements.
As discussed in the Risk Factors and in Note 13 of the Notes to Consolidated Financial Statements, we are a party to discussions with the objective of reaching potential terms of a broad resolution of the remaining opioid-litigation and claims. Although we are not able to predict the outcome or reasonably estimate a range of possible losses in these matters, an adverse judgment or negotiated resolution in any of these matters could have a material adverse impact on our financial position, cash flows or liquidity.
As of September 30, 2019 and 2018, our cash and cash equivalents held by foreign subsidiaries were $826.8 million and $842.5 million, respectively, and are generally based in U.S. dollar denominated holdings. Our position is that we are not permanently reinvested with respect to foreign subsidiaries whose undistributed earnings are able to be repatriated with minimal to no additional tax impact. In fiscal year ended September 30, 2019, we repatriated $350.0 million of cash held by foreign subsidiaries to use for general corporate purposes.
We have increased seasonal needs related to our inventory build during the December and March quarters that, depending on our cash balance, may require the use of our credit facilities to fund short-term capital needs. Our cash balance in the fiscal years ended September 30, 2019 and 2018 needed to be supplemented by intra-period credit facility borrowings to cover short-term working capital needs. The largest amount of intra-period borrowings under our revolving and securitization credit facilities that was outstanding at any one time during the fiscal years ended September 30, 2019 and 2018 was $240.6 million and $1,508.2 million, respectively. We had $606.0 million, $25,115.3 million, and $9,324.7 million of cumulative intra-period borrowings that were repaid under our credit facilities during the fiscal years ended September 30, 2019, 2018, and 2017, respectively.
In December 2017, we issued $750 million of 3.45% senior notes due December 15, 2027 (the "2027 Notes") and $500 million of 4.30% senior notes due December 15, 2047 ("the 2047 Notes"). The 2027 Notes were sold at 99.76% of the principal amount and have an effective yield of 3.48%. The 2047 Notes were sold at 99.51% of the principal amount and have an effective yield of 4.33%. Interest on the 2027 Notes and the 2047 Notes is payable semi-annually in arrears and commenced on June 15, 2018.
We used the proceeds from the 2027 Notes and the 2047 Notes to finance the early retirement of our $400 million of 4.875% senior notes that were due in 2019, including the payment of a $22.3 million prepayment premium, and to finance the acquisition of H.D. Smith, which was completed in January 2018.
In the fiscal year ended September 30, 2017, we repaid the $600 million of 1.15% senior notes that became due, and we repaid $150.0 million of amounts outstanding under our Term Loans (defined below).
We have a $1.4 billion multi-currency senior unsecured revolving credit facility ("Multi-Currency Revolving Credit Facility") with a syndicate of lenders, which was scheduled to expire in October 2023. In September 2019, we entered into an amendment to, among other things, extend the maturity to September 2024. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based upon our debt rating and ranges from 70 basis points to 112.5 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (91 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee as of September 30, 2019) and from 0 basis points to 12.5 basis points over the alternate base rate and Canadian prime rate, as applicable. We pay facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based upon our debt rating, ranging from 5 basis points to 12.5 basis points, annually, of the total commitment (9 basis points as of September 30, 2019). We may choose to repay or reduce our commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which we were compliant as of September 30, 2019.
We have a commercial paper program whereby we may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase our borrowing capacity as it is fully backed by our Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under our commercial paper program as of September 30, 2019 and 2018.

38

We have a $1,450 million receivables securitization facility ("Receivables Securitization Facility"), which was scheduled to expire in October 2021. In September 2019, we entered into an amendment to extend the maturity to September 2022. We have available to us an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based upon prevailing market rates for short-term commercial paper or LIBOR plus a program fee. We pay a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of September 30, 2019.
In April 2019, we elected to repay $150.0 million of our outstanding Receivables Securitization Facility balance prior to the scheduled maturity date.
In connection with the Receivables Securitization Facility, AmerisourceBergen Drug Corporation sells on a revolving basis certain accounts receivable to Amerisource Receivables Financial Corporation, a wholly-owned special purpose entity, which in turn sells a percentage ownership interest in the receivables to financial institutions and commercial paper conduits sponsored by financial institutions. AmerisourceBergen Drug Corporation is the servicer of the accounts receivable under the Receivables Securitization Facility. As sold receivables are collected, additional receivables may be sold up to the maximum amount available under the facility. We use the facility as a financing vehicle because it generally offers an attractive interest rate relative to other financing sources.
We have an uncommitted, unsecured line of credit available to us pursuant to a revolving credit note ("Revolving Credit Note"). The Revolving Credit Note provides us with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million. The Revolving Credit Note may be decreased or terminated by the bank or us at any time without prior notice. We also have a £30 million uncommitted U.K. overdraft facility ("Overdraft Facility"), which expires in February 2021, to fund short-term, normal trading cycle fluctuations related to our MWI business.
In October 2018, we refinanced $400 million of outstanding term loans by issuing a new $400 million variable-rate term loan ("October 2018 Term Loan"), which matures in October 2020. The October 2018 Term Loan bears interest at a rate equal to a base rate or LIBOR, plus a margin of 65 basis points. The October 2018 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we were compliant as of September 30, 2019
In addition to the 2027 Notes and the 2047 Notes, both of which were issued in the fiscal year ended September 30, 2018, we have $500 million of 3.50% senior notes due November 15, 2021, $500 million of 3.40% senior notes due May 15, 2024, $500 million of 3.25% senior notes due March 1, 2025, and $500 million of 4.25% senior notes due March 1, 2045 (collectively, the "Notes"). Interest on the Notes is payable semiannually in arrears.
Nonrecourse debt is comprised of short-term and long-term debt belonging to the Brazil subsidiaries and is repaid solely from the Brazil subsidiaries' cash flows and such debt agreements provide that the repayment of the loans (and interest thereon) is secured solely by the capital stock, physical assets, contracts, and cash flows of the Brazil subsidiaries.
In September 2016, we entered into an Accelerated Share Repurchase ("ASR") transaction with a financial institution and paid $400.0 million for shares of our common stock. The initial payment of $400.0 million funded stock purchases of $380.0 million and a share holdback of $20.0 million. The ASR transaction was settled in November 2016, at which time the financial institution delivered additional shares to us. The number of shares ultimately received was based upon the volume-weighted average price of our common stock during the term of the ASR. We applied the $400.0 million ASR to the May 2016 share repurchase program. During the fiscal year ended September 30, 2017, we purchased an additional $118.8 million of our common stock to complete our authorization under this program.
In November 2016, our board of directors authorized a share repurchase program allowing us to purchase up to $1.0 billion in shares of our common stock, subject to market conditions. During the fiscal year ended September 30, 2017, we purchased $211.1 million under this share repurchase program. During the fiscal year ended September 30, 2018, we purchased $663.1 million of our common stock under this program, which included $24.0 million of September 2018 purchases that cash settled in October 2018. During the fiscal year ended September 30, 2019, we purchased $125.8 million of our common stock under this program, which excluded $24.0 million of September 2018 purchases that cash settled in October 2018, to complete our authorization under this program.
In October 2018, our board of directors authorized a new share repurchase program allowing us to purchase up to $1.0 billion of our shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2019, we purchased $538.9 million of our common stock under this program, which included $14.8 million of September 2019 purchases that cash settled in October 2019. As of September 30, 2019, we had $461.1 million of availability remaining under this program.

39

The following is a summary of our contractual obligations for future principal and interest payments on our debt, minimum rental payments on our noncancelable operating leases and financing obligations, and minimum payments on our other commitments as of September 30, 2019:

Payments Due by Period (in thousands)
 
Debt, Including Interest Payments
 
Operating
Leases
 
Financing Obligations 1
 
Other Commitments
 
Total
Within 1 year
 
$
260,630

 
$
94,958

 
$
22,468

 
$
107,167

 
$
485,223

1-3 years
 
1,584,747

 
156,226

 
66,704

 
64,575

 
1,872,252

4-5 years
 
710,156

 
119,884

 
71,226

 
56,023

 
957,289

After 5 years
 
3,291,377

 
177,267

 
270,410

 
105,105

 
3,844,159

Total
 
$
5,846,910

 
$
548,335

 
$
430,808

 
$
332,870

 
$
7,158,923

 
 
 
 
 
 
 
 
 
 
 
1 Represents the portion of future minimum lease payments relating to facility leases where we were determined to be the accounting owner (see Note 1 of the Notes to Consolidated Financial Statements). These payments are recognized as reductions to the financing obligation and as interest expense and exclude the future non-cash termination of the financing obligation.

The 2017 Tax Act requires a one-time transition tax to be recognized on historical foreign earnings and profits. We currently estimate that our liability related to the transition tax is $182.6 million, net of overpayments and tax credits, as of September 30, 2019, which is payable in installments over a six-year period commencing in January 2021. The transition tax commitment is included in "Other Commitments" in the above table.
Our liability for uncertain tax positions was $124.2 million (including interest and penalties) as of September 30, 2019. This liability represents an estimate of tax positions that we have taken in our tax returns which may ultimately not be sustained upon examination by taxing authorities. Since the amount and timing of any future cash settlements cannot be predicted with reasonable certainty, the estimated liability has been excluded from the above contractual obligations table.
During the fiscal years ended September 30, 2019 and 2018, our operating activities provided cash of $2,344.0 million and $1,411.4 million, respectively. Cash provided by operations in the fiscal year ended September 30, 2019 was principally the result of an increase in accounts payable of $1,561.0 million, non-cash items of $1,120.7 million, and net income of $854.1 million, offset in part by an increase in accounts receivable of $1,241.9 million. The increase in accounts payable was primarily driven by the timing of scheduled payments to suppliers. Non-cash items were comprised primarily of a $570 million impairment of PharMEDium's long-lived assets (see Note 1 of the Notes to Consolidated Financial Statements), $321.1 million of depreciation expense, and $176.4 million of amortization expense. The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers.
Deterioration of general economic conditions, among other factors, could adversely affect the number of prescriptions that are filled and the amount of pharmaceutical products purchased by consumers and, therefore, could reduce purchases by our customers. In addition, volatility in financial markets may also negatively impact our customers' ability to obtain credit to finance their businesses on acceptable terms. Reduced purchases by our customers or changes in the ability of our customers to remit payments to us could adversely affect our revenue growth, our profitability, and our cash flow from operations.
We use days sales outstanding, days inventory on hand, and days payable outstanding to evaluate our working capital performance. The below financial metrics are calculated based upon an annual average and can be impacted by the timing of cash receipts and disbursements, which can vary significantly depending upon the day of the week in which the month ends.
 
 
Fiscal Year Ended September 30,
 
 
2019
 
2018
 
2017
Days sales outstanding
 
25.2
 
24.5
 
23.8
Days inventory on hand
 
28.4
 
29.9
 
30.1
Days payable outstanding
 
57.6
 
56.7
 
57.4
Our cash flows from operating activities can vary significantly from period to period based upon fluctuations in our period end working capital. Additionally, any changes to payment terms with a significant customer or manufacturer supplier could have a material impact to our cash flows from operations. Operating cash flows during the fiscal year ended September 30, 2019 included $167.4 million of interest payments and $117.7 million of income tax payments, net of refunds. Operating cash flows during the fiscal year ended September 30, 2018 included $162.1 million of interest payments and $104.0 million of income tax payments, net of refunds. Operating cash flows during the fiscal year ended September 30, 2017 included $125.3 million of interest payments and $105.0 million of income tax payments, net of refunds.

40

During the fiscal years ended September 30, 2018 and 2017, our operating activities provided cash of $1,411.4 million and $1,504.1 million, respectively. Cash provided by operations in the fiscal year ended September 30, 2018 was principally the result of net income of $1,615.9 million, an increase in accounts payable of $859.0 million, an increase in income taxes payable of $209.9 million, offset in part by an increase in accounts receivable of $657.8 million and a decrease in accrued expenses and other liabilities of $551.1 million. The increase in accounts payable was primarily driven by the timing of scheduled payments to our suppliers. The increase in income taxes payable was primarily driven by a one-time transition tax on historical foreign earnings and profits through December 31, 2017 in connection with tax reform. The decrease in accrued expenses was primarily driven by the payment of a legal settlement of $625.0 million, plus interest (see Note 13 of the Notes to the Consolidated Financial Statements). The increase in accounts receivable was the result of our revenue growth and the timing of payments from our customers. Non-cash items were comprised primarily of a $795.5 million deferred income tax benefit, $318.5 million of depreciation expense, and $191.6 million of amortization expense. The deferred income tax benefit was primarily the result of applying a lower U.S. federal income tax rate to our net deferred tax liabilities as of December 31, 2017 in connection with tax reform.
Capital expenditures in the fiscal years ended September 30, 2019, 2018, and 2017 were $310.2 million, $336.4 million, and $466.4 million, respectively. Significant capital expenditures in fiscal 2019 included costs associated with the construction of a new support facility and technology initiatives, including costs related to enhancing and upgrading our information technology systems. Significant capital expenditures in fiscal 2018 and 2017 included technology initiatives, including costs related to enhancing and upgrading our information technology systems and costs associated with expanding distribution capacity.
We currently expect to spend approximately $400 million for capital expenditures during fiscal 2020. Larger 2020 capital expenditures will include costs related to new facilities and various technology initiatives.
We acquired businesses to support our animal health business for $54.0 million and $70.0 million in the fiscal years ended September 30, 2019 and 2018, respectively. In the fiscal year ended September 30, 2018, we acquired H.D. Smith, the largest independent pharmaceutical wholesaler in the United States, for $815.0 million. In addition, we made incremental investments in Brazil totaling $78.1 million. The cash used for the above investments was offset by $179.6 million of cash consolidated in connection with the Brazil investments (see Note 2 of the Notes to Consolidated Financial Statements).
Net cash used in financing activities in the fiscal year ended September 30, 2019 principally resulted from $674.0 million in purchases of our common stock, and $339.0 million in cash dividends paid on our common stock.
Net cash used in financing activities in the fiscal year ended September 30, 2018 principally included the early retirement of the $400 million of 4.875% senior notes, $639.2 million in purchases of our common stock, and $333.0 million in cash dividends paid on our common stock, offset in part by the issuance of $750.0 million of 3.45% senior notes and $500 million of 4.3% senior notes.
Net cash provided by financing activities in the fiscal year ended September 30, 2017 primarily included the $600.0 million repayment of our 1.15% senior notes, $329.9 million in purchases of our common stock, and $320.3 million in cash dividends paid on our common stock.
Our board of directors approved the following quarterly dividend increases:
Dividend Increases
 
 
Per Share
 
 
Date
 
New Rate
 
Old Rate
 
% Increase
November 2016
 
$0.365
 
$0.340
 
7%
November 2017
 
$0.380
 
$0.365
 
4%
November 2018
 
$0.400
 
$0.380
 
5%
We anticipate that we will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of our board of directors and will depend upon our future earnings, financial condition, capital requirements, and other factors.
Market Risk
We have market risk exposure to interest rate fluctuations relating to our debt. We manage interest rate risk by using a combination of fixed-rate and variable-rate debt. The amount of variable-rate debt fluctuates during the year based on our working capital requirements. We had $0.9 billion of variable-rate debt outstanding as of September 30, 2019. We periodically evaluate financial instruments to manage our exposure to fixed and variable interest rates. However, there are no assurances that such instruments will be available in the combinations we want and/or on terms acceptable to us. There were no such financial instruments in effect as of September 30, 2019.

41

We also have market risk exposure to interest rate fluctuations relating to our cash and cash equivalents. We had $3,374.2 million in cash and cash equivalents as of September 30, 2019. The unfavorable impact of a hypothetical decrease in interest rates on cash and cash equivalents would be partially offset by the favorable impact of such a decrease on variable-rate debt. For every $100 million of cash invested that is in excess of variable-rate debt, a 10 basis point decrease in interest rates would increase our annual net interest expense by $0.1 million. 
We have minimal exposure to foreign currency and exchange rate risk from our non-U.S. operations. Our largest exposure to foreign exchange rates exists primarily with the Euro, the U.K. Pound Sterling, the Canadian Dollar, and the Brazilian Real. Revenue from our foreign operations is approximately two percent of our consolidated revenue. We may utilize foreign currency denominated forward contracts to hedge against changes in foreign exchange rates. We may use derivative instruments to hedge our foreign currency exposure, but not for speculative or trading purposes.



42

Cautionary Note Regarding Forward-Looking Statements
Certain of the statements contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," "intend," "plan," "continue," "sustain," "synergy," "on track," "believe," "seek," "estimate," "anticipate," "may," "possible," "assume," variations of such words, and similar expressions are intended to identify such forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel and pharmaceutical compounding; declining reimbursement rates for pharmaceuticals; continued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of alleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of the multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and the Company, including principally with respect to the pharmaceutical distribution agreement and/or the global generic purchasing services arrangement; changes in tax laws or legislative initiatives that could adversely affect the Company’s tax positions and/or the Company’s tax liabilities or adverse resolution of challenges to the Company’s tax positions; regulatory or enforcement action in connection with the production, labeling or packaging of products compounded by our compounded sterile preparations (CSP) business or the related consent decree; suspension of production of CSPs, including continued suspension at PharMEDium's Memphis facility; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market volatility and disruption; the loss, bankruptcy or insolvency of a major supplier; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; natural disasters or other unexpected events that affect the Company’s operations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations or PharMEDium), resulting in a charge to earnings; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, including the integration of PharMEDium, or the inability to capture all of the anticipated synergies related thereto or to capture the anticipated synergies within the expected time period; the Company's ability to manage and complete divestitures; the disruption of the Company’s cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Company’s business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) elsewhere in this Management's Discussion and Analysis of Financial Condition and Results of Operations, (ii) in Item 1A (Risk Factors), (iii) Item 1 (Business), (iv) elsewhere in this report, and (v) in other reports filed by the Company pursuant to the Securities Exchange Act. The Company undertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities laws.
ITEM 7A.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company's most significant market risks are the effects of changing interest rates, foreign currency risk, and the changes in the price of the Company's common stock. See discussion on page 41 under the heading "Market Risk," which is incorporated by reference herein.


43

ITEM 8.    FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

44

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Stockholders and Board of Directors of AmerisourceBergen Corporation

Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of AmerisourceBergen Corporation and subsidiaries (the Company) as of September 30, 2019 and 2018, the related consolidated statements of operations, comprehensive income, stockholders' equity, and cash flows for each of the three years in the period ended September 30, 2019, and the related notes and financial statement schedule listed in the Index at Item 15(a) (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at September 30, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended September 30, 2019, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of September 30, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated November 19, 2019 expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
 
Legal Contingencies
Description of the Matter
As discussed in Note 13 of the consolidated financial statements, the Company is involved in lawsuits, administrative proceedings, government subpoenas, government investigations and other disputes. The Company recognizes a liability for those legal contingencies for which it is probable that a liability has been incurred at the date of the consolidated financial statements and the amount is reasonably estimable. The Company also performs an assessment of the materiality of legal contingencies where a loss is either reasonably possible or it is reasonably possible that an exposure to loss exists in excess of the amount accrued. If it is reasonably possible that such a loss or an additional loss may have been incurred and the effect on the consolidated financial statements is material, the Company discloses the nature of the loss contingency and an estimate of the possible loss or range of loss or a statement that such an estimate cannot be made within the notes to the consolidated financial statements.
 
 

    





45

 
For example, as of September 30, 2019, a significant number of counties, municipalities, and other governmental entities in a majority of U.S. states and Puerto Rico, as well as several states and tribes, have filed lawsuits in various federal, state and other courts against pharmaceutical wholesale distributors (including the Company and its subsidiary AmerisourceBergen Drug Corporation ("ABDC")), pharmaceutical manufacturers, retail chains, medical practices, and physicians relating to the distribution of prescription opioid pain medications ("opioid matters"). Other lawsuits regarding the distribution of prescription opioid pain medications have been filed by other parties. While the Company is currently engaged in negotiations with plaintiffs’ representatives regarding a potential settlement framework, it continues to litigate the opioid matters. The Company has not recognized a liability related to the potential framework as of September 30, 2019.
 
 
 
Auditing management's determination of whether a loss for a legal contingency is probable and reasonably estimable, reasonably possible or remote, and the related disclosures, is highly subjective and requires significant judgment. For instance, auditing management's judgments related to the opioid matters was challenging due to the significant judgment applied in determining the likelihood of resolution of the opioid matters through settlement or litigation given the current status of negotiations with plaintiffs' representatives and the complexity and uncertainty associated with any potential settlement.
 
 
How We Addressed the Matter in Our Audit

We tested the Company's internal controls that address the risks of material misstatement related to the completeness, valuation, presentation and disclosure of legal contingencies. This included testing controls related to the Company's process for identification, recognition, measurement and disclosure of legal contingencies, including the opioid matters. For example, we tested controls over management’s review of correspondence from external legal counsel, historical legal settlements executed by the Company and those executed by other defendants, actions and statements made by the Company, and communications with the plaintiffs to determine the completeness and accuracy of legal contingencies and the related financial statement footnote disclosures. We also tested controls over management's assessment of the likelihood of the resolution of the opioid matters through settlement or litigation.
 
 
 
To test the Company's legal contingencies, our substantive audit procedures included, among others, testing the completeness of the legal contingencies subject to evaluation by the Company and evaluating the Company's analysis of its assessment of the probability of outcome for each material legal contingency through inspection of responses to inquiry letters sent to both internal and external legal counsel, discussions with internal and external legal counsel to confirm our understanding of the allegations, and obtaining written representations from executives of the Company. We also compared the Company's assessment with its relevant history of similar legal contingencies that have been settled or otherwise resolved to evaluate the consistency of the Company's assessment for outstanding legal contingencies at the balance sheet date. For example, for the opioid matters, we considered the litigation, claims or assessments, progress of the respective legal cases, communications with plaintiffs and the experience of other similar entities when evaluating the Company's conclusions.
 
 
 
For those legal contingencies for which the Company has determined that a loss is probable and reasonably estimable and is therefore required to be recognized, and for those legal contingencies for which the Company has determined that a loss is either probable or reasonably possible, but the Company is unable to estimate the range of loss, and is therefore required to be disclosed, we evaluated the method of measuring the amounts of the recorded and disclosed contingencies. We assessed the Company’s estimate of the amount of the loss, for both contingencies that are probable and reasonably possible, through inspection of responses to inquiry letters sent to both internal and external legal counsel, direct discussions with internal and external legal counsel, inspection of court rulings, and inspection of settlement agreements. We also obtained written representations from executives of the Company.
 
 










46

 
Goodwill - Identification of Reporting Units
Description of the Matter
The Company tests goodwill for impairment at the level of reporting referred to as a reporting unit. As discussed in Note 1 of the consolidated financial statements, the Company identified its reporting units based upon its management reporting structure. Goodwill arising from acquisitions has been assigned to the reporting unit or units as of the acquisition date that are expected to benefit from the synergies of the combination. When identifying its reporting units, the Company has aggregated two or more components within an operating segment that have similar economic characteristics.
 
 
 
The determination of whether two or more components within an operating segment have similar economic characteristics requires the Company to evaluate the characteristics of the respective components, which include the similarity of long-term gross margins, the nature of the products and services, the nature of the production processes, the type or class of customer, the methods used to distribute products or provide their services, and the nature of the regulatory environment. However, not each of these factors must be met for two components to be considered economically similar, and the considerations are not limited to these factors.
 
 
 
Auditing management's determination of reporting units is highly subjective and significant judgment is involved when evaluating whether two or more components have similar economic characteristics for purposes of aggregation into a single reporting unit. A change in the judgment used in the determination of a reporting unit could result in goodwill impairment.
 
 
How We Addressed the Matter in Our Audit
We tested the Company's internal controls related to management's identification of its reporting units. For example, we tested controls over management's review of documentation of the criteria assessed when determining whether one or more components within an operating segment have similar economic characteristics.
 
 
 
To test the Company's aggregation of two or more components within an operating segment into a single reporting unit, our substantive audit procedures included, among others, evaluating whether the aggregated components have similar economic characteristics. As part of our evaluation, we considered (i) the similarity of long-term gross margins of the aggregated components; (ii) the similarity of the nature of the regulatory environments of the aggregated components; (iii) the similarity of the products and services of the aggregated components; (iv) the similarity of the types or classes of customer of the aggregated components, and (v) the methods used to distribute products or provide services of the aggregated components. We corroborated the Company’s assessment of aggregation of components by reviewing reports used by segment management, including the financial performance of the respective components, to assess the aggregation criteria.
 
 
 
PharMEDium long-lived asset impairment
Description of the Matter

As discussed in Note 1 of the consolidated financial statements, the Company recognized an impairment loss on PharMEDium's long-lived assets. The continued suspension of production activities at PharMEDium’s compounding facility in Memphis, Tennessee, and further negotiations with the FDA and DOJ regarding a potential consent decree resulted in the Company revising its long-range plan and identifying an impairment indicator of the asset group. At March 31, 2019, the Company evaluated the PharMEDium long-lived assets for recoverability utilizing undiscounted cash flows that were based on the weighted average of multiple strategic alternatives and determined that the assets were not recoverable and were therefore impaired. As a result, the Company recognized a $570 million impairment loss, which represented the amount by which the carrying value exceeded the estimated fair value of these assets.
 
 
 
Auditing the Company's impairment loss on PharMEDium's long-lived assets was complex due to the significant estimation uncertainty in determining the fair value of the PharMEDium asset group. Significant assumptions used in the Company's fair value estimate of the PharMEDium asset group included (i) the discount rate; (ii) the period in which PharMEDium will resume production at or near capacity; (iii) estimated revenue growth rates; (iv) the estimated EBITDA (earnings before interest, taxes, depreciation, and amortization) margins when considering the likelihood of higher operating and compliance costs; and (v) future economic conditions and demand. Each of these assumptions was forward-looking and could have been affected by the outcome of the negotiations with the FDA and DOJ, the provisions of the final consent decree, the results of the third-party audits, and future economic conditions and demand.




47


How We Addressed the Matter in Our Audit

We tested the Company's internal controls over the process for the recognition and measurement of the long-lived asset impairment. For example, we tested controls over management’s review of the forecasted cash flows and their review of the significant assumptions and other inputs used in the fair value measurement, such as the discount rate.
 
 
 
To test the PharMEDium long-lived asset impairment loss, our substantive audit procedures included, among others, the performance of a sensitivity analysis of the assumptions to evaluate the change in the fair value of the PharMEDium asset group resulting from changes in the assumptions and therefore identify the assumptions that have the most significant impact on the fair value calculation. We involved valuation specialists to assist with our evaluation of the methodology used by the Company and significant assumptions used in the fair value measurement of the PharMEDium asset group, including the evaluation of the reasonableness of the discount rate selected by the Company. We compared the forecasted cash flows to business plans, current industry, market and economic trends, and information from discussions with management and external legal counsel about the status of negotiations with the FDA and DOJ, reviewed the provisions of the final consent decree and compared previous forecasts to actual results to assess the forecasted cash flows utilized in the fair value measurement.
 
 





 /s/ Ernst & Young LLP
 
 

We have served as the Company's auditor since 1985.
Philadelphia, Pennsylvania
November 19, 2019

48

AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
 
 
September 30,
(in thousands, except share and per share data)
 
2019
 
2018
ASSETS
 
 

 
 

Current assets:
 
 

 
 

Cash and cash equivalents
 
$
3,374,194

 
$
2,492,516

Accounts receivable, less allowances for returns and doubtful accounts:
2019 — $1,222,906; 2018 — $1,036,333
 
12,386,879

 
11,314,226

Inventories (Note 1)
 
11,060,254

 
11,918,508

Right to recover asset (Note 1)
 
1,147,483

 
—

Prepaid expenses and other
 
163,244

 
169,122

Total current assets
 
28,132,054

 
25,894,372

 
 
 
 
 
Property and equipment, at cost:
 
 

 
 

Land
 
44,142

 
39,875

Buildings and improvements
 
942,129

 
1,086,909

Machinery, equipment, and other
 
2,362,869

 
2,281,124

Total property and equipment
 
3,349,140

 
3,407,908

Less accumulated depreciation
 
(1,578,624
)
 
(1,515,484
)
Property and equipment, net
 
1,770,516

 
1,892,424

 
 
 
 
 
Goodwill
 
6,705,507

 
6,664,272

Other intangible assets
 
2,294,836

 
2,947,828

Other assets
 
269,067

 
270,942

 
 
 
 
 
TOTAL ASSETS
 
$
39,171,980

 
$
37,669,838

 
 
 
 
 
LIABILITIES AND STOCKHOLDERS' EQUITY
 
 

 
 

 
 
 
 
 
Current liabilities:
 
 

 
 

Accounts payable
 
$
28,385,074

 
$
26,836,873

Accrued expenses and other
 
1,057,208

 
881,157

Short-term debt
 
139,012

 
151,657

Total current liabilities
 
29,581,294

 
27,869,687

 
 
 
 
 
Long-term debt
 
4,033,880

 
4,158,532

Long-term financing obligation
 
320,518

 
352,296

Accrued income taxes
 
284,075

 
299,600

Deferred income taxes
 
1,860,195

 
1,829,410

Other liabilities
 
98,812

 
110,352

Commitments and contingencies (Note 13)
 


 


Stockholders' equity:
 
 

 
 

Common stock, $0.01 par value — authorized, issued, and outstanding:
2019 — 600,000,000 shares, 285,295,170 shares and 206,760,654 shares;
2018 — 600,000,000 shares, 283,588,463 shares and 213,217,882 shares
 
2,853

 
2,836

Additional paid-in capital
 
4,850,142

 
4,715,473

Retained earnings
 
4,235,491

 
3,720,582

Accumulated other comprehensive loss
 
(111,965
)
 
(79,253
)
Treasury stock, at cost: 2019 — 78,534,516 shares; 2018 — 70,370,581 shares
 
(6,097,604
)
 
(5,426,814
)
Total AmerisourceBergen Corporation stockholders' equity
 
2,878,917

 
2,932,824

Noncontrolling interest
 
114,289

 
117,137

Total equity
 
2,993,206

 
3,049,961

 
 


 


TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
 
$
39,171,980

 
$
37,669,838

See notes to consolidated financial statements.

49

AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

 
 
Fiscal Year Ended September 30,
(in thousands, except per share data)
 
2019
 
2018
 
2017
Revenue
 
$
179,589,121

 
$
167,939,635

 
$
153,143,826

Cost of goods sold
 
174,450,809

 
163,327,318

 
148,597,824

Gross profit
 
5,138,312

 
4,612,317

 
4,546,002

Operating expenses:
 
 

 
 

 
 

Distribution, selling, and administrative
 
2,663,508

 
2,460,301

 
2,128,730

Depreciation
 
294,965

 
283,971

 
237,100

Amortization
 
167,442

 
181,156

 
160,503

Employee severance, litigation, and other
 
330,474

 
183,520

 
959,327

Goodwill impairment
 
—

 
59,684

 
—

Impairment of long-lived assets (Note 1)
 
570,000

 
—

 
—

Operating income
 
1,111,923

 
1,443,685

 
1,060,342

Other (income) loss
 
(12,952
)
 
25,469

 
(2,730
)
Interest expense, net
 
157,769

 
174,699

 
145,185

Loss on consolidation of equity investments
 
—

 
42,328

 
—

Loss on early retirement of debt
 
—

 
23,766

 
—

Income before income taxes
 
967,106

 
1,177,423

 
917,887

Income tax expense (benefit)
 
112,971

 
(438,469
)
 
553,403

Net income
 
854,135

 
1,615,892

 
364,484

Net loss attributable to noncontrolling interest
 
1,230

 
42,513

 
—

Net income attributable to AmerisourceBergen Corporation
 
$
855,365

 
$
1,658,405

 
$
364,484

 
 
 
 
 
 
 
Earnings per share:
 
 

 
 

 
 

Basic
 
$
4.07

 
$
7.61

 
$
1.67

Diluted
 
$
4.04

 
$
7.53

 
$
1.64

 
 
 
 
 
 
 
Weighted average common shares outstanding:
 
 

 
 

 
 

Basic
 
210,165

 
217,872

 
218,375

Diluted
 
211,840

 
220,336

 
221,602

See notes to consolidated financial statements.


50

AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Net income
 
$
854,135

 
$
1,615,892

 
$
364,484

Other comprehensive (loss) income:
 
 

 
 

 
 

Foreign currency translation adjustments
 
(32,957
)
 
(36,904
)
 
16,540

Loss on consolidation of equity investments
 
—

 
45,941

 
—

Other
 
(271
)
 
(756
)
 
1,918

Total other comprehensive (loss) income
 
(33,228
)
 
8,281

 
18,458

Total comprehensive income
 
820,907

 
1,624,173

 
382,942

Comprehensive loss attributable to noncontrolling interest
 
1,746

 
50,829

 
—

Comprehensive income attributable to AmerisourceBergen Corporation
 
$
822,653

 
$
1,675,002

 
$
382,942

See notes to consolidated financial statements.

51

AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(in thousands, except per share data)
 
Common
Stock
 
Additional
Paid-in
Capital
 
Retained
Earnings
 
Accumulated
Other
Comprehensive
Loss
 
Treasury
Stock
 
Non-controlling Interest
 
Total
September 30, 2016
 
$
2,778

 
$
4,333,001

 
$
2,303,941

 
$
(114,308
)
 
$
(4,396,008
)
 
$
—

 
$
2,129,404

Adoption of ASU 2016-09 (see Note 1)
 
—

 
—

 
47,063

 
—

 
—

 
—

 
47,063

Net income
 
—

 
—

 
364,484

 
—

 
—

 
—

 
364,484

Other comprehensive income
 
—

 
—

 
—

 
18,458

 
—

 
—

 
18,458

Cash dividends, $1.46 per share
 
—

 
—

 
(320,270
)
 
—

 
—

 
—

 
(320,270
)
Exercises of stock options
 
25

 
102,898

 
—

 
—

 
—

 
—

 
102,923

Share-based compensation expense
 
—

 
62,206

 
—

 
—

 
—

 
—

 
62,206

Common stock purchases for employee stock purchase plan
 
—

 
(467
)
 
—

 
—

 
—

 
—

 
(467
)
Purchases of common stock
 
—

 
—

 
—

 
—

 
(329,929
)
 
—

 
(329,929
)
Settlement of accelerated share repurchase transaction
 
—

 
20,000

 
—

 
—

 
(20,000
)
 
—

 
—

Employee tax withholdings related to restricted share vesting
 
—

 
—

 
—

 
—

 
(9,411
)
 
—

 
(9,411
)
Other
 
3

 
(3
)
 
—

 
—

 
—

 
—

 
—

September 30, 2017
 
2,806

 
4,517,635

 
2,395,218

 
(95,850
)
 
(4,755,348
)
 
—

 
2,064,461

Consolidation of variable interest entity
 
—

 
—

 
—

 
—

 
—

 
167,966

 
167,966

Net income (loss)
 
—

 
—

 
1,658,405

 
—

 
—

 
(42,513
)
 
1,615,892

Other comprehensive income (loss)
 
—

 
—

 
—

 
16,597

 
—

 
(8,316
)
 
8,281

Cash dividends, $1.52 per share
 
—

 
—

 
(333,041
)
 
—

 
—

 
—

 
(333,041
)
Exercises of stock options
 
27

 
138,429

 
—

 
—

 
—

 
—

 
138,456

Share-based compensation expense
 
—

 
62,316

 
—

 
—

 
—

 
—

 
62,316

Common stock purchases for employee stock purchase plan
 
—

 
(341
)
 
—

 
—

 
—

 
—

 
(341
)
Purchases of common stock
 
—

 
—

 
—

 
—

 
(663,220
)
 
—

 
(663,220
)
Employee tax withholdings related to restricted share vesting
 
—

 
—

 
—

 
—

 
(8,246
)
 
—

 
(8,246
)
Other
 
3

 
(2,566
)
 
—

 
—

 
—

 
—

 
(2,563
)
September 30, 2018
 
2,836

 
4,715,473

 
3,720,582

 
(79,253
)
 
(5,426,814
)
 
117,137

 
3,049,961

Adoption of ASC 606 (Note 1)
 
—

 
—

 
(1,482
)
 
—

 
—

 
(1,102
)
 
(2,584
)
Net income (loss)
 
—

 
—

 
855,365

 
—

 
—

 
(1,230
)
 
854,135

Other comprehensive loss
 
—

 
—

 
—

 
(32,712
)
 
—

 
(516
)
 
(33,228
)
Cash dividends, $1.60 per share
 
—

 
—

 
(338,974
)
 
—

 
—

 
—

 
(338,974
)
Exercises of stock options
 
15

 
76,219

 
—

 
—

 
—

 
—

 
76,234

Share-based compensation expense
 
—

 
58,874

 
—

 
—

 
—

 
—

 
58,874

Purchases of common stock
 
—

 
—

 
—

 
—

 
(664,803
)
 
—

 
(664,803
)
Employee tax withholdings related to restricted share vesting
 
—

 
—

 
—

 
—

 
(5,987
)
 
—

 
(5,987
)
Other
 
2

 
(424
)
 
—

 
—

 
—

 
—

 
(422
)
September 30, 2019
 
$
2,853

 
$
4,850,142

 
$
4,235,491

 
$
(111,965
)
 
$
(6,097,604
)
 
$
114,289

 
$
2,993,206

See notes to consolidated financial statements.

52

AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOW
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
OPERATING ACTIVITIES
 
 

 
 

 
 

Net income
 
$
854,135

 
$
1,615,892

 
$
364,484

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
 
 
 

Depreciation, including amounts charged to cost of goods sold
 
321,102

 
318,483

 
262,420

Amortization, including amounts charged to interest expense
 
176,410

 
191,626

 
169,911

Provision for doubtful accounts
 
25,196

 
16,660

 
8,934

Provision (benefit) for deferred income taxes
 
28,537

 
(795,524
)
 
319,069

Share-based compensation expense
 
58,874

 
62,316

 
62,206

LIFO (credit) expense
 
(22,544
)
 
67,324

 
(157,782
)
Impairment of long-lived assets
 
570,000

 
—

 
—

Gain on sale of an equity investment
 
(13,692
)
 
—

 
—

Goodwill impairment
 
—

 
59,684

 
—

Impairment of non-customer note receivable
 
—

 
30,000

 
—

Loss on consolidation of equity investments
 
—

 
42,328

 
—

Loss on early retirement of debt
 
—

 
23,766

 
—

Other
 
(23,193
)
 
(19,078
)
 
7,744

Changes in operating assets and liabilities, excluding the effects of acquisitions and
divestitures:
 
 

 
 

 
 

Accounts receivable
 
(1,241,890
)
 
(657,770
)
 
(1,277,896
)
Inventories
 
(167,990
)
 
(4,923
)
 
(431,454
)
Prepaid expenses and other assets
 
(6,733
)
 
(57,211
)
 
33,646

Accounts payable
 
1,561,048

 
859,036

 
1,473,389

Income taxes payable
 
(13,353
)
 
209,899

 
27,192

Accrued expenses and other liabilities
 
238,116

 
(551,120
)
 
642,275

NET CASH PROVIDED BY OPERATING ACTIVITIES
 
2,344,023

 
1,411,388

 
1,504,138

INVESTING ACTIVITIES
 
 

 
 

 
 

Capital expenditures
 
(310,222
)
 
(336,411
)
 
(466,397
)
Cost of acquired companies, net of cash acquired
 
(63,951
)
 
(785,299
)
 
(61,648
)
Cost of equity investments
 
—

 
—

 
(11,347
)
Proceeds from sale of business
 
—

 
—

 
12,094

Proceeds from sales of investment securities available-for-sale
 
—

 
—

 
74,778

Purchases of investment securities available-for-sale
 
—

 
—

 
(48,635
)
Other
 
(1,659
)
 
10,596

 
3,114

NET CASH USED IN INVESTING ACTIVITIES
 
(375,832
)
 
(1,111,114
)
 
(498,041
)
FINANCING ACTIVITIES
 
 

 
 

 
 

Senior notes and other loan borrowings
 
506,948

 
1,314,430

 
—

Senior notes and other loan repayments
 
(510,863
)
 
(681,001
)
 
(750,000
)
Borrowings under revolving and securitization credit facilities
 
640,126

 
25,129,704

 
9,336,400

Repayments under revolving and securitization credit facilities
 
(769,284
)
 
(25,127,438
)
 
(9,335,953
)
Payment of premium on early retirement of debt
 
—

 
(22,348
)
 
—

Purchases of common stock
 
(674,031
)
 
(639,235
)
 
(329,929
)
Exercises of stock options
 
76,234

 
138,456

 
102,923

Cash dividends on common stock
 
(338,974
)
 
(333,041
)
 
(320,270
)
Tax withholdings related to restricted share vesting
 
(5,987
)
 
(8,246
)
 
(9,411
)
Other
 
(10,682
)
 
(14,154
)
 
(6,574
)
NET CASH USED IN FINANCING ACTIVITIES
 
(1,086,513
)
 
(242,873
)
 
(1,312,814
)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
 
881,678

 
57,401

 
(306,717
)
Cash and cash equivalents at beginning of year
 
2,492,516

 
2,435,115

 
2,741,832

CASH AND CASH EQUIVALENTS AT END OF YEAR
 
$
3,374,194

 
$
2,492,516

 
$
2,435,115


See notes to consolidated financial statements.

53

AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2019
Note 1. Summary of Significant Accounting Policies
AmerisourceBergen Corporation and its subsidiaries, including less than wholly-owned subsidiaries in which AmerisourceBergen Corporation has a controlling financial interest (the "Company"), is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company delivers innovative programs and services designed to improve the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.
Basis of Presentation
The accompanying financial statements present the consolidated financial position, results of operations, and cash flows of the Company as of the dates and for the periods indicated. All intercompany accounts and transactions have been eliminated in consolidation.
The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts due to uncertainties inherent in such estimates. Management periodically evaluates estimates used in the preparation of the financial statements for continued reasonableness. Certain reclassifications have been made to prior-period amounts in order to conform to the current year presentation.
Recently Adopted Accounting Pronouncements
In March 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"). ASU 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are exercised. It also allows an employer to repurchase more of an employee's shares for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 was effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. On October 1, 2016, the Company early adopted ASU 2016-09, which resulted in a cumulative adjustment to retained earnings and the establishment of a deferred tax asset of $47.1 million for previously unrecognized tax benefits. The Company elected to adopt the Statement of Cash Flows presentation of the excess tax benefits prospectively.
In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)" ("ASU 2014-09"). ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification ("ASC") 605 - "Revenue Recognition" and most industry-specific guidance throughout the Codification. ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard's core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. 
In March 2016, the FASB issued ASU No. 2016-08, "Revenue from Contracts with Customers (Topic 606) - Principal versus Agent Considerations" ("ASU 2016-08"), which clarified the implementation guidance for principal versus agent considerations in ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10, "Revenue from Contracts with Customers (Topic 606) - Identifying Performance Obligations and Licensing" ("ASU 2016-10"), which amended the guidance in ASU 2014-09 related to identifying performance obligations and accounting for licenses of intellectual property. The Company was required to adopt ASU 2016-08 and ASU 2016-10 with ASU 2014-09, collectively ASC 606.
The Company adopted ASC 606 as of October 1, 2018 on a modified retrospective basis for all open contracts as of October 1, 2018. The adoption had an immaterial impact on the Company's October 1, 2018 retained earnings and will not have a material impact on the Company's revenues, results of operations, or cash flows. The Company did not record any material contract assets, contract liabilities, or deferred contract costs in its Consolidated Balance Sheet upon adoption.
The Company elected the practical expedient to expense costs to obtain a contract when incurred when the amortization period would have been one year or less. Additionally, the Company elected the practical expedients to not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for services performed, and (iii) for contracts for which the variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation.


54

For the Company's revenue recognition policy, refer to the "Revenue Recognition" section of Note 1.
Recently Issued Accounting Pronouncements Not Yet Adopted
 In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)" ("ASU 2016-02" or "ASC 842")). ASU 2016-02 aims to increase transparency and comparability across organizations by requiring lease assets and lease liabilities to be recognized on the balance sheet as well as key information to be disclosed regarding lease arrangements. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018 and interim periods within those fiscal years.
The Company will adopt ASC 842 in the first quarter of fiscal 2020 and will adopt using the modified retrospective approach. The Company will elect the transition package of practical expedients provided within the amended guidance, which eliminates the requirements to reassess lease identification, lease classification, and initial direct costs for leases that commenced before the effective date. The Company will also elect to combine lease and non-lease components and to exclude short-term leases from its consolidated balance sheets. The Company did not elect the hindsight practical expedient in determining the lease term.
The adoption of the amended guidance is expected to have a material impact on the consolidated balance sheet from the recognition of lease assets and liabilities. While the Company continues to finalize the impact of adoption, it anticipates recognizing operating lease liabilities of approximately $550 million based on the present value of the remaining minimum lease commitments using the Company's incremental borrowing rates as of the effective date. The Company will also record corresponding right-of-use ("ROU") assets based upon the operating lease liabilities adjusted for prepaid and deferred rents. Upon adoption, the Company will also derecognize assets and liabilities associated with leased assets where the Company was deemed the owner of the leased assets for accounting purposes. The difference between the derecognized assets and liabilities will be recognized as a net of tax cumulative adjustment to retained earnings. The Company is finalizing the impact that the amended lease guidance will have on its consolidated financial statements, systems, processes, and internal controls. The Company does not expect that the adoption of ASC 842 will have a material impact on its results of operations or cash flows.
In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectibility of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. ASU 2016-13 is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years, and a modified retrospective approach is required, with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. Entities are permitted to adopt the standard early in fiscal years beginning after December 15, 2018. The Company is currently evaluating the impact of adopting this new accounting guidance.
As of September 30, 2019, there were no other recently issued accounting standards that may have a material impact on the Company's financial position, results of operations, or cash flows upon their adoption.
Business Combinations
The assets acquired and liabilities assumed from the acquired business are recorded at fair value, with the residual of the purchase price recorded as goodwill. The results of operations of the acquired businesses are included in the Company's operating results from the dates of acquisition.
Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.
Concentrations of Credit Risk and Allowance for Doubtful Accounts
The Company sells its inventories to a large number of customers in the healthcare industry that include institutional and retail healthcare providers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physician offices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies, pharmacy departments of supermarkets and mass merchandisers, and veterinarians. The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.
The Company's trade accounts receivables are exposed to credit risk. Revenue from the various agreements and arrangements with the Company's largest customer in the fiscal year ended September 30, 2019, Walgreens Boots Alliance, Inc.

55

("WBA"), accounted for approximately 34% of revenue and represented approximately 49% of accounts receivable, net of incentives, as of September 30, 2019. Express Scripts, Inc., the Company's second largest customer in the fiscal year ended September 30, 2019, accounted for approximately 13% of revenue and represented approximately 8% of accounts receivable as of September 30, 2019. The Company generally does not require collateral for trade receivables. In determining the appropriate allowance for doubtful accounts, the Company considers a combination of factors, such as the aging of trade receivables, industry trends, and its customers' financial strength, credit standing, and payment and default history. Changes in these factors, among others, may lead to adjustments in the Company's allowance for doubtful accounts. The calculation of the required allowance requires judgment by Company management as to the impact of those and other factors on the ultimate realization of its trade receivables. Each of the Company's business units performs ongoing credit evaluations of its customers' financial condition and maintains reserves for probable bad debt losses based upon historical experience and for specific credit problems when they arise. There were no significant changes to this process during the fiscal years ended September 30, 2019, 2018, and 2017, and bad debt expense was computed in a consistent manner during these periods.
The Company maintains cash and cash equivalents with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and, therefore, bear minimal credit risk. The Company seeks to mitigate such risks by monitoring the risk profiles of these counterparties. The Company also seeks to mitigate risk by monitoring the investment strategy of money market accounts in which it is invested, which are classified as cash equivalents.
Contingencies
Loss Contingencies: In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, and other disputes, including antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, the Company provides disclosure of the loss contingency in the notes to its financial statements. The Company reviews all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made. Among the loss contingencies that the Company considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 13. Although the Company is not able to predict the outcome or reasonably estimate a range of possible losses in these matters, an adverse judgment or negotiated resolution in any of these matters could have a material adverse effect on the Company's results of operations, consolidated financial position, cash flows or liquidity.
Gain Contingencies: The Company records gain contingencies when they are realized. Gains from antitrust litigation settlements are realized upon the receipt of cash and recorded as a reduction to cost of goods sold because they represent a recovery of amounts historically paid to manufacturers to originally acquire the pharmaceuticals that were the subject of the antitrust litigation settlements (see Note 14).
Derivative Financial Instruments
The Company records all derivative financial instruments on the balance sheet at fair value and complies with established criteria for designation and effectiveness of hedging relationships. The Company's policy prohibits it from entering into derivative financial instruments for speculative or trading purposes.
Foreign Currency
When the functional currency of the Company's foreign operations is the applicable local currency, assets and liabilities are translated into U.S. dollars using the current exchange rates in effect at the balance sheet date, while revenues and expenses are translated at the weighted average exchange rates for the period. The resulting translation adjustments are recorded as a component of Accumulated Other Comprehensive Loss within Stockholders' Equity.

56

Goodwill and Other Intangible Assets
Goodwill arises from acquisitions or consolidations of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. The Company identifies its reporting units based upon the Company's management reporting structure, beginning with its operating segments. The Company aggregates two or more components within an operating segment that have similar economic characteristics. The Company evaluates whether the components within its operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment. The Company's reporting units include Pharmaceutical Distribution Services, Profarma Distribuidora de Produtos Farmacêuticos S.A. ("Profarma"), AmerisourceBergen Consulting Services ("ABCS"), World Courier, and MWI Animal Health ("MWI").
Goodwill and other intangible assets with indefinite lives, such as certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, the Company can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite-lived intangible assets, respectively. Such qualitative factors can include, among others, industry and market conditions, overall financial performance, and relevant entity-specific events. If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis. The Company elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2019, with the exception of its testing of goodwill in the Profarma reporting unit. In the fourth quarter of fiscal 2018 and 2017, the Company elected to bypass performing the qualitative assessment and went directly to performing our annual quantitative assessments of the goodwill and indefinite-lived intangible assets.
The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized. If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.
When performing a quantitative impairment assessment, the Company utilizes an income-based approach to value its reporting units, with the exception of the Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium. The income-based approach relies on a discounted cash flow analysis, which considers forecasted cash flows discounted at an appropriate discount rate, to determine the fair value of each reporting unit. The Company generally believes that market participants would use a discounted cash flow analysis to determine the fair value of the Company's reporting units in a sale transaction. The annual goodwill impairment test requires the Company to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon the Company's long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While the Company uses the best available information to prepare its cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged.
The quantitative impairment test for indefinite-lived intangibles other than goodwill (certain trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method. The Company believes the relief from royalty method is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.
The Company completed its required annual impairment tests relating to goodwill and indefinite-lived intangible assets in the fourth quarter of the fiscal years ended September 30, 2019, 2018, and 2017. The Company recorded a goodwill impairment of $59.7 million in its Profarma reporting unit in connection with its fiscal 2018 annual impairment test (see Note 5). No goodwill impairments were recorded in the fiscal years ended September 30, 2019 and 2017. No indefinite-lived intangible asset impairments were recorded in the fiscal years ended September 30, 2019, 2018, and 2017.
Finite-lived intangible assets are amortized using the straight-line method over the estimated useful lives of the assets. The Company performs a recoverability assessment of its long-lived assets when impairment indicators are present.
After U.S. Food and Drug Administration ("FDA") inspections of PharMEDium Healthcare Holdings, Inc.'s ("PharMEDium") compounding facilities, the Company voluntarily suspended production activities in December 2017 at its largest

57

compounding facility located in Memphis, Tennessee pending execution of certain remedial measures. On May 17, 2019, PharMEDium reached an agreement on the terms of a consent decree (the "Consent Decree") with the FDA and the Consumer Protection Branch of the Civil Division of the Department of Justice ("DOJ") that was entered by the United States District Court for the Northern District of Illinois on May 22, 2019. The Consent Decree permits commercial operations to continue at PharMEDium’s Dayton, New Jersey and Sugar Land, Texas compounding facilities and administrative operations to continue at its Lake Forest, Illinois headquarters subject to compliance with requirements set forth therein. As required by the Consent Decree, initial audit inspections were conducted by an independent current Good Manufacturing Practice ("cGMP") expert of the Dayton and Sugar Land facilities. The cGMP expert has notified FDA that all of the short-term corrective actions taken are acceptable. The Company has submitted to FDA several additional longer-term corrective actions, and the independent cGMP expert will assess the effectiveness of the implementation of these items in future audits. Additional audit inspections by the independent cGMP expert of the Sugar Land and Dayton facilities are also required at least annually for a period of four years.
The Consent Decree also establishes requirements that must be satisfied prior to the resumption of commercial operations at the Memphis, Tennessee facility. The requirements include a work plan approved by the FDA and an audit inspection and certification by an independent cGMP expert that the facilities, methods and controls at the Memphis facility and PharMEDium’s Lake Forest, Illinois headquarters comply with the Consent Decree. If PharMEDium receives written notification from the FDA of compliance with the requirements to resume operations at the Memphis facility, additional audit inspections are required for five years, during which time PharMEDium must correct any deviations from the Consent Decree observed by the independent cGMP expert.
After five years, PharMEDium may petition the district court for full relief from the Consent Decree, or for specific relief with regard to one or more facilities. If, at the time of such petition, all obligations under the Consent Decree with respect to the specific facilities for which PharMEDium is seeking relief have been satisfied, and there has been continuous compliance with the Consent Decree for at least five years, the federal government will not oppose the petition, and PharMEDium may request that the district court grant such relief.
As a result of the suspension of production activities at PharMEDium's compounding facility located in Memphis, Tennessee and the aforementioned regulatory matters, the Company performed a recoverability assessment of PharMEDium's long-lived assets and recorded a $570.0 million impairment loss in the quarter ended March 31, 2019 for the amount that the carrying value of the PharMEDium asset group exceeded its fair value. Prior to the impairment, the carrying value of the asset group was $792 million. The fair value of the asset group was $222 million as of March 31, 2019. The PharMEDium asset group is included in the Pharmaceutical Distribution Services reportable segment. Significant assumptions used in estimating the fair value of PharMEDium's asset group included (i) a 15% discount rate, which contemplated a higher risk at PharMEDium; (ii) the period in which PharMEDium will resume production at or near capacity; and (iii) the estimated EBITDA (earnings before interest, taxes, depreciation, and amortization) margins when considering the likelihood of higher operating and compliance costs. The Company believes that its fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment are inherently uncertain and include assumptions that could differ from actual results in future periods. This represents a Level 3 nonrecurring fair value measurement. The Company allocated $522.1 million of the impairment to finite-lived intangibles ($420.8 million of customer relationships, $79.9 million of a trade name, and $21.4 million of software technology) and $47.9 million of the impairment to property and equipment.
The Company updated its recoverability assessment of PharMEDium's long-lived assets as of September 30, 2019. The Company concluded that PharMEDium’s long-lived assets were recoverable as of September 30, 2019.
Income Taxes
The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities (commonly known as the asset and liability method). In assessing the need to establish a valuation allowance on deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.
The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based upon the technical merits of the position. Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.

58

Inventories
Inventories are stated at the lower of cost or market. Cost for approximately 75% of the Company's inventories as of September 30, 2019 and 2018 has been determined using the last-in, first-out ("LIFO") method. If the Company had used the first-in, first-out method of inventory valuation, which approximates current replacement cost, inventories would have been approximately $1,511.8 million and $1,534.4 million higher than the amounts reported as of September 30, 2019 and 2018, respectively. The Company recorded LIFO credits of $22.5 million and $157.8 million in the fiscal years ended September 30, 2019 and 2017, respectively, and LIFO expense of $67.3 million in the fiscal year ended September 30, 2018. The annual LIFO provision is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences, many of which are difficult to predict. Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.
Investments
The Company first evaluates its investments in accordance with the variable interest model to determine whether it has a controlling financial interest in an investment. This evaluation is made as of the date on which the Company makes its initial investment, and subsequent evaluations are made if the structure of the investment changes. If it has determined that an investment is a variable interest entity ("VIE"), the Company evaluates whether the VIE is required to be consolidated. When the Company holds rights that give it the power to direct the activities of an entity that most significantly impact the entity's economic performance, combined with the obligation to absorb an entity's losses and the right to receive benefits, the Company consolidates a VIE. If it is determined that an investment is not a VIE, the Company then evaluates its investments under the voting interest model and generally consolidates investments in which it holds an ownership interest of greater than 50%. When the Company consolidates less than wholly-owned subsidiaries, it discloses its noncontrolling interest in its consolidated financial statements.
For equity securities without a readily determinable fair value, the Company uses the fair value measurement alternative and measures the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which the Company can exercise significant influence but does not control, it uses the equity method of accounting. The Company's share of earnings and losses is recorded in Other Income (Loss) in the Consolidated Statements of Operations. The Company monitors its investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions.
Leases
The Company is often involved in the construction of its distribution facilities. In certain cases, the Company makes payments for certain structural components included in the lessor's construction of the leased assets, which result in the Company being deemed the owner of the leased assets for accounting purposes. As a result, regardless of the significance of the payments, Accounting Standards Codification 840, Leases, ("ASC 840") defines those payments as automatic indicators of ownership and requires the Company to capitalize the lessor's total project cost with a corresponding financing obligation. Upon completion of the lessor's project, the Company performs a sale-leaseback analysis pursuant to ASC 840 to determine if these assets and the related financing obligations can be derecognized from the Company's Consolidated Balance Sheet. If the Company is deemed to have "continuing involvement," the leased assets and the related financing obligations remain on the Company's Consolidated Balance Sheet and are amortized over the life of the assets and the lease term, respectively. All other leases are considered operating leases in accordance with ASC 840. Assets subject to an operating lease and the related lease payments are not recorded on the Company's Consolidated Balance Sheet. Rent expense is recognized on a straight-line basis over the expected lease term and is recorded in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations.
Manufacturer Incentives
The Company considers fees and other incentives received from its suppliers relating to the purchase or distribution of inventory to represent product discounts, and, as a result, they are recognized within cost of goods sold upon the sale of the related inventory.
Property and Equipment
Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 40 years for buildings and improvements and from 3 to 10 years for machinery, equipment, and other. The costs of repairs and maintenance are charged to expense as incurred.
The Company capitalizes project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application development stage. Costs that are associated with preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred. Software development costs are depreciated using the straight-line method over the estimated useful lives, which range from 3 to 10 years.

59

Revenue Recognition
The Company's revenues are primarily generated from the distribution of pharmaceutical products. The Company also generates revenues from global commercialization services, which include clinical trial support, post-approval and commercialization support, and global specialty transportation and logistics for the biopharmaceutical industry. See Note 15 for the Company's disaggregated revenue.

The Company recognizes revenue related to the distribution of products at a point in time when title and control transfers to customers and there is no further obligation to provide services related to such products. Service revenue is recognized over the period that services are provided to the customer. The Company is generally the principal in a transaction; therefore, revenue is primarily recorded on a gross basis. When the Company is the principal in a transaction, it has determined that it controls the ability to direct the use of the product or service prior to the transfer to a customer, it is primarily responsible for fulfilling the promise to provide the product or service to its customer, it has discretion in establishing pricing, and it controls the relationship with the customer. Revenue is recognized at the amount of consideration expected to be received. For the distribution business, revenue is primarily generated from a contract related to a confirmed purchase order with a customer in a distribution arrangement and is net of estimated sales returns and allowances, other customer incentives, and sales tax.
The Company's customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. The Company records an accrual for estimated customer sales returns at the time of sale to the customer based upon historical return trends. As of September 30, 2019 and 2018, the Company's accrual for estimated customer sales returns was $1,147.5 million and $988.8 million, respectively. In fiscal 2019, due to the adoption of ASC 606, the Company records an asset for the right to recover products from its customers in Right to Recover Asset on its Consolidated Balance Sheet. The Company's asset for the right to recover products from its customers was included in Inventories on its Consolidated Balance Sheet as of September 30, 2018 and for all prior periods.
Share-Based Compensation
The Company accounts for the compensation cost of all share-based payments at fair value. The Company estimates the fair value of option grants using a binomial option pricing model. The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company’s common stock.
Share-based compensation expense is recognized over the requisite service period within Distribution, Selling, and Administrative in the Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees. Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.
The income tax effects of awards are recognized when the awards vest or are settled and are recognized in Income Tax Expense in the Company’s Consolidated Statements of Operations and in cash flows from operations in the Consolidated Statements of Cash Flows. Prior to fiscal 2017, tax benefits from share-based compensation were recorded as adjustments to Additional Paid-in Capital within Stockholders’ Equity and as cash flows from financing activities within the Statement of Cash Flows (see Recently Adopted Accounting Pronouncements).
Shipping and Handling Costs
Shipping and handling costs include all costs to warehouse, pick, pack, and deliver inventory to customers. These costs, which were $619.7 million, $590.8 million, and $517.3 million for the fiscal years ended September 30, 2019, 2018, and 2017, respectively, are included in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations.
Supplier Reserves
The Company establishes reserves against amounts due from its suppliers relating to various price and rebate incentives, including deductions or billings taken against payments otherwise due to them from the Company. These reserve estimates are established based upon the judgment of Company management after carefully considering the status of current outstanding claims, historical experience with the suppliers, the specific incentive programs, and any other pertinent information available to the Company. The Company evaluates the amounts due from its suppliers on a continual basis and adjusts the reserve estimates when appropriate based upon changes in factual circumstances. The ultimate outcome of any outstanding claim may be different than the Company's estimate.

60

Note 2. Acquisitions and Investments
NEVSCO
In December 2017, the Company acquired Northeast Veterinary Supply Company ("NEVSCO") for $70.0 million. NEVSCO was an independent, regional distributor of veterinary pharmaceuticals and medical supplies serving primarily the northeast region of the United States and strengthens MWI Animal Health's ("MWI") support of independent veterinary practices and provides even greater value and care to current and future animal health customers. NEVSCO is included within the MWI operating segment.
The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their fair values on the date of the acquisition. The purchase price exceeded the fair value of the net tangible and intangible assets acquired by $30.4 million, which was allocated to goodwill. The fair value of accounts receivable, inventory, and accounts payable and accrued expenses acquired was $8.5 million, $6.7 million, and $2.9 million, respectively. The fair value of the intangible assets acquired of $29.8 million primarily consisted of customer relationships, which the Company is amortizing over its estimated useful life of 15 years. Goodwill and intangible assets resulting from the acquisition are deductible for income tax purposes.
H.D. Smith
In January 2018, the Company acquired H.D. Smith Holding Company ("H.D. Smith") for $815.0 million. The Company funded the acquisition through the issuance of new long-term debt (see Note 6). H.D. Smith was the largest independent pharmaceutical wholesaler in the United States and provides full-line distribution of brand, generic, and specialty drugs, as well as high-value services and solutions for manufacturers and healthcare providers. H.D. Smith's customers included retail pharmacies, specialty pharmacies, long-term care facilities, institutional/hospital systems, and independent physicians and clinics. The acquisition strengthens the Company's core business, expands and enhances its strategic scale in pharmaceutical distribution, and expands the Company's support for independent community pharmacies. H.D. Smith has been integrated into the Pharmaceutical Distribution reportable segment.
The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their fair values on the date of acquisition. The purchase price exceeded the fair value of the net tangible and intangible assets acquired by $499.9 million, which was allocated to goodwill. The fair value of accounts receivable, inventory, and accounts payable and accrued expenses acquired was $163.1 million, $350.7 million, and $366.1 million, respectively. The fair value of the intangible assets acquired of $167.8 million consisted of customer relationships of $156.6 million and a tradename of $11.2 million. The Company is amortizing the fair value of the customer relationships and the tradename over their estimated useful lives of 12 years and 2 years, respectively. The Company established a deferred tax liability of $60.6 million primarily in connection with the intangible assets acquired. Goodwill and intangible assets resulting from the acquisition are not deductible for income tax purposes.
Profarma and Specialty Joint Venture
As of September 30, 2017, the Company held a noncontrolling ownership interest in Profarma, a leading pharmaceutical wholesaler in Brazil, and an ownership interest in a joint venture with Profarma to provide specialty distribution and services to the Brazilian marketplace (the "specialty joint venture"). The Company had accounted for these interests as equity method investments, which were reported in Other Assets on the Company's Consolidated Balance Sheets. In January 2018, the Company invested an additional $62.5 million in Profarma and an additional $15.6 million in the specialty joint venture to increase its ownership interests to 38.2% and 64.5%, respectively. In connection with the additional investment in Profarma, the Company received substantial governance rights, thereby requiring it to begin consolidating the operating results of Profarma as of March 31, 2018 (see Note 3). The Company also began to consolidate the operating results of the specialty joint venture as of March 31, 2018 due to its majority ownership interest. In September 2018, the Company made an additional investment of $23.6 million in the specialty joint venture to increase its ownership interest to 89.9%. Profarma and the specialty joint venture are included within the Pharmaceutical Distribution Services reportable segment and Other, respectively.
The fair value of Profarma, including the noncontrolling interest, was determined based upon an agreed-upon stock price and was allocated to the underlying assets and liabilities consolidated based upon their fair values at the time of the January 2018 investment. The fair value of Profarma upon obtaining control exceeded the fair value of the net tangible and intangible assets consolidated by $142.0 million, which was allocated to goodwill. The fair value of accounts receivable, inventory, accounts payable and accrued expenses was $160.1 million, $190.5 million, and $167.7 million, respectively. The Company consolidated short-term debt and long-term debt of $209.9 million and $12.4 million, respectively, cash of $150.8 million, and recorded a noncontrolling interest of $168.0 million. The estimated fair value of the intangible assets consolidated of $84.6 million consisted of customer relationships of $25.9 million and a tradename of $58.7 million. The Company is amortizing the customer relationships over its estimated useful life of 15 years and the tradenames over their estimated useful lives of between 15 years and 25 years. The Company established a deferred tax liability of $50.1 million primarily in connection with the intangible assets that were recognized. Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.

61

The fair value of the specialty joint venture was determined based upon the cost of the incremental ownership percentage acquired from the January 2018 investment and was allocated to the underlying assets and liabilities consolidated based upon their fair values at the time of the January 2018 investment. The fair value of the specialty joint venture exceeded the fair value of the net tangible and intangible assets consolidated by $3.5 million, which was allocated to goodwill. The fair value of accounts receivable, inventory, accounts payable and accrued expenses was $65.0 million, $29.1 million, and $54.3 million, respectively. The Company consolidated short-term debt and cash of $32.7 million and $28.9 million, respectively. The estimated fair value of the intangible assets consolidated of $4.6 million is being amortized over its estimated useful life of 15 years. Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.
In connection with the incremental January 2018 Brazil investments, the Company adjusted the carrying values of its previously held equity interests in Profarma and the specialty joint venture to equal their fair values, which were determined to be $103.1 million and $31.2 million, respectively. These represent Level 2 nonrecurring fair value measurements. The adjustments resulted in a pretax loss of $42.3 million in fiscal 2018 and were comprised of foreign currency translation adjustments from Accumulated Other Comprehensive Loss of $45.9 million, a $12.4 million gain on the remeasurement of Profarma's previously held equity interest, and an $8.8 million loss on the remeasurement of the specialty joint venture's previously held equity interest.
Note 3. Variable Interest Entity
As discussed in Note 2, the Company made an additional investment in Profarma in January 2018. In connection with this investment, the Company obtained substantial governance rights, allowing it to direct the activities that significantly impact Profarma’s economic performance. As such, the Company consolidated the operating results of Profarma in its consolidated financial statements as of and for the periods ended September 30, 2019 and September 30, 2018. The Company is not obligated to provide future financial support to Profarma.
The following assets and liabilities of Profarma are included in the Company's Consolidated Balance Sheet:
(in thousands)
 
September 30,
2019
 
September 30,
2018
Cash and cash equivalents
 
$
9,431

 
$
26,801

Accounts receivables, net
 
154,491

 
144,646

Inventories
 
185,602

 
168,931

Prepaid expenses and other
 
64,119

 
61,924

Property and equipment, net
 
30,961

 
32,667

Goodwill
 
82,309

 
82,309

Other intangible assets
 
74,429

 
80,974

Other long-term assets
 
9,169

 
8,912

Total assets
 
$
610,511

 
$
607,164

 
 
 
 
 
Accounts payable
 
$
165,053

 
$
150,102

Accrued expenses and other
 
49,191

 
37,195

Short-term debt
 
106,439

 
115,461

Long-term debt
 
60,973

 
39,704

Deferred income taxes
 
42,371

 
46,137

Other long-term liabilities
 
5,303

 
31,988

Total liabilities
 
$
429,330

 
$
420,587


Profarma's assets can only be used to settle its obligations, and its creditors do not have recourse to the general credit of the Company.
Note 4. Income Taxes
The following table summarizes the Company's income before income taxes for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Domestic
 
$
336,150

 
$
704,935

 
$
394,721

Foreign
 
630,956

 
472,488

 
523,166

Total
 
$
967,106

 
$
1,177,423

 
$
917,887



62

The components of the Company's consolidated income tax expense (benefit) are summarized in the following table for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Current provision:
 
 

 
 

 
 

Federal
 
$
(12,801
)
 
$
247,755

 
$
141,071

State and local
 
15,246

 
39,328

 
35,950

Foreign
 
81,989

 
69,972

 
57,313

Total current provision
 
84,434

 
357,055

 
234,334

Deferred provision (benefit):
 
 

 
 

 
 

Federal
 
61,819

 
(828,023
)
 
265,074

State and local
 
(31,086
)
 
33,887

 
54,995

Foreign
 
(2,196
)
 
(1,388
)
 
(1,000
)
Total deferred provision (benefit)
 
28,537

 
(795,524
)
 
319,069

Provision (benefit) for income taxes
 
$
112,971

 
$
(438,469
)
 
$
553,403


A reconciliation of the statutory U.S. federal income tax rate to the Company's consolidated effective income tax rate is as follows for the periods indicated:
 
Fiscal Year Ended September 30,
 
2019
 
2018
 
2017
Statutory U.S. federal income tax rate
21.0%
 
24.5%
 
35.0%
State and local income tax rate, net of federal tax benefit
2.4
 
(0.1)
 
5.4
Foreign tax rate differential
(6.7)
 
(6.2)
 
(14.6)
Valuation allowance
—
 
(1.4)
 
2.2
Excess tax benefits related to share-based compensation
(0.8)
 
(1.8)
 
(3.8)
Litigation settlements and accruals (see Note 14)
0.1
 
(6.3)
 
34.3
Goodwill impairment (see Note 5)
—
 
1.7
 
—
Tax reform
(3.6)
 
(52.0)
 
—
Capital gain on distribution
—
 
3.6
 
—
Other
(0.7)
 
0.8
 
1.8
Effective income tax rate
11.7%
 
(37.2)%
 
60.3%

U.S. Tax Reform: Tax Cuts and Jobs Act
On December 22, 2017, the U.S. Tax Cuts and Jobs Act (the "2017 Tax Act") was signed into law. The 2017 Tax Act included a broad range of tax reform provisions affecting businesses, including lower corporate tax rates, changes in business deductions, and new international tax provisions. In response to the 2017 Tax Act, the U.S. Securities and Exchange Commission staff issued guidance regarding the accounting for income taxes associated with the 2017 Tax Act to allow companies to record provisional amounts during a one-year measurement period. For the fiscal year ended September 30, 2018, the Company recognized income tax benefits of $612.6 million on the Company's Consolidated Statements of Operations related to effects of the 2017 Tax Act, which consisted of a deferred income tax benefit of $897.6 million as a result of applying a lower U.S. federal income tax rate to the Company's net deferred tax liabilities as of December 31, 2017 and a one-time transition tax on historical foreign earnings and profits. In the fiscal year ended September 30, 2018, the Company initially recorded a current U.S. income tax expense of $285.0 million on historical foreign earnings and profits through December 31, 2017. The Company completed the accounting for the effects of the 2017 Tax Act in the fiscal quarter ended December 31, 2018 and recognized an income tax benefit of $37.0 million related to a decrease in its foreign earnings and profits through December 31, 2017 (the "transition tax"). The Company expects to pay $182.6 million related to the transition tax, which is net of overpayments and tax credits, over a six-year period commencing in January 2021. There were no adjustments recorded to deferred income taxes related to the 2017 Tax Act during the one-year measurement period.
Prior to the 2017 Tax Act, the Company intended to indefinitely reinvest its foreign cash in foreign investments and foreign operations. After further assessment of the impact of the 2017 Tax Act, the Company reevaluated its position and determined that it was no longer reinvested with respect to foreign subsidiaries whose undistributed earnings are able to be repatriated with minimal to no additional tax impact. Cumulative undistributed earnings of international subsidiaries were $2.4 billion as of

63

September 30, 2019, $1.6 billion of which is considered permanently reinvested. It is not practicable to estimate the taxes that would be due if such earnings were to be repatriated in the future.
Deferred income taxes reflect the future tax consequences of differences between the tax bases of assets and liabilities and their financial reporting amounts. Significant components of the Company's deferred tax liabilities (assets) are as follows:
 
 
September 30,
(in thousands)
 
2019
 
2018
Inventories
 
$
1,293,075

 
$
1,189,801

Property and equipment
 
143,851

 
133,417

Goodwill and other intangible assets
 
709,015

 
853,747

Other
 
1,892

 
747

Gross deferred tax liabilities
 
2,147,833

 
2,177,712

 
 
 
 
 
Net operating loss and tax credit carryforwards
 
(318,868
)
 
(421,808
)
Allowance for doubtful accounts
 
(22,544
)
 
(20,126
)
Accrued expenses
 
(33,312
)
 
(17,363
)
Employee and retiree benefits
 
(12,420
)
 
(10,210
)
Share-based compensation
 
(39,961
)
 
(28,888
)
Other
 
(60,215
)
 
(49,892
)
Gross deferred tax assets
 
(487,320
)
 
(548,287
)
Valuation allowance for deferred tax assets
 
199,682

 
199,985

Deferred tax assets, net of valuation allowance
 
(287,638
)
 
(348,302
)
Net deferred tax liabilities
 
$
1,860,195

 
$
1,829,410


The following tax net operating loss and credit carryforward information is presented as of September 30, 2019. The Company had $12.4 million of potential tax benefits from federal net operating loss carryforwards, which expire in 1 to 18 years, $171.0 million of potential tax benefits from state net operating loss carryforwards expiring in 1 to 20 years, and $58.7 million of potential tax benefits from foreign net operating loss carryforwards, which have varying expiration dates. The Company had $6.7 million of state tax credit carryforwards, $84.1 million in federal alternative minimum tax credit carryforwards, and $2.1 million in foreign alternative minimum tax credit carryforwards.
The Company assesses the available positive and negative evidence to determine whether deferred tax assets are more likely than not to be realized. As a result of this assessment, valuation allowances have been recorded on certain deferred tax assets. For the fiscal year ended September 30, 2019, the Company decreased the valuation allowance on deferred tax assets by $0.3 million primarily due to a legislative change which will enable the Company to utilize select net operating losses prospectively. This decrease was offset in part by the additional valuation allowances on certain state and foreign net operating loss carryforwards. In the fiscal year ended September 30, 2018, the Company decreased the valuation allowance on deferred tax assets by $11.1 million primarily due to the utilization of capital loss and foreign tax credit carryforwards for which a valuation allowance had been recorded.
In the fiscal year ended September 30, 2019, 2018, and 2017 tax benefits of $7.9 million, $22.7 million and $36.7 million, respectively, related to the exercise of employee stock options and lapses of restricted stock units were recorded in Income Tax Expense (Benefit) in the Company's Consolidated Statements of Operations. The tax benefits recognized in the fiscal years ended September 30, 2019, 2018, and 2017 are not necessarily indicative of amounts that may arise in future periods.
Income tax payments, net of refunds, were $117.7 million, $104.0 million, and $105.0 million in the fiscal years ended September 30, 2019, 2018, and 2017, respectively.
The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or foreign income tax examinations by tax authorities for years before 2015.
As of September 30, 2019 and 2018, the Company had unrecognized tax benefits, defined as the aggregate tax effect of differences between tax return positions and the benefits recognized in the Company's financial statements, of $124.2 million and $112.9 million, respectively ($95.0 million and $89.4 million, net of federal tax benefit, respectively). If recognized in the fiscal years ended September 30, 2019 and 2018, $76.8 million and $71.1 million, respectively, of these benefits would have reduced income tax expense and the effective tax rate. As of September 30, 2019 and 2018, included in the unrecognized tax benefits are

64

$18.6 million and $14.8 million of interest and penalties, respectively, which the Company records in Income Tax Expense (Benefit) in the Company's Consolidated Statements of Operations.
A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, for the periods indicated is as follows:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Unrecognized tax benefits at beginning of period
 
$
98,124

 
$
323,869

 
$
75,766

Additions of tax positions of the current year
 
18,819

 
2,804

 
252,866

Additions to tax positions of the prior years
 
751

 
558

 
1,049

Reductions of tax positions of the prior years
 
(10,317
)
 
(224,878
)
 
(668
)
Settlements with taxing authorities
 
—

 
(1,847
)
 
(3,285
)
Expiration of statutes of limitations
 
(1,720
)
 
(2,382
)
 
(1,859
)
Unrecognized tax benefits at end of period
 
$
105,657

 
$
98,124

 
$
323,869


Included in the additions of unrecognized tax positions in the fiscal year ended September 30, 2017 is approximately $235.1 million for an uncertain tax position related to the $625.0 million civil litigation reserve recognized during the fiscal year (see Note 13). In the fiscal year ended September 30, 2017, this reserve was considered to be non-deductible. In September 2018, the Company made a payment of $625.0 million, plus interest, to resolve this litigation and it was determined that a portion of the settlement was deductible. Accordingly, the Company reduced its uncertain tax position by $10.3 million and $224.9 million in the fiscal years ended September 30, 2019 and 2018, respectively. During the next 12 months, it is reasonably possible that state tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately $12.4 million.
Note 5. Goodwill and Other Intangible Assets
The following is a summary of the changes in the carrying value of goodwill, by reportable segment, for the fiscal years ended September 30, 2019 and 2018:
(in thousands)
 
Pharmaceutical
Distribution Services
 
Other
 
Total
Goodwill as of September 30, 2017
 
$
4,270,550

 
$
1,773,731

 
$
6,044,281

Goodwill recognized in connection with acquisitions
 
641,909

 
39,352

 
681,261

Goodwill impairment
 
(59,684
)
 
—

 
(59,684
)
Foreign currency translation
 
—

 
(1,586
)
 
(1,586
)
Goodwill as of September 30, 2018
 
4,852,775

 
1,811,497

 
6,664,272

Goodwill recognized in connection with acquisitions
 
—

 
43,418

 
43,418

Foreign currency translation
 
—

 
(2,183
)
 
(2,183
)
Goodwill as of September 30, 2019
 
$
4,852,775

 
$
1,852,732

 
$
6,705,507


In connection with the Company's annual goodwill impairment test as of July 1, 2018, the Company recorded a goodwill impairment of $59.7 million in its Profarma reporting unit. The fair value of the reporting unit was determined based upon Profarma's publicly-traded stock price, plus an estimated purchase premium. This represents a Level 2 nonrecurring fair value measurement.

65

The following is a summary of other intangible assets:
 
 
September 30, 2019
 
September 30, 2018
(dollars in thousands)
 
Weighted Average Remaining Useful Life
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
Indefinite-lived trade names
 
 
 
$
685,324

 
$
—

 
$
685,324

 
$
685,380

 
$
—

 
$
685,380

Finite-lived:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Customer relationships
 
14 years
 
1,931,212

 
(489,471
)
 
1,441,741

 
2,549,245

 
(555,440
)
 
1,993,805

Trade names and other
 
13 years
 
271,521

 
(103,750
)
 
167,771

 
397,946

 
(129,303
)
 
268,643

Total other intangible assets
 
 
 
$
2,888,057

 
$
(593,221
)
 
$
2,294,836

 
$
3,632,571

 
$
(684,743
)
 
$
2,947,828


Amortization expense for finite-lived intangible assets was $167.4 million, $181.2 million, and $160.5 million in the fiscal years ended September 30, 2019, 2018, and 2017, respectively. Amortization expense for finite-lived intangible assets is estimated to be $134.1 million in fiscal 2020, $130.2 million in fiscal 2021, $128.5 million in fiscal 2022, $127.2 million in fiscal 2023, $126.2 million in 2024, and $963.3 million thereafter.
Note 6. Debt
Debt consisted of the following:
 
 
September 30,
(in thousands)
 
2019
 
2018
Revolving credit note
 
$
—

 
$
—

Term loans due 2020
 
399,778

 
398,665

Overdraft facility due 2021 (£30,000)
 
32,573

 
13,269

Receivables securitization facility due 2022
 
350,000

 
500,000

Multi-currency revolving credit facility due 2024
 
—

 
—

$500,000, 3.50% senior notes due 2021
 
498,908

 
498,392

$500,000, 3.40% senior notes due 2024
 
497,744

 
497,255

$500,000, 3.25% senior notes due 2025
 
496,311

 
495,632

$750,000, 3.45% senior notes due 2027
 
743,099

 
742,258

$500,000, 4.25% senior notes due 2045
 
494,514

 
494,298

$500,000, 4.30% senior notes due 2047
 
492,488

 
492,222

Capital lease obligations
 
—

 
745

Nonrecourse debt
 
167,477

 
177,453

Total debt
 
4,172,892

 
4,310,189

Less AmerisourceBergen Corporation current portion
 
32,573

 
13,976

Less nonrecourse current portion
 
106,439

 
137,681

Total, net of current portion
 
$
4,033,880

 
$
4,158,532


Multi-Currency Revolving Credit Facility
The Company has a $1.4 billion multi-currency senior unsecured revolving credit facility ("Multi-Currency Revolving Credit Facility"), which was scheduled to expire in October 2023, with a syndicate of lenders. In September 2019, the Company entered into an amendment to, among other things, extend the maturity to September 2024. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based upon the Company's debt rating and ranges from 70 basis points to 112.5 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (91 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee as of September 30, 2019) and from 0 basis points to 12.5 basis points over the alternate base rate and Canadian prime rate, as applicable. The Company pays facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on its debt rating, ranging from 5 basis points to 12.5 basis points, annually, of the total commitment (9 basis points as of September 30, 2019). The Company may choose to repay or reduce its commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which the Company was compliant as of September 30, 2019.

66

Commercial Paper Program
The Company has a commercial paper program whereby it may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under the commercial paper program as of September 30, 2019 and 2018.
Receivables Securitization Facility
The Company has a $1,450 million receivables securitization facility ("Receivables Securitization Facility"), which was scheduled to expire in October 2021. In September 2019, the Company entered into an amendment to extend the maturity to September 2022. The Company has available to it an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based on prevailing market rates for short-term commercial paper or LIBOR, plus a program fee. The Company pays a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility.
In connection with the Receivables Securitization Facility, AmerisourceBergen Drug Corporation sells on a revolving basis certain accounts receivable to Amerisource Receivables Financial Corporation, a wholly-owned special purpose entity, which in turn sells a percentage ownership interest in the receivables to financial institutions and commercial paper conduits sponsored by financial institutions. AmerisourceBergen Drug Corporation is the servicer of the accounts receivable under the Receivables Securitization Facility. As sold receivables are collected, additional receivables may be sold up to the maximum amount available under the facility. The facility is a financing vehicle utilized by the Company because it generally offers an attractive interest rate relative to other financing sources. The Company securitizes its trade accounts, which are generally non-interest bearing, in transactions that are accounted for as borrowings. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of September 30, 2019.
Revolving Credit Note and Overdraft Facility
The Company has an uncommitted, unsecured line of credit available to it pursuant to a revolving credit note ("Revolving Credit Note"). The Revolving Credit Note provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million. The Revolving Credit Note may be decreased or terminated by the bank or the Company at any time without prior notice. The Company also has a £30 million uncommitted U.K. overdraft facility ("Overdraft Facility"), which expires in February 2021, to fund short-term normal trading cycle fluctuations related to its MWI business.
Term Loans
In October 2018, the Company refinanced $400 million of outstanding Term Loans by issuing a new $400 million variable-rate term loan ("October 2018 Term Loan"), which matures in October 2020. The October 2018 Term Loan bears interest at a rate equal to a base rate or LIBOR, plus a margin of 65 basis points. The October 2018 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility.
Senior Notes
In December 2017, the Company issued $750 million of 3.45% senior notes due December 15, 2027 (the "2027 Notes") and $500 million of 4.30% senior notes due December 15, 2047 (the "2047 Notes"). The 2027 Notes were sold at 99.76% of the principal amount and have an effective yield of 3.48%. The 2047 Notes were sold at 99.51% of the principal amount and have an effective yield of 4.33%. Interest on the 2027 Notes and the 2047 Notes is payable semi-annually in arrears and commenced on June 15, 2018. The 2027 and 2047 Notes rank pari passu to the Company's other senior notes, the Multi-Currency Revolving Credit Facility, the Revolving Credit Note, the Overdraft Facility, and the October 2018 Term Loan.

The Company used the proceeds from the 2027 Notes and the 2047 Notes to finance the early retirement of the $400 million of 4.875% senior notes that were due in 2019, including the payment of a $22.3 million prepayment premium, and to finance the acquisition of H.D. Smith, which was completed in January 2018 (see Note 2).
The senior notes are collectively referred to as the "Notes." Interest on the Notes is payable semiannually in arrears. The Notes were sold at small discounts to the principal amounts and, therefore, have effective yields that are greater than the stated interest rates in the table above. Costs incurred in connection with the issuance of the Notes were deferred and are being amortized over the terms of the Notes. The indentures governing the Notes contain restrictions and covenants, which include limitations on

67

additional indebtedness; distributions to stockholders; the repurchase of stock and the making of other restricted payments; issuance of preferred stock; creation of certain liens; transactions with subsidiaries and other affiliates; and certain corporate acts such as mergers, consolidations, and the sale of substantially all assets. An additional covenant requires compliance with a financial leverage ratio test, with which the Company was compliant as of September 30, 2019.
Nonrecourse Debt
Nonrecourse debt is comprised of short-term and long-term debt belonging to the Brazil subsidiaries and is repaid solely from the Brazil subsidiaries' cash flows and such debt agreements provide that the repayment of the loans (and interest thereon) is secured solely by the capital stock, physical assets, contracts, and cash flows of the Brazil subsidiaries.
Other Information
Scheduled future principal payments of debt are $111.2 million in fiscal 2020, $450.3 million in fiscal 2021, $877.8 million in fiscal 2022, $4.7 million in fiscal 2023, $501.4 million in fiscal 2024, and $2.3 billion thereafter.
Interest paid on the above indebtedness during the fiscal years ended September 30, 2019, 2018, and 2017 was $167.4 million, $162.1 million, and $125.3 million, respectively.
Total amortization of financing fees and the accretion of original issue discounts, which are recorded as components of Interest Expense, Net on the Consolidated Statements of Operations, were $7.1 million, $7.7 million, and $6.2 million, for the fiscal years ended September 30, 2019, 2018, and 2017, respectively.
Note 7. Stockholders' Equity and Weighted Average Common Shares Outstanding
The authorized capital stock of the Company consists of 600,000,000 shares of common stock, par value $0.01 per share (the "common stock"), and 10,000,000 shares of preferred stock, par value $0.01 per share (the "preferred stock").
The board of directors is authorized to provide for the issuance of shares of preferred stock in one or more series with various designations and preferences and relative, participating, optional, or other special rights and qualifications, limitations, or restrictions. Except as required by law, or as otherwise provided by the board of directors of the Company, the holders of preferred stock will have no voting rights and will not be entitled to notice of meetings of stockholders. Holders of preferred stock will be entitled to receive, when declared by the board of directors, out of legally available funds, dividends at the rates fixed by the board of directors for the respective series of preferred stock, and no more, before any dividends will be declared and paid, or set apart for payment, on common stock with respect to the same dividend period. No shares of preferred stock have been issued as of September 30, 2019.
The holders of the Company's common stock are entitled to one vote per share and have the exclusive right to vote for the board of directors and for all other purposes as provided by law. Subject to the rights of holders of the Company's preferred stock, holders of common stock are entitled to receive ratably on a per share basis such dividends and other distributions in cash, stock, or property of the Company as may be declared by the board of directors from time to time out of the legally available assets or funds of the Company.
The following illustrates the components of Accumulated Other Comprehensive Loss, net of income taxes:
 
 
September 30,
(in thousands)
 
2019
 
2018
Pension and postretirement adjustments
 
$
(5,344
)
 
$
(5,065
)
Foreign currency translation
 
(107,252
)
 
(74,811
)
Other
 
631

 
623

Total accumulated other comprehensive loss
 
$
(111,965
)
 
$
(79,253
)

In September 2016, the Company entered into an Accelerated Share Repurchase ("ASR") transaction with a financial institution and paid $400.0 million for the delivery of 4.5 million shares of its common stock. The initial payment of $400.0 million funded stock purchases of $380.0 million and a share holdback of $20.0 million. The ASR transaction was settled in November 2016, at which time the financial institution delivered an additional 0.5 million shares of the Company's common stock. The number of shares ultimately received was based upon the volume-weighted average price of the Company's common stock during the term of the ASR. The Company applied the 4.5 million shares from the ASR to the May 2016 share repurchase program. During the fiscal year ended September 30, 2017, the Company purchased 2.1 million shares of its common stock (included 0.5 million

68

shares of common stock received as part of the settlement of the ASR) for a total of $118.8 million to complete its authorization under the May 2016 program.
In November 2016, the Company's board of directors authorized a share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2017, the Company purchased 2.7 million shares of its common stock for a total of $211.1 million under this program. During the fiscal year ended September 30, 2018, the Company purchased 7.7 million shares of its common stock for a total of $663.1 million, which included $24.0 million of September 2018 purchases that cash settled in October 2018. During the fiscal year ended September 30, 2019, the Company purchased 1.4 million shares of its common stock for a total of $125.8 million, which excluded $24.0 million of September 2018 purchases that cash settled in October 2018, to complete its authorization under this program.
In October 2018, the Company's board of directors authorized a new share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2019, the Company purchased 6.7 million shares of its common stock for a total of $538.9 million under this program, which included $14.8 million of September 2019 purchases that cash settled in October 2019. As of September 30, 2019, the Company had $461.1 million of availability under this program.
Common Shares Outstanding
Basic earnings per share is computed by dividing net income attributable to AmerisourceBergen Corporation by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed by dividing net income attributable to AmerisourceBergen Corporation by the weighted average number of shares of common stock outstanding, plus the dilutive effect of stock options and restricted stock units during the periods presented.
The following illustrates the components of diluted weighted average shares outstanding:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Weighted average common shares outstanding - basic
 
210,165

 
217,872

 
218,375

Effect of dilutive securities - stock options and restricted stock units
 
1,675

 
2,464

 
3,227

Weighted average common shares outstanding - diluted
 
211,840

 
220,336

 
221,602


The potentially dilutive stock options and restricted stock units that were antidilutive for the fiscal years ended September 30, 2019, 2018, and 2017 were 4.6 million, 3.2 million, and 4.1 million, respectively.
Note 8. Related Party Transactions
WBA owns more than 10% of the Company's outstanding common stock and is, therefore, considered a related party. The Company operates under various agreements and arrangements with WBA, including a pharmaceutical distribution agreement pursuant to which the Company distributes pharmaceutical products to WBA and an agreement that provides the Company the ability to access favorable economic pricing and generic products through a generic purchasing services arrangement with Walgreens Boots Alliance Development GmbH. Both of these agreements expire in 2026.
 
Revenue from the various agreements and arrangements with WBA was $60.3 billion, $54.7 billion, and $45.4 billion in the fiscal years ended September 30, 2019, 2018, and 2017, respectively. The Company's receivable from WBA, net of incentives, was $6.1 billion and $5.6 billion as of September 30, 2019 and 2018, respectively.
Note 9. Retirement and Other Benefit Plans
The Company sponsors various retirement benefit plans and a deferred compensation plan covering eligible employees.
The Compensation and Succession Planning Committee ("Compensation Committee") of the Company's board of directors has delegated the administration of the Company's retirement and other benefit plans to its Benefits Committee, an internal committee, comprised of senior finance, human resources, and legal executives. The Benefits Committee is responsible for the investment options under the Company's savings plans, as well as performance of the investment advisers and plan administrators.

69

Defined Contribution Plans
The Company sponsors the AmerisourceBergen Employee Investment Plan (the "Plan"), which is a defined contribution 401(k) plan covering salaried and certain hourly employees. Eligible participants may contribute to the plan from 1% to 50% of their regular compensation before taxes. Prior to January 1, 2017, the Company contributed $1.00 for each $1.00 invested by the participant up to the first 3% of the participant's salary and $0.50 for each additional $1.00 invested by the participant of up to an additional 2% of salary. Effective January 1, 2017, the Company contributed $1.00 for each $1.00 invested by the participant up to the first 3% of the participant's salary. Effective January 1, 2019, the Company contributes $1.00 for each $1.00 invested by the participant up to the first 3% of the participant's salary and $0.50 for each additional $1.00 invested by the participant of up to an additional 2% of salary. An additional discretionary contribution, in an amount not to exceed the limits established by the Internal Revenue Code ("IRC"), may also be made depending upon the Company's performance. Based on the Company's performance in fiscal 2019 and 2018, the Company recognized an expense for a discretionary contribution to the Plan in the fiscal years ended September 30, 2019 and 2018. There were no discretionary contributions recognized in the fiscal year ended September 30, 2017. All contributions are invested at the direction of the employee in one or more funds. All contributions vest immediately except for the discretionary contributions made by the Company, which vest in full after five years of credited service.
The Company also sponsors the AmerisourceBergen Corporation Benefit Restoration Plan. This unfunded plan provides benefits to selected key management, including all of the Company's executive officers. Prior to January 1, 2017, the Company contributed an amount equal to 4% of the participant's total cash compensation to the extent that his or her compensation exceeded the annual compensation limit established by Section 401(a) (17) of the IRC. Effective January 1, 2017, this plan provided eligible participants with an annual amount equal to 3% of the participant's total cash compensation to the extent that his or her compensation exceeds the annual compensation limit established by Section 401(a) (17) of the IRC. Effective January 1, 2019, this plan provides eligible participants with an annual amount equal to 4% of the participant's total cash compensation to the extent that his or her compensation exceeds the annual compensation limit established by Section 401(a) (17) of the IRC.
Costs of the defined contribution plans charged to expense for the fiscal years ended September 30, 2019, 2018, and 2017 were $51.0 million, $37.9 million, and $28.3 million, respectively.
Deferred Compensation Plan
The Company sponsors the AmerisourceBergen Corporation 2001 Deferred Compensation Plan. This unfunded plan, under which 2.96 million shares of common stock are authorized for issuance, allows eligible officers, directors, and key management employees to defer a portion of their annual compensation. The amount deferred may be allocated by the employee to cash, mutual funds, or stock credits. Stock credits, including dividend equivalents, are equal to the full and fractional number of shares of common stock that could be purchased with the participant's compensation allocated to stock credits based upon the average of closing prices of common stock during each month, plus, at the discretion of the board of directors, up to one-half of a share of common stock for each full share credited. Stock credit distributions are made in shares of common stock. No shares of common stock have been issued under the deferred compensation plan through September 30, 2019. The Company's liability relating to its deferred compensation plan as of September 30, 2019 and 2018 was $28.0 million and $27.5 million, respectively.
Note 10. Share-Based Compensation
Stock Options
The Company's employee stock option plans provide for the granting of incentive and nonqualified stock options to acquire shares of common stock to employees at a price not less than the fair market value of the common stock on the date the option is granted. Option terms and vesting periods are determined at the date of grant by the Compensation Committee of the board of directors. Employee options generally vest ratably, in equal amounts, over a four-year service period and expire in seven years. The Company's non-employee director stock option plans provide for the granting of nonqualified stock options to acquire shares of common stock to non-employee directors at the fair market value of the common stock on the date of the grant. Non-employee director options vest ratably, in equal amounts, over a three-year service period and expire in ten years. Non-employee director options have not been granted since February 2011.
As of September 30, 2019, employee and non-employee director stock options for an additional 12.8 million shares may be granted under the AmerisourceBergen Corporation Omnibus Incentive Plan (the "Plan").
The estimated fair value of options granted is expensed on a straight-line basis over the requisite service periods of the awards and are net of estimated forfeitures. The Company estimates the fair values of option grants using a binomial option pricing model. Expected volatilities are based upon the historical volatility of the Company's common stock and other factors, such as implied market volatility. The Company uses historical exercise data, taking into consideration the optionees' ages at grant date, to estimate the terms for which the options are expected to be outstanding. The Company anticipates that the terms of options

70

granted in the future will be similar to those granted in the past. The risk-free rates during the terms of such options are based upon the U.S. Treasury yield curve in effect at the time of grant.
The weighted average fair values of the options granted during the fiscal years ended September 30, 2019, 2018, and 2017 were $18.60, $14.16, and $13.57, respectively. The following weighted average assumptions were used to estimate the fair values of options granted:
 
Fiscal Year Ended September 30,
 
2019
 
2018
 
2017
Risk-free interest rate
2.91%
 
1.89%
 
1.26%
Expected dividend yield
1.79%
 
1.96%
 
1.80%
Volatility of common stock
27.67%
 
26.54%
 
26.78%
Expected life of the options
3.77 years
 
3.76 years
 
3.74 years

During the fiscal years ended September 30, 2019, 2018, and 2017, the Company recognized stock option expense of $21.0 million, $22.6 million, and $28.6 million, respectively.
A summary of the Company's stock option activity and related information for its option plans for the fiscal year ended September 30, 2019 is presented below:
(in thousands, except exercise price and contractual term)
 
Options
 
Weighted
Average
Exercise
Price
 
Weighted
Average
Remaining
Contractual
Term
 
Aggregate
Intrinsic
Value
Outstanding as of September 30, 2018
 
8,421

 
$77
 
4 years
 
$
142,557

Granted
 
1,137

 
$90
 
 
 
 

Exercised
 
(1,531
)
 
$50
 
 
 
 

Forfeited
 
(213
)
 
$84
 
 
 
 

Expired
 
(155
)
 
$97
 
 
 
 
Outstanding as of September 30, 2019
 
7,659

 
$83
 
4 years
 
$
35,319

Exercisable as of September 30, 2019
 
4,395

 
$83
 
3 years
 
$
25,049

Expected to vest after September 30, 2019
 
3,162

 
$83
 
5 years
 
$
10,010


The intrinsic value of stock option exercises during the fiscal years ended September 30, 2019, 2018, and 2017 was $51.2 million, $116.7 million, and $116.6 million, respectively.
A summary of the status of the Company's nonvested options as of September 30, 2019 and changes during the fiscal year ended September 30, 2019 is presented below:
(in thousands, except grant date fair value)
 
Options
 
Weighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 2018
 
3,860

 
$15
Granted
 
1,137

 
$19
Vested
 
(1,519
)
 
$15
Forfeited
 
(213
)
 
$16
Nonvested as of September 30, 2019
 
3,265

 
$16

During the fiscal years ended September 30, 2019, 2018, and 2017, the total fair values of options vested were $22.7 million, $25.8 million, and $25.2 million, respectively. Expected future compensation expense relating to the 3.3 million nonvested options outstanding as of September 30, 2019 is $21.6 million, which will be recognized over a weighted average period of 2.0 years.

71

Restricted Stock Units
Restricted stock units vest in full after three years. The estimated fair value of restricted stock units under the Company's restricted stock unit plans is determined by the product of the number of shares granted and the grant date market price of the Company's common stock. The estimated fair value of restricted stock units is expensed on a straight-line basis over the requisite service period, net of estimated forfeitures. During the fiscal years ended September 30, 2019, 2018, and 2017, the Company recognized restricted stock unit expense of $29.2 million, $26.8 million, and $25.1 million, respectively.
A summary of the status of the Company's nonvested restricted stock units as of September 30, 2019 and changes during the fiscal year ended September 30, 2019 are presented below:
(in thousands, except grant date fair value)
 
Restricted
Stock Units
 
Weighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 2018
 
1,023

 
$80
Granted
 
442

 
$89
Vested
 
(152
)
 
$95
Forfeited
 
(91
)
 
$81
Nonvested as of September 30, 2019
 
1,222

 
$81

During the fiscal years ended September 30, 2019, 2018, and 2017, the total fair values of restricted stock units vested were $14.5 million, $15.8 million, and $13.8 million, respectively. Expected future compensation expense relating to the 1.2 million restricted stock units outstanding as of September 30, 2019 is $30.1 million, which will be recognized over a weighted average period of 1.2 years.
Performance Stock Units
Performance stock units are granted to certain executive employees under the Plan and represent common stock potentially issuable in the future. Performance stock units vest at the end of a three-year performance period based upon achievement of specific performance goals. Based upon the extent to which the targets are achieved, vested shares for awards granted prior to fiscal 2018 may range from 0% to 150% of the target award amount. For awards granted beginning in fiscal 2018, vested shares may range from 0% to 200% of the target award amount. The fair value of performance stock units is determined by the grant date market price of the Company's common stock. Compensation expense associated with nonvested performance stock units is recognized over the requisite service period and is dependent on the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued. During the fiscal years ended September 30, 2019, 2018, and 2017, the Company recognized performance stock expense of $8.5 million, $12.8 million, and $8.4 million, respectively.
A summary of the status of the Company's nonvested performance stock units as of September 30, 2019 and changes during the fiscal year ended September 30, 2019 is presented below (based upon target award amounts).
(in thousands, except grant date fair value)
 
Performance
Stock
Units
 
Weighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 2018
 
244

 
$77
Granted
 
147

 
$90
Vested
 
(105
)
 
$76
Forfeited
 
(3
)
 
$90
Nonvested as of September 30, 2019
 
283

 
$84

Shares that vested over the three-year performance period ended September 30, 2019 were distributed to employees in November 2019.
Note 11. Lease Commitments
The Company has long-term leases for facilities and equipment. In the normal course of business, leases are generally renewed or replaced by other leases. Certain leases include escalation clauses. During the fiscal years ended September 30, 2019, 2018, and 2017, the Company recorded rental expense of $108.9 million, $114.9 million, and $80.7 million, respectively, in Distribution, Selling, and Administrative in the Consolidated Statements of Operations.

72

As of September 30, 2019, future minimum rental payments under noncancelable operating leases and financing obligations were as follows:
Payments Due by Fiscal Year (in thousands)
 
Operating
Leases
 
Financing Obligations 1
 
Total
2020
 
$
94,958

 
$
22,468

 
$
117,426

2021
 
84,002

 
29,790

 
113,792

2022
 
72,224

 
36,914

 
109,138

2023
 
63,507

 
35,950

 
99,457

2024
 
56,377

 
35,276

 
91,653

Thereafter
 
177,267

 
270,410

 
447,677

Total minimum lease payments
 
$
548,335

 
$
430,808

 
$
979,143

 
 
 
 
 
 
 
1 Represents the portion of future minimum lease payments relating to facility leases where the Company was determined to be the accounting owner (see Note 1). These payments are recognized as reductions to the financing obligation and as interest expense and exclude the future non-cash termination of the financing obligation.

Note 12. Employee Severance, Litigation, and Other
The following illustrates the charges incurred by the Company relating to Employee Severance, Litigation, and Other for the periods indicated:
 
 
Fiscal Year Ended September 30,
 (in thousands)
 
2019
 
2018
 
2017
Employee severance
 
$
34,147

 
$
36,694

 
$
7,767

Litigation and opioid-related costs
 
185,145

 
61,527

 
917,573

Acquisition-related deal and integration costs
 
43,184

 
33,912

 
16,990

Business transformation efforts
 
55,437

 
32,963

 
3,700

Other restructuring initiatives
 
12,561

 
18,424

 
13,297

Total employee severance, litigation, and other
 
$
330,474

 
$
183,520

 
$
959,327


Employee severance in the fiscal year ended September 30, 2019 included costs primarily related to PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D. Smith, and restructuring activities related to our consulting business. Employee severance in the fiscal year ended September 30, 2018 included costs primarily related to position eliminations resulting from the Company's business transformation efforts and restructuring activities related to our consulting business. Employee severance in the fiscal year ended September 30, 2017 included costs primarily related to position eliminations as the Company began to reorganize to further align the organization to its customers' needs.
Litigation and opioid-related costs in the fiscal year ended September 30, 2019 consisted of $116.7 million of legal settlements and accruals and $68.5 million of legal fees in connection with opioid lawsuits and investigations. Litigation and opioid-related costs in the fiscal year ended September 30, 2018 primarily related to opioid lawsuits, investigations, and related initiatives. Litigation and opioid-related costs in the fiscal year ended September 30, 2017 primarily related to litigation settlements and accruals.
Acquisition-related deal and integration costs in the fiscal year ended September 30, 2019 are primarily related to the integration of H.D. Smith. Integration costs primarily include costs to transition servicing legacy H.D. Smith customers to existing company distribution facilities and operating systems. Acquisition-related deal and integration costs in the fiscal year ended September 30, 2018 were primarily related to the acquisition of H.D. Smith.
Business transformation efforts in the fiscal years ended September 30, 2019 and 2018 were primarily related to costs associated with reorganizing the Company to further align the organization to its customers' needs. The majority of these costs were related to services provided by third-party consultants.
Note 13. Legal Matters and Contingencies
In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties

73

may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.

 For those matters for which the Company has not recognized a liability, the Company cannot predict the outcome of their impact on the Company as uncertainty remains with regard to whether such matters will proceed to trial, whether settlements will be reached, and the amount and terms of any such settlements. Outcomes may include settlements in significant amounts that are not currently estimable, limitations on the Company's conduct, the imposition of corporate integrity agreement obligations, consent decrees, and/or other civil and criminal penalties. From time to time, the Company is also involved in disputes with its customers, which the Company generally seeks to resolve through commercial negotiations. If negotiations are unsuccessful, the parties may litigate the dispute or otherwise attempt to settle the matter.

With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.

Opioid Lawsuits and Investigations

A significant number of counties, municipalities, and other governmental entities in a majority of U.S. states and Puerto Rico, as well as several states and tribes, have filed lawsuits in various federal, state and other courts against pharmaceutical wholesale distributors (including the Company and its subsidiaries AmerisourceBergen Drug Corporation ("ABDC") and H.D. Smith, which was acquired in January 2018), pharmaceutical manufacturers, retail chains, medical practices, and physicians relating to the distribution of prescription opioid pain medications. Other lawsuits regarding the distribution of prescription opioid pain medications have been filed by: third-party payors and similar entities; hospitals; hospital groups; and individuals, including cases styled as putative class actions. The lawsuits, which have been and continue to be filed in federal, state, and other courts, generally allege violations of controlled substance laws and various other statutes as well as common law claims, including negligence, public nuisance, and unjust enrichment, and seek equitable relief and monetary damages. An initial group of cases was consolidated for Multidistrict Litigation ("MDL") proceedings before the United States District Court for the Northern District of Ohio (the "Court") in December 2017. Additional cases have been, and will likely continue to be, transferred to the MDL. Further, in June 2018, the Court granted a motion permitting the United States, through the DOJ, to participate in settlement discussions and as a friend of the Court by providing information to facilitate non-monetary remedies.

In April 2018, the Court issued an order creating a litigation track, which includes dispositive motion practice, discovery, and trials in certain bellwether jurisdictions. On December 31, 2018, the Court issued an order selecting two additional cases for a second bellwether discovery and trial track. The timing of discovery, motion practice, and trials for the second set of bellwether cases has not yet been determined.

On October 21, 2019, the Company announced an agreement in principle with two Ohio counties, Cuyahoga and Summit, to settle all claims brought by the two counties against the Company in the first track of the MDL. All claims against the Company were dismissed with prejudice pursuant to the settlement. As a result, the Company recorded a charge of $66.7 million in the fourth quarter of the fiscal year ended September 30, 2019 within Employee Severance, Litigation and Other in its Statement of Operations and in Accrued Expenses and Other on the Company’s Consolidated Balance Sheet.

The Court has continued to oversee court-ordered settlement discussions with attorneys for the plaintiffs and certain states that it instituted at the beginning of the MDL proceedings. On October 21, 2019, the Attorneys General for North Carolina, Pennsylvania, Tennessee, and Texas announced certain proposed settlement terms intended to provide a potential framework for a global resolution of the MDL and other related state court litigation, including cases currently filed and that could be filed. The attorneys general's announcement outlined that the largest U.S. pharmaceutical distributors would be expected to pay an aggregate amount of up to $18.0 billion over 18 years, of which the Company's portion would be 31%, in addition to the development and participation in a program for free or rebated distribution of opioid-abuse medications for a period of 10 years and the implementation of industry-wide changes to be specified to controlled substance anti-diversion programs. The Company is currently engaged in discussions that include the four attorneys general and other parties with the objective of reaching potential terms for a global resolution. The Company is also engaged in related discussions with plaintiffs' lawyers representing local governments and other parties with the same goal of reaching a global resolution with all parties. If agreed, the potential terms for a global resolution would then need to be presented to numerous other states and local governments, and a significant number of such jurisdictions would need to accept the proposed terms in order to achieve an agreement in principle that would provide the finality that the Company requires from a global resolution. Given the large number of parties involved, the complexity and difficulty of the underlying issues, and the resulting uncertainty of achieving a potential global resolution, the Company continues to litigate and

74

prepare for trial in the cases pending in the MDL as well as in state courts where lawsuits have been filed, and intends to continue to vigorously defend itself in all such cases. A liability associated with a global resolution has not been recognized as of September 30, 2019, since the Company is unable to predict the outcome of settlement discussions with the states and local governments that will need to participate and, therefore, a global resolution cannot be considered probable. Furthermore, significant uncertainty remains with regard to whether such matters will proceed to trial, and, given the inherent uncertainty related to such litigation, the Company is not in a position to assess the likely outcome, and therefore unable to estimate the range of possible loss.

In June 2019, attorneys for some of the plaintiffs filed a motion proposing a procedure to certify a nationwide "negotiation class" of cities and counties for the purpose of negotiating and settling with defendants engaged in the nationwide manufacturing, sale, or distribution of opioids. The attorneys subsequently withdrew the motion and refiled an amended motion on July 9, 2019. The Court granted the motion on September 11, 2019 and certain defendants, including ABDC, are appealing.

On November 6, 2019, a New York state court entered an order accelerating the trial date for cases brought by Nassau and Suffolk Counties and the New York Attorney General against a variety of defendants, including the Company. Pursuant to that order, the trial, which is not part of the MDL, was scheduled to begin on January 20, 2020, however during a subsequent meeting on November 13, 2019, the court amended the trial date to begin in March 2020.

Aside from those parties that have already filed suit, other entities, including additional attorneys general’s offices, counties, and cities in multiple states, have indicated their intent to sue. The Company is vigorously defending itself in the pending lawsuits and intends to vigorously defend itself against any threatened lawsuits. The Company is not in a position to assess the likely outcome or its exposure, if any, with respect to these matters.

The Company has also received subpoenas, civil investigative demands, and other requests for information, requesting the production of documents regarding the distribution of prescription opioid pain medications from government agencies in other jurisdictions, including certain states. The Company is engaged in discussions with representatives from these government agencies regarding the requests and has been producing responsive documents.

Since July 2017, the Company has received subpoenas from several U.S. Attorney's Offices. Those subpoenas request the production of a broad range of documents pertaining to ABDC's distribution of controlled substances and diversion control programs. The Company has been engaged in discussions with the various U.S. Attorney’s Offices, including the Health Care and Government Fraud Unit of the Criminal Division of the U.S. Attorney's Office for the District of New Jersey, and has been producing documents in response to the subpoenas.
In June 2012, the Attorney General of the State of West Virginia ("West Virginia AG") filed complaints, which were amended, in the Circuit Court of Boone County, West Virginia, against a number of pharmaceutical wholesale distributors, including the Company's subsidiary ABDC, alleging, among other claims, that the distributors failed to provide effective controls and procedures to guard against diversion of controlled substances for illegitimate purposes in West Virginia, acted negligently by distributing controlled substances to pharmacies that serve individuals who abuse controlled substances, and failed to report suspicious orders of uncontrolled substances in accordance with state regulations. The West Virginia AG was seeking monetary damages and injunctive and other equitable relief. This matter was dismissed with prejudice on January 9, 2017 pursuant to a settlement agreement that provided for the payment of $16.0 million and express denial of the allegations in the complaints and any wrongdoing. During the fiscal year ended September 30, 2017, the Company recognized the $16.0 million settlement in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations. The Company paid the $16.0 million settlement in fiscal 2017.
Government Enforcement and Related Litigation Matters

Various government agencies, including the FDA, the Consumer Protection Branch of the Civil Division of the DOJ, and state boards of pharmacy, regulate the compounding of pharmaceutical products. The Company’s subsidiary, PharMEDium, operates Section 503B outsourcing facilities that must comply with current Good Manufacturing Practice ("cGMP") requirements and are inspected by the FDA periodically to determine compliance. The FDA and the DOJ have broad enforcement powers, including the authority to enjoin PharMEDium's Section 503B outsourcing facilities from distributing pharmaceutical products.

On May 17, 2019, PharMEDium reached an agreement on the terms of the Consent Decree with the FDA and the DOJ that was entered by the United States District Court for the Northern District of Illinois on May 22, 2019. The Consent Decree permits commercial operations to continue at PharMEDium’s Dayton, New Jersey and Sugar Land, Texas compounding facilities and administrative operations to continue at its Lake Forest, Illinois headquarters subject to compliance with requirements set forth therein. As required by the Consent Decree, initial audit inspections were conducted by an independent cGMP expert of the Dayton and Sugar Land facilities. The cGMP expert has notified the FDA that all of the short-term corrective actions taken are

75

acceptable. The Company has submitted to the FDA several additional longer-term corrective actions, and the independent cGMP expert will assess the effectiveness of the implementation of these items in future audits. Additional audit inspections by the independent cGMP expert of the Sugar Land and Dayton facilities are required at least annually for a period of four years.

The Consent Decree also establishes requirements that must be satisfied prior to the resumption of commercial operations at the Memphis, Tennessee facility. The requirements include a work plan approved by the FDA and an audit inspection and certification by an independent cGMP expert that the facilities, methods and controls at the Memphis facility and PharMEDium’s Lake Forest, Illinois headquarters comply with the Consent Decree. If PharMEDium receives written notification from the FDA of compliance with the requirements to resume operations at the Memphis facility, additional audit inspections are required for five years, during which time PharMEDium must correct any deviations from the Consent Decree observed by the independent cGMP expert.

After five years, PharMEDium may petition the district court for full relief from the Consent Decree, or for specific relief with regard to one or more facilities. If, at the time of such petition, all obligations under the Consent Decree with respect to the specific facilities for which PharMEDium is seeking relief have been satisfied, and there has been continuous compliance with the Consent Decree for at least five years, the federal government will not oppose the petition, and PharMEDium may request that the district court grant such relief.

Additionally, state boards of pharmacy may revoke, limit, or deny approval of licenses required under state law to compound or distribute pharmaceutical products. As a result of reciprocal state actions initiated due to the FDA’s inspectional observations, PharMEDium has suspended shipping of its compounded sterile preparations into several states, either voluntarily, by consent or pursuant to orders of state licensing authorities.

Subpoenas and Ongoing Investigations

From time to time, the Company receives subpoenas or requests for information from various government agencies relating to the Company's business or to the business of a customer, supplier, or other industry participant. The Company's responses often require time and effort and can result in considerable costs being incurred. Most of these matters are resolved without incident; however, such subpoenas or requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the healthcare industry, as well as to substantial settlements.

In January 2017, the Company's subsidiary U.S. Bioservices Corporation ("U.S. Bio") received a subpoena for information from the U.S. Attorney's Office for the Eastern District of New York ("USAO-EDNY") relating to its activities in connection with billing for products and making returns of potential overpayments to government payers. The Company engaged in discussions with the USAO-EDNY and produced documents in response to the subpoena. In April 2019, the government informed the Company that it had filed a notice with the U.S. District Court for the Eastern District of New York that it was declining to intervene in a filed qui tam action related to its investigation. The case was unsealed in April 2019 and counsel for the relator has stated that they intend to file an amended complaint under seal, which they intend to submit to the USAO-EDNY for further consideration.

The Company and its subsidiary AmerisourceBergen Specialty Group ("ABSG") had previously responded to subpoenas from the USAO-EDNY requesting production of documents and information relating to the pre-filled syringe program of ABSG’s subsidiary Medical Initiatives, Inc., ABSG's oncology distribution center, its group purchasing organization for oncologists, and intercompany transfers of certain oncology products. Medical Initiatives, Inc. voluntarily ceased operations in early 2014.
On September 27, 2017, pursuant to the terms of a plea agreement, ABSG entered a guilty plea to a one-count strict-liability misdemeanor violation of the Federal Food, Drug, and Cosmetic Act in the United States District Court of the Eastern District of New York. Under the terms of the agreement, which were approved by the Court, ABSG paid a total criminal fine and forfeiture of $260.0 million in fiscal 2017. The guilty plea resolves the federal criminal investigation related to the failure of Medical Initiatives, Inc. to duly register with the FDA. The Company also entered into a Compliance Agreement with the United States Department of Justice for a period of three years. During the fiscal year ended September 30, 2017, the Company recognized the $260.0 million settlement in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations.
The USAO-EDNY also pursued alleged civil claims under the False Claims Act. ABSG reached an agreement in principle with the USAO-EDNY during the fiscal quarter ended December 31, 2017, which the Company expected would resolve the alleged civil claims in their entirety. In the fourth quarter of the fiscal year ended September 30, 2018, the Company reached final terms of the settlement agreement with the USAO-EDNY, resolved potential administrative action by the Office of Inspector General of the U.S. Department of Health and Human Services by entering into a Corporate Integrity Agreement, and obtained dismissal

76

with prejudice of the potential civil claims. The Corporate Integrity Agreement has a five-year term, which commenced on September 28, 2018, and requires, among other things, the maintenance of a compliance program, an independent review organization and a financial recoupment program. Pursuant to the terms of the settlement agreement with the USAO-EDNY, ABSG made a payment on September 28, 2018 to resolve the civil litigation without making any admission of liability in the amount of $625.0 million, plus interest from December 1, 2017. As a result of the agreement in principle, the Company had previously accrued a reserve in the amount of $625.0 million in the fiscal year ended September 30, 2017. The reserve was recognized in Employee Severance, Litigation, and Other on the Company's Statement of Operations.
The Company’s subsidiary U.S. Bio settled claims with the U.S. Attorney’s Office for the Southern District of New York ("USAO-SDNY") and with various states arising from the previously disclosed matter involving the dispensing of one product and U.S. Bio’s relationship with the manufacturer of that product. In accordance with the settlement agreements, the United States’ complaint against U.S. Bio was dismissed and the participating states agreed not to bring, and to dismiss with prejudice, any state law claims that they had the authority to bring against U.S. Bio. The Company paid the United States $10.7 million in fiscal 2017 and paid the participating states $2.8 million in fiscal 2018. During the year ended September 30, 2017, the Company recognized the $13.4 million settlement in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations.
Other Contingencies
New York State ("NYS") enacted the Opioid Stewardship Act ("OSA"), which went into effect on July 1, 2018. The OSA established an annual $100 million Opioid Stewardship Fund (the "Fund") and requires manufacturers, distributors, and importers licensed in NYS to ratably source the Fund. The ratable share of the assessment for each licensee was to be based upon opioids sold or distributed to or within NYS. In the fourth quarter of the fiscal year ended September 30, 2018, the Company accrued $22.0 million as an estimate of its liability under the OSA for opioids distributed from January 1, 2017 through September 30, 2018 and recognized this reserve in Cost of Goods Sold on its Consolidated Statement of Operations and in Accrued Expenses and Other on its Consolidated Balance Sheet as of September 30, 2018. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York, and, as a result, the Company reversed the $22.0 million accrual in the fiscal quarter ended December 31, 2018. NYS filed an appeal of the court decision on January 17, 2019; however, the Company does not believe a loss contingency is probable.
Note 14. Litigation Settlements
Antitrust Settlements
Numerous lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. These lawsuits are generally brought as class actions. The Company has not been a named a plaintiff in any of these lawsuits, but has been a member of the direct purchasers' class (i.e., those purchasers who purchase directly from these pharmaceutical manufacturers). None of the lawsuits has gone to trial, but some have settled in the past with the Company receiving proceeds from the settlement funds. During the fiscal years ended September 30, 2019, 2018, and 2017, the Company recognized gains of $145.9 million, $35.9 million, and $1.4 million, respectively, relating to these lawsuits. These gains, which are net of attorney fees and estimated payments due to other parties, were recorded as reductions to cost of goods sold in the Company's Consolidated Statements of Operations.
Note 15. Business Segment Information
The Company is organized based upon the products and services it provides to its customers. The Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in Other for the purpose of reportable segment presentation. Other consists of operating segments that focus on global commercialization services and animal health (MWI Animal Health). The operating segments that focus on global commercialization services include AmerisourceBergen Consulting Services ("ABCS") and World Courier.
The chief operating decision maker ("CODM") of the Company is the Chairman, President & Chief Executive Officer of the Company, whose function is to allocate resources to, and assess the performance of, the Company's operating segments.
The Pharmaceutical Distribution Services reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. Through a number of operating businesses, the Pharmaceutical Distribution Services

77

reportable segment provides pharmaceutical distribution (including plasma and other blood products, injectible pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. Additionally, the Pharmaceutical Distribution Services reportable segment provides data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The Pharmaceutical Distribution Services reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. Additionally, it delivers packaging solutions to institutional and retail healthcare providers.
ABCS, through a number of operating businesses, provides a full suite of integrated manufacturer services that range from clinical trial support to product post-approval and commercialization support. World Courier, which operates in over 50 countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. MWI is a leading animal health distribution company in the United States and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. Additionally, MWI offers demand-creating sales force services to manufacturers.
The following illustrates reportable and operating segment revenue information for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Pharmaceutical Distribution Services
 
$
172,813,537

 
$
161,699,343

 
$
147,453,495

Other:
 
 
 
 
 
 
MWI Animal Health
 
3,975,232

 
3,789,759

 
3,636,305

Global Commercialization Services
 
2,893,109

 
2,542,971

 
2,111,558

Total Other
 
6,868,341

 
6,332,730

 
5,747,863

Intersegment eliminations
 
(92,757
)
 
(92,438
)
 
(57,532
)
Revenue
 
$
179,589,121

 
$
167,939,635

 
$
153,143,826


Intersegment eliminations primarily represent the elimination of certain Pharmaceutical Distribution Services reportable segment sales to MWI.
The following illustrates reportable segment operating income information for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Pharmaceutical Distribution Services
 
$
1,671,251

 
$
1,626,748

 
$
1,643,629

Other
 
380,660

 
355,091

 
373,797

Intersegment eliminations
 
(659
)
 
(609
)
 
(556
)
Total segment operating income
 
$
2,051,252

 
$
1,981,230

 
$
2,016,870



78

The following reconciles total segment operating income to income before income taxes for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Total segment operating income
 
$
2,051,252

 
$
1,981,230

 
$
2,016,870

Gain from antitrust litigation settlements
 
145,872

 
35,938

 
1,395

LIFO credit (expense)
 
22,544

 
(67,324
)
 
157,782

PharMEDium remediation costs
 
(69,423
)
 
(66,204
)
 
—

New York State Opioid Stewardship Act
 
22,000

 
(22,000
)
 
—

Acquisition-related intangibles amortization
 
(159,848
)
 
(174,751
)
 
(156,378
)
Employee severance, litigation, and other
 
(330,474
)
 
(183,520
)
 
(959,327
)
Goodwill impairment
 
—

 
(59,684
)
 
—

Impairment of long-lived assets
 
(570,000
)
 
—

 
—

Operating income
 
1,111,923

 
1,443,685

 
1,060,342

Other (income) loss
 
(12,952
)
 
25,469

 
(2,730
)
Interest expense, net
 
157,769

 
174,699

 
145,185

Loss on consolidation of equity investments
 
—

 
42,328

 
—

Loss on early retirement of debt
 
—

 
23,766

 
—

Income before income taxes
 
$
967,106

 
$
1,177,423

 
$
917,887


Segment operating income is evaluated by the CODM of the Company and excludes gain from antitrust litigation settlements; LIFO credit (expense); PharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation, and other; goodwill impairment; and impairment of long-lived assets. Segment measures were adjusted in fiscal 2019 to exclude impairment of long-lived assets as the CODM excludes these costs in the measurement of segment performance. All corporate office expenses are allocated to the operating segment level.
The Company incurred remediation costs in connection with the suspended production activities at PharMEDium (see Notes 1 and 13). These remediation costs are primarily classified in Cost of Goods sold in the Consolidated Statements of Operations. Future remediation costs will also include costs related to remediation activities responsive to FDA inspectional observations generally applicable to all of PharMEDium’s 503B outsourcing facilities, including product stability studies.
The Company recorded a $13.7 million gain on the sale of an equity investment in Other (Income) Loss in the Company's Consolidated Statement of Operations in the fiscal year ended September 30, 2019.
The Company recorded a $30.0 million impairment of a non-customer note receivable related to a start-up venture in Other (Income) Loss in the Company's Consolidated Statement of Operations in the fiscal year ended September 30, 2018.
The following illustrates total assets by reportable segment for the periods indicated:
 
 
September 30,
(in thousands)
 
2019
 
2018
 
2017
Pharmaceutical Distribution Services
 
$
33,160,529

 
$
31,892,621

 
$
29,691,127

Other
 
6,011,451

 
5,777,217

 
5,625,343

Total assets
 
$
39,171,980

 
$
37,669,838

 
$
35,316,470


The CODM does not review assets by operating segment for the purpose of assessing performance or allocating resources.

79

The following illustrates depreciation and amortization by reportable segment for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Pharmaceutical Distribution Services
 
$
232,735

 
$
225,608

 
$
188,065

Other
 
69,824

 
64,768

 
53,160

Acquisition-related intangibles amortization
 
159,848

 
174,751

 
156,378

Total depreciation and amortization
 
$
462,407

 
$
465,127

 
$
397,603


Depreciation and amortization includes depreciation and amortization of property and equipment and intangible assets, but excludes amortization of deferred financing costs and other debt-related items, which are included in interest expense, net.
The following illustrates capital expenditures by reportable segment for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Pharmaceutical Distribution Services
 
$
210,161

 
$
190,191

 
$
339,478

Other
 
100,061

 
146,220

 
126,919

Total capital expenditures
 
$
310,222

 
$
336,411

 
$
466,397


Note 16. Fair Value of Financial Instruments
The recorded amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable as of September 30, 2019 and 2018 approximate fair value based upon the relatively short-term nature of these financial instruments. Within Cash and Cash Equivalents, the Company had $1,552.0 million and $1,050.0 million of investments in money market accounts as of September 30, 2019 and 2018. The fair value of the money market accounts was determined based upon unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs.
The recorded amount of long-term debt (see Note 6) and the corresponding fair value as of September 30, 2019 were $4,033.9 million and $4,158.4 million, respectively. The recorded amount of long-term debt and the corresponding fair value as of September 30, 2018 were $4,158.5 million and $4,000.1 million, respectively. The fair value of long-term debt was determined based upon inputs other than quoted prices, otherwise known as Level 2 inputs.

80

Note 17. Quarterly Financial Information (Unaudited)
 
 
Fiscal Year Ended September 30, 2019
(in thousands, except per share amounts)
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
 
Fiscal
Year
Revenue
 
$
45,392,452

 
$
43,319,602

 
$
45,239,265

 
$
45,637,802

 
$
179,589,121

Gross profit (a)
 
$
1,297,580

 
$
1,424,756

 
$
1,231,239

 
$
1,184,737

 
$
5,138,312

Distribution, selling, and administrative expenses; depreciation; and amortization
 
779,085

 
751,802

 
764,539

 
830,489

 
3,125,915

Employee severance, litigation, and other
 
40,672

 
55,389

 
60,006

 
174,407

 
330,474

Impairment of long-lived assets
 
—

 
570,000

 
—

 
—

 
570,000

Operating income
 
$
477,823

 
$
47,565

 
$
406,694

 
$
179,841

 
$
1,111,923

Net income (b)
 
$
391,753

 
$
28,073

 
$
302,002

 
$
132,307

 
$
854,135

Net income attributable to AmerisourceBergen Corporation (b)
 
$
393,652

 
$
27,135

 
$
301,959

 
$
132,619

 
$
855,365

Earnings per share operations:
 
 

 
 

 
 

 
 

 
 

Basic
 
$
1.86

 
$
0.13

 
$
1.44

 
$
0.64

 
$
4.07

Diluted
 
$
1.84

 
$
0.13

 
$
1.43

 
$
0.63

 
$
4.04

__________________________________________________________
(a)
The first, second, third, and fourth quarters of the fiscal year ended September 30, 2019 include gains from antitrust litigation settlements of $87.3 million, $52.0 million, $3.5 million, and $3.1 million, respectively. The first, second, and third quarter of the fiscal year ended September 30, 2019 include LIFO credits of $3.0 million, $66.8 million, and $9.9 million, respectively. The fourth quarter of the fiscal year ended September 30, 2019 includes LIFO expense of $57.2 million. The first, second, third, and fourth quarters of the fiscal year ended September 30, 2019 include PharMEDium remediation costs of $17.9 million, $12.3 million, $11.7 million, and $6.7 million, respectively. The first quarter of the fiscal year ended September 30, 2019 includes a $22.0 million reversal of a previous estimate of our liability under the New York State Opioid Stewardship Act.
(b)
The first quarter of the fiscal year ended September 30, 2019 includes a $37.0 million income tax benefit adjustment to the one-time transition tax on historical foreign earnings and profits through December 31, 2017. The second quarter of the fiscal year ended September 30, 2019 includes a gain on the sale of an equity investment of $13.7 million.
 
 
Fiscal Year Ended September 30, 2018
(in thousands, except per share amounts)
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
 
Fiscal
Year
Revenue
 
$
40,466,332

 
$
41,033,858

 
$
43,142,309

 
$
43,297,136

 
$
167,939,635

Gross profit (a)
 
$
1,112,652

 
$
1,255,683

 
$
1,211,341

 
$
1,032,641

 
$
4,612,317

Distribution, selling, and administrative expenses; depreciation; and amortization
 
663,658

 
736,814

 
746,593

 
778,363

 
2,925,428

Employee severance, litigation, and other
 
30,021

 
37,449

 
75,553

 
40,497

 
183,520

Goodwill impairment
 
—

 
—

 
—

 
59,684

 
59,684

Operating income
 
$
418,973

 
$
481,420

 
$
389,195

 
$
154,097

 
$
1,443,685

Net income (b)
 
$
861,853

 
$
282,160

 
$
277,875

 
$
194,004

 
$
1,615,892

Net income attributable to AmerisourceBergen Corporation (b)
 
$
861,853

 
$
287,455

 
$
275,809

 
$
233,288

 
$
1,658,405

Earnings per share operations:
 
 

 
 

 
 

 
 

 
 

Basic
 
$
3.95

 
$
1.31

 
$
1.26

 
$
1.08

 
$
7.61

Diluted
 
$
3.90

 
$
1.29

 
$
1.25

 
$
1.07

 
$
7.53

__________________________________________________________
(a)
The second and third quarters of the fiscal year ended September 30, 2018 include gains from antitrust litigation settlements of $0.3 million and $35.6 million, respectively. The third quarter of the fiscal year ended September 30, 2018 includes a LIFO credit of $16.1 million. The fourth quarter of the fiscal year ended September 30, 2018 includes LIFO expense of $83.5 million. The second, third, and fourth quarters of the fiscal year ended September 30, 2018 include PharMEDium remediation costs of $22.5 million, $12.0 million, and $26.6 million, respectively. The fourth quarter of the fiscal year ended September 30, 2018 includes a $22.0 million estimate of our liability under the New York State Opioid Stewardship Act.

81

(b)
The first quarter of the fiscal year ended September 30, 2018 includes a loss on early retirement of debt of $23.8 million. The second quarter of the fiscal year ended September 30, 2018 includes a $42.3 million loss on consolidation of equity investments and a $30.0 million impairment of a non-customer note receivable. The first and fourth quarters of the fiscal year ended September 30, 2018 included discrete income tax benefits recognized in connection with the 2017 Tax Act of $587.6 million and $25.0 million, respectively.
ITEM 9.    CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
ITEM 9A.    CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
The Company maintains disclosure controls and procedures that are intended to ensure that information required to be disclosed in the Company's reports submitted under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also are intended to ensure that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.
The Company's Chief Executive Officer and Chief Financial Officer, with the participation of other members of the Company's management, have evaluated the effectiveness of the Company's disclosure controls and procedures (as such term is defined in Rules 13a — 15(e) and 15d — 15(e) under the Exchange Act) and have concluded that the Company's disclosure controls and procedures were effective for their intended purposes as of the end of the period covered by this report.
Changes in Internal Control over Financial Reporting
There were no changes during the fiscal quarter ended September 30, 2019 in the Company's internal control over financial reporting that materially affected, or are reasonably likely to materially affect, those controls.
MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
The management of AmerisourceBergen Corporation ("AmerisourceBergen" or the "Company") is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended. AmerisourceBergen's internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. The Company's internal control over financial reporting includes those policies and procedures that:
(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;
(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and
(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.
Because of inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
AmerisourceBergen's management assessed the effectiveness of AmerisourceBergen's internal control over financial reporting as of September 30, 2019. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control — Integrated Framework (2013). Based on management's assessment and those criteria, management has concluded that AmerisourceBergen's internal control over financial reporting was effective as of September 30, 2019.
AmerisourceBergen's independent registered public accounting firm, Ernst & Young LLP, has issued an attestation report on the effectiveness of AmerisourceBergen's internal control over financial reporting. This report is set forth below.

82

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and the Board of Directors of AmerisourceBergen Corporation
Opinion on Internal Control over Financial Reporting
We have audited AmerisourceBergen Corporation and subsidiaries' internal control over financial reporting as of September 30, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, AmerisourceBergen Corporation and subsidiaries (the Company) maintained, in all material respects, effective internal control over financial reporting as of September 30, 2019, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2019 consolidated financial statements of the Company and our report dated November 19, 2019 expressed an unqualified opinion thereon.
Basis for Opinion
The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 
/s/ Ernst & Young LLP
Philadelphia, Pennsylvania
November 19, 2019

83

ITEM 9B.    OTHER INFORMATION
None.
PART III

ITEM 10.    DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Information appearing in our Notice of Annual Meeting of Stockholders and Proxy Statement for the 2020 Annual Meeting of Stockholders (the "2020 Proxy Statement"), including information appearing under "Proxy Statement Highlights - Director Nominees and Board Summary," "Corporate Governance and Related Matters," "Audit Committee Matters," and "Delinquent Section 16(a) Reports," is incorporated herein by reference. We will file the 2020 Proxy Statement with the Securities and Exchange Commission pursuant to Regulation 14A within 120 days after the close of the fiscal year.
Information with respect to Executive Officers of the Company appears in Part I of this report.
We adopted a Code of Ethics for Designated Senior Officers that applies to our Chief Executive Officer, Chief Financial Officer, and Corporate Controller. A copy of this Code of Ethics is posted on our Internet website, which is investor.amerisourcebergen.com. Any amendment to, or waiver from, any provision of this Code of Ethics will be posted on our Internet website.
ITEM 11.    EXECUTIVE COMPENSATION
Information contained in the 2020 Proxy Statement, including information appearing under "Corporate Governance and Related Matters" and "Executive Compensation and Related Matters" in the 2020 Proxy Statement, is incorporated herein by reference.
ITEM 12.    SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
Information contained in the 2020 Proxy Statement, including information appearing under "Beneficial Ownership of Common Stock" and "Equity Compensation Plan Information" in the 2020 Proxy Statement, is incorporated herein by reference.
ITEM 13.    CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
Information contained in the 2020 Proxy Statement, including information appearing under "Corporate Governance and Related Matters" and "Related Person Transactions" in the 2020 Proxy Statement, is incorporated herein by reference.
ITEM 14.    PRINCIPAL ACCOUNTANT FEES AND SERVICES
Information contained in the 2020 Proxy Statement, including information appearing under "Audit Committee Matters" in the 2020 Proxy Statement, is incorporated herein by reference.

84

PART IV

ITEM 15.    EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
(a) (1) and (2) List of Financial Statements and Schedules.
Financial Statements: The following consolidated financial statements are submitted in response to Item 15(a)(1):
 
Page
Financial Statement Schedule: The following financial statement schedule is submitted in response to
Item 15(a)(2):
 
All other schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission are not required under the related instructions or are inapplicable and, therefore, have been omitted.

85

(a) (3) List of Exhibits.*

Exhibit
Number
Description
3.1
3.2
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
4.10
4.11
4.12
4.13
4.14
10.1

86

Exhibit
Number
Description
10.2
‡10.3
‡10.4
‡10.5
‡10.6
‡10.7
‡10.8
‡10.9
‡10.10
‡10.11
‡10.12
‡10.13
‡10.14
‡10.15
‡10.16
‡10.17
‡10.18
‡10.19
‡10.20
‡10.21


87

Exhibit
Number
Description
‡10.22
10.23
10.24
10.25
10.26
10.27
10.28
10.29
10.30
10.31
10.32
10.33
10.34
10.35



88

Exhibit
Number
Description
10.36
10.37
10.38
10.39
10.40
10.41
10.42
10.43
10.44
10.45
10.46
10.47
10.48
10.49


89

Exhibit
Number
Description
10.50
10.51
21
23
31.1
31.2
32
101
Financial statements from the Annual Report on Form 10-K of AmerisourceBergen Corporation for the fiscal year ended September 30, 2019, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations, (iii) the Consolidated Statements of Comprehensive Income, (iv) the Consolidated Statements of Changes in Stockholders' Equity, (v) the Consolidated Statements of Cash Flows, and (vi) the Notes to Consolidated Financial Statements.
104
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).
__________________________________________________________
*
Copies of the exhibits will be furnished to any security holder of the Registrant upon payment of the reasonable cost of reproduction.
‡
Each marked exhibit is a management contract or a compensatory plan, contract or arrangement in which a director or executive officer of the Registrant participates or has participated.
ITEM 16.    FORM 10-K SUMMARY

Not applicable.


90

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
AMERISOURCEBERGEN CORPORATION
Date: November 19, 2019
 
By:
 
/s/ STEVEN H. COLLIS
Steven H. Collis
Chairman, President and Chief Executive Officer
 Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below as of November 19, 2019 by the following persons on behalf of the Registrant and in the capacities indicated.

Signature
 
Title
 
 
 
/s/ STEVEN H. COLLIS___________________________
Steven H. Collis
 
Chairman, President and Chief Executive Officer
(Principal Executive Officer)
 
 
 
/s/ JAMES F. CLEARY____________________________
James F. Cleary
 
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)
 
 
 
/s/ LAZARUS KRIKORIAN________________________
Lazarus Krikorian
 
Senior Vice President and Chief Accounting Officer
(Principal Accounting Officer)
 
 
 
/s/ _____________________________________________
Ornella Barra
 
Director
 
 
 
/s/ D. MARK DURCAN____________________________
D. Mark Durcan
 
Director
 
 
 
/s/ RICHARD W. GOCHNAUER____________________
Richard W. Gochnauer
 
Director
 
 
 
/s/ LON R. GREENBERG__________________________
Lon R. Greenberg
 
Director

91

Signature
 
Title
 
 
 
/s/ JANE E. HENNEY, M.D.________________________
Jane E. Henney, M.D.
 
Lead Independent Director
 
 
 
/s/ KATHLEEN W. HYLE__________________________
Kathleen W. Hyle
 
Director
 
 
 
/s/ MICHAEL J. LONG____________________________
Michael J. Long
 
Director
 
 
 
/s/ HENRY W. MCGEE____________________________
Henry W. McGee
 
Director

92

AMERISOURCEBERGEN CORPORATION AND SUBSIDIARIES
SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS
(In thousands)
 
Balance at
Beginning
of Period
 
Charged to
Costs and
Expenses (1)
 
Deductions-
Describe (2)
 
Balance at
End of
Period (3)
Year Ended September 30, 2019
 
 

 
 

 
 

 
 

Allowances for returns and doubtful accounts
 
$
1,049,901

 
$
3,720,642

 
$
(3,546,656
)
 
$
1,223,887

 
 
 
 
 
 
 
 
 
Year Ended September 30, 2018
 
 

 
 

 
 

 
 

Allowances for returns and doubtful accounts
 
$
1,068,251

 
$
3,397,562

 
$
(3,415,912
)
 
$
1,049,901

 
 
 
 
 
 
 
 
 
Year Ended September 30, 2017
 
 

 
 

 
 

 
 

Allowances for returns and doubtful accounts
 
$
926,034

 
$
3,157,960

 
$
(3,015,743
)
 
$
1,068,251

__________________________________________________________

(1)
Represents the provision for returns and doubtful accounts.
(2)
Represents reductions to the returns allowance and accounts receivable written off during year, net of recoveries.
(3)
Includes an allowance for doubtful accounts for long-term accounts receivable within Other Assets on the Consolidated Balance Sheets of $981 thousand, $13,568 thousand and $17,890 thousand as of September 30, 2019, 2018, and 2017, respectively.


93
 EX-4.14 2 exhibit414-9302019.htm EXHIBIT 4.14 Exhibit



Exhibit 4.14

DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934

The following summary describes the common stock, par value $0.01 per share, of AmerisourceBergen Corporation (“AmerisourceBergen,” “we,” “us,” and “our”), which are the only securities of AmerisourceBergen registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended.
The following description is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, our amended and restated certificate of incorporation, as amended (which we refer to as our “certificate of incorporation”) and our amended and restated bylaws (which we refer to as our “bylaws”), each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.14 is a part. The terms of these securities also may be affected by the General Corporation Law of the State of Delaware (which we refer to below as the “DGCL”).
Authorized Capital Stock
We are authorized to issue a total of 610,000,000 shares of capital stock consisting of 600,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of preferred stock, par value $0.01 per share.
Common Stock
Our authorized common stock consists of 600,000,000 shares of common stock, par value $0.01 per share. Each outstanding share of common stock is entitled to one vote per share. Except as may be provided in a certificate of designations for a series of preferred stock, the holders of common stock have the exclusive right to vote for the election of directors and for all other purposes as provided by law and do not have cumulative voting rights.
Subject to the preferences that may be applicable to any then outstanding shares of preferred stock, holders of common stock are entitled to receive ratably on a per share basis such dividends and other distributions in cash, stock or property of AmerisourceBergen as may be declared by the board of directors from time to time out of the legally available assets or funds of AmerisourceBergen. Upon our voluntary or involuntary liquidation, dissolution or winding up, holders of common stock are entitled to receive ratably all assets of AmerisourceBergen available for distribution to its stockholders.
Holders of our common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to our common stock.
Holders of common stock will have no liability for further calls or assessments and will not be personally liable for the payment of our debts except as they may be liable by reason of their own conduct or acts.
Our board of directors may authorize the issuance of preferred stock with voting, conversion, dividend, liquidation and other rights that may adversely affect the rights of the holder of our common stock.
Preferred Stock
Our authorized preferred stock consists of 10,000,000 shares of preferred stock, par value $0.01 per share. We may issue preferred stock from time to time in one or more series, without stockholder approval, when authorized by our board of directors. Subject to the limits imposed by the DGCL, our board of directors is authorized to fix for any series of preferred stock the number of shares of such series and the voting powers (if any), designation, preferences and relative, participating, optional or other special rights, and qualifications, limitations or restrictions of such series. As of the date of the Annual Report on Form 10-K of which this Exhibit 4.14 is a part, no shares of preferred stock are outstanding.

1


Certain Anti-Takeover Provisions of Our Certificate Incorporation, Bylaws and Delaware Law
The following is a summary of certain provisions of our certificate of incorporation, bylaws and the DGCL that may have the effect of delaying, deterring or preventing hostile takeovers or changes in control or management of AmerisourceBergen. Such provisions could deprive our stockholders of opportunities to realize a premium on their stock. At the same time, these provisions may have the effect of inducing any persons seeking to acquire or control us to negotiate terms acceptable to our board of directors. Throughout the summary we have included parenthetical references to sections of our certificate of incorporation and bylaws to help you locate the provisions being discussed.
Undesignated Preferred Stock
Our certificate of incorporation authorizes our board of directors to issue shares of preferred stock and set the voting powers, designations, preferences, and other rights related to that preferred stock without stockholder approval. Any such designation and issuance of shares of preferred stock could delay, defer or prevent any attempt to acquire or control us. (Section 4.03 of our certificate of incorporation).
Vacancies on the Board of Directors
Our certificate of incorporation and our bylaws provide that, subject to any rights of holders of our preferred stock, any vacancies in our board of directors for any reason will be filled only by a majority of our directors remaining in office, and directors so elected will hold office until the next election of directors. The inability of our stockholders to fill vacancies on the board of directors may make it more difficult to change the composition of our board of directors. (Section 5.06 of our certificate of incorporation and Section 3.14 of our bylaws)
Cumulative Voting
Our certificate of incorporation and bylaws do not provide for cumulative voting. Accordingly, the holders of a majority of the shares of common stock entitled to vote in any election of directors may elect all of the directors standing for election.
No Stockholder Action by Written Consent
Our certificate of incorporation and our bylaws provide that our stockholders may not act by written consent, which may require our stockholders to wait for a regularly scheduled annual meeting to change the composition of our board of directors. (Section 6.03 of our certificate of incorporation and Section 2.10 of our bylaws)
Ability to Call Special Meeting of Stockholders
Our certificate of incorporation and our bylaws provide that special meetings of stockholders may be called at any time by (i) our board of directors pursuant to a resolution duly adopted by a majority of the members of our board of directors or (ii) our stockholders holding at least 25% of the outstanding shares of common stock, subject to the procedures and other requirements set forth in our bylaws. (Section 6.03 of our certificate of incorporation and Section 2.02 of our bylaws)
Advance Notification of Stockholder Nominations and Proposals
Our certificate of incorporation and our bylaws provide that in order for nominations of directors or other business to be properly brought before an annual meeting by our stockholders, subject to certain limited exceptions, the stockholders must give notice to us not less than 90 days nor more than 120 days prior to the anniversary of our previous annual meeting of stockholders. The notice must contain specific information regarding the nominee for director, or other business to be addressed, as well as information regarding the stockholder who is proposing the nomination. (Section 6.04 of our certificate of incorporation and Section 2.03 of our bylaws)

2


Amendments to Bylaws
Our certificate of incorporation and our bylaws provide that our board of directors is expressly authorized to make, alter, amend or repeal the bylaws without the assent or vote of our stockholders. Our certificate of incorporation and our bylaws also provide that our stockholders may, at any annual or special meeting, make, alter, amend or repeal the bylaws by the affirmative vote of a majority of the votes cast for and against the adoption, alteration, amendment or repeal by the holders of shares of our stock present in person or represented by proxy at a meeting of our stockholders and entitled to vote on the adoption, alteration, amendment or repeal. (Section 11.01 of our certificate of incorporation and Section 9.01 of our bylaws)
Business Combinations under Delaware Law
We are a Delaware corporation. Section 203 of the DGCL prohibits a Delaware corporation from engaging in a business combination with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder. The term “business combination” is broadly defined to include mergers, consolidations, and sales and other dispositions of assets having an aggregate market value equal to 10% or more of the consolidated assets of the corporation, and other specified transactions resulting in financial benefits to the interested stockholder. Under Section 203, an “interested stockholder” generally is defined as a person who, together with affiliates and associates, owns (or within the three prior years did own) 15% or more of the corporation’s outstanding voting stock.
This prohibition is effective unless:
•
the business combination or the transaction that resulted in the interested stockholder becoming an interested stockholder is approved by the corporation’s board of directors prior to the time the interested stockholder becomes an interested stockholder;
•
upon consummation of the transaction that resulted in the interested stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation, other than stock held by directors who are also officers or by specified employee stock plans; or
•
at or after the time the stockholder becomes an interested stockholder, the business combination is approved by a majority of the board of directors and, at an annual or special meeting, by the affirmative vote of two-thirds of the outstanding voting stock that is not owned by the interested stockholder.

These restrictions generally prohibit or delay the accomplishment of mergers or other takeover or change-in-control attempts that are not approved by a company’s board of directors. A corporation can elect to have Section 203 of the DGCL not apply to it by expressly providing so in its certificate of incorporation or bylaws; we have not made such an election. (Section 9.01 of our certificate of incorporation)
Limitation of Personal Liability of Directors and Officers
Our certificate of incorporation provides that our directors are entitled to the benefits of all limitations on the liability of directors that are now or hereafter become available under the DGCL. The DGCL authorizes corporations to limit or eliminate the personal liability of directors to corporations and their stockholders for monetary damages for breaches of directors’ fiduciary duties. The DGCL and our certificate of incorporation do not permit exculpation for liability:
•
for any breach of the director’s duty of loyalty to us or our stockholders,
•
for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law,
•
under section 174 of the Delaware law, which pertains, among other things, to liability for the unlawful payment of dividends, or
•
for any transaction from which the director derived an improper personal benefit. (Section 7.01 of our certificate of incorporation)

3


In addition, subject to certain exceptions set forth therein, our certificate of incorporation provides that we will indemnify any person who is or was a director or officer of ours, or is or was serving at our request as a director, officer or trustee of another corporation, trust or other enterprise, with respect to actions taken or omitted by such person in any capacity in which such person serves us or such other corporation, trust or other enterprise, to the full extent authorized or permitted by law, as now or hereafter in effect, and such right to indemnification will continue as to a person who has ceased to be a director, officer or trustee, as the case may be, and will inure to the benefit of such person’s heirs, executors and personal and legal representatives. (Section 7.02 of our certificate of incorporation)
In addition, our certificate of incorporation provides that we may advance to a director or officer expenses incurred in defending any action in advance of its final disposition. (Section 7.03 of our certificate of incorporation)
The limitation of liability, indemnification and advancement of expenses provisions in our certificate of incorporation may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers in accordance with these indemnification provisions.
Forum Selection
Our bylaws provide, unless we consent in writing to an alternative forum, that the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to any provision of the DGCL, our certificate of incorporation or our bylaws (in each case, as they may be amended from time to time), or (iv) any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine, will be the Court of Chancery of the State of Delaware (or, if the Court of Chancery lacks subject matter jurisdiction, another state court located in the State of Delaware or, if no state court located in the State of Delaware has jurisdiction, the federal district court for the District of Delaware). (Section 8.05 of our bylaws) Any person that purchases or otherwise acquires an interest in our stock will be deemed to have notice of and agree to comply with the foregoing provisions.
Transfer Agent and Registrar
Computershare serves as the registrar and transfer agent for our common stock.
Stock Exchange Listing
Our common stock is listed on the New York Stock Exchange under the trading symbol “ABC.”


4
 EX-21 3 exhibit21-9302019.htm EXHIBIT 21 Exhibit


Exhibit 21

SUBSIDIARIES OF THE REGISTRANT

The following is a list of significant subsidiaries of the Registrant.
Subsidiary
 
Jurisdiction of Incorporation
Amerisource Receivables Financial Corporation
 
Delaware
AmerisourceBergen Drug Corporation
 
Delaware
AmerisourceBergen Global Holdings GmbH
 
Switzerland
AmerisourceBergen Global Manufacturer Services GmbH
 
Switzerland
AmerisourceBergen Group AG
 
Switzerland
AmerisourceBergen Luxembourg S.a.r.L.
 
Luxembourg
AmerisourceBergen Services Corporation
 
Delaware
AmerisourceBergen Specialty Group, LLC
 
Delaware
ASD Specialty Healthcare, LLC
 
California
BPL Group, LLC
 
Delaware
BPLH Ireland Unlimited Company
 
Ireland
MWI Veterinary Supply, Co.
 
Idaho
MWI Veterinary Supply, Inc.
 
Delaware
World Courier Group S.à r.l.
 
Luxembourg



 EX-23 4 exhibit23-9302019.htm EXHIBIT 23 Exhibit


Exhibit 23

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)
Registration Statement (Form S-3 No. 333-228489) of AmerisourceBergen Corporation,
(2)
Registration Statement (Form S-8 No. 333-86012) pertaining to the AmerisourceBergen Employee Investment Plan,
(3)
Registration Statements (Form S-8 Nos. 333-88230, 333-110431, and 333-140470) pertaining to the AmerisourceBergen Corporation 2002 Management Stock Incentive Plan, as amended,
(4)
Registration Statement (Form S-8 No. 333-101042) pertaining to the AmerisourceBergen Corporation 2001 Deferred Compensation Plan and the AmerisourceBergen Corporation 2001 Restricted Stock Plan,
(5)
Registration Statement (Form S-8 No. 333-101043) pertaining to the AmerisourceBergen Corporation 2001 Non-Employee Directors' Stock Option Plan,
(6)
Registration Statement (Form S-8 No. 333-159924) pertaining to the AmerisourceBergen Corporation Management Incentive Plan,
(7)
Registration Statement (Form S-8 No. 333-173982) pertaining to the AmerisourceBergen Corporation 2011 Employee Stock Purchase Plan, and
(8)
Registration Statement (Form S-8 No. 333-194325) pertaining to the AmerisourceBergen Corporation Omnibus Incentive Plan;

of our reports dated November 19, 2019, with respect to the consolidated financial statements and schedule of AmerisourceBergen Corporation and subsidiaries and the effectiveness of internal control over financial reporting of AmerisourceBergen Corporation and subsidiaries included in this Annual Report (Form 10-K) of AmerisourceBergen Corporation and subsidiaries for the year ended September 30, 2019.


/s/ Ernst & Young LLP

Philadelphia, Pennsylvania
November 19, 2019



 EX-31.1 5 exhibit311-9302019.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1

Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer

I, Steven H. Collis, certify that:

         1. I have reviewed this Annual Report on Form 10-K (the "Report") of AmerisourceBergen Corporation (the "Registrant");

         2. Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;

         3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this Report;

         4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

         (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;

         (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

         (c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and

         (d) Disclosed in this Report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

         5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of Registrant's board of directors:

         (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

         (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.
 
/s/ Steven H. Collis
Steven H. Collis
Chairman, President and Chief Executive Officer
Date: November 19, 2019





EX-31.2 6 exhibit312-9302019.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2

Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer

I, James F. Cleary, certify that:

         1. I have reviewed this Annual Report on Form 10-K (the "Report") of AmerisourceBergen Corporation (the "Registrant");

         2. Based on my knowledge, this Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this Report;

         3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this Report;

         4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

         (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Report is being prepared;

         (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

         (c) Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this Report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this Report based on such evaluation; and

         (d) Disclosed in this Report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

         5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of Registrant's board of directors:

         (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

         (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.
 
/s/ James F. Cleary
James F. Cleary
Executive Vice President and Chief Financial Officer
Date: November 19, 2019



EX-32 7 exhibit32-9302019.htm EXHIBIT 32 Exhibit


Exhibit 32

Section 1350 Certification of Chief Executive Officer

         In connection with the Annual Report of AmerisourceBergen Corporation (the "Company") on Form 10-K for the fiscal year ended September 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Steven H. Collis, Chairman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

         (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

         (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ Steven H. Collis
Steven H. Collis
Chairman, President and Chief Executive Officer
November 19, 2019

Section 1350 Certification of Chief Financial Officer

         In connection with the Annual Report of AmerisourceBergen Corporation (the "Company") on Form 10-K for the fiscal year ended September 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, James F. Cleary, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

         (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

         (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
/s/ James F. Cleary
James F. Cleary
Executive Vice President and Chief Financial Officer
November 19, 2019

         A signed original of this written statement required by Section 906 has been provided to AmerisourceBergen Corporation and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

         This certification accompanies the Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.



 EX-101.SCH 8 abc-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2103100 - Disclosure - Acquisitions and Investments link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Acquisitions and Investments - H.D. Smith (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Acquisitions and Investments - NEVSCO (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Acquisitions and Investments - Proforma and Specialty Joint Venture (Details) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Business Segment Information link:presentationLink link:calculationLink link:definitionLink 2418404 - Disclosure - Business Segment Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2418403 - Disclosure - Business Segment Information - Reconciliation of Segment Operating Income to Income From Continuing Operations (Details) link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Business Segment Information - Reconciliation of Segment Revenue, Operating Income, Assets, Depreciation and Amortization, and Capital Expenditures (Details) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - Business Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOW link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 1004501 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Debt - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Debt - Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Debt - Debt Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Employee Severance, Litigation, and Other link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Employee Severance, Litigation, and Other (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Employee Severance, Litigation, and Other (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2419401 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Goodwill and Other Intangible Assets - Changes in Carrying Value of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Goodwill and Other Intangible Assets - Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Goodwill and Other Intangible Assets - Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2407407 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Income Taxes - Domestic and Foreign Income From Continuing Operations Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Income Taxes - Income Tax Provision (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 2407406 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2407405 - Disclosure - Income Taxes - Significant Components of Deferred Tax Liabilities (Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Lease Commitments link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Lease Commitments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Lease Commitments - Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Lease Commitments - Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Lease Commitments (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Legal Matters and Contingencies link:presentationLink link:calculationLink link:definitionLink 2416401 - Disclosure - Legal Matters and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Litigation Settlements link:presentationLink link:calculationLink link:definitionLink 2417401 - Disclosure - Litigation Settlements (Details) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Quarterly Financial Information (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Quarterly Financial Information (Unaudited) (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Quarterly Financial Information (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2411401 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Retirement and Other Benefit Plans link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Retirement and Other Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2122100 - Schedule - Schedule II - Valuation and Qualifying Accounts link:presentationLink link:calculationLink link:definitionLink 2422402 - Schedule - Schedule II - Valuation and Qualifying Accounts - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2422401 - Schedule - Schedule II - Valuation and Qualifying Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Share-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - Share-Based Compensation - Nonvested Options (Details) link:presentationLink link:calculationLink link:definitionLink 2413407 - Disclosure - Share-Based Compensation - Nonvested Performance Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - Share-Based Compensation - Nonvested Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 2413404 - Disclosure - Share-Based Compensation - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Accumulated Other Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Diluted Weighted Average Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 2401405 - Disclosure - Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2401407 - Disclosure - Summary of Significant Accounting Policies - Merchandise Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Summary of Significant Accounting Policies - New Accounting Pronouncements (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2401408 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2401409 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 2401410 - Disclosure - Summary of Significant Accounting Policies - Shipping and Handling Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Variable Interest Entity link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Variable Interest Entity (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Variable Interest Entity (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 abc-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 abc-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 abc-20190930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Statement of Financial Position [Abstract] Current assets: Assets, Current [Abstract] Allowances for returns and doubtful accounts Allowances for returns and doubtful accounts Allowances for returns and doubtful accounts. Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Common stock, authorized (shares) Common Stock, Shares Authorized Common stock, issued (shares) Common Stock, Shares, Issued Common stock, outstanding (shares) Common Stock, Shares, Outstanding Treasury stock (shares) Treasury Stock, Shares Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Accounting Policies [Abstract] Schedule of Assets [Table] Schedule of Impaired Long-Lived Assets Held and Used [Table] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Customer relationships [Member] Customer Relationships [Member] Trade names [Member] Trade Names [Member] Software technology [Member] Computer Software, Intangible Asset [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] PharMEDium Healthcare Holdings, Inc [Member] Pharmedium Healthcare Holdings Inc [Member] Represents information pertaining to PharMEDium Healthcare Holdings, Inc. Assets Held and Used [Line Items] Impaired Long-Lived Assets Held and Used [Line Items] Goodwill impairment Goodwill, Impairment Loss Indefinite-lived intangible asset impairment Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Impairment of long-lived assets Asset Impairment Charges Carrying value of asset group, excluding goodwill Long-Lived Assets Fair value of asset group Assets, Fair Value Disclosure Discount rate (as a percentage) Asset, Fair Value, Discount Rate Asset, Fair Value, Discount Rate Finite-lived intangible asset impairment Impairment of Intangible Assets, Finite-lived Property and equipment impairment Impairment of Long-Lived Assets Held-for-use Equity [Abstract] Stockholders' Equity and Weighted Average Common Shares Outstanding Stockholders' Equity and Weighted Average Common Shares Outstanding [Text Block] Stockholders' Equity and Weighted Average Common Shares Outstanding Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Variable Interest Entities [Table] Schedule of Variable Interest Entities [Table] Variable Interest Entities [Axis] Variable Interest Entities [Axis] Variable Interest Entity, Classification [Domain] Variable Interest Entity, Classification [Domain] Variable Interest Entity, Primary Beneficiary [Member] Variable Interest Entity, Primary Beneficiary [Member] Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accounts receivables, net Accounts Receivable, after Allowance for Credit Loss Inventories Inventory, Net Prepaid expenses and other Prepaid Expense and Other Assets Property and equipment, net Property, Plant and Equipment, Net Goodwill Goodwill Other intangible assets Other Intangible Assets, Net Other long-term assets Other Assets, Noncurrent TOTAL ASSETS Assets Accounts payable Accounts Payable Accrued expenses and other Accrued Liabilities and Other Liabilities Short-term debt Short-term Debt Long-term debt Long-term Debt Deferred income taxes Deferred Income Tax Liabilities, Net Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Scenario [Axis] Scenario [Axis] Scenario [Domain] Scenario [Domain] Forecast [Member] Forecast [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-09 [Member] Accounting Standards Update 2016-09 [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Retained Earnings [Member] Retained Earnings [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Cumulative effect adjustment, share-based compensation Cumulative Effect of New Accounting Principle in Period of Adoption Deferred tax assets Deferred Tax Assets, Gross Lease, liability Operating Lease, Liability Retirement Benefits [Abstract] Retirement and Other Benefit Plans Pension and Other Postretirement Benefits Disclosure [Text Block] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Defined Contribution Plan Tranches [Axis] Defined Contribution Plan Tranches [Axis] Defined Contribution Plan Tranches [Axis] Defined Contribution Plan Tranches [Domain] Defined Contribution Plan Tranches [Domain] [Domain] for Defined Contribution Plan Tranches [Axis] Employee contribution, first 3% of salary [Member] Employee Contribution First Three Percent Of Salary [Member] Represents the information pertaining to the employee contribution up to the first three percent of the salary. Employee contribution, additional 2% of salary [Member] Employee Contribution Additional Two Percent Of Salary [Member] Represents the information pertaining to the employee contribution by additional two percentage of the salary. Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Minimum allowed employee contributions, percent of salary Defined Contribution Plan, Minimum Annual Contributions Per Employee, Percent Defined Contribution Plan, Minimum Annual Contributions Per Employee, Percent Maximum allowed employee contributions, percent of salary Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Employer matching contribution, percent of match Defined Contribution Plan, Employer Matching Contribution, Percent of Match Employer matching contribution, percent of salary Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Discretionary contributions Defined Contribution Plan, Employer Discretionary Contribution Amount Discretionary contributions, vesting period (in years) Defined Contribution Plan, Employer Discretionary Contribution, Vesting Period Defined Contribution Plan, Employer Discretionary Contribution, Vesting Period Deferred compensation, annual benefit, percent of compensation, Benefit Restoration Plan Deferred Compensation Arrangement with Individual, Annual Distributions Represents the percentage of the annual amount of the participant's base salary and bonus incentive by which the compensation exceeds the annual compensation limit established by the provisions of the Internal Revenue Code. Defined contribution plans expense Defined Contribution Plan, Cost Deferred compensation, common stock authorized for issuance (shares) Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance Deferred compensation, common stock issued (shares) Deferred Compensation Arrangement with Individual, Shares Issued Deferred compensation liability Deferred Compensation Arrangement with Individual, Recorded Liability SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract] Schedule II - Valuation and Qualifying Accounts SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block] Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] CDOR / LIBOR / EURIBOR / Bankers Acceptance Stamping Fee [Member] Cdor Libor Euribor Bankers Acceptance Stamping Fee [Member] CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee. Alternate base rate and Canadian prime rate [Member] Alternate Base Rate And Canadian Prime Rate Cdor Rate [Member] Alternate base rate and Canadian prime rate. LIBOR [Member] London Interbank Offered Rate (LIBOR) [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Multi-currency revolving credit facility due 2021 [Member] Multi Currency Revolving Credit Facility [Member] Commercial paper [Member] Commercial Paper [Member] Receivables securitization facility due 2022 [Member] Receivables Securitization Facility [Member] Revolving credit note [Member] Revolving Credit Note [Member] Overdraft facility due in 2021 [Member] Overdraft Facility [Member] Refers to overdraft facility. Term Loan Agreement October 2018 [Member] Term Loan Agreement October 2018 [Member] Term Loan Agreement October 2018 [Member] $750,000, 3.45% senior notes due 2027 [Member] Senior Notes Due2027 [Member] Senior Notes Due2027 [Member] $500,000, 4.3% senior notes due 2047 [Member] Senior Notes Due2047 [Member] Senior Notes Due2047 [Member] $400,000, 4.875% senior notes due 2019 [Member] Senior Notes Due2019 [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Variable rate spread Debt Instrument, Basis Spread on Variable Rate Minimum facility fee rate Debt Instrument Facility Fee Rate Effective Percentage Rate Range Minimum Debt Instrument Facility Fee Rate Effective Percentage Rate Range Minimum Maximum facility fee rate Debt Instrument Facility Fee Rate Effective Percentage Rate Range Maximum Debt Instrument Facility Fee Rate Effective Percentage Rate Range Maximum Facility fee, period end Line of Credit Facility, Commitment Fee Percentage Short-term debt Accordion feature, potential increase in commitment Ability to Increase Debt Commitment Under Accordion Feature in December and March Quarters Ability to Increase Debt Commitment Under Accordion Feature in December and March Quarters Principal amount Debt Instrument, Face Amount Interest rate Debt Instrument, Interest Rate, Stated Percentage Percentage of principal amount Debt Instrument, Face Amount Percentage Debt Instrument, Face Amount Percentage Effective yield percentage Debt Instrument, Interest Rate, Effective Percentage Payment of premium on early retirement of debt Payment for Debt Extinguishment or Debt Prepayment Cost Scheduled future principal payments, in fiscal 2020 Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months Scheduled future principal payments, in fiscal 2021 Long-term Debt, Maturities, Repayments of Principal in Year Two Scheduled future principal payments, in fiscal 2022 Long-term Debt, Maturities, Repayments of Principal in Year Three Scheduled future principal payments, in fiscal 2023 Long-term Debt, Maturities, Repayments of Principal in Year Four Scheduled future principal payments, in fiscal 2024 Long-term Debt, Maturities, Repayments of Principal in Year Five Scheduled future principal payments, thereafter Long-term Debt, Maturities, Repayments of Principal after Year Five Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Amortization of financing fees and accretion of original issue discounts Debt Related Commitment Fees and Debt Issuance Costs Statement of Stockholders' Equity [Abstract] Cash dividends (usd per share) Common Stock, Dividends, Per Share, Cash Paid Segment Reporting [Abstract] Reconciliation of revenue from segments to consolidated Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Reconciliation of segment operating income, depreciation and amortization, and capital expenditures from segments to consolidated Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block] Reconciliation of total segment operating income to income from continuing operations before income taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Reconciliation of assets from segment to consolidated Reconciliation of Assets from Segment to Consolidated [Table Text Block] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Unrecognized tax benefits at beginning of period Unrecognized Tax Benefits Additions of tax positions of the current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Additions to tax positions of the prior years Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Reductions of tax positions of the prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Settlements with taxing authorities Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Expiration of statutes of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Unrecognized tax benefits at end of period Components of Deferred Tax Assets and Liabilities [Abstract] Components of Deferred Tax Assets and Liabilities [Abstract] Inventories Deferred Tax Liabilities, Inventory Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Goodwill and other intangible assets Deferred Tax Liabilities, Goodwill and Intangible Assets Other Deferred Tax Liabilities, Other Gross deferred tax liabilities Deferred Tax Liabilities, Gross Net operating loss and tax credit carryforwards Deferred Tax Assets, Net Operating Loss and Tax Credit Carryforwards Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards and net operating loss. Allowance for doubtful accounts Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts Accrued expenses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Employee and retiree benefits Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits Share-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Other Deferred Tax Assets, Other Gross deferred tax assets Valuation allowance for deferred tax assets Deferred Tax Assets, Valuation Allowance Deferred tax assets, net of valuation allowance Deferred Tax Assets, Net of Valuation Allowance Net deferred tax liabilities Deferred Tax Liabilities, Net Statement of Cash Flows [Abstract] OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation, including amounts charged to cost of goods sold Depreciation Amortization, including amounts charged to interest expense Amortization Provision for doubtful accounts Accounts Receivable, Credit Loss Expense (Reversal) Provision (benefit) for deferred income taxes Deferred Income Tax Expense (Benefit) Share-based compensation expense Share-based Payment Arrangement, Noncash Expense LIFO (credit) expense Inventory, LIFO Reserve, Period Charge Gain on sale of an equity investment Equity Method Investment, Realized Gain (Loss) on Disposal Impairment of non-customer note receivable Note Receivable Impairment Note Receivable Impairment Loss on consolidation of equity investments Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss Loss on early retirement of debt Gain (Loss) on Extinguishment of Debt Other Other Noncash Income (Expense) Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Income taxes payable Increase (Decrease) in Income Taxes Payable Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities NET CASH PROVIDED BY OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Capital expenditures Payments to Acquire Property, Plant, and Equipment Cost of acquired companies, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Cost of equity investments Payments to Acquire Equity Method Investments Proceeds from sale of business Proceeds from Divestiture of Businesses Proceeds from sales of investment securities available-for-sale Proceeds from Sale of Debt Securities, Available-for-sale Purchases of investment securities available-for-sale Payments to Acquire Debt Securities, Available-for-sale Other Payments for (Proceeds from) Other Investing Activities NET CASH USED IN INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Senior notes and other loan borrowings Proceeds from Issuance of Debt Senior notes and other loan repayments Repayments of Long-term Debt Borrowings under revolving and securitization credit facilities Proceeds from Long-term Lines of Credit Repayments under revolving and securitization credit facilities Repayments of Long-term Lines of Credit Payment of premium on early retirement of debt Purchases of common stock Payments for Repurchase of Common Stock Exercises of stock options Proceeds and Excess Tax Benefit from Share-based Compensation Cash dividends on common stock Payments of Ordinary Dividends, Common Stock Tax withholdings related to restricted share vesting Payment, Tax Withholding, Share-based Payment Arrangement Other Proceeds from (Payments for) Other Financing Activities NET CASH USED IN FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of year CASH AND CASH EQUIVALENTS AT END OF YEAR Share-based Payment Arrangement [Abstract] Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, beginning of period (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Expired (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Outstanding, end of period (shares) Exercisable, end of period (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Expected to vest after end of period (shares) Options Expected to Vest No definition available. Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding, beginning of period (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Forfeited (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expired (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Outstanding, end of period (usd per share) Exercisable, end of period (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Expected to vest after end of period (usd per share) Options Expected to Vest Weighted Average Exercise Price No definition available. Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term No definition available Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Expected to vest after end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Aggregate Intrinsic Value No definition available Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Expected to vest after end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Debt Instruments Schedule of Long-term Debt Instruments [Table Text Block] Income Statement [Abstract] Revenue Revenues Cost of goods sold Cost of Goods and Services Sold Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Distribution, selling, and administrative Selling, General and Administrative Expense Depreciation Depreciation, Nonproduction Amortization Amortization of Intangible Assets Employee severance, litigation, and other Restructuring Charges Goodwill impairment Impairment of long-lived assets (Note 1) Operating income Operating Income (Loss) Other (income) loss Nonoperating Income (Expense) Interest expense, net Interest Income (Expense), Nonoperating, Net Loss on consolidation of equity investments Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income tax expense (benefit) Income Tax Expense (Benefit) Net income Net loss attributable to noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Net income attributable to AmerisourceBergen Corporation Net Income (Loss) Attributable to Parent Earnings per share: Earnings Per Share [Abstract] Basic (usd per share) Earnings Per Share, Basic Diluted (usd per share) Earnings Per Share, Diluted Weighted average common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (shares) Weighted Average Number of Shares Outstanding, Basic Diluted (shares) Weighted Average Number of Shares Outstanding, Diluted Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Schedule of Variable Interest Entities Schedule of Variable Interest Entities [Table Text Block] Debt Debt Disclosure [Text Block] Statement [Table] Statement [Table] Common Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Accumulated Other Comprehensive Loss [Member] AOCI Attributable to Parent [Member] Treasury Stock [Member] Treasury Stock [Member] Noncontrolling Interest [Member] Noncontrolling Interest [Member] Statement [Line Items] Statement [Line Items] Increase (decrease) in stockholders' equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance, beginning of period Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Adoption of ASU Consolidation of variable interest entity Stockholders' Equity, Change in Reporting Entity Net income (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Cash dividends Dividends, Common Stock, Cash Exercises of stock options Stock Issued During Period, Value, Stock Options Exercised Share-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Common stock purchases for employee stock purchase plan Adjustments to Additional Paid in Capital, Other Purchases of common stock Treasury Stock, Value, Acquired, Cost Method Settlement of accelerated share repurchase transaction Accelerated Share Repurchase Program, Adjustment Employee tax withholdings related to restricted share vesting Employee Tax Withholdings Related to Restricted Share Vesting Withholdings Related to Restricted Share Vesting Other Shareholders Equity Other No definition available. Balance, end of period Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Allowances for returns and doubtful accounts [Member] Allowance For Returns And Doubtful Accounts [Member] Represents the allowance for returns and doubtful accounts. SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Balance at Beginning of Period SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Charged to Costs and Expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Deductions SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Balance at End of Period Commitments and Contingencies Disclosure [Abstract] Operating Leases Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Rental expense Operating Leases, Rent Expense Litigation Settlement [Abstract] Litigation Settlements Commitments and Contingencies Disclosure [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Performance stock units [Member] Performance Shares [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Performance Stock Units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Nonvested, beginning of period (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Forfeited (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Nonvested, end of period (shares) Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Nonvested, beginning of period (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Nonvested, end of period (usd per share) Restructuring and Related Activities [Abstract] Employee severance, litigation, and other charges Restructuring and Related Costs [Table Text Block] Percentage of inventories, cost determined using LIFO Percentage of LIFO Inventory Excess cost of inventories over LIFO, if used FIFO Excess of Replacement or Current Costs over Stated LIFO Value LIFO charges (credit) Shipping and Handling [Table] Shipping and Handling [Table] Shipping and Handling [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Shipping and Handling [Member] Shipping and Handling [Member] Shipping and Handling [Line Items] Shipping and Handling [Line Items] [Line Items] for Shipping and Handling [Table] Domestic and foreign income from continuing operations before income taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Income tax provision Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Reconciliation of the effective income tax rate Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Significant components of deferred tax liabilities (assets) Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties Summary of Income Tax Contingencies [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Operating segments [Member] Operating Segments [Member] Segment reconciling items [Member] Segment Reconciling Items [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Operating income Gain from antitrust litigation settlements Gain (Loss) Related to Litigation Settlement LIFO credit (expense) PharMEDium remediation costs Remediation Costs Remediation Costs New York State Opioid Stewardship Act New York State Opioid Stewardship Act Expense New York State Opioid Stewardship Act Expense Acquisition-related intangibles amortization Other Depreciation and Amortization Employee severance, litigation, and other Goodwill impairment Impairment of long-lived assets Income before income taxes Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] USAO-EDNY Matter [Member] USAO-EDNY Matter [Member] USAO-EDNY Matter [Member] USAO - EDNY Civil Claims [Member] USAO - EDNY Civil Claims [Member] USAO - EDNY Civil Claims [Member] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Federal [Member] Domestic Tax Authority [Member] State [Member] State and Local Jurisdiction [Member] Foreign [Member] Foreign Tax Authority [Member] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Alternative minimum tax credit carryforwards [Member] Alternative Minimum Tax [Member] Represents information pertaining to alternative minimum tax. Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Tax Cuts and Jobs Act, recognized income tax benefits Tax Cuts and Jobs Act, Income Tax Expense (Benefit) Tax Cuts and Jobs Act, deferred income tax benefit as result of applying a lower U.S. federal income tax rate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Tax Cuts and Jobs Act, current income tax expense on historical foreign earnings and profits Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount Income tax benefit Tax Cuts and Jobs Act, decrease in provisional transition tax Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit) Adjustments recorded to deferred income taxes related to 2017 Tax Act Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit) Undistributed earnings of international subsidiaries Undistributed Earnings of Foreign Subsidiaries Permanently reinvested cumulative undistributed earnings Undistributed Earnings of Foreign Subsidiaries Permanently Reinvested Undistributed Earnings of Foreign Subsidiaries Permanently Reinvested Potential tax benefits from net operating loss carryforwards Operating Loss Carryforwards Net operating loss carryforwards, term (in years) Operating Loss Carryforwards, Term Term operating loss carryforwards. Tax credit carryforwards Tax Credit Carryforward, Amount Valuation allowance - increase (decrease) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Excess tax benefit from the exercise of stock options and lapses of restricted stock units Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount Income tax payments, net of refunds Income Taxes Paid, Net Unrecognized tax benefits, including interest and penalties Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued Unrecognized tax benefits, including interest and penalties, net of federal benefit Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued, Net of Federal Benefit Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued, Net of Federal Benefit Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized tax benefits, interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Litigation settlement, unrecognized tax benefit Litigation settlement, accrued reserve Litigation Settlement, Amount Awarded to Other Party Litigation settlement, payment Payments for Legal Settlements Reduction of unrecognized tax benefits reasonably possible Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Legal Matters and Contingencies Legal Matters and Contingencies [Text Block] Employee options [Member] Share-based Payment Arrangement, Option [Member] Non-employee options [Member] Non Employee [Member] Represents information pertaining to compensation granted to Non-employee director. Restricted stock units [Member] Restricted Stock Units (RSUs) [Member] Vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Expiration period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Shares granted Share Based Compensation Arrangement By Share Based Payment Award Number of Shares Available for Grant Under AmerisourceBergen Equity Incentive Plan Share Based Compensation Arrangement By Share Based Payment Award Number of Shares Available for Grant Under AmerisourceBergen Equity Incentive Plan Weighted average fair values of options granted (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Stock option expense Stock or Unit Option Plan Expense Intrinsic value of stock option exercises Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Total fair values of options vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Nonvested options outstanding (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Expected future compensation expense relating to nonvested options outstanding Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Weighted average period over which expected future compensation expense relating to nonvested options outstanding will be recognized Weighted Average Period of Unrecognized Option Compensation No definition available. Restricted stock expense Restricted Stock or Unit Expense Total fair values of restricted shares vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Nonvested shares outstanding (shares) Expected future compensation expense relating to restricted shares outstanding Restricted Stock Compensation Not Yet Recognized No definition available. Weighted average period over which expected future compensation expense relating to restricted shares outstanding will be recognized Weighted Average Period of Unrecognized Restricted Stock Compensation No definition available. Vesting percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Performance stock unit expense Performance Share Expense No definition available. Components of accumulated other comprehensive loss Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Components of diluted weighted average shares outstanding Schedule of Weighted Average Number of Shares [Table Text Block] 2020 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2021 Operating Leases, Future Minimum Payments, Due in Two Years 2022 Operating Leases, Future Minimum Payments, Due in Three Years 2023 Operating Leases, Future Minimum Payments, Due in Four Years 2024 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total minimum lease payments Operating Leases, Future Minimum Payments Due Financing Obligations Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] 2020 Capital Leases, Future Minimum Payments Due, Next Twelve Months 2021 Capital Leases, Future Minimum Payments Due in Two Years 2022 Capital Leases, Future Minimum Payments Due in Three Years 2023 Capital Leases, Future Minimum Payments Due in Four Years 2024 Capital Leases, Future Minimum Payments Due in Five Years Thereafter Capital Leases, Future Minimum Payments Due Thereafter Total minimum lease payments Capital Leases, Future Minimum Payments Due Operating and Financing Obligations Operating and Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Operating and Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] 2020 Operating and Capital Leases, Future Minimum Payments Due, Next Twelve Months Operating and Capital Leases, Future Minimum Payments Due, Next Twelve Months 2021 Operating and Capital Leases, Future Minimum Payments Due in Two Years Operating and Capital Leases, Future Minimum Payments Due in Two Years 2022 Operating and Capital Leases, Future Minimum Payments Due in Three Years Operating and Capital Leases, Future Minimum Payments Due in Three Years 2023 Operating and Capital Leases, Future Minimum Payments Due in Four Years Operating and Capital Leases, Future Minimum Payments Due in Four Years 2024 Operating and Capital Leases, Future Minimum Payments Due in Five Years Operating and Capital Leases, Future Minimum Payments Due in Five Years Thereafter Operating and Capital Leases, Future Minimum Payments Due Thereafter Operating and Capital Leases, Future Minimum Payments Due Thereafter Total minimum lease payments Operating and Capital Leases, Future Minimum Payments Due Operating and Capital Leases, Future Minimum Payments Due Restricted Stock Units Weighted Average Grant Date Fair Value Employee Severance, Litigation, and Other Restructuring and Related Activities Disclosure [Text Block] Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Fair Value, Recurring [Member] Fair Value, Recurring [Member] Foreign currency translation [Member] Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Profarma Distribuidora de Produtos Farmaceuticos S.A. [Member] Profarma Distribuidora de Produtos Farmaceuticos S.A. [Member] Profarma Distribuidora de Produtos Farmaceuticos S.A. Profarma Joint Venture [Member] Profarma Joint Venture [Member] Profarma Joint Venture [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Investment in profarma Investment in specialty joint venture Payments to Acquire Interest in Joint Venture Ownership interest in profarma Equity Method Investment, Ownership Percentage Ownership in specialty joint venture Joint Venture, Ownership Percentage Joint Venture, Ownership Percentage Goodwill Estimated fair value of accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Estimated fair value of inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Estimated fair value of accounts payable and accrued expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Assumed short-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt Assumed long-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Assumed cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Noncontrolling interest Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Estimated fair value of the intangible assets acquired, finite-lived Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Estimated useful life (in years) Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Net deferred tax liabilities Fair value of equity interests Equity Method Investment, Quoted Market Value Foreign currency translation adjustment from AOCI Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Investment Transferred from Equity Method to Consolidation, Net of Tax Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Investment Transferred from Equity Method to Consolidation, Net of Tax Gain on remeasurement of Profarma's previously held equity interest Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain Statement of Comprehensive Income [Abstract] Other comprehensive (loss) income: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Loss on consolidation of equity investments Other Other Comprehensive Income, Other, Net of Tax Total other comprehensive (loss) income Total comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss attributable to noncontrolling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Comprehensive income attributable to AmerisourceBergen Corporation Comprehensive Income (Loss), Net of Tax, Attributable to Parent Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Northeast Veterinary Supply Company NEVSCO [Member] Northeast Veterinary Supply Company NEVSCO [Member] Northeast Veterinary Supply Company NEVSCO [Member] Cash paid to acquire business, including purchase price adjustments Payments to Acquire Businesses, Gross Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Volatility of common stock Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected life of the options Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Concentration Risk [Table] Concentration Risk [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Walgreens Boots Alliance, Inc. [Member] Walgreens Boots Alliance Inc [Member] Represents information pertaining to Walgreens Boots Alliance, Inc. Express Scripts, Inc. [Member] Express Scripts [Member] Represent major customer Express Scripts Concentration Risk [Line Items] Concentration Risk [Line Items] Major customer, percentage of revenue Customer Revenue as Percentage of Total Revenue No definition available. Major customer, percentage of accounts receivable Trade Receivable Due From Single Customer As Percentage of Accounts Receivable No definition available. Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] AOCI Attributable to Parent [Member] Pension and postretirement adjustments [Member] Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Other [Member] Accumulated Other Adjustments Attributable to Parent [Member] Accumulated Other Adjustments Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated other comprehensive loss Stockholders' Equity Attributable to Parent Variable Interest Entity Variable Interest Entity Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Carrying amount [Member] Reported Value Measurement [Member] Fair value [Member] Estimate of Fair Value Measurement [Member] Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instrument [Domain] Financial Instruments [Domain] Money market accounts [Member] Money Market Funds [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Long-term debt Long-term Debt, Fair Value ASSETS Assets [Abstract] Accounts receivable, less allowances for returns and doubtful accounts: 2019 — $1,222,906; 2018 — $1,036,333 Accounts Receivable, after Allowance for Credit Loss, Current Inventories (Note 1) Right to recover asset (Note 1) Contract with Customer, Asset, Gross, Current Prepaid expenses and other Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, at cost: Property, Plant and Equipment, Net [Abstract] Land Land Buildings and improvements Buildings and Improvements, Gross Machinery, equipment, and other Machinery and Equipment, Gross Total property and equipment Property, Plant and Equipment, Gross Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Goodwill Other intangible assets Intangible Assets, Net (Excluding Goodwill) Other assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses and other Accrued Liabilities, Current Short-term debt Debt, Current Total current liabilities Liabilities, Current Long-term debt Long-term Debt, Excluding Current Maturities Long-term financing obligation Capital Lease Obligations, Noncurrent Accrued income taxes Accrued Income Taxes, Noncurrent Other liabilities Commitments and contingencies (Note 13) Commitments and Contingencies Common stock, $0.01 par value — authorized, issued, and outstanding: 2019 — 600,000,000 shares, 285,295,170 shares and 206,760,654 shares; 2018 — 600,000,000 shares, 283,588,463 shares and 213,217,882 shares Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Retained earnings Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Treasury stock, at cost: 2019 — 78,534,516 shares; 2018 — 70,370,581 shares Treasury Stock, Value Total AmerisourceBergen Corporation stockholders' equity Noncontrolling interest Stockholders' Equity Attributable to Noncontrolling Interest Total equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity Class of Treasury Stock [Table] Class of Treasury Stock [Table] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] May 2016 Share Repurchase Program [Member] May 2016 Share Repurchase Program [Member] May 2016 Share Repurchase Program [Member] November 2016 Share Repurchase Program [Member] November 2016 Share Repurchase Program [Member] November 2016 Share Repurchase Program [Member] October 2018 Share Repurchase Program [Member] October 2018 Share Repurchase Program [Member] October 2018 Share Repurchase Program [Member] Equity, Class of Treasury Stock [Line Items] Equity, Class of Treasury Stock [Line Items] Preferred stock, authorized (shares) Preferred Stock, Shares Authorized Preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, issued (shares) Preferred Stock, Shares Issued Accelerated share repurchase program, amount paid Accelerated Share Repurchases, Settlement (Payment) or Receipt Shares repurchased (shares) Treasury Stock, Shares, Acquired Accelerated share repurchase program, initial funding allocated to shares repurchased Accelerated Share Repurchases, Funded Stock Purchases Accelerated Share Repurchases, Funded Stock Purchases Accelerated share repurchase program, initial funding allocated to share holdback Accelerated Share Repurchases, Share Holdback Accelerated Share Repurchases, Share Holdback Settlement of accelerated share repurchase transaction (shares) Accelerated Share Repurchases, Settlement, Shares Accelerated Share Repurchases, Settlement, Shares Shares repurchased Share repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Shares repurchased, cash settled Treasury Stock, Value, Acquired, Cost Method, Settlements Treasury Stock, Value, Acquired, Cost Method, Settlements Share repurchase program, availability remaining Stock Repurchase Program, Remaining Authorized Repurchase Amount Antidilutive securities excluded from computation of diluted earnings per share (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount H.D. Smith [Member] H.D. Smith [Member] H.D. Smith [Member] Payment to acquire business, net of cash acquired Gain (loss) related to litigation settlement Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Opioid Lawsuits and Investigations [Member] Opioid Lawsuits and Investigations [Member] Opioid Lawsuits and Investigations [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Employee severance Severance Costs Litigation and opioid-related costs Litigation Settlement, Expense Acquisition-related deal and integration costs Business Combination, Acquisition Related Costs Business transformation efforts Business Transformation Efforts Business Transformation Efforts Other restructuring initiatives Other Restructuring Costs Total employee severance, litigation, and other Legal fees Legal Fees Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets [Line Items] Indefinite-lived Intangible Assets [Line Items] Indefinite-lived intangibles Indefinite-lived Intangible Assets (Excluding Goodwill) Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Trade names and other [Member] Trade Names And Other [Member] Represents trade names and other. Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Finite-lived intangible asset, weighted average remaining useful life Finite-Lived Intangible Asset, Useful Life Finite-lived intangibles, gross carrying amount Finite-Lived Intangible Assets, Gross Finite-lived intangibles, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Finite-lived intangibles, net carrying amount Finite-Lived Intangible Assets, Net Total other intangible assets, gross carrying amount Intangible Assets, Gross (Excluding Goodwill) Total other intangible assets, net carrying amount Quarterly Financial Information Disclosure [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Other Nonoperating Income (Expense) [Member] Other Nonoperating Income (Expense) [Member] Gross profit Distribution, selling, and administrative expenses; depreciation; and amortization Distribution, Selling and Administrative, Depreciation and Amortization Expenses Represents the distribution, selling and administrative, depreciation and amortization expenses during the period. Employee severance, litigation, and other Restructuring Charges and Defined Benefit Plan, Recognized Net Gain (Loss) Due to Settlements Restructuring Charges and Defined Benefit Plan, Recognized Net Gain (Loss) Due to Settlements Net income attributable to AmerisourceBergen Corporation Earnings per share operations: Earnings Per Share From Net Income [Abstract] No definition available. Basic (usd per share) PharMEDium remediation costs Estimated liability under the New York Opioid Stewardship Act Estimated Liability for New York Opioid Stewardship Act Estimated Liability for New York Opioid Stewardship Act Discrete income tax benefits recognized in connection with 2017 Tax Act Gain on sale of equity investment Gain (Loss) on Sale of Equity Investments Impairment of non-customer note receivable Provision for Loan, Lease, and Other Losses Leases Commitments Commitments Disclosure [Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Acquisitions and Investments Business Combination Disclosure [Text Block] Term loans due in 2020 [Member] Term Loan Agreement [Member] Represents the term loan credit agreement. $500,000, 3.50% senior notes due 2021 [Member] Senior Notes Due2021 [Member] $500,000, 3.40% senior notes due 2024 [Member] Senior Notes Due2024 [Member] $500,000, 3.25% senior notes due 2025 [Member] Senior Notes Due2025 [Member] Represents the 3.25% senior notes due March 1, 2025. $500,000, 4.25% senior notes due 2045 [Member] Senior Notes Due2045 [Member] Represents the 4.25% senior notes due March 1, 2045. Non-recourse Debt [Member] Non-recourse Debt [Member] Non-recourse Debt [Member] Corporation Debt [Member] Corporation Debt [Member] Corporation Debt [Member] Debt Capital lease obligations Capital Lease Obligations Total debt Long-term Debt and Lease Obligation, Including Current Maturities Less nonrecourse current portion Long-term Debt, Current Maturities Total, net of current portion Quarterly Financial Information (Unaudited) Quarterly Financial Information [Text Block] Share-Based Compensation Share-based Payment Arrangement [Text Block] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Other [Member] Other Segments [Member] Subsegments [Axis] Subsegments [Axis] Subsegments [Domain] Subsegments [Domain] World Courier [Member] World Courier [Member] World Courier [Member] Number of countries in which entity operates (over) Number of Countries in which Entity Operates Intersegment eliminations [Member] Intersegment Eliminations [Member] Pharmaceutical Distribution [Member] Pharmaceutical Distribution [Member] MWI Animal Health [Member] MWI Animal Health [Member] MWI Animal Health [Member] Global Commercialization Services [Member] Global Commercialization Services [Member] Global Commercialization Services [Member] Operating income Assets Depreciation and amortization Depreciation, Depletion and Amortization Acquisition-related intangibles amortization Capital expenditures Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Investor [Member] Investor [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Ownership percentage (more than) Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Revenue from related party Revenue from Related Parties Receivable from related party Accounts Receivable, Related Parties Allowance for Doubtful Accounts for Long-term Accounts Receivable [Member] Allowance For Returns and Doubtful Accounts, Noncurrent [Member] Allowance For Returns and Doubtful Accounts, Noncurrent [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other Assets [Member] Other Noncurrent Assets [Member] Allowance for doubtful accounts for long-term accounts receivable Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Reclassifications Reclassification, Policy [Policy Text Block] New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Business Combinations Business Combinations Policy [Policy Text Block] Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Concentrations of Credit Risk and Allowance for Doubtful Accounts Receivable [Policy Text Block] Contingencies Commitments and Contingencies, Policy [Policy Text Block] Derivative Financial Instruments Derivatives, Policy [Policy Text Block] Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Goodwill and Other Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Investments Equity Method Investments [Policy Text Block] Investments, Equity Securities Marketable Securities, Policy [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Revenue Recognition Revenue [Policy Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Share-Based Compensation Share-based Payment Arrangement [Policy Text Block] Shipping and Handling Costs Shipping and Handling Costs [Policy Text Block] Shipping and Handling Costs [Policy Text Block] Supplier Reserves Supplier Reserves Policy [Policy Text Block] Supplier Reserves Policy Loss Contingencies [Table] Loss Contingencies [Table] Settlement with Ohio Counties [Member] Settlement with Ohio Counties [Member] Settlement with Ohio Counties [Member] MDL and Other Related State Court Litigation [Member] MDL and Other Related State Court Litigation [Member] MDL and Other Related State Court Litigation [Member] West Virginia AG Matter [Member] West Virginia AG Matter [Member] West Virginia AG Matter USAO-EDNY Misdemeanor Violation [Member] USAO-EDNY Misdemeanor Violation [Member] USAO-EDNY Misdemeanor Violation [Member] USAO-EDNY Matter [Member] USAO-SDNY Matter [Member] USAO-SDNY Matter [Member] USAO-SDNY Matter [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Litigation settlement Aggregate legal settlement (up to) Aggregate Legal Settlement Due From Largest U.S. Pharmaceutical Distributors Aggregate Legal Settlement Due From Largest U.S. Pharmaceutical Distributors Legal settlement term (in years) Legal Settlement Payment Term Legal Settlement Payment Term Company's portion of aggregate legal settlement Percentage of Aggregate Legal Settlement Due Percentage of Aggregate Legal Settlement Due Program period (in years) Opioid Program Term Opioid Program Term Annual fund commitment total Annual Fund Commitment Total Annual Fund Commitment Total Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward] Nonvested, beginning of period (shares) Vested (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Nonvested, end of period (shares) Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Nonvested, beginning of period (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price Granted (usd per share) Vested (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Forfeited (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value Nonvested, end of period (usd per share) Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Future minimum rental payments, operating leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Future minimum rental payments, financing obligations Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] Goodwill and Other Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Weighted average common shares outstanding — basic (shares) Effect of dilutive securities — stock options, restricted stock, restricted stock units, and the unsettled ASR transaction (shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Weighted average common shares outstanding — diluted (shares) Current provision: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Current Federal Tax Expense (Benefit) State and local Current State and Local Tax Expense (Benefit) Foreign Current Foreign Tax Expense (Benefit) Total current provision Current Income Tax Expense (Benefit) Deferred provision (benefit): Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) State and local Deferred State and Local Income Tax Expense (Benefit) Foreign Deferred Foreign Income Tax Expense (Benefit) Total deferred provision (benefit) Provision (benefit) for income taxes Changes in the carrying value of goodwill Schedule of Goodwill [Table Text Block] Other intangible assets - indefinite-lived Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Other intangible assets - finite-lived Schedule of Finite-Lived Intangible Assets [Table Text Block] Business Segment Information Segment Reporting Disclosure [Text Block] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Goodwill [Line Items] Goodwill [Line Items] Goodwill [Roll Forward] Goodwill [Roll Forward] Beginning balance Goodwill recognized in connection with acquisitions Goodwill, Acquired During Period Goodwill impairment Goodwill, Written off Related to Sale of Business Unit Foreign currency translation Goodwill, Foreign Currency Translation Gain (Loss) Ending balance Weighted average assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Stock options Share-based Payment Arrangement, Option, Activity [Table Text Block] Nonvested options Schedule of Nonvested Share Activity [Table Text Block] Nonvested restricted shares Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Nonvested performance stock units Schedule of Nonvested Performance-based Units Activity [Table Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Building and improvements [Member] Building and Building Improvements [Member] Machinery, equipment and other [Member] Machinery and Equipment [Member] Software and software development costs [Member] Software and Software Development Costs [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Estimated useful lives Property, Plant and Equipment, Useful Life Amortization expense, fiscal year maturity Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Amortization expense 2020 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2024 Finite-Lived Intangible Assets, Amortization Expense, Year Five Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Cover page. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Document Type Document Type Document Annual Report Document Annual Report Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Tax Identification Number Entity Tax Identification Number Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol Title of 12(b) Security Title of 12(b) Security Security Exchange Name Security Exchange Name Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Amendment Flag Amendment Flag Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Public Float Entity Public Float City Area Code City Area Code Local Phone Number Local Phone Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Quarterly financial information Quarterly Financial Information [Table Text Block] Accrual for estimated customer sales returns Accrual for Estimated Customer Sales Returns No definition available. Statutory U.S. federal income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent State and local income tax rate, net of federal tax benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Foreign tax rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Excess tax benefits related to share-based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent Litigation settlements and accruals (see Note 14) Effective Income Tax Rate Reconciliation, Tax Settlement, Percent Goodwill impairment (see Note 5) Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent Tax reform Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Capital gain on distribution Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent Other Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Effective income tax rate Effective Income Tax Rate Reconciliation, Percent EX-101.PRE 12 abc-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 performancegraphfy2019a02.jpg begin 644 performancegraphfy2019a02.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1#T17AI9@ 34T *@ @ ! $[ ( M . (2H=I 0 ! (6)R= $ < 0T.H< < @, /@ M 2P@ M4W1E=F4 60 P " % $*:0! " % $+J2D0 " S,X "2 MD@ " S,X #J' ' (# ")H '.H ( M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M R,#$Y.C$P.C(T(#$Q.C(T.C4W #(P,3DZ,3 Z M,C0@,3$Z,C0Z-3< !4 &\ < !L &4 >0 L " 4P!T &4 =@!E _^$+ M(&AT=' Z+R]N&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN M/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX-"CQX.GAM M<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&('AM;&YS M.G)D9CTB:'1T<#HO+W=W=RYW,RYO&UL;G,Z M#IX;7!M971A/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K M970@96YD/2=W)S\^_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5 M&AD8%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @* M"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ M*BHJ*BHJ*BHJ*BHJ*BHJ_\ $0@"+0.= P$B (1 0,1 ?_$ !\ $% 0$! M 0$! ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" M P $$042(3%!!A-180'EZ@X2% MAH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ M ! @,$!08'" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,082 M05$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3 ME)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+C MY.7FY^CIZO+S]/7V]_CY^O_: P# 0 "$0,1 #\ ^D:*** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH ***"0JDL< RBDO]4,;;7FL(%:,'V9V7=]1D5W?@[QOH7CO1SJ7AN\^T1(VR5&4K)$WHRG MI]>A[&@#?HKR[Q5^T+X'\*ZM+ILDM[J=S YCF&GPJZQL.H+,R@D=.":Z7P/\ M2_#/Q"MI9/#MXS30 &:UG39+&#T)7N/<$B@#K**\V'QT\+_\+&_X0M[74X]0 M^V_8?.:*/R3)G Y\S=@G@?+WK2^(GQ7T'X9_8!KT-]>VC*)[G9(S?D#0![-16#XG\9:3X4\&S^)M0D:; M3HHTD4VV':4.0%V9(!SN'?IS6=\/?B7HGQ*TV[O-!CNX!9S"*6&\15<9&0V% M9A@\CKU4T =?17G_ ,0OC+X>^&VK6NG:[9ZG<37,'GHUG%&RA=Q7!W.O.17/ MZ3^TWX#U34HK29-4TT2L%%Q>0((U)_O%'8@>^,"@#V"BN2\4?$;2/"7B7P_H MFHP7DUSK\X@M9+=$:-6+J@+DL"!EQT!XS53Q[\7?"WPZGBMMIYQ0!W%%<%X$^,WA+XA7S6&CS7-M?A2ZVE[$$=U'4J5+*< M>F<^U7O'/Q/\,?#R.+_A(;QQ"/%VK1:9!->:;=SL$A34(E02L>BAE9@">V2,]!S6U\0?BGH7PUFTM/$,-\ MZZFT@C>UB5Q&$V;B^6!Q^\'0$\&@#M**YWQ=XVTOP;X.D\2WZSW5@GED?8PK MLX<@*1N8 CD'KTK4T358->T#3]7LTD2WU"UCNHEE #JKJ& 8 D9P><$T 7J* MP?%_C70? NCC4?$EZ+:%FV1H%+/*WHJCD_R'?%<#I'[2_@'5=26TF;4=-#MM M6XO;=1$3[E'8@>Y % 'KE%Z5X \,IKNK175S:23)"HLE1V)8$@_,RC M&!ZUYS_PU7X(_P"@5X@_\!X/_CU 'MM%0V=TE]8P7<081SQK(H8<@,,C/OS7 M!?$#XU>&_AQKD&DZW:ZE<7,UN+@?8HHV55+,HSN=>_$K1_B5 MIUY>:%;7UO':2B*07D:*22,\;6;BF^//B9I/PZDTXZ_9:BUK?R&-;NVB1XHF M&.')<$<'/ .0#C.* .QHKG_%OC71_!?A.7Q%JTK/9+LV"WPSS%C\H0$@$GKU MZ GM7+Z]\;M!\-^$]$\0:KI.M16VM!VMH?)B\T*N"&8>9@ @@C!/![4 >D45 MXE_PU7X(_P"@5X@_\!X/_CU>O3:U9V_AQ]<^^* +]% M>?\ P]^,OAOXDZI=:=HD&H6US;0^>4O8T3>F0"5VNV<$C.<=16C\0OB5H_PU MTZSO-=MKZXCNY3%&+.-&((&>=S+Q0!U]%>+6_P"U-X%FN$CDLM 2!U/J* ->BN"UOXOZ!H/P[TKQG>6FI/IVJ2) M'#%%%&9E+*[#<"X &$/1CVK9\'>.](\;>$/^$CTSSK>R#2+(+I55X]GWMP4D M=.>O0T =)17G'@+XX>&_B)XB;1M%LM5@N5@:7&KPZ1;WL+:3<"WG-TB*&;+#*[6;(^4]<4 =717*1_$329/B=+X%6WO M?[3BM_M#3%$\DKM#8SNW9P1_#1HGQ$TG7O'NL>$K.WO4O](3?/)*B")AE1\I M#$G[PZ@4 =7117GGQ ^-7AGX\3>-=+\+^!9?%EV)[K38XXI1]D56=UD954J&('\8/7I7F?_ U7X(_Z M!7B#_P !X/\ X]0![;17E<7[0GA2;PQ;:ZNGZR+6YU%M-1##%O$@1')(\S&W M#CG.R&&)O+5\X5LR#YA@YQD>YH ]-HKR#1/VE?!^O:_I^D6>FZ MXEQJ%U':Q-+!"$5G8*"Q$I.,GG ->OT %%>)?\-5^"/^@5X@_P# >#_X]73> M!/C?X9^(.M7.FZ3:ZE:26MH]Y++?1Q1QB-653RLC<_.#R,8!YH ]'HKR'5/V MF? .G:DUI"=3U!5;:;FTME,?7U=U)'N ?:O0O"?C'0_&^C#4_#=\MU;[MCC! M5XF_NLIY!_GVH W**\2_X:K\$?\ 0*\0?^ \'_QZNI\ ?&OPY\1]>GTG1+/5 M+>>"U:Z9[R*-4V*RJ0"LC'.7';UH ]$HKS;PG\=?"?C+QE_PC>E1WZ73>9Y, MT\<:Q3;,D[2').0"1D#@5U?C7QA8>!/"UQK^KPW,UK;LBLEJJLY+,%& S =3 MZT ;U%4=$U6#7M T_5[-)$M]0M8[J)90 ZJZA@& )&<'G!-7J "BO*O%G[0O MA3P=XIO= U/3]9ENK)E61[>")D)*AN"9 >C#M5GP;\?/!OC77(M(LC?6%[.2 ML"7\*H)3C. 59AGV.,T >F45YKXY^.OAGX?^)6T/6;'5I[E8DE+VD,;)ANG+ M2*<\>E9OA[]H_P (>)?$=AHMCIVMQW-_.L$3S00A S' )(E)Q] : /7**\G\ M3_M%>$O"GB:^T/4=.UJ2ZL9/+D>""(H3@'@F4''/H*/#'[17A+Q7XFL=#T[3 MM:CNKZ3RXWG@B" X)Y(E)QQZ&@#UBBN4\"?$32?B%;ZA-HMO>P+I]Q]GE%VB M*6;&XT^ZDM96B@A*,R,5)4F4'&1QD"MWP)\;/"7Q MU4Z9I+W=I?E"Z6]]$J-*!R=I5F!('.,YQSV- 'H5%<1!\6?#TWQ0F\!NEY!J ML9PLLL:"&1M@?:K!B<[3W Z$>F;GB+XB:3X9\8Z)X:O[>]DO-;<);R0HAC0[ MMOSDL".3V!H ZNBN=U+QOH^E^)--T::4R2W[7"F>)D,5J88_,83$L"F0>.#[ MXK?BECGA2:"19(I%#(Z-E6!Y!!'44 /HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "N#^-NI7.D_!?Q%=6+,LQ@2'@& M*D\0>']&^'WP\\6:GX/TNWTR\DL)YVEMUPQ<(Q4^P4DD <#MBO/M*T3XX?#K M3_\ A'/#-II'B'28F86EW.ZJT"$YQAI$(ZYQA@.@.,5W?P\\)^+H/#^K1?$S M6O[6DU;<#9!@\=NC!MRAL#KNQM'R@ 4 8G[-^@:99_"6RU:"VB-_J,DS7,Y M4%SME=%7/7&%!Q[D]ZYGQ'86OA3]K;PU)X?6.S_M:V!O((EVJQ;S$8D#CD*I M_P!YUJU)>PT+0+%[(;#Q%;S16$YGC;S&8L5. Q*XR#\P%'-.TGSM6TV16NK?[3$OE@(X^\7"GEAT)KZ H ^:/BHS6?A7 MX<_#'5+^"RD:.WDU2:2942!% C!+'C:"9#_P 5=\(:SH?A']IR]T_P .:E8W M6A>)H 8_L,ZRQ138+!25) .]7 '82"MIOA-?>.?C;KVN_$31F/A]8O(TV(W@ M'F[2%5OW3[E& S8..7_"JGQ&^ EOIUCI>J?"/1?(UJRODE9/MK'A'4T 4?C=JUWH7Q\\':GIVES:M=6UIOCL8,[YSYDGRC"L<_@:Y_Q?XSU[ MX[WUIX)L?",.BW]M<^?*UY=@RQ!5(889$( #9( ).!Q7I?BCPAXFU[XU>"/% M$6D&.RL;5/MY-Q%FV5)'8"@##^,%K]A^*WPDM YD\B^ABWD8W;9X!G]*N_$KP+X MTT[XI0_$+P!:VFJSB!8Y;*Y"DH0NW(!(R,8^Z0P.>QJSXX\)^+_&'C'X:Z\- M!^SMI=U'/JT7VJ$_92)HF;'S_.,(Q&W)QCOQ2>-/A_XUT/XGS>/?A>;2YN+Z M$17NG73!1(0%'&2 0=BG[P(([YX ,7PMXXT;5_C!IC?$/P)-X=\8,/)L[_S) M8TD8AE ,9(!SN*ACOSD#/3$W@FPM?%7[3_C*_P!>A6ZETD>7913@,L85@@8* M?0#(]V)Z\U/I?@7XC>._B/HGB7XFP:?I-IH4@FM[.S<,SN&##&UGX+*I)+=% MP!R:TO'/PV\6:?\ $-O'WPNNK==2N(Q'>V%R0%GX XSP00JY!(Y&0I6-U$(+A5 =@QVE,]2,'./5:XGXRK+XMT3X/+J4[>=K%N! M<3*.=TJVNYA[Y8FMS4O WQ7^+.H6-K\1H[#P_H5K,)9+:RD5FE(!&0 [Y;!( MRS8&2<&ND^+'@'6M=\2?#Y_"^F":PT*[)N<31QB"(/!MX9@3Q&W ST^E 'E> ML>(KVS^!OBCX<^)6VZQX;NH$AR?]=;>>FTCN0,C!_NNE?1OPX_Y)9X4_[ MG M_P"B$KS'X_?"#4_&=Q9:[X0LUN-44?9[N 2I%YL?57RY RIXZY((]*]7\%:? M=:1X!\/Z;J$7DW=GIEM!/'N#;'2)589!(."#R#B@#Q_QC9V_BK]K'0-$UY!< M:;9V!EBM9.4D?;(_(/7)"Y'<)BN^^,?AW2=7^$NN_;[6'=8V,EQ:R; &B>-2 MR[3VR1CCJ#BLOXK?#+5O$FLZ9XM\$W\=AXETD;8S*<+,F20N<'!&YNHP0Q!K MC]:T3XY_$73_ /A'?$5GI.@:7(RBZN8)%)F4'/(61R>F< +G@'C- '*^(=0N M=1_8WT!KR0R/#J0@1CUV(TH4?@H ^@%=WX<^,GC$P:58'X2:X+@"Y7@WBWP%\3M2^.%_XH\)&PTV)+58+ M*^O)4\?7NM>!+F/7]+ODPNFZA<_):G MJ=JLZ 8/0@]#@CB@#3^#'Q"UCQ=%K6B>+8HTUW0+CR+F2, "7YF7H. 0R,#C M@\5V'CCPC9>.?!U]H.H85;A,Q2XR89!RCCZ'\QD=ZY7X._#S4_!UMK&K^*9X MIO$&O7/VB[\HY6/EFVYZ$EG8G''(';->E4 ?*'@O1O$GQ%\4Z7\/O%K :1X+ MDD-ZH;F;:^U4)[_W >R;CUKLOVFY6L6\$RVML9FM[]VCMXQ@N5\LA!@'KC'2 MNF^'?@O7]"^,7C?7-5L/(T[5)2UG/YT;>:/,)^ZK%AQZ@5!\>?!WBCQ5_P ( MU/X/TQ=0GTR[DGD5YXXPOW"N=[+D$J>AH J0?&[QM-'_^_P"G_P E4WQ;\/?$WQ(^*7AF7Q;HRQ^&K"P4WI2Z0*T[(6D50K[\;]B9 M]%)R>I .&N;OPY\-/B3X"UCPWKNF7UO]C33]8^P7<.O%_P ,O!%I-HK-K.F3K_:$37<.0$&P2;M^T[@ V 2> M: .:\<__'>GR^ 9/A^VDZIJA1(DU*[VLIW9!59(X\$X(!SU]>E>\_#SPW M<>$?A[H^A7LJRW%G;[963[NXDL0/4 G&?:N:^-7PS/Q!\*K+I2*NO::3+8ON M"&3^]$6/3.,@GH0.@)KH_A[/XFE\%VKH)M*6#[48'^Y(Y:0D$=#_ *E!CT..]>P:YX1T M#Q)I2:;K>DVUW9QLK1Q,F A!XVD8(_#MQTKC_BQ\-K_QB^E:YX6OTT_Q'HLG MF6DLG"2#(.TG!Q@C(X(Y(/!R.0NX_P!H+Q/%'I5S;Z7X&_!ME801V]M;ZB(XHHUPJ*% ],5WGQR_P"2 M)^)/^N"?^C4JE\4?AEJ7C?XZ"/"GB'3-(L-/E9!U[Q/\ M6/#VJZ?IXETIX;6+59?/C7R]C_/\I8%ODQT!Z4 8'P5T)?#7[1%[I"KM:UT5 M5D]Y#' SG\6+&NK_ &C>"->L_VG-=\62Z<(]#N[%8 MH;H31_._EP@C8&W#YD?DCM[USC^"/B?\-O&VN:C\-;73M:TO6IS.UK=2*OE$ MDD AG3D;F *L5&/YD4WX;_\G1>/_P#K@?\ MT..M7X6_#_Q7;>/M6\>_$-[:/5]0A\B.TMW#"-?E&3MR. BJ ">Y/->&_ MBMX7^,?B;Q-X+\,66H6^J-Y:/>7,6UD^4Y"^CQZO\;=5T'7K/ M6_"&FVCS:9)'8O8W,:N;AF1!RT[ (TC<@QA\!?L[^%H?!5@/'.@_:-= M8,UT1>RJ$)8[5_=R;>%P,COF@#3_ &<_%7_"0_"J"RGDW76C2&T<$\F/[T9^ MFT[?^ 5@^-O^3P?!7_8+'\[JM#X??#K7/AW\:-9_L?2R/!FI0@1RBZ1O)90& M4%6;S#@ETZ'[P.:O>*?!7B#4?VD?"_BFRL/,T:PL!#X6UO"G5E4E@/JR&4 M?@*Z;X[>"]?\9Z?X?B\-V'VU[/4/.G'G1Q[$QU^=AG\*Z/XM^$9O&_PSU32+ M&(27Q59K120,RHP8#)( R,KDG'S4 >A58@/\ KI63\4-=OO#7[4NBZMI6BW&NW=OI?[O3[;=YDVY)U.-JL> Q M;H>%_&NH^ GPV\0^%+O6-;\;VQAU6YCBM+-/ F@V^IBQL!"AN;B-8RY$J,"ID1N%DSQWH W_"?Q9\5^(?%-EI M>I_"[6=&M;EF62_N#+LA 4G)S HY( ZCK7JM>.:7XD^/,NL6<>J^"M"@L7G1 M;F6.92R1%AN8?Z2>0,GH?H:]CH \2_:K_P"26:;_ -AJ+_T1/6M\=M1N=/\ M@'=?9'9#/0AL=!D8KK?A%\+M1\(7NI^)/%U\M_XEU?(G=#E8D+;BH.!DD@$ MXX&T =* ,/\ :K_Y)9IO_8:B_P#1$]=9\4O% \)?!>^ODDV7,]HMI;$'GS)% MV@CW +-_P&L[]H#P=KOC?P#9:;X8L?MUW%J<<[Q^$$4JDY=@.K+QG/-9_ MQ;\#>)O'6H>#]#M-/+:#;2I+JMQ]HC79T4@*6#$JF_H/XAS0!X[?1Z)X+\"_ M#_Q/X?UG3+K7].N?.U"UM;R-IF60^8%=5.1M ,9X_BKVOX^WUOJ?[/\ >7]E M()+:Z-I-$X_B1I$(/Y$4GB#]G?P'/X;U"+0="^RZFUL_V28WL[!)=IVY#2$8 MSCJ*P)/!/CO4OV9)/!^HZ*PUNUN$CMX3=PGS8%E5P=P?:, E<$Y^4>M 'JOP MX_Y)9X4_[ MG_P"B$KI*\$T34_C_ *#H&GZ19^!]#>WT^UCM8FEN(R[*BA06 M(N0,X'. *]J\/S:K<>';";Q#;16FJR0(UW!"%8Y*X'RX'S<]J]#\+>"O$&G?M(^*/%-[8> M7HU_8&&VNO.C/F/F#C8&W#_5MU Z?2LCQ+\.?$WA7XRVGC?X:Z<+RVO6/]JZ M>D\<.9C>R@A_O#T=<^E '-_$#Q#J'A?\ :GAU32-!N=?NHM-55L+4MO<- M&P)&U6/ .>G:O0?!WQ6\5>)?%EGI.J_#'6-"M+C?YFH7)E\N':C,,[H5')4+ MU'+?A7->._"_Q&MOCC'XT\#>'K?45BL5A0W=Q$J9*%6!4RHV1GZ?6MC1/$?Q MUGU_3XM<\%Z';:9)=1K>313*7CA+ .R_Z2>0N2.#]#0!U7QB_P"2.>)O^O%O MYBJOP-_Y(GX;_P"N#_\ HUZU_B5H]]X@^&NNZ5I$'VB]N[5HX8MZKO;(XRQ M'XFH/A3H>H^&OA=HFD:U;_9KZUB99HMZOM)D8CE20>".AH \Z_9A_P"03XK_ M .PK_P"RTOAZ-G_;/\5,HR(]*1F]AY5J/YD53M_!7Q3^%_BC69?AQ9:;K>CZ MI<&=;>Z=5,1))&070@C..&((P<>G2?"?X?>)],\8ZWXW\?26ZZUJL?DBWMV# M"-,J3G'R_P " $\#D\T >6>'?'VI^ ?BM\2+S3/"EWXABEU2EQF%TBN%E>638P ;&#N_>9W% M0, "NU^%O@G7_#GQ,\?:KK6G_9['6+YI;*7SHW\Y#-*V<*Q*\,IPP'6LFQ^' M7B?X>?&TZUX&TW[9X7U; O[5+B./[.&/.%=AG:?F7'8E>.X!YKXX\.ZGKWQ^ M\:W.@RNFIZ);)JML(QEG:+[/P/?#$@=R .];NK>,[;Q[\2OA/KEOM66201W4 M2G_53+*H=?ZCV(->B>%O!7B#3OVD?%'BF]L/+T:_L##;77G1GS'S!QL#;A_J MVZ@=/I7%W'P0UW1/C]I^M^'-.67PTNH1WK.L\:"URV7386#$ CC /! [4 =5 MXS^!2^*/&%[K]O<:;:REH9+6#["/+D;?NF-R,YE+#H01U]LGUVTMH;*SAM;6 M*.&""-8XXXEVJBJ, =@ .E2T4 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !14%]>VVFZ?./$%SI-O87^GRC,ED]Y%M6\B"(Q9?0X MD#;>?E96SR0 #T*BN9@\?Z'=_$*3P;9S/<:G#:M#U H ]!HK@]0^,/A MS3?%K:'/;ZFR17265QJD=KFRMYVZ1/+GAN@Z$#/7@X[R@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S?$B>;X6U6/\ LX:IOLY5 M-@7V?:@4/[K< <;NF<=Z\$^!WB"_'CV31_#UUJ%QH4IDDO[#48-\FG,MM J, MUQM4D[T:%4Q@+%G'((^C:BAM;>WDF>W@CB>XD\V9D0*9'VA=S$=3M51D]E [ M4 >3V.@Z7X<_:4LK/0K""SA;PS+*R1C'F2&XY9CU9C@ M.%]2F\31:Y<>V?JBB@#YFUR8VVE^,/A MU(EU_P )-KGBXWVGPK;N?,@DDB<3!\;< 1MGGC\#CZ9HHH S+^;4;-UG$]J] MNUQ%'Y7V=@^'D5/O[\9&[/W:TZSM<_Y!\7_7Y:_^CXZT: "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,[7/\ D'Q? M]?EK_P"CXZT:SM<_Y!\7_7Y:_P#H^.M&@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH ***R-1\7>&](F:'5?$&EV4J?>CN;V.-A^!(- M&O17$W?QD^'EE_KO%FGM_P!<7,O_ * #6)=?M%_#:W.(]8GN?^N5E+_[,HH M]1J*>ZM[7R_M,\+>._$E[XF^*%OX9MO#&J7MA9RK;1:G I\JSO'9?]+R%8$P@\ D]@'2*=#MD4>V1D'NI![UL4 %%%% !1110 M4444 %%%% !1110 4444 %%%% #)98X(7FGD6.*-2SN[850.223T%Q.?: MLNS^)7@_4/&$GA>RUVWFUB-F4VZJV"RC+*'QL9AW )(P?0UP.E>%K'PO^TI' M!I33O->>'9KJXN+J9I9)IFGP78GV51@ #CIUKA/AOJU_H_\ PA5G6T?@[QWH%QNP2W*9!M;,^?)D= MB%R%/^\10!VU4-*US3-;^V?V3>1W7V*Y>TN/+/\ JY4QN0^XR*^>/&?QP\3> M-;6'1_ /AK4K2&_9A'J M6*I;+#!)'8M;(7##89,*!,"25;?DL&ZY"D 'VY03@9-<5H>MCXK_ SN)K9- M4\.F^1[?S,;)8SQ\\;=UYZ\=QQ7C_C/X5^!?!8LV^(?COQ%,;TL(E0;B^W&[ M^%\ ;E_.@#Z$O/$.C:?G[?J]A:[>OG7*)C\S52P\;^%M5U5-,TOQ'I5[>R E M+>WO(Y'; R< $YP 3CT!-?/^A^&/V=[NYA@C\07EU+(P55O9)H02>@)\M!^M M>T^&_A%X'\):K#J>A:%';WT ;RYWGEE91WG[3W@&V8K;IJUYCH8+50&_[[9:]3?7-(%U):/J=EYZ M'8\!N$W*?0KG-/L]-TRU ?3[*TA!Y#01*N?Q H \=_X:1CO3C0? FOZAN^[\ M@7/_ 'R&K3\._%;QQK_B2PM'^%NI:=IT\RQSW5U*Z>4AZO\ -&HP!SCOC Y- M>MT4 %>,7FF_M :A?S_9]:\/:9 78)L0, N>",QN>GK7L]% 'B/_ K3XPZA MC^U?B@MMG@_8HV&/IM"58L?@7XA&HV]YK/Q3\07KPR*^V-G3H2XNKR9IYLWDJJ78Y8X5AC).<5Z)10!P]G\&/AW M8X\GPG8-C_GN&E_]#)K:18BTT_QKKT4(=Y,>38L2SL79B3;$DEF))/\,?V#?:E=OJ] M_JBZ3:6-QJ$GFW,D$04R-@#\!QG P,DG M&22=:B@"L=,L6U1=3:RMS?K%Y"W9B7S1'G.P/C.W/.,XS4$7A_1H-:DUB#2; M&/4Y1MDO4MD$SC &"X&X\ =^PK0HH SY?#^C3ZU'K$^DV,FIQ#;'>O;(9D&" M,!R-PX)[]S6A110!G:Y_R#XO^ORU_P#1\=:-9VN?\@^+_K\M?_1\=:- !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%8$GCKPM%KT M6BOK^G_VE,2%MA.I;(!.#CIP.^* -^@G R:X[4?B;X775/[ TOQ#ITVOW0:* MSAW-+&9\?(KL@(7G'!(/XUYW/\(_B3XVBF;X@>._LT+*VS3]-!\LY' ;&U< M^H8X[T >@^)_B[X(\);TU77K=[E.#:VI\Z7/H0N=O_ L5B>!?C#Y;:JL!D# !7D\8#$\]*\_P##?[*"K(LOB[Q!O4'FWTU,9'_7 M1Q_[+7NWA7PII'@O08]'\/VQM[2-B^UG+LS'JQ)[F@#C/B]:>/\ 7K1/#?@O M2[-],U*!H[^_N+@(8LG&T#<"!CG(#9Z8]>2^'7[-4/AO6K/6O$^K1W]Q;'>M ME;P_N=V"/F9N7'/3:*]YHH Y?QCX'M/%D-E*EW=:;J6FES8WEK/)$8MX 92( MV4E6"@'!!QG!&37,3_"R_P!<5;+Q!JMPFF%@;B&WUC4)FNU!!V$2S%44]QAC MZ$'FO3Z* $1%C1410JJ,!0, #TJM?Z78:K (=4L;:]B!R$N85D4'UPP-6J* M.9_X5OX)^U1W*^$M%CFB8.CQV,:$-G.>!UKIJ** /,=>_9]\!^(-6N]2N;2\ MM[J\E::9K>Z8 NQRQ ;(&22<#BM3X?\ PDT#X;7M[?'3[4C\_7):O;J* ,_0;;4K/P_96^NWJ7^HQPJMS=) M&$$K]V"CI_GI7&?$#4/BI9:U ?A[I&D:CIP@!D%VX60R[CD2Z7D01MV >-K,",'UKJZ,4 8GBGQEH'@NQAO/$^I)8032>5&S(SEFP3 M@!03T'7&*QK3XP_#V]<+#XMTU23@>=)Y0_-P*Z75]#TKQ!9"TUW3;74;<,'$ M5U"LBAAQD C@\GGWKEY_@U\/+A@TGA/3P1T\M2@_)2* .W!# $'(/(([UR5O MK>O^))99O#3Z98ZKCC2*-8XE"(@ M"JJC '05X+8_#'P?H7BBQU'Q=/JVFZQH]S"]O,A+6MZD) A8'8W)5$W)N#; MLXX() /7] UN]N[RZTK7K2*TU:S59'$#EX9XFR%DC8@'&5(*D94CN""=VN6T M)Y]=\57/B+[-/:Z>EHMG9"YB,IH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBLC1O%>@^(;R]M=#U>TOY["3R[F." M4,8S@'\1SC(R,@C.00 #7HJLVHV2ZFNG->6XOGB,RVIE7S6C!P7"9R5SQG&* M2?4["VU"VL+F]MXKR[W&VMY)562?:,ML4G+8')QT% %JBL^7Q!HT&M1Z//JU MC'J >W8UH4 9VN?\@^+_K\M?\ T?'6C6=KG_(/B_Z_ M+7_T?'6C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117(>*?BIX,\',\ M>MZY;K=)P;2 ^;,#Z%%R5_X%B@#KZ*^''6*0D17FJ$@-C MKB-3SC(_B[CBN9\%>*_BK\1?'^CW*5=R.I5AZ@\&N'\.?!GP)X8E$UCH,$]P"2)[TF=@?;?D#\!0!Y3X-\-^. M/C?HK:UXL\9WNGZ0UP8A86<)B$J@#)&,+CG )#=ZZ2^_9<\'SM8BQO\ 4K)( M05N2'5WN<]\D84_08]J]K50JA5 P !TI: .-\)_";P9X+>.;1=%A^V1\K> M7/[V8'&,AF^[_P !Q79444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110!D>+DMI/!6MI?WG:]I=PR1S*MG;.T;0MAN4*R%G'^L=@!U(^C)(TFB:.5 M%>-U*LC#(8'J".XKDO"GPN\)>"M9OM4\/Z8L%W>,3O9B_DH0,QQY^ZI()]:K-/X;GO;FYN0/D'G8V1HO"H%7A>>2?6N$T;X MA:1XB^/GA7Q9?ZLPEN+BZMC9>3(5T^%HC%;19VX9F=V9BI(!?L!7TH_AW2Y/ M%,?B-[7.K1VILTN/,;B$MN*[<[>O.<9]Z+WPYI6H^(-,UN\M?,U'2A*+.;S& M'E>8NU_E!P#[[QA%XIN]"MY-9B=76X+. 77HQ0'8S#U()X'H*ZF@ M#%UJZF*1P&PN%C^VVP^T%H]G^O3MOW>W2MJL[7/^0?%_U^6O_H^.M&@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BD=UC0O(P55&2Q. *X+Q9\:?!'A2VN!-K5O?7L:G99V;^ M:SMV4LH(7\>E '<_:K?[9]D\^/[3Y?F^3O&_9G&[;UQGC-2UXFFD>)[K0A\5 M(]86/77C$PM8K59(%T_/^JVD"1OD_>;=P);C /(XCXA0?%;Q?MN;"[O+_3;R MYEM?[-T8D1V^S;_K& 96SN5FSE>3M/% 'NWB;XI>#/".]-:UZU2X3(-M"WG M2@CL43)7\<"N B^/&M^*+Y8?AUX#U#4[8.HDO+P^5&!W!V@JOU+?A7%_#_\ M9P\2QZY8:KXHFL-.@MYTF>SVK=22A3DJVG4_2OIZ.-(8ECA18XT&U448 M"CT H \4N?COK?B2XEL_A=X(O]6=6*?;;Q"D2D''(';_ 'F4^U:'PU^#UK:0 MWFL_$'P[I,VOWEY)<84M,D:M@XVL2F=V[IVQS7KH '08[\44 96I>%]!UEK0 MZOHUA>_8L_9A<6R.(E:#:K:;=07E MK*,QSV\@D1QG'##@\BK% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1103@9- !16:OB/1'U=-*36+!M1D!*68N4 M,K8&3A,Y.!STZ5Y_X\^*7B70_$5QH'A#P)J6LW<*J3>-$_V?YE#<;1\P&<'D M<@B@#U*L[5_$.C:!")=&/# M5A!>ZYKEE:6]RGF6[-*&\Y< [D R6&".1GJ/6O#-?^/?BCQ5XY7PU\+ULTMK MB9(+?4)+=W=BV 7(88102/] M0U+G)M+3*Q*?;=P/P05RUG^R;?-#.=1\46T<@#>2EO:,RD_PEF+ @>HP?K7T MU10!XGX2\'W?@31YM*T,>-;2ZGD\R:VA2PG@DDP%WB>2$J$P!UP>%)/!W@VVTRYE$UT299V!!4,< *I"J,*H51P.%Z#H.HHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HKSKQMXUTS3_%6FV-QXW70+/[%=37+ MVKV[R&57@$:D21R8^5Y3@ $X/I6#%\1/"E[;SFP^,>I>QT5@^#_$%MK_A;2[E=2MKV[ELXGN##(A/F% 6R%Z'.>.U;U !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 5%#=6]Q),EO/'*]O)Y4RHX8QOM#;6 Z':RG![,#W MJCXF\S_A$]6$&HQZ7*;*81WTK[$MF*'$A;L%.#GVKP?X&6^F:'X^FLK^#5=. MURY5D5XKI;G3]146T$AS*,AI/F:88P%67&3D"@#Z+HKQG1;'7K/]IJ-_$^JQ M7]S<^'Y9HX[>(I%:Q^> L29.6QMR6."2?:LFV\&PV/Q>TF+0]4NM8\6P:BU_ MXBUA2Z10VC XMW4NR@L-JJHR<#/ Q@ ]\HKYFUR$W.E^,/B+(]U_PDVA^+C8 MZ?,MPX\N".2)!"$SMP1(V>.?Q.?IF@#.US_D'Q?]?EK_ .CXZT:Q=:NIBDI->'?\+*^*WCGY? 7@H:/9/]W4-4]/[R[MJG M\ ].B^ WB#Q3*MS\4O'-]J?(8V5BVV)3[%A@?@@^M &C\0OC+X*T?6?#\L6K M)JDNFZC)<3PZ=B4A3:7$7#9"9WR*,;L]?2L]/VE(K8BXUSP-KNGZ;(%^?#_C>UU^W3_ECJ2_O'_%PW_H8H_P"%L?%#PSQXS^&D MMS&O#W.ELQ4#U.WS!^HH ]PHKR/2/VE/ E^XBU-[_1I@=K+>6Q8 ^F8]WZ@5 MZ#HOC3PSXB"_V'KVGWS-TCAN%+CZKG(_*@#;HHHH **** "BBB@ HHHH *** M* "BBJ]]J%EI=JUSJ5W!9VZ\-+<2K&@_$G% %BBJFFZMIVLVOVG1]0M;^#./ M-M9EE7/U4D5;)P,F@ HKE]<^)?@OPX2NL>)=/@D7K$LOF2#_ ( F6_2H==^* MG@KPWI]K=ZKK]M&EY MQ;I&&DDEC895@B@M@^I % '745\T^(/COXX\6>(+C M3_A1I,LE@,+%PT'2+G5-7N5M;*U3S)IG!(4?0KZ5H1@\)6VB:]<_P!N[;<0W,U[&&^U M>I=3D'/OGWS4]AX?T;2BITO2;&S*+L4V]LD9"^G Z4 >.#Q[\9?&BI_PB?@J M'P]:R#_CZU)LLN?XAO"Y'T1JCN/@1XP\82+-\1?B%/B@#S[P;\$?!?@C4(-1TRSGN=1@SY=W=SEV7(P2%&%!P3SCO7H-%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 453U'6-,T>'S=7U&TL(\9WW4 MZQ#\V(KAM8^/7PZT;($O9!_RSLHGFS_P(#;^M 'HM%>(M^T7-K+&/P+X" MUO6SG =DVJ/)O^/'1=(\,P-]V6X*LX^H8N?_'!0![?65J_ MBG0- 4G6]:T_3\#I2?\*7\?>(.?&GQ/O2C??MM/#"-OU5?_'* MUM(_9K\ :

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end XML 14 R15.htm IDEA: XBRL DOCUMENT v3.19.3
Stockholders' Equity and Weighted Average Common Shares Outstanding
 12 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Stockholders' Equity and Weighted Average Common Shares Outstanding Stockholders' Equity and Weighted Average Common Shares Outstanding
The authorized capital stock of the Company consists of 600,000,000 shares of common stock, par value $0.01 per share (the "common stock"), and 10,000,000 shares of preferred stock, par value $0.01 per share (the "preferred stock").
The board of directors is authorized to provide for the issuance of shares of preferred stock in one or more series with various designations and preferences and relative, participating, optional, or other special rights and qualifications, limitations, or restrictions. Except as required by law, or as otherwise provided by the board of directors of the Company, the holders of preferred stock will have no voting rights and will not be entitled to notice of meetings of stockholders. Holders of preferred stock will be entitled to receive, when declared by the board of directors, out of legally available funds, dividends at the rates fixed by the board of directors for the respective series of preferred stock, and no more, before any dividends will be declared and paid, or set apart for payment, on common stock with respect to the same dividend period. No shares of preferred stock have been issued as of September 30, 2019.
The holders of the Company's common stock are entitled to one vote per share and have the exclusive right to vote for the board of directors and for all other purposes as provided by law. Subject to the rights of holders of the Company's preferred stock, holders of common stock are entitled to receive ratably on a per share basis such dividends and other distributions in cash, stock, or property of the Company as may be declared by the board of directors from time to time out of the legally available assets or funds of the Company.
The following illustrates the components of Accumulated Other Comprehensive Loss, net of income taxes:
 
 
September 30,
(in thousands)
 
2019
 
2018
Pension and postretirement adjustments
 
$
(5,344
)
 
$
(5,065
)
Foreign currency translation
 
(107,252
)
 
(74,811
)
Other
 
631

 
623

Total accumulated other comprehensive loss
 
$
(111,965
)
 
$
(79,253
)

In September 2016, the Company entered into an Accelerated Share Repurchase ("ASR") transaction with a financial institution and paid $400.0 million for the delivery of 4.5 million shares of its common stock. The initial payment of $400.0 million funded stock purchases of $380.0 million and a share holdback of $20.0 million. The ASR transaction was settled in November 2016, at which time the financial institution delivered an additional 0.5 million shares of the Company's common stock. The number of shares ultimately received was based upon the volume-weighted average price of the Company's common stock during the term of the ASR. The Company applied the 4.5 million shares from the ASR to the May 2016 share repurchase program. During the fiscal year ended September 30, 2017, the Company purchased 2.1 million shares of its common stock (included 0.5 million
shares of common stock received as part of the settlement of the ASR) for a total of $118.8 million to complete its authorization under the May 2016 program.
In November 2016, the Company's board of directors authorized a share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2017, the Company purchased 2.7 million shares of its common stock for a total of $211.1 million under this program. During the fiscal year ended September 30, 2018, the Company purchased 7.7 million shares of its common stock for a total of $663.1 million, which included $24.0 million of September 2018 purchases that cash settled in October 2018. During the fiscal year ended September 30, 2019, the Company purchased 1.4 million shares of its common stock for a total of $125.8 million, which excluded $24.0 million of September 2018 purchases that cash settled in October 2018, to complete its authorization under this program.
In October 2018, the Company's board of directors authorized a new share repurchase program allowing the Company to purchase up to $1.0 billion of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2019, the Company purchased 6.7 million shares of its common stock for a total of $538.9 million under this program, which included $14.8 million of September 2019 purchases that cash settled in October 2019. As of September 30, 2019, the Company had $461.1 million of availability under this program.
Common Shares Outstanding
Basic earnings per share is computed by dividing net income attributable to AmerisourceBergen Corporation by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed by dividing net income attributable to AmerisourceBergen Corporation by the weighted average number of shares of common stock outstanding, plus the dilutive effect of stock options and restricted stock units during the periods presented.
The following illustrates the components of diluted weighted average shares outstanding:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Weighted average common shares outstanding - basic
 
210,165

 
217,872

 
218,375

Effect of dilutive securities - stock options and restricted stock units
 
1,675

 
2,464

 
3,227

Weighted average common shares outstanding - diluted
 
211,840

 
220,336

 
221,602


The potentially dilutive stock options and restricted stock units that were antidilutive for the fiscal years ended September 30, 2019, 2018, and 2017 were 4.6 million, 3.2 million, and 4.1 million, respectively.

XML 15 R11.htm IDEA: XBRL DOCUMENT v3.19.3
Variable Interest Entity
 12 Months Ended
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Variable Interest Entity Variable Interest Entity
As discussed in Note 2, the Company made an additional investment in Profarma in January 2018. In connection with this investment, the Company obtained substantial governance rights, allowing it to direct the activities that significantly impact Profarma’s economic performance. As such, the Company consolidated the operating results of Profarma in its consolidated financial statements as of and for the periods ended September 30, 2019 and September 30, 2018. The Company is not obligated to provide future financial support to Profarma.
The following assets and liabilities of Profarma are included in the Company's Consolidated Balance Sheet:
(in thousands)
 
September 30,
2019
 
September 30,
2018
Cash and cash equivalents
 
$
9,431

 
$
26,801

Accounts receivables, net
 
154,491

 
144,646

Inventories
 
185,602

 
168,931

Prepaid expenses and other
 
64,119

 
61,924

Property and equipment, net
 
30,961

 
32,667

Goodwill
 
82,309

 
82,309

Other intangible assets
 
74,429

 
80,974

Other long-term assets
 
9,169

 
8,912

Total assets
 
$
610,511

 
$
607,164

 
 
 
 
 
Accounts payable
 
$
165,053

 
$
150,102

Accrued expenses and other
 
49,191

 
37,195

Short-term debt
 
106,439

 
115,461

Long-term debt
 
60,973

 
39,704

Deferred income taxes
 
42,371

 
46,137

Other long-term liabilities
 
5,303

 
31,988

Total liabilities
 
$
429,330

 
$
420,587


Profarma's assets can only be used to settle its obligations, and its creditors do not have recourse to the general credit of the Company.
XML 16 R19.htm IDEA: XBRL DOCUMENT v3.19.3
Lease Commitments
 12 Months Ended
Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
Leases Commitments Lease Commitments
The Company has long-term leases for facilities and equipment. In the normal course of business, leases are generally renewed or replaced by other leases. Certain leases include escalation clauses. During the fiscal years ended September 30, 2019, 2018, and 2017, the Company recorded rental expense of $108.9 million, $114.9 million, and $80.7 million, respectively, in Distribution, Selling, and Administrative in the Consolidated Statements of Operations.
As of September 30, 2019, future minimum rental payments under noncancelable operating leases and financing obligations were as follows:
Payments Due by Fiscal Year (in thousands)
 
Operating
Leases
 
Financing Obligations 1
 
Total
2020
 
$
94,958

 
$
22,468

 
$
117,426

2021
 
84,002

 
29,790

 
113,792

2022
 
72,224

 
36,914

 
109,138

2023
 
63,507

 
35,950

 
99,457

2024
 
56,377

 
35,276

 
91,653

Thereafter
 
177,267

 
270,410

 
447,677

Total minimum lease payments
 
$
548,335

 
$
430,808

 
$
979,143

 
 
 
 
 
 
 
1 Represents the portion of future minimum lease payments relating to facility leases where the Company was determined to be the accounting owner (see Note 1). These payments are recognized as reductions to the financing obligation and as interest expense and exclude the future non-cash termination of the financing obligation.
XML 17 R32.htm IDEA: XBRL DOCUMENT v3.19.3
Stockholders' Equity and Weighted Average Common Shares Outstanding (Tables)
 12 Months Ended
Sep. 30, 2019
Equity [Abstract]  
Components of accumulated other comprehensive loss
The following illustrates the components of Accumulated Other Comprehensive Loss, net of income taxes:
 
 
September 30,
(in thousands)
 
2019
 
2018
Pension and postretirement adjustments
 
$
(5,344
)
 
$
(5,065
)
Foreign currency translation
 
(107,252
)
 
(74,811
)
Other
 
631

 
623

Total accumulated other comprehensive loss
 
$
(111,965
)
 
$
(79,253
)
Components of diluted weighted average shares outstanding
The following illustrates the components of diluted weighted average shares outstanding:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Weighted average common shares outstanding - basic
 
210,165

 
217,872

 
218,375

Effect of dilutive securities - stock options and restricted stock units
 
1,675

 
2,464

 
3,227

Weighted average common shares outstanding - diluted
 
211,840

 
220,336

 
221,602
XML 18 R36.htm IDEA: XBRL DOCUMENT v3.19.3
Business Segment Information (Tables)
 12 Months Ended
Sep. 30, 2019
Segment Reporting [Abstract]  
Reconciliation of revenue from segments to consolidated The following illustrates reportable and operating segment revenue information for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Pharmaceutical Distribution Services
 
$
172,813,537

 
$
161,699,343

 
$
147,453,495

Other:
 
 
 
 
 
 
MWI Animal Health
 
3,975,232

 
3,789,759

 
3,636,305

Global Commercialization Services
 
2,893,109

 
2,542,971

 
2,111,558

Total Other
 
6,868,341

 
6,332,730

 
5,747,863

Intersegment eliminations
 
(92,757
)
 
(92,438
)
 
(57,532
)
Revenue
 
$
179,589,121

 
$
167,939,635

 
$
153,143,826
Reconciliation of segment operating income, depreciation and amortization, and capital expenditures from segments to consolidated
The following illustrates reportable segment operating income information for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Pharmaceutical Distribution Services
 
$
1,671,251

 
$
1,626,748

 
$
1,643,629

Other
 
380,660

 
355,091

 
373,797

Intersegment eliminations
 
(659
)
 
(609
)
 
(556
)
Total segment operating income
 
$
2,051,252

 
$
1,981,230

 
$
2,016,870


The following illustrates depreciation and amortization by reportable segment for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Pharmaceutical Distribution Services
 
$
232,735

 
$
225,608

 
$
188,065

Other
 
69,824

 
64,768

 
53,160

Acquisition-related intangibles amortization
 
159,848

 
174,751

 
156,378

Total depreciation and amortization
 
$
462,407

 
$
465,127

 
$
397,603


The following illustrates capital expenditures by reportable segment for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Pharmaceutical Distribution Services
 
$
210,161

 
$
190,191

 
$
339,478

Other
 
100,061

 
146,220

 
126,919

Total capital expenditures
 
$
310,222

 
$
336,411

 
$
466,397
Reconciliation of total segment operating income to income from continuing operations before income taxes
The following reconciles total segment operating income to income before income taxes for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Total segment operating income
 
$
2,051,252

 
$
1,981,230

 
$
2,016,870

Gain from antitrust litigation settlements
 
145,872

 
35,938

 
1,395

LIFO credit (expense)
 
22,544

 
(67,324
)
 
157,782

PharMEDium remediation costs
 
(69,423
)
 
(66,204
)
 
—

New York State Opioid Stewardship Act
 
22,000

 
(22,000
)
 
—

Acquisition-related intangibles amortization
 
(159,848
)
 
(174,751
)
 
(156,378
)
Employee severance, litigation, and other
 
(330,474
)
 
(183,520
)
 
(959,327
)
Goodwill impairment
 
—

 
(59,684
)
 
—

Impairment of long-lived assets
 
(570,000
)
 
—

 
—

Operating income
 
1,111,923

 
1,443,685

 
1,060,342

Other (income) loss
 
(12,952
)
 
25,469

 
(2,730
)
Interest expense, net
 
157,769

 
174,699

 
145,185

Loss on consolidation of equity investments
 
—

 
42,328

 
—

Loss on early retirement of debt
 
—

 
23,766

 
—

Income before income taxes
 
$
967,106

 
$
1,177,423

 
$
917,887
Reconciliation of assets from segment to consolidated
The following illustrates total assets by reportable segment for the periods indicated:
 
 
September 30,
(in thousands)
 
2019
 
2018
 
2017
Pharmaceutical Distribution Services
 
$
33,160,529

 
$
31,892,621

 
$
29,691,127

Other
 
6,011,451

 
5,777,217

 
5,625,343

Total assets
 
$
39,171,980

 
$
37,669,838

 
$
35,316,470
JSON 19 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a10-kx9302019.htm": { "axisCustom": 1, "axisStandard": 33, "contextCount": 290, "dts": { "calculationLink": { "local": [ "abc-20190930_cal.xml" ] }, "definitionLink": { "local": [ "abc-20190930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "a10-kx9302019.htm" ] }, "labelLink": { "local": [ "abc-20190930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "abc-20190930_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-ref-2019-01-31.xml" ] }, "schema": { "local": [ "abc-20190930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 738, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 40, "http://www.amerisourcebergen.com/20190930": 4, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 49 }, "keyCustom": 54, "keyStandard": 486, "memberCustom": 47, "memberStandard": 42, "nsprefix": "abc", "nsuri": "http://www.amerisourcebergen.com/20190930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationStateCountryCode", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover", "role": "http://www.amerisourcebergen.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityIncorporationStateCountryCode", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Acquisitions and Investments", "role": "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestments", "shortName": "Acquisitions and Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Variable Interest Entity", "role": "http://www.amerisourcebergen.com/role/VariableInterestEntity", "shortName": "Variable Interest Entity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Income Taxes", "role": "http://www.amerisourcebergen.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Goodwill and Other Intangible Assets", "role": "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssets", "shortName": "Goodwill and Other Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Debt", "role": "http://www.amerisourcebergen.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "abc:StockholdersEquityandWeightedAverageCommonSharesOutstandingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding", "role": "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstanding", "shortName": "Stockholders' Equity and Weighted Average Common Shares Outstanding", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "abc:StockholdersEquityandWeightedAverageCommonSharesOutstandingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Related Party Transactions", "role": "http://www.amerisourcebergen.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Retirement and Other Benefit Plans", "role": "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlans", "shortName": "Retirement and Other Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Share-Based Compensation", "role": "http://www.amerisourcebergen.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Lease Commitments", "role": "http://www.amerisourcebergen.com/role/LeaseCommitments", "shortName": "Lease Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Employee Severance, Litigation, and Other", "role": "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOther", "shortName": "Employee Severance, Litigation, and Other", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - Legal Matters and Contingencies", "role": "http://www.amerisourcebergen.com/role/LegalMattersAndContingencies", "shortName": "Legal Matters and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalMattersAndContingenciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - Litigation Settlements", "role": "http://www.amerisourcebergen.com/role/LitigationSettlements", "shortName": "Litigation Settlements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - Business Segment Information", "role": "http://www.amerisourcebergen.com/role/BusinessSegmentInformation", "shortName": "Business Segment Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119100 - Disclosure - Fair Value of Financial Instruments", "role": "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120100 - Disclosure - Quarterly Financial Information (Unaudited)", "role": "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnaudited", "shortName": "Quarterly Financial Information (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:QuarterlyFinancialInformationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "2122100 - Schedule - Schedule II - Valuation and Qualifying Accounts", "role": "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccounts", "shortName": "Schedule II - Valuation and Qualifying Accounts", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Variable Interest Entity (Tables)", "role": "http://www.amerisourcebergen.com/role/VariableInterestEntityTables", "shortName": "Variable Interest Entity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Income Taxes (Tables)", "role": "http://www.amerisourcebergen.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "role": "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsTables", "shortName": "Goodwill and Other Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Debt (Tables)", "role": "http://www.amerisourcebergen.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding (Tables)", "role": "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingTables", "shortName": "Stockholders' Equity and Weighted Average Common Shares Outstanding (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.amerisourcebergen.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - Lease Commitments (Tables)", "role": "http://www.amerisourcebergen.com/role/LeaseCommitmentsTables", "shortName": "Lease Commitments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315301 - Disclosure - Employee Severance, Litigation, and Other (Tables)", "role": "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherTables", "shortName": "Employee Severance, Litigation, and Other (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318301 - Disclosure - Business Segment Information (Tables)", "role": "http://www.amerisourcebergen.com/role/BusinessSegmentInformationTables", "shortName": "Business Segment Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320301 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)", "role": "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedTables", "shortName": "Quarterly Financial Information (Unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "I2019Q1Oct01", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - Summary of Significant Accounting Policies - New Accounting Pronouncements (Details)", "role": "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails", "shortName": "Summary of Significant Accounting Policies - New Accounting Pronouncements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "I2019Q1Oct01", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD_us-gaap_ConcentrationRiskByTypeAxis_abc_WalgreensBootsAllianceIncMember", "decimals": "2", "first": true, "lang": null, "name": "abc:CustomerRevenueAsPercentageOfTotalRevenue", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401403 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)", "role": "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails", "shortName": "Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD_us-gaap_ConcentrationRiskByTypeAxis_abc_WalgreensBootsAllianceIncMember", "decimals": "2", "first": true, "lang": null, "name": "abc:CustomerRevenueAsPercentageOfTotalRevenue", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2018Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401405 - Disclosure - Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details)", "role": "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails", "shortName": "Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:InventoryPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2018Q4", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:PercentageOfLIFOInventory", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401407 - Disclosure - Summary of Significant Accounting Policies - Merchandise Inventories (Details)", "role": "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesMerchandiseInventoriesDetails", "shortName": "Summary of Significant Accounting Policies - Merchandise Inventories (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401408 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)", "role": "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:RevenueRecognitionPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "abc:AccrualForEstimatedCustomerSalesReturns", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401409 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details)", "role": "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails", "shortName": "Summary of Significant Accounting Policies - Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:RevenueRecognitionPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "abc:AccrualForEstimatedCustomerSalesReturns", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401410 - Disclosure - Summary of Significant Accounting Policies - Shipping and Handling Costs (Details)", "role": "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesShippingAndHandlingCostsDetails", "shortName": "Summary of Significant Accounting Policies - Shipping and Handling Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ShippingAndHandlingMember", "decimals": "-5", "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Acquisitions and Investments - NEVSCO (Details)", "role": "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsNevscoDetails", "shortName": "Acquisitions and Investments - NEVSCO (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "D2018Q1Dec_us-gaap_BusinessAcquisitionAxis_abc_NortheastVeterinarySupplyCompanyNEVSCOMember", "decimals": "-5", "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - Acquisitions and Investments - H.D. Smith (Details)", "role": "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails", "shortName": "Acquisitions and Investments - H.D. Smith (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "D2018Q1Jan_us-gaap_BusinessAcquisitionAxis_abc_H.D.SmithMember", "decimals": "-5", "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - Acquisitions and Investments - Proforma and Specialty Joint Venture (Details)", "role": "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "shortName": "Acquisitions and Investments - Proforma and Specialty Joint Venture (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "D2018Q1Jan_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_abc_ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member", "decimals": "-5", "lang": null, "name": "us-gaap:PaymentsToAcquireEquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Variable Interest Entity (Details)", "role": "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails", "shortName": "Variable Interest Entity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Income Taxes - Domestic and Foreign Income From Continuing Operations Before Income Taxes (Details)", "role": "http://www.amerisourcebergen.com/role/IncomeTaxesDomesticAndForeignIncomeFromContinuingOperationsBeforeIncomeTaxesDetails", "shortName": "Income Taxes - Domestic and Foreign Income From Continuing Operations Before Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "role": "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Income Taxes - Income Tax Provision (Details)", "role": "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails", "shortName": "Income Taxes - Income Tax Provision (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)", "role": "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails", "shortName": "Income Taxes - Reconciliation of Effective Income Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407405 - Disclosure - Income Taxes - Significant Components of Deferred Tax Liabilities (Assets) (Details)", "role": "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails", "shortName": "Income Taxes - Significant Components of Deferred Tax Liabilities (Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407406 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "role": "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q1QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407407 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2018Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Goodwill and Other Intangible Assets - Changes in Carrying Value of Goodwill (Details)", "role": "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsChangesInCarryingValueOfGoodwillDetails", "shortName": "Goodwill and Other Intangible Assets - Changes in Carrying Value of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:GoodwillAcquiredDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2018Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Details)", "role": "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsAdditionalInformationDetails", "shortName": "Goodwill and Other Intangible Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - Goodwill and Other Intangible Assets - Other Intangible Assets (Details)", "role": "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails", "shortName": "Goodwill and Other Intangible Assets - Other Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "I2019Q1Oct31", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Debt - Debt Instruments (Details)", "role": "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails", "shortName": "Debt - Debt Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "-3", "lang": null, "name": "us-gaap:CapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "I2019Q1Oct31", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Debt - Additional Information (Details)", "role": "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "shortName": "Debt - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "D2018Q1Dec", "decimals": "-5", "lang": null, "name": "us-gaap:PaymentsOfDebtExtinguishmentCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "role": "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2016Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Additional Information (Details)", "role": "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails", "shortName": "Stockholders' Equity and Weighted Average Common Shares Outstanding - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Accumulated Other Comprehensive Loss (Details)", "role": "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfAccumulatedOtherComprehensiveLossDetails", "shortName": "Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Accumulated Other Comprehensive Loss (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Diluted Weighted Average Shares Outstanding (Details)", "role": "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfDilutedWeightedAverageSharesOutstandingDetails", "shortName": "Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Diluted Weighted Average Shares Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4_srt_CounterpartyNameAxis_abc_WalgreensBootsAllianceIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_InvestorMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411401 - Disclosure - Related Party Transactions (Details)", "role": "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4_srt_CounterpartyNameAxis_abc_WalgreensBootsAllianceIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_InvestorMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "abc:DefinedContributionPlanMinimumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412401 - Disclosure - Retirement and Other Benefit Plans (Details)", "role": "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails", "shortName": "Retirement and Other Benefit Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "INF", "first": true, "lang": null, "name": "abc:DefinedContributionPlanMinimumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "abc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantUnderAmerisourcebergenEquityIncentivePlan", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - Share-Based Compensation - Additional Information (Details)", "role": "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "shortName": "Share-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "lang": null, "name": "us-gaap:StockOptionPlanExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413403 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details)", "role": "http://www.amerisourcebergen.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails", "shortName": "Share-Based Compensation - Weighted Average Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413404 - Disclosure - Share-Based Compensation - Stock Options (Details)", "role": "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails", "shortName": "Share-Based Compensation - Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2018Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - Share-Based Compensation - Nonvested Options (Details)", "role": "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails", "shortName": "Share-Based Compensation - Nonvested Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413406 - Disclosure - Share-Based Compensation - Nonvested Restricted Stock Units (Details)", "role": "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails", "shortName": "Share-Based Compensation - Nonvested Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1004501 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)", "role": "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413407 - Disclosure - Share-Based Compensation - Nonvested Performance Stock Units (Details)", "role": "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "shortName": "Share-Based Compensation - Nonvested Performance Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - Lease Commitments - Minimum Lease Payments (Details)", "role": "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails", "shortName": "Lease Commitments - Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414403 - Disclosure - Lease Commitments - Additional Information (Details)", "role": "http://www.amerisourcebergen.com/role/LeaseCommitmentsAdditionalInformationDetails", "shortName": "Lease Commitments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LeaseAndRentalExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415402 - Disclosure - Employee Severance, Litigation, and Other (Details)", "role": "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails", "shortName": "Employee Severance, Litigation, and Other (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LitigationSettlementExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416401 - Disclosure - Legal Matters and Contingencies (Details)", "role": "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails", "shortName": "Legal Matters and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "I2018Q3Jul01", "decimals": "-6", "lang": null, "name": "abc:AnnualFundCommitmentTotal", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GainLossRelatedToLitigationSettlement", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417401 - Disclosure - Litigation Settlements (Details)", "role": "http://www.amerisourcebergen.com/role/LitigationSettlementsDetails", "shortName": "Litigation Settlements (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418402 - Disclosure - Business Segment Information - Reconciliation of Segment Revenue, Operating Income, Assets, Depreciation and Amortization, and Capital Expenditures (Details)", "role": "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails", "shortName": "Business Segment Information - Reconciliation of Segment Revenue, Operating Income, Assets, Depreciation and Amortization, and Capital Expenditures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418403 - Disclosure - Business Segment Information - Reconciliation of Segment Operating Income to Income From Continuing Operations (Details)", "role": "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "shortName": "Business Segment Information - Reconciliation of Segment Operating Income to Income From Continuing Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember", "decimals": "-3", "lang": null, "name": "us-gaap:GainLossRelatedToLitigationSettlement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember_us-gaap_SubsegmentsAxis_abc_WorldCourierMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfCountriesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "country", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418404 - Disclosure - Business Segment Information - Additional Information (Details)", "role": "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "shortName": "Business Segment Information - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4_us-gaap_StatementBusinessSegmentsAxis_us-gaap_AllOtherSegmentsMember_us-gaap_SubsegmentsAxis_abc_WorldCourierMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfCountriesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "country", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419401 - Disclosure - Fair Value of Financial Instruments (Details)", "role": "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails", "shortName": "Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOW", "role": "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOW", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": "-3", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420402 - Disclosure - Quarterly Financial Information (Unaudited) (Details)", "role": "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails", "shortName": "Quarterly Financial Information (Unaudited) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4QTD", "decimals": "-3", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_abc_AllowanceForReturnsAndDoubtfulAccountsMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "2422401 - Schedule - Schedule II - Valuation and Qualifying Accounts (Details)", "role": "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsDetails", "shortName": "Schedule II - Valuation and Qualifying Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_abc_AllowanceForReturnsAndDoubtfulAccountsMember", "decimals": "-3", "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "td", "tr", "table", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_ValuationAllowancesAndReservesTypeAxis_abc_AllowanceForReturnsandDoubtfulAccountsNoncurrentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "2422402 - Schedule - Schedule II - Valuation and Qualifying Accounts - Additional Information (Details)", "role": "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsAdditionalInformationDetails", "shortName": "Schedule II - Valuation and Qualifying Accounts - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "td", "tr", "table", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_ValuationAllowancesAndReservesTypeAxis_abc_AllowanceForReturnsandDoubtfulAccountsNoncurrentMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "FD2019Q4YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "a10-kx9302019.htm", "contextRef": "I2019Q1Oct01_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - a10-kx9302019.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - a10-kx9302019.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 91, "tag": { "abc_AbilitytoIncreaseDebtCommitmentUnderAccordionFeatureinDecemberandMarchQuarters": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Ability to Increase Debt Commitment Under Accordion Feature in December and March Quarters", "label": "Ability to Increase Debt Commitment Under Accordion Feature in December and March Quarters", "terseLabel": "Accordion feature, potential increase in commitment" } } }, "localname": "AbilitytoIncreaseDebtCommitmentUnderAccordionFeatureinDecemberandMarchQuarters", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_AcceleratedShareRepurchasesFundedStockPurchases": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Accelerated Share Repurchases, Funded Stock Purchases", "label": "Accelerated Share Repurchases, Funded Stock Purchases", "terseLabel": "Accelerated share repurchase program, initial funding allocated to shares repurchased" } } }, "localname": "AcceleratedShareRepurchasesFundedStockPurchases", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_AcceleratedShareRepurchasesSettlementShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accelerated Share Repurchases, Settlement, Shares", "label": "Accelerated Share Repurchases, Settlement, Shares", "terseLabel": "Settlement of accelerated share repurchase transaction (shares)" } } }, "localname": "AcceleratedShareRepurchasesSettlementShares", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "abc_AcceleratedShareRepurchasesShareHoldback": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Accelerated Share Repurchases, Share Holdback", "label": "Accelerated Share Repurchases, Share Holdback", "terseLabel": "Accelerated share repurchase program, initial funding allocated to share holdback" } } }, "localname": "AcceleratedShareRepurchasesShareHoldback", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_AccrualForEstimatedCustomerSalesReturns": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Accrual for Estimated Customer Sales Returns", "terseLabel": "Accrual for estimated customer sales returns" } } }, "localname": "AccrualForEstimatedCustomerSalesReturns", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "abc_AccumulatedOtherAdjustmentsAttributabletoParentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accumulated Other Adjustments Attributable to Parent [Member]", "label": "Accumulated Other Adjustments Attributable to Parent [Member]", "terseLabel": "Other [Member]" } } }, "localname": "AccumulatedOtherAdjustmentsAttributabletoParentMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "abc_AggregateIntrinsicValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available", "label": "Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "AggregateIntrinsicValue", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "abc_AggregateLegalSettlementDueFromLargestU.S.PharmaceuticalDistributors": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate Legal Settlement Due From Largest U.S. Pharmaceutical Distributors", "label": "Aggregate Legal Settlement Due From Largest U.S. Pharmaceutical Distributors", "terseLabel": "Aggregate legal settlement (up to)" } } }, "localname": "AggregateLegalSettlementDueFromLargestU.S.PharmaceuticalDistributors", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "abc_AllowanceForReturnsAndDoubtfulAccountsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the allowance for returns and doubtful accounts.", "label": "Allowance For Returns And Doubtful Accounts [Member]", "terseLabel": "Allowances for returns and doubtful accounts [Member]" } } }, "localname": "AllowanceForReturnsAndDoubtfulAccountsMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "abc_AllowanceForReturnsandDoubtfulAccountsNoncurrentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Allowance For Returns and Doubtful Accounts, Noncurrent [Member]", "label": "Allowance For Returns and Doubtful Accounts, Noncurrent [Member]", "terseLabel": "Allowance for Doubtful Accounts for Long-term Accounts Receivable [Member]" } } }, "localname": "AllowanceForReturnsandDoubtfulAccountsNoncurrentMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_AllowancesForReturnsAndDoubtfulAccounts": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Allowances for returns and doubtful accounts.", "label": "Allowances for returns and doubtful accounts", "verboseLabel": "Allowances for returns and doubtful accounts" } } }, "localname": "AllowancesForReturnsAndDoubtfulAccounts", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "abc_AlternateBaseRateAndCanadianPrimeRateCdorRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alternate base rate and Canadian prime rate.", "label": "Alternate Base Rate And Canadian Prime Rate Cdor Rate [Member]", "terseLabel": "Alternate base rate and Canadian prime rate [Member]" } } }, "localname": "AlternateBaseRateAndCanadianPrimeRateCdorRateMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_AlternativeMinimumTaxMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to alternative minimum tax.", "label": "Alternative Minimum Tax [Member]", "terseLabel": "Alternative minimum tax credit carryforwards [Member]" } } }, "localname": "AlternativeMinimumTaxMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_AnnualFundCommitmentTotal": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Annual Fund Commitment Total", "label": "Annual Fund Commitment Total", "terseLabel": "Annual fund commitment total" } } }, "localname": "AnnualFundCommitmentTotal", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "abc_AssetFairValueDiscountRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset, Fair Value, Discount Rate", "label": "Asset, Fair Value, Discount Rate", "terseLabel": "Discount rate (as a percentage)" } } }, "localname": "AssetFairValueDiscountRate", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "percentItemType" }, "abc_BusinessTransformationEfforts": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails": { "order": 4.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Transformation Efforts", "label": "Business Transformation Efforts", "terseLabel": "Business transformation efforts" } } }, "localname": "BusinessTransformationEfforts", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "abc_CdorLiborEuriborBankersAcceptanceStampingFeeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee.", "label": "Cdor Libor Euribor Bankers Acceptance Stamping Fee [Member]", "terseLabel": "CDOR / LIBOR / EURIBOR / Bankers Acceptance Stamping Fee [Member]" } } }, "localname": "CdorLiborEuriborBankersAcceptanceStampingFeeMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_CorporationDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Corporation Debt [Member]", "label": "Corporation Debt [Member]", "terseLabel": "Corporation Debt [Member]" } } }, "localname": "CorporationDebtMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_CustomerRevenueAsPercentageOfTotalRevenue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Customer Revenue as Percentage of Total Revenue", "terseLabel": "Major customer, percentage of revenue" } } }, "localname": "CustomerRevenueAsPercentageOfTotalRevenue", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "percentItemType" }, "abc_DebtInstrumentFaceAmountPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Face Amount Percentage", "label": "Debt Instrument, Face Amount Percentage", "terseLabel": "Percentage of principal amount" } } }, "localname": "DebtInstrumentFaceAmountPercentage", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "abc_DebtInstrumentFacilityFeeRateEffectivePercentageRateRangeMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument Facility Fee Rate Effective Percentage Rate Range Maximum", "label": "Debt Instrument Facility Fee Rate Effective Percentage Rate Range Maximum", "terseLabel": "Maximum facility fee rate" } } }, "localname": "DebtInstrumentFacilityFeeRateEffectivePercentageRateRangeMaximum", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "abc_DebtInstrumentFacilityFeeRateEffectivePercentageRateRangeMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument Facility Fee Rate Effective Percentage Rate Range Minimum", "label": "Debt Instrument Facility Fee Rate Effective Percentage Rate Range Minimum", "terseLabel": "Minimum facility fee rate" } } }, "localname": "DebtInstrumentFacilityFeeRateEffectivePercentageRateRangeMinimum", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "abc_DeferredCompensationArrangementWithIndividualAnnualDistributions": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the percentage of the annual amount of the participant's base salary and bonus incentive by which the compensation exceeds the annual compensation limit established by the provisions of the Internal Revenue Code.", "label": "Deferred Compensation Arrangement with Individual, Annual Distributions", "terseLabel": "Deferred compensation, annual benefit, percent of compensation, Benefit Restoration Plan" } } }, "localname": "DeferredCompensationArrangementWithIndividualAnnualDistributions", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "abc_DeferredTaxAssetsNetOperatingLossAndTaxCreditCarryforwards": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards and net operating loss.", "label": "Deferred Tax Assets, Net Operating Loss and Tax Credit Carryforwards", "negatedLabel": "Net operating loss and tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsNetOperatingLossAndTaxCreditCarryforwards", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "abc_DefinedContributionPlanEmployerDiscretionaryContributionVestingPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined Contribution Plan, Employer Discretionary Contribution, Vesting Period", "label": "Defined Contribution Plan, Employer Discretionary Contribution, Vesting Period", "terseLabel": "Discretionary contributions, vesting period (in years)" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionVestingPeriod", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails" ], "xbrltype": "durationItemType" }, "abc_DefinedContributionPlanMinimumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined Contribution Plan, Minimum Annual Contributions Per Employee, Percent", "label": "Defined Contribution Plan, Minimum Annual Contributions Per Employee, Percent", "terseLabel": "Minimum allowed employee contributions, percent of salary" } } }, "localname": "DefinedContributionPlanMinimumAnnualContributionsPerEmployeePercent", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "abc_DefinedContributionPlanTranchesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Defined Contribution Plan Tranches [Axis]", "label": "Defined Contribution Plan Tranches [Axis]", "terseLabel": "Defined Contribution Plan Tranches [Axis]" } } }, "localname": "DefinedContributionPlanTranchesAxis", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails" ], "xbrltype": "stringItemType" }, "abc_DefinedContributionPlanTranchesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Defined Contribution Plan Tranches [Axis]", "label": "Defined Contribution Plan Tranches [Domain]", "terseLabel": "Defined Contribution Plan Tranches [Domain]" } } }, "localname": "DefinedContributionPlanTranchesDomain", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails" ], "xbrltype": "domainItemType" }, "abc_DistributionSellingAndAdministrativeDepreciationAndAmortizationExpenses": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the distribution, selling and administrative, depreciation and amortization expenses during the period.", "label": "Distribution, Selling and Administrative, Depreciation and Amortization Expenses", "terseLabel": "Distribution, selling, and administrative expenses; depreciation; and amortization" } } }, "localname": "DistributionSellingAndAdministrativeDepreciationAndAmortizationExpenses", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "abc_EarningsPerShareFromNetIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Earnings Per Share From Net Income [Abstract]", "terseLabel": "Earnings per share operations:" } } }, "localname": "EarningsPerShareFromNetIncomeAbstract", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "stringItemType" }, "abc_EmployeeContributionAdditionalTwoPercentOfSalaryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to the employee contribution by additional two percentage of the salary.", "label": "Employee Contribution Additional Two Percent Of Salary [Member]", "terseLabel": "Employee contribution, additional 2% of salary [Member]" } } }, "localname": "EmployeeContributionAdditionalTwoPercentOfSalaryMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails" ], "xbrltype": "domainItemType" }, "abc_EmployeeContributionFirstThreePercentOfSalaryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the information pertaining to the employee contribution up to the first three percent of the salary.", "label": "Employee Contribution First Three Percent Of Salary [Member]", "terseLabel": "Employee contribution, first 3% of salary [Member]" } } }, "localname": "EmployeeContributionFirstThreePercentOfSalaryMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails" ], "xbrltype": "domainItemType" }, "abc_EmployeeTaxWithholdingsRelatedToRestrictedShareVesting": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Withholdings Related to Restricted Share Vesting", "label": "Employee Tax Withholdings Related to Restricted Share Vesting", "negatedLabel": "Employee tax withholdings related to restricted share vesting" } } }, "localname": "EmployeeTaxWithholdingsRelatedToRestrictedShareVesting", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "abc_EstimatedLiabilityforNewYorkOpioidStewardshipAct": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Estimated Liability for New York Opioid Stewardship Act", "label": "Estimated Liability for New York Opioid Stewardship Act", "terseLabel": "Estimated liability under the New York Opioid Stewardship Act" } } }, "localname": "EstimatedLiabilityforNewYorkOpioidStewardshipAct", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "abc_ExpressScriptsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represent major customer Express Scripts", "label": "Express Scripts [Member]", "terseLabel": "Express Scripts, Inc. [Member]" } } }, "localname": "ExpressScriptsMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "abc_GlobalCommercializationServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Global Commercialization Services [Member]", "label": "Global Commercialization Services [Member]", "terseLabel": "Global Commercialization Services [Member]" } } }, "localname": "GlobalCommercializationServicesMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails" ], "xbrltype": "domainItemType" }, "abc_H.D.SmithMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "H.D. Smith [Member]", "label": "H.D. Smith [Member]", "terseLabel": "H.D. Smith [Member]" } } }, "localname": "H.D.SmithMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails" ], "xbrltype": "domainItemType" }, "abc_JointVentureOwnershipPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Joint Venture, Ownership Percentage", "label": "Joint Venture, Ownership Percentage", "terseLabel": "Ownership in specialty joint venture" } } }, "localname": "JointVentureOwnershipPercentage", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "percentItemType" }, "abc_LegalSettlementPaymentTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Legal Settlement Payment Term", "label": "Legal Settlement Payment Term", "terseLabel": "Legal settlement term (in years)" } } }, "localname": "LegalSettlementPaymentTerm", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "durationItemType" }, "abc_MDLandOtherRelatedStateCourtLitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "MDL and Other Related State Court Litigation [Member]", "label": "MDL and Other Related State Court Litigation [Member]", "terseLabel": "MDL and Other Related State Court Litigation [Member]" } } }, "localname": "MDLandOtherRelatedStateCourtLitigationMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "abc_MWIAnimalHealthMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "MWI Animal Health [Member]", "label": "MWI Animal Health [Member]", "terseLabel": "MWI Animal Health [Member]" } } }, "localname": "MWIAnimalHealthMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails" ], "xbrltype": "domainItemType" }, "abc_May2016ShareRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "May 2016 Share Repurchase Program [Member]", "label": "May 2016 Share Repurchase Program [Member]", "terseLabel": "May 2016 Share Repurchase Program [Member]" } } }, "localname": "May2016ShareRepurchaseProgramMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_MultiCurrencyRevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Multi Currency Revolving Credit Facility [Member]", "terseLabel": "Multi-currency revolving credit facility due 2021 [Member]" } } }, "localname": "MultiCurrencyRevolvingCreditFacilityMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_NewYorkStateOpioidStewardshipActExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "New York State Opioid Stewardship Act Expense", "label": "New York State Opioid Stewardship Act Expense", "negatedTerseLabel": "New York State Opioid Stewardship Act" } } }, "localname": "NewYorkStateOpioidStewardshipActExpense", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails" ], "xbrltype": "monetaryItemType" }, "abc_NonEmployeeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to compensation granted to Non-employee director.", "label": "Non Employee [Member]", "terseLabel": "Non-employee options [Member]" } } }, "localname": "NonEmployeeMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_NonrecourseDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Non-recourse Debt [Member]", "label": "Non-recourse Debt [Member]", "terseLabel": "Non-recourse Debt [Member]" } } }, "localname": "NonrecourseDebtMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_NortheastVeterinarySupplyCompanyNEVSCOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Northeast Veterinary Supply Company NEVSCO [Member]", "label": "Northeast Veterinary Supply Company NEVSCO [Member]", "terseLabel": "Northeast Veterinary Supply Company NEVSCO [Member]" } } }, "localname": "NortheastVeterinarySupplyCompanyNEVSCOMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsNevscoDetails" ], "xbrltype": "domainItemType" }, "abc_NoteReceivableImpairment": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Note Receivable Impairment", "label": "Note Receivable Impairment", "terseLabel": "Impairment of non-customer note receivable" } } }, "localname": "NoteReceivableImpairment", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "abc_November2016ShareRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "November 2016 Share Repurchase Program [Member]", "label": "November 2016 Share Repurchase Program [Member]", "terseLabel": "November 2016 Share Repurchase Program [Member]" } } }, "localname": "November2016ShareRepurchaseProgramMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_October2018ShareRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "October 2018 Share Repurchase Program [Member]", "label": "October 2018 Share Repurchase Program [Member]", "terseLabel": "October 2018 Share Repurchase Program [Member]" } } }, "localname": "October2018ShareRepurchaseProgramMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_OperatingLossCarryforwardsTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term operating loss carryforwards.", "label": "Operating Loss Carryforwards, Term", "terseLabel": "Net operating loss carryforwards, term (in years)" } } }, "localname": "OperatingLossCarryforwardsTerm", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDue": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and Capital Leases, Future Minimum Payments Due", "label": "Operating and Capital Leases, Future Minimum Payments Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "OperatingandCapitalLeasesFutureMinimumPaymentsDue", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDueFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating and Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]", "label": "Operating and Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]", "terseLabel": "Operating and Financing Obligations" } } }, "localname": "OperatingandCapitalLeasesFutureMinimumPaymentsDueFiscalYearMaturityAbstract", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDueNextTwelveMonths": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and Capital Leases, Future Minimum Payments Due, Next Twelve Months", "label": "Operating and Capital Leases, Future Minimum Payments Due, Next Twelve Months", "totalLabel": "2020" } } }, "localname": "OperatingandCapitalLeasesFutureMinimumPaymentsDueNextTwelveMonths", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 6.0, "parentTag": "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and Capital Leases, Future Minimum Payments Due Thereafter", "label": "Operating and Capital Leases, Future Minimum Payments Due Thereafter", "totalLabel": "Thereafter" } } }, "localname": "OperatingandCapitalLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDueinFiveYears": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and Capital Leases, Future Minimum Payments Due in Five Years", "label": "Operating and Capital Leases, Future Minimum Payments Due in Five Years", "totalLabel": "2024" } } }, "localname": "OperatingandCapitalLeasesFutureMinimumPaymentsDueinFiveYears", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDueinFourYears": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and Capital Leases, Future Minimum Payments Due in Four Years", "label": "Operating and Capital Leases, Future Minimum Payments Due in Four Years", "totalLabel": "2023" } } }, "localname": "OperatingandCapitalLeasesFutureMinimumPaymentsDueinFourYears", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDueinThreeYears": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and Capital Leases, Future Minimum Payments Due in Three Years", "label": "Operating and Capital Leases, Future Minimum Payments Due in Three Years", "totalLabel": "2022" } } }, "localname": "OperatingandCapitalLeasesFutureMinimumPaymentsDueinThreeYears", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDueinTwoYears": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating and Capital Leases, Future Minimum Payments Due in Two Years", "label": "Operating and Capital Leases, Future Minimum Payments Due in Two Years", "totalLabel": "2021" } } }, "localname": "OperatingandCapitalLeasesFutureMinimumPaymentsDueinTwoYears", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "abc_OpioidLawsuitsandInvestigationsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Opioid Lawsuits and Investigations [Member]", "label": "Opioid Lawsuits and Investigations [Member]", "terseLabel": "Opioid Lawsuits and Investigations [Member]" } } }, "localname": "OpioidLawsuitsandInvestigationsMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails" ], "xbrltype": "domainItemType" }, "abc_OpioidProgramTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Opioid Program Term", "label": "Opioid Program Term", "terseLabel": "Program period (in years)" } } }, "localname": "OpioidProgramTerm", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "durationItemType" }, "abc_OptionsExpectedToVest": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Options Expected to Vest", "terseLabel": "Expected to vest after end of period (shares)" } } }, "localname": "OptionsExpectedToVest", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "abc_OptionsExpectedToVestWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Options Expected to Vest Weighted Average Exercise Price", "terseLabel": "Expected to vest after end of period (usd per share)" } } }, "localname": "OptionsExpectedToVestWeightedAverageExercisePrice", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "abc_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIforInvestmentTransferredfromEquityMethodtoConsolidationNetofTax": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Investment Transferred from Equity Method to Consolidation, Net of Tax", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Investment Transferred from Equity Method to Consolidation, Net of Tax", "negatedLabel": "Foreign currency translation adjustment from AOCI", "terseLabel": "Loss on consolidation of equity investments" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIforInvestmentTransferredfromEquityMethodtoConsolidationNetofTax", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "abc_OverdraftFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Refers to overdraft facility.", "label": "Overdraft Facility [Member]", "terseLabel": "Overdraft facility due in 2021 [Member]" } } }, "localname": "OverdraftFacilityMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_PercentageofAggregateLegalSettlementDue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of Aggregate Legal Settlement Due", "label": "Percentage of Aggregate Legal Settlement Due", "terseLabel": "Company's portion of aggregate legal settlement" } } }, "localname": "PercentageofAggregateLegalSettlementDue", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "abc_PerformanceShareExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Performance Share Expense", "terseLabel": "Performance stock unit expense" } } }, "localname": "PerformanceShareExpense", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_PharmaceuticalDistributionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Pharmaceutical Distribution [Member]", "terseLabel": "Pharmaceutical Distribution [Member]" } } }, "localname": "PharmaceuticalDistributionMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails", "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsChangesInCarryingValueOfGoodwillDetails" ], "xbrltype": "domainItemType" }, "abc_PharmediumHealthcareHoldingsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to PharMEDium Healthcare Holdings, Inc.", "label": "Pharmedium Healthcare Holdings Inc [Member]", "terseLabel": "PharMEDium Healthcare Holdings, Inc [Member]" } } }, "localname": "PharmediumHealthcareHoldingsIncMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "abc_ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Profarma Distribuidora de Produtos Farmaceuticos S.A.", "label": "Profarma Distribuidora de Produtos Farmaceuticos S.A. [Member]", "terseLabel": "Profarma Distribuidora de Produtos Farmaceuticos S.A. [Member]" } } }, "localname": "ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "domainItemType" }, "abc_ProfarmaJointVentureMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Profarma Joint Venture [Member]", "label": "Profarma Joint Venture [Member]", "terseLabel": "Profarma Joint Venture [Member]" } } }, "localname": "ProfarmaJointVentureMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "domainItemType" }, "abc_ReceivablesSecuritizationFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Receivables Securitization Facility [Member]", "terseLabel": "Receivables securitization facility due 2022 [Member]" } } }, "localname": "ReceivablesSecuritizationFacilityMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_RemediationCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Remediation Costs", "label": "Remediation Costs", "negatedTerseLabel": "PharMEDium remediation costs", "terseLabel": "PharMEDium remediation costs" } } }, "localname": "RemediationCosts", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "abc_RestrictedStockCompensationNotYetRecognized": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Restricted Stock Compensation Not Yet Recognized", "terseLabel": "Expected future compensation expense relating to restricted shares outstanding" } } }, "localname": "RestrictedStockCompensationNotYetRecognized", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_RestructuringChargesandDefinedBenefitPlanRecognizedNetGainLossDuetoSettlements": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Restructuring Charges and Defined Benefit Plan, Recognized Net Gain (Loss) Due to Settlements", "label": "Restructuring Charges and Defined Benefit Plan, Recognized Net Gain (Loss) Due to Settlements", "terseLabel": "Employee severance, litigation, and other" } } }, "localname": "RestructuringChargesandDefinedBenefitPlanRecognizedNetGainLossDuetoSettlements", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "abc_RevolvingCreditNoteMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Revolving Credit Note [Member]", "terseLabel": "Revolving credit note [Member]" } } }, "localname": "RevolvingCreditNoteMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_SeniorNotesDue2019Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Senior Notes Due2019 [Member]", "terseLabel": "$400,000, 4.875% senior notes due 2019 [Member]" } } }, "localname": "SeniorNotesDue2019Member", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_SeniorNotesDue2021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Senior Notes Due2021 [Member]", "terseLabel": "$500,000, 3.50% senior notes due 2021 [Member]" } } }, "localname": "SeniorNotesDue2021Member", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_SeniorNotesDue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "", "label": "Senior Notes Due2024 [Member]", "terseLabel": "$500,000, 3.40% senior notes due 2024 [Member]" } } }, "localname": "SeniorNotesDue2024Member", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_SeniorNotesDue2025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the 3.25% senior notes due March 1, 2025.", "label": "Senior Notes Due2025 [Member]", "terseLabel": "$500,000, 3.25% senior notes due 2025 [Member]" } } }, "localname": "SeniorNotesDue2025Member", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_SeniorNotesDue2027Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes Due2027 [Member]", "label": "Senior Notes Due2027 [Member]", "terseLabel": "$750,000, 3.45% senior notes due 2027 [Member]" } } }, "localname": "SeniorNotesDue2027Member", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_SeniorNotesDue2045Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the 4.25% senior notes due March 1, 2045.", "label": "Senior Notes Due2045 [Member]", "terseLabel": "$500,000, 4.25% senior notes due 2045 [Member]" } } }, "localname": "SeniorNotesDue2045Member", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_SeniorNotesDue2047Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Senior Notes Due2047 [Member]", "label": "Senior Notes Due2047 [Member]", "terseLabel": "$500,000, 4.3% senior notes due 2047 [Member]" } } }, "localname": "SeniorNotesDue2047Member", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_SettlementwithOhioCountiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Settlement with Ohio Counties [Member]", "label": "Settlement with Ohio Counties [Member]", "terseLabel": "Settlement with Ohio Counties [Member]" } } }, "localname": "SettlementwithOhioCountiesMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "abc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantUnderAmerisourcebergenEquityIncentivePlan": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Number of Shares Available for Grant Under AmerisourceBergen Equity Incentive Plan", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number of Shares Available for Grant Under AmerisourceBergen Equity Incentive Plan", "terseLabel": "Shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantUnderAmerisourcebergenEquityIncentivePlan", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "abc_ShareholdersEquityOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Shareholders Equity Other", "terseLabel": "Other" } } }, "localname": "ShareholdersEquityOther", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "abc_ShippingandHandlingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shipping and Handling Costs [Policy Text Block]", "label": "Shipping and Handling Costs [Policy Text Block]", "terseLabel": "Shipping and Handling Costs" } } }, "localname": "ShippingandHandlingCostsPolicyTextBlock", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "abc_ShippingandHandlingLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Shipping and Handling [Table]", "label": "Shipping and Handling [Line Items]", "terseLabel": "Shipping and Handling [Line Items]" } } }, "localname": "ShippingandHandlingLineItems", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesShippingAndHandlingCostsDetails" ], "xbrltype": "stringItemType" }, "abc_ShippingandHandlingTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shipping and Handling [Table]", "label": "Shipping and Handling [Table]", "terseLabel": "Shipping and Handling [Table]" } } }, "localname": "ShippingandHandlingTable", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesShippingAndHandlingCostsDetails" ], "xbrltype": "stringItemType" }, "abc_StockholdersEquityandWeightedAverageCommonSharesOutstandingTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stockholders' Equity and Weighted Average Common Shares Outstanding", "label": "Stockholders' Equity and Weighted Average Common Shares Outstanding [Text Block]", "verboseLabel": "Stockholders' Equity and Weighted Average Common Shares Outstanding" } } }, "localname": "StockholdersEquityandWeightedAverageCommonSharesOutstandingTextBlock", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstanding" ], "xbrltype": "textBlockItemType" }, "abc_SupplierReservesPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supplier Reserves Policy", "label": "Supplier Reserves Policy [Policy Text Block]", "terseLabel": "Supplier Reserves" } } }, "localname": "SupplierReservesPolicyPolicyTextBlock", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "abc_TermLoanAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents the term loan credit agreement.", "label": "Term Loan Agreement [Member]", "terseLabel": "Term loans due in 2020 [Member]" } } }, "localname": "TermLoanAgreementMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "abc_TermLoanAgreementOctober2018Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan Agreement October 2018 [Member]", "label": "Term Loan Agreement October 2018 [Member]", "terseLabel": "Term Loan Agreement October 2018 [Member]" } } }, "localname": "TermLoanAgreementOctober2018Member", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_TradeNamesAndOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents trade names and other.", "label": "Trade Names And Other [Member]", "terseLabel": "Trade names and other [Member]" } } }, "localname": "TradeNamesAndOtherMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "abc_TradeReceivableDueFromSingleCustomerAsPercentageOfAccountsReceivable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Trade Receivable Due From Single Customer As Percentage of Accounts Receivable", "terseLabel": "Major customer, percentage of accounts receivable" } } }, "localname": "TradeReceivableDueFromSingleCustomerAsPercentageOfAccountsReceivable", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "percentItemType" }, "abc_TreasuryStockValueAcquiredCostMethodSettlements": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Treasury Stock, Value, Acquired, Cost Method, Settlements", "label": "Treasury Stock, Value, Acquired, Cost Method, Settlements", "verboseLabel": "Shares repurchased, cash settled" } } }, "localname": "TreasuryStockValueAcquiredCostMethodSettlements", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_USAOEDNYCivilClaimsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "USAO - EDNY Civil Claims [Member]", "label": "USAO - EDNY Civil Claims [Member]", "terseLabel": "USAO - EDNY Civil Claims [Member]", "verboseLabel": "USAO-EDNY Matter [Member]" } } }, "localname": "USAOEDNYCivilClaimsMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "abc_USAOEDNYMatterMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "USAO-EDNY Matter [Member]", "label": "USAO-EDNY Matter [Member]", "terseLabel": "USAO-EDNY Matter [Member]" } } }, "localname": "USAOEDNYMatterMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "abc_USAOEDNYMisdemeanorViolationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "USAO-EDNY Misdemeanor Violation [Member]", "label": "USAO-EDNY Misdemeanor Violation [Member]", "terseLabel": "USAO-EDNY Misdemeanor Violation [Member]" } } }, "localname": "USAOEDNYMisdemeanorViolationMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "abc_USAOSDNYMatterMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "USAO-SDNY Matter [Member]", "label": "USAO-SDNY Matter [Member]", "terseLabel": "USAO-SDNY Matter [Member]" } } }, "localname": "USAOSDNYMatterMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "abc_UndistributedEarningsofForeignSubsidiariesPermanentlyReinvested": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Undistributed Earnings of Foreign Subsidiaries Permanently Reinvested", "label": "Undistributed Earnings of Foreign Subsidiaries Permanently Reinvested", "terseLabel": "Permanently reinvested cumulative undistributed earnings" } } }, "localname": "UndistributedEarningsofForeignSubsidiariesPermanentlyReinvested", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_UnrecognizedTaxBenefitsIncludingIncomeTaxPenaltiesandInterestAccrued": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued", "label": "Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits, including interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncludingIncomeTaxPenaltiesandInterestAccrued", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_UnrecognizedTaxBenefitsIncludingIncomeTaxPenaltiesandInterestAccruedNetofFederalBenefit": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued, Net of Federal Benefit", "label": "Unrecognized Tax Benefits, Including Income Tax Penalties and Interest Accrued, Net of Federal Benefit", "terseLabel": "Unrecognized tax benefits, including interest and penalties, net of federal benefit" } } }, "localname": "UnrecognizedTaxBenefitsIncludingIncomeTaxPenaltiesandInterestAccruedNetofFederalBenefit", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "abc_WalgreensBootsAllianceIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Represents information pertaining to Walgreens Boots Alliance, Inc.", "label": "Walgreens Boots Alliance Inc [Member]", "terseLabel": "Walgreens Boots Alliance, Inc. [Member]" } } }, "localname": "WalgreensBootsAllianceIncMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "abc_WeightedAveragePeriodOfUnrecognizedOptionCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Weighted Average Period of Unrecognized Option Compensation", "terseLabel": "Weighted average period over which expected future compensation expense relating to nonvested options outstanding will be recognized" } } }, "localname": "WeightedAveragePeriodOfUnrecognizedOptionCompensation", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "abc_WeightedAveragePeriodOfUnrecognizedRestrictedStockCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available.", "label": "Weighted Average Period of Unrecognized Restricted Stock Compensation", "terseLabel": "Weighted average period over which expected future compensation expense relating to restricted shares outstanding will be recognized" } } }, "localname": "WeightedAveragePeriodOfUnrecognizedRestrictedStockCompensation", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "abc_WeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "No definition available", "label": "Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term" } } }, "localname": "WeightedAverageRemainingContractualTerm", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "abc_WestVirginiaAGMatterMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "West Virginia AG Matter", "label": "West Virginia AG Matter [Member]", "terseLabel": "West Virginia AG Matter [Member]" } } }, "localname": "WestVirginiaAGMatterMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "abc_WorldCourierMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "World Courier [Member]", "label": "World Courier [Member]", "terseLabel": "World Courier [Member]" } } }, "localname": "WorldCourierMember", "nsuri": "http://www.amerisourcebergen.com/20190930", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r534" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r533" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r535" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r535" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r535" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r536" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r535" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r535" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r535" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r535" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r531" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r532" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r166", "r178" ], "lang": { "en-US": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails", "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsChangesInCarryingValueOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails", "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsChangesInCarryingValueOfGoodwillDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r57", "r120", "r539" ], "lang": { "en-US": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of investment, including named security. Excludes consolidated entity.", "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.", "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.", "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r180", "r287", "r289", "r522", "r523" ], "lang": { "en-US": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesShippingAndHandlingCostsDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesShippingAndHandlingCostsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r537" ], "lang": { "en-US": { "role": { "documentation": "Information reported for future period.", "label": "Forecast [Member]", "terseLabel": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r192" ], "lang": { "en-US": { "role": { "documentation": "Information by name of investment, including named security. Excludes consolidated entity.", "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "stringItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r128", "r538" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "Schedule II - Valuation and Qualifying Accounts" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccounts" ], "xbrltype": "textBlockItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r257", "r473" ], "lang": { "en-US": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2019-01-31", "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r128", "r538" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AcceleratedShareRepurchaseProgramAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount needed to adjust previously recorded stockholders' equity balances to the actual aggregate amounts paid, whether in cash or other consideration, to acquire all of the shares purchased under an Accelerated Share Repurchase arrangement.", "label": "Accelerated Share Repurchase Program, Adjustment", "terseLabel": "Settlement of accelerated share repurchase transaction" } } }, "localname": "AcceleratedShareRepurchaseProgramAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt": { "auth_ref": [ "r280" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.", "label": "Accelerated Share Repurchases, Settlement (Payment) or Receipt", "negatedTerseLabel": "Accelerated share repurchase program, amount paid" } } }, "localname": "AcceleratedShareRepurchasesSettlementPaymentOrReceipt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201609Member": { "auth_ref": [ "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-09 Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.", "label": "Accounting Standards Update 2016-09 [Member]", "terseLabel": "Accounting Standards Update 2016-09 [Member]" } } }, "localname": "AccountingStandardsUpdate201609Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r498", "r519" ], "calculation": { "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r23", "r508" ], "calculation": { "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "Accounts Receivable, after Allowance for Credit Loss", "terseLabel": "Accounts receivables, net" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r23", "r183", "r184", "r288" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "verboseLabel": "Accounts receivable, less allowances for returns and doubtful accounts: 2019 \u2014 $1,222,906; 2018 \u2014 $1,036,333" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedParties": { "auth_ref": [ "r22", "r118", "r465", "r467", "r468", "r516" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.", "label": "Accounts Receivable, Related Parties", "terseLabel": "Receivable from related party" } } }, "localname": "AccountsReceivableRelatedParties", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r17", "r493", "r510" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "Accrued Income Taxes, Noncurrent", "terseLabel": "Accrued income taxes" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "terseLabel": "Accrued expenses and other" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "verboseLabel": "Accrued expenses and other" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r60", "r64", "r65", "r293", "r420" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Pension and postretirement adjustments [Member]" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r35", "r240" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r62", "r63", "r64" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r61", "r64", "r65", "r420" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss [Member]", "verboseLabel": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r59", "r64", "r65", "r420" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r223" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Estimated useful life (in years)" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsNevscoDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r24" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r109", "r230" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "verboseLabel": "Amortization, including amounts charged to interest expense" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Adjustments to Additional Paid in Capital, Other", "terseLabel": "Common stock purchases for employee stock purchase plan" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r302", "r304", "r350", "r351" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r158", "r159", "r160", "r161", "r162", "r163" ], "lang": { "en-US": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "Other [Member]" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails", "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsChangesInCarryingValueOfGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r109", "r221", "r230" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense", "verboseLabel": "Amortization" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r141" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of diluted earnings per share (shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r109", "r237" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 }, "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "negatedLabel": "Impairment of long-lived assets", "terseLabel": "Impairment of long-lived assets", "verboseLabel": "Impairment of long-lived assets (Note 1)" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r169", "r491", "r509" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails", "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets", "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r56" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets", "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r437" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Fair value of asset group" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r305", "r338" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r434", "r435" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingAndBuildingImprovementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Building and Building Improvements [Member]", "terseLabel": "Building and improvements [Member]" } } }, "localname": "BuildingAndBuildingImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r8", "r239" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "verboseLabel": "Buildings and improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsNevscoDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r402", "r403" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsNevscoDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsNevscoDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": { "auth_ref": [ "r406" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.", "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value", "terseLabel": "Noncontrolling interest" } } }, "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r400" ], "calculation": { "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails": { "order": 3.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Acquisition-related deal and integration costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r411" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions and Investments" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r405" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Assumed cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r405" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Estimated fair value of accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsNevscoDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r405" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "terseLabel": "Estimated fair value of accounts payable and accrued expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsNevscoDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r405" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt", "terseLabel": "Assumed short-term debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r404", "r405" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Estimated fair value of the intangible assets acquired, finite-lived" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsNevscoDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r404", "r405" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Estimated fair value of inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsNevscoDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r405" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt", "terseLabel": "Assumed long-term debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": { "auth_ref": [ "r401" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain", "terseLabel": "Gain on remeasurement of Profarma's previously held equity interest" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "In a business combination achieved in stages, this element represents the amount of loss recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss", "terseLabel": "Loss on consolidation of equity investments", "verboseLabel": "Loss on consolidation of equity investments" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r114", "r399" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalLeaseObligations": { "auth_ref": [ "r16", "r462", "r512" ], "calculation": { "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.", "label": "Capital Lease Obligations", "terseLabel": "Capital lease obligations" } } }, "localname": "CapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsNoncurrent": { "auth_ref": [ "r44", "r461", "r462" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.", "label": "Capital Lease Obligations, Noncurrent", "terseLabel": "Long-term financing obligation" } } }, "localname": "CapitalLeaseObligationsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r462" ], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetailsCalc2": { "order": 2.0, "parentTag": "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases.", "label": "Capital Leases, Future Minimum Payments Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]", "terseLabel": "Financing Obligations" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r462" ], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDueNextTwelveMonths", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2020" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r462" ], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due in Five Years", "terseLabel": "2024" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r462" ], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due in Four Years", "terseLabel": "2023" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r462" ], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due in Three Years", "terseLabel": "2022" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r462" ], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due in Two Years", "terseLabel": "2021" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r462" ], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_CapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of minimum lease payments for capital leases due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Capital Leases, Future Minimum Payments Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "CapitalLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r446", "r447" ], "lang": { "en-US": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying amount [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r31", "r111" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF YEAR", "periodStartLabel": "Cash and cash equivalents at beginning of year", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow", "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.", "label": "Cash and Cash Equivalents, Period Increase (Decrease)", "totalLabel": "INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r10", "r112", "r114" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ClassOfTreasuryStockTable": { "auth_ref": [ "r281", "r282", "r283", "r284" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Class of Treasury Stock [Table]", "terseLabel": "Class of Treasury Stock [Table]" } } }, "localname": "ClassOfTreasuryStockTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassificationOfVariableInterestEntityDomain": { "auth_ref": [ "r421", "r422", "r423", "r424" ], "lang": { "en-US": { "role": { "documentation": "Categorization of Variable Interest Entities (VIE) for consolidation and (or) disclosure purposes, whether individually or in aggregate, by: (1) VIEs consolidated because the entity is the primary beneficiary, (2) VIEs not consolidated because the entity is not the primary beneficiary, and (3) VIEs or potential VIEs that are not consolidated because necessary information is not available. In general, a VIE is a corporation, partnership, trust, or any other legal structure used for business purposes that either (a) does not have equity investors with voting rights or (b) has equity investors that do not provide sufficient financial resources for the entity to support its activities. A VIE often holds financial assets, including loans or receivables, real estate or other property. A VIE may be essentially passive or it may engage in research and development or other activities on behalf of another company.", "label": "Variable Interest Entity, Classification [Domain]", "terseLabel": "Variable Interest Entity, Classification [Domain]" } } }, "localname": "ClassificationOfVariableInterestEntityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r46", "r256", "r499", "r518" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 13)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r255", "r263" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Litigation Settlements" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LitigationSettlements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r114", "r266", "r527", "r528" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "Leases Commitments" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Cash dividends (usd per share)" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (usd per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r21", "r274" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding (shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r21" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01 par value \u2014 authorized, issued, and outstanding: 2019 \u2014 600,000,000 shares, 285,295,170 shares and 206,760,654 shares; 2018 \u2014 600,000,000 shares, 283,588,463 shares and 213,217,882 shares" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Components of Deferred Tax Assets and Liabilities [Abstract]", "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]" } } }, "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r68", "r70", "r71" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income attributable to AmerisourceBergen Corporation" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r68", "r70", "r415", "r416", "r428" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "negatedTerseLabel": "Comprehensive loss attributable to noncontrolling interest" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r68", "r70", "r414", "r428" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "auth_ref": [ "r222", "r228", "r409" ], "lang": { "en-US": { "role": { "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Software, Intangible Asset [Member]", "terseLabel": "Software technology [Member]" } } }, "localname": "ComputerSoftwareIntangibleAssetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r152", "r153", "r448", "r449", "r525" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r151", "r152", "r153", "r154", "r448", "r450" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r152", "r153", "r448", "r449" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetGrossCurrent": { "auth_ref": [ "r285", "r286" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, Gross, Current", "terseLabel": "Right to recover asset (Note 1)" } } }, "localname": "ContractWithCustomerAssetGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r82" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Cumulative effect adjustment, share-based compensation", "verboseLabel": "Adoption of ASU" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r117", "r388", "r392" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r124", "r390" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r117", "r388", "r392" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Total current provision" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "verboseLabel": "Current provision:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r117", "r388", "r392" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State and local" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r408" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsNevscoDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt, Current", "terseLabel": "Short-term debt" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r273" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r15", "r16", "r492", "r495", "r507" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable rate spread" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r456", "r457" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r43", "r270", "r456" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective yield percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r43" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r44", "r121", "r275", "r276", "r277", "r278", "r455", "r456", "r457", "r504" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.", "label": "Debt Related Commitment Fees and Debt Issuance Costs", "verboseLabel": "Amortization of financing fees and accretion of original issue discounts" } } }, "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualRecordedLiability": { "auth_ref": [ "r290" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of the liability as of the balance sheet date to an individual under a deferred compensation arrangement. This amount may be the result of periodic accruals made over the period of active employment, or reflect termination benefits resulting contractual terms or a death benefit.", "label": "Deferred Compensation Arrangement with Individual, Recorded Liability", "terseLabel": "Deferred compensation liability" } } }, "localname": "DeferredCompensationArrangementWithIndividualRecordedLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of shares authorized for issuance under the deferred compensation arrangement as of the balance sheet date.", "label": "Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance", "terseLabel": "Deferred compensation, common stock authorized for issuance (shares)" } } }, "localname": "DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualSharesIssued": { "auth_ref": [ "r337" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued pursuant to the terms of a deferred compensation arrangement.", "label": "Deferred Compensation Arrangement with Individual, Shares Issued", "terseLabel": "Deferred compensation, common stock issued (shares)" } } }, "localname": "DeferredCompensationArrangementWithIndividualSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r117", "r389", "r392" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r117", "r389", "r392" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r109", "r117", "r389", "r392" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Total deferred provision (benefit)", "verboseLabel": "Provision (benefit) for deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow", "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred provision (benefit):" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r18", "r19", "r378", "r494", "r506" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "totalLabel": "Gross deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r363", "r382" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets", "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r117", "r389", "r392" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State and local" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r379" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "negatedTotalLabel": "Gross deferred tax assets", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r380" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "negatedTotalLabel": "Deferred tax assets, net of valuation allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r356", "r386", "r387" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "negatedLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": { "auth_ref": [ "r354", "r386", "r387" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits", "negatedLabel": "Employee and retiree benefits" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r354", "r386", "r387" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "negatedLabel": "Share-based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r354", "r386", "r387" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities", "negatedLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": { "auth_ref": [ "r354", "r386", "r387" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts", "negatedLabel": "Allowance for doubtful accounts" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r381" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "terseLabel": "Valuation allowance for deferred tax assets" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r363", "r382" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "Deferred Tax Liabilities, Net", "totalLabel": "Net deferred tax liabilities", "verboseLabel": "Net deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": { "auth_ref": [ "r355", "r386", "r387" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.", "label": "Deferred Tax Liabilities, Inventory", "terseLabel": "Inventories" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": { "auth_ref": [ "r356", "r386", "r387" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets", "terseLabel": "Goodwill and other intangible assets" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r356", "r386", "r387" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r356", "r386", "r387" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "terseLabel": "Property and equipment" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r300" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Defined contribution plans expense" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Discretionary contributions" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Employer matching contribution, percent of salary" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Employer matching contribution, percent of match" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Maximum allowed employee contributions, percent of salary" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r109", "r238" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation, including amounts charged to cost of goods sold" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r109", "r167" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationNonproduction": { "auth_ref": [ "r109", "r238" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.", "label": "Depreciation, Nonproduction", "verboseLabel": "Depreciation" } } }, "localname": "DepreciationNonproduction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r114", "r125", "r430", "r431", "r432", "r433", "r436" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r353" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r279" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Cash dividends" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r76", "r131", "r136", "r138", "r139", "r140", "r143", "r501", "r521" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (usd per share)", "verboseLabel": "Basic (usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r76", "r131", "r136", "r138", "r139", "r140", "r143", "r501", "r521" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r123", "r364", "r365" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r364", "r365", "r391" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Statutory U.S. federal income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r364", "r365", "r391" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r364", "r365", "r391" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails": { "order": 9.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Tax reform" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r364", "r365", "r391" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent", "terseLabel": "Foreign tax rate differential" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": { "auth_ref": [ "r364", "r365", "r391" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent", "terseLabel": "Goodwill impairment (see Note 5)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r364", "r365", "r391" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r364", "r365", "r391" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails": { "order": 10.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent", "terseLabel": "Capital gain on distribution" } } }, "localname": "EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "auth_ref": [ "r352", "r364" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount", "negatedLabel": "Excess tax benefit from the exercise of stock options and lapses of restricted stock units" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r352", "r364" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent", "terseLabel": "Excess tax benefits related to share-based compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r364", "r365", "r391" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State and local income tax rate, net of federal tax benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": { "auth_ref": [ "r364", "r365", "r391" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.", "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent", "terseLabel": "Litigation settlements and accruals (see Note 14)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r336" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Expected future compensation expense relating to nonvested options outstanding" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r335" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Employee options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity, Class of Treasury Stock [Line Items]" } } }, "localname": "EquityClassOfTreasuryStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r274" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r192" ], "lang": { "en-US": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "verboseLabel": "Ownership interest in profarma" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestmentQuotedMarketValue": { "auth_ref": [ "r194" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available.", "label": "Equity Method Investment, Quoted Market Value", "terseLabel": "Fair value of equity interests" } } }, "localname": "EquityMethodInvestmentQuotedMarketValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "auth_ref": [ "r78", "r79", "r109" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.", "label": "Equity Method Investment, Realized Gain (Loss) on Disposal", "negatedTerseLabel": "Gain on sale of an equity investment" } } }, "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r32", "r103", "r114", "r193", "r451" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r445" ], "lang": { "en-US": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair value [Member]" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessOfReplacementOrCurrentCostsOverStatedLIFOValue": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The excess of replacement or current cost over the stated LIFO (last in first out) inventory value when the LIFO inventory method is utilized.", "label": "Excess of Replacement or Current Costs over Stated LIFO Value", "terseLabel": "Excess cost of inventories over LIFO, if used FIFO" } } }, "localname": "ExcessOfReplacementOrCurrentCostsOverStatedLIFOValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesMerchandiseInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r437", "r446", "r447" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r291", "r292", "r299", "r438", "r474" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r437", "r442" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r437", "r438", "r439", "r440", "r443" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r441" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r291", "r292", "r299", "r438", "r475" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r291", "r292", "r299", "r438", "r476" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r441", "r443" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]", "terseLabel": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]" } } }, "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-lived intangible asset, weighted average remaining useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r229" ], "calculation": { "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Finite-lived intangibles, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r222", "r225", "r229", "r233", "r478" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsNevscoDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]", "terseLabel": "Amortization expense, fiscal year maturity" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r229", "r478" ], "calculation": { "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-lived intangibles, gross carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r222", "r228" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsNevscoDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r229" ], "calculation": { "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Finite-lived intangibles, net carrying amount" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r114", "r452", "r454" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnSaleOfEquityInvestments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence.", "label": "Gain (Loss) on Sale of Equity Investments", "netLabel": "Gain on sale of equity investment" } } }, "localname": "GainLossOnSaleOfEquityInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r256" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "terseLabel": "Gain (loss) related to litigation settlement", "verboseLabel": "Gain from antitrust litigation settlements" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails", "http://www.amerisourcebergen.com/role/LitigationSettlementsDetails", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossRelatedToLitigationSettlementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Settlement [Abstract]" } } }, "localname": "GainLossRelatedToLitigationSettlementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r109", "r271", "r272" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on early retirement of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r210", "r212" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "netLabel": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsNevscoDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets", "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsChangesInCarryingValueOfGoodwillDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r213" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "verboseLabel": "Goodwill recognized in connection with acquisitions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsChangesInCarryingValueOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "verboseLabel": "Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r114", "r217", "r226" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r216" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "verboseLabel": "Foreign currency translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsChangesInCarryingValueOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r109", "r211", "r215", "r218" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 }, "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "negatedTerseLabel": "Goodwill impairment", "netLabel": "Goodwill impairment", "terseLabel": "Goodwill impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsChangesInCarryingValueOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsChangesInCarryingValueOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "auth_ref": [ "r214" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Written off Related to Sale of Business Unit", "negatedLabel": "Goodwill impairment" } } }, "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsChangesInCarryingValueOfGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r81" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Gross profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairedLongLivedAssetsHeldAndUsedLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Impaired Long-Lived Assets Held and Used [Line Items]", "terseLabel": "Assets Held and Used [Line Items]" } } }, "localname": "ImpairedLongLivedAssetsHeldAndUsedLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r109", "r234" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Finite-lived intangible asset impairment" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r109", "r234" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangible asset impairment" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r109", "r237", "r242", "r530" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment of Long-Lived Assets Held-for-use", "terseLabel": "Property and equipment impairment" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r122" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesDomesticAndForeignIncomeFromContinuingOperationsBeforeIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesDomesticAndForeignIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r122" ], "calculation": { "http://www.amerisourcebergen.com/role/IncomeTaxesDomesticAndForeignIncomeFromContinuingOperationsBeforeIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesDomesticAndForeignIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r122" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/IncomeTaxesDomesticAndForeignIncomeFromContinuingOperationsBeforeIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "Income before income taxes", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/IncomeTaxesDomesticAndForeignIncomeFromContinuingOperationsBeforeIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r368" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r398" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r117", "r168", "r395" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Income tax benefit", "totalLabel": "Provision (benefit) for income taxes", "verboseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r72", "r114", "r361", "r362", "r376", "r377", "r383", "r396", "r529" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r359", "r364", "r365" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "negatedTerseLabel": "Tax Cuts and Jobs Act, deferred income tax benefit as result of applying a lower U.S. federal income tax rate" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r364", "r365" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount", "terseLabel": "Tax Cuts and Jobs Act, current income tax expense on historical foreign earnings and profits" } } }, "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r113" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income tax payments, net of refunds" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r108" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r108" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r108" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income taxes payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r108" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "verboseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r108" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r108" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (decrease) in stockholders' equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r137", "r142" ], "calculation": { "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfDilutedWeightedAverageSharesOutstandingDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Effect of dilutive securities \u2014 stock options, restricted stock, restricted stock units, and the unsettled ASR transaction (shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfDilutedWeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r224", "r232" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r232" ], "calculation": { "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived intangibles" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r224", "r232" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "totalLabel": "Total other intangible assets, gross carrying amount" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r220", "r227" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other intangible assets", "totalLabel": "Total other intangible assets, net carrying amount" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets", "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "negatedLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r101", "r105", "r113" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r175" ], "lang": { "en-US": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]", "terseLabel": "Intersegment eliminations [Member]" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryLIFOReservePeriodCharge": { "auth_ref": [ "r53", "r54", "r55", "r209" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.", "label": "Inventory, LIFO Reserve, Period Charge", "negatedLabel": "LIFO credit (expense)", "terseLabel": "LIFO (credit) expense", "verboseLabel": "LIFO charges (credit)" } } }, "localname": "InventoryLIFOReservePeriodCharge", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesMerchandiseInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r50", "r206" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "verboseLabel": "Inventories (Note 1)" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets", "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r9", "r51", "r114", "r144", "r207", "r208" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestorMember": { "auth_ref": [ "r466" ], "lang": { "en-US": { "role": { "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.", "label": "Investor [Member]", "terseLabel": "Investor [Member]" } } }, "localname": "InvestorMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Land": { "auth_ref": [ "r7", "r34" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "verboseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Rental expense" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r83" ], "calculation": { "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails": { "order": 6.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal Fees", "terseLabel": "Legal fees" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalMattersAndContingenciesTextBlock": { "auth_ref": [ "r263" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.", "label": "Legal Matters and Contingencies [Text Block]", "terseLabel": "Legal Matters and Contingencies" } } }, "localname": "LegalMattersAndContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r464" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r40" ], "calculation": { "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r28", "r497", "r515" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Facility fee, period end" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "verboseLabel": "Litigation settlement, accrued reserve" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails": { "order": 2.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "netLabel": "Litigation and opioid-related costs", "verboseLabel": "Litigation settlement" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails", "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r16", "r269", "r495", "r512" ], "calculation": { "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term debt", "verboseLabel": "Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.", "label": "Long-term Debt and Lease Obligation, Including Current Maturities", "totalLabel": "Total debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Less nonrecourse current portion" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "auth_ref": [ "r127", "r268" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal after Year Five", "terseLabel": "Scheduled future principal payments, thereafter" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r127", "r268" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months", "terseLabel": "Scheduled future principal payments, in fiscal 2020" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "auth_ref": [ "r127", "r268" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Five", "terseLabel": "Scheduled future principal payments, in fiscal 2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r127", "r268" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Four", "terseLabel": "Scheduled future principal payments, in fiscal 2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r127", "r268" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three", "terseLabel": "Scheduled future principal payments, in fiscal 2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r127", "r268" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "terseLabel": "Scheduled future principal payments, in fiscal 2021" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "verboseLabel": "Total, net of current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r264", "r265" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r8", "r239" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "verboseLabel": "Machinery, equipment, and other" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery, equipment and other [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r503" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Investments, Equity Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r175", "r176" ], "lang": { "en-US": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Segment reconciling items [Member]" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r49", "r496", "r514" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Ownership percentage (more than)" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r291" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market accounts [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r104" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "NET CASH USED IN FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r104" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r104", "r107", "r110" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "NET CASH PROVIDED BY OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r66", "r69", "r75", "r110", "r142", "r500", "r520" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income attributable to AmerisourceBergen Corporation", "totalLabel": "Net income attributable to AmerisourceBergen Corporation" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r66", "r69", "r418", "r427" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedLabel": "Net loss attributable to noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r130", "r132" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r412" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r181" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Carrying value of asset group, excluding goodwill" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r85" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedLabel": "Other (income) loss" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfCountriesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of countries in which the entity operates as of balance sheet date.", "label": "Number of Countries in which Entity Operates", "terseLabel": "Number of countries in which entity operates (over)" } } }, "localname": "NumberOfCountriesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating income", "totalLabel": "Operating income", "verboseLabel": "Operating income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r463" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Lease, liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r458", "r459" ], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetailsCalc2": { "order": 1.0, "parentTag": "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]", "terseLabel": "Operating Leases" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": { "auth_ref": [ "r458", "r459" ], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "abc_OperatingandCapitalLeasesFutureMinimumPaymentsDueNextTwelveMonths", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months", "terseLabel": "2020" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": { "auth_ref": [ "r458", "r459" ], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Five Years", "terseLabel": "2024" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": { "auth_ref": [ "r458", "r459" ], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Four Years", "terseLabel": "2023" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": { "auth_ref": [ "r458", "r459" ], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Three Years", "terseLabel": "2022" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": { "auth_ref": [ "r458", "r459" ], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due in Two Years", "terseLabel": "2021" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": { "auth_ref": [ "r458", "r459" ], "calculation": { "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Operating Leases, Future Minimum Payments, Due Thereafter", "terseLabel": "Thereafter" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r384" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Potential tax benefits from net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r385" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r166", "r178" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails", "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsChangesInCarryingValueOfGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets", "verboseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets", "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r58", "r453" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r67", "r70", "r73", "r274" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss)", "totalLabel": "Total other comprehensive (loss) income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive (loss) income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeOtherNetOfTax": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in other comprehensive income, after tax, from changes classified as other.", "label": "Other Comprehensive Income, Other, Net of Tax", "terseLabel": "Other" } } }, "localname": "OtherComprehensiveIncomeOtherNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherDepreciationAndAmortization": { "auth_ref": [ "r83", "r109", "r238" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.", "label": "Other Depreciation and Amortization", "negatedLabel": "Acquisition-related intangibles amortization", "terseLabel": "Acquisition-related intangibles amortization" } } }, "localname": "OtherDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIntangibleAssetsNet": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.", "label": "Other Intangible Assets, Net", "terseLabel": "Other intangible assets" } } }, "localname": "OtherIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "verboseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets", "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r110" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "verboseLabel": "Other Assets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other Nonoperating Income (Expense) [Member]" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherRestructuringCosts": { "auth_ref": [ "r109", "r246", "r250", "r252" ], "calculation": { "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails": { "order": 5.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.", "label": "Other Restructuring Costs", "terseLabel": "Other restructuring initiatives" } } }, "localname": "OtherRestructuringCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForLegalSettlements": { "auth_ref": [ "r106" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.", "label": "Payments for Legal Settlements", "terseLabel": "Litigation settlement, payment" } } }, "localname": "PaymentsForLegalSettlements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r90", "r94", "r126" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r97" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchases of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "auth_ref": [ "r99" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.", "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "negatedTerseLabel": "Payment of premium on early retirement of debt", "terseLabel": "Payment of premium on early retirement of debt" } } }, "localname": "PaymentsOfDebtExtinguishmentCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow", "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r97" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Cash dividends on common stock" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r97" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Tax withholdings related to restricted share vesting" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r87", "r91", "r191" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchases of investment securities available-for-sale" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r92", "r410" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash paid to acquire business, including purchase price adjustments" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsNevscoDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r92" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Cost of acquired companies, net of cash acquired", "terseLabel": "Payment to acquire business, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r92" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments to Acquire Equity Method Investments", "negatedLabel": "Cost of equity investments", "verboseLabel": "Investment in profarma" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInterestInJointVenture": { "auth_ref": [ "r92" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.", "label": "Payments to Acquire Interest in Joint Venture", "terseLabel": "Investment in specialty joint venture" } } }, "localname": "PaymentsToAcquireInterestInJointVenture", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r93" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Capital expenditures", "terseLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for pension and other postretirement benefits.", "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "Retirement and Other Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PercentageOfLIFOInventory": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The percentage of LIFO (last in first out) inventory to total inventory as of the balance sheet date if other than 100 percent.", "label": "Percentage of LIFO Inventory", "terseLabel": "Percentage of inventories, cost determined using LIFO" } } }, "localname": "PercentageOfLIFOInventory", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesMerchandiseInventoriesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance stock units [Member]" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r444" ], "lang": { "en-US": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (usd per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r20" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r29", "r30" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.", "label": "Reclassification, Policy [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsAndExcessTaxBenefitFromSharebasedCompensation": { "auth_ref": [], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate cash inflow comprised of the amount received from (a) employees to acquire the entity's shares under incentive awards, including stock option exercises and restricted stock arrangements, and (b) the excess tax benefit arising from such transactions.", "label": "Proceeds and Excess Tax Benefit from Share-based Compensation", "terseLabel": "Exercises of stock options" } } }, "localname": "ProceedsAndExcessTaxBenefitFromSharebasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r89" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from sale of business" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r95" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Senior notes and other loan borrowings" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r95" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-term Lines of Credit", "verboseLabel": "Borrowings under revolving and securitization credit facilities" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r96", "r100", "r126" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "verboseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r87", "r88", "r191" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from sales of investment securities available-for-sale" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r66", "r69", "r102", "r169", "r179", "r414", "r417", "r419", "r427", "r428" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r35", "r241" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r34", "r239" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r11", "r12", "r241", "r517" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets", "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment, Net [Abstract]", "verboseLabel": "Property and equipment, at cost:" } } }, "localname": "PropertyPlantAndEquipmentNetAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r33", "r114", "r241" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r11", "r239" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r77", "r196" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "verboseLabel": "Provision for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForLoanLeaseAndOtherLosses": { "auth_ref": [ "r108", "r185", "r502" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related loan transactions, lease transactions, credit loss from transactions other than loan and lease transactions, and other loss based on assessment of uncollectability from the counterparty to reduce the account to their net realizable value.", "label": "Provision for Loan, Lease, and Other Losses", "terseLabel": "Impairment of non-customer note receivable" } } }, "localname": "ProvisionForLoanLeaseAndOtherLosses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Quarterly Financial Information Disclosure [Abstract]" } } }, "localname": "QuarterlyFinancialInformationDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_QuarterlyFinancialInformationTextBlock": { "auth_ref": [ "r146" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.", "label": "Quarterly Financial Information [Text Block]", "terseLabel": "Quarterly Financial Information (Unaudited)" } } }, "localname": "QuarterlyFinancialInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r114", "r186", "r188", "r189", "r190" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk and Allowance for Doubtful Accounts" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": { "auth_ref": [ "r173", "r176" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.", "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of assets from segment to consolidated" } } }, "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r172", "r176" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of total segment operating income to income from continuing operations before income taxes" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r174", "r176" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.", "label": "Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of segment operating income, depreciation and amortization, and capital expenditures from segments to consolidated" } } }, "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r171", "r176" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of revenue from segments to consolidated" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]", "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]" } } }, "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r471" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r294", "r466", "r467", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r471" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r98" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Senior notes and other loan repayments" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r98" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-term Lines of Credit", "negatedLabel": "Repayments under revolving and securitization credit facilities" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockExpense": { "auth_ref": [ "r109" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.", "label": "Restricted Stock or Unit Expense", "terseLabel": "Restricted stock expense" } } }, "localname": "RestrictedStockExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Employee Severance, Litigation, and Other" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOther" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r109", "r246", "r250", "r252" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 }, "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "negatedLabel": "Employee severance, litigation, and other", "terseLabel": "Employee severance, litigation, and other", "totalLabel": "Total employee severance, litigation, and other" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r25", "r279", "r513" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r80", "r526" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Revenue from related party" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r115", "r116" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r74", "r165", "r166", "r177" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r64" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Components of accumulated other comprehensive loss" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r402", "r403" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsNevscoDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Income tax provision" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r44", "r121", "r275", "r276", "r277", "r278", "r455", "r456", "r457", "r504" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "verboseLabel": "Debt Instruments" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r382" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Significant components of deferred tax liabilities (assets)" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r295", "r296", "r297", "r298", "r299" ], "lang": { "en-US": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r364" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Reconciliation of the effective income tax rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r222", "r228" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r222", "r228" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Other intangible assets - finite-lived" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock": { "auth_ref": [ "r462" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.", "label": "Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]", "terseLabel": "Future minimum rental payments, financing obligations" } } }, "localname": "ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": { "auth_ref": [ "r460" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Future minimum rental payments, operating leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LeaseCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r217", "r219" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsChangesInCarryingValueOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r217", "r219" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "verboseLabel": "Changes in the carrying value of goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "For a long-lived asset to be held and used by an entity, the table may include a description of the impaired long-lived asset and facts and circumstances leading to the impairment, amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported.", "label": "Schedule of Impaired Long-Lived Assets Held and Used [Table]", "terseLabel": "Schedule of Assets [Table]" } } }, "localname": "ScheduleOfImpairedLongLivedAssetsHeldAndUsedTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r122" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Domestic and foreign income from continuing operations before income taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r232", "r235" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r232", "r235" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Other intangible assets - indefinite-lived" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.", "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]", "terseLabel": "Nonvested performance stock units" } } }, "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.", "label": "Schedule of Nonvested Share Activity [Table Text Block]", "terseLabel": "Nonvested options" } } }, "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r35", "r241" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.", "label": "Quarterly Financial Information [Table Text Block]", "terseLabel": "Quarterly financial information" } } }, "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r119", "r466", "r467", "r468", "r469", "r470" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r248", "r249", "r251" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r248", "r249", "r251" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Employee severance, litigation, and other charges" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r164", "r169", "r170", "r175", "r217" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r305", "r338" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r312", "r324", "r327" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Stock options" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Weighted average assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Nonvested restricted shares" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "auth_ref": [ "r421", "r422", "r423", "r424", "r425" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table]", "terseLabel": "Schedule of Variable Interest Entities [Table]" } } }, "localname": "ScheduleOfVariableInterestEntitiesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "auth_ref": [ "r421", "r422", "r423", "r424", "r425" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table Text Block]", "terseLabel": "Schedule of Variable Interest Entities" } } }, "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Components of diluted weighted average shares outstanding" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails", "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsChangesInCarryingValueOfGoodwillDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r182" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Business Segment Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r84", "r205" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "verboseLabel": "Distribution, selling, and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesShippingAndHandlingCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r109", "r246", "r250", "r252" ], "calculation": { "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails": { "order": 1.0, "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Employee severance" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r108" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r323" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r321" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r321" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r320" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Nonvested, end of period (shares)", "periodStartLabel": "Nonvested, beginning of period (shares)", "terseLabel": "Nonvested shares outstanding (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Stock Units", "verboseLabel": "Performance Stock Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r320" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Nonvested, end of period (usd per share)", "periodStartLabel": "Nonvested, beginning of period (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r322" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r326" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Total fair values of restricted shares vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r322" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r332" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility of common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r334" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable, end of period (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r315" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable, end of period (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r326" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of stock option exercises" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r318" ], "lang": { "en-US": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedTerseLabel": "Expired (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r317" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r325" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair values of options granted (usd per share)", "verboseLabel": "Granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r338" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r314", "r338" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, end of period (shares)", "periodStartLabel": "Outstanding, beginning of period (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r313" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, end of period (usd per share)", "periodStartLabel": "Outstanding, beginning of period (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r329" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Expected to vest after end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r303", "r309" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (usd per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r114", "r305", "r310" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r306" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r307" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r331", "r349" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life of the options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r338" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "periodEndLabel": "Nonvested, end of period (shares)", "periodStartLabel": "Nonvested, beginning of period (shares)", "terseLabel": "Nonvested options outstanding (shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options forfeited.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (usd per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Nonvested, end of period (usd per share)", "periodStartLabel": "Nonvested, beginning of period (usd per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r328" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r328" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Expected to vest after end of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r311" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Total fair values of options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "negatedLabel": "Vested (shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (usd per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShippingAndHandlingMember": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "Packing and transport of product.", "label": "Shipping and Handling [Member]", "terseLabel": "Shipping and Handling [Member]" } } }, "localname": "ShippingAndHandlingMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesShippingAndHandlingCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r13", "r492", "r511" ], "calculation": { "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Short-term debt", "verboseLabel": "Short-term debt" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r129" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "auth_ref": [ "r367" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "terseLabel": "Reduction of unrecognized tax benefits reasonably possible" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.", "label": "Software and Software Development Costs [Member]", "terseLabel": "Software and software development costs [Member]" } } }, "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r169", "r217", "r245", "r247", "r253", "r522" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails", "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsChangesInCarryingValueOfGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r48", "r274" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfAccumulatedOtherComprehensiveLossDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r20", "r21", "r274", "r279", "r316" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r48", "r274", "r279" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercises of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r109" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Stock or Unit Option Plan Expense", "terseLabel": "Stock option expense" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Share repurchase program, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Share repurchase program, availability remaining" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r21", "r26", "r27", "r187" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total AmerisourceBergen Corporation stockholders' equity", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets", "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfAccumulatedOtherComprehensiveLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets", "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityChangeInReportingEntity": { "auth_ref": [ "r133" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Impact on total stockholders' equity of cumulative effect of change in reporting entity. A change in reporting entity is considered as follows: (1) presenting consolidated statements in place of the financial statements of individual reporting entities; (2) changing the combination of subsidiaries that make up the group for which the consolidated financial statements are presented; and (3) changing the entities included in the combined financial statements. A business combination accounted for under the purchase method and the consolidation of a variable interest entity are not considered a change in reporting entity.", "label": "Stockholders' Equity, Change in Reporting Entity", "terseLabel": "Consolidation of variable interest entity" } } }, "localname": "StockholdersEquityChangeInReportingEntity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r412", "r413", "r426" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of period", "terseLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets", "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]", "terseLabel": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r472" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r472" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": { "auth_ref": [ "r367", "r375", "r377" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Summary of Income Tax Contingencies [Table Text Block]", "terseLabel": "Reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties" } } }, "localname": "SummaryOfIncomeTaxContingenciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r384" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforwards" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r385" ], "lang": { "en-US": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r385" ], "lang": { "en-US": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit": { "auth_ref": [ "r390" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of income tax expense (benefit) from effect of Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Income Tax Expense (Benefit)", "negatedLabel": "Tax Cuts and Jobs Act, recognized income tax benefits", "negatedTerseLabel": "Discrete income tax benefits recognized in connection with 2017 Tax Act" } } }, "localname": "TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit": { "auth_ref": [ "r393" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of reasonable estimate for income tax expense (benefit) for which accounting for tax effect is incomplete pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit)", "verboseLabel": "Tax Cuts and Jobs Act, decrease in provisional transition tax" } } }, "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit": { "auth_ref": [ "r394" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of income tax expense (benefit) for measurement period adjustment from accounting for tax effect pursuant to Tax Cuts and Jobs Act.", "label": "Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit)", "terseLabel": "Adjustments recorded to deferred income taxes related to 2017 Tax Act" } } }, "localname": "TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r407" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "verboseLabel": "Trade names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails", "http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails", "http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails", "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instrument [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r47", "r281" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r47", "r281" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "verboseLabel": "Treasury stock (shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r21", "r274", "r279" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Shares repurchased (shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r47", "r281", "r284" ], "calculation": { "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost: 2019 \u2014 78,534,516 shares; 2018 \u2014 70,370,581 shares" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r274", "r279", "r281" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Purchases of common stock", "terseLabel": "Shares repurchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity", "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UndistributedEarningsOfForeignSubsidiaries": { "auth_ref": [ "r357", "r397", "r505", "r524" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.", "label": "Undistributed Earnings of Foreign Subsidiaries", "terseLabel": "Undistributed earnings of international subsidiaries" } } }, "localname": "UndistributedEarningsOfForeignSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r358", "r369" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized tax benefits at end of period", "periodStartLabel": "Unrecognized tax benefits at beginning of period", "terseLabel": "Litigation settlement, unrecognized tax benefit" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r370" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions", "negatedLabel": "Reductions of tax positions of the prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r372" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedLabel": "Settlements with taxing authorities" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r366" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Unrecognized tax benefits, interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r371" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Additions of tax positions of the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r370" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Additions to tax positions of the prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r373" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedLabel": "Expiration of statutes of limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r374" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized tax benefits that would impact effective tax rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r147", "r148", "r149", "r150", "r155", "r156", "r157" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r360" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "verboseLabel": "Valuation allowance - increase (decrease)" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r128" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Balance at End of Period", "periodStartLabel": "Balance at Beginning of Period", "terseLabel": "Allowance for doubtful accounts for long-term accounts receivable" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r128" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Charged to Costs and Expenses" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r128" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedLabel": "Deductions" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis": { "auth_ref": [ "r421", "r422", "r424" ], "lang": { "en-US": { "role": { "documentation": "Information by category of Variable Interest Entity (VIE).", "label": "Variable Interest Entities [Axis]", "terseLabel": "Variable Interest Entities [Axis]" } } }, "localname": "VariableInterestEntitiesByClassificationOfEntityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityDisclosureTextBlock": { "auth_ref": [ "r429" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.", "label": "Variable Interest Entity Disclosure [Text Block]", "terseLabel": "Variable Interest Entity" } } }, "localname": "VariableInterestEntityDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntity" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Variable Interest Entity [Line Items]", "terseLabel": "Variable Interest Entity [Line Items]" } } }, "localname": "VariableInterestEntityLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Primary Beneficiary [Member]" } } }, "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/VariableInterestEntityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails", "http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r135", "r140" ], "calculation": { "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfDilutedWeightedAverageSharesOutstandingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (shares)", "totalLabel": "Weighted average common shares outstanding \u2014 diluted (shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfDilutedWeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Weighted average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r134", "r140" ], "calculation": { "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfDilutedWeightedAverageSharesOutstandingDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (shares)", "verboseLabel": "Weighted average common shares outstanding \u2014 basic (shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations", "http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfDilutedWeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=SL94080555-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22624-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "270", "URI": "http://asc.fasb.org/topic&trid=2126967" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8615-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8654-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8657-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8660-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8663-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8672-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r182": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.L)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e99989-122729" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r254": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r255": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r263": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r273": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79507997-165333" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79507997-165333" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508013-165333" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508013-165333" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508029-165333" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508029-165333" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508043-165333" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508043-165333" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508057-165333" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116863282&loc=SL79508057-165333" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=117330312&loc=d3e23163-113944" }, "r353": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28200-109314" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32059-109318" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.EE.Q2(b))", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.EE.Q2(f))", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r398": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r411": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5710-111685" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5728-111685" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6759159-111685" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=d3e5747-111685" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=118582676&loc=SL6228884-111685" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686" }, "r429": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164758&loc=d3e45023-112735" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r471": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.11)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62652-112803" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=116637345&loc=SL114874292-224272" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(a)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=114873921&loc=SL114875236-224282" }, "r531": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r532": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r533": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r534": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r535": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r536": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r537": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "11", "Subsection": "03" }, "r538": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r539": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" } }, "version": "2.1" } XML 20 R57.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Other Intangible Assets - Other Intangible Assets (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Sep. 30, 2018
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangibles, accumulated amortization $ (593,221) $ (684,743)
Total other intangible assets, gross carrying amount 2,888,057 3,632,571
Total other intangible assets, net carrying amount 2,294,836 2,947,828
Trade names [Member]    
Indefinite-lived Intangible Assets [Line Items]    
Indefinite-lived intangibles $ 685,324 685,380
Customer relationships [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible asset, weighted average remaining useful life 14 years  
Finite-lived intangibles, gross carrying amount $ 1,931,212 2,549,245
Finite-lived intangibles, accumulated amortization (489,471) (555,440)
Finite-lived intangibles, net carrying amount $ 1,441,741 1,993,805
Trade names and other [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible asset, weighted average remaining useful life 13 years  
Finite-lived intangibles, gross carrying amount $ 271,521 397,946
Finite-lived intangibles, accumulated amortization (103,750) (129,303)
Finite-lived intangibles, net carrying amount $ 167,771 $ 268,643
XML 21 R53.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Unrecognized tax benefits at beginning of period $ 98,124 $ 323,869 $ 75,766
Additions of tax positions of the current year 18,819 2,804 252,866
Additions to tax positions of the prior years 751 558 1,049
Reductions of tax positions of the prior years (10,317) (224,878) (668)
Settlements with taxing authorities 0 (1,847) (3,285)
Expiration of statutes of limitations (1,720) (2,382) (1,859)
Unrecognized tax benefits at end of period $ 105,657 $ 98,124 $ 323,869
XML 22 R78.htm IDEA: XBRL DOCUMENT v3.19.3
Business Segment Information - Additional Information (Details)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2019
USD ($)
Mar. 31, 2018
USD ($)
Sep. 30, 2019
USD ($)
country
Sep. 30, 2018
USD ($)
Other [Member] | World Courier [Member]        
Segment Reporting Information [Line Items]        
Number of countries in which entity operates (over) | country     50  
Other Nonoperating Income (Expense) [Member]        
Segment Reporting Information [Line Items]        
Gain on sale of equity investment $ 13.7   $ 13.7  
Impairment of non-customer note receivable   $ 30.0   $ 30.0
XML 23 R70.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation - Nonvested Performance Stock Units (Details) - Performance stock units [Member]
shares in Thousands
 12 Months Ended
Sep. 30, 2019
$ / shares
shares
Performance Stock Units  
Nonvested, beginning of period (shares) | shares 244
Granted (shares) | shares 147
Vested (shares) | shares (105)
Forfeited (shares) | shares (3)
Nonvested, end of period (shares) | shares 283
Weighted Average Grant Date Fair Value  
Nonvested, beginning of period (usd per share) | $ / shares $ 77
Granted (usd per share) | $ / shares 90
Vested (usd per share) | $ / shares 76
Forfeited (usd per share) | $ / shares 90
Nonvested, end of period (usd per share) | $ / shares $ 84
XML 24 R80.htm IDEA: XBRL DOCUMENT v3.19.3
Quarterly Financial Information (Unaudited) (Details) - USD ($)
 3 Months Ended 12 Months Ended
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Segment Reporting Information [Line Items]                      
Revenue $ 45,637,802,000 $ 45,239,265,000 $ 43,319,602,000 $ 45,392,452,000 $ 43,297,136,000 $ 43,142,309,000 $ 41,033,858,000 $ 40,466,332,000 $ 179,589,121,000 $ 167,939,635,000 $ 153,143,826,000
Gross profit 1,184,737,000 1,231,239,000 1,424,756,000 1,297,580,000 1,032,641,000 1,211,341,000 1,255,683,000 1,112,652,000 5,138,312,000 4,612,317,000 4,546,002,000
Distribution, selling, and administrative expenses; depreciation; and amortization 830,489,000 764,539,000 751,802,000 779,085,000 778,363,000 746,593,000 736,814,000 663,658,000 3,125,915,000 2,925,428,000  
Employee severance, litigation, and other 174,407,000 60,006,000 55,389,000 40,672,000 40,497,000 75,553,000 37,449,000 30,021,000 330,474,000 183,520,000  
Impairment of long-lived assets 0 0 570,000,000 0         570,000,000 0 0
Goodwill impairment         59,684,000 0 0 0 0 59,684,000 0
Operating income 179,841,000 406,694,000 47,565,000 477,823,000 154,097,000 389,195,000 481,420,000 418,973,000 1,111,923,000 1,443,685,000 1,060,342,000
Net income 132,307,000 302,002,000 28,073,000 391,753,000 194,004,000 277,875,000 282,160,000 861,853,000 854,135,000 1,615,892,000 364,484,000
Net income attributable to AmerisourceBergen Corporation $ 132,619,000 $ 301,959,000 $ 27,135,000 $ 393,652,000 $ 233,288,000 $ 275,809,000 $ 287,455,000 $ 861,853,000 $ 855,365,000 $ 1,658,405,000 $ 364,484,000
Earnings per share operations:                      
Basic (usd per share) $ 0.64 $ 1.44 $ 0.13 $ 1.86 $ 1.08 $ 1.26 $ 1.31 $ 3.95 $ 4.07 $ 7.61 $ 1.67
Diluted (usd per share) $ 0.63 $ 1.43 $ 0.13 $ 1.84 $ 1.07 $ 1.25 $ 1.29 $ 3.90 $ 4.04 $ 7.53 $ 1.64
Gain (loss) related to litigation settlement $ 3,100,000 $ 3,500,000 $ 52,000,000.0 $ 87,300,000   $ 35,600,000 $ 300,000   $ 145,900,000 $ 35,900,000 $ 1,400,000
LIFO charges (credit) 57,200,000 (9,900,000) (66,800,000) (3,000,000.0) $ 83,500,000 (16,100,000)     (22,544,000) 67,324,000 (157,782,000)
PharMEDium remediation costs $ 6,700,000 $ 11,700,000 12,300,000 17,900,000 26,600,000 $ 12,000,000.0 22,500,000        
Estimated liability under the New York Opioid Stewardship Act       (22,000,000.0) 22,000,000.0            
Discrete income tax benefits recognized in connection with 2017 Tax Act       $ 37,000,000.0 $ 25,000,000.0     $ 587,600,000   612,600,000  
Loss on early retirement of debt               $ 23,800,000 0 23,766,000 0
Loss on consolidation of equity investments             42,300,000   0 42,328,000 $ 0
Other Nonoperating Income (Expense) [Member]                      
Earnings per share operations:                      
Gain on sale of equity investment     $ 13,700,000           $ 13,700,000    
Impairment of non-customer note receivable             $ 30,000,000.0     $ 30,000,000.0  
XML 25 R74.htm IDEA: XBRL DOCUMENT v3.19.3
Legal Matters and Contingencies (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Oct. 21, 2019
Sep. 28, 2018
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Jul. 01, 2018
Loss Contingencies [Line Items]                          
Litigation settlement                   $ 185,145 $ 61,527 $ 917,573  
Gain (loss) related to litigation settlement     $ 3,100 $ 3,500 $ 52,000 $ 87,300   $ 35,600 $ 300 145,900 35,900 1,400  
Annual fund commitment total                         $ 100,000
Estimated liability under the New York Opioid Stewardship Act           $ (22,000) $ 22,000            
Settlement with Ohio Counties [Member]                          
Loss Contingencies [Line Items]                          
Litigation settlement                   $ 66,700      
West Virginia AG Matter [Member]                          
Loss Contingencies [Line Items]                          
Gain (loss) related to litigation settlement                       (16,000)  
Litigation settlement, payment                       16,000  
USAO-EDNY Misdemeanor Violation [Member]                          
Loss Contingencies [Line Items]                          
Litigation settlement                       260,000  
USAO-EDNY Matter [Member]                          
Loss Contingencies [Line Items]                          
Litigation settlement, payment   $ 625,000                      
Litigation settlement, accrued reserve                       625,000  
USAO-SDNY Matter [Member]                          
Loss Contingencies [Line Items]                          
Litigation settlement                       13,400  
Litigation settlement, payment                     $ 2,800 $ 10,700  
Subsequent Event [Member] | MDL and Other Related State Court Litigation [Member]                          
Loss Contingencies [Line Items]                          
Aggregate legal settlement (up to) $ 18,000,000                        
Legal settlement term (in years) 18 years                        
Company's portion of aggregate legal settlement 31.00%                        
Program period (in years) 10 years                        
XML 26 R42.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies - Property and Equipment (Details)
 12 Months Ended
Sep. 30, 2019
Building and improvements [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 3 years
Building and improvements [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 40 years
Machinery, equipment and other [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 3 years
Machinery, equipment and other [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 10 years
Software and software development costs [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 3 years
Software and software development costs [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Estimated useful lives 10 years
XML 27 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 28 R46.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisitions and Investments - H.D. Smith (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Jan. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Business Acquisition [Line Items]        
Payment to acquire business, net of cash acquired   $ 63,951 $ 785,299 $ 61,648
Goodwill   6,705,507 6,664,272 $ 6,044,281
Net deferred tax liabilities   $ 1,860,195 $ 1,829,410  
H.D. Smith [Member]        
Business Acquisition [Line Items]        
Payment to acquire business, net of cash acquired $ 815,000      
Goodwill 499,900      
Estimated fair value of accounts receivable 163,100      
Estimated fair value of inventory 350,700      
Estimated fair value of accounts payable and accrued expenses 366,100      
Estimated fair value of the intangible assets acquired, finite-lived 167,800      
Net deferred tax liabilities 60,600      
Customer relationships [Member] | H.D. Smith [Member]        
Business Acquisition [Line Items]        
Estimated fair value of the intangible assets acquired, finite-lived $ 156,600      
Estimated useful life (in years) 12 years      
Trade names [Member] | H.D. Smith [Member]        
Business Acquisition [Line Items]        
Estimated fair value of the intangible assets acquired, finite-lived $ 11,200      
Estimated useful life (in years) 2 years      
XML 29 R65.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation - Additional Information (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares granted 12,800 12,800    
Weighted average fair values of options granted (usd per share)   $ 18.60 $ 14.16 $ 13.57
Stock option expense   $ 21.0 $ 22.6 $ 28.6
Intrinsic value of stock option exercises   51.2 116.7 116.6
Total fair values of options vested   $ 22.7 $ 25.8 25.2
Nonvested options outstanding (shares) 3,265 3,265 3,860  
Expected future compensation expense relating to nonvested options outstanding $ 21.6 $ 21.6    
Weighted average period over which expected future compensation expense relating to nonvested options outstanding will be recognized 2 years      
Employee options [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting period (in years)   4 years    
Expiration period (in years)   7 years    
Non-employee options [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting period (in years)   3 years    
Expiration period (in years)   10 years    
Restricted stock units [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting period (in years)   3 years    
Restricted stock expense   $ 29.2 $ 26.8 25.1
Total fair values of restricted shares vested   $ 14.5 $ 15.8 13.8
Nonvested shares outstanding (shares) 1,222 1,222 1,023  
Expected future compensation expense relating to restricted shares outstanding $ 30.1 $ 30.1    
Weighted average period over which expected future compensation expense relating to restricted shares outstanding will be recognized 1 year 2 months 12 days      
Performance stock units [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting period (in years)   3 years    
Nonvested shares outstanding (shares) 283 283 244  
Performance stock unit expense   $ 8.5 $ 12.8 $ 8.4
Performance stock units [Member] | Minimum [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting percentage   0.00% 0.00%  
Performance stock units [Member] | Maximum [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Vesting percentage   200.00% 150.00%  
XML 30 R61.htm IDEA: XBRL DOCUMENT v3.19.3
Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Accumulated Other Comprehensive Loss (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Sep. 30, 2018
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Accumulated other comprehensive loss $ 2,878,917 $ 2,932,824
AOCI Attributable to Parent [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Accumulated other comprehensive loss (111,965) (79,253)
Pension and postretirement adjustments [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Accumulated other comprehensive loss (5,344) (5,065)
Foreign currency translation [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Accumulated other comprehensive loss (107,252) (74,811)
Other [Member]    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Accumulated other comprehensive loss $ 631 $ 623
XML 31 R69.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation - Nonvested Restricted Stock Units (Details) - Restricted stock units [Member]
shares in Thousands
 12 Months Ended
Sep. 30, 2019
$ / shares
shares
Restricted Stock Units  
Nonvested, beginning of period (shares) | shares 1,023
Granted (shares) | shares 442
Vested (shares) | shares (152)
Forfeited (shares) | shares (91)
Nonvested, end of period (shares) | shares 1,222
Weighted Average Grant Date Fair Value  
Nonvested, beginning of period (usd per share) | $ / shares $ 80
Granted (usd per share) | $ / shares 89
Vested (usd per share) | $ / shares 95
Forfeited (usd per share) | $ / shares 81
Nonvested, end of period (usd per share) | $ / shares $ 81
XML 32 R3.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2019
Sep. 30, 2018
Current assets:    
Allowances for returns and doubtful accounts $ 1,222,906 $ 1,036,333
Stockholders' equity:    
Common stock, par value (usd per share) $ 0.01 $ 0.01
Common stock, authorized (shares) 600,000,000 600,000,000
Common stock, issued (shares) 285,295,170 283,588,463
Common stock, outstanding (shares) 206,760,654 213,217,882
Treasury stock (shares) 78,534,516 70,370,581
XML 33 R7.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Statement of Stockholders' Equity [Abstract]      
Cash dividends (usd per share) $ 1.60 $ 1.52 $ 1.46
XML 34 R27.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Basis of Presentation
The accompanying financial statements present the consolidated financial position, results of operations, and cash flows of the Company as of the dates and for the periods indicated. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts due to uncertainties inherent in such estimates. Management periodically evaluates estimates used in the preparation of the financial statements for continued reasonableness.
Reclassifications Certain reclassifications have been made to prior-period amounts in order to conform to the current year presentation.
New Accounting Pronouncements
In March 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"). ASU 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are exercised. It also allows an employer to repurchase more of an employee's shares for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 was effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. On October 1, 2016, the Company early adopted ASU 2016-09, which resulted in a cumulative adjustment to retained earnings and the establishment of a deferred tax asset of $47.1 million for previously unrecognized tax benefits. The Company elected to adopt the Statement of Cash Flows presentation of the excess tax benefits prospectively.
In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)" ("ASU 2014-09"). ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification ("ASC") 605 - "Revenue Recognition" and most industry-specific guidance throughout the Codification. ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard's core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. 
In March 2016, the FASB issued ASU No. 2016-08, "Revenue from Contracts with Customers (Topic 606) - Principal versus Agent Considerations" ("ASU 2016-08"), which clarified the implementation guidance for principal versus agent considerations in ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10, "Revenue from Contracts with Customers (Topic 606) - Identifying Performance Obligations and Licensing" ("ASU 2016-10"), which amended the guidance in ASU 2014-09 related to identifying performance obligations and accounting for licenses of intellectual property. The Company was required to adopt ASU 2016-08 and ASU 2016-10 with ASU 2014-09, collectively ASC 606.
The Company adopted ASC 606 as of October 1, 2018 on a modified retrospective basis for all open contracts as of October 1, 2018. The adoption had an immaterial impact on the Company's October 1, 2018 retained earnings and will not have a material impact on the Company's revenues, results of operations, or cash flows. The Company did not record any material contract assets, contract liabilities, or deferred contract costs in its Consolidated Balance Sheet upon adoption.
The Company elected the practical expedient to expense costs to obtain a contract when incurred when the amortization period would have been one year or less. Additionally, the Company elected the practical expedients to not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for services performed, and (iii) for contracts for which the variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation.

For the Company's revenue recognition policy, refer to the "Revenue Recognition" section of Note 1.
Recently Issued Accounting Pronouncements Not Yet Adopted
 In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)" ("ASU 2016-02" or "ASC 842")). ASU 2016-02 aims to increase transparency and comparability across organizations by requiring lease assets and lease liabilities to be recognized on the balance sheet as well as key information to be disclosed regarding lease arrangements. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018 and interim periods within those fiscal years.
The Company will adopt ASC 842 in the first quarter of fiscal 2020 and will adopt using the modified retrospective approach. The Company will elect the transition package of practical expedients provided within the amended guidance, which eliminates the requirements to reassess lease identification, lease classification, and initial direct costs for leases that commenced before the effective date. The Company will also elect to combine lease and non-lease components and to exclude short-term leases from its consolidated balance sheets. The Company did not elect the hindsight practical expedient in determining the lease term.
The adoption of the amended guidance is expected to have a material impact on the consolidated balance sheet from the recognition of lease assets and liabilities. While the Company continues to finalize the impact of adoption, it anticipates recognizing operating lease liabilities of approximately $550 million based on the present value of the remaining minimum lease commitments using the Company's incremental borrowing rates as of the effective date. The Company will also record corresponding right-of-use ("ROU") assets based upon the operating lease liabilities adjusted for prepaid and deferred rents. Upon adoption, the Company will also derecognize assets and liabilities associated with leased assets where the Company was deemed the owner of the leased assets for accounting purposes. The difference between the derecognized assets and liabilities will be recognized as a net of tax cumulative adjustment to retained earnings. The Company is finalizing the impact that the amended lease guidance will have on its consolidated financial statements, systems, processes, and internal controls. The Company does not expect that the adoption of ASC 842 will have a material impact on its results of operations or cash flows.
In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectibility of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. ASU 2016-13 is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years, and a modified retrospective approach is required, with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. Entities are permitted to adopt the standard early in fiscal years beginning after December 15, 2018. The Company is currently evaluating the impact of adopting this new accounting guidance.
As of September 30, 2019, there were no other recently issued accounting standards that may have a material impact on the Company's financial position, results of operations, or cash flows upon their adoption.
Business Combinations
The assets acquired and liabilities assumed from the acquired business are recorded at fair value, with the residual of the purchase price recorded as goodwill. The results of operations of the acquired businesses are included in the Company's operating results from the dates of acquisition.
Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.
Concentrations of Credit Risk and Allowance for Doubtful Accounts
The Company sells its inventories to a large number of customers in the healthcare industry that include institutional and retail healthcare providers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physician offices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies, pharmacy departments of supermarkets and mass merchandisers, and veterinarians. The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.
The Company's trade accounts receivables are exposed to credit risk. Revenue from the various agreements and arrangements with the Company's largest customer in the fiscal year ended September 30, 2019, Walgreens Boots Alliance, Inc.
("WBA"), accounted for approximately 34% of revenue and represented approximately 49% of accounts receivable, net of incentives, as of September 30, 2019. Express Scripts, Inc., the Company's second largest customer in the fiscal year ended September 30, 2019, accounted for approximately 13% of revenue and represented approximately 8% of accounts receivable as of September 30, 2019. The Company generally does not require collateral for trade receivables. In determining the appropriate allowance for doubtful accounts, the Company considers a combination of factors, such as the aging of trade receivables, industry trends, and its customers' financial strength, credit standing, and payment and default history. Changes in these factors, among others, may lead to adjustments in the Company's allowance for doubtful accounts. The calculation of the required allowance requires judgment by Company management as to the impact of those and other factors on the ultimate realization of its trade receivables. Each of the Company's business units performs ongoing credit evaluations of its customers' financial condition and maintains reserves for probable bad debt losses based upon historical experience and for specific credit problems when they arise. There were no significant changes to this process during the fiscal years ended September 30, 2019, 2018, and 2017, and bad debt expense was computed in a consistent manner during these periods.
The Company maintains cash and cash equivalents with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and, therefore, bear minimal credit risk. The Company seeks to mitigate such risks by monitoring the risk profiles of these counterparties. The Company also seeks to mitigate risk by monitoring the investment strategy of money market accounts in which it is invested, which are classified as cash equivalents.
Contingencies
Loss Contingencies: In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, and other disputes, including antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, the Company provides disclosure of the loss contingency in the notes to its financial statements. The Company reviews all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made. Among the loss contingencies that the Company considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 13. Although the Company is not able to predict the outcome or reasonably estimate a range of possible losses in these matters, an adverse judgment or negotiated resolution in any of these matters could have a material adverse effect on the Company's results of operations, consolidated financial position, cash flows or liquidity.
Gain Contingencies: The Company records gain contingencies when they are realized. Gains from antitrust litigation settlements are realized upon the receipt of cash and recorded as a reduction to cost of goods sold because they represent a recovery of amounts historically paid to manufacturers to originally acquire the pharmaceuticals that were the subject of the antitrust litigation settlements (see Note 14).
Derivative Financial Instruments
The Company records all derivative financial instruments on the balance sheet at fair value and complies with established criteria for designation and effectiveness of hedging relationships. The Company's policy prohibits it from entering into derivative financial instruments for speculative or trading purposes.
Foreign Currency
When the functional currency of the Company's foreign operations is the applicable local currency, assets and liabilities are translated into U.S. dollars using the current exchange rates in effect at the balance sheet date, while revenues and expenses are translated at the weighted average exchange rates for the period. The resulting translation adjustments are recorded as a component of Accumulated Other Comprehensive Loss within Stockholders' Equity.
Goodwill and Other Intangible Assets
Goodwill arises from acquisitions or consolidations of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. The Company identifies its reporting units based upon the Company's management reporting structure, beginning with its operating segments. The Company aggregates two or more components within an operating segment that have similar economic characteristics. The Company evaluates whether the components within its operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment. The Company's reporting units include Pharmaceutical Distribution Services, Profarma Distribuidora de Produtos Farmacêuticos S.A. ("Profarma"), AmerisourceBergen Consulting Services ("ABCS"), World Courier, and MWI Animal Health ("MWI").
Goodwill and other intangible assets with indefinite lives, such as certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, the Company can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite-lived intangible assets, respectively. Such qualitative factors can include, among others, industry and market conditions, overall financial performance, and relevant entity-specific events. If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis. The Company elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2019, with the exception of its testing of goodwill in the Profarma reporting unit. In the fourth quarter of fiscal 2018 and 2017, the Company elected to bypass performing the qualitative assessment and went directly to performing our annual quantitative assessments of the goodwill and indefinite-lived intangible assets.
The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized. If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.
When performing a quantitative impairment assessment, the Company utilizes an income-based approach to value its reporting units, with the exception of the Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium. The income-based approach relies on a discounted cash flow analysis, which considers forecasted cash flows discounted at an appropriate discount rate, to determine the fair value of each reporting unit. The Company generally believes that market participants would use a discounted cash flow analysis to determine the fair value of the Company's reporting units in a sale transaction. The annual goodwill impairment test requires the Company to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon the Company's long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While the Company uses the best available information to prepare its cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged.
The quantitative impairment test for indefinite-lived intangibles other than goodwill (certain trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method. The Company believes the relief from royalty method is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.
The Company completed its required annual impairment tests relating to goodwill and indefinite-lived intangible assets in the fourth quarter of the fiscal years ended September 30, 2019, 2018, and 2017. The Company recorded a goodwill impairment of $59.7 million in its Profarma reporting unit in connection with its fiscal 2018 annual impairment test (see Note 5). No goodwill impairments were recorded in the fiscal years ended September 30, 2019 and 2017. No indefinite-lived intangible asset impairments were recorded in the fiscal years ended September 30, 2019, 2018, and 2017.
Finite-lived intangible assets are amortized using the straight-line method over the estimated useful lives of the assets. The Company performs a recoverability assessment of its long-lived assets when impairment indicators are present.
After U.S. Food and Drug Administration ("FDA") inspections of PharMEDium Healthcare Holdings, Inc.'s ("PharMEDium") compounding facilities, the Company voluntarily suspended production activities in December 2017 at its largest
compounding facility located in Memphis, Tennessee pending execution of certain remedial measures. On May 17, 2019, PharMEDium reached an agreement on the terms of a consent decree (the "Consent Decree") with the FDA and the Consumer Protection Branch of the Civil Division of the Department of Justice ("DOJ") that was entered by the United States District Court for the Northern District of Illinois on May 22, 2019. The Consent Decree permits commercial operations to continue at PharMEDium’s Dayton, New Jersey and Sugar Land, Texas compounding facilities and administrative operations to continue at its Lake Forest, Illinois headquarters subject to compliance with requirements set forth therein. As required by the Consent Decree, initial audit inspections were conducted by an independent current Good Manufacturing Practice ("cGMP") expert of the Dayton and Sugar Land facilities. The cGMP expert has notified FDA that all of the short-term corrective actions taken are acceptable. The Company has submitted to FDA several additional longer-term corrective actions, and the independent cGMP expert will assess the effectiveness of the implementation of these items in future audits. Additional audit inspections by the independent cGMP expert of the Sugar Land and Dayton facilities are also required at least annually for a period of four years.
The Consent Decree also establishes requirements that must be satisfied prior to the resumption of commercial operations at the Memphis, Tennessee facility. The requirements include a work plan approved by the FDA and an audit inspection and certification by an independent cGMP expert that the facilities, methods and controls at the Memphis facility and PharMEDium’s Lake Forest, Illinois headquarters comply with the Consent Decree. If PharMEDium receives written notification from the FDA of compliance with the requirements to resume operations at the Memphis facility, additional audit inspections are required for five years, during which time PharMEDium must correct any deviations from the Consent Decree observed by the independent cGMP expert.
After five years, PharMEDium may petition the district court for full relief from the Consent Decree, or for specific relief with regard to one or more facilities. If, at the time of such petition, all obligations under the Consent Decree with respect to the specific facilities for which PharMEDium is seeking relief have been satisfied, and there has been continuous compliance with the Consent Decree for at least five years, the federal government will not oppose the petition, and PharMEDium may request that the district court grant such relief.
As a result of the suspension of production activities at PharMEDium's compounding facility located in Memphis, Tennessee and the aforementioned regulatory matters, the Company performed a recoverability assessment of PharMEDium's long-lived assets and recorded a $570.0 million impairment loss in the quarter ended March 31, 2019 for the amount that the carrying value of the PharMEDium asset group exceeded its fair value. Prior to the impairment, the carrying value of the asset group was $792 million. The fair value of the asset group was $222 million as of March 31, 2019. The PharMEDium asset group is included in the Pharmaceutical Distribution Services reportable segment. Significant assumptions used in estimating the fair value of PharMEDium's asset group included (i) a 15% discount rate, which contemplated a higher risk at PharMEDium; (ii) the period in which PharMEDium will resume production at or near capacity; and (iii) the estimated EBITDA (earnings before interest, taxes, depreciation, and amortization) margins when considering the likelihood of higher operating and compliance costs. The Company believes that its fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment are inherently uncertain and include assumptions that could differ from actual results in future periods. This represents a Level 3 nonrecurring fair value measurement. The Company allocated $522.1 million of the impairment to finite-lived intangibles ($420.8 million of customer relationships, $79.9 million of a trade name, and $21.4 million of software technology) and $47.9 million of the impairment to property and equipment.
The Company updated its recoverability assessment of PharMEDium's long-lived assets as of September 30, 2019. The Company concluded that PharMEDium’s long-lived assets were recoverable as of September 30, 2019.
Income Taxes
The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities (commonly known as the asset and liability method). In assessing the need to establish a valuation allowance on deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.
The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based upon the technical merits of the position. Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.
Inventories
Inventories are stated at the lower of cost or market. Cost for approximately 75% of the Company's inventories as of September 30, 2019 and 2018 has been determined using the last-in, first-out ("LIFO") method. If the Company had used the first-in, first-out method of inventory valuation, which approximates current replacement cost, inventories would have been approximately $1,511.8 million and $1,534.4 million higher than the amounts reported as of September 30, 2019 and 2018, respectively. The Company recorded LIFO credits of $22.5 million and $157.8 million in the fiscal years ended September 30, 2019 and 2017, respectively, and LIFO expense of $67.3 million in the fiscal year ended September 30, 2018. The annual LIFO provision is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences, many of which are difficult to predict. Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.
Investments
The Company first evaluates its investments in accordance with the variable interest model to determine whether it has a controlling financial interest in an investment. This evaluation is made as of the date on which the Company makes its initial investment, and subsequent evaluations are made if the structure of the investment changes. If it has determined that an investment is a variable interest entity ("VIE"), the Company evaluates whether the VIE is required to be consolidated. When the Company holds rights that give it the power to direct the activities of an entity that most significantly impact the entity's economic performance, combined with the obligation to absorb an entity's losses and the right to receive benefits, the Company consolidates a VIE. If it is determined that an investment is not a VIE, the Company then evaluates its investments under the voting interest model and generally consolidates investments in which it holds an ownership interest of greater than 50%. When the Company consolidates less than wholly-owned subsidiaries, it discloses its noncontrolling interest in its consolidated financial statements.
Investments, Equity Securities
For equity securities without a readily determinable fair value, the Company uses the fair value measurement alternative and measures the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which the Company can exercise significant influence but does not control, it uses the equity method of accounting. The Company's share of earnings and losses is recorded in Other Income (Loss) in the Consolidated Statements of Operations. The Company monitors its investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions.
Leases
The Company is often involved in the construction of its distribution facilities. In certain cases, the Company makes payments for certain structural components included in the lessor's construction of the leased assets, which result in the Company being deemed the owner of the leased assets for accounting purposes. As a result, regardless of the significance of the payments, Accounting Standards Codification 840, Leases, ("ASC 840") defines those payments as automatic indicators of ownership and requires the Company to capitalize the lessor's total project cost with a corresponding financing obligation. Upon completion of the lessor's project, the Company performs a sale-leaseback analysis pursuant to ASC 840 to determine if these assets and the related financing obligations can be derecognized from the Company's Consolidated Balance Sheet. If the Company is deemed to have "continuing involvement," the leased assets and the related financing obligations remain on the Company's Consolidated Balance Sheet and are amortized over the life of the assets and the lease term, respectively. All other leases are considered operating leases in accordance with ASC 840. Assets subject to an operating lease and the related lease payments are not recorded on the Company's Consolidated Balance Sheet. Rent expense is recognized on a straight-line basis over the expected lease term and is recorded in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations.
Revenue Recognition
The Company's revenues are primarily generated from the distribution of pharmaceutical products. The Company also generates revenues from global commercialization services, which include clinical trial support, post-approval and commercialization support, and global specialty transportation and logistics for the biopharmaceutical industry. See Note 15 for the Company's disaggregated revenue.

The Company recognizes revenue related to the distribution of products at a point in time when title and control transfers to customers and there is no further obligation to provide services related to such products. Service revenue is recognized over the period that services are provided to the customer. The Company is generally the principal in a transaction; therefore, revenue is primarily recorded on a gross basis. When the Company is the principal in a transaction, it has determined that it controls the ability to direct the use of the product or service prior to the transfer to a customer, it is primarily responsible for fulfilling the promise to provide the product or service to its customer, it has discretion in establishing pricing, and it controls the relationship with the customer. Revenue is recognized at the amount of consideration expected to be received. For the distribution business, revenue is primarily generated from a contract related to a confirmed purchase order with a customer in a distribution arrangement and is net of estimated sales returns and allowances, other customer incentives, and sales tax.
The Company's customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. The Company records an accrual for estimated customer sales returns at the time of sale to the customer based upon historical return trends. As of September 30, 2019 and 2018, the Company's accrual for estimated customer sales returns was $1,147.5 million and $988.8 million, respectively. In fiscal 2019, due to the adoption of ASC 606, the Company records an asset for the right to recover products from its customers in Right to Recover Asset on its Consolidated Balance Sheet. The Company's asset for the right to recover products from its customers was included in Inventories on its Consolidated Balance Sheet as of September 30, 2018 and for all prior periods.
The Company considers fees and other incentives received from its suppliers relating to the purchase or distribution of inventory to represent product discounts, and, as a result, they are recognized within cost of goods sold upon the sale of the related inventory.
Property and Equipment
Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 40 years for buildings and improvements and from 3 to 10 years for machinery, equipment, and other. The costs of repairs and maintenance are charged to expense as incurred.
The Company capitalizes project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application development stage. Costs that are associated with preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred. Software development costs are depreciated using the straight-line method over the estimated useful lives, which range from 3 to 10 years.
Share-Based Compensation
The Company accounts for the compensation cost of all share-based payments at fair value. The Company estimates the fair value of option grants using a binomial option pricing model. The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company’s common stock.
Share-based compensation expense is recognized over the requisite service period within Distribution, Selling, and Administrative in the Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees. Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.
The income tax effects of awards are recognized when the awards vest or are settled and are recognized in Income Tax Expense in the Company’s Consolidated Statements of Operations and in cash flows from operations in the Consolidated Statements of Cash Flows. Prior to fiscal 2017, tax benefits from share-based compensation were recorded as adjustments to Additional Paid-in Capital within Stockholders’ Equity and as cash flows from financing activities within the Statement of Cash Flows (see Recently Adopted Accounting Pronouncements).
Shipping and Handling Costs Shipping and handling costs include all costs to warehouse, pick, pack, and deliver inventory to customers.
Supplier Reserves
The Company establishes reserves against amounts due from its suppliers relating to various price and rebate incentives, including deductions or billings taken against payments otherwise due to them from the Company. These reserve estimates are established based upon the judgment of Company management after carefully considering the status of current outstanding claims, historical experience with the suppliers, the specific incentive programs, and any other pertinent information available to the Company. The Company evaluates the amounts due from its suppliers on a continual basis and adjusts the reserve estimates when appropriate based upon changes in factual circumstances. The ultimate outcome of any outstanding claim may be different than the Company's estimate.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.19.3
Business Segment Information
 12 Months Ended
Sep. 30, 2019
Segment Reporting [Abstract]  
Business Segment Information Business Segment Information
The Company is organized based upon the products and services it provides to its customers. The Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in Other for the purpose of reportable segment presentation. Other consists of operating segments that focus on global commercialization services and animal health (MWI Animal Health). The operating segments that focus on global commercialization services include AmerisourceBergen Consulting Services ("ABCS") and World Courier.
The chief operating decision maker ("CODM") of the Company is the Chairman, President & Chief Executive Officer of the Company, whose function is to allocate resources to, and assess the performance of, the Company's operating segments.
The Pharmaceutical Distribution Services reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. Through a number of operating businesses, the Pharmaceutical Distribution Services
reportable segment provides pharmaceutical distribution (including plasma and other blood products, injectible pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. Additionally, the Pharmaceutical Distribution Services reportable segment provides data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The Pharmaceutical Distribution Services reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. Additionally, it delivers packaging solutions to institutional and retail healthcare providers.
ABCS, through a number of operating businesses, provides a full suite of integrated manufacturer services that range from clinical trial support to product post-approval and commercialization support. World Courier, which operates in over 50 countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. MWI is a leading animal health distribution company in the United States and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. Additionally, MWI offers demand-creating sales force services to manufacturers.
The following illustrates reportable and operating segment revenue information for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Pharmaceutical Distribution Services
 
$
172,813,537

 
$
161,699,343

 
$
147,453,495

Other:
 
 
 
 
 
 
MWI Animal Health
 
3,975,232

 
3,789,759

 
3,636,305

Global Commercialization Services
 
2,893,109

 
2,542,971

 
2,111,558

Total Other
 
6,868,341

 
6,332,730

 
5,747,863

Intersegment eliminations
 
(92,757
)
 
(92,438
)
 
(57,532
)
Revenue
 
$
179,589,121

 
$
167,939,635

 
$
153,143,826


Intersegment eliminations primarily represent the elimination of certain Pharmaceutical Distribution Services reportable segment sales to MWI.
The following illustrates reportable segment operating income information for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Pharmaceutical Distribution Services
 
$
1,671,251

 
$
1,626,748

 
$
1,643,629

Other
 
380,660

 
355,091

 
373,797

Intersegment eliminations
 
(659
)
 
(609
)
 
(556
)
Total segment operating income
 
$
2,051,252

 
$
1,981,230

 
$
2,016,870


The following reconciles total segment operating income to income before income taxes for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Total segment operating income
 
$
2,051,252

 
$
1,981,230

 
$
2,016,870

Gain from antitrust litigation settlements
 
145,872

 
35,938

 
1,395

LIFO credit (expense)
 
22,544

 
(67,324
)
 
157,782

PharMEDium remediation costs
 
(69,423
)
 
(66,204
)
 
—

New York State Opioid Stewardship Act
 
22,000

 
(22,000
)
 
—

Acquisition-related intangibles amortization
 
(159,848
)
 
(174,751
)
 
(156,378
)
Employee severance, litigation, and other
 
(330,474
)
 
(183,520
)
 
(959,327
)
Goodwill impairment
 
—

 
(59,684
)
 
—

Impairment of long-lived assets
 
(570,000
)
 
—

 
—

Operating income
 
1,111,923

 
1,443,685

 
1,060,342

Other (income) loss
 
(12,952
)
 
25,469

 
(2,730
)
Interest expense, net
 
157,769

 
174,699

 
145,185

Loss on consolidation of equity investments
 
—

 
42,328

 
—

Loss on early retirement of debt
 
—

 
23,766

 
—

Income before income taxes
 
$
967,106

 
$
1,177,423

 
$
917,887


Segment operating income is evaluated by the CODM of the Company and excludes gain from antitrust litigation settlements; LIFO credit (expense); PharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation, and other; goodwill impairment; and impairment of long-lived assets. Segment measures were adjusted in fiscal 2019 to exclude impairment of long-lived assets as the CODM excludes these costs in the measurement of segment performance. All corporate office expenses are allocated to the operating segment level.
The Company incurred remediation costs in connection with the suspended production activities at PharMEDium (see Notes 1 and 13). These remediation costs are primarily classified in Cost of Goods sold in the Consolidated Statements of Operations. Future remediation costs will also include costs related to remediation activities responsive to FDA inspectional observations generally applicable to all of PharMEDium’s 503B outsourcing facilities, including product stability studies.
The Company recorded a $13.7 million gain on the sale of an equity investment in Other (Income) Loss in the Company's Consolidated Statement of Operations in the fiscal year ended September 30, 2019.
The Company recorded a $30.0 million impairment of a non-customer note receivable related to a start-up venture in Other (Income) Loss in the Company's Consolidated Statement of Operations in the fiscal year ended September 30, 2018.
The following illustrates total assets by reportable segment for the periods indicated:
 
 
September 30,
(in thousands)
 
2019
 
2018
 
2017
Pharmaceutical Distribution Services
 
$
33,160,529

 
$
31,892,621

 
$
29,691,127

Other
 
6,011,451

 
5,777,217

 
5,625,343

Total assets
 
$
39,171,980

 
$
37,669,838

 
$
35,316,470


The CODM does not review assets by operating segment for the purpose of assessing performance or allocating resources.
The following illustrates depreciation and amortization by reportable segment for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Pharmaceutical Distribution Services
 
$
232,735

 
$
225,608

 
$
188,065

Other
 
69,824

 
64,768

 
53,160

Acquisition-related intangibles amortization
 
159,848

 
174,751

 
156,378

Total depreciation and amortization
 
$
462,407

 
$
465,127

 
$
397,603


Depreciation and amortization includes depreciation and amortization of property and equipment and intangible assets, but excludes amortization of deferred financing costs and other debt-related items, which are included in interest expense, net.
The following illustrates capital expenditures by reportable segment for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Pharmaceutical Distribution Services
 
$
210,161

 
$
190,191

 
$
339,478

Other
 
100,061

 
146,220

 
126,919

Total capital expenditures
 
$
310,222

 
$
336,411

 
$
466,397
XML 36 R43.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($)
$ in Millions
Sep. 30, 2019
Sep. 30, 2018
Accounting Policies [Abstract]    
Accrual for estimated customer sales returns $ 1,147.5 $ 988.8
XML 37 R47.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisitions and Investments - Proforma and Specialty Joint Venture (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2018
Jan. 31, 2018
Mar. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Business Acquisition [Line Items]            
Investment in profarma       $ 0 $ 0 $ 11,347
Goodwill $ 6,664,272     6,705,507 6,664,272 6,044,281
Net deferred tax liabilities 1,829,410     1,860,195 1,829,410  
Loss on consolidation of equity investments     $ 42,300 0 42,328 0
Foreign currency translation adjustment from AOCI       $ 0 (45,941) $ 0
Profarma Distribuidora de Produtos Farmaceuticos S.A. [Member]            
Business Acquisition [Line Items]            
Investment in profarma   $ 62,500        
Ownership interest in profarma     38.20%      
Goodwill   142,000        
Estimated fair value of accounts receivable   160,100        
Estimated fair value of inventory   190,500        
Estimated fair value of accounts payable and accrued expenses   167,700        
Assumed short-term debt   209,900        
Assumed long-term debt   12,400        
Assumed cash   150,800        
Noncontrolling interest   168,000        
Estimated fair value of the intangible assets acquired, finite-lived   84,600        
Net deferred tax liabilities   50,100        
Profarma Joint Venture [Member]            
Business Acquisition [Line Items]            
Investment in specialty joint venture $ 23,600 15,600        
Ownership in specialty joint venture     64.50% 89.90%    
Goodwill   3,500        
Estimated fair value of accounts receivable   65,000        
Estimated fair value of inventory   29,100        
Estimated fair value of accounts payable and accrued expenses   54,300        
Assumed short-term debt   32,700        
Assumed cash   28,900        
Estimated fair value of the intangible assets acquired, finite-lived   $ 4,600        
Estimated useful life (in years)   15 years        
Loss on consolidation of equity investments         8,800  
Gain on remeasurement of Profarma's previously held equity interest         12,400  
Customer relationships [Member] | Profarma Distribuidora de Produtos Farmaceuticos S.A. [Member]            
Business Acquisition [Line Items]            
Estimated fair value of the intangible assets acquired, finite-lived   $ 25,900        
Customer relationships [Member] | Profarma Joint Venture [Member]            
Business Acquisition [Line Items]            
Estimated useful life (in years)   15 years        
Trade names [Member] | Profarma Distribuidora de Produtos Farmaceuticos S.A. [Member]            
Business Acquisition [Line Items]            
Estimated fair value of the intangible assets acquired, finite-lived   $ 58,700        
Foreign currency translation [Member]            
Business Acquisition [Line Items]            
Foreign currency translation adjustment from AOCI         $ 45,900  
Fair Value, Recurring [Member] | Level 2 [Member] | Profarma Distribuidora de Produtos Farmaceuticos S.A. [Member]            
Business Acquisition [Line Items]            
Fair value of equity interests   103,100        
Fair Value, Recurring [Member] | Level 2 [Member] | Profarma Joint Venture [Member]            
Business Acquisition [Line Items]            
Fair value of equity interests   $ 31,200        
Minimum [Member] | Trade names [Member] | Profarma Distribuidora de Produtos Farmaceuticos S.A. [Member]            
Business Acquisition [Line Items]            
Estimated useful life (in years)   15 years        
Maximum [Member] | Trade names [Member] | Profarma Distribuidora de Produtos Farmaceuticos S.A. [Member]            
Business Acquisition [Line Items]            
Estimated useful life (in years)   25 years        
XML 38 R68.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation - Nonvested Options (Details) - $ / shares
shares in Thousands
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Options      
Nonvested, beginning of period (shares) 3,860    
Granted (shares) 1,137    
Vested (shares) (1,519)    
Forfeited (shares) (213)    
Nonvested, end of period (shares) 3,265 3,860  
Weighted Average Grant Date Fair Value      
Nonvested, beginning of period (usd per share) $ 15    
Granted (usd per share) 18.60 $ 14.16 $ 13.57
Vested (usd per share) 15    
Forfeited (usd per share) 16    
Nonvested, end of period (usd per share) $ 16 $ 15  
XML 39 R64.htm IDEA: XBRL DOCUMENT v3.19.3
Retirement and Other Benefit Plans (Details) - USD ($)
 3 Months Ended 12 Months Ended 24 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2019
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2018
Defined Benefit Plan Disclosure [Line Items]              
Minimum allowed employee contributions, percent of salary       1.00%      
Maximum allowed employee contributions, percent of salary       50.00%      
Discretionary contributions $ 0            
Discretionary contributions, vesting period (in years)       5 years      
Deferred compensation, annual benefit, percent of compensation, Benefit Restoration Plan   4.00%         3.00%
Defined contribution plans expense       $ 51,000,000.0 $ 37,900,000 $ 28,300,000  
Deferred compensation, common stock authorized for issuance (shares)       2,960,000      
Deferred compensation, common stock issued (shares)       0      
Deferred compensation liability       $ 28,000,000.0 $ 27,500,000    
Employee contribution, first 3% of salary [Member]              
Defined Benefit Plan Disclosure [Line Items]              
Employer matching contribution, percent of match   100.00%         100.00%
Employer matching contribution, percent of salary   3.00%         3.00%
Employee contribution, additional 2% of salary [Member]              
Defined Benefit Plan Disclosure [Line Items]              
Employer matching contribution, percent of match   50.00%          
Employer matching contribution, percent of salary   2.00%          
Forecast [Member]              
Defined Benefit Plan Disclosure [Line Items]              
Deferred compensation, annual benefit, percent of compensation, Benefit Restoration Plan     4.00%        
Forecast [Member] | Employee contribution, first 3% of salary [Member]              
Defined Benefit Plan Disclosure [Line Items]              
Employer matching contribution, percent of match     100.00%        
Employer matching contribution, percent of salary     3.00%        
Forecast [Member] | Employee contribution, additional 2% of salary [Member]              
Defined Benefit Plan Disclosure [Line Items]              
Employer matching contribution, percent of match     50.00%        
Employer matching contribution, percent of salary     2.00%        
XML 40 R60.htm IDEA: XBRL DOCUMENT v3.19.3
Stockholders' Equity and Weighted Average Common Shares Outstanding - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Nov. 30, 2016
Sep. 30, 2016
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Oct. 31, 2018
Equity, Class of Treasury Stock [Line Items]            
Common stock, authorized (shares)     600,000,000 600,000,000    
Common stock, par value (usd per share)     $ 0.01 $ 0.01    
Preferred stock, authorized (shares)     10,000,000      
Preferred stock, par value (usd per share)     $ 0.01      
Preferred stock, issued (shares)     0      
Shares repurchased     $ 664,803,000 $ 663,220,000 $ 329,929,000  
Antidilutive securities excluded from computation of diluted earnings per share (shares)     4,600,000 3,200,000 4,100,000  
May 2016 Share Repurchase Program [Member]            
Equity, Class of Treasury Stock [Line Items]            
Accelerated share repurchase program, amount paid   $ 400,000,000.0        
Shares repurchased (shares) 500,000 4,500,000     2,100,000  
Accelerated share repurchase program, initial funding allocated to shares repurchased   $ 380,000,000.0        
Accelerated share repurchase program, initial funding allocated to share holdback   $ 20,000,000.0        
Settlement of accelerated share repurchase transaction (shares)         500,000  
Shares repurchased         $ 118,800,000  
November 2016 Share Repurchase Program [Member]            
Equity, Class of Treasury Stock [Line Items]            
Shares repurchased (shares)     1,400,000 7,700,000 2,700,000  
Shares repurchased     $ 125,800,000 $ 663,100,000 $ 211,100,000  
Share repurchase program, authorized amount $ 1,000,000,000.0          
Shares repurchased, cash settled     $ 24,000,000.0      
October 2018 Share Repurchase Program [Member]            
Equity, Class of Treasury Stock [Line Items]            
Shares repurchased (shares)     6,700,000      
Shares repurchased     $ 538,900,000      
Share repurchase program, authorized amount           $ 1,000,000,000.0
Shares repurchased, cash settled     14,800,000      
Share repurchase program, availability remaining     $ 461,100,000      
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.19.3
Schedule II - Valuation and Qualifying Accounts
 12 Months Ended
Sep. 30, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
Schedule II - Valuation and Qualifying Accounts
SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS
(In thousands)
 
Balance at
Beginning
of Period
 
Charged to
Costs and
Expenses (1)
 
Deductions-
Describe (2)
 
Balance at
End of
Period (3)
Year Ended September 30, 2019
 
 

 
 

 
 

 
 

Allowances for returns and doubtful accounts
 
$
1,049,901

 
$
3,720,642

 
$
(3,546,656
)
 
$
1,223,887

 
 
 
 
 
 
 
 
 
Year Ended September 30, 2018
 
 

 
 

 
 

 
 

Allowances for returns and doubtful accounts
 
$
1,068,251

 
$
3,397,562

 
$
(3,415,912
)
 
$
1,049,901

 
 
 
 
 
 
 
 
 
Year Ended September 30, 2017
 
 

 
 

 
 

 
 

Allowances for returns and doubtful accounts
 
$
926,034

 
$
3,157,960

 
$
(3,015,743
)
 
$
1,068,251

__________________________________________________________

(1)
Represents the provision for returns and doubtful accounts.
(2)
Represents reductions to the returns allowance and accounts receivable written off during year, net of recoveries.
(3)
Includes an allowance for doubtful accounts for long-term accounts receivable within Other Assets on the Consolidated Balance Sheets of $981 thousand, $13,568 thousand and $17,890 thousand as of September 30, 2019, 2018, and 2017, respectively.
XML 42 R22.htm IDEA: XBRL DOCUMENT v3.19.3
Litigation Settlements
 12 Months Ended
Sep. 30, 2019
Litigation Settlement [Abstract]  
Litigation Settlements Litigation Settlements
Antitrust Settlements
Numerous lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. These lawsuits are generally brought as class actions. The Company has not been a named a plaintiff in any of these lawsuits, but has been a member of the direct purchasers' class (i.e., those purchasers who purchase directly from these pharmaceutical manufacturers). None of the lawsuits has gone to trial, but some have settled in the past with the Company receiving proceeds from the settlement funds. During the fiscal years ended September 30, 2019, 2018, and 2017, the Company recognized gains of $145.9 million, $35.9 million, and $1.4 million, respectively, relating to these lawsuits. These gains, which are net of attorney fees and estimated payments due to other parties, were recorded as reductions to cost of goods sold in the Company's Consolidated Statements of Operations.
XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 290 540 1 false 91 0 false 6 false false R1.htm 0001000 - Document - Cover Sheet http://www.amerisourcebergen.com/role/Cover Cover Cover 1 false false R2.htm 1001000 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.amerisourcebergen.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 1003000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfComprehensiveIncome CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 5 false false R6.htm 1004000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 1004501 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) Statements 7 false false R8.htm 1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOW Sheet http://www.amerisourcebergen.com/role/ConsolidatedStatementsOfCashFlow CONSOLIDATED STATEMENTS OF CASH FLOW Statements 8 false false R9.htm 2101100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2103100 - Disclosure - Acquisitions and Investments Sheet http://www.amerisourcebergen.com/role/AcquisitionsAndInvestments Acquisitions and Investments Notes 10 false false R11.htm 2104100 - Disclosure - Variable Interest Entity Sheet http://www.amerisourcebergen.com/role/VariableInterestEntity Variable Interest Entity Notes 11 false false R12.htm 2107100 - Disclosure - Income Taxes Sheet http://www.amerisourcebergen.com/role/IncomeTaxes Income Taxes Notes 12 false false R13.htm 2108100 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 13 false false R14.htm 2109100 - Disclosure - Debt Sheet http://www.amerisourcebergen.com/role/Debt Debt Notes 14 false false R15.htm 2110100 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding Sheet http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstanding Stockholders' Equity and Weighted Average Common Shares Outstanding Notes 15 false false R16.htm 2111100 - Disclosure - Related Party Transactions Sheet http://www.amerisourcebergen.com/role/RelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 2112100 - Disclosure - Retirement and Other Benefit Plans Sheet http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlans Retirement and Other Benefit Plans Notes 17 false false R18.htm 2113100 - Disclosure - Share-Based Compensation Sheet http://www.amerisourcebergen.com/role/ShareBasedCompensation Share-Based Compensation Notes 18 false false R19.htm 2114100 - Disclosure - Lease Commitments Sheet http://www.amerisourcebergen.com/role/LeaseCommitments Lease Commitments Notes 19 false false R20.htm 2115100 - Disclosure - Employee Severance, Litigation, and Other Sheet http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOther Employee Severance, Litigation, and Other Notes 20 false false R21.htm 2116100 - Disclosure - Legal Matters and Contingencies Sheet http://www.amerisourcebergen.com/role/LegalMattersAndContingencies Legal Matters and Contingencies Notes 21 false false R22.htm 2117100 - Disclosure - Litigation Settlements Sheet http://www.amerisourcebergen.com/role/LitigationSettlements Litigation Settlements Notes 22 false false R23.htm 2118100 - Disclosure - Business Segment Information Sheet http://www.amerisourcebergen.com/role/BusinessSegmentInformation Business Segment Information Notes 23 false false R24.htm 2119100 - Disclosure - Fair Value of Financial Instruments Sheet http://www.amerisourcebergen.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 24 false false R25.htm 2120100 - Disclosure - Quarterly Financial Information (Unaudited) Sheet http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnaudited Quarterly Financial Information (Unaudited) Notes 25 false false R26.htm 2122100 - Schedule - Schedule II - Valuation and Qualifying Accounts Sheet http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccounts Schedule II - Valuation and Qualifying Accounts Uncategorized 26 false false R27.htm 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Notes 27 false false R28.htm 2304301 - Disclosure - Variable Interest Entity (Tables) Sheet http://www.amerisourcebergen.com/role/VariableInterestEntityTables Variable Interest Entity (Tables) Tables http://www.amerisourcebergen.com/role/VariableInterestEntity 28 false false R29.htm 2307301 - Disclosure - Income Taxes (Tables) Sheet http://www.amerisourcebergen.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.amerisourcebergen.com/role/IncomeTaxes 29 false false R30.htm 2308301 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssets 30 false false R31.htm 2309301 - Disclosure - Debt (Tables) Sheet http://www.amerisourcebergen.com/role/DebtTables Debt (Tables) Tables http://www.amerisourcebergen.com/role/Debt 31 false false R32.htm 2310301 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding (Tables) Sheet http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingTables Stockholders' Equity and Weighted Average Common Shares Outstanding (Tables) Tables http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstanding 32 false false R33.htm 2313301 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.amerisourcebergen.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.amerisourcebergen.com/role/ShareBasedCompensation 33 false false R34.htm 2314301 - Disclosure - Lease Commitments (Tables) Sheet http://www.amerisourcebergen.com/role/LeaseCommitmentsTables Lease Commitments (Tables) Tables http://www.amerisourcebergen.com/role/LeaseCommitments 34 false false R35.htm 2315301 - Disclosure - Employee Severance, Litigation, and Other (Tables) Sheet http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherTables Employee Severance, Litigation, and Other (Tables) Tables http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOther 35 false false R36.htm 2318301 - Disclosure - Business Segment Information (Tables) Sheet http://www.amerisourcebergen.com/role/BusinessSegmentInformationTables Business Segment Information (Tables) Tables http://www.amerisourcebergen.com/role/BusinessSegmentInformation 36 false false R37.htm 2320301 - Disclosure - Quarterly Financial Information (Unaudited) (Tables) Sheet http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedTables Quarterly Financial Information (Unaudited) (Tables) Tables http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnaudited 37 false false R38.htm 2401402 - Disclosure - Summary of Significant Accounting Policies - New Accounting Pronouncements (Details) Sheet http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails Summary of Significant Accounting Policies - New Accounting Pronouncements (Details) Details 38 false false R39.htm 2401403 - Disclosure - Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) Sheet http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesConcentrationsOfCreditRiskDetails Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) Details 39 false false R40.htm 2401405 - Disclosure - Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details) Sheet http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesGoodwillAndOtherIntangibleAssetsDetails Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details) Details 40 false false R41.htm 2401407 - Disclosure - Summary of Significant Accounting Policies - Merchandise Inventories (Details) Sheet http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesMerchandiseInventoriesDetails Summary of Significant Accounting Policies - Merchandise Inventories (Details) Details 41 false false R42.htm 2401408 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) Sheet http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails Summary of Significant Accounting Policies - Property and Equipment (Details) Details 42 false false R43.htm 2401409 - Disclosure - Summary of Significant Accounting Policies - Revenue Recognition (Details) Sheet http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails Summary of Significant Accounting Policies - Revenue Recognition (Details) Details 43 false false R44.htm 2401410 - Disclosure - Summary of Significant Accounting Policies - Shipping and Handling Costs (Details) Sheet http://www.amerisourcebergen.com/role/SummaryOfSignificantAccountingPoliciesShippingAndHandlingCostsDetails Summary of Significant Accounting Policies - Shipping and Handling Costs (Details) Details 44 false false R45.htm 2403402 - Disclosure - Acquisitions and Investments - NEVSCO (Details) Sheet http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsNevscoDetails Acquisitions and Investments - NEVSCO (Details) Details 45 false false R46.htm 2403403 - Disclosure - Acquisitions and Investments - H.D. Smith (Details) Sheet http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsHDSmithDetails Acquisitions and Investments - H.D. Smith (Details) Details 46 false false R47.htm 2403404 - Disclosure - Acquisitions and Investments - Proforma and Specialty Joint Venture (Details) Sheet http://www.amerisourcebergen.com/role/AcquisitionsAndInvestmentsProformaAndSpecialtyJointVentureDetails Acquisitions and Investments - Proforma and Specialty Joint Venture (Details) Details 47 false false R48.htm 2404402 - Disclosure - Variable Interest Entity (Details) Sheet http://www.amerisourcebergen.com/role/VariableInterestEntityDetails Variable Interest Entity (Details) Details http://www.amerisourcebergen.com/role/VariableInterestEntityTables 48 false false R49.htm 2407402 - Disclosure - Income Taxes - Domestic and Foreign Income From Continuing Operations Before Income Taxes (Details) Sheet http://www.amerisourcebergen.com/role/IncomeTaxesDomesticAndForeignIncomeFromContinuingOperationsBeforeIncomeTaxesDetails Income Taxes - Domestic and Foreign Income From Continuing Operations Before Income Taxes (Details) Details 49 false false R50.htm 2407403 - Disclosure - Income Taxes - Income Tax Provision (Details) Sheet http://www.amerisourcebergen.com/role/IncomeTaxesIncomeTaxProvisionDetails Income Taxes - Income Tax Provision (Details) Details 50 false false R51.htm 2407404 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details) Sheet http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfEffectiveIncomeTaxRateDetails Income Taxes - Reconciliation of Effective Income Tax Rate (Details) Details 51 false false R52.htm 2407405 - Disclosure - Income Taxes - Significant Components of Deferred Tax Liabilities (Assets) (Details) Sheet http://www.amerisourcebergen.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxLiabilitiesAssetsDetails Income Taxes - Significant Components of Deferred Tax Liabilities (Assets) (Details) Details 52 false false R53.htm 2407406 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Sheet http://www.amerisourcebergen.com/role/IncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Details 53 false false R54.htm 2407407 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.amerisourcebergen.com/role/IncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 54 false false R55.htm 2408402 - Disclosure - Goodwill and Other Intangible Assets - Changes in Carrying Value of Goodwill (Details) Sheet http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsChangesInCarryingValueOfGoodwillDetails Goodwill and Other Intangible Assets - Changes in Carrying Value of Goodwill (Details) Details 55 false false R56.htm 2408403 - Disclosure - Goodwill and Other Intangible Assets - Additional Information (Details) Sheet http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsAdditionalInformationDetails Goodwill and Other Intangible Assets - Additional Information (Details) Details 56 false false R57.htm 2408404 - Disclosure - Goodwill and Other Intangible Assets - Other Intangible Assets (Details) Sheet http://www.amerisourcebergen.com/role/GoodwillAndOtherIntangibleAssetsOtherIntangibleAssetsDetails Goodwill and Other Intangible Assets - Other Intangible Assets (Details) Details 57 false false R58.htm 2409402 - Disclosure - Debt - Debt Instruments (Details) Sheet http://www.amerisourcebergen.com/role/DebtDebtInstrumentsDetails Debt - Debt Instruments (Details) Details 58 false false R59.htm 2409403 - Disclosure - Debt - Additional Information (Details) Sheet http://www.amerisourcebergen.com/role/DebtAdditionalInformationDetails Debt - Additional Information (Details) Details 59 false false R60.htm 2410402 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Additional Information (Details) Sheet http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingAdditionalInformationDetails Stockholders' Equity and Weighted Average Common Shares Outstanding - Additional Information (Details) Details 60 false false R61.htm 2410403 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Accumulated Other Comprehensive Loss (Details) Sheet http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfAccumulatedOtherComprehensiveLossDetails Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Accumulated Other Comprehensive Loss (Details) Details 61 false false R62.htm 2410404 - Disclosure - Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Diluted Weighted Average Shares Outstanding (Details) Sheet http://www.amerisourcebergen.com/role/StockholdersEquityAndWeightedAverageCommonSharesOutstandingComponentsOfDilutedWeightedAverageSharesOutstandingDetails Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Diluted Weighted Average Shares Outstanding (Details) Details 62 false false R63.htm 2411401 - Disclosure - Related Party Transactions (Details) Sheet http://www.amerisourcebergen.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.amerisourcebergen.com/role/RelatedPartyTransactions 63 false false R64.htm 2412401 - Disclosure - Retirement and Other Benefit Plans (Details) Sheet http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlansDetails Retirement and Other Benefit Plans (Details) Details http://www.amerisourcebergen.com/role/RetirementAndOtherBenefitPlans 64 false false R65.htm 2413402 - Disclosure - Share-Based Compensation - Additional Information (Details) Sheet http://www.amerisourcebergen.com/role/ShareBasedCompensationAdditionalInformationDetails Share-Based Compensation - Additional Information (Details) Details 65 false false R66.htm 2413403 - Disclosure - Share-Based Compensation - Weighted Average Assumptions (Details) Sheet http://www.amerisourcebergen.com/role/ShareBasedCompensationWeightedAverageAssumptionsDetails Share-Based Compensation - Weighted Average Assumptions (Details) Details 66 false false R67.htm 2413404 - Disclosure - Share-Based Compensation - Stock Options (Details) Sheet http://www.amerisourcebergen.com/role/ShareBasedCompensationStockOptionsDetails Share-Based Compensation - Stock Options (Details) Details 67 false false R68.htm 2413405 - Disclosure - Share-Based Compensation - Nonvested Options (Details) Sheet http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedOptionsDetails Share-Based Compensation - Nonvested Options (Details) Details 68 false false R69.htm 2413406 - Disclosure - Share-Based Compensation - Nonvested Restricted Stock Units (Details) Sheet http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedRestrictedStockUnitsDetails Share-Based Compensation - Nonvested Restricted Stock Units (Details) Details 69 false false R70.htm 2413407 - Disclosure - Share-Based Compensation - Nonvested Performance Stock Units (Details) Sheet http://www.amerisourcebergen.com/role/ShareBasedCompensationNonvestedPerformanceStockUnitsDetails Share-Based Compensation - Nonvested Performance Stock Units (Details) Details 70 false false R71.htm 2414402 - Disclosure - Lease Commitments - Minimum Lease Payments (Details) Sheet http://www.amerisourcebergen.com/role/LeaseCommitmentsMinimumLeasePaymentsDetails Lease Commitments - Minimum Lease Payments (Details) Details 71 false false R72.htm 2414403 - Disclosure - Lease Commitments - Additional Information (Details) Sheet http://www.amerisourcebergen.com/role/LeaseCommitmentsAdditionalInformationDetails Lease Commitments - Additional Information (Details) Details 72 false false R73.htm 2415402 - Disclosure - Employee Severance, Litigation, and Other (Details) Sheet http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherDetails Employee Severance, Litigation, and Other (Details) Details http://www.amerisourcebergen.com/role/EmployeeSeveranceLitigationAndOtherTables 73 false false R74.htm 2416401 - Disclosure - Legal Matters and Contingencies (Details) Sheet http://www.amerisourcebergen.com/role/LegalMattersAndContingenciesDetails Legal Matters and Contingencies (Details) Details http://www.amerisourcebergen.com/role/LegalMattersAndContingencies 74 false false R75.htm 2417401 - Disclosure - Litigation Settlements (Details) Sheet http://www.amerisourcebergen.com/role/LitigationSettlementsDetails Litigation Settlements (Details) Details http://www.amerisourcebergen.com/role/LitigationSettlements 75 false false R76.htm 2418402 - Disclosure - Business Segment Information - Reconciliation of Segment Revenue, Operating Income, Assets, Depreciation and Amortization, and Capital Expenditures (Details) Sheet http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentRevenueOperatingIncomeAssetsDepreciationAndAmortizationAndCapitalExpendituresDetails Business Segment Information - Reconciliation of Segment Revenue, Operating Income, Assets, Depreciation and Amortization, and Capital Expenditures (Details) Details 76 false false R77.htm 2418403 - Disclosure - Business Segment Information - Reconciliation of Segment Operating Income to Income From Continuing Operations (Details) Sheet http://www.amerisourcebergen.com/role/BusinessSegmentInformationReconciliationOfSegmentOperatingIncomeToIncomeFromContinuingOperationsDetails Business Segment Information - Reconciliation of Segment Operating Income to Income From Continuing Operations (Details) Details 77 false false R78.htm 2418404 - Disclosure - Business Segment Information - Additional Information (Details) Sheet http://www.amerisourcebergen.com/role/BusinessSegmentInformationAdditionalInformationDetails Business Segment Information - Additional Information (Details) Details 78 false false R79.htm 2419401 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://www.amerisourcebergen.com/role/FairValueOfFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) Details http://www.amerisourcebergen.com/role/FairValueOfFinancialInstruments 79 false false R80.htm 2420402 - Disclosure - Quarterly Financial Information (Unaudited) (Details) Sheet http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedDetails Quarterly Financial Information (Unaudited) (Details) Details http://www.amerisourcebergen.com/role/QuarterlyFinancialInformationUnauditedTables 80 false false R81.htm 2422401 - Schedule - Schedule II - Valuation and Qualifying Accounts (Details) Sheet http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsDetails Schedule II - Valuation and Qualifying Accounts (Details) Details 81 false false R82.htm 2422402 - Schedule - Schedule II - Valuation and Qualifying Accounts - Additional Information (Details) Sheet http://www.amerisourcebergen.com/role/ScheduleIiValuationAndQualifyingAccountsAdditionalInformationDetails Schedule II - Valuation and Qualifying Accounts - Additional Information (Details) Details 82 false false R9999.htm Uncategorized Items - a10-kx9302019.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - a10-kx9302019.htm Cover 83 false false All Reports Book All Reports a10-kx9302019.htm abc-20190930.xsd abc-20190930_cal.xml abc-20190930_def.xml abc-20190930_lab.xml abc-20190930_pre.xml exhibit21-9302019.htm exhibit23-9302019.htm exhibit311-9302019.htm exhibit312-9302019.htm exhibit32-9302019.htm exhibit414-9302019.htm performancegraphfy2019a02.jpg http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 44 R2.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2019
Sep. 30, 2018
Current assets:    
Cash and cash equivalents $ 3,374,194 $ 2,492,516
Accounts receivable, less allowances for returns and doubtful accounts: 2019 — $1,222,906; 2018 — $1,036,333 12,386,879 11,314,226
Inventories (Note 1) 11,060,254 11,918,508
Right to recover asset (Note 1) 1,147,483 0
Prepaid expenses and other 163,244 169,122
Total current assets 28,132,054 25,894,372
Property and equipment, at cost:    
Land 44,142 39,875
Buildings and improvements 942,129 1,086,909
Machinery, equipment, and other 2,362,869 2,281,124
Total property and equipment 3,349,140 3,407,908
Less accumulated depreciation (1,578,624) (1,515,484)
Property and equipment, net 1,770,516 1,892,424
Goodwill 6,705,507 6,664,272
Other intangible assets 2,294,836 2,947,828
Other assets 269,067 270,942
TOTAL ASSETS 39,171,980 37,669,838
Current liabilities:    
Accounts payable 28,385,074 26,836,873
Accrued expenses and other 1,057,208 881,157
Short-term debt 139,012 151,657
Total current liabilities 29,581,294 27,869,687
Long-term debt 4,033,880 4,158,532
Long-term financing obligation 320,518 352,296
Accrued income taxes 284,075 299,600
Deferred income taxes 1,860,195 1,829,410
Other liabilities 98,812 110,352
Commitments and contingencies (Note 13)
Stockholders' equity:    
Common stock, $0.01 par value — authorized, issued, and outstanding: 2019 — 600,000,000 shares, 285,295,170 shares and 206,760,654 shares; 2018 — 600,000,000 shares, 283,588,463 shares and 213,217,882 shares 2,853 2,836
Additional paid-in capital 4,850,142 4,715,473
Retained earnings 4,235,491 3,720,582
Accumulated other comprehensive loss (111,965) (79,253)
Treasury stock, at cost: 2019 — 78,534,516 shares; 2018 — 70,370,581 shares (6,097,604) (5,426,814)
Total AmerisourceBergen Corporation stockholders' equity 2,878,917 2,932,824
Noncontrolling interest 114,289 117,137
Total equity 2,993,206 3,049,961
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 39,171,980 $ 37,669,838
XML 45 R6.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Loss [Member]
Treasury Stock [Member]
Noncontrolling Interest [Member]
Balance, beginning of period at Sep. 30, 2016 $ 2,129,404 $ 2,778 $ 4,333,001 $ 2,303,941 $ (114,308) $ (4,396,008) $ 0
Increase (decrease) in stockholders' equity              
Net income (loss) 364,484     364,484      
Other comprehensive income (loss) 18,458       18,458    
Cash dividends (320,270)     (320,270)      
Exercises of stock options 102,923 25 102,898        
Share-based compensation expense 62,206   62,206        
Common stock purchases for employee stock purchase plan (467)   (467)        
Purchases of common stock (329,929)         (329,929)  
Settlement of accelerated share repurchase transaction 0   20,000     (20,000)  
Employee tax withholdings related to restricted share vesting (9,411)         (9,411)  
Other 0 3 (3)        
Balance, end of period at Sep. 30, 2017 2,064,461 2,806 4,517,635 2,395,218 (95,850) (4,755,348) 0
Increase (decrease) in stockholders' equity              
Consolidation of variable interest entity 167,966           167,966
Net income (loss) 1,615,892     1,658,405     (42,513)
Other comprehensive income (loss) 8,281       16,597   (8,316)
Cash dividends (333,041)     (333,041)      
Exercises of stock options 138,456 27 138,429        
Share-based compensation expense 62,316   62,316        
Common stock purchases for employee stock purchase plan (341)   (341)        
Purchases of common stock (663,220)         (663,220)  
Employee tax withholdings related to restricted share vesting (8,246)         (8,246)  
Other (2,563) 3 (2,566)        
Balance, end of period at Sep. 30, 2018 3,049,961 2,836 4,715,473 3,720,582 (79,253) (5,426,814) 117,137
Increase (decrease) in stockholders' equity              
Net income (loss) 854,135     855,365     (1,230)
Other comprehensive income (loss) (33,228)       (32,712)   (516)
Cash dividends (338,974)     (338,974)      
Exercises of stock options 76,234 15 76,219        
Share-based compensation expense 58,874   58,874        
Purchases of common stock (664,803)         (664,803)  
Employee tax withholdings related to restricted share vesting (5,987)         (5,987)  
Other (422) 2 (424)        
Balance, end of period at Sep. 30, 2019 $ 2,993,206 $ 2,853 $ 4,850,142 $ 4,235,491 $ (111,965) $ (6,097,604) $ 114,289
XML 46 R18.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation
 12 Months Ended
Sep. 30, 2019
Share-based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based Compensation
Stock Options
The Company's employee stock option plans provide for the granting of incentive and nonqualified stock options to acquire shares of common stock to employees at a price not less than the fair market value of the common stock on the date the option is granted. Option terms and vesting periods are determined at the date of grant by the Compensation Committee of the board of directors. Employee options generally vest ratably, in equal amounts, over a four-year service period and expire in seven years. The Company's non-employee director stock option plans provide for the granting of nonqualified stock options to acquire shares of common stock to non-employee directors at the fair market value of the common stock on the date of the grant. Non-employee director options vest ratably, in equal amounts, over a three-year service period and expire in ten years. Non-employee director options have not been granted since February 2011.
As of September 30, 2019, employee and non-employee director stock options for an additional 12.8 million shares may be granted under the AmerisourceBergen Corporation Omnibus Incentive Plan (the "Plan").
The estimated fair value of options granted is expensed on a straight-line basis over the requisite service periods of the awards and are net of estimated forfeitures. The Company estimates the fair values of option grants using a binomial option pricing model. Expected volatilities are based upon the historical volatility of the Company's common stock and other factors, such as implied market volatility. The Company uses historical exercise data, taking into consideration the optionees' ages at grant date, to estimate the terms for which the options are expected to be outstanding. The Company anticipates that the terms of options
granted in the future will be similar to those granted in the past. The risk-free rates during the terms of such options are based upon the U.S. Treasury yield curve in effect at the time of grant.
The weighted average fair values of the options granted during the fiscal years ended September 30, 2019, 2018, and 2017 were $18.60, $14.16, and $13.57, respectively. The following weighted average assumptions were used to estimate the fair values of options granted:
 
Fiscal Year Ended September 30,
 
2019
 
2018
 
2017
Risk-free interest rate
2.91%
 
1.89%
 
1.26%
Expected dividend yield
1.79%
 
1.96%
 
1.80%
Volatility of common stock
27.67%
 
26.54%
 
26.78%
Expected life of the options
3.77 years
 
3.76 years
 
3.74 years

During the fiscal years ended September 30, 2019, 2018, and 2017, the Company recognized stock option expense of $21.0 million, $22.6 million, and $28.6 million, respectively.
A summary of the Company's stock option activity and related information for its option plans for the fiscal year ended September 30, 2019 is presented below:
(in thousands, except exercise price and contractual term)
 
Options
 
Weighted
Average
Exercise
Price
 
Weighted
Average
Remaining
Contractual
Term
 
Aggregate
Intrinsic
Value
Outstanding as of September 30, 2018
 
8,421

 
$77
 
4 years
 
$
142,557

Granted
 
1,137

 
$90
 
 
 
 

Exercised
 
(1,531
)
 
$50
 
 
 
 

Forfeited
 
(213
)
 
$84
 
 
 
 

Expired
 
(155
)
 
$97
 
 
 
 
Outstanding as of September 30, 2019
 
7,659

 
$83
 
4 years
 
$
35,319

Exercisable as of September 30, 2019
 
4,395

 
$83
 
3 years
 
$
25,049

Expected to vest after September 30, 2019
 
3,162

 
$83
 
5 years
 
$
10,010


The intrinsic value of stock option exercises during the fiscal years ended September 30, 2019, 2018, and 2017 was $51.2 million, $116.7 million, and $116.6 million, respectively.
A summary of the status of the Company's nonvested options as of September 30, 2019 and changes during the fiscal year ended September 30, 2019 is presented below:
(in thousands, except grant date fair value)
 
Options
 
Weighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 2018
 
3,860

 
$15
Granted
 
1,137

 
$19
Vested
 
(1,519
)
 
$15
Forfeited
 
(213
)
 
$16
Nonvested as of September 30, 2019
 
3,265

 
$16

During the fiscal years ended September 30, 2019, 2018, and 2017, the total fair values of options vested were $22.7 million, $25.8 million, and $25.2 million, respectively. Expected future compensation expense relating to the 3.3 million nonvested options outstanding as of September 30, 2019 is $21.6 million, which will be recognized over a weighted average period of 2.0 years.
Restricted Stock Units
Restricted stock units vest in full after three years. The estimated fair value of restricted stock units under the Company's restricted stock unit plans is determined by the product of the number of shares granted and the grant date market price of the Company's common stock. The estimated fair value of restricted stock units is expensed on a straight-line basis over the requisite service period, net of estimated forfeitures. During the fiscal years ended September 30, 2019, 2018, and 2017, the Company recognized restricted stock unit expense of $29.2 million, $26.8 million, and $25.1 million, respectively.
A summary of the status of the Company's nonvested restricted stock units as of September 30, 2019 and changes during the fiscal year ended September 30, 2019 are presented below:
(in thousands, except grant date fair value)
 
Restricted
Stock Units
 
Weighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 2018
 
1,023

 
$80
Granted
 
442

 
$89
Vested
 
(152
)
 
$95
Forfeited
 
(91
)
 
$81
Nonvested as of September 30, 2019
 
1,222

 
$81

During the fiscal years ended September 30, 2019, 2018, and 2017, the total fair values of restricted stock units vested were $14.5 million, $15.8 million, and $13.8 million, respectively. Expected future compensation expense relating to the 1.2 million restricted stock units outstanding as of September 30, 2019 is $30.1 million, which will be recognized over a weighted average period of 1.2 years.
Performance Stock Units
Performance stock units are granted to certain executive employees under the Plan and represent common stock potentially issuable in the future. Performance stock units vest at the end of a three-year performance period based upon achievement of specific performance goals. Based upon the extent to which the targets are achieved, vested shares for awards granted prior to fiscal 2018 may range from 0% to 150% of the target award amount. For awards granted beginning in fiscal 2018, vested shares may range from 0% to 200% of the target award amount. The fair value of performance stock units is determined by the grant date market price of the Company's common stock. Compensation expense associated with nonvested performance stock units is recognized over the requisite service period and is dependent on the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued. During the fiscal years ended September 30, 2019, 2018, and 2017, the Company recognized performance stock expense of $8.5 million, $12.8 million, and $8.4 million, respectively.
A summary of the status of the Company's nonvested performance stock units as of September 30, 2019 and changes during the fiscal year ended September 30, 2019 is presented below (based upon target award amounts).
(in thousands, except grant date fair value)
 
Performance
Stock
Units
 
Weighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 2018
 
244

 
$77
Granted
 
147

 
$90
Vested
 
(105
)
 
$76
Forfeited
 
(3
)
 
$90
Nonvested as of September 30, 2019
 
283

 
$84

Shares that vested over the three-year performance period ended September 30, 2019 were distributed to employees in November 2019.
XML 47 R14.htm IDEA: XBRL DOCUMENT v3.19.3
Debt
 12 Months Ended
Sep. 30, 2019
Debt Disclosure [Abstract]  
Debt Debt
Debt consisted of the following:
 
 
September 30,
(in thousands)
 
2019
 
2018
Revolving credit note
 
$
—

 
$
—

Term loans due 2020
 
399,778

 
398,665

Overdraft facility due 2021 (£30,000)
 
32,573

 
13,269

Receivables securitization facility due 2022
 
350,000

 
500,000

Multi-currency revolving credit facility due 2024
 
—

 
—

$500,000, 3.50% senior notes due 2021
 
498,908

 
498,392

$500,000, 3.40% senior notes due 2024
 
497,744

 
497,255

$500,000, 3.25% senior notes due 2025
 
496,311

 
495,632

$750,000, 3.45% senior notes due 2027
 
743,099

 
742,258

$500,000, 4.25% senior notes due 2045
 
494,514

 
494,298

$500,000, 4.30% senior notes due 2047
 
492,488

 
492,222

Capital lease obligations
 
—

 
745

Nonrecourse debt
 
167,477

 
177,453

Total debt
 
4,172,892

 
4,310,189

Less AmerisourceBergen Corporation current portion
 
32,573

 
13,976

Less nonrecourse current portion
 
106,439

 
137,681

Total, net of current portion
 
$
4,033,880

 
$
4,158,532


Multi-Currency Revolving Credit Facility
The Company has a $1.4 billion multi-currency senior unsecured revolving credit facility ("Multi-Currency Revolving Credit Facility"), which was scheduled to expire in October 2023, with a syndicate of lenders. In September 2019, the Company entered into an amendment to, among other things, extend the maturity to September 2024. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based upon the Company's debt rating and ranges from 70 basis points to 112.5 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (91 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee as of September 30, 2019) and from 0 basis points to 12.5 basis points over the alternate base rate and Canadian prime rate, as applicable. The Company pays facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on its debt rating, ranging from 5 basis points to 12.5 basis points, annually, of the total commitment (9 basis points as of September 30, 2019). The Company may choose to repay or reduce its commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which the Company was compliant as of September 30, 2019.
Commercial Paper Program
The Company has a commercial paper program whereby it may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under the commercial paper program as of September 30, 2019 and 2018.
Receivables Securitization Facility
The Company has a $1,450 million receivables securitization facility ("Receivables Securitization Facility"), which was scheduled to expire in October 2021. In September 2019, the Company entered into an amendment to extend the maturity to September 2022. The Company has available to it an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based on prevailing market rates for short-term commercial paper or LIBOR, plus a program fee. The Company pays a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility.
In connection with the Receivables Securitization Facility, AmerisourceBergen Drug Corporation sells on a revolving basis certain accounts receivable to Amerisource Receivables Financial Corporation, a wholly-owned special purpose entity, which in turn sells a percentage ownership interest in the receivables to financial institutions and commercial paper conduits sponsored by financial institutions. AmerisourceBergen Drug Corporation is the servicer of the accounts receivable under the Receivables Securitization Facility. As sold receivables are collected, additional receivables may be sold up to the maximum amount available under the facility. The facility is a financing vehicle utilized by the Company because it generally offers an attractive interest rate relative to other financing sources. The Company securitizes its trade accounts, which are generally non-interest bearing, in transactions that are accounted for as borrowings. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of September 30, 2019.
Revolving Credit Note and Overdraft Facility
The Company has an uncommitted, unsecured line of credit available to it pursuant to a revolving credit note ("Revolving Credit Note"). The Revolving Credit Note provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million. The Revolving Credit Note may be decreased or terminated by the bank or the Company at any time without prior notice. The Company also has a £30 million uncommitted U.K. overdraft facility ("Overdraft Facility"), which expires in February 2021, to fund short-term normal trading cycle fluctuations related to its MWI business.
Term Loans
In October 2018, the Company refinanced $400 million of outstanding Term Loans by issuing a new $400 million variable-rate term loan ("October 2018 Term Loan"), which matures in October 2020. The October 2018 Term Loan bears interest at a rate equal to a base rate or LIBOR, plus a margin of 65 basis points. The October 2018 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility.
Senior Notes
In December 2017, the Company issued $750 million of 3.45% senior notes due December 15, 2027 (the "2027 Notes") and $500 million of 4.30% senior notes due December 15, 2047 (the "2047 Notes"). The 2027 Notes were sold at 99.76% of the principal amount and have an effective yield of 3.48%. The 2047 Notes were sold at 99.51% of the principal amount and have an effective yield of 4.33%. Interest on the 2027 Notes and the 2047 Notes is payable semi-annually in arrears and commenced on June 15, 2018. The 2027 and 2047 Notes rank pari passu to the Company's other senior notes, the Multi-Currency Revolving Credit Facility, the Revolving Credit Note, the Overdraft Facility, and the October 2018 Term Loan.

The Company used the proceeds from the 2027 Notes and the 2047 Notes to finance the early retirement of the $400 million of 4.875% senior notes that were due in 2019, including the payment of a $22.3 million prepayment premium, and to finance the acquisition of H.D. Smith, which was completed in January 2018 (see Note 2).
The senior notes are collectively referred to as the "Notes." Interest on the Notes is payable semiannually in arrears. The Notes were sold at small discounts to the principal amounts and, therefore, have effective yields that are greater than the stated interest rates in the table above. Costs incurred in connection with the issuance of the Notes were deferred and are being amortized over the terms of the Notes. The indentures governing the Notes contain restrictions and covenants, which include limitations on
additional indebtedness; distributions to stockholders; the repurchase of stock and the making of other restricted payments; issuance of preferred stock; creation of certain liens; transactions with subsidiaries and other affiliates; and certain corporate acts such as mergers, consolidations, and the sale of substantially all assets. An additional covenant requires compliance with a financial leverage ratio test, with which the Company was compliant as of September 30, 2019.
Nonrecourse Debt
Nonrecourse debt is comprised of short-term and long-term debt belonging to the Brazil subsidiaries and is repaid solely from the Brazil subsidiaries' cash flows and such debt agreements provide that the repayment of the loans (and interest thereon) is secured solely by the capital stock, physical assets, contracts, and cash flows of the Brazil subsidiaries.
Other Information
Scheduled future principal payments of debt are $111.2 million in fiscal 2020, $450.3 million in fiscal 2021, $877.8 million in fiscal 2022, $4.7 million in fiscal 2023, $501.4 million in fiscal 2024, and $2.3 billion thereafter.
Interest paid on the above indebtedness during the fiscal years ended September 30, 2019, 2018, and 2017 was $167.4 million, $162.1 million, and $125.3 million, respectively.
Total amortization of financing fees and the accretion of original issue discounts, which are recorded as components of Interest Expense, Net on the Consolidated Statements of Operations, were $7.1 million, $7.7 million, and $6.2 million, for the fiscal years ended September 30, 2019, 2018, and 2017, respectively.
XML 48 R10.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisitions and Investments
 12 Months Ended
Sep. 30, 2019
Business Combinations [Abstract]  
Acquisitions and Investments Acquisitions and Investments
NEVSCO
In December 2017, the Company acquired Northeast Veterinary Supply Company ("NEVSCO") for $70.0 million. NEVSCO was an independent, regional distributor of veterinary pharmaceuticals and medical supplies serving primarily the northeast region of the United States and strengthens MWI Animal Health's ("MWI") support of independent veterinary practices and provides even greater value and care to current and future animal health customers. NEVSCO is included within the MWI operating segment.
The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their fair values on the date of the acquisition. The purchase price exceeded the fair value of the net tangible and intangible assets acquired by $30.4 million, which was allocated to goodwill. The fair value of accounts receivable, inventory, and accounts payable and accrued expenses acquired was $8.5 million, $6.7 million, and $2.9 million, respectively. The fair value of the intangible assets acquired of $29.8 million primarily consisted of customer relationships, which the Company is amortizing over its estimated useful life of 15 years. Goodwill and intangible assets resulting from the acquisition are deductible for income tax purposes.
H.D. Smith
In January 2018, the Company acquired H.D. Smith Holding Company ("H.D. Smith") for $815.0 million. The Company funded the acquisition through the issuance of new long-term debt (see Note 6). H.D. Smith was the largest independent pharmaceutical wholesaler in the United States and provides full-line distribution of brand, generic, and specialty drugs, as well as high-value services and solutions for manufacturers and healthcare providers. H.D. Smith's customers included retail pharmacies, specialty pharmacies, long-term care facilities, institutional/hospital systems, and independent physicians and clinics. The acquisition strengthens the Company's core business, expands and enhances its strategic scale in pharmaceutical distribution, and expands the Company's support for independent community pharmacies. H.D. Smith has been integrated into the Pharmaceutical Distribution reportable segment.
The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their fair values on the date of acquisition. The purchase price exceeded the fair value of the net tangible and intangible assets acquired by $499.9 million, which was allocated to goodwill. The fair value of accounts receivable, inventory, and accounts payable and accrued expenses acquired was $163.1 million, $350.7 million, and $366.1 million, respectively. The fair value of the intangible assets acquired of $167.8 million consisted of customer relationships of $156.6 million and a tradename of $11.2 million. The Company is amortizing the fair value of the customer relationships and the tradename over their estimated useful lives of 12 years and 2 years, respectively. The Company established a deferred tax liability of $60.6 million primarily in connection with the intangible assets acquired. Goodwill and intangible assets resulting from the acquisition are not deductible for income tax purposes.
Profarma and Specialty Joint Venture
As of September 30, 2017, the Company held a noncontrolling ownership interest in Profarma, a leading pharmaceutical wholesaler in Brazil, and an ownership interest in a joint venture with Profarma to provide specialty distribution and services to the Brazilian marketplace (the "specialty joint venture"). The Company had accounted for these interests as equity method investments, which were reported in Other Assets on the Company's Consolidated Balance Sheets. In January 2018, the Company invested an additional $62.5 million in Profarma and an additional $15.6 million in the specialty joint venture to increase its ownership interests to 38.2% and 64.5%, respectively. In connection with the additional investment in Profarma, the Company received substantial governance rights, thereby requiring it to begin consolidating the operating results of Profarma as of March 31, 2018 (see Note 3). The Company also began to consolidate the operating results of the specialty joint venture as of March 31, 2018 due to its majority ownership interest. In September 2018, the Company made an additional investment of $23.6 million in the specialty joint venture to increase its ownership interest to 89.9%. Profarma and the specialty joint venture are included within the Pharmaceutical Distribution Services reportable segment and Other, respectively.
The fair value of Profarma, including the noncontrolling interest, was determined based upon an agreed-upon stock price and was allocated to the underlying assets and liabilities consolidated based upon their fair values at the time of the January 2018 investment. The fair value of Profarma upon obtaining control exceeded the fair value of the net tangible and intangible assets consolidated by $142.0 million, which was allocated to goodwill. The fair value of accounts receivable, inventory, accounts payable and accrued expenses was $160.1 million, $190.5 million, and $167.7 million, respectively. The Company consolidated short-term debt and long-term debt of $209.9 million and $12.4 million, respectively, cash of $150.8 million, and recorded a noncontrolling interest of $168.0 million. The estimated fair value of the intangible assets consolidated of $84.6 million consisted of customer relationships of $25.9 million and a tradename of $58.7 million. The Company is amortizing the customer relationships over its estimated useful life of 15 years and the tradenames over their estimated useful lives of between 15 years and 25 years. The Company established a deferred tax liability of $50.1 million primarily in connection with the intangible assets that were recognized. Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.
The fair value of the specialty joint venture was determined based upon the cost of the incremental ownership percentage acquired from the January 2018 investment and was allocated to the underlying assets and liabilities consolidated based upon their fair values at the time of the January 2018 investment. The fair value of the specialty joint venture exceeded the fair value of the net tangible and intangible assets consolidated by $3.5 million, which was allocated to goodwill. The fair value of accounts receivable, inventory, accounts payable and accrued expenses was $65.0 million, $29.1 million, and $54.3 million, respectively. The Company consolidated short-term debt and cash of $32.7 million and $28.9 million, respectively. The estimated fair value of the intangible assets consolidated of $4.6 million is being amortized over its estimated useful life of 15 years. Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.
In connection with the incremental January 2018 Brazil investments, the Company adjusted the carrying values of its previously held equity interests in Profarma and the specialty joint venture to equal their fair values, which were determined to be $103.1 million and $31.2 million, respectively. These represent Level 2 nonrecurring fair value measurements. The adjustments resulted in a pretax loss of $42.3 million in fiscal 2018 and were comprised of foreign currency translation adjustments from Accumulated Other Comprehensive Loss of $45.9 million, a $12.4 million gain on the remeasurement of Profarma's previously held equity interest, and an $8.8 million loss on the remeasurement of the specialty joint venture's previously held equity interest.
XML 49 R33.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation (Tables)
 12 Months Ended
Sep. 30, 2019
Share-based Payment Arrangement [Abstract]  
Weighted average assumptions The following weighted average assumptions were used to estimate the fair values of options granted:
 
Fiscal Year Ended September 30,
 
2019
 
2018
 
2017
Risk-free interest rate
2.91%
 
1.89%
 
1.26%
Expected dividend yield
1.79%
 
1.96%
 
1.80%
Volatility of common stock
27.67%
 
26.54%
 
26.78%
Expected life of the options
3.77 years
 
3.76 years
 
3.74 years
Stock options
A summary of the Company's stock option activity and related information for its option plans for the fiscal year ended September 30, 2019 is presented below:
(in thousands, except exercise price and contractual term)
 
Options
 
Weighted
Average
Exercise
Price
 
Weighted
Average
Remaining
Contractual
Term
 
Aggregate
Intrinsic
Value
Outstanding as of September 30, 2018
 
8,421

 
$77
 
4 years
 
$
142,557

Granted
 
1,137

 
$90
 
 
 
 

Exercised
 
(1,531
)
 
$50
 
 
 
 

Forfeited
 
(213
)
 
$84
 
 
 
 

Expired
 
(155
)
 
$97
 
 
 
 
Outstanding as of September 30, 2019
 
7,659

 
$83
 
4 years
 
$
35,319

Exercisable as of September 30, 2019
 
4,395

 
$83
 
3 years
 
$
25,049

Expected to vest after September 30, 2019
 
3,162

 
$83
 
5 years
 
$
10,010
Nonvested options
A summary of the status of the Company's nonvested options as of September 30, 2019 and changes during the fiscal year ended September 30, 2019 is presented below:
(in thousands, except grant date fair value)
 
Options
 
Weighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 2018
 
3,860

 
$15
Granted
 
1,137

 
$19
Vested
 
(1,519
)
 
$15
Forfeited
 
(213
)
 
$16
Nonvested as of September 30, 2019
 
3,265

 
$16
Nonvested restricted shares
A summary of the status of the Company's nonvested restricted stock units as of September 30, 2019 and changes during the fiscal year ended September 30, 2019 are presented below:
(in thousands, except grant date fair value)
 
Restricted
Stock Units
 
Weighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 2018
 
1,023

 
$80
Granted
 
442

 
$89
Vested
 
(152
)
 
$95
Forfeited
 
(91
)
 
$81
Nonvested as of September 30, 2019
 
1,222

 
$81
Nonvested performance stock units
A summary of the status of the Company's nonvested performance stock units as of September 30, 2019 and changes during the fiscal year ended September 30, 2019 is presented below (based upon target award amounts).
(in thousands, except grant date fair value)
 
Performance
Stock
Units
 
Weighted
Average
Grant Date
Fair Value
Nonvested as of September 30, 2018
 
244

 
$77
Granted
 
147

 
$90
Vested
 
(105
)
 
$76
Forfeited
 
(3
)
 
$90
Nonvested as of September 30, 2019
 
283

 
$84
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.19.3
Quarterly Financial Information (Unaudited) (Tables)
 12 Months Ended
Sep. 30, 2019
Quarterly Financial Information Disclosure [Abstract]  
Quarterly financial information
 
 
Fiscal Year Ended September 30, 2019
(in thousands, except per share amounts)
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
 
Fiscal
Year
Revenue
 
$
45,392,452

 
$
43,319,602

 
$
45,239,265

 
$
45,637,802

 
$
179,589,121

Gross profit (a)
 
$
1,297,580

 
$
1,424,756

 
$
1,231,239

 
$
1,184,737

 
$
5,138,312

Distribution, selling, and administrative expenses; depreciation; and amortization
 
779,085

 
751,802

 
764,539

 
830,489

 
3,125,915

Employee severance, litigation, and other
 
40,672

 
55,389

 
60,006

 
174,407

 
330,474

Impairment of long-lived assets
 
—

 
570,000

 
—

 
—

 
570,000

Operating income
 
$
477,823

 
$
47,565

 
$
406,694

 
$
179,841

 
$
1,111,923

Net income (b)
 
$
391,753

 
$
28,073

 
$
302,002

 
$
132,307

 
$
854,135

Net income attributable to AmerisourceBergen Corporation (b)
 
$
393,652

 
$
27,135

 
$
301,959

 
$
132,619

 
$
855,365

Earnings per share operations:
 
 

 
 

 
 

 
 

 
 

Basic
 
$
1.86

 
$
0.13

 
$
1.44

 
$
0.64

 
$
4.07

Diluted
 
$
1.84

 
$
0.13

 
$
1.43

 
$
0.63

 
$
4.04

__________________________________________________________
(a)
The first, second, third, and fourth quarters of the fiscal year ended September 30, 2019 include gains from antitrust litigation settlements of $87.3 million, $52.0 million, $3.5 million, and $3.1 million, respectively. The first, second, and third quarter of the fiscal year ended September 30, 2019 include LIFO credits of $3.0 million, $66.8 million, and $9.9 million, respectively. The fourth quarter of the fiscal year ended September 30, 2019 includes LIFO expense of $57.2 million. The first, second, third, and fourth quarters of the fiscal year ended September 30, 2019 include PharMEDium remediation costs of $17.9 million, $12.3 million, $11.7 million, and $6.7 million, respectively. The first quarter of the fiscal year ended September 30, 2019 includes a $22.0 million reversal of a previous estimate of our liability under the New York State Opioid Stewardship Act.
(b)
The first quarter of the fiscal year ended September 30, 2019 includes a $37.0 million income tax benefit adjustment to the one-time transition tax on historical foreign earnings and profits through December 31, 2017. The second quarter of the fiscal year ended September 30, 2019 includes a gain on the sale of an equity investment of $13.7 million.
 
 
Fiscal Year Ended September 30, 2018
(in thousands, except per share amounts)
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
 
Fiscal
Year
Revenue
 
$
40,466,332

 
$
41,033,858

 
$
43,142,309

 
$
43,297,136

 
$
167,939,635

Gross profit (a)
 
$
1,112,652

 
$
1,255,683

 
$
1,211,341

 
$
1,032,641

 
$
4,612,317

Distribution, selling, and administrative expenses; depreciation; and amortization
 
663,658

 
736,814

 
746,593

 
778,363

 
2,925,428

Employee severance, litigation, and other
 
30,021

 
37,449

 
75,553

 
40,497

 
183,520

Goodwill impairment
 
—

 
—

 
—

 
59,684

 
59,684

Operating income
 
$
418,973

 
$
481,420

 
$
389,195

 
$
154,097

 
$
1,443,685

Net income (b)
 
$
861,853

 
$
282,160

 
$
277,875

 
$
194,004

 
$
1,615,892

Net income attributable to AmerisourceBergen Corporation (b)
 
$
861,853

 
$
287,455

 
$
275,809

 
$
233,288

 
$
1,658,405

Earnings per share operations:
 
 

 
 

 
 

 
 

 
 

Basic
 
$
3.95

 
$
1.31

 
$
1.26

 
$
1.08

 
$
7.61

Diluted
 
$
3.90

 
$
1.29

 
$
1.25

 
$
1.07

 
$
7.53

__________________________________________________________
XML 51 R56.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Other Intangible Assets - Additional Information (Details) - USD ($)
 3 Months Ended 12 Months Ended
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]              
Goodwill impairment $ 59,684,000 $ 0 $ 0 $ 0 $ 0 $ 59,684,000 $ 0
Amortization expense, fiscal year maturity              
Amortization expense         167,442,000 $ 181,156,000 $ 160,503,000
2020         134,100,000    
2021         130,200,000    
2022         128,500,000    
2023         127,200,000    
2024         126,200,000    
Thereafter         $ 963,300,000    
XML 52 R52.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes - Significant Components of Deferred Tax Liabilities (Assets) (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Sep. 30, 2018
Components of Deferred Tax Assets and Liabilities [Abstract]    
Inventories $ 1,293,075 $ 1,189,801
Property and equipment 143,851 133,417
Goodwill and other intangible assets 709,015 853,747
Other 1,892 747
Gross deferred tax liabilities 2,147,833 2,177,712
Net operating loss and tax credit carryforwards (318,868) (421,808)
Allowance for doubtful accounts (22,544) (20,126)
Accrued expenses (33,312) (17,363)
Employee and retiree benefits (12,420) (10,210)
Share-based compensation (39,961) (28,888)
Other (60,215) (49,892)
Gross deferred tax assets (487,320) (548,287)
Valuation allowance for deferred tax assets 199,682 199,985
Deferred tax assets, net of valuation allowance (287,638) (348,302)
Net deferred tax liabilities $ 1,860,195 $ 1,829,410
XML 53 R71.htm IDEA: XBRL DOCUMENT v3.19.3
Lease Commitments - Minimum Lease Payments (Details)
$ in Thousands
Sep. 30, 2019
USD ($)
Operating Leases  
2020 $ 94,958
2021 84,002
2022 72,224
2023 63,507
2024 56,377
Thereafter 177,267
Total minimum lease payments 548,335
Financing Obligations  
2020 22,468
2021 29,790
2022 36,914
2023 35,950
2024 35,276
Thereafter 270,410
Total minimum lease payments 430,808
Operating and Financing Obligations  
2020 117,426
2021 113,792
2022 109,138
2023 99,457
2024 91,653
Thereafter 447,677
Total minimum lease payments $ 979,143
XML 54 R81.htm IDEA: XBRL DOCUMENT v3.19.3
Schedule II - Valuation and Qualifying Accounts (Details) - Allowances for returns and doubtful accounts [Member] - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Period $ 1,049,901 $ 1,068,251 $ 926,034
Charged to Costs and Expenses 3,720,642 3,397,562 3,157,960
Deductions (3,546,656) (3,415,912) (3,015,743)
Balance at End of Period $ 1,223,887 $ 1,049,901 $ 1,068,251
XML 55 R75.htm IDEA: XBRL DOCUMENT v3.19.3
Litigation Settlements (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Litigation Settlement [Abstract]                  
Gain (loss) related to litigation settlement $ 3.1 $ 3.5 $ 52.0 $ 87.3 $ 35.6 $ 0.3 $ 145.9 $ 35.9 $ 1.4
XML 56 R79.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value of Financial Instruments (Details) - USD ($)
$ in Millions
Sep. 30, 2019
Sep. 30, 2018
Carrying amount [Member]    
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]    
Long-term debt $ 4,033.9 $ 4,158.5
Fair value [Member] | Level 1 [Member] | Money market accounts [Member]    
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]    
Cash and cash equivalents 1,552.0 1,050.0
Fair value [Member] | Level 2 [Member]    
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]    
Long-term debt $ 4,158.4 $ 4,000.1
XML 57 R66.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation - Weighted Average Assumptions (Details)
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Share-based Payment Arrangement [Abstract]      
Risk-free interest rate 2.91% 1.89% 1.26%
Expected dividend yield 1.79% 1.96% 1.80%
Volatility of common stock 27.67% 26.54% 26.78%
Expected life of the options 3 years 9 months 7 days 3 years 9 months 3 days 3 years 8 months 26 days
XML 59 R62.htm IDEA: XBRL DOCUMENT v3.19.3
Stockholders' Equity and Weighted Average Common Shares Outstanding - Components of Diluted Weighted Average Shares Outstanding (Details) - shares
shares in Thousands
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Equity [Abstract]      
Weighted average common shares outstanding — basic (shares) 210,165 217,872 218,375
Effect of dilutive securities — stock options, restricted stock, restricted stock units, and the unsettled ASR transaction (shares) 1,675 2,464 3,227
Weighted average common shares outstanding — diluted (shares) 211,840 220,336 221,602
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes - Domestic and Foreign Income From Continuing Operations Before Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Income Tax Disclosure [Abstract]      
Domestic $ 336,150 $ 704,935 $ 394,721
Foreign 630,956 472,488 523,166
Income before income taxes $ 967,106 $ 1,177,423 $ 917,887
XML 61 R41.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies - Merchandise Inventories (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Accounting Policies [Abstract]                  
Percentage of inventories, cost determined using LIFO 75.00%       75.00%   75.00% 75.00%  
Excess cost of inventories over LIFO, if used FIFO $ 1,511,800       $ 1,534,400   $ 1,511,800 $ 1,534,400  
LIFO charges (credit) $ 57,200 $ (9,900) $ (66,800) $ (3,000) $ 83,500 $ (16,100) $ (22,544) $ 67,324 $ (157,782)
XML 62 R45.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisitions and Investments - NEVSCO (Details) - USD ($)
$ in Thousands
 1 Months Ended
Dec. 31, 2017
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Business Acquisition [Line Items]        
Goodwill   $ 6,705,507 $ 6,664,272 $ 6,044,281
Northeast Veterinary Supply Company NEVSCO [Member]        
Business Acquisition [Line Items]        
Cash paid to acquire business, including purchase price adjustments $ 70,000      
Goodwill 30,400      
Estimated fair value of accounts receivable 8,500      
Estimated fair value of inventory 6,700      
Estimated fair value of accounts payable and accrued expenses 2,900      
Estimated fair value of the intangible assets acquired, finite-lived $ 29,800      
Customer relationships [Member] | Northeast Veterinary Supply Company NEVSCO [Member]        
Business Acquisition [Line Items]        
Estimated useful life (in years) 15 years      
XML 63 R24.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value of Financial Instruments
 12 Months Ended
Sep. 30, 2019
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments Fair Value of Financial Instruments
The recorded amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable as of September 30, 2019 and 2018 approximate fair value based upon the relatively short-term nature of these financial instruments. Within Cash and Cash Equivalents, the Company had $1,552.0 million and $1,050.0 million of investments in money market accounts as of September 30, 2019 and 2018. The fair value of the money market accounts was determined based upon unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs.
The recorded amount of long-term debt (see Note 6) and the corresponding fair value as of September 30, 2019 were $4,033.9 million and $4,158.4 million, respectively. The recorded amount of long-term debt and the corresponding fair value as of September 30, 2018 were $4,158.5 million and $4,000.1 million, respectively. The fair value of long-term debt was determined based upon inputs other than quoted prices, otherwise known as Level 2 inputs.
XML 64 R20.htm IDEA: XBRL DOCUMENT v3.19.3
Employee Severance, Litigation, and Other
 12 Months Ended
Sep. 30, 2019
Restructuring and Related Activities [Abstract]  
Employee Severance, Litigation, and Other Employee Severance, Litigation, and Other
The following illustrates the charges incurred by the Company relating to Employee Severance, Litigation, and Other for the periods indicated:
 
 
Fiscal Year Ended September 30,
 (in thousands)
 
2019
 
2018
 
2017
Employee severance
 
$
34,147

 
$
36,694

 
$
7,767

Litigation and opioid-related costs
 
185,145

 
61,527

 
917,573

Acquisition-related deal and integration costs
 
43,184

 
33,912

 
16,990

Business transformation efforts
 
55,437

 
32,963

 
3,700

Other restructuring initiatives
 
12,561

 
18,424

 
13,297

Total employee severance, litigation, and other
 
$
330,474

 
$
183,520

 
$
959,327


Employee severance in the fiscal year ended September 30, 2019 included costs primarily related to PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D. Smith, and restructuring activities related to our consulting business. Employee severance in the fiscal year ended September 30, 2018 included costs primarily related to position eliminations resulting from the Company's business transformation efforts and restructuring activities related to our consulting business. Employee severance in the fiscal year ended September 30, 2017 included costs primarily related to position eliminations as the Company began to reorganize to further align the organization to its customers' needs.
Litigation and opioid-related costs in the fiscal year ended September 30, 2019 consisted of $116.7 million of legal settlements and accruals and $68.5 million of legal fees in connection with opioid lawsuits and investigations. Litigation and opioid-related costs in the fiscal year ended September 30, 2018 primarily related to opioid lawsuits, investigations, and related initiatives. Litigation and opioid-related costs in the fiscal year ended September 30, 2017 primarily related to litigation settlements and accruals.
Acquisition-related deal and integration costs in the fiscal year ended September 30, 2019 are primarily related to the integration of H.D. Smith. Integration costs primarily include costs to transition servicing legacy H.D. Smith customers to existing company distribution facilities and operating systems. Acquisition-related deal and integration costs in the fiscal year ended September 30, 2018 were primarily related to the acquisition of H.D. Smith.
Business transformation efforts in the fiscal years ended September 30, 2019 and 2018 were primarily related to costs associated with reorganizing the Company to further align the organization to its customers' needs. The majority of these costs were related to services provided by third-party consultants.
XML 65 R8.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED STATEMENTS OF CASH FLOW - USD ($)
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
OPERATING ACTIVITIES      
Net income $ 854,135,000 $ 1,615,892,000 $ 364,484,000
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation, including amounts charged to cost of goods sold 321,102,000 318,483,000 262,420,000
Amortization, including amounts charged to interest expense 176,410,000 191,626,000 169,911,000
Provision for doubtful accounts 25,196,000 16,660,000 8,934,000
Provision (benefit) for deferred income taxes 28,537,000 (795,524,000) 319,069,000
Share-based compensation expense 58,874,000 62,316,000 62,206,000
LIFO (credit) expense (22,544,000) 67,324,000 (157,782,000)
Impairment of long-lived assets 570,000,000 0 0
Gain on sale of an equity investment (13,692,000) 0 0
Goodwill impairment 0 59,684,000 0
Impairment of non-customer note receivable 0 30,000,000 0
Loss on consolidation of equity investments 0 42,328,000 0
Loss on early retirement of debt 0 23,766,000 0
Other (23,193,000) (19,078,000) 7,744,000
Changes in operating assets and liabilities, excluding the effects of acquisitions and divestitures:      
Accounts receivable (1,241,890,000) (657,770,000) (1,277,896,000)
Inventories (167,990,000) (4,923,000) (431,454,000)
Prepaid expenses and other assets (6,733,000) (57,211,000) 33,646,000
Accounts payable 1,561,048,000 859,036,000 1,473,389,000
Income taxes payable (13,353,000) 209,899,000 27,192,000
Accrued expenses and other liabilities 238,116,000 (551,120,000) 642,275,000
NET CASH PROVIDED BY OPERATING ACTIVITIES 2,344,023,000 1,411,388,000 1,504,138,000
INVESTING ACTIVITIES      
Capital expenditures (310,222,000) (336,411,000) (466,397,000)
Cost of acquired companies, net of cash acquired (63,951,000) (785,299,000) (61,648,000)
Cost of equity investments 0 0 (11,347,000)
Proceeds from sale of business 0 0 12,094,000
Proceeds from sales of investment securities available-for-sale 0 0 74,778,000
Purchases of investment securities available-for-sale 0 0 (48,635,000)
Other (1,659,000) 10,596,000 3,114,000
NET CASH USED IN INVESTING ACTIVITIES (375,832,000) (1,111,114,000) (498,041,000)
FINANCING ACTIVITIES      
Senior notes and other loan borrowings 506,948,000 1,314,430,000 0
Senior notes and other loan repayments (510,863,000) (681,001,000) (750,000,000)
Borrowings under revolving and securitization credit facilities 640,126,000 25,129,704,000 9,336,400,000
Repayments under revolving and securitization credit facilities (769,284,000) (25,127,438,000) (9,335,953,000)
Payment of premium on early retirement of debt 0 (22,348,000) 0
Purchases of common stock (674,031,000) (639,235,000) (329,929,000)
Exercises of stock options 76,234,000 138,456,000 102,923,000
Cash dividends on common stock (338,974,000) (333,041,000) (320,270,000)
Tax withholdings related to restricted share vesting (5,987,000) (8,246,000) (9,411,000)
Other (10,682,000) (14,154,000) (6,574,000)
NET CASH USED IN FINANCING ACTIVITIES (1,086,513,000) (242,873,000) (1,312,814,000)
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 881,678,000 57,401,000 (306,717,000)
Cash and cash equivalents at beginning of year 2,492,516,000 2,435,115,000 2,741,832,000
CASH AND CASH EQUIVALENTS AT END OF YEAR $ 3,374,194,000 $ 2,492,516,000 $ 2,435,115,000
XML 66 R28.htm IDEA: XBRL DOCUMENT v3.19.3
Variable Interest Entity (Tables)
 12 Months Ended
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Variable Interest Entities
The following assets and liabilities of Profarma are included in the Company's Consolidated Balance Sheet:
(in thousands)
 
September 30,
2019
 
September 30,
2018
Cash and cash equivalents
 
$
9,431

 
$
26,801

Accounts receivables, net
 
154,491

 
144,646

Inventories
 
185,602

 
168,931

Prepaid expenses and other
 
64,119

 
61,924

Property and equipment, net
 
30,961

 
32,667

Goodwill
 
82,309

 
82,309

Other intangible assets
 
74,429

 
80,974

Other long-term assets
 
9,169

 
8,912

Total assets
 
$
610,511

 
$
607,164

 
 
 
 
 
Accounts payable
 
$
165,053

 
$
150,102

Accrued expenses and other
 
49,191

 
37,195

Short-term debt
 
106,439

 
115,461

Long-term debt
 
60,973

 
39,704

Deferred income taxes
 
42,371

 
46,137

Other long-term liabilities
 
5,303

 
31,988

Total liabilities
 
$
429,330

 
$
420,587
EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Income Statement [Abstract]      
Revenue $ 179,589,121,000 $ 167,939,635,000 $ 153,143,826,000
Cost of goods sold 174,450,809,000 163,327,318,000 148,597,824,000
Gross profit 5,138,312,000 4,612,317,000 4,546,002,000
Operating expenses:      
Distribution, selling, and administrative 2,663,508,000 2,460,301,000 2,128,730,000
Depreciation 294,965,000 283,971,000 237,100,000
Amortization 167,442,000 181,156,000 160,503,000
Employee severance, litigation, and other 330,474,000 183,520,000 959,327,000
Goodwill impairment 0 59,684,000 0
Impairment of long-lived assets (Note 1) 570,000,000 0 0
Operating income 1,111,923,000 1,443,685,000 1,060,342,000
Other (income) loss (12,952,000) 25,469,000 (2,730,000)
Interest expense, net 157,769,000 174,699,000 145,185,000
Loss on consolidation of equity investments 0 42,328,000 0
Loss on early retirement of debt 0 23,766,000 0
Income before income taxes 967,106,000 1,177,423,000 917,887,000
Income tax expense (benefit) 112,971,000 (438,469,000) 553,403,000
Net income 854,135,000 1,615,892,000 364,484,000
Net loss attributable to noncontrolling interest 1,230,000 42,513,000 0
Net income attributable to AmerisourceBergen Corporation $ 855,365,000 $ 1,658,405,000 $ 364,484,000
Earnings per share:      
Basic (usd per share) $ 4.07 $ 7.61 $ 1.67
Diluted (usd per share) $ 4.04 $ 7.53 $ 1.64
Weighted average common shares outstanding:      
Basic (shares) 210,165 217,872 218,375
Diluted (shares) 211,840 220,336 221,602

XML 69 R39.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details)
 12 Months Ended
Sep. 30, 2019
Walgreens Boots Alliance, Inc. [Member]  
Concentration Risk [Line Items]  
Major customer, percentage of revenue 34.00%
Major customer, percentage of accounts receivable 49.00%
Express Scripts, Inc. [Member]  
Concentration Risk [Line Items]  
Major customer, percentage of revenue 13.00%
Major customer, percentage of accounts receivable 8.00%
XML 70 R31.htm IDEA: XBRL DOCUMENT v3.19.3
Debt (Tables)
 12 Months Ended
Sep. 30, 2019
Debt Disclosure [Abstract]  
Debt Instruments
Debt consisted of the following:
 
 
September 30,
(in thousands)
 
2019
 
2018
Revolving credit note
 
$
—

 
$
—

Term loans due 2020
 
399,778

 
398,665

Overdraft facility due 2021 (£30,000)
 
32,573

 
13,269

Receivables securitization facility due 2022
 
350,000

 
500,000

Multi-currency revolving credit facility due 2024
 
—

 
—

$500,000, 3.50% senior notes due 2021
 
498,908

 
498,392

$500,000, 3.40% senior notes due 2024
 
497,744

 
497,255

$500,000, 3.25% senior notes due 2025
 
496,311

 
495,632

$750,000, 3.45% senior notes due 2027
 
743,099

 
742,258

$500,000, 4.25% senior notes due 2045
 
494,514

 
494,298

$500,000, 4.30% senior notes due 2047
 
492,488

 
492,222

Capital lease obligations
 
—

 
745

Nonrecourse debt
 
167,477

 
177,453

Total debt
 
4,172,892

 
4,310,189

Less AmerisourceBergen Corporation current portion
 
32,573

 
13,976

Less nonrecourse current portion
 
106,439

 
137,681

Total, net of current portion
 
$
4,033,880

 
$
4,158,532
XML 71 R35.htm IDEA: XBRL DOCUMENT v3.19.3
Employee Severance, Litigation, and Other (Tables)
 12 Months Ended
Sep. 30, 2019
Restructuring and Related Activities [Abstract]  
Employee severance, litigation, and other charges
The following illustrates the charges incurred by the Company relating to Employee Severance, Litigation, and Other for the periods indicated:
 
 
Fiscal Year Ended September 30,
 (in thousands)
 
2019
 
2018
 
2017
Employee severance
 
$
34,147

 
$
36,694

 
$
7,767

Litigation and opioid-related costs
 
185,145

 
61,527

 
917,573

Acquisition-related deal and integration costs
 
43,184

 
33,912

 
16,990

Business transformation efforts
 
55,437

 
32,963

 
3,700

Other restructuring initiatives
 
12,561

 
18,424

 
13,297

Total employee severance, litigation, and other
 
$
330,474

 
$
183,520

 
$
959,327
XML 72 R16.htm IDEA: XBRL DOCUMENT v3.19.3
Related Party Transactions
 12 Months Ended
Sep. 30, 2019
Related Party Transactions [Abstract]  
Related Party Transactions Related Party Transactions
WBA owns more than 10% of the Company's outstanding common stock and is, therefore, considered a related party. The Company operates under various agreements and arrangements with WBA, including a pharmaceutical distribution agreement pursuant to which the Company distributes pharmaceutical products to WBA and an agreement that provides the Company the ability to access favorable economic pricing and generic products through a generic purchasing services arrangement with Walgreens Boots Alliance Development GmbH. Both of these agreements expire in 2026.
 
Revenue from the various agreements and arrangements with WBA was $60.3 billion, $54.7 billion, and $45.4 billion in the fiscal years ended September 30, 2019, 2018, and 2017, respectively. The Company's receivable from WBA, net of incentives, was $6.1 billion and $5.6 billion as of September 30, 2019 and 2018, respectively.
XML 73 R12.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes
 12 Months Ended
Sep. 30, 2019
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The following table summarizes the Company's income before income taxes for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Domestic
 
$
336,150

 
$
704,935

 
$
394,721

Foreign
 
630,956

 
472,488

 
523,166

Total
 
$
967,106

 
$
1,177,423

 
$
917,887


The components of the Company's consolidated income tax expense (benefit) are summarized in the following table for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Current provision:
 
 

 
 

 
 

Federal
 
$
(12,801
)
 
$
247,755

 
$
141,071

State and local
 
15,246

 
39,328

 
35,950

Foreign
 
81,989

 
69,972

 
57,313

Total current provision
 
84,434

 
357,055

 
234,334

Deferred provision (benefit):
 
 

 
 

 
 

Federal
 
61,819

 
(828,023
)
 
265,074

State and local
 
(31,086
)
 
33,887

 
54,995

Foreign
 
(2,196
)
 
(1,388
)
 
(1,000
)
Total deferred provision (benefit)
 
28,537

 
(795,524
)
 
319,069

Provision (benefit) for income taxes
 
$
112,971

 
$
(438,469
)
 
$
553,403


A reconciliation of the statutory U.S. federal income tax rate to the Company's consolidated effective income tax rate is as follows for the periods indicated:
 
Fiscal Year Ended September 30,
 
2019
 
2018
 
2017
Statutory U.S. federal income tax rate
21.0%
 
24.5%
 
35.0%
State and local income tax rate, net of federal tax benefit
2.4
 
(0.1)
 
5.4
Foreign tax rate differential
(6.7)
 
(6.2)
 
(14.6)
Valuation allowance
—
 
(1.4)
 
2.2
Excess tax benefits related to share-based compensation
(0.8)
 
(1.8)
 
(3.8)
Litigation settlements and accruals (see Note 14)
0.1
 
(6.3)
 
34.3
Goodwill impairment (see Note 5)
—
 
1.7
 
—
Tax reform
(3.6)
 
(52.0)
 
—
Capital gain on distribution
—
 
3.6
 
—
Other
(0.7)
 
0.8
 
1.8
Effective income tax rate
11.7%
 
(37.2)%
 
60.3%

U.S. Tax Reform: Tax Cuts and Jobs Act
On December 22, 2017, the U.S. Tax Cuts and Jobs Act (the "2017 Tax Act") was signed into law. The 2017 Tax Act included a broad range of tax reform provisions affecting businesses, including lower corporate tax rates, changes in business deductions, and new international tax provisions. In response to the 2017 Tax Act, the U.S. Securities and Exchange Commission staff issued guidance regarding the accounting for income taxes associated with the 2017 Tax Act to allow companies to record provisional amounts during a one-year measurement period. For the fiscal year ended September 30, 2018, the Company recognized income tax benefits of $612.6 million on the Company's Consolidated Statements of Operations related to effects of the 2017 Tax Act, which consisted of a deferred income tax benefit of $897.6 million as a result of applying a lower U.S. federal income tax rate to the Company's net deferred tax liabilities as of December 31, 2017 and a one-time transition tax on historical foreign earnings and profits. In the fiscal year ended September 30, 2018, the Company initially recorded a current U.S. income tax expense of $285.0 million on historical foreign earnings and profits through December 31, 2017. The Company completed the accounting for the effects of the 2017 Tax Act in the fiscal quarter ended December 31, 2018 and recognized an income tax benefit of $37.0 million related to a decrease in its foreign earnings and profits through December 31, 2017 (the "transition tax"). The Company expects to pay $182.6 million related to the transition tax, which is net of overpayments and tax credits, over a six-year period commencing in January 2021. There were no adjustments recorded to deferred income taxes related to the 2017 Tax Act during the one-year measurement period.
Prior to the 2017 Tax Act, the Company intended to indefinitely reinvest its foreign cash in foreign investments and foreign operations. After further assessment of the impact of the 2017 Tax Act, the Company reevaluated its position and determined that it was no longer reinvested with respect to foreign subsidiaries whose undistributed earnings are able to be repatriated with minimal to no additional tax impact. Cumulative undistributed earnings of international subsidiaries were $2.4 billion as of
September 30, 2019, $1.6 billion of which is considered permanently reinvested. It is not practicable to estimate the taxes that would be due if such earnings were to be repatriated in the future.
Deferred income taxes reflect the future tax consequences of differences between the tax bases of assets and liabilities and their financial reporting amounts. Significant components of the Company's deferred tax liabilities (assets) are as follows:
 
 
September 30,
(in thousands)
 
2019
 
2018
Inventories
 
$
1,293,075

 
$
1,189,801

Property and equipment
 
143,851

 
133,417

Goodwill and other intangible assets
 
709,015

 
853,747

Other
 
1,892

 
747

Gross deferred tax liabilities
 
2,147,833

 
2,177,712

 
 
 
 
 
Net operating loss and tax credit carryforwards
 
(318,868
)
 
(421,808
)
Allowance for doubtful accounts
 
(22,544
)
 
(20,126
)
Accrued expenses
 
(33,312
)
 
(17,363
)
Employee and retiree benefits
 
(12,420
)
 
(10,210
)
Share-based compensation
 
(39,961
)
 
(28,888
)
Other
 
(60,215
)
 
(49,892
)
Gross deferred tax assets
 
(487,320
)
 
(548,287
)
Valuation allowance for deferred tax assets
 
199,682

 
199,985

Deferred tax assets, net of valuation allowance
 
(287,638
)
 
(348,302
)
Net deferred tax liabilities
 
$
1,860,195

 
$
1,829,410


The following tax net operating loss and credit carryforward information is presented as of September 30, 2019. The Company had $12.4 million of potential tax benefits from federal net operating loss carryforwards, which expire in 1 to 18 years, $171.0 million of potential tax benefits from state net operating loss carryforwards expiring in 1 to 20 years, and $58.7 million of potential tax benefits from foreign net operating loss carryforwards, which have varying expiration dates. The Company had $6.7 million of state tax credit carryforwards, $84.1 million in federal alternative minimum tax credit carryforwards, and $2.1 million in foreign alternative minimum tax credit carryforwards.
The Company assesses the available positive and negative evidence to determine whether deferred tax assets are more likely than not to be realized. As a result of this assessment, valuation allowances have been recorded on certain deferred tax assets. For the fiscal year ended September 30, 2019, the Company decreased the valuation allowance on deferred tax assets by $0.3 million primarily due to a legislative change which will enable the Company to utilize select net operating losses prospectively. This decrease was offset in part by the additional valuation allowances on certain state and foreign net operating loss carryforwards. In the fiscal year ended September 30, 2018, the Company decreased the valuation allowance on deferred tax assets by $11.1 million primarily due to the utilization of capital loss and foreign tax credit carryforwards for which a valuation allowance had been recorded.
In the fiscal year ended September 30, 2019, 2018, and 2017 tax benefits of $7.9 million, $22.7 million and $36.7 million, respectively, related to the exercise of employee stock options and lapses of restricted stock units were recorded in Income Tax Expense (Benefit) in the Company's Consolidated Statements of Operations. The tax benefits recognized in the fiscal years ended September 30, 2019, 2018, and 2017 are not necessarily indicative of amounts that may arise in future periods.
Income tax payments, net of refunds, were $117.7 million, $104.0 million, and $105.0 million in the fiscal years ended September 30, 2019, 2018, and 2017, respectively.
The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or foreign income tax examinations by tax authorities for years before 2015.
As of September 30, 2019 and 2018, the Company had unrecognized tax benefits, defined as the aggregate tax effect of differences between tax return positions and the benefits recognized in the Company's financial statements, of $124.2 million and $112.9 million, respectively ($95.0 million and $89.4 million, net of federal tax benefit, respectively). If recognized in the fiscal years ended September 30, 2019 and 2018, $76.8 million and $71.1 million, respectively, of these benefits would have reduced income tax expense and the effective tax rate. As of September 30, 2019 and 2018, included in the unrecognized tax benefits are
$18.6 million and $14.8 million of interest and penalties, respectively, which the Company records in Income Tax Expense (Benefit) in the Company's Consolidated Statements of Operations.
A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, for the periods indicated is as follows:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Unrecognized tax benefits at beginning of period
 
$
98,124

 
$
323,869

 
$
75,766

Additions of tax positions of the current year
 
18,819

 
2,804

 
252,866

Additions to tax positions of the prior years
 
751

 
558

 
1,049

Reductions of tax positions of the prior years
 
(10,317
)
 
(224,878
)
 
(668
)
Settlements with taxing authorities
 
—

 
(1,847
)
 
(3,285
)
Expiration of statutes of limitations
 
(1,720
)
 
(2,382
)
 
(1,859
)
Unrecognized tax benefits at end of period
 
$
105,657

 
$
98,124

 
$
323,869


Included in the additions of unrecognized tax positions in the fiscal year ended September 30, 2017 is approximately $235.1 million for an uncertain tax position related to the $625.0 million civil litigation reserve recognized during the fiscal year (see Note 13). In the fiscal year ended September 30, 2017, this reserve was considered to be non-deductible. In September 2018, the Company made a payment of $625.0 million, plus interest, to resolve this litigation and it was determined that a portion of the settlement was deductible. Accordingly, the Company reduced its uncertain tax position by $10.3 million and $224.9 million in the fiscal years ended September 30, 2019 and 2018, respectively. During the next 12 months, it is reasonably possible that state tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately $12.4 million.
XML 74 R73.htm IDEA: XBRL DOCUMENT v3.19.3
Employee Severance, Litigation, and Other (Details) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Restructuring Cost and Reserve [Line Items]      
Employee severance $ 34,147 $ 36,694 $ 7,767
Litigation and opioid-related costs 185,145 61,527 917,573
Acquisition-related deal and integration costs 43,184 33,912 16,990
Business transformation efforts 55,437 32,963 3,700
Other restructuring initiatives 12,561 18,424 13,297
Total employee severance, litigation, and other 330,474 183,520 $ 959,327
Opioid Lawsuits and Investigations [Member]      
Restructuring Cost and Reserve [Line Items]      
Litigation settlement, accrued reserve $ 116,700    
Legal fees   $ 68,500  
XML 75 R77.htm IDEA: XBRL DOCUMENT v3.19.3
Business Segment Information - Reconciliation of Segment Operating Income to Income From Continuing Operations (Details) - USD ($)
 3 Months Ended 12 Months Ended
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Segment Reporting Information [Line Items]                      
Operating income $ 179,841,000 $ 406,694,000 $ 47,565,000 $ 477,823,000 $ 154,097,000 $ 389,195,000 $ 481,420,000 $ 418,973,000 $ 1,111,923,000 $ 1,443,685,000 $ 1,060,342,000
Gain from antitrust litigation settlements 3,100,000 3,500,000 52,000,000.0 87,300,000   35,600,000 300,000   145,900,000 35,900,000 1,400,000
LIFO credit (expense) (57,200,000) 9,900,000 66,800,000 3,000,000.0 (83,500,000) 16,100,000     22,544,000 (67,324,000) 157,782,000
PharMEDium remediation costs (6,700,000) (11,700,000) (12,300,000) (17,900,000) (26,600,000) (12,000,000.0) (22,500,000)        
Employee severance, litigation, and other                 (330,474,000) (183,520,000) (959,327,000)
Goodwill impairment         $ (59,684,000) $ 0 0 0 0 (59,684,000) 0
Impairment of long-lived assets $ 0 $ 0 $ (570,000,000) $ 0         (570,000,000) 0 0
Other (income) loss                 (12,952,000) 25,469,000 (2,730,000)
Interest expense, net                 157,769,000 174,699,000 145,185,000
Loss on consolidation of equity investments             $ 42,300,000   0 42,328,000 0
Loss on early retirement of debt               $ 23,800,000 0 23,766,000 0
Income before income taxes                 967,106,000 1,177,423,000 917,887,000
Operating segments [Member]                      
Segment Reporting Information [Line Items]                      
Operating income                 2,051,252,000 1,981,230,000 2,016,870,000
Segment reconciling items [Member]                      
Segment Reporting Information [Line Items]                      
Gain from antitrust litigation settlements                 145,872,000 35,938,000 1,395,000
LIFO credit (expense)                 22,544,000 (67,324,000) 157,782,000
PharMEDium remediation costs                 (69,423,000) (66,204,000) 0
New York State Opioid Stewardship Act                 22,000,000 (22,000,000) 0
Acquisition-related intangibles amortization                 (159,848,000) (174,751,000) (156,378,000)
Employee severance, litigation, and other                 (330,474,000) (183,520,000) (959,327,000)
Goodwill impairment                 0 (59,684,000) 0
Impairment of long-lived assets                 $ (570,000,000) $ 0 $ 0
XML 76 R54.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes - Additional Information (Details) - USD ($)
 3 Months Ended 12 Months Ended
Sep. 30, 2019
Sep. 28, 2018
Sep. 30, 2019
Dec. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2016
Operating Loss Carryforwards [Line Items]                    
Tax Cuts and Jobs Act, recognized income tax benefits       $ 37,000,000.0 $ 25,000,000.0 $ 587,600,000   $ 612,600,000    
Tax Cuts and Jobs Act, deferred income tax benefit as result of applying a lower U.S. federal income tax rate               897,600,000    
Tax Cuts and Jobs Act, current income tax expense on historical foreign earnings and profits               285,000,000.0    
Income tax benefit       $ 37,000,000.0     $ (112,971,000) 438,469,000 $ (553,403,000)  
Tax Cuts and Jobs Act, decrease in provisional transition tax     $ 182,600,000              
Adjustments recorded to deferred income taxes related to 2017 Tax Act             0      
Undistributed earnings of international subsidiaries $ 2,400,000,000   2,400,000,000       2,400,000,000      
Permanently reinvested cumulative undistributed earnings 1,600,000,000   1,600,000,000       1,600,000,000      
Valuation allowance - increase (decrease)             (300,000) (11,100,000)    
Excess tax benefit from the exercise of stock options and lapses of restricted stock units             7,900,000 22,700,000 36,700,000  
Income tax payments, net of refunds             117,700,000 104,000,000.0 105,000,000.0  
Unrecognized tax benefits, including interest and penalties 124,200,000   124,200,000   112,900,000   124,200,000 112,900,000    
Unrecognized tax benefits, including interest and penalties, net of federal benefit 95,000,000.0   95,000,000.0   89,400,000   95,000,000.0 89,400,000    
Unrecognized tax benefits that would impact effective tax rate 76,800,000   76,800,000   71,100,000   76,800,000 71,100,000    
Unrecognized tax benefits, interest and penalties 18,600,000   18,600,000   14,800,000   18,600,000 14,800,000    
Litigation settlement, unrecognized tax benefit 105,657,000   105,657,000   $ 98,124,000   105,657,000 98,124,000 323,869,000 $ 75,766,000
Reductions of tax positions of the prior years             (10,317,000) $ (224,878,000) (668,000)  
Reduction of unrecognized tax benefits reasonably possible 12,400,000   12,400,000       12,400,000      
Federal [Member]                    
Operating Loss Carryforwards [Line Items]                    
Potential tax benefits from net operating loss carryforwards 12,400,000   12,400,000       12,400,000      
Federal [Member] | Alternative minimum tax credit carryforwards [Member]                    
Operating Loss Carryforwards [Line Items]                    
Tax credit carryforwards $ 84,100,000   84,100,000       84,100,000      
Federal [Member] | Minimum [Member]                    
Operating Loss Carryforwards [Line Items]                    
Net operating loss carryforwards, term (in years) 1 year                  
Federal [Member] | Maximum [Member]                    
Operating Loss Carryforwards [Line Items]                    
Net operating loss carryforwards, term (in years) 18 years                  
State [Member]                    
Operating Loss Carryforwards [Line Items]                    
Potential tax benefits from net operating loss carryforwards $ 171,000,000.0   171,000,000.0       171,000,000.0      
Tax credit carryforwards $ 6,700,000   6,700,000       6,700,000      
State [Member] | Minimum [Member]                    
Operating Loss Carryforwards [Line Items]                    
Net operating loss carryforwards, term (in years) 1 year                  
State [Member] | Maximum [Member]                    
Operating Loss Carryforwards [Line Items]                    
Net operating loss carryforwards, term (in years) 20 years                  
Foreign [Member]                    
Operating Loss Carryforwards [Line Items]                    
Potential tax benefits from net operating loss carryforwards $ 58,700,000   58,700,000       58,700,000      
Foreign [Member] | Alternative minimum tax credit carryforwards [Member]                    
Operating Loss Carryforwards [Line Items]                    
Tax credit carryforwards $ 2,100,000   $ 2,100,000       $ 2,100,000      
USAO-EDNY Matter [Member]                    
Operating Loss Carryforwards [Line Items]                    
Litigation settlement, unrecognized tax benefit                 235,100,000  
USAO - EDNY Civil Claims [Member]                    
Operating Loss Carryforwards [Line Items]                    
Litigation settlement, accrued reserve                 $ 625,000,000.0  
Litigation settlement, payment   $ 625,000,000.0                
XML 77 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 R50.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes - Income Tax Provision (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Current provision:        
Federal   $ (12,801) $ 247,755 $ 141,071
State and local   15,246 39,328 35,950
Foreign   81,989 69,972 57,313
Total current provision   84,434 357,055 234,334
Deferred provision (benefit):        
Federal   61,819 (828,023) 265,074
State and local   (31,086) 33,887 54,995
Foreign   (2,196) (1,388) (1,000)
Total deferred provision (benefit)   28,537 (795,524) 319,069
Provision (benefit) for income taxes $ (37,000) $ 112,971 $ (438,469) $ 553,403
XML 79 R58.htm IDEA: XBRL DOCUMENT v3.19.3
Debt - Debt Instruments (Details)
Sep. 30, 2019
USD ($)
Sep. 30, 2019
GBP (£)
Oct. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Debt Instrument [Line Items]          
Debt     $ 400,000,000    
Capital lease obligations $ 0     $ 745,000  
Total debt 4,172,892,000     4,310,189,000  
Total, net of current portion 4,033,880,000     4,158,532,000  
Revolving credit note [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity 75,000,000        
Debt 0     0  
Term loans due in 2020 [Member]          
Debt Instrument [Line Items]          
Debt 399,778,000     398,665,000  
Overdraft facility due in 2021 [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity | £   £ 30,000,000      
Debt 32,573,000     13,269,000  
Receivables securitization facility due 2022 [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity 1,450,000,000        
Debt 350,000,000     500,000,000  
Multi-currency revolving credit facility due 2021 [Member]          
Debt Instrument [Line Items]          
Maximum borrowing capacity 1,400,000,000        
Debt 0     0  
$500,000, 3.50% senior notes due 2021 [Member]          
Debt Instrument [Line Items]          
Principal amount $ 500,000,000        
Interest rate 3.50% 3.50%      
Debt $ 498,908,000     498,392,000  
$500,000, 3.40% senior notes due 2024 [Member]          
Debt Instrument [Line Items]          
Principal amount $ 500,000,000        
Interest rate 3.40% 3.40%      
Debt $ 497,744,000     497,255,000  
$500,000, 3.25% senior notes due 2025 [Member]          
Debt Instrument [Line Items]          
Principal amount $ 500,000,000        
Interest rate 3.25% 3.25%      
Debt $ 496,311,000     495,632,000  
$750,000, 3.45% senior notes due 2027 [Member]          
Debt Instrument [Line Items]          
Principal amount $ 750,000,000       $ 750,000,000
Interest rate 3.45% 3.45%     3.45%
Debt $ 743,099,000     742,258,000  
$500,000, 4.25% senior notes due 2045 [Member]          
Debt Instrument [Line Items]          
Principal amount $ 500,000,000        
Interest rate 4.25% 4.25%      
Debt $ 494,514,000     494,298,000  
$500,000, 4.3% senior notes due 2047 [Member]          
Debt Instrument [Line Items]          
Principal amount $ 500,000,000       $ 500,000,000
Interest rate 4.30% 4.30%     4.30%
Debt $ 492,488,000     492,222,000  
Non-recourse Debt [Member]          
Debt Instrument [Line Items]          
Debt 167,477,000     177,453,000  
Less nonrecourse current portion 106,439,000     137,681,000  
Corporation Debt [Member]          
Debt Instrument [Line Items]          
Less nonrecourse current portion $ 32,573,000     $ 13,976,000  
XML 81 R30.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Other Intangible Assets (Tables)
 12 Months Ended
Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Changes in the carrying value of goodwill
The following is a summary of the changes in the carrying value of goodwill, by reportable segment, for the fiscal years ended September 30, 2019 and 2018:
(in thousands)
 
Pharmaceutical
Distribution Services
 
Other
 
Total
Goodwill as of September 30, 2017
 
$
4,270,550

 
$
1,773,731

 
$
6,044,281

Goodwill recognized in connection with acquisitions
 
641,909

 
39,352

 
681,261

Goodwill impairment
 
(59,684
)
 
—

 
(59,684
)
Foreign currency translation
 
—

 
(1,586
)
 
(1,586
)
Goodwill as of September 30, 2018
 
4,852,775

 
1,811,497

 
6,664,272

Goodwill recognized in connection with acquisitions
 
—

 
43,418

 
43,418

Foreign currency translation
 
—

 
(2,183
)
 
(2,183
)
Goodwill as of September 30, 2019
 
$
4,852,775

 
$
1,852,732

 
$
6,705,507
Other intangible assets - indefinite-lived
The following is a summary of other intangible assets:
 
 
September 30, 2019
 
September 30, 2018
(dollars in thousands)
 
Weighted Average Remaining Useful Life
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
Indefinite-lived trade names
 
 
 
$
685,324

 
$
—

 
$
685,324

 
$
685,380

 
$
—

 
$
685,380

Finite-lived:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Customer relationships
 
14 years
 
1,931,212

 
(489,471
)
 
1,441,741

 
2,549,245

 
(555,440
)
 
1,993,805

Trade names and other
 
13 years
 
271,521

 
(103,750
)
 
167,771

 
397,946

 
(129,303
)
 
268,643

Total other intangible assets
 
 
 
$
2,888,057

 
$
(593,221
)
 
$
2,294,836

 
$
3,632,571

 
$
(684,743
)
 
$
2,947,828
Other intangible assets - finite-lived
The following is a summary of other intangible assets:
 
 
September 30, 2019
 
September 30, 2018
(dollars in thousands)
 
Weighted Average Remaining Useful Life
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
Indefinite-lived trade names
 
 
 
$
685,324

 
$
—

 
$
685,324

 
$
685,380

 
$
—

 
$
685,380

Finite-lived:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Customer relationships
 
14 years
 
1,931,212

 
(489,471
)
 
1,441,741

 
2,549,245

 
(555,440
)
 
1,993,805

Trade names and other
 
13 years
 
271,521

 
(103,750
)
 
167,771

 
397,946

 
(129,303
)
 
268,643

Total other intangible assets
 
 
 
$
2,888,057

 
$
(593,221
)
 
$
2,294,836

 
$
3,632,571

 
$
(684,743
)
 
$
2,947,828
XML 82 R34.htm IDEA: XBRL DOCUMENT v3.19.3
Lease Commitments (Tables)
 12 Months Ended
Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
Future minimum rental payments, operating leases
As of September 30, 2019, future minimum rental payments under noncancelable operating leases and financing obligations were as follows:
Payments Due by Fiscal Year (in thousands)
 
Operating
Leases
 
Financing Obligations 1
 
Total
2020
 
$
94,958

 
$
22,468

 
$
117,426

2021
 
84,002

 
29,790

 
113,792

2022
 
72,224

 
36,914

 
109,138

2023
 
63,507

 
35,950

 
99,457

2024
 
56,377

 
35,276

 
91,653

Thereafter
 
177,267

 
270,410

 
447,677

Total minimum lease payments
 
$
548,335

 
$
430,808

 
$
979,143

 
 
 
 
 
 
 
1 Represents the portion of future minimum lease payments relating to facility leases where the Company was determined to be the accounting owner (see Note 1). These payments are recognized as reductions to the financing obligation and as interest expense and exclude the future non-cash termination of the financing obligation.
Future minimum rental payments, financing obligations
As of September 30, 2019, future minimum rental payments under noncancelable operating leases and financing obligations were as follows:
Payments Due by Fiscal Year (in thousands)
 
Operating
Leases
 
Financing Obligations 1
 
Total
2020
 
$
94,958

 
$
22,468

 
$
117,426

2021
 
84,002

 
29,790

 
113,792

2022
 
72,224

 
36,914

 
109,138

2023
 
63,507

 
35,950

 
99,457

2024
 
56,377

 
35,276

 
91,653

Thereafter
 
177,267

 
270,410

 
447,677

Total minimum lease payments
 
$
548,335

 
$
430,808

 
$
979,143

 
 
 
 
 
 
 
1 Represents the portion of future minimum lease payments relating to facility leases where the Company was determined to be the accounting owner (see Note 1). These payments are recognized as reductions to the financing obligation and as interest expense and exclude the future non-cash termination of the financing obligation.
XML 83 R38.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies - New Accounting Pronouncements (Details) - USD ($)
$ in Thousands
Oct. 01, 2019
Sep. 30, 2019
Oct. 01, 2018
Sep. 30, 2018
Oct. 01, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative effect adjustment, share-based compensation     $ (2,584)   $ 47,063
Deferred tax assets   $ 487,320   $ 548,287  
Retained Earnings [Member]          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative effect adjustment, share-based compensation     $ (1,482)   47,063
Accounting Standards Update 2016-09 [Member]          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Deferred tax assets         47,100
Accounting Standards Update 2016-09 [Member] | Retained Earnings [Member]          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Cumulative effect adjustment, share-based compensation         $ 47,100
Forecast [Member] | Subsequent Event [Member]          
New Accounting Pronouncements or Change in Accounting Principle [Line Items]          
Lease, liability $ 550,000        
XML 84 R17.htm IDEA: XBRL DOCUMENT v3.19.3
Retirement and Other Benefit Plans
 12 Months Ended
Sep. 30, 2019
Retirement Benefits [Abstract]  
Retirement and Other Benefit Plans Retirement and Other Benefit Plans
The Company sponsors various retirement benefit plans and a deferred compensation plan covering eligible employees.
The Compensation and Succession Planning Committee ("Compensation Committee") of the Company's board of directors has delegated the administration of the Company's retirement and other benefit plans to its Benefits Committee, an internal committee, comprised of senior finance, human resources, and legal executives. The Benefits Committee is responsible for the investment options under the Company's savings plans, as well as performance of the investment advisers and plan administrators.
Defined Contribution Plans
The Company sponsors the AmerisourceBergen Employee Investment Plan (the "Plan"), which is a defined contribution 401(k) plan covering salaried and certain hourly employees. Eligible participants may contribute to the plan from 1% to 50% of their regular compensation before taxes. Prior to January 1, 2017, the Company contributed $1.00 for each $1.00 invested by the participant up to the first 3% of the participant's salary and $0.50 for each additional $1.00 invested by the participant of up to an additional 2% of salary. Effective January 1, 2017, the Company contributed $1.00 for each $1.00 invested by the participant up to the first 3% of the participant's salary. Effective January 1, 2019, the Company contributes $1.00 for each $1.00 invested by the participant up to the first 3% of the participant's salary and $0.50 for each additional $1.00 invested by the participant of up to an additional 2% of salary. An additional discretionary contribution, in an amount not to exceed the limits established by the Internal Revenue Code ("IRC"), may also be made depending upon the Company's performance. Based on the Company's performance in fiscal 2019 and 2018, the Company recognized an expense for a discretionary contribution to the Plan in the fiscal years ended September 30, 2019 and 2018. There were no discretionary contributions recognized in the fiscal year ended September 30, 2017. All contributions are invested at the direction of the employee in one or more funds. All contributions vest immediately except for the discretionary contributions made by the Company, which vest in full after five years of credited service.
The Company also sponsors the AmerisourceBergen Corporation Benefit Restoration Plan. This unfunded plan provides benefits to selected key management, including all of the Company's executive officers. Prior to January 1, 2017, the Company contributed an amount equal to 4% of the participant's total cash compensation to the extent that his or her compensation exceeded the annual compensation limit established by Section 401(a) (17) of the IRC. Effective January 1, 2017, this plan provided eligible participants with an annual amount equal to 3% of the participant's total cash compensation to the extent that his or her compensation exceeds the annual compensation limit established by Section 401(a) (17) of the IRC. Effective January 1, 2019, this plan provides eligible participants with an annual amount equal to 4% of the participant's total cash compensation to the extent that his or her compensation exceeds the annual compensation limit established by Section 401(a) (17) of the IRC.
Costs of the defined contribution plans charged to expense for the fiscal years ended September 30, 2019, 2018, and 2017 were $51.0 million, $37.9 million, and $28.3 million, respectively.
Deferred Compensation Plan
The Company sponsors the AmerisourceBergen Corporation 2001 Deferred Compensation Plan. This unfunded plan, under which 2.96 million shares of common stock are authorized for issuance, allows eligible officers, directors, and key management employees to defer a portion of their annual compensation. The amount deferred may be allocated by the employee to cash, mutual funds, or stock credits. Stock credits, including dividend equivalents, are equal to the full and fractional number of shares of common stock that could be purchased with the participant's compensation allocated to stock credits based upon the average of closing prices of common stock during each month, plus, at the discretion of the board of directors, up to one-half of a share of common stock for each full share credited. Stock credit distributions are made in shares of common stock. No shares of common stock have been issued under the deferred compensation plan through September 30, 2019. The Company's liability relating to its deferred compensation plan as of September 30, 2019 and 2018 was $28.0 million and $27.5 million, respectively.
XML 85 R13.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Other Intangible Assets
 12 Months Ended
Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets
The following is a summary of the changes in the carrying value of goodwill, by reportable segment, for the fiscal years ended September 30, 2019 and 2018:
(in thousands)
 
Pharmaceutical
Distribution Services
 
Other
 
Total
Goodwill as of September 30, 2017
 
$
4,270,550

 
$
1,773,731

 
$
6,044,281

Goodwill recognized in connection with acquisitions
 
641,909

 
39,352

 
681,261

Goodwill impairment
 
(59,684
)
 
—

 
(59,684
)
Foreign currency translation
 
—

 
(1,586
)
 
(1,586
)
Goodwill as of September 30, 2018
 
4,852,775

 
1,811,497

 
6,664,272

Goodwill recognized in connection with acquisitions
 
—

 
43,418

 
43,418

Foreign currency translation
 
—

 
(2,183
)
 
(2,183
)
Goodwill as of September 30, 2019
 
$
4,852,775

 
$
1,852,732

 
$
6,705,507


In connection with the Company's annual goodwill impairment test as of July 1, 2018, the Company recorded a goodwill impairment of $59.7 million in its Profarma reporting unit. The fair value of the reporting unit was determined based upon Profarma's publicly-traded stock price, plus an estimated purchase premium. This represents a Level 2 nonrecurring fair value measurement.
The following is a summary of other intangible assets:
 
 
September 30, 2019
 
September 30, 2018
(dollars in thousands)
 
Weighted Average Remaining Useful Life
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
 
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Net
Carrying
Amount
Indefinite-lived trade names
 
 
 
$
685,324

 
$
—

 
$
685,324

 
$
685,380

 
$
—

 
$
685,380

Finite-lived:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Customer relationships
 
14 years
 
1,931,212

 
(489,471
)
 
1,441,741

 
2,549,245

 
(555,440
)
 
1,993,805

Trade names and other
 
13 years
 
271,521

 
(103,750
)
 
167,771

 
397,946

 
(129,303
)
 
268,643

Total other intangible assets
 
 
 
$
2,888,057

 
$
(593,221
)
 
$
2,294,836

 
$
3,632,571

 
$
(684,743
)
 
$
2,947,828


Amortization expense for finite-lived intangible assets was $167.4 million, $181.2 million, and $160.5 million in the fiscal years ended September 30, 2019, 2018, and 2017, respectively. Amortization expense for finite-lived intangible assets is estimated to be $134.1 million in fiscal 2020, $130.2 million in fiscal 2021, $128.5 million in fiscal 2022, $127.2 million in fiscal 2023, $126.2 million in 2024, and $963.3 million thereafter.
XML 86 R9999.htm IDEA: XBRL DOCUMENT v3.19.3
Label Element Value
Noncontrolling Interest [Member]  
Cumulative Effect of New Accounting Principle in Period of Adoption us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption $ (1,102,000)
XML 87 R72.htm IDEA: XBRL DOCUMENT v3.19.3
Lease Commitments - Additional Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Operating Leases      
Rental expense $ 108.9 $ 114.9 $ 80.7
XML 88 R82.htm IDEA: XBRL DOCUMENT v3.19.3
Schedule II - Valuation and Qualifying Accounts - Additional Information (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Allowance for Doubtful Accounts for Long-term Accounts Receivable [Member] | Other Assets [Member]      
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]      
Allowance for doubtful accounts for long-term accounts receivable $ 981 $ 13,568 $ 17,890
XML 89 R76.htm IDEA: XBRL DOCUMENT v3.19.3
Business Segment Information - Reconciliation of Segment Revenue, Operating Income, Assets, Depreciation and Amortization, and Capital Expenditures (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Segment Reporting Information [Line Items]                      
Revenue $ 45,637,802 $ 45,239,265 $ 43,319,602 $ 45,392,452 $ 43,297,136 $ 43,142,309 $ 41,033,858 $ 40,466,332 $ 179,589,121 $ 167,939,635 $ 153,143,826
Operating income 179,841 $ 406,694 $ 47,565 $ 477,823 154,097 $ 389,195 $ 481,420 $ 418,973 1,111,923 1,443,685 1,060,342
Assets 39,171,980       37,669,838       39,171,980 37,669,838 35,316,470
Depreciation and amortization                 462,407 465,127 397,603
Capital expenditures                 310,222 336,411 466,397
Pharmaceutical Distribution [Member]                      
Segment Reporting Information [Line Items]                      
Assets 33,160,529       31,892,621       33,160,529 31,892,621 29,691,127
Capital expenditures                 210,161 190,191 339,478
Other [Member]                      
Segment Reporting Information [Line Items]                      
Assets $ 6,011,451       $ 5,777,217       6,011,451 5,777,217 5,625,343
Capital expenditures                 100,061 146,220 126,919
Operating segments [Member]                      
Segment Reporting Information [Line Items]                      
Operating income                 2,051,252 1,981,230 2,016,870
Operating segments [Member] | Pharmaceutical Distribution [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 172,813,537 161,699,343 147,453,495
Operating income                 1,671,251 1,626,748 1,643,629
Depreciation and amortization                 232,735 225,608 188,065
Operating segments [Member] | MWI Animal Health [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 3,975,232 3,789,759 3,636,305
Operating segments [Member] | Global Commercialization Services [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 2,893,109 2,542,971 2,111,558
Operating segments [Member] | Other [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 6,868,341 6,332,730 5,747,863
Operating income                 380,660 355,091 373,797
Depreciation and amortization                 69,824 64,768 53,160
Intersegment eliminations [Member]                      
Segment Reporting Information [Line Items]                      
Revenue                 (92,757) (92,438) (57,532)
Operating income                 (659) (609) (556)
Segment reconciling items [Member]                      
Segment Reporting Information [Line Items]                      
Acquisition-related intangibles amortization                 $ 159,848 $ 174,751 $ 156,378
XML 90 R59.htm IDEA: XBRL DOCUMENT v3.19.3
Debt - Additional Information (Details)
 1 Months Ended 12 Months Ended
Oct. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2019
GBP (£)
Debt Instrument [Line Items]            
Long-term debt $ 400,000,000          
Payment of premium on early retirement of debt   $ 22,300,000 $ 0 $ 22,348,000 $ 0  
Scheduled future principal payments, in fiscal 2020     111,200,000      
Scheduled future principal payments, in fiscal 2021     450,300,000      
Scheduled future principal payments, in fiscal 2022     877,800,000      
Scheduled future principal payments, in fiscal 2023     4,700,000      
Scheduled future principal payments, in fiscal 2024     501,400,000      
Scheduled future principal payments, thereafter     2,300,000,000      
Interest paid     167,400,000 162,100,000 125,300,000  
Amortization of financing fees and accretion of original issue discounts     7,100,000 7,700,000 $ 6,200,000  
Multi-currency revolving credit facility due 2021 [Member]            
Debt Instrument [Line Items]            
Maximum borrowing capacity     $ 1,400,000,000      
Minimum facility fee rate     0.05%      
Maximum facility fee rate     0.125%      
Facility fee, period end     0.09%      
Long-term debt     $ 0 0    
Commercial paper [Member]            
Debt Instrument [Line Items]            
Maximum borrowing capacity     1,400,000,000      
Short-term debt     0 0    
Receivables securitization facility due 2022 [Member]            
Debt Instrument [Line Items]            
Maximum borrowing capacity     1,450,000,000      
Accordion feature, potential increase in commitment     250,000,000      
Long-term debt     350,000,000 500,000,000    
Revolving credit note [Member]            
Debt Instrument [Line Items]            
Maximum borrowing capacity     75,000,000      
Long-term debt     0 0    
Overdraft facility due in 2021 [Member]            
Debt Instrument [Line Items]            
Maximum borrowing capacity | £           £ 30,000,000
Long-term debt     32,573,000 13,269,000    
Term Loan Agreement October 2018 [Member]            
Debt Instrument [Line Items]            
Principal amount $ 400,000,000          
$750,000, 3.45% senior notes due 2027 [Member]            
Debt Instrument [Line Items]            
Long-term debt     743,099,000 742,258,000    
Principal amount   $ 750,000,000 $ 750,000,000      
Interest rate   3.45% 3.45%     3.45%
Percentage of principal amount   99.76%        
Effective yield percentage   3.48%        
$500,000, 4.3% senior notes due 2047 [Member]            
Debt Instrument [Line Items]            
Long-term debt     $ 492,488,000 $ 492,222,000    
Principal amount   $ 500,000,000 $ 500,000,000      
Interest rate   4.30% 4.30%     4.30%
Percentage of principal amount   99.51%        
Effective yield percentage   4.33%        
$400,000, 4.875% senior notes due 2019 [Member]            
Debt Instrument [Line Items]            
Principal amount   $ 400,000,000        
Interest rate   4.875%        
CDOR / LIBOR / EURIBOR / Bankers Acceptance Stamping Fee [Member] | Multi-currency revolving credit facility due 2021 [Member]            
Debt Instrument [Line Items]            
Variable rate spread     0.91%      
CDOR / LIBOR / EURIBOR / Bankers Acceptance Stamping Fee [Member] | Minimum [Member] | Multi-currency revolving credit facility due 2021 [Member]            
Debt Instrument [Line Items]            
Variable rate spread     0.70%      
CDOR / LIBOR / EURIBOR / Bankers Acceptance Stamping Fee [Member] | Maximum [Member] | Multi-currency revolving credit facility due 2021 [Member]            
Debt Instrument [Line Items]            
Variable rate spread     1.125%      
Alternate base rate and Canadian prime rate [Member] | Minimum [Member] | Multi-currency revolving credit facility due 2021 [Member]            
Debt Instrument [Line Items]            
Variable rate spread     0.00%      
Alternate base rate and Canadian prime rate [Member] | Maximum [Member] | Multi-currency revolving credit facility due 2021 [Member]            
Debt Instrument [Line Items]            
Variable rate spread     0.125%      
LIBOR [Member] | Term Loan Agreement October 2018 [Member]            
Debt Instrument [Line Items]            
Variable rate spread 0.65%          
XML 91 R55.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Other Intangible Assets - Changes in Carrying Value of Goodwill (Details) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Goodwill [Roll Forward]    
Beginning balance $ 6,664,272 $ 6,044,281
Goodwill recognized in connection with acquisitions 43,418 681,261
Goodwill impairment   (59,684)
Foreign currency translation (2,183) (1,586)
Ending balance 6,705,507 6,664,272
Operating segments [Member] | Pharmaceutical Distribution [Member]    
Goodwill [Roll Forward]    
Beginning balance 4,852,775 4,270,550
Goodwill recognized in connection with acquisitions 0 641,909
Goodwill impairment   (59,684)
Foreign currency translation 0 0
Ending balance 4,852,775 4,852,775
Operating segments [Member] | Other [Member]    
Goodwill [Roll Forward]    
Beginning balance 1,811,497 1,773,731
Goodwill recognized in connection with acquisitions 43,418 39,352
Goodwill impairment   0
Foreign currency translation (2,183) (1,586)
Ending balance $ 1,852,732 $ 1,811,497
XML 92 R51.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes - Reconciliation of Effective Income Tax Rate (Details)
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Income Tax Disclosure [Abstract]      
Statutory U.S. federal income tax rate 21.00% 24.50% 35.00%
State and local income tax rate, net of federal tax benefit 2.40% (0.10%) 5.40%
Foreign tax rate differential (6.70%) (6.20%) (14.60%)
Valuation allowance 0.00% (1.40%) 2.20%
Excess tax benefits related to share-based compensation (0.80%) (1.80%) (3.80%)
Litigation settlements and accruals (see Note 14) 0.10% (6.30%) 34.30%
Goodwill impairment (see Note 5) 0.00% 1.70% 0.00%
Tax reform (3.60%) (52.00%) 0.00%
Capital gain on distribution 0.00% 3.60% 0.00%
Other (0.70%) 0.80% 1.80%
Effective income tax rate 11.70% (37.20%) 60.30%
XML 93 R67.htm IDEA: XBRL DOCUMENT v3.19.3
Share-Based Compensation - Stock Options (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Options      
Outstanding, beginning of period (shares)     8,421
Granted (shares)     1,137
Exercised (shares)     (1,531)
Forfeited (shares)     (213)
Expired (shares)     (155)
Outstanding, end of period (shares) 7,659 8,421 7,659
Exercisable, end of period (shares) 4,395   4,395
Expected to vest after end of period (shares) 3,162   3,162
Weighted Average Exercise Price      
Outstanding, beginning of period (usd per share)     $ 77
Granted (usd per share)     90
Exercised (usd per share)     50
Forfeited (usd per share)     84
Expired (usd per share)     97
Outstanding, end of period (usd per share) $ 83 $ 77 83
Exercisable, end of period (usd per share) 83   83
Expected to vest after end of period (usd per share) $ 83   $ 83
Weighted Average Remaining Contractual Term      
Outstanding 4 years 4 years  
Exercisable 3 years    
Expected to vest after end of period 5 years    
Aggregate Intrinsic Value      
Outstanding $ 35,319 $ 142,557 $ 35,319
Exercisable 25,049   25,049
Expected to vest after end of period $ 10,010   $ 10,010
XML 94 R63.htm IDEA: XBRL DOCUMENT v3.19.3
Related Party Transactions (Details) - Walgreens Boots Alliance, Inc. [Member] - Investor [Member] - USD ($)
$ in Billions
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Related Party Transaction [Line Items]      
Ownership percentage (more than) 10.00%    
Revenue from related party $ 60.3 $ 54.7 $ 45.4
Receivable from related party $ 6.1 $ 5.6  
XML 95 R40.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details) - USD ($)
 3 Months Ended 12 Months Ended
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Assets Held and Used [Line Items]                      
Goodwill impairment         $ 59,684,000 $ 0 $ 0 $ 0 $ 0 $ 59,684,000 $ 0
Indefinite-lived intangible asset impairment                 0 0 0
Impairment of long-lived assets $ 0 $ 0 $ 570,000,000 $ 0         $ 570,000,000 $ 0 $ 0
Finite-lived intangible asset impairment     522,100,000                
Property and equipment impairment     47,900,000                
PharMEDium Healthcare Holdings, Inc [Member]                      
Assets Held and Used [Line Items]                      
Carrying value of asset group, excluding goodwill     792,000,000                
Fair value of asset group     $ 222,000,000                
Discount rate (as a percentage)     15.00%                
Customer relationships [Member]                      
Assets Held and Used [Line Items]                      
Finite-lived intangible asset impairment     $ 420,800,000                
Trade names [Member]                      
Assets Held and Used [Line Items]                      
Finite-lived intangible asset impairment     79,900,000                
Software technology [Member]                      
Assets Held and Used [Line Items]                      
Finite-lived intangible asset impairment     $ 21,400,000                
XML 96 R44.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies - Shipping and Handling Costs (Details) - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Shipping and Handling [Line Items]      
Distribution, selling, and administrative $ 2,663,508 $ 2,460,301 $ 2,128,730
Shipping and Handling [Member]      
Shipping and Handling [Line Items]      
Distribution, selling, and administrative $ 619,700 $ 590,800 $ 517,300
XML 97 R48.htm IDEA: XBRL DOCUMENT v3.19.3
Variable Interest Entity (Details) - USD ($)
$ in Thousands
Sep. 30, 2019
Oct. 31, 2018
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2016
Variable Interest Entity [Line Items]          
Cash and cash equivalents $ 3,374,194   $ 2,492,516 $ 2,435,115 $ 2,741,832
Inventories 11,060,254   11,918,508    
Property and equipment, net 1,770,516   1,892,424    
Goodwill 6,705,507   6,664,272 6,044,281  
Other long-term assets 269,067   270,942    
TOTAL ASSETS 39,171,980   37,669,838 $ 35,316,470  
Long-term debt   $ 400,000      
Deferred income taxes 1,860,195   1,829,410    
Other long-term liabilities 98,812   110,352    
Variable Interest Entity, Primary Beneficiary [Member]          
Variable Interest Entity [Line Items]          
Cash and cash equivalents 9,431   26,801    
Accounts receivables, net 154,491   144,646    
Inventories 185,602   168,931    
Prepaid expenses and other 64,119   61,924    
Property and equipment, net 30,961   32,667    
Goodwill 82,309   82,309    
Other intangible assets 74,429   80,974    
Other long-term assets 9,169   8,912    
TOTAL ASSETS 610,511   607,164    
Accounts payable 165,053   150,102    
Accrued expenses and other 49,191   37,195    
Short-term debt 106,439   115,461    
Long-term debt 60,973   39,704    
Deferred income taxes 42,371   46,137    
Other long-term liabilities 5,303   31,988    
Total liabilities $ 429,330   $ 420,587    
XML 98 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Cover - USD ($)
 12 Months Ended
Sep. 30, 2019
Oct. 31, 2019
Mar. 31, 2019
Cover page.      
Entity Incorporation, State or Country Code DE    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Sep. 30, 2019    
Document Fiscal Year Focus 2019    
Document Transition Report false    
Entity File Number 1-16671    
Entity Registrant Name AMERISOURCEBERGEN CORP    
Entity Tax Identification Number 23-3079390    
Entity Central Index Key 0001140859    
Trading Symbol ABC    
Title of 12(b) Security Common stock    
Security Exchange Name NYSE    
Document Fiscal Period Focus FY    
Current Fiscal Year End Date --09-30    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   205,922,186  
Amendment Flag false    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Public Float     $ 9,817,515,026
City Area Code 610    
Local Phone Number 727-7000    
Entity Address, Address Line One 1300 Morris Drive    
Entity Address, City or Town Chesterbrook,    
Entity Address, State or Province PA    
Entity Address, Postal Zip Code 19087-5594    
XML 99 R29.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes (Tables)
 12 Months Ended
Sep. 30, 2019
Income Tax Disclosure [Abstract]  
Domestic and foreign income from continuing operations before income taxes
The following table summarizes the Company's income before income taxes for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Domestic
 
$
336,150

 
$
704,935

 
$
394,721

Foreign
 
630,956

 
472,488

 
523,166

Total
 
$
967,106

 
$
1,177,423

 
$
917,887
Income tax provision
The components of the Company's consolidated income tax expense (benefit) are summarized in the following table for the periods indicated:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Current provision:
 
 

 
 

 
 

Federal
 
$
(12,801
)
 
$
247,755

 
$
141,071

State and local
 
15,246

 
39,328

 
35,950

Foreign
 
81,989

 
69,972

 
57,313

Total current provision
 
84,434

 
357,055

 
234,334

Deferred provision (benefit):
 
 

 
 

 
 

Federal
 
61,819

 
(828,023
)
 
265,074

State and local
 
(31,086
)
 
33,887

 
54,995

Foreign
 
(2,196
)
 
(1,388
)
 
(1,000
)
Total deferred provision (benefit)
 
28,537

 
(795,524
)
 
319,069

Provision (benefit) for income taxes
 
$
112,971

 
$
(438,469
)
 
$
553,403
Reconciliation of the effective income tax rate
A reconciliation of the statutory U.S. federal income tax rate to the Company's consolidated effective income tax rate is as follows for the periods indicated:
 
Fiscal Year Ended September 30,
 
2019
 
2018
 
2017
Statutory U.S. federal income tax rate
21.0%
 
24.5%
 
35.0%
State and local income tax rate, net of federal tax benefit
2.4
 
(0.1)
 
5.4
Foreign tax rate differential
(6.7)
 
(6.2)
 
(14.6)
Valuation allowance
—
 
(1.4)
 
2.2
Excess tax benefits related to share-based compensation
(0.8)
 
(1.8)
 
(3.8)
Litigation settlements and accruals (see Note 14)
0.1
 
(6.3)
 
34.3
Goodwill impairment (see Note 5)
—
 
1.7
 
—
Tax reform
(3.6)
 
(52.0)
 
—
Capital gain on distribution
—
 
3.6
 
—
Other
(0.7)
 
0.8
 
1.8
Effective income tax rate
11.7%
 
(37.2)%
 
60.3%
Significant components of deferred tax liabilities (assets) Significant components of the Company's deferred tax liabilities (assets) are as follows:
 
 
September 30,
(in thousands)
 
2019
 
2018
Inventories
 
$
1,293,075

 
$
1,189,801

Property and equipment
 
143,851

 
133,417

Goodwill and other intangible assets
 
709,015

 
853,747

Other
 
1,892

 
747

Gross deferred tax liabilities
 
2,147,833

 
2,177,712

 
 
 
 
 
Net operating loss and tax credit carryforwards
 
(318,868
)
 
(421,808
)
Allowance for doubtful accounts
 
(22,544
)
 
(20,126
)
Accrued expenses
 
(33,312
)
 
(17,363
)
Employee and retiree benefits
 
(12,420
)
 
(10,210
)
Share-based compensation
 
(39,961
)
 
(28,888
)
Other
 
(60,215
)
 
(49,892
)
Gross deferred tax assets
 
(487,320
)
 
(548,287
)
Valuation allowance for deferred tax assets
 
199,682

 
199,985

Deferred tax assets, net of valuation allowance
 
(287,638
)
 
(348,302
)
Net deferred tax liabilities
 
$
1,860,195

 
$
1,829,410
Reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties
A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, for the periods indicated is as follows:
 
 
Fiscal Year Ended September 30,
(in thousands)
 
2019
 
2018
 
2017
Unrecognized tax benefits at beginning of period
 
$
98,124

 
$
323,869

 
$
75,766

Additions of tax positions of the current year
 
18,819

 
2,804

 
252,866

Additions to tax positions of the prior years
 
751

 
558

 
1,049

Reductions of tax positions of the prior years
 
(10,317
)
 
(224,878
)
 
(668
)
Settlements with taxing authorities
 
—

 
(1,847
)
 
(3,285
)
Expiration of statutes of limitations
 
(1,720
)
 
(2,382
)
 
(1,859
)
Unrecognized tax benefits at end of period
 
$
105,657

 
$
98,124

 
$
323,869
XML 100 R5.htm IDEA: XBRL DOCUMENT v3.19.3
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
$ in Thousands
 12 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2017
Statement of Comprehensive Income [Abstract]      
Net income $ 854,135 $ 1,615,892 $ 364,484
Other comprehensive (loss) income:      
Foreign currency translation adjustments (32,957) (36,904) 16,540
Loss on consolidation of equity investments 0 45,941 0
Other (271) (756) 1,918
Total other comprehensive (loss) income (33,228) 8,281 18,458
Total comprehensive income 820,907 1,624,173 382,942
Comprehensive loss attributable to noncontrolling interest 1,746 50,829 0
Comprehensive income attributable to AmerisourceBergen Corporation $ 822,653 $ 1,675,002 $ 382,942
XML 101 R25.htm IDEA: XBRL DOCUMENT v3.19.3
Quarterly Financial Information (Unaudited)
 12 Months Ended
Sep. 30, 2019
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Information (Unaudited) Quarterly Financial Information (Unaudited)
 
 
Fiscal Year Ended September 30, 2019
(in thousands, except per share amounts)
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
 
Fiscal
Year
Revenue
 
$
45,392,452

 
$
43,319,602

 
$
45,239,265

 
$
45,637,802

 
$
179,589,121

Gross profit (a)
 
$
1,297,580

 
$
1,424,756

 
$
1,231,239

 
$
1,184,737

 
$
5,138,312

Distribution, selling, and administrative expenses; depreciation; and amortization
 
779,085

 
751,802

 
764,539

 
830,489

 
3,125,915

Employee severance, litigation, and other
 
40,672

 
55,389

 
60,006

 
174,407

 
330,474

Impairment of long-lived assets
 
—

 
570,000

 
—

 
—

 
570,000

Operating income
 
$
477,823

 
$
47,565

 
$
406,694

 
$
179,841

 
$
1,111,923

Net income (b)
 
$
391,753

 
$
28,073

 
$
302,002

 
$
132,307

 
$
854,135

Net income attributable to AmerisourceBergen Corporation (b)
 
$
393,652

 
$
27,135

 
$
301,959

 
$
132,619

 
$
855,365

Earnings per share operations:
 
 

 
 

 
 

 
 

 
 

Basic
 
$
1.86

 
$
0.13

 
$
1.44

 
$
0.64

 
$
4.07

Diluted
 
$
1.84

 
$
0.13

 
$
1.43

 
$
0.63

 
$
4.04

__________________________________________________________
(a)
The first, second, third, and fourth quarters of the fiscal year ended September 30, 2019 include gains from antitrust litigation settlements of $87.3 million, $52.0 million, $3.5 million, and $3.1 million, respectively. The first, second, and third quarter of the fiscal year ended September 30, 2019 include LIFO credits of $3.0 million, $66.8 million, and $9.9 million, respectively. The fourth quarter of the fiscal year ended September 30, 2019 includes LIFO expense of $57.2 million. The first, second, third, and fourth quarters of the fiscal year ended September 30, 2019 include PharMEDium remediation costs of $17.9 million, $12.3 million, $11.7 million, and $6.7 million, respectively. The first quarter of the fiscal year ended September 30, 2019 includes a $22.0 million reversal of a previous estimate of our liability under the New York State Opioid Stewardship Act.
(b)
The first quarter of the fiscal year ended September 30, 2019 includes a $37.0 million income tax benefit adjustment to the one-time transition tax on historical foreign earnings and profits through December 31, 2017. The second quarter of the fiscal year ended September 30, 2019 includes a gain on the sale of an equity investment of $13.7 million.
 
 
Fiscal Year Ended September 30, 2018
(in thousands, except per share amounts)
 
First
Quarter
 
Second
Quarter
 
Third
Quarter
 
Fourth
Quarter
 
Fiscal
Year
Revenue
 
$
40,466,332

 
$
41,033,858

 
$
43,142,309

 
$
43,297,136

 
$
167,939,635

Gross profit (a)
 
$
1,112,652

 
$
1,255,683

 
$
1,211,341

 
$
1,032,641

 
$
4,612,317

Distribution, selling, and administrative expenses; depreciation; and amortization
 
663,658

 
736,814

 
746,593

 
778,363

 
2,925,428

Employee severance, litigation, and other
 
30,021

 
37,449

 
75,553

 
40,497

 
183,520

Goodwill impairment
 
—

 
—

 
—

 
59,684

 
59,684

Operating income
 
$
418,973

 
$
481,420

 
$
389,195

 
$
154,097

 
$
1,443,685

Net income (b)
 
$
861,853

 
$
282,160

 
$
277,875

 
$
194,004

 
$
1,615,892

Net income attributable to AmerisourceBergen Corporation (b)
 
$
861,853

 
$
287,455

 
$
275,809

 
$
233,288

 
$
1,658,405

Earnings per share operations:
 
 

 
 

 
 

 
 

 
 

Basic
 
$
3.95

 
$
1.31

 
$
1.26

 
$
1.08

 
$
7.61

Diluted
 
$
3.90

 
$
1.29

 
$
1.25

 
$
1.07

 
$
7.53

__________________________________________________________
(a)
The second and third quarters of the fiscal year ended September 30, 2018 include gains from antitrust litigation settlements of $0.3 million and $35.6 million, respectively. The third quarter of the fiscal year ended September 30, 2018 includes a LIFO credit of $16.1 million. The fourth quarter of the fiscal year ended September 30, 2018 includes LIFO expense of $83.5 million. The second, third, and fourth quarters of the fiscal year ended September 30, 2018 include PharMEDium remediation costs of $22.5 million, $12.0 million, and $26.6 million, respectively. The fourth quarter of the fiscal year ended September 30, 2018 includes a $22.0 million estimate of our liability under the New York State Opioid Stewardship Act.
(b)
The first quarter of the fiscal year ended September 30, 2018 includes a loss on early retirement of debt of $23.8 million. The second quarter of the fiscal year ended September 30, 2018 includes a $42.3 million loss on consolidation of equity investments and a $30.0 million impairment of a non-customer note receivable. The first and fourth quarters of the fiscal year ended September 30, 2018 included discrete income tax benefits recognized in connection with the 2017 Tax Act of $587.6 million and $25.0 million, respectively.
XML 102 R21.htm IDEA: XBRL DOCUMENT v3.19.3
Legal Matters and Contingencies
 12 Months Ended
Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
Legal Matters and Contingencies Legal Matters and Contingencies
In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties
may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.

 For those matters for which the Company has not recognized a liability, the Company cannot predict the outcome of their impact on the Company as uncertainty remains with regard to whether such matters will proceed to trial, whether settlements will be reached, and the amount and terms of any such settlements. Outcomes may include settlements in significant amounts that are not currently estimable, limitations on the Company's conduct, the imposition of corporate integrity agreement obligations, consent decrees, and/or other civil and criminal penalties. From time to time, the Company is also involved in disputes with its customers, which the Company generally seeks to resolve through commercial negotiations. If negotiations are unsuccessful, the parties may litigate the dispute or otherwise attempt to settle the matter.

With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.

Opioid Lawsuits and Investigations

A significant number of counties, municipalities, and other governmental entities in a majority of U.S. states and Puerto Rico, as well as several states and tribes, have filed lawsuits in various federal, state and other courts against pharmaceutical wholesale distributors (including the Company and its subsidiaries AmerisourceBergen Drug Corporation ("ABDC") and H.D. Smith, which was acquired in January 2018), pharmaceutical manufacturers, retail chains, medical practices, and physicians relating to the distribution of prescription opioid pain medications. Other lawsuits regarding the distribution of prescription opioid pain medications have been filed by: third-party payors and similar entities; hospitals; hospital groups; and individuals, including cases styled as putative class actions. The lawsuits, which have been and continue to be filed in federal, state, and other courts, generally allege violations of controlled substance laws and various other statutes as well as common law claims, including negligence, public nuisance, and unjust enrichment, and seek equitable relief and monetary damages. An initial group of cases was consolidated for Multidistrict Litigation ("MDL") proceedings before the United States District Court for the Northern District of Ohio (the "Court") in December 2017. Additional cases have been, and will likely continue to be, transferred to the MDL. Further, in June 2018, the Court granted a motion permitting the United States, through the DOJ, to participate in settlement discussions and as a friend of the Court by providing information to facilitate non-monetary remedies.

In April 2018, the Court issued an order creating a litigation track, which includes dispositive motion practice, discovery, and trials in certain bellwether jurisdictions. On December 31, 2018, the Court issued an order selecting two additional cases for a second bellwether discovery and trial track. The timing of discovery, motion practice, and trials for the second set of bellwether cases has not yet been determined.

On October 21, 2019, the Company announced an agreement in principle with two Ohio counties, Cuyahoga and Summit, to settle all claims brought by the two counties against the Company in the first track of the MDL. All claims against the Company were dismissed with prejudice pursuant to the settlement. As a result, the Company recorded a charge of $66.7 million in the fourth quarter of the fiscal year ended September 30, 2019 within Employee Severance, Litigation and Other in its Statement of Operations and in Accrued Expenses and Other on the Company’s Consolidated Balance Sheet.

The Court has continued to oversee court-ordered settlement discussions with attorneys for the plaintiffs and certain states that it instituted at the beginning of the MDL proceedings. On October 21, 2019, the Attorneys General for North Carolina, Pennsylvania, Tennessee, and Texas announced certain proposed settlement terms intended to provide a potential framework for a global resolution of the MDL and other related state court litigation, including cases currently filed and that could be filed. The attorneys general's announcement outlined that the largest U.S. pharmaceutical distributors would be expected to pay an aggregate amount of up to $18.0 billion over 18 years, of which the Company's portion would be 31%, in addition to the development and participation in a program for free or rebated distribution of opioid-abuse medications for a period of 10 years and the implementation of industry-wide changes to be specified to controlled substance anti-diversion programs. The Company is currently engaged in discussions that include the four attorneys general and other parties with the objective of reaching potential terms for a global resolution. The Company is also engaged in related discussions with plaintiffs' lawyers representing local governments and other parties with the same goal of reaching a global resolution with all parties. If agreed, the potential terms for a global resolution would then need to be presented to numerous other states and local governments, and a significant number of such jurisdictions would need to accept the proposed terms in order to achieve an agreement in principle that would provide the finality that the Company requires from a global resolution. Given the large number of parties involved, the complexity and difficulty of the underlying issues, and the resulting uncertainty of achieving a potential global resolution, the Company continues to litigate and
prepare for trial in the cases pending in the MDL as well as in state courts where lawsuits have been filed, and intends to continue to vigorously defend itself in all such cases. A liability associated with a global resolution has not been recognized as of September 30, 2019, since the Company is unable to predict the outcome of settlement discussions with the states and local governments that will need to participate and, therefore, a global resolution cannot be considered probable. Furthermore, significant uncertainty remains with regard to whether such matters will proceed to trial, and, given the inherent uncertainty related to such litigation, the Company is not in a position to assess the likely outcome, and therefore unable to estimate the range of possible loss.

In June 2019, attorneys for some of the plaintiffs filed a motion proposing a procedure to certify a nationwide "negotiation class" of cities and counties for the purpose of negotiating and settling with defendants engaged in the nationwide manufacturing, sale, or distribution of opioids. The attorneys subsequently withdrew the motion and refiled an amended motion on July 9, 2019. The Court granted the motion on September 11, 2019 and certain defendants, including ABDC, are appealing.

On November 6, 2019, a New York state court entered an order accelerating the trial date for cases brought by Nassau and Suffolk Counties and the New York Attorney General against a variety of defendants, including the Company. Pursuant to that order, the trial, which is not part of the MDL, was scheduled to begin on January 20, 2020, however during a subsequent meeting on November 13, 2019, the court amended the trial date to begin in March 2020.

Aside from those parties that have already filed suit, other entities, including additional attorneys general’s offices, counties, and cities in multiple states, have indicated their intent to sue. The Company is vigorously defending itself in the pending lawsuits and intends to vigorously defend itself against any threatened lawsuits. The Company is not in a position to assess the likely outcome or its exposure, if any, with respect to these matters.

The Company has also received subpoenas, civil investigative demands, and other requests for information, requesting the production of documents regarding the distribution of prescription opioid pain medications from government agencies in other jurisdictions, including certain states. The Company is engaged in discussions with representatives from these government agencies regarding the requests and has been producing responsive documents.

Since July 2017, the Company has received subpoenas from several U.S. Attorney's Offices. Those subpoenas request the production of a broad range of documents pertaining to ABDC's distribution of controlled substances and diversion control programs. The Company has been engaged in discussions with the various U.S. Attorney’s Offices, including the Health Care and Government Fraud Unit of the Criminal Division of the U.S. Attorney's Office for the District of New Jersey, and has been producing documents in response to the subpoenas.
In June 2012, the Attorney General of the State of West Virginia ("West Virginia AG") filed complaints, which were amended, in the Circuit Court of Boone County, West Virginia, against a number of pharmaceutical wholesale distributors, including the Company's subsidiary ABDC, alleging, among other claims, that the distributors failed to provide effective controls and procedures to guard against diversion of controlled substances for illegitimate purposes in West Virginia, acted negligently by distributing controlled substances to pharmacies that serve individuals who abuse controlled substances, and failed to report suspicious orders of uncontrolled substances in accordance with state regulations. The West Virginia AG was seeking monetary damages and injunctive and other equitable relief. This matter was dismissed with prejudice on January 9, 2017 pursuant to a settlement agreement that provided for the payment of $16.0 million and express denial of the allegations in the complaints and any wrongdoing. During the fiscal year ended September 30, 2017, the Company recognized the $16.0 million settlement in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations. The Company paid the $16.0 million settlement in fiscal 2017.
Government Enforcement and Related Litigation Matters

Various government agencies, including the FDA, the Consumer Protection Branch of the Civil Division of the DOJ, and state boards of pharmacy, regulate the compounding of pharmaceutical products. The Company’s subsidiary, PharMEDium, operates Section 503B outsourcing facilities that must comply with current Good Manufacturing Practice ("cGMP") requirements and are inspected by the FDA periodically to determine compliance. The FDA and the DOJ have broad enforcement powers, including the authority to enjoin PharMEDium's Section 503B outsourcing facilities from distributing pharmaceutical products.

On May 17, 2019, PharMEDium reached an agreement on the terms of the Consent Decree with the FDA and the DOJ that was entered by the United States District Court for the Northern District of Illinois on May 22, 2019. The Consent Decree permits commercial operations to continue at PharMEDium’s Dayton, New Jersey and Sugar Land, Texas compounding facilities and administrative operations to continue at its Lake Forest, Illinois headquarters subject to compliance with requirements set forth therein. As required by the Consent Decree, initial audit inspections were conducted by an independent cGMP expert of the Dayton and Sugar Land facilities. The cGMP expert has notified the FDA that all of the short-term corrective actions taken are
acceptable. The Company has submitted to the FDA several additional longer-term corrective actions, and the independent cGMP expert will assess the effectiveness of the implementation of these items in future audits. Additional audit inspections by the independent cGMP expert of the Sugar Land and Dayton facilities are required at least annually for a period of four years.

The Consent Decree also establishes requirements that must be satisfied prior to the resumption of commercial operations at the Memphis, Tennessee facility. The requirements include a work plan approved by the FDA and an audit inspection and certification by an independent cGMP expert that the facilities, methods and controls at the Memphis facility and PharMEDium’s Lake Forest, Illinois headquarters comply with the Consent Decree. If PharMEDium receives written notification from the FDA of compliance with the requirements to resume operations at the Memphis facility, additional audit inspections are required for five years, during which time PharMEDium must correct any deviations from the Consent Decree observed by the independent cGMP expert.

After five years, PharMEDium may petition the district court for full relief from the Consent Decree, or for specific relief with regard to one or more facilities. If, at the time of such petition, all obligations under the Consent Decree with respect to the specific facilities for which PharMEDium is seeking relief have been satisfied, and there has been continuous compliance with the Consent Decree for at least five years, the federal government will not oppose the petition, and PharMEDium may request that the district court grant such relief.

Additionally, state boards of pharmacy may revoke, limit, or deny approval of licenses required under state law to compound or distribute pharmaceutical products. As a result of reciprocal state actions initiated due to the FDA’s inspectional observations, PharMEDium has suspended shipping of its compounded sterile preparations into several states, either voluntarily, by consent or pursuant to orders of state licensing authorities.

Subpoenas and Ongoing Investigations

From time to time, the Company receives subpoenas or requests for information from various government agencies relating to the Company's business or to the business of a customer, supplier, or other industry participant. The Company's responses often require time and effort and can result in considerable costs being incurred. Most of these matters are resolved without incident; however, such subpoenas or requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the healthcare industry, as well as to substantial settlements.

In January 2017, the Company's subsidiary U.S. Bioservices Corporation ("U.S. Bio") received a subpoena for information from the U.S. Attorney's Office for the Eastern District of New York ("USAO-EDNY") relating to its activities in connection with billing for products and making returns of potential overpayments to government payers. The Company engaged in discussions with the USAO-EDNY and produced documents in response to the subpoena. In April 2019, the government informed the Company that it had filed a notice with the U.S. District Court for the Eastern District of New York that it was declining to intervene in a filed qui tam action related to its investigation. The case was unsealed in April 2019 and counsel for the relator has stated that they intend to file an amended complaint under seal, which they intend to submit to the USAO-EDNY for further consideration.

The Company and its subsidiary AmerisourceBergen Specialty Group ("ABSG") had previously responded to subpoenas from the USAO-EDNY requesting production of documents and information relating to the pre-filled syringe program of ABSG’s subsidiary Medical Initiatives, Inc., ABSG's oncology distribution center, its group purchasing organization for oncologists, and intercompany transfers of certain oncology products. Medical Initiatives, Inc. voluntarily ceased operations in early 2014.
On September 27, 2017, pursuant to the terms of a plea agreement, ABSG entered a guilty plea to a one-count strict-liability misdemeanor violation of the Federal Food, Drug, and Cosmetic Act in the United States District Court of the Eastern District of New York. Under the terms of the agreement, which were approved by the Court, ABSG paid a total criminal fine and forfeiture of $260.0 million in fiscal 2017. The guilty plea resolves the federal criminal investigation related to the failure of Medical Initiatives, Inc. to duly register with the FDA. The Company also entered into a Compliance Agreement with the United States Department of Justice for a period of three years. During the fiscal year ended September 30, 2017, the Company recognized the $260.0 million settlement in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations.
The USAO-EDNY also pursued alleged civil claims under the False Claims Act. ABSG reached an agreement in principle with the USAO-EDNY during the fiscal quarter ended December 31, 2017, which the Company expected would resolve the alleged civil claims in their entirety. In the fourth quarter of the fiscal year ended September 30, 2018, the Company reached final terms of the settlement agreement with the USAO-EDNY, resolved potential administrative action by the Office of Inspector General of the U.S. Department of Health and Human Services by entering into a Corporate Integrity Agreement, and obtained dismissal
with prejudice of the potential civil claims. The Corporate Integrity Agreement has a five-year term, which commenced on September 28, 2018, and requires, among other things, the maintenance of a compliance program, an independent review organization and a financial recoupment program. Pursuant to the terms of the settlement agreement with the USAO-EDNY, ABSG made a payment on September 28, 2018 to resolve the civil litigation without making any admission of liability in the amount of $625.0 million, plus interest from December 1, 2017. As a result of the agreement in principle, the Company had previously accrued a reserve in the amount of $625.0 million in the fiscal year ended September 30, 2017. The reserve was recognized in Employee Severance, Litigation, and Other on the Company's Statement of Operations.
The Company’s subsidiary U.S. Bio settled claims with the U.S. Attorney’s Office for the Southern District of New York ("USAO-SDNY") and with various states arising from the previously disclosed matter involving the dispensing of one product and U.S. Bio’s relationship with the manufacturer of that product. In accordance with the settlement agreements, the United States’ complaint against U.S. Bio was dismissed and the participating states agreed not to bring, and to dismiss with prejudice, any state law claims that they had the authority to bring against U.S. Bio. The Company paid the United States $10.7 million in fiscal 2017 and paid the participating states $2.8 million in fiscal 2018. During the year ended September 30, 2017, the Company recognized the $13.4 million settlement in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations.
Other Contingencies
New York State ("NYS") enacted the Opioid Stewardship Act ("OSA"), which went into effect on July 1, 2018. The OSA established an annual $100 million Opioid Stewardship Fund (the "Fund") and requires manufacturers, distributors, and importers licensed in NYS to ratably source the Fund. The ratable share of the assessment for each licensee was to be based upon opioids sold or distributed to or within NYS. In the fourth quarter of the fiscal year ended September 30, 2018, the Company accrued $22.0 million as an estimate of its liability under the OSA for opioids distributed from January 1, 2017 through September 30, 2018 and recognized this reserve in Cost of Goods Sold on its Consolidated Statement of Operations and in Accrued Expenses and Other on its Consolidated Balance Sheet as of September 30, 2018. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York, and, as a result, the Company reversed the $22.0 million accrual in the fiscal quarter ended December 31, 2018. NYS filed an appeal of the court decision on January 17, 2019; however, the Company does not believe a loss contingency is probable.
XML 103 R9.htm IDEA: XBRL DOCUMENT v3.19.3
Summary of Significant Accounting Policies
 12 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
AmerisourceBergen Corporation and its subsidiaries, including less than wholly-owned subsidiaries in which AmerisourceBergen Corporation has a controlling financial interest (the "Company"), is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company delivers innovative programs and services designed to improve the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.
Basis of Presentation
The accompanying financial statements present the consolidated financial position, results of operations, and cash flows of the Company as of the dates and for the periods indicated. All intercompany accounts and transactions have been eliminated in consolidation.
The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts due to uncertainties inherent in such estimates. Management periodically evaluates estimates used in the preparation of the financial statements for continued reasonableness. Certain reclassifications have been made to prior-period amounts in order to conform to the current year presentation.
Recently Adopted Accounting Pronouncements
In March 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"). ASU 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are exercised. It also allows an employer to repurchase more of an employee's shares for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 was effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. On October 1, 2016, the Company early adopted ASU 2016-09, which resulted in a cumulative adjustment to retained earnings and the establishment of a deferred tax asset of $47.1 million for previously unrecognized tax benefits. The Company elected to adopt the Statement of Cash Flows presentation of the excess tax benefits prospectively.
In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)" ("ASU 2014-09"). ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification ("ASC") 605 - "Revenue Recognition" and most industry-specific guidance throughout the Codification. ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard's core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. 
In March 2016, the FASB issued ASU No. 2016-08, "Revenue from Contracts with Customers (Topic 606) - Principal versus Agent Considerations" ("ASU 2016-08"), which clarified the implementation guidance for principal versus agent considerations in ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10, "Revenue from Contracts with Customers (Topic 606) - Identifying Performance Obligations and Licensing" ("ASU 2016-10"), which amended the guidance in ASU 2014-09 related to identifying performance obligations and accounting for licenses of intellectual property. The Company was required to adopt ASU 2016-08 and ASU 2016-10 with ASU 2014-09, collectively ASC 606.
The Company adopted ASC 606 as of October 1, 2018 on a modified retrospective basis for all open contracts as of October 1, 2018. The adoption had an immaterial impact on the Company's October 1, 2018 retained earnings and will not have a material impact on the Company's revenues, results of operations, or cash flows. The Company did not record any material contract assets, contract liabilities, or deferred contract costs in its Consolidated Balance Sheet upon adoption.
The Company elected the practical expedient to expense costs to obtain a contract when incurred when the amortization period would have been one year or less. Additionally, the Company elected the practical expedients to not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for services performed, and (iii) for contracts for which the variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation.

For the Company's revenue recognition policy, refer to the "Revenue Recognition" section of Note 1.
Recently Issued Accounting Pronouncements Not Yet Adopted
 In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)" ("ASU 2016-02" or "ASC 842")). ASU 2016-02 aims to increase transparency and comparability across organizations by requiring lease assets and lease liabilities to be recognized on the balance sheet as well as key information to be disclosed regarding lease arrangements. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018 and interim periods within those fiscal years.
The Company will adopt ASC 842 in the first quarter of fiscal 2020 and will adopt using the modified retrospective approach. The Company will elect the transition package of practical expedients provided within the amended guidance, which eliminates the requirements to reassess lease identification, lease classification, and initial direct costs for leases that commenced before the effective date. The Company will also elect to combine lease and non-lease components and to exclude short-term leases from its consolidated balance sheets. The Company did not elect the hindsight practical expedient in determining the lease term.
The adoption of the amended guidance is expected to have a material impact on the consolidated balance sheet from the recognition of lease assets and liabilities. While the Company continues to finalize the impact of adoption, it anticipates recognizing operating lease liabilities of approximately $550 million based on the present value of the remaining minimum lease commitments using the Company's incremental borrowing rates as of the effective date. The Company will also record corresponding right-of-use ("ROU") assets based upon the operating lease liabilities adjusted for prepaid and deferred rents. Upon adoption, the Company will also derecognize assets and liabilities associated with leased assets where the Company was deemed the owner of the leased assets for accounting purposes. The difference between the derecognized assets and liabilities will be recognized as a net of tax cumulative adjustment to retained earnings. The Company is finalizing the impact that the amended lease guidance will have on its consolidated financial statements, systems, processes, and internal controls. The Company does not expect that the adoption of ASC 842 will have a material impact on its results of operations or cash flows.
In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectibility of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. ASU 2016-13 is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years, and a modified retrospective approach is required, with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. Entities are permitted to adopt the standard early in fiscal years beginning after December 15, 2018. The Company is currently evaluating the impact of adopting this new accounting guidance.
As of September 30, 2019, there were no other recently issued accounting standards that may have a material impact on the Company's financial position, results of operations, or cash flows upon their adoption.
Business Combinations
The assets acquired and liabilities assumed from the acquired business are recorded at fair value, with the residual of the purchase price recorded as goodwill. The results of operations of the acquired businesses are included in the Company's operating results from the dates of acquisition.
Cash Equivalents
The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.
Concentrations of Credit Risk and Allowance for Doubtful Accounts
The Company sells its inventories to a large number of customers in the healthcare industry that include institutional and retail healthcare providers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physician offices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies, pharmacy departments of supermarkets and mass merchandisers, and veterinarians. The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.
The Company's trade accounts receivables are exposed to credit risk. Revenue from the various agreements and arrangements with the Company's largest customer in the fiscal year ended September 30, 2019, Walgreens Boots Alliance, Inc.
("WBA"), accounted for approximately 34% of revenue and represented approximately 49% of accounts receivable, net of incentives, as of September 30, 2019. Express Scripts, Inc., the Company's second largest customer in the fiscal year ended September 30, 2019, accounted for approximately 13% of revenue and represented approximately 8% of accounts receivable as of September 30, 2019. The Company generally does not require collateral for trade receivables. In determining the appropriate allowance for doubtful accounts, the Company considers a combination of factors, such as the aging of trade receivables, industry trends, and its customers' financial strength, credit standing, and payment and default history. Changes in these factors, among others, may lead to adjustments in the Company's allowance for doubtful accounts. The calculation of the required allowance requires judgment by Company management as to the impact of those and other factors on the ultimate realization of its trade receivables. Each of the Company's business units performs ongoing credit evaluations of its customers' financial condition and maintains reserves for probable bad debt losses based upon historical experience and for specific credit problems when they arise. There were no significant changes to this process during the fiscal years ended September 30, 2019, 2018, and 2017, and bad debt expense was computed in a consistent manner during these periods.
The Company maintains cash and cash equivalents with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and, therefore, bear minimal credit risk. The Company seeks to mitigate such risks by monitoring the risk profiles of these counterparties. The Company also seeks to mitigate risk by monitoring the investment strategy of money market accounts in which it is invested, which are classified as cash equivalents.
Contingencies
Loss Contingencies: In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, and other disputes, including antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, the Company provides disclosure of the loss contingency in the notes to its financial statements. The Company reviews all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made. Among the loss contingencies that the Company considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 13. Although the Company is not able to predict the outcome or reasonably estimate a range of possible losses in these matters, an adverse judgment or negotiated resolution in any of these matters could have a material adverse effect on the Company's results of operations, consolidated financial position, cash flows or liquidity.
Gain Contingencies: The Company records gain contingencies when they are realized. Gains from antitrust litigation settlements are realized upon the receipt of cash and recorded as a reduction to cost of goods sold because they represent a recovery of amounts historically paid to manufacturers to originally acquire the pharmaceuticals that were the subject of the antitrust litigation settlements (see Note 14).
Derivative Financial Instruments
The Company records all derivative financial instruments on the balance sheet at fair value and complies with established criteria for designation and effectiveness of hedging relationships. The Company's policy prohibits it from entering into derivative financial instruments for speculative or trading purposes.
Foreign Currency
When the functional currency of the Company's foreign operations is the applicable local currency, assets and liabilities are translated into U.S. dollars using the current exchange rates in effect at the balance sheet date, while revenues and expenses are translated at the weighted average exchange rates for the period. The resulting translation adjustments are recorded as a component of Accumulated Other Comprehensive Loss within Stockholders' Equity.
Goodwill and Other Intangible Assets
Goodwill arises from acquisitions or consolidations of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. The Company identifies its reporting units based upon the Company's management reporting structure, beginning with its operating segments. The Company aggregates two or more components within an operating segment that have similar economic characteristics. The Company evaluates whether the components within its operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment. The Company's reporting units include Pharmaceutical Distribution Services, Profarma Distribuidora de Produtos Farmacêuticos S.A. ("Profarma"), AmerisourceBergen Consulting Services ("ABCS"), World Courier, and MWI Animal Health ("MWI").
Goodwill and other intangible assets with indefinite lives, such as certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, the Company can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite-lived intangible assets, respectively. Such qualitative factors can include, among others, industry and market conditions, overall financial performance, and relevant entity-specific events. If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis. The Company elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2019, with the exception of its testing of goodwill in the Profarma reporting unit. In the fourth quarter of fiscal 2018 and 2017, the Company elected to bypass performing the qualitative assessment and went directly to performing our annual quantitative assessments of the goodwill and indefinite-lived intangible assets.
The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized. If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.
When performing a quantitative impairment assessment, the Company utilizes an income-based approach to value its reporting units, with the exception of the Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium. The income-based approach relies on a discounted cash flow analysis, which considers forecasted cash flows discounted at an appropriate discount rate, to determine the fair value of each reporting unit. The Company generally believes that market participants would use a discounted cash flow analysis to determine the fair value of the Company's reporting units in a sale transaction. The annual goodwill impairment test requires the Company to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon the Company's long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While the Company uses the best available information to prepare its cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged.
The quantitative impairment test for indefinite-lived intangibles other than goodwill (certain trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method. The Company believes the relief from royalty method is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.
The Company completed its required annual impairment tests relating to goodwill and indefinite-lived intangible assets in the fourth quarter of the fiscal years ended September 30, 2019, 2018, and 2017. The Company recorded a goodwill impairment of $59.7 million in its Profarma reporting unit in connection with its fiscal 2018 annual impairment test (see Note 5). No goodwill impairments were recorded in the fiscal years ended September 30, 2019 and 2017. No indefinite-lived intangible asset impairments were recorded in the fiscal years ended September 30, 2019, 2018, and 2017.
Finite-lived intangible assets are amortized using the straight-line method over the estimated useful lives of the assets. The Company performs a recoverability assessment of its long-lived assets when impairment indicators are present.
After U.S. Food and Drug Administration ("FDA") inspections of PharMEDium Healthcare Holdings, Inc.'s ("PharMEDium") compounding facilities, the Company voluntarily suspended production activities in December 2017 at its largest
compounding facility located in Memphis, Tennessee pending execution of certain remedial measures. On May 17, 2019, PharMEDium reached an agreement on the terms of a consent decree (the "Consent Decree") with the FDA and the Consumer Protection Branch of the Civil Division of the Department of Justice ("DOJ") that was entered by the United States District Court for the Northern District of Illinois on May 22, 2019. The Consent Decree permits commercial operations to continue at PharMEDium’s Dayton, New Jersey and Sugar Land, Texas compounding facilities and administrative operations to continue at its Lake Forest, Illinois headquarters subject to compliance with requirements set forth therein. As required by the Consent Decree, initial audit inspections were conducted by an independent current Good Manufacturing Practice ("cGMP") expert of the Dayton and Sugar Land facilities. The cGMP expert has notified FDA that all of the short-term corrective actions taken are acceptable. The Company has submitted to FDA several additional longer-term corrective actions, and the independent cGMP expert will assess the effectiveness of the implementation of these items in future audits. Additional audit inspections by the independent cGMP expert of the Sugar Land and Dayton facilities are also required at least annually for a period of four years.
The Consent Decree also establishes requirements that must be satisfied prior to the resumption of commercial operations at the Memphis, Tennessee facility. The requirements include a work plan approved by the FDA and an audit inspection and certification by an independent cGMP expert that the facilities, methods and controls at the Memphis facility and PharMEDium’s Lake Forest, Illinois headquarters comply with the Consent Decree. If PharMEDium receives written notification from the FDA of compliance with the requirements to resume operations at the Memphis facility, additional audit inspections are required for five years, during which time PharMEDium must correct any deviations from the Consent Decree observed by the independent cGMP expert.
After five years, PharMEDium may petition the district court for full relief from the Consent Decree, or for specific relief with regard to one or more facilities. If, at the time of such petition, all obligations under the Consent Decree with respect to the specific facilities for which PharMEDium is seeking relief have been satisfied, and there has been continuous compliance with the Consent Decree for at least five years, the federal government will not oppose the petition, and PharMEDium may request that the district court grant such relief.
As a result of the suspension of production activities at PharMEDium's compounding facility located in Memphis, Tennessee and the aforementioned regulatory matters, the Company performed a recoverability assessment of PharMEDium's long-lived assets and recorded a $570.0 million impairment loss in the quarter ended March 31, 2019 for the amount that the carrying value of the PharMEDium asset group exceeded its fair value. Prior to the impairment, the carrying value of the asset group was $792 million. The fair value of the asset group was $222 million as of March 31, 2019. The PharMEDium asset group is included in the Pharmaceutical Distribution Services reportable segment. Significant assumptions used in estimating the fair value of PharMEDium's asset group included (i) a 15% discount rate, which contemplated a higher risk at PharMEDium; (ii) the period in which PharMEDium will resume production at or near capacity; and (iii) the estimated EBITDA (earnings before interest, taxes, depreciation, and amortization) margins when considering the likelihood of higher operating and compliance costs. The Company believes that its fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment are inherently uncertain and include assumptions that could differ from actual results in future periods. This represents a Level 3 nonrecurring fair value measurement. The Company allocated $522.1 million of the impairment to finite-lived intangibles ($420.8 million of customer relationships, $79.9 million of a trade name, and $21.4 million of software technology) and $47.9 million of the impairment to property and equipment.
The Company updated its recoverability assessment of PharMEDium's long-lived assets as of September 30, 2019. The Company concluded that PharMEDium’s long-lived assets were recoverable as of September 30, 2019.
Income Taxes
The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities (commonly known as the asset and liability method). In assessing the need to establish a valuation allowance on deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.
The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based upon the technical merits of the position. Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.
Inventories
Inventories are stated at the lower of cost or market. Cost for approximately 75% of the Company's inventories as of September 30, 2019 and 2018 has been determined using the last-in, first-out ("LIFO") method. If the Company had used the first-in, first-out method of inventory valuation, which approximates current replacement cost, inventories would have been approximately $1,511.8 million and $1,534.4 million higher than the amounts reported as of September 30, 2019 and 2018, respectively. The Company recorded LIFO credits of $22.5 million and $157.8 million in the fiscal years ended September 30, 2019 and 2017, respectively, and LIFO expense of $67.3 million in the fiscal year ended September 30, 2018. The annual LIFO provision is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences, many of which are difficult to predict. Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.
Investments
The Company first evaluates its investments in accordance with the variable interest model to determine whether it has a controlling financial interest in an investment. This evaluation is made as of the date on which the Company makes its initial investment, and subsequent evaluations are made if the structure of the investment changes. If it has determined that an investment is a variable interest entity ("VIE"), the Company evaluates whether the VIE is required to be consolidated. When the Company holds rights that give it the power to direct the activities of an entity that most significantly impact the entity's economic performance, combined with the obligation to absorb an entity's losses and the right to receive benefits, the Company consolidates a VIE. If it is determined that an investment is not a VIE, the Company then evaluates its investments under the voting interest model and generally consolidates investments in which it holds an ownership interest of greater than 50%. When the Company consolidates less than wholly-owned subsidiaries, it discloses its noncontrolling interest in its consolidated financial statements.
For equity securities without a readily determinable fair value, the Company uses the fair value measurement alternative and measures the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which the Company can exercise significant influence but does not control, it uses the equity method of accounting. The Company's share of earnings and losses is recorded in Other Income (Loss) in the Consolidated Statements of Operations. The Company monitors its investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions.
Leases
The Company is often involved in the construction of its distribution facilities. In certain cases, the Company makes payments for certain structural components included in the lessor's construction of the leased assets, which result in the Company being deemed the owner of the leased assets for accounting purposes. As a result, regardless of the significance of the payments, Accounting Standards Codification 840, Leases, ("ASC 840") defines those payments as automatic indicators of ownership and requires the Company to capitalize the lessor's total project cost with a corresponding financing obligation. Upon completion of the lessor's project, the Company performs a sale-leaseback analysis pursuant to ASC 840 to determine if these assets and the related financing obligations can be derecognized from the Company's Consolidated Balance Sheet. If the Company is deemed to have "continuing involvement," the leased assets and the related financing obligations remain on the Company's Consolidated Balance Sheet and are amortized over the life of the assets and the lease term, respectively. All other leases are considered operating leases in accordance with ASC 840. Assets subject to an operating lease and the related lease payments are not recorded on the Company's Consolidated Balance Sheet. Rent expense is recognized on a straight-line basis over the expected lease term and is recorded in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations.
Manufacturer Incentives
The Company considers fees and other incentives received from its suppliers relating to the purchase or distribution of inventory to represent product discounts, and, as a result, they are recognized within cost of goods sold upon the sale of the related inventory.
Property and Equipment
Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which range from 3 to 40 years for buildings and improvements and from 3 to 10 years for machinery, equipment, and other. The costs of repairs and maintenance are charged to expense as incurred.
The Company capitalizes project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application development stage. Costs that are associated with preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred. Software development costs are depreciated using the straight-line method over the estimated useful lives, which range from 3 to 10 years.
Revenue Recognition
The Company's revenues are primarily generated from the distribution of pharmaceutical products. The Company also generates revenues from global commercialization services, which include clinical trial support, post-approval and commercialization support, and global specialty transportation and logistics for the biopharmaceutical industry. See Note 15 for the Company's disaggregated revenue.

The Company recognizes revenue related to the distribution of products at a point in time when title and control transfers to customers and there is no further obligation to provide services related to such products. Service revenue is recognized over the period that services are provided to the customer. The Company is generally the principal in a transaction; therefore, revenue is primarily recorded on a gross basis. When the Company is the principal in a transaction, it has determined that it controls the ability to direct the use of the product or service prior to the transfer to a customer, it is primarily responsible for fulfilling the promise to provide the product or service to its customer, it has discretion in establishing pricing, and it controls the relationship with the customer. Revenue is recognized at the amount of consideration expected to be received. For the distribution business, revenue is primarily generated from a contract related to a confirmed purchase order with a customer in a distribution arrangement and is net of estimated sales returns and allowances, other customer incentives, and sales tax.
The Company's customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. The Company records an accrual for estimated customer sales returns at the time of sale to the customer based upon historical return trends. As of September 30, 2019 and 2018, the Company's accrual for estimated customer sales returns was $1,147.5 million and $988.8 million, respectively. In fiscal 2019, due to the adoption of ASC 606, the Company records an asset for the right to recover products from its customers in Right to Recover Asset on its Consolidated Balance Sheet. The Company's asset for the right to recover products from its customers was included in Inventories on its Consolidated Balance Sheet as of September 30, 2018 and for all prior periods.
Share-Based Compensation
The Company accounts for the compensation cost of all share-based payments at fair value. The Company estimates the fair value of option grants using a binomial option pricing model. The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company’s common stock.
Share-based compensation expense is recognized over the requisite service period within Distribution, Selling, and Administrative in the Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees. Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.
The income tax effects of awards are recognized when the awards vest or are settled and are recognized in Income Tax Expense in the Company’s Consolidated Statements of Operations and in cash flows from operations in the Consolidated Statements of Cash Flows. Prior to fiscal 2017, tax benefits from share-based compensation were recorded as adjustments to Additional Paid-in Capital within Stockholders’ Equity and as cash flows from financing activities within the Statement of Cash Flows (see Recently Adopted Accounting Pronouncements).
Shipping and Handling Costs
Shipping and handling costs include all costs to warehouse, pick, pack, and deliver inventory to customers. These costs, which were $619.7 million, $590.8 million, and $517.3 million for the fiscal years ended September 30, 2019, 2018, and 2017, respectively, are included in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations.
Supplier Reserves
The Company establishes reserves against amounts due from its suppliers relating to various price and rebate incentives, including deductions or billings taken against payments otherwise due to them from the Company. These reserve estimates are established based upon the judgment of Company management after carefully considering the status of current outstanding claims, historical experience with the suppliers, the specific incentive programs, and any other pertinent information available to the Company. The Company evaluates the amounts due from its suppliers on a continual basis and adjusts the reserve estimates when appropriate based upon changes in factual circumstances. The ultimate outcome of any outstanding claim may be different than the Company's estimate.
ZIP 104 0001140859-19-000040-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140859-19-000040-xbrl.zip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�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a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�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end XML 105 a10-kx9302019_htm.xml IDEA: XBRL DOCUMENT 0001140859 2018-10-01 2019-09-30 0001140859 2019-03-31 0001140859 2019-10-31 0001140859 2018-09-30 0001140859 2019-09-30 0001140859 2017-10-01 2018-09-30 0001140859 2016-10-01 2017-09-30 0001140859 us-gaap:TreasuryStockMember 2016-09-30 0001140859 us-gaap:RetainedEarningsMember 2016-09-30 0001140859 us-gaap:AdditionalPaidInCapitalMember 2016-10-01 2017-09-30 0001140859 us-gaap:AdditionalPaidInCapitalMember 2017-10-01 2018-09-30 0001140859 us-gaap:CommonStockMember 2018-10-01 2019-09-30 0001140859 us-gaap:CommonStockMember 2019-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-10-01 2019-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-10-01 2018-09-30 0001140859 us-gaap:TreasuryStockMember 2019-09-30 0001140859 2016-10-01 0001140859 us-gaap:NoncontrollingInterestMember 2016-09-30 0001140859 us-gaap:RetainedEarningsMember 2016-10-01 2017-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2017-10-01 2018-09-30 0001140859 us-gaap:TreasuryStockMember 2016-10-01 2017-09-30 0001140859 us-gaap:CommonStockMember 2018-09-30 0001140859 us-gaap:CommonStockMember 2016-09-30 0001140859 2018-10-01 0001140859 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2019-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001140859 us-gaap:TreasuryStockMember 2017-10-01 2018-09-30 0001140859 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-10-01 2017-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001140859 us-gaap:CommonStockMember 2017-10-01 2018-09-30 0001140859 us-gaap:RetainedEarningsMember 2019-09-30 0001140859 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001140859 us-gaap:RetainedEarningsMember 2017-10-01 2018-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2019-09-30 0001140859 us-gaap:TreasuryStockMember 2018-10-01 2019-09-30 0001140859 2017-09-30 0001140859 2016-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2018-10-01 0001140859 us-gaap:TreasuryStockMember 2018-09-30 0001140859 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-09-30 0001140859 us-gaap:TreasuryStockMember 2017-09-30 0001140859 us-gaap:CommonStockMember 2017-09-30 0001140859 us-gaap:RetainedEarningsMember 2017-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2018-09-30 0001140859 us-gaap:RetainedEarningsMember 2018-10-01 2019-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2018-10-01 2019-09-30 0001140859 us-gaap:CommonStockMember 2016-10-01 2017-09-30 0001140859 us-gaap:NoncontrollingInterestMember 2017-09-30 0001140859 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0001140859 us-gaap:RetainedEarningsMember 2018-09-30 0001140859 us-gaap:RetainedEarningsMember 2016-10-01 0001140859 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001140859 us-gaap:RetainedEarningsMember 2018-10-01 0001140859 us-gaap:ShippingAndHandlingMember 2017-10-01 2018-09-30 0001140859 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2018-10-01 2019-09-30 0001140859 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-03-31 0001140859 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-10-01 2019-09-30 0001140859 abc:PharmediumHealthcareHoldingsIncMember 2019-03-31 0001140859 abc:ExpressScriptsMember 2018-10-01 2019-09-30 0001140859 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2018-10-01 2019-09-30 0001140859 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-10-01 2019-09-30 0001140859 2019-01-01 2019-03-31 0001140859 abc:ExpressScriptsMember 2019-09-30 0001140859 srt:ScenarioForecastMember us-gaap:SubsequentEventMember 2019-10-01 0001140859 us-gaap:TradeNamesMember 2019-01-01 2019-03-31 0001140859 abc:WalgreensBootsAllianceIncMember 2019-09-30 0001140859 us-gaap:AccountingStandardsUpdate201609Member us-gaap:RetainedEarningsMember 2016-10-01 0001140859 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-01-01 2019-03-31 0001140859 us-gaap:ShippingAndHandlingMember 2018-10-01 2019-09-30 0001140859 us-gaap:ShippingAndHandlingMember 2016-10-01 2017-09-30 0001140859 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2018-10-01 2019-09-30 0001140859 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2018-10-01 2019-09-30 0001140859 abc:WalgreensBootsAllianceIncMember 2018-10-01 2019-09-30 0001140859 us-gaap:AccountingStandardsUpdate201609Member 2016-10-01 0001140859 abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-01-31 0001140859 abc:ProfarmaJointVentureMember 2018-01-31 0001140859 abc:H.D.SmithMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-01-31 0001140859 abc:ProfarmaJointVentureMember 2018-09-01 2018-09-30 0001140859 abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member 2018-01-01 2018-01-31 0001140859 abc:H.D.SmithMember us-gaap:TradeNamesMember 2018-01-01 2018-01-31 0001140859 abc:NortheastVeterinarySupplyCompanyNEVSCOMember 2017-12-31 0001140859 abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member 2018-01-31 0001140859 abc:ProfarmaJointVentureMember 2017-10-01 2018-09-30 0001140859 abc:ProfarmaJointVentureMember 2018-01-01 2018-01-31 0001140859 abc:H.D.SmithMember 2018-01-31 0001140859 abc:NortheastVeterinarySupplyCompanyNEVSCOMember 2017-12-01 2017-12-31 0001140859 abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member us-gaap:TradeNamesMember 2018-01-31 0001140859 abc:NortheastVeterinarySupplyCompanyNEVSCOMember us-gaap:CustomerRelationshipsMember 2017-12-01 2017-12-31 0001140859 abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member us-gaap:CustomerRelationshipsMember 2018-01-31 0001140859 us-gaap:AccumulatedTranslationAdjustmentMember 2017-10-01 2018-09-30 0001140859 abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member 2018-03-31 0001140859 abc:H.D.SmithMember us-gaap:TradeNamesMember 2018-01-31 0001140859 abc:ProfarmaJointVentureMember 2018-03-31 0001140859 srt:MinimumMember abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member us-gaap:TradeNamesMember 2018-01-01 2018-01-31 0001140859 abc:ProfarmaJointVentureMember 2019-09-30 0001140859 srt:MaximumMember abc:ProfarmaDistribuidoradeProdutosFarmaceuticosS.A.Member us-gaap:TradeNamesMember 2018-01-01 2018-01-31 0001140859 abc:ProfarmaJointVentureMember us-gaap:CustomerRelationshipsMember 2018-01-01 2018-01-31 0001140859 abc:ProfarmaJointVentureMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-01-31 0001140859 abc:H.D.SmithMember 2018-01-01 2018-01-31 0001140859 abc:H.D.SmithMember us-gaap:CustomerRelationshipsMember 2018-01-31 0001140859 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2019-09-30 0001140859 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2018-09-30 0001140859 us-gaap:StateAndLocalJurisdictionMember 2019-09-30 0001140859 2018-10-01 2018-12-31 0001140859 abc:USAOEDNYMatterMember 2017-09-30 0001140859 srt:MaximumMember us-gaap:StateAndLocalJurisdictionMember 2019-09-30 2019-09-30 0001140859 us-gaap:DomesticCountryMember abc:AlternativeMinimumTaxMember 2019-09-30 0001140859 2019-07-01 2019-09-30 0001140859 us-gaap:ForeignCountryMember 2019-09-30 0001140859 us-gaap:DomesticCountryMember 2019-09-30 0001140859 srt:MinimumMember us-gaap:DomesticCountryMember 2019-09-30 2019-09-30 0001140859 srt:MinimumMember us-gaap:StateAndLocalJurisdictionMember 2019-09-30 2019-09-30 0001140859 srt:MaximumMember us-gaap:DomesticCountryMember 2019-09-30 2019-09-30 0001140859 us-gaap:ForeignCountryMember abc:AlternativeMinimumTaxMember 2019-09-30 0001140859 abc:USAOEDNYCivilClaimsMember 2016-10-01 2017-09-30 0001140859 abc:USAOEDNYCivilClaimsMember 2018-09-28 2018-09-28 0001140859 us-gaap:TradeNamesMember 2018-09-30 0001140859 abc:TradeNamesAndOtherMember 2019-09-30 0001140859 us-gaap:CustomerRelationshipsMember 2019-09-30 2019-09-30 0001140859 us-gaap:CustomerRelationshipsMember 2018-09-30 0001140859 abc:TradeNamesAndOtherMember 2018-09-30 0001140859 us-gaap:TradeNamesMember 2019-09-30 0001140859 us-gaap:CustomerRelationshipsMember 2019-09-30 0001140859 abc:TradeNamesAndOtherMember 2019-09-30 2019-09-30 0001140859 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2017-10-01 2018-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:PharmaceuticalDistributionMember 2018-10-01 2019-09-30 0001140859 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2018-09-30 0001140859 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2018-10-01 2019-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:PharmaceuticalDistributionMember 2017-10-01 2018-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:PharmaceuticalDistributionMember 2019-09-30 0001140859 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2019-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:PharmaceuticalDistributionMember 2018-09-30 0001140859 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2017-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:PharmaceuticalDistributionMember 2017-09-30 0001140859 abc:SeniorNotesDue2047Member 2019-09-30 0001140859 abc:SeniorNotesDue2027Member 2019-09-30 0001140859 abc:NonrecourseDebtMember 2019-09-30 0001140859 abc:NonrecourseDebtMember 2018-09-30 0001140859 abc:ReceivablesSecuritizationFacilityMember 2018-09-30 0001140859 abc:SeniorNotesDue2024Member 2018-09-30 0001140859 abc:TermLoanAgreementMember 2019-09-30 0001140859 abc:RevolvingCreditNoteMember 2019-09-30 0001140859 abc:SeniorNotesDue2021Member 2018-09-30 0001140859 abc:OverdraftFacilityMember 2019-09-30 0001140859 abc:ReceivablesSecuritizationFacilityMember 2019-09-30 0001140859 abc:SeniorNotesDue2045Member 2018-09-30 0001140859 abc:SeniorNotesDue2027Member 2018-09-30 0001140859 abc:MultiCurrencyRevolvingCreditFacilityMember 2019-09-30 0001140859 abc:TermLoanAgreementMember 2018-09-30 0001140859 abc:SeniorNotesDue2047Member 2018-09-30 0001140859 abc:SeniorNotesDue2024Member 2019-09-30 0001140859 abc:CorporationDebtMember 2018-09-30 0001140859 abc:SeniorNotesDue2021Member 2019-09-30 0001140859 abc:MultiCurrencyRevolvingCreditFacilityMember 2018-09-30 0001140859 abc:CorporationDebtMember 2019-09-30 0001140859 abc:SeniorNotesDue2025Member 2019-09-30 0001140859 abc:SeniorNotesDue2045Member 2019-09-30 0001140859 abc:RevolvingCreditNoteMember 2018-09-30 0001140859 abc:OverdraftFacilityMember 2018-09-30 0001140859 abc:SeniorNotesDue2025Member 2018-09-30 0001140859 abc:SeniorNotesDue2027Member 2017-12-31 0001140859 abc:SeniorNotesDue2047Member 2017-12-31 0001140859 2017-12-01 2017-12-31 0001140859 us-gaap:CommercialPaperMember 2019-09-30 0001140859 abc:SeniorNotesDue2019Member 2017-12-31 0001140859 2018-10-31 0001140859 abc:TermLoanAgreementOctober2018Member 2018-10-31 0001140859 abc:MultiCurrencyRevolvingCreditFacilityMember 2018-10-01 2019-09-30 0001140859 abc:MultiCurrencyRevolvingCreditFacilityMember abc:CdorLiborEuriborBankersAcceptanceStampingFeeMember 2018-10-01 2019-09-30 0001140859 srt:MaximumMember abc:MultiCurrencyRevolvingCreditFacilityMember abc:AlternateBaseRateAndCanadianPrimeRateCdorRateMember 2018-10-01 2019-09-30 0001140859 srt:MinimumMember abc:MultiCurrencyRevolvingCreditFacilityMember abc:AlternateBaseRateAndCanadianPrimeRateCdorRateMember 2018-10-01 2019-09-30 0001140859 us-gaap:CommercialPaperMember 2018-09-30 0001140859 abc:TermLoanAgreementOctober2018Member us-gaap:LondonInterbankOfferedRateLIBORMember 2018-10-01 2018-10-31 0001140859 srt:MaximumMember abc:MultiCurrencyRevolvingCreditFacilityMember abc:CdorLiborEuriborBankersAcceptanceStampingFeeMember 2018-10-01 2019-09-30 0001140859 srt:MinimumMember abc:MultiCurrencyRevolvingCreditFacilityMember abc:CdorLiborEuriborBankersAcceptanceStampingFeeMember 2018-10-01 2019-09-30 0001140859 abc:AccumulatedOtherAdjustmentsAttributabletoParentMember 2019-09-30 0001140859 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0001140859 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-09-30 0001140859 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-09-30 0001140859 abc:AccumulatedOtherAdjustmentsAttributabletoParentMember 2018-09-30 0001140859 us-gaap:AccumulatedTranslationAdjustmentMember 2018-09-30 0001140859 abc:November2016ShareRepurchaseProgramMember 2018-10-01 2019-09-30 0001140859 abc:October2018ShareRepurchaseProgramMember 2018-10-01 2019-09-30 0001140859 abc:May2016ShareRepurchaseProgramMember 2016-10-01 2017-09-30 0001140859 abc:May2016ShareRepurchaseProgramMember 2016-09-01 2016-09-30 0001140859 abc:November2016ShareRepurchaseProgramMember 2016-11-30 0001140859 abc:May2016ShareRepurchaseProgramMember 2016-11-01 2016-11-30 0001140859 abc:November2016ShareRepurchaseProgramMember 2016-10-01 2017-09-30 0001140859 abc:November2016ShareRepurchaseProgramMember 2017-10-01 2018-09-30 0001140859 abc:May2016ShareRepurchaseProgramMember 2016-09-30 0001140859 abc:October2018ShareRepurchaseProgramMember 2019-09-30 0001140859 abc:October2018ShareRepurchaseProgramMember 2018-10-31 0001140859 abc:WalgreensBootsAllianceIncMember us-gaap:InvestorMember 2018-09-30 0001140859 abc:WalgreensBootsAllianceIncMember us-gaap:InvestorMember 2019-09-30 0001140859 abc:WalgreensBootsAllianceIncMember us-gaap:InvestorMember 2018-10-01 2019-09-30 0001140859 abc:WalgreensBootsAllianceIncMember us-gaap:InvestorMember 2017-10-01 2018-09-30 0001140859 abc:WalgreensBootsAllianceIncMember us-gaap:InvestorMember 2016-10-01 2017-09-30 0001140859 abc:EmployeeContributionFirstThreePercentOfSalaryMember 2016-10-01 2016-12-31 0001140859 srt:ScenarioForecastMember abc:EmployeeContributionAdditionalTwoPercentOfSalaryMember 2019-01-01 2019-12-31 0001140859 2016-10-01 2016-12-31 0001140859 2017-01-01 2018-12-31 0001140859 abc:EmployeeContributionFirstThreePercentOfSalaryMember 2017-01-01 2018-12-31 0001140859 srt:ScenarioForecastMember 2019-01-01 2019-12-31 0001140859 abc:EmployeeContributionAdditionalTwoPercentOfSalaryMember 2016-10-01 2016-12-31 0001140859 srt:ScenarioForecastMember abc:EmployeeContributionFirstThreePercentOfSalaryMember 2019-01-01 2019-12-31 0001140859 2017-10-01 2017-12-31 0001140859 2019-09-30 2019-09-30 0001140859 2018-09-30 2018-09-30 0001140859 us-gaap:PerformanceSharesMember 2018-10-01 2019-09-30 0001140859 us-gaap:PerformanceSharesMember 2019-09-30 0001140859 us-gaap:PerformanceSharesMember 2018-09-30 0001140859 srt:MinimumMember us-gaap:PerformanceSharesMember 2017-10-01 2018-09-30 0001140859 srt:MinimumMember us-gaap:PerformanceSharesMember 2018-10-01 2019-09-30 0001140859 us-gaap:RestrictedStockUnitsRSUMember 2019-09-30 2019-09-30 0001140859 us-gaap:RestrictedStockUnitsRSUMember 2017-10-01 2018-09-30 0001140859 us-gaap:RestrictedStockUnitsRSUMember 2019-09-30 0001140859 srt:MaximumMember us-gaap:PerformanceSharesMember 2017-10-01 2018-09-30 0001140859 us-gaap:RestrictedStockUnitsRSUMember 2018-10-01 2019-09-30 0001140859 abc:NonEmployeeMember 2018-10-01 2019-09-30 0001140859 us-gaap:RestrictedStockUnitsRSUMember 2016-10-01 2017-09-30 0001140859 us-gaap:PerformanceSharesMember 2016-10-01 2017-09-30 0001140859 srt:MaximumMember us-gaap:PerformanceSharesMember 2018-10-01 2019-09-30 0001140859 us-gaap:PerformanceSharesMember 2017-10-01 2018-09-30 0001140859 us-gaap:RestrictedStockUnitsRSUMember 2018-09-30 0001140859 us-gaap:EmployeeStockOptionMember 2018-10-01 2019-09-30 0001140859 abc:OpioidLawsuitsandInvestigationsMember 2018-10-01 2019-09-30 0001140859 abc:OpioidLawsuitsandInvestigationsMember 2017-10-01 2018-09-30 0001140859 abc:USAOSDNYMatterMember 2016-10-01 2017-09-30 0001140859 2018-07-01 2018-09-30 0001140859 abc:WestVirginiaAGMatterMember 2016-10-01 2017-09-30 0001140859 abc:USAOEDNYMisdemeanorViolationMember 2016-10-01 2017-09-30 0001140859 abc:SettlementwithOhioCountiesMember 2018-10-01 2019-09-30 0001140859 abc:MDLandOtherRelatedStateCourtLitigationMember us-gaap:SubsequentEventMember 2019-10-21 2019-10-21 0001140859 abc:USAOSDNYMatterMember 2017-10-01 2018-09-30 0001140859 2018-07-01 0001140859 us-gaap:MaterialReconcilingItemsMember 2017-10-01 2018-09-30 0001140859 us-gaap:MaterialReconcilingItemsMember 2016-10-01 2017-09-30 0001140859 us-gaap:OperatingSegmentsMember 2018-10-01 2019-09-30 0001140859 us-gaap:OperatingSegmentsMember 2017-10-01 2018-09-30 0001140859 us-gaap:MaterialReconcilingItemsMember 2018-10-01 2019-09-30 0001140859 us-gaap:OperatingSegmentsMember 2016-10-01 2017-09-30 0001140859 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2016-10-01 2017-09-30 0001140859 us-gaap:IntersegmentEliminationMember 2016-10-01 2017-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:PharmaceuticalDistributionMember 2016-10-01 2017-09-30 0001140859 us-gaap:IntersegmentEliminationMember 2017-10-01 2018-09-30 0001140859 us-gaap:IntersegmentEliminationMember 2018-10-01 2019-09-30 0001140859 abc:PharmaceuticalDistributionMember 2017-10-01 2018-09-30 0001140859 abc:PharmaceuticalDistributionMember 2018-10-01 2019-09-30 0001140859 abc:PharmaceuticalDistributionMember 2016-10-01 2017-09-30 0001140859 us-gaap:AllOtherSegmentsMember 2016-10-01 2017-09-30 0001140859 us-gaap:AllOtherSegmentsMember 2017-10-01 2018-09-30 0001140859 us-gaap:AllOtherSegmentsMember 2018-10-01 2019-09-30 0001140859 us-gaap:AllOtherSegmentsMember abc:WorldCourierMember 2019-09-30 0001140859 us-gaap:OtherNonoperatingIncomeExpenseMember 2018-10-01 2019-09-30 0001140859 us-gaap:OtherNonoperatingIncomeExpenseMember 2017-10-01 2018-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:MWIAnimalHealthMember 2017-10-01 2018-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:GlobalCommercializationServicesMember 2016-10-01 2017-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:MWIAnimalHealthMember 2018-10-01 2019-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:MWIAnimalHealthMember 2016-10-01 2017-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:GlobalCommercializationServicesMember 2017-10-01 2018-09-30 0001140859 us-gaap:OperatingSegmentsMember abc:GlobalCommercializationServicesMember 2018-10-01 2019-09-30 0001140859 us-gaap:AllOtherSegmentsMember 2018-09-30 0001140859 abc:PharmaceuticalDistributionMember 2019-09-30 0001140859 us-gaap:AllOtherSegmentsMember 2019-09-30 0001140859 us-gaap:AllOtherSegmentsMember 2017-09-30 0001140859 abc:PharmaceuticalDistributionMember 2017-09-30 0001140859 abc:PharmaceuticalDistributionMember 2018-09-30 0001140859 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-09-30 0001140859 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MoneyMarketFundsMember 2019-09-30 0001140859 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-09-30 0001140859 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-09-30 0001140859 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-09-30 0001140859 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:MoneyMarketFundsMember 2018-09-30 0001140859 2018-04-01 2018-06-30 0001140859 2018-01-01 2018-03-31 0001140859 2019-04-01 2019-06-30 0001140859 us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-03-31 0001140859 us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-03-31 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsMember 2017-10-01 2018-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsMember 2019-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsMember 2018-10-01 2019-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsMember 2016-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsMember 2018-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsMember 2016-10-01 2017-09-30 0001140859 abc:AllowanceForReturnsAndDoubtfulAccountsMember 2017-09-30 0001140859 us-gaap:OtherNoncurrentAssetsMember abc:AllowanceForReturnsandDoubtfulAccountsNoncurrentMember 2018-09-30 0001140859 us-gaap:OtherNoncurrentAssetsMember abc:AllowanceForReturnsandDoubtfulAccountsNoncurrentMember 2019-09-30 0001140859 us-gaap:OtherNoncurrentAssetsMember abc:AllowanceForReturnsandDoubtfulAccountsNoncurrentMember 2017-09-30 iso4217:USD pure shares iso4217:USD shares iso4217:GBP abc:country 1036333000 1222906000 0.00125 0.0005 false --09-30 FY 2019 0001140859 1.46 1.52 1.60 0.01 600000000 283588463 285295170 213217882 206760654 0.0065 0.00125 0.01125 0 0.0070 0.0091 500000000 500000000 500000000 750000000 500000000 500000000 0.0350 0.034 0.0325 0.0345 0.0425 0.0430 47100000 0 0 0 0.0009 0.75 P3Y P4Y P3Y P7Y 0 70370581 78534516 10-K true 2019-09-30 false 1-16671 AMERISOURCEBERGEN CORP DE 23-3079390 1300 Morris Drive Chesterbrook, PA 19087-5594 610 727-7000 Common stock ABC NYSE Yes No Yes Yes Large Accelerated Filer false false false 9817515026 205922186 3374194000 2492516000 12386879000 11314226000 11060254000 11918508000 1147483000 0 163244000 169122000 28132054000 25894372000 44142000 39875000 942129000 1086909000 2362869000 2281124000 3349140000 3407908000 1578624000 1515484000 1770516000 1892424000 6705507000 6664272000 2294836000 2947828000 269067000 270942000 39171980000 37669838000 28385074000 26836873000 1057208000 881157000 139012000 151657000 29581294000 27869687000 4033880000 4158532000 320518000 352296000 284075000 299600000 1860195000 1829410000 98812000 110352000 2853000 2836000 4850142000 4715473000 4235491000 3720582000 -111965000 -79253000 6097604000 5426814000 2878917000 2932824000 114289000 117137000 2993206000 3049961000 39171980000 37669838000 179589121000 167939635000 153143826000 174450809000 163327318000 148597824000 5138312000 4612317000 4546002000 2663508000 2460301000 2128730000 294965000 283971000 237100000 167442000 181156000 160503000 330474000 183520000 959327000 0 59684000 0 570000000 0 0 1111923000 1443685000 1060342000 12952000 -25469000 2730000 -157769000 -174699000 -145185000 0 42328000 0 0 -23766000 0 967106000 1177423000 917887000 112971000 -438469000 553403000 854135000 1615892000 364484000 -1230000 -42513000 0 855365000 1658405000 364484000 4.07 7.61 1.67 4.04 7.53 1.64 210165000 217872000 218375000 211840000 220336000 221602000 854135000 1615892000 364484000 -32957000 -36904000 16540000 0 45941000 0 -271000 -756000 1918000 -33228000 8281000 18458000 820907000 1624173000 382942000 -1746000 -50829000 0 822653000 1675002000 382942000 2778000 4333001000 2303941000 -114308000 -4396008000 0 2129404000 47063000 47063000 364484000 364484000 18458000 18458000 320270000 320270000 25000 102898000 102923000 62206000 62206000 -467000 -467000 329929000 329929000 20000000 -20000000 0 9411000 9411000 3000 -3000 0 2806000 4517635000 2395218000 -95850000 -4755348000 0 2064461000 167966000 167966000 1658405000 -42513000 1615892000 16597000 -8316000 8281000 333041000 333041000 27000 138429000 138456000 62316000 62316000 -341000 -341000 663220000 663220000 8246000 8246000 3000 -2566000 -2563000 2836000 4715473000 3720582000 -79253000 -5426814000 117137000 3049961000 -1482000 -1102000 -2584000 855365000 -1230000 854135000 -32712000 -516000 -33228000 338974000 338974000 15000 76219000 76234000 58874000 58874000 664803000 664803000 5987000 5987000 2000 -424000 -422000 2853000 4850142000 4235491000 -111965000 -6097604000 114289000 2993206000 854135000 1615892000 364484000 321102000 318483000 262420000 176410000 191626000 169911000 25196000 16660000 8934000 28537000 -795524000 319069000 58874000 62316000 62206000 -22544000 67324000 -157782000 570000000 0 0 13692000 0 0 0 59684000 0 0 30000000 0 0 42328000 0 0 -23766000 0 23193000 19078000 -7744000 1241890000 657770000 1277896000 167990000 4923000 431454000 6733000 57211000 -33646000 1561048000 859036000 1473389000 -13353000 209899000 27192000 238116000 -551120000 642275000 2344023000 1411388000 1504138000 310222000 336411000 466397000 63951000 785299000 61648000 0 0 11347000 0 0 12094000 0 0 74778000 0 0 48635000 1659000 -10596000 -3114000 -375832000 -1111114000 -498041000 506948000 1314430000 0 510863000 681001000 750000000 640126000 25129704000 9336400000 769284000 25127438000 9335953000 0 22348000 0 674031000 639235000 329929000 76234000 138456000 102923000 338974000 333041000 320270000 5987000 8246000 9411000 -10682000 -14154000 -6574000 -1086513000 -242873000 -1312814000 881678000 57401000 -306717000 2492516000 2435115000 2741832000 3374194000 2492516000 2435115000 Summary of Significant Accounting Policies<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">AmerisourceBergen Corporation and its subsidiaries, including less than wholly-owned subsidiaries in which AmerisourceBergen Corporation has a controlling financial interest (the "Company"), is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company delivers innovative programs and services designed to improve the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying financial statements present the consolidated financial position, results of operations, and cash flows of the Company as of the dates and for the periods indicated. All intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts due to uncertainties inherent in such estimates. Management periodically evaluates estimates used in the preparation of the financial statements for continued reasonableness. Certain reclassifications have been made to prior-period amounts in order to conform to the current year presentation.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"). ASU 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are exercised. It also allows an employer to repurchase more of an employee's shares for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 was effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. On October 1, 2016, the Company early adopted ASU 2016-09, which resulted in a cumulative adjustment to retained earnings and the establishment of a deferred tax asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$47.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for previously unrecognized tax benefits. The Company elected to adopt the Statement of Cash Flows presentation of the excess tax benefits prospectively. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)" ("ASU 2014-09"). ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification ("ASC") 605 - "Revenue Recognition" and most industry-specific guidance throughout the Codification. ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard's core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-08, "Revenue from Contracts with Customers (Topic 606) - Principal versus Agent Considerations" ("ASU 2016-08"), which clarified the implementation guidance for principal versus agent considerations in ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10, "Revenue from Contracts with Customers (Topic 606) - Identifying Performance Obligations and Licensing" ("ASU 2016-10"), which amended the guidance in ASU 2014-09 related to identifying performance obligations and accounting for licenses of intellectual property. The Company was required to adopt ASU 2016-08 and ASU 2016-10 with ASU 2014-09, collectively ASC 606.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted ASC 606 as of October 1, 2018 on a modified retrospective basis for all open contracts as of October 1, 2018. The adoption had an immaterial impact on the Company's October 1, 2018 retained earnings and will not have a material impact on the Company's revenues, results of operations, or cash flows. The Company did not record any material contract assets, contract liabilities, or deferred contract costs in its Consolidated Balance Sheet upon adoption.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company elected the practical expedient to expense costs to obtain a contract when incurred when the amortization period would have been one year or less. Additionally, the Company elected the practical expedients to not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for services performed, and (iii) for contracts for which the variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the Company's revenue recognition policy, refer to the "Revenue Recognition" section of Note 1.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)" ("ASU 2016-02" or "ASC 842")). ASU 2016-02 aims to increase transparency and comparability across organizations by requiring lease assets and lease liabilities to be recognized on the balance sheet as well as key information to be disclosed regarding lease arrangements. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018 and interim periods within those fiscal years. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company will adopt ASC 842 in the first quarter of fiscal 2020 and will adopt using the modified retrospective approach. The Company will elect the transition package of practical expedients provided within the amended guidance, which eliminates the requirements to reassess lease identification, lease classification, and initial direct costs for leases that commenced before the effective date. The Company will also elect to combine lease and non-lease components and to exclude short-term leases from its consolidated balance sheets. The Company did not elect the hindsight practical expedient in determining the lease term.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The adoption of the amended guidance is expected to have a material impact on the consolidated balance sheet from the recognition of lease assets and liabilities. While the Company continues to finalize the impact of adoption, it anticipates recognizing operating lease liabilities of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$550 million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the present value of the remaining minimum lease commitments using the Company's incremental borrowing rates as of the effective date. The Company will also record corresponding right-of-use ("ROU") assets based upon the operating lease liabilities adjusted for prepaid and deferred rents. Upon adoption, the Company will also derecognize assets and liabilities associated with leased assets where the Company was deemed the owner of the leased assets for accounting purposes. The difference between the derecognized assets and liabilities will be recognized as a net of tax cumulative adjustment to retained earnings. The Company is finalizing the impact that the amended lease guidance will have on its consolidated financial statements, systems, processes, and internal controls. The Company does not expect that the adoption of ASC 842 will have a material impact on its results of operations or cash flows. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectibility of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. ASU 2016-13 is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years, and a modified retrospective approach is required, with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. Entities are permitted to adopt the standard early in fiscal years beginning after December 15, 2018. The Company is currently evaluating the impact of adopting this new accounting guidance.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were no other recently issued accounting standards that may have a material impact on the Company's financial position, results of operations, or cash flows upon their adoption.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Combinations</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The assets acquired and liabilities assumed from the acquired business are recorded at fair value, with the residual of the purchase price recorded as goodwill. The results of operations of the acquired businesses are included in the Company's operating results from the dates of acquisition.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Equivalents</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk and Allowance for Doubtful Accounts</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">The Company sells its inventories to a large number of customers in the healthcare industry that include institutional and retail healthcare providers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physician offices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies, pharmacy departments of supermarkets and mass merchandisers, and veterinarians. The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's trade accounts receivables are exposed to credit risk. Revenue from the various agreements and arrangements with the Company's largest customer in the fiscal year ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, Walgreens Boots Alliance, Inc. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">("WBA"), accounted for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>34%</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue and represented approximately </span><span style="font-family:inherit;font-size:10pt;"><span>49%</span></span><span style="font-family:inherit;font-size:10pt;"> of accounts receivable, net of incentives, as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. Express Scripts, Inc., the Company's second largest customer in the fiscal year ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, accounted for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>13%</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue and represented approximately </span><span style="font-family:inherit;font-size:10pt;"><span>8%</span></span><span style="font-family:inherit;font-size:10pt;"> of accounts receivable as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company generally does not require collateral for trade receivables. In determining the appropriate allowance for doubtful accounts, the Company considers a combination of factors, such as the aging of trade receivables, industry trends, and its customers' financial strength, credit standing, and payment and default history. Changes in these factors, among others, may lead to adjustments in the Company's allowance for doubtful accounts. The calculation of the required allowance requires judgment by Company management as to the impact of those and other factors on the ultimate realization of its trade receivables. Each of the Company's business units performs ongoing credit evaluations of its customers' financial condition and maintains reserves for probable bad debt losses based upon historical experience and for specific credit problems when they arise. There were no significant changes to this process during the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, and bad debt expense was computed in a consistent manner during these periods.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company maintains cash and cash equivalents with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and, therefore, bear minimal credit risk. The Company seeks to mitigate such risks by monitoring the risk profiles of these counterparties. The Company also seeks to mitigate risk by monitoring the investment strategy of money market accounts in which it is invested, which are classified as cash equivalents.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Loss Contingencies:</span><span style="font-family:inherit;font-size:10pt;"> In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, and other disputes, including antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, the Company provides disclosure of the loss contingency in the notes to its financial statements. The Company reviews all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made. Among the loss contingencies that the Company considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 13. Although the Company is not able to predict the outcome or reasonably estimate a range of possible losses in these matters, an adverse judgment or negotiated resolution in any of these matters could have a material adverse effect on the Company's results of operations, consolidated financial position, cash flows or liquidity.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gain Contingencies:</span><span style="font-family:inherit;font-size:10pt;"> The Company records gain contingencies when they are realized. Gains from antitrust litigation settlements are realized upon the receipt of cash and recorded as a reduction to cost of goods sold because they represent a recovery of amounts historically paid to manufacturers to originally acquire the pharmaceuticals that were the subject of the antitrust litigation settlements (see </span><span style="font-weight:normal;">Note 14</span><span style="font-family:inherit;font-size:10pt;">).</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derivative Financial Instruments</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records all derivative financial instruments on the balance sheet at fair value and complies with established criteria for designation and effectiveness of hedging relationships. The Company's policy prohibits it from entering into derivative financial instruments for speculative or trading purposes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:54px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When the functional currency of the Company's foreign operations is the applicable local currency, assets and liabilities are translated into U.S. dollars using the current exchange rates in effect at the balance sheet date, while revenues and expenses are translated at the weighted average exchange rates for the period. The resulting translation adjustments are recorded as a component of Accumulated Other Comprehensive Loss within Stockholders' Equity.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill and Other Intangible Assets</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">Goodwill arises from acquisitions or consolidations of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. The Company identifies its reporting units based upon the Company's management reporting structure, beginning with its operating segments. The Company aggregates two or more components within an operating segment that have similar economic characteristics. The Company evaluates whether the components within its operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment. The Company's reporting units include Pharmaceutical Distribution Services, Profarma Distribuidora de Produtos Farmacêuticos S.A. ("Profarma"), AmerisourceBergen Consulting Services ("ABCS"), World Courier, and MWI Animal Health ("MWI").</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill and other intangible assets with indefinite lives, such as certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, the Company can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite-lived intangible assets, respectively. Such qualitative factors can include, among others, industry and market conditions, overall financial performance, and relevant entity-specific events. If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis. The Company elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2019, with the exception of its testing of goodwill in the Profarma reporting unit. In the fourth quarter of fiscal 2018 and 2017, the Company elected to bypass performing the qualitative assessment and went directly to performing our annual quantitative assessments of the goodwill and indefinite-lived intangible assets.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized. If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When performing a quantitative impairment assessment, the Company utilizes an income-based approach to value its reporting units, with the exception of the Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium. The income-based approach relies on a discounted cash flow analysis, which considers forecasted cash flows discounted at an appropriate discount rate, to determine the fair value of each reporting unit. The Company generally believes that market participants would use a discounted cash flow analysis to determine the fair value of the Company's reporting units in a sale transaction. The annual goodwill impairment test requires the Company to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon the Company's long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While the Company uses the best available information to prepare its cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The quantitative impairment test for indefinite-lived intangibles other than goodwill (certain trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method. The Company believes the relief from royalty method is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company completed its required annual impairment tests relating to goodwill and indefinite-lived intangible assets in the fourth quarter of the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. The Company recorded a goodwill impairment of </span><span style="font-family:inherit;font-size:10pt;"><span>$59.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in its Profarma reporting unit in connection with its fiscal 2018 annual impairment test (see Note 5). </span><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> goodwill impairments were recorded in the fiscal years ended September 30, 2019 and 2017. </span><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> indefinite-lived intangible asset impairments were recorded in the fiscal years ended September 30, 2019, 2018, and 2017.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finite-lived intangible assets are amortized using the straight-line method over the estimated useful lives of the assets. The Company performs a recoverability assessment of its long-lived assets when impairment indicators are present.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After U.S. Food and Drug Administration ("FDA") inspections of PharMEDium Healthcare Holdings, Inc.'s ("PharMEDium") compounding facilities, the Company voluntarily suspended production activities in December 2017 at its largest </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">compounding facility located in Memphis, Tennessee pending execution of certain remedial measures. On May 17, 2019, PharMEDium reached an agreement on the terms of a consent decree (the "Consent Decree") with the FDA and the Consumer Protection Branch of the Civil Division of the Department of Justice ("DOJ") that was entered by the United States District Court for the Northern District of Illinois on May 22, 2019. The Consent Decree permits commercial operations to continue at PharMEDium’s Dayton, New Jersey and Sugar Land, Texas compounding facilities and administrative operations to continue at its Lake Forest, Illinois headquarters subject to compliance with requirements set forth therein. As required by the Consent Decree, initial audit inspections were conducted by an independent current Good Manufacturing Practice ("cGMP") expert of the Dayton and Sugar Land facilities. The cGMP expert has notified FDA that all of the short-term corrective actions taken are acceptable. The Company has submitted to FDA several additional longer-term corrective actions, and the independent cGMP expert will assess the effectiveness of the implementation of these items in future audits. Additional audit inspections by the independent cGMP expert of the Sugar Land and Dayton facilities are also required at least annually for a period of four years.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Consent Decree also establishes requirements that must be satisfied prior to the resumption of commercial operations at the Memphis, Tennessee facility. The requirements include a work plan approved by the FDA and an audit inspection and certification by an independent cGMP expert that the facilities, methods and controls at the Memphis facility and PharMEDium’s Lake Forest, Illinois headquarters comply with the Consent Decree. If PharMEDium receives written notification from the FDA of compliance with the requirements to resume operations at the Memphis facility, additional audit inspections are required for five years, during which time PharMEDium must correct any deviations from the Consent Decree observed by the independent cGMP expert.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After five years, PharMEDium may petition the district court for full relief from the Consent Decree, or for specific relief with regard to one or more facilities. If, at the time of such petition, all obligations under the Consent Decree with respect to the specific facilities for which PharMEDium is seeking relief have been satisfied, and there has been continuous compliance with the Consent Decree for at least five years, the federal government will not oppose the petition, and PharMEDium may request that the district court grant such relief.</span></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the suspension of production activities at PharMEDium's compounding facility located in Memphis, Tennessee and the aforementioned regulatory matters, the Company performed a recoverability assessment of PharMEDium's long-lived assets and recorded a </span><span style="font-family:inherit;font-size:10pt;"><span>$570.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> impairment loss in the quarter ended March 31, 2019 for the amount that the carrying value of the PharMEDium asset group exceeded its fair value. Prior to the impairment, the carrying value of the asset group was </span><span style="font-family:inherit;font-size:10pt;"><span>$792 million</span></span><span style="font-family:inherit;font-size:10pt;">. The fair value of the asset group was </span><span style="font-family:inherit;font-size:10pt;"><span>$222 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of March 31, 2019. The PharMEDium asset group is included in the Pharmaceutical Distribution Services reportable segment. Significant assumptions used in estimating the fair value of PharMEDium's asset group included (i) a </span><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span><span style="font-family:inherit;font-size:10pt;"> discount rate, which contemplated a higher risk at PharMEDium; (ii) the period in which PharMEDium will resume production at or near capacity; and (iii) the estimated EBITDA (earnings before interest, taxes, depreciation, and amortization) margins when considering the likelihood of higher operating and compliance costs. The Company believes that its fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment are inherently uncertain and include assumptions that could differ from actual results in future periods. This represents a Level 3 nonrecurring fair value measurement. The Company allocated </span><span style="font-family:inherit;font-size:10pt;"><span>$522.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the impairment to finite-lived intangibles (</span><span style="font-family:inherit;font-size:10pt;"><span>$420.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> of customer relationships, </span><span style="font-family:inherit;font-size:10pt;"><span>$79.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of a trade name, and </span><span style="font-family:inherit;font-size:10pt;"><span>$21.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of software technology) and </span><span style="font-family:inherit;font-size:10pt;"><span>$47.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the impairment to property and equipment.</span></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company updated its recoverability assessment of PharMEDium's long-lived assets as of September 30, 2019. The Company concluded that PharMEDium’s long-lived assets were recoverable as of September 30, 2019.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities (commonly known as the asset and liability method). In assessing the need to establish a valuation allowance on deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based upon the technical merits of the position. Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost or market. Cost for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>75%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company's inventories as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> has been determined using the last-in, first-out ("LIFO") method. If the Company had used the first-in, first-out method of inventory valuation, which approximates current replacement cost, inventories would have been approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1,511.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1,534.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> higher than the amounts reported as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company recorded LIFO credits of </span><span style="font-family:inherit;font-size:10pt;"><span>$22.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$157.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the fiscal years ended September 30, 2019 and 2017, respectively, and LIFO expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$67.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the fiscal year ended September 30, 2018. The annual LIFO provision is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences, many of which are difficult to predict. Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investments</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">The Company first evaluates its investments in accordance with the variable interest model to determine whether it has a controlling financial interest in an investment. This evaluation is made as of the date on which the Company makes its initial investment, and subsequent evaluations are made if the structure of the investment changes. If it has determined that an investment is a variable interest entity ("VIE"), the Company evaluates whether the VIE is required to be consolidated. When the Company holds rights that give it the power to direct the activities of an entity that most significantly impact the entity's economic performance, combined with the obligation to absorb an entity's losses and the right to receive benefits, the Company consolidates a VIE. If it is determined that an investment is not a VIE, the Company then evaluates its investments under the voting interest model and generally consolidates investments in which it holds an ownership interest of greater than 50%. When the Company consolidates less than wholly-owned subsidiaries, it discloses its noncontrolling interest in its consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For equity securities without a readily determinable fair value, the Company uses the fair value measurement alternative and measures the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which the Company can exercise significant influence but does not control, it uses the equity method of accounting. The Company's share of earnings and losses is recorded in Other Income (Loss) in the Consolidated Statements of Operations. The Company monitors its investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is often involved in the construction of its distribution facilities. In certain cases, the Company makes payments for certain structural components included in the lessor's construction of the leased assets, which result in the Company being deemed the owner of the leased assets for accounting purposes. As a result, regardless of the significance of the payments, Accounting Standards Codification 840, Leases, ("ASC 840") defines those payments as automatic indicators of ownership and requires the Company to capitalize the lessor's total project cost with a corresponding financing obligation. Upon completion of the lessor's project, the Company performs a sale-leaseback analysis pursuant to ASC 840 to determine if these assets and the related financing obligations can be derecognized from the Company's Consolidated Balance Sheet. If the Company is deemed to have "continuing involvement," the leased assets and the related financing obligations remain on the Company's Consolidated Balance Sheet and are amortized over the life of the assets and the lease term, respectively. All other leases are considered operating leases in accordance with ASC 840. Assets subject to an operating lease and the related lease payments are not recorded on the Company's Consolidated Balance Sheet. Rent expense is recognized on a straight-line basis over the expected lease term and is recorded in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Manufacturer Incentives</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company considers fees and other incentives received from its suppliers relating to the purchase or distribution of inventory to represent product discounts, and, as a result, they are recognized within cost of goods sold upon the sale of the related inventory.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which range from </span><span style="font-family:inherit;font-size:10pt;"><span>3</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>40</span></span><span style="font-family:inherit;font-size:10pt;"> years for buildings and improvements and from </span><span style="font-family:inherit;font-size:10pt;"><span>3</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;"> years for machinery, equipment, and other. The costs of repairs and maintenance are charged to expense as incurred.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company capitalizes project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application development stage. Costs that are associated with preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred. Software development costs are depreciated using the straight-line method over the estimated useful lives, which range from </span><span style="font-family:inherit;font-size:10pt;"><span>3</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;"> years.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's revenues are primarily generated from the distribution of pharmaceutical products. The Company also generates revenues from global commercialization services, which include clinical trial support, post-approval and commercialization support, and global specialty transportation and logistics for the biopharmaceutical industry. See </span><span style="font-weight:normal;">Note 15</span><span style="font-family:inherit;font-size:10pt;"> for the Company's disaggregated revenue.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue related to the distribution of products at a point in time when title and control transfers to customers and there is no further obligation to provide services related to such products. Service revenue is recognized over the period that services are provided to the customer. The Company is generally the principal in a transaction; therefore, revenue is primarily recorded on a gross basis. When the Company is the principal in a transaction, it has determined that it controls the ability to direct the use of the product or service prior to the transfer to a customer, it is primarily responsible for fulfilling the promise to provide the product or service to its customer, it has discretion in establishing pricing, and it controls the relationship with the customer. Revenue is recognized at the amount of consideration expected to be received. For the distribution business, revenue is primarily generated from a contract related to a confirmed purchase order with a customer in a distribution arrangement and is net of estimated sales returns and allowances, other customer incentives, and sales tax.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. The Company records an accrual for estimated customer sales returns at the time of sale to the customer based upon historical return trends. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company's accrual for estimated customer sales returns was </span><span style="font-family:inherit;font-size:10pt;"><span>$1,147.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$988.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. In fiscal 2019, due to the adoption of ASC 606, the Company records an asset for the right to recover products from its customers in Right to Recover Asset on its Consolidated Balance Sheet. The Company's asset for the right to recover products from its customers was included in Inventories on its Consolidated Balance Sheet as of September 30, 2018 and for all prior periods.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for the compensation cost of all share-based payments at fair value. The Company estimates the fair value of option grants using a binomial option pricing model. The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company’s common stock. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense is recognized over the requisite service period within Distribution, Selling, and Administrative in the Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees. Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The income tax effects of awards are recognized when the awards vest or are settled and are recognized in Income Tax Expense in the Company’s Consolidated Statements of Operations and in cash flows from operations in the Consolidated Statements of Cash Flows. Prior to fiscal 2017, tax benefits from share-based compensation were recorded as adjustments to Additional Paid-in Capital within Stockholders’ Equity and as cash flows from financing activities within the Statement of Cash Flows (see Recently Adopted Accounting Pronouncements).</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shipping and Handling Costs</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shipping and handling costs include all costs to warehouse, pick, pack, and deliver inventory to customers. These costs, which were </span><span style="font-family:inherit;font-size:10pt;"><span>$619.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$590.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$517.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively, are included in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Supplier Reserves</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company establishes reserves against amounts due from its suppliers relating to various price and rebate incentives, including deductions or billings taken against payments otherwise due to them from the Company. These reserve estimates are established based upon the judgment of Company management after carefully considering the status of current outstanding claims, historical experience with the suppliers, the specific incentive programs, and any other pertinent information available to the Company. The Company evaluates the amounts due from its suppliers on a continual basis and adjusts the reserve estimates when appropriate based upon changes in factual circumstances. The ultimate outcome of any outstanding claim may be different than the Company's estimate.</span></div> <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying financial statements present the consolidated financial position, results of operations, and cash flows of the Company as of the dates and for the periods indicated. All intercompany accounts and transactions have been eliminated in consolidation.</span></div> The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts due to uncertainties inherent in such estimates. Management periodically evaluates estimates used in the preparation of the financial statements for continued reasonableness. Certain reclassifications have been made to prior-period amounts in order to conform to the current year presentation. <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"). ASU 2016-09 requires all income tax effects of awards to be recognized in the income statement when the awards vest or are exercised. It also allows an employer to repurchase more of an employee's shares for tax withholding purposes without triggering liability accounting and to make a policy election to account for forfeitures as they occur. ASU 2016-09 was effective for annual reporting periods beginning after December 15, 2016 and interim periods within those fiscal years. On October 1, 2016, the Company early adopted ASU 2016-09, which resulted in a cumulative adjustment to retained earnings and the establishment of a deferred tax asset of </span><span style="font-family:inherit;font-size:10pt;"><span>$47.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for previously unrecognized tax benefits. The Company elected to adopt the Statement of Cash Flows presentation of the excess tax benefits prospectively. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)" ("ASU 2014-09"). ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification ("ASC") 605 - "Revenue Recognition" and most industry-specific guidance throughout the Codification. ASU 2014-09 outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The standard's core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-08, "Revenue from Contracts with Customers (Topic 606) - Principal versus Agent Considerations" ("ASU 2016-08"), which clarified the implementation guidance for principal versus agent considerations in ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10, "Revenue from Contracts with Customers (Topic 606) - Identifying Performance Obligations and Licensing" ("ASU 2016-10"), which amended the guidance in ASU 2014-09 related to identifying performance obligations and accounting for licenses of intellectual property. The Company was required to adopt ASU 2016-08 and ASU 2016-10 with ASU 2014-09, collectively ASC 606.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company adopted ASC 606 as of October 1, 2018 on a modified retrospective basis for all open contracts as of October 1, 2018. The adoption had an immaterial impact on the Company's October 1, 2018 retained earnings and will not have a material impact on the Company's revenues, results of operations, or cash flows. The Company did not record any material contract assets, contract liabilities, or deferred contract costs in its Consolidated Balance Sheet upon adoption.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company elected the practical expedient to expense costs to obtain a contract when incurred when the amortization period would have been one year or less. Additionally, the Company elected the practical expedients to not disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less, (ii) contracts for which the Company recognizes revenue at the amount to which it has the right to invoice for services performed, and (iii) for contracts for which the variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the Company's revenue recognition policy, refer to the "Revenue Recognition" section of Note 1.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> In February 2016, the FASB issued ASU No. 2016-02, "Leases (Topic 842)" ("ASU 2016-02" or "ASC 842")). ASU 2016-02 aims to increase transparency and comparability across organizations by requiring lease assets and lease liabilities to be recognized on the balance sheet as well as key information to be disclosed regarding lease arrangements. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018 and interim periods within those fiscal years. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company will adopt ASC 842 in the first quarter of fiscal 2020 and will adopt using the modified retrospective approach. The Company will elect the transition package of practical expedients provided within the amended guidance, which eliminates the requirements to reassess lease identification, lease classification, and initial direct costs for leases that commenced before the effective date. The Company will also elect to combine lease and non-lease components and to exclude short-term leases from its consolidated balance sheets. The Company did not elect the hindsight practical expedient in determining the lease term.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The adoption of the amended guidance is expected to have a material impact on the consolidated balance sheet from the recognition of lease assets and liabilities. While the Company continues to finalize the impact of adoption, it anticipates recognizing operating lease liabilities of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$550 million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the present value of the remaining minimum lease commitments using the Company's incremental borrowing rates as of the effective date. The Company will also record corresponding right-of-use ("ROU") assets based upon the operating lease liabilities adjusted for prepaid and deferred rents. Upon adoption, the Company will also derecognize assets and liabilities associated with leased assets where the Company was deemed the owner of the leased assets for accounting purposes. The difference between the derecognized assets and liabilities will be recognized as a net of tax cumulative adjustment to retained earnings. The Company is finalizing the impact that the amended lease guidance will have on its consolidated financial statements, systems, processes, and internal controls. The Company does not expect that the adoption of ASC 842 will have a material impact on its results of operations or cash flows. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments" ("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectibility of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. ASU 2016-13 is effective for annual reporting periods beginning after December 15, 2019, including interim periods within those fiscal years, and a modified retrospective approach is required, with a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. Entities are permitted to adopt the standard early in fiscal years beginning after December 15, 2018. The Company is currently evaluating the impact of adopting this new accounting guidance.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were no other recently issued accounting standards that may have a material impact on the Company's financial position, results of operations, or cash flows upon their adoption.</span></div> 47100000 550000000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The assets acquired and liabilities assumed from the acquired business are recorded at fair value, with the residual of the purchase price recorded as goodwill. The results of operations of the acquired businesses are included in the Company's operating results from the dates of acquisition.</span></div> <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The carrying value of cash equivalents approximates fair value.</span></div> <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">The Company sells its inventories to a large number of customers in the healthcare industry that include institutional and retail healthcare providers. Institutional healthcare providers include acute care hospitals, health systems, mail order pharmacies, long-term care and other alternate care pharmacies and providers of pharmacy services to such facilities, and physician offices. Retail healthcare providers include national and regional retail drugstore chains, independent community pharmacies, pharmacy departments of supermarkets and mass merchandisers, and veterinarians. The financial condition of the Company's customers can be affected by changes in government reimbursement policies as well as by other economic pressures in the healthcare industry.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's trade accounts receivables are exposed to credit risk. Revenue from the various agreements and arrangements with the Company's largest customer in the fiscal year ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, Walgreens Boots Alliance, Inc. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">("WBA"), accounted for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>34%</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue and represented approximately </span><span style="font-family:inherit;font-size:10pt;"><span>49%</span></span><span style="font-family:inherit;font-size:10pt;"> of accounts receivable, net of incentives, as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. Express Scripts, Inc., the Company's second largest customer in the fiscal year ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, accounted for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>13%</span></span><span style="font-family:inherit;font-size:10pt;"> of revenue and represented approximately </span><span style="font-family:inherit;font-size:10pt;"><span>8%</span></span><span style="font-family:inherit;font-size:10pt;"> of accounts receivable as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company generally does not require collateral for trade receivables. In determining the appropriate allowance for doubtful accounts, the Company considers a combination of factors, such as the aging of trade receivables, industry trends, and its customers' financial strength, credit standing, and payment and default history. Changes in these factors, among others, may lead to adjustments in the Company's allowance for doubtful accounts. The calculation of the required allowance requires judgment by Company management as to the impact of those and other factors on the ultimate realization of its trade receivables. Each of the Company's business units performs ongoing credit evaluations of its customers' financial condition and maintains reserves for probable bad debt losses based upon historical experience and for specific credit problems when they arise. There were no significant changes to this process during the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, and bad debt expense was computed in a consistent manner during these periods.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company maintains cash and cash equivalents with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and, therefore, bear minimal credit risk. The Company seeks to mitigate such risks by monitoring the risk profiles of these counterparties. The Company also seeks to mitigate risk by monitoring the investment strategy of money market accounts in which it is invested, which are classified as cash equivalents.</span></div> 0.34 0.49 0.13 0.08 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Loss Contingencies:</span><span style="font-family:inherit;font-size:10pt;"> In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, and other disputes, including antitrust, commercial, environmental, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a liability when it is probable that a loss has been incurred and the amount is reasonably estimable. The Company also performs an assessment of the materiality of loss contingencies where a loss is either not probable or it is reasonably possible that a loss could be incurred in excess of amounts accrued. If a loss or an additional loss has at least a reasonable possibility of occurring and the impact on the financial statements would be material, the Company provides disclosure of the loss contingency in the notes to its financial statements. The Company reviews all contingencies at least quarterly to determine whether the likelihood of loss has changed and to assess whether a reasonable estimate of the loss or the range of the loss can be made. Among the loss contingencies that the Company considered in accordance with the foregoing in connection with the preparation of the accompanying financial statements were the opioid matters described in Note 13. Although the Company is not able to predict the outcome or reasonably estimate a range of possible losses in these matters, an adverse judgment or negotiated resolution in any of these matters could have a material adverse effect on the Company's results of operations, consolidated financial position, cash flows or liquidity.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gain Contingencies:</span><span style="font-family:inherit;font-size:10pt;"> The Company records gain contingencies when they are realized. Gains from antitrust litigation settlements are realized upon the receipt of cash and recorded as a reduction to cost of goods sold because they represent a recovery of amounts historically paid to manufacturers to originally acquire the pharmaceuticals that were the subject of the antitrust litigation settlements (see </span><span style="font-weight:normal;">Note 14</span><span style="font-family:inherit;font-size:10pt;">).</span></div> <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records all derivative financial instruments on the balance sheet at fair value and complies with established criteria for designation and effectiveness of hedging relationships. The Company's policy prohibits it from entering into derivative financial instruments for speculative or trading purposes.</span></div> <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:54px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When the functional currency of the Company's foreign operations is the applicable local currency, assets and liabilities are translated into U.S. dollars using the current exchange rates in effect at the balance sheet date, while revenues and expenses are translated at the weighted average exchange rates for the period. The resulting translation adjustments are recorded as a component of Accumulated Other Comprehensive Loss within Stockholders' Equity.</span></div> <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">Goodwill arises from acquisitions or consolidations of specific operating companies and is assigned to the reporting unit in which a particular operating company resides. The Company identifies its reporting units based upon the Company's management reporting structure, beginning with its operating segments. The Company aggregates two or more components within an operating segment that have similar economic characteristics. The Company evaluates whether the components within its operating segments have similar economic characteristics, which include the similarity of long-term gross margins, the nature of the components' products, services, and production processes, the types of customers and the methods by which products or services are delivered to customers, and the components' regulatory environment. The Company's reporting units include Pharmaceutical Distribution Services, Profarma Distribuidora de Produtos Farmacêuticos S.A. ("Profarma"), AmerisourceBergen Consulting Services ("ABCS"), World Courier, and MWI Animal Health ("MWI").</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill and other intangible assets with indefinite lives, such as certain trademarks and trade names, are not amortized; rather, they are tested for impairment at least annually. For the purpose of these impairment tests, the Company can elect to perform a qualitative assessment to determine if it is more likely than not that the fair values of its reporting units and indefinite-lived intangible assets are less than the respective carrying values of those reporting units and indefinite-lived intangible assets, respectively. Such qualitative factors can include, among others, industry and market conditions, overall financial performance, and relevant entity-specific events. If the Company concludes based on its qualitative assessment that it is more likely than not that the fair value of a reporting unit is less than its carrying value, it performs a quantitative analysis. The Company elected to perform a qualitative impairment assessment of goodwill and indefinite-lived intangible assets in the fourth quarter of fiscal 2019, with the exception of its testing of goodwill in the Profarma reporting unit. In the fourth quarter of fiscal 2018 and 2017, the Company elected to bypass performing the qualitative assessment and went directly to performing our annual quantitative assessments of the goodwill and indefinite-lived intangible assets.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The quantitative goodwill impairment test requires us to compare the carrying value of the reporting unit's net assets to the fair value of the reporting unit. If the fair value exceeds the carrying value, no further evaluation is required, and no impairment loss is recognized. If the carrying amount exceeds the fair value, the difference between the carrying value and the fair value is recorded as an impairment loss, the amount of which may not exceed the total amount of goodwill allocated to the reporting unit.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">When performing a quantitative impairment assessment, the Company utilizes an income-based approach to value its reporting units, with the exception of the Profarma reporting unit, the fair value of which is based upon its publicly-traded stock price, plus an estimated control premium. The income-based approach relies on a discounted cash flow analysis, which considers forecasted cash flows discounted at an appropriate discount rate, to determine the fair value of each reporting unit. The Company generally believes that market participants would use a discounted cash flow analysis to determine the fair value of the Company's reporting units in a sale transaction. The annual goodwill impairment test requires the Company to make a number of assumptions and estimates concerning future levels of revenue growth, operating margins, depreciation, amortization, capital expenditures, and working capital requirements, which are based upon the Company's long-range plan. The discount rate is an estimate of the overall after-tax rate of return required by a market participant whose weighted average cost of capital includes both debt and equity, including a risk premium. While the Company uses the best available information to prepare its cash flows and discount rate assumptions, actual future cash flows and/or market conditions could differ significantly resulting in future impairment charges related to recorded goodwill balances. While there are always changes in assumptions to reflect changing business and market conditions, the Company's overall methodology and the population of assumptions used have remained unchanged.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The quantitative impairment test for indefinite-lived intangibles other than goodwill (certain trademarks and trade names) consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset as of the impairment testing date. The Company estimates the fair value of its indefinite-lived intangibles using the relief from royalty method. The Company believes the relief from royalty method is a widely used valuation technique for such assets. The fair value derived from the relief from royalty method is measured as the discounted cash flow savings realized from owning such indefinite-lived trademarks and trade names and not having to pay a royalty for their use.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company completed its required annual impairment tests relating to goodwill and indefinite-lived intangible assets in the fourth quarter of the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">. The Company recorded a goodwill impairment of </span><span style="font-family:inherit;font-size:10pt;"><span>$59.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in its Profarma reporting unit in connection with its fiscal 2018 annual impairment test (see Note 5). </span><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> goodwill impairments were recorded in the fiscal years ended September 30, 2019 and 2017. </span><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> indefinite-lived intangible asset impairments were recorded in the fiscal years ended September 30, 2019, 2018, and 2017.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finite-lived intangible assets are amortized using the straight-line method over the estimated useful lives of the assets. The Company performs a recoverability assessment of its long-lived assets when impairment indicators are present.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After U.S. Food and Drug Administration ("FDA") inspections of PharMEDium Healthcare Holdings, Inc.'s ("PharMEDium") compounding facilities, the Company voluntarily suspended production activities in December 2017 at its largest </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">compounding facility located in Memphis, Tennessee pending execution of certain remedial measures. On May 17, 2019, PharMEDium reached an agreement on the terms of a consent decree (the "Consent Decree") with the FDA and the Consumer Protection Branch of the Civil Division of the Department of Justice ("DOJ") that was entered by the United States District Court for the Northern District of Illinois on May 22, 2019. The Consent Decree permits commercial operations to continue at PharMEDium’s Dayton, New Jersey and Sugar Land, Texas compounding facilities and administrative operations to continue at its Lake Forest, Illinois headquarters subject to compliance with requirements set forth therein. As required by the Consent Decree, initial audit inspections were conducted by an independent current Good Manufacturing Practice ("cGMP") expert of the Dayton and Sugar Land facilities. The cGMP expert has notified FDA that all of the short-term corrective actions taken are acceptable. The Company has submitted to FDA several additional longer-term corrective actions, and the independent cGMP expert will assess the effectiveness of the implementation of these items in future audits. Additional audit inspections by the independent cGMP expert of the Sugar Land and Dayton facilities are also required at least annually for a period of four years.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Consent Decree also establishes requirements that must be satisfied prior to the resumption of commercial operations at the Memphis, Tennessee facility. The requirements include a work plan approved by the FDA and an audit inspection and certification by an independent cGMP expert that the facilities, methods and controls at the Memphis facility and PharMEDium’s Lake Forest, Illinois headquarters comply with the Consent Decree. If PharMEDium receives written notification from the FDA of compliance with the requirements to resume operations at the Memphis facility, additional audit inspections are required for five years, during which time PharMEDium must correct any deviations from the Consent Decree observed by the independent cGMP expert.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After five years, PharMEDium may petition the district court for full relief from the Consent Decree, or for specific relief with regard to one or more facilities. If, at the time of such petition, all obligations under the Consent Decree with respect to the specific facilities for which PharMEDium is seeking relief have been satisfied, and there has been continuous compliance with the Consent Decree for at least five years, the federal government will not oppose the petition, and PharMEDium may request that the district court grant such relief.</span></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the suspension of production activities at PharMEDium's compounding facility located in Memphis, Tennessee and the aforementioned regulatory matters, the Company performed a recoverability assessment of PharMEDium's long-lived assets and recorded a </span><span style="font-family:inherit;font-size:10pt;"><span>$570.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> impairment loss in the quarter ended March 31, 2019 for the amount that the carrying value of the PharMEDium asset group exceeded its fair value. Prior to the impairment, the carrying value of the asset group was </span><span style="font-family:inherit;font-size:10pt;"><span>$792 million</span></span><span style="font-family:inherit;font-size:10pt;">. The fair value of the asset group was </span><span style="font-family:inherit;font-size:10pt;"><span>$222 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of March 31, 2019. The PharMEDium asset group is included in the Pharmaceutical Distribution Services reportable segment. Significant assumptions used in estimating the fair value of PharMEDium's asset group included (i) a </span><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span><span style="font-family:inherit;font-size:10pt;"> discount rate, which contemplated a higher risk at PharMEDium; (ii) the period in which PharMEDium will resume production at or near capacity; and (iii) the estimated EBITDA (earnings before interest, taxes, depreciation, and amortization) margins when considering the likelihood of higher operating and compliance costs. The Company believes that its fair value assumptions were representative of market participant assumptions; however, the forecasted cash flows used to estimate fair value and measure the related impairment are inherently uncertain and include assumptions that could differ from actual results in future periods. This represents a Level 3 nonrecurring fair value measurement. The Company allocated </span><span style="font-family:inherit;font-size:10pt;"><span>$522.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the impairment to finite-lived intangibles (</span><span style="font-family:inherit;font-size:10pt;"><span>$420.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> of customer relationships, </span><span style="font-family:inherit;font-size:10pt;"><span>$79.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of a trade name, and </span><span style="font-family:inherit;font-size:10pt;"><span>$21.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of software technology) and </span><span style="font-family:inherit;font-size:10pt;"><span>$47.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the impairment to property and equipment.</span></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company updated its recoverability assessment of PharMEDium's long-lived assets as of September 30, 2019. The Company concluded that PharMEDium’s long-lived assets were recoverable as of September 30, 2019.</span></div> 59700000 0 0 570000000.0 792000000 222000000 0.15 522100000 420800000 79900000 21400000 47900000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes using a method that requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company's assets and liabilities (commonly known as the asset and liability method). In assessing the need to establish a valuation allowance on deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the taxing authorities, including resolutions of any related appeals or litigation processes, based upon the technical merits of the position. Tax benefits associated with uncertain tax positions that have met the recognition criteria are measured and recorded based upon the highest probable outcome that is more than 50% likely to be realized after full disclosure and resolution of a tax examination.</span></div> <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost or market. Cost for approximately </span><span style="font-family:inherit;font-size:10pt;"><span>75%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company's inventories as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> has been determined using the last-in, first-out ("LIFO") method. If the Company had used the first-in, first-out method of inventory valuation, which approximates current replacement cost, inventories would have been approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1,511.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1,534.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> higher than the amounts reported as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company recorded LIFO credits of </span><span style="font-family:inherit;font-size:10pt;"><span>$22.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$157.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the fiscal years ended September 30, 2019 and 2017, respectively, and LIFO expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$67.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the fiscal year ended September 30, 2018. The annual LIFO provision is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences, many of which are difficult to predict. Changes to any of the above factors can have a material impact to the Company's annual LIFO provision.</span></div> 0.75 1511800000 1534400000 -22500000 -157800000 67300000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">The Company first evaluates its investments in accordance with the variable interest model to determine whether it has a controlling financial interest in an investment. This evaluation is made as of the date on which the Company makes its initial investment, and subsequent evaluations are made if the structure of the investment changes. If it has determined that an investment is a variable interest entity ("VIE"), the Company evaluates whether the VIE is required to be consolidated. When the Company holds rights that give it the power to direct the activities of an entity that most significantly impact the entity's economic performance, combined with the obligation to absorb an entity's losses and the right to receive benefits, the Company consolidates a VIE. If it is determined that an investment is not a VIE, the Company then evaluates its investments under the voting interest model and generally consolidates investments in which it holds an ownership interest of greater than 50%. When the Company consolidates less than wholly-owned subsidiaries, it discloses its noncontrolling interest in its consolidated financial statements.</span></div> <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For equity securities without a readily determinable fair value, the Company uses the fair value measurement alternative and measures the securities at cost less impairment, if any, including adjustments for observable price changes in orderly transactions for an identical or similar investment of the same issuer. For investments in which the Company can exercise significant influence but does not control, it uses the equity method of accounting. The Company's share of earnings and losses is recorded in Other Income (Loss) in the Consolidated Statements of Operations. The Company monitors its investments for impairment by considering factors such as the operating performance of the investment and current economic and market conditions.</span></div> <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is often involved in the construction of its distribution facilities. In certain cases, the Company makes payments for certain structural components included in the lessor's construction of the leased assets, which result in the Company being deemed the owner of the leased assets for accounting purposes. As a result, regardless of the significance of the payments, Accounting Standards Codification 840, Leases, ("ASC 840") defines those payments as automatic indicators of ownership and requires the Company to capitalize the lessor's total project cost with a corresponding financing obligation. Upon completion of the lessor's project, the Company performs a sale-leaseback analysis pursuant to ASC 840 to determine if these assets and the related financing obligations can be derecognized from the Company's Consolidated Balance Sheet. If the Company is deemed to have "continuing involvement," the leased assets and the related financing obligations remain on the Company's Consolidated Balance Sheet and are amortized over the life of the assets and the lease term, respectively. All other leases are considered operating leases in accordance with ASC 840. Assets subject to an operating lease and the related lease payments are not recorded on the Company's Consolidated Balance Sheet. Rent expense is recognized on a straight-line basis over the expected lease term and is recorded in Distribution, Selling, and Administrative in the Company's Consolidated Statements of Operations.</span></div> <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, which range from </span><span style="font-family:inherit;font-size:10pt;"><span>3</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>40</span></span><span style="font-family:inherit;font-size:10pt;"> years for buildings and improvements and from </span><span style="font-family:inherit;font-size:10pt;"><span>3</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;"> years for machinery, equipment, and other. The costs of repairs and maintenance are charged to expense as incurred.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company capitalizes project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application development stage. Costs that are associated with preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred. Software development costs are depreciated using the straight-line method over the estimated useful lives, which range from </span><span style="font-family:inherit;font-size:10pt;"><span>3</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;"> years.</span></div> P3Y P40Y P3Y P10Y P3Y P10Y <div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's revenues are primarily generated from the distribution of pharmaceutical products. The Company also generates revenues from global commercialization services, which include clinical trial support, post-approval and commercialization support, and global specialty transportation and logistics for the biopharmaceutical industry. See </span><span style="font-weight:normal;">Note 15</span><span style="font-family:inherit;font-size:10pt;"> for the Company's disaggregated revenue.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes revenue related to the distribution of products at a point in time when title and control transfers to customers and there is no further obligation to provide services related to such products. Service revenue is recognized over the period that services are provided to the customer. The Company is generally the principal in a transaction; therefore, revenue is primarily recorded on a gross basis. When the Company is the principal in a transaction, it has determined that it controls the ability to direct the use of the product or service prior to the transfer to a customer, it is primarily responsible for fulfilling the promise to provide the product or service to its customer, it has discretion in establishing pricing, and it controls the relationship with the customer. Revenue is recognized at the amount of consideration expected to be received. For the distribution business, revenue is primarily generated from a contract related to a confirmed purchase order with a customer in a distribution arrangement and is net of estimated sales returns and allowances, other customer incentives, and sales tax.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's customer sales return policy generally allows customers to return products only if the products can be resold at full value or returned to suppliers for full credit. The Company records an accrual for estimated customer sales returns at the time of sale to the customer based upon historical return trends. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company's accrual for estimated customer sales returns was </span><span style="font-family:inherit;font-size:10pt;"><span>$1,147.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$988.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. In fiscal 2019, due to the adoption of ASC 606, the Company records an asset for the right to recover products from its customers in Right to Recover Asset on its Consolidated Balance Sheet. The Company's asset for the right to recover products from its customers was included in Inventories on its Consolidated Balance Sheet as of September 30, 2018 and for all prior periods.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company considers fees and other incentives received from its suppliers relating to the purchase or distribution of inventory to represent product discounts, and, as a result, they are recognized within cost of goods sold upon the sale of the related inventory.</span></div> 1147500000 988800000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for the compensation cost of all share-based payments at fair value. The Company estimates the fair value of option grants using a binomial option pricing model. The fair value of restricted stock units and performance stock units is based upon the grant date market price of the Company’s common stock. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation expense is recognized over the requisite service period within Distribution, Selling, and Administrative in the Consolidated Statements of Operations to correspond with the same line item as the cash compensation paid to employees. Compensation expense associated with nonvested performance stock units is dependent upon the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The income tax effects of awards are recognized when the awards vest or are settled and are recognized in Income Tax Expense in the Company’s Consolidated Statements of Operations and in cash flows from operations in the Consolidated Statements of Cash Flows. Prior to fiscal 2017, tax benefits from share-based compensation were recorded as adjustments to Additional Paid-in Capital within Stockholders’ Equity and as cash flows from financing activities within the Statement of Cash Flows (see Recently Adopted Accounting Pronouncements).</span></div> Shipping and handling costs include all costs to warehouse, pick, pack, and deliver inventory to customers. 619700000 590800000 517300000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company establishes reserves against amounts due from its suppliers relating to various price and rebate incentives, including deductions or billings taken against payments otherwise due to them from the Company. These reserve estimates are established based upon the judgment of Company management after carefully considering the status of current outstanding claims, historical experience with the suppliers, the specific incentive programs, and any other pertinent information available to the Company. The Company evaluates the amounts due from its suppliers on a continual basis and adjusts the reserve estimates when appropriate based upon changes in factual circumstances. The ultimate outcome of any outstanding claim may be different than the Company's estimate.</span></div> Acquisitions and Investments<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NEVSCO</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">In December 2017, the Company acquired Northeast Veterinary Supply Company ("NEVSCO") for </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. NEVSCO was an independent, regional distributor of veterinary pharmaceuticals and medical supplies serving primarily the northeast region of the United States and strengthens MWI Animal Health's ("MWI") support of independent veterinary practices and provides even greater value and care to current and future animal health customers. NEVSCO is included within the MWI operating segment. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their fair values on the date of the acquisition. The purchase price exceeded the fair value of the net tangible and intangible assets acquired by </span><span style="font-family:inherit;font-size:10pt;"><span>$30.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was allocated to goodwill. The fair value of accounts receivable, inventory, and accounts payable and accrued expenses acquired was </span><span style="font-family:inherit;font-size:10pt;"><span>$8.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$6.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The fair value of the intangible assets acquired of </span><span style="font-family:inherit;font-size:10pt;"><span>$29.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> primarily consisted of customer relationships, which the Company is amortizing over its estimated useful life of </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">. Goodwill and intangible assets resulting from the acquisition are deductible for income tax purposes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">H.D. Smith</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2018, the Company acquired H.D. Smith Holding Company ("H.D. Smith") for </span><span style="font-family:inherit;font-size:10pt;"><span>$815.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company funded the acquisition through the issuance of new long-term debt (see </span><span style="font-weight:normal;">Note 6</span><span style="font-family:inherit;font-size:10pt;">). H.D. Smith was the largest independent pharmaceutical wholesaler in the United States and provides full-line distribution of brand, generic, and specialty drugs, as well as high-value services and solutions for manufacturers and healthcare providers. H.D. Smith's customers included retail pharmacies, specialty pharmacies, long-term care facilities, institutional/hospital systems, and independent physicians and clinics. The acquisition strengthens the Company's core business, expands and enhances its strategic scale in pharmaceutical distribution, and expands the Company's support for independent community pharmacies. H.D. Smith has been integrated into the Pharmaceutical Distribution reportable segment.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The purchase price was allocated to the underlying assets acquired and liabilities assumed based upon their fair values on the date of acquisition. The purchase price exceeded the fair value of the net tangible and intangible assets acquired by </span><span style="font-family:inherit;font-size:10pt;"><span>$499.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was allocated to goodwill. The fair value of accounts receivable, inventory, and accounts payable and accrued expenses acquired was </span><span style="font-family:inherit;font-size:10pt;"><span>$163.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$350.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$366.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The fair value of the intangible assets acquired of </span><span style="font-family:inherit;font-size:10pt;"><span>$167.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> consisted of customer relationships of </span><span style="font-family:inherit;font-size:10pt;"><span>$156.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and a tradename of </span><span style="font-family:inherit;font-size:10pt;"><span>$11.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company is amortizing the fair value of the customer relationships and the tradename over their estimated useful lives of </span><span style="font-family:inherit;font-size:10pt;"><span>12</span></span><span style="font-family:inherit;font-size:10pt;"> years and </span><span style="font-family:inherit;font-size:10pt;"><span>2</span></span><span style="font-family:inherit;font-size:10pt;"> years, respectively. The Company established a deferred tax liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$60.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> primarily in connection with the intangible assets acquired. Goodwill and intangible assets resulting from the acquisition are not deductible for income tax purposes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Profarma and Specialty Joint Venture</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">As of September 30, 2017, the Company held a noncontrolling ownership interest in Profarma, a leading pharmaceutical wholesaler in Brazil, and an ownership interest in a joint venture with Profarma to provide specialty distribution and services to the Brazilian marketplace (the "specialty joint venture"). The Company had accounted for these interests as equity method investments, which were reported in Other Assets on the Company's Consolidated Balance Sheets. In January 2018, the Company invested an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$62.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in Profarma and an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$15.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the specialty joint venture to increase its ownership interests to </span><span style="font-family:inherit;font-size:10pt;"><span>38.2%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>64.5%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. In connection with the additional investment in Profarma, the Company received substantial governance rights, thereby requiring it to begin consolidating the operating results of Profarma as of March 31, 2018 (see </span><span style="font-weight:normal;">Note 3</span><span style="font-family:inherit;font-size:10pt;">). The Company also began to consolidate the operating results of the specialty joint venture as of March 31, 2018 due to its majority ownership interest. In September 2018, the Company made an additional investment of </span><span style="font-family:inherit;font-size:10pt;"><span>$23.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the specialty joint venture to increase its ownership interest to </span><span style="font-family:inherit;font-size:10pt;"><span>89.9%</span></span><span style="font-family:inherit;font-size:10pt;">. Profarma and the specialty joint venture are included within the Pharmaceutical Distribution Services reportable segment and Other, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of Profarma, including the noncontrolling interest, was determined based upon an agreed-upon stock price and was allocated to the underlying assets and liabilities consolidated based upon their fair values at the time of the January 2018 investment. The fair value of Profarma upon obtaining control exceeded the fair value of the net tangible and intangible assets consolidated by </span><span style="font-family:inherit;font-size:10pt;"><span>$142.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was allocated to goodwill. The fair value of accounts receivable, inventory, accounts payable and accrued expenses was </span><span style="font-family:inherit;font-size:10pt;"><span>$160.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$190.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$167.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company consolidated short-term debt and long-term debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$209.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$12.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, cash of </span><span style="font-family:inherit;font-size:10pt;"><span>$150.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, and recorded a noncontrolling interest of </span><span style="font-family:inherit;font-size:10pt;"><span>$168.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The estimated fair value of the intangible assets consolidated of </span><span style="font-family:inherit;font-size:10pt;"><span>$84.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> consisted of customer relationships of </span><span style="font-family:inherit;font-size:10pt;"><span>$25.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and a tradename of </span><span style="font-family:inherit;font-size:10pt;"><span>$58.7 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Company is amortizing the customer relationships over its estimated useful life of </span><span style="font-family:inherit;font-size:10pt;"><span>15</span></span><span style="font-family:inherit;font-size:10pt;"> years and the tradenames over their estimated useful lives of between </span><span style="font-family:inherit;font-size:10pt;"><span>15</span></span><span style="font-family:inherit;font-size:10pt;"> years and </span><span style="font-family:inherit;font-size:10pt;"><span>25</span></span><span style="font-family:inherit;font-size:10pt;"> years. The Company established a deferred tax liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$50.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> primarily in connection with the intangible assets that were recognized. Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the specialty joint venture was determined based upon the cost of the incremental ownership percentage acquired from the January 2018 investment and was allocated to the underlying assets and liabilities consolidated based upon their fair values at the time of the January 2018 investment. The fair value of the specialty joint venture exceeded the fair value of the net tangible and intangible assets consolidated by </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was allocated to goodwill. The fair value of accounts receivable, inventory, accounts payable and accrued expenses was </span><span style="font-family:inherit;font-size:10pt;"><span>$65.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$29.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$54.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company consolidated short-term debt and cash of </span><span style="font-family:inherit;font-size:10pt;"><span>$32.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$28.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The estimated fair value of the intangible assets consolidated of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> is being amortized over its estimated useful life of </span><span style="font-family:inherit;font-size:10pt;"><span>15</span></span><span style="font-family:inherit;font-size:10pt;"> years. Goodwill and intangible assets resulting from the consolidation are not deductible for income tax purposes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the incremental January 2018 Brazil investments, the Company adjusted the carrying values of its previously held equity interests in Profarma and the specialty joint venture to equal their fair values, which were determined to be </span><span style="font-family:inherit;font-size:10pt;"><span>$103.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$31.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. These represent Level 2 nonrecurring fair value measurements. The adjustments resulted in a pretax loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$42.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal 2018 and were comprised of foreign currency translation adjustments from Accumulated Other Comprehensive Loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$45.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, a </span><span style="font-family:inherit;font-size:10pt;"><span>$12.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> gain on the remeasurement of Profarma's previously held equity interest, and an </span><span style="font-family:inherit;font-size:10pt;"><span>$8.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss on the remeasurement of the specialty joint venture's previously held equity interest.</span></div> 70000000.0 30400000 8500000 6700000 2900000 29800000 P15Y 815000000.0 499900000 163100000 350700000 366100000 167800000 156600000 11200000 P12Y P2Y 60600000 62500000 15600000 0.382 0.645 23600000 0.899 142000000.0 160100000 190500000 167700000 209900000 12400000 150800000 168000000.0 84600000 25900000 58700000 P15Y P15Y P25Y 50100000 3500000 65000000.0 29100000 54300000 32700000 28900000 4600000 P15Y 103100000 31200000 42300000 -45900000 12400000 8800000 Variable Interest Entity<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed in </span><span style="font-weight:normal;">Note 2</span><span style="font-family:inherit;font-size:10pt;">, the Company made an additional investment in Profarma in January 2018. In connection with this investment, the Company obtained substantial governance rights, allowing it to direct the activities that significantly impact Profarma’s economic performance. As such, the Company consolidated the operating results of Profarma in its consolidated financial statements as of and for the periods ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;">. The Company is not obligated to provide future financial support to Profarma.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following assets and liabilities of Profarma are included in the Company's Consolidated Balance Sheet:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,431</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,801</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivables, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154,491</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144,646</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>185,602</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>168,931</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,119</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,924</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,961</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,667</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,309</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,309</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,974</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,169</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,912</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>610,511</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>607,164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term debt</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106,439</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,461</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,973</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,704</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,371</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,137</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,988</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>429,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>420,587</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Profarma's assets can only be used to settle its obligations, and its creditors do not have recourse to the general credit of the Company. <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following assets and liabilities of Profarma are included in the Company's Consolidated Balance Sheet:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,431</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26,801</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivables, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154,491</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>144,646</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>185,602</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>168,931</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,119</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,924</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,961</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,667</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,309</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82,309</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80,974</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9,169</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,912</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>610,511</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>607,164</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150,102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,191</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term debt</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106,439</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115,461</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,973</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,704</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,371</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46,137</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,988</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>429,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>420,587</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 9431000 26801000 154491000 144646000 185602000 168931000 64119000 61924000 30961000 32667000 82309000 82309000 74429000 80974000 9169000 8912000 610511000 607164000 165053000 150102000 49191000 37195000 106439000 115461000 60973000 39704000 42371000 46137000 5303000 31988000 429330000 420587000 Income Taxes<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company's income before income taxes for the periods indicated:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>336,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>704,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>394,721</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>630,956</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>472,488</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>523,166</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>967,106</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,177,423</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>917,887</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of the Company's consolidated income tax expense (benefit) are summarized in the following table for the periods indicated:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current provision:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,801</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>247,755</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,071</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State and local</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,246</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,328</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,950</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,989</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,972</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current provision</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,434</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>357,055</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234,334</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred provision (benefit):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,819</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(828,023</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>265,074</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State and local</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(31,086</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,887</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,388</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred provision (benefit)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,537</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(795,524</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>319,069</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision (benefit) for income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,971</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(438,469</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>553,403</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the statutory U.S. federal income tax rate to the Company's consolidated effective income tax rate is as follows for the periods indicated:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:53%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statutory U.S. federal income tax rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.5%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.0%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State and local income tax rate, net of federal tax benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.4</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign tax rate differential</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.7)</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.2)</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14.6)</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.4)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.2</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Excess tax benefits related to share-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.8)</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.8)</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.8)</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Litigation settlements and accruals (see Note 14)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.3)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.3</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill impairment (see Note 5)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax reform</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.6)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(52.0)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital gain on distribution</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.7)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective income tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.7%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(37.2)%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60.3%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">U.S. Tax Reform: Tax Cuts and Jobs Act</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2017, the U.S. Tax Cuts and Jobs Act (the "2017 Tax Act") was signed into law. The 2017 Tax Act included a broad range of tax reform provisions affecting businesses, including lower corporate tax rates, changes in business deductions, and new international tax provisions. In response to the 2017 Tax Act, the U.S. Securities and Exchange Commission staff issued guidance regarding the accounting for income taxes associated with the 2017 Tax Act to allow companies to record provisional amounts during a one-year measurement period. For the fiscal year ended September 30, 2018, the Company recognized income tax benefits of </span><span style="font-family:inherit;font-size:10pt;"><span>$612.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> on the Company's Consolidated Statements of Operations related to effects of the 2017 Tax Act, which consisted of a deferred income tax benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$897.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> as a result of applying a lower U.S. federal income tax rate to the Company's net deferred tax liabilities as of December 31, 2017 and a one-time transition tax on historical foreign earnings and profits. In the fiscal year ended September 30, 2018, the Company initially recorded a current U.S. income tax expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$285.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> on historical foreign earnings and profits through December 31, 2017. The Company completed the accounting for the effects of the 2017 Tax Act in the fiscal quarter ended December 31, 2018 and recognized an income tax benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$37.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to a decrease in its foreign earnings and profits through December 31, 2017 (the "transition tax"). The Company expects to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$182.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to the transition tax, which is net of overpayments and tax credits, over a six-year period commencing in January 2021. There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> adjustments recorded to deferred income taxes related to the 2017 Tax Act during the one-year measurement period.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to the 2017 Tax Act, the Company intended to indefinitely reinvest its foreign cash in foreign investments and foreign operations. After further assessment of the impact of the 2017 Tax Act, the Company reevaluated its position and determined that it was no longer reinvested with respect to foreign subsidiaries whose undistributed earnings are able to be repatriated with minimal to no additional tax impact. Cumulative undistributed earnings of international subsidiaries were </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.6 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of which is considered permanently reinvested. It is not practicable to estimate the taxes that would be due if such earnings were to be repatriated in the future.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes reflect the future tax consequences of differences between the tax bases of assets and liabilities and their financial reporting amounts. Significant components of the Company's deferred tax liabilities (assets) are as follows:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,293,075</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,189,801</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143,851</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133,417</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill and other intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>709,015</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>853,747</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>747</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross deferred tax liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,147,833</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,177,712</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss and tax credit carryforwards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(318,868</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(421,808</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,544</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20,126</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33,312</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17,363</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee and retiree benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,420</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,210</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39,961</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28,888</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(60,215</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(49,892</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross deferred tax assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(487,320</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(548,287</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance for deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199,682</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199,985</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets, net of valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(287,638</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(348,302</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,860,195</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,829,410</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tax net operating loss and credit carryforward information is presented as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$12.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of potential tax benefits from federal net operating loss carryforwards, which expire in </span><span style="font-family:inherit;font-size:10pt;"><span>1</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>18</span></span><span style="font-family:inherit;font-size:10pt;"> years, </span><span style="font-family:inherit;font-size:10pt;"><span>$171.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of potential tax benefits from state net operating loss carryforwards expiring in </span><span style="font-family:inherit;font-size:10pt;"><span>1</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>20</span></span><span style="font-family:inherit;font-size:10pt;"> years, and </span><span style="font-family:inherit;font-size:10pt;"><span>$58.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of potential tax benefits from foreign net operating loss carryforwards, which have varying expiration dates. The Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$6.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of state tax credit carryforwards, </span><span style="font-family:inherit;font-size:10pt;"><span>$84.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in federal alternative minimum tax credit carryforwards, and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in foreign alternative minimum tax credit carryforwards. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assesses the available positive and negative evidence to determine whether deferred tax assets are more likely than not to be realized. As a result of this assessment, valuation allowances have been recorded on certain deferred tax assets. For the fiscal year ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, the Company decreased the valuation allowance on deferred tax assets by </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> primarily due to a legislative change which will enable the Company to utilize select net operating losses prospectively. This decrease was offset in part by the additional valuation allowances on certain state and foreign net operating loss carryforwards. In the fiscal year ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company decreased the valuation allowance on deferred tax assets by </span><span style="font-family:inherit;font-size:10pt;"><span>$11.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> primarily due to the utilization of capital loss and foreign tax credit carryforwards for which a valuation allowance had been recorded.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the fiscal year ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and 2017 tax benefits of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$22.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$36.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, related to the exercise of employee stock options and lapses of restricted stock units were recorded in Income Tax Expense (Benefit) in the Company's Consolidated Statements of Operations. The tax benefits recognized in the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and 2017 are not necessarily indicative of amounts that may arise in future periods.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax payments, net of refunds, were </span><span style="font-family:inherit;font-size:10pt;"><span>$117.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$104.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$105.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company and its subsidiaries file income tax returns in the U.S. federal jurisdiction and various states and foreign jurisdictions. With few exceptions, the Company is no longer subject to U.S. federal, state and local, or foreign income tax examinations by tax authorities for years before 2015.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, the Company had unrecognized tax benefits, defined as the aggregate tax effect of differences between tax return positions and the benefits recognized in the Company's financial statements, of </span><span style="font-family:inherit;font-size:10pt;"><span>$124.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$112.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively (</span><span style="font-family:inherit;font-size:10pt;"><span>$95.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$89.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of federal tax benefit, respectively). If recognized in the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$76.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$71.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, of these benefits would have reduced income tax expense and the effective tax rate. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, included in the unrecognized tax benefits are </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$18.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$14.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> of interest and penalties, respectively, which the Company records in Income Tax Expense (Benefit) in the Company's Consolidated Statements of Operations.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, for the periods indicated is as follows:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits at beginning of period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98,124</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>323,869</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,766</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions of tax positions of the current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,819</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,804</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>252,866</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions to tax positions of the prior years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>751</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>558</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,049</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reductions of tax positions of the prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,317</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(224,878</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(668</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements with taxing authorities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,847</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,285</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expiration of statutes of limitations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,382</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,859</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits at end of period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,657</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98,124</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>323,869</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Included in the additions of unrecognized tax positions in the fiscal year ended September 30, 2017 is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$235.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for an uncertain tax position related to the </span><span style="font-family:inherit;font-size:10pt;"><span>$625.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> civil litigation reserve recognized during the fiscal year (see </span><span style="font-weight:normal;">Note 13</span><span style="font-family:inherit;font-size:10pt;">). In the fiscal year ended September 30, 2017, this reserve was considered to be non-deductible. In September 2018, the Company made a payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$625.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, plus interest, to resolve this litigation and it was determined that a portion of the settlement was deductible. Accordingly, the Company reduced its uncertain tax position by </span><span style="font-family:inherit;font-size:10pt;"><span>$10.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$224.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the fiscal years ended September 30, 2019 and 2018, respectively. During the next 12 months, it is reasonably possible that state tax audit resolutions and the expiration of statutes of limitations could result in a reduction of unrecognized tax benefits by approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$12.4 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div> <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company's income before income taxes for the periods indicated:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Domestic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>336,150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>704,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>394,721</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>630,956</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>472,488</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>523,166</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>967,106</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,177,423</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>917,887</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 336150000 704935000 394721000 630956000 472488000 523166000 967106000 1177423000 917887000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of the Company's consolidated income tax expense (benefit) are summarized in the following table for the periods indicated:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current provision:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,801</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>247,755</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141,071</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State and local</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,246</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,328</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,950</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81,989</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,972</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57,313</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current provision</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,434</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>357,055</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234,334</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred provision (benefit):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,819</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(828,023</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>265,074</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State and local</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(31,086</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,887</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,196</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,388</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total deferred provision (benefit)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,537</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(795,524</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>319,069</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision (benefit) for income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112,971</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(438,469</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>553,403</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -12801000 247755000 141071000 15246000 39328000 35950000 81989000 69972000 57313000 84434000 357055000 234334000 61819000 -828023000 265074000 -31086000 33887000 54995000 -2196000 -1388000 -1000000 28537000 -795524000 319069000 112971000 -438469000 553403000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the statutory U.S. federal income tax rate to the Company's consolidated effective income tax rate is as follows for the periods indicated:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:53%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Statutory U.S. federal income tax rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.5%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.0%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State and local income tax rate, net of federal tax benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.4</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign tax rate differential</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.7)</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.2)</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14.6)</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.4)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.2</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Excess tax benefits related to share-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.8)</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.8)</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.8)</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Litigation settlements and accruals (see Note 14)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.3)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.3</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill impairment (see Note 5)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Tax reform</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.6)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(52.0)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital gain on distribution</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.7)</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective income tax rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.7%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(37.2)%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60.3%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.210 0.245 0.350 0.024 -0.001 0.054 -0.067 -0.062 -0.146 0 -0.014 0.022 -0.008 -0.018 -0.038 0.001 -0.063 0.343 0 0.017 0 -0.036 -0.520 0 0 0.036 0 -0.007 0.008 0.018 0.117 -0.372 0.603 -612600000 -897600000 285000000.0 -37000000.0 182600000 0 2400000000 1600000000 Significant components of the Company's deferred tax liabilities (assets) are as follows:<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,293,075</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,189,801</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>143,851</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>133,417</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill and other intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>709,015</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>853,747</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>747</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross deferred tax liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,147,833</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,177,712</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net operating loss and tax credit carryforwards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(318,868</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(421,808</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,544</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20,126</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33,312</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17,363</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee and retiree benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,420</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,210</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Share-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(39,961</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(28,888</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(60,215</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(49,892</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross deferred tax assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(487,320</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(548,287</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Valuation allowance for deferred tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199,682</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>199,985</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax assets, net of valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(287,638</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(348,302</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,860,195</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,829,410</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1293075000 1189801000 143851000 133417000 709015000 853747000 1892000 747000 2147833000 2177712000 318868000 421808000 22544000 20126000 33312000 17363000 12420000 10210000 39961000 28888000 60215000 49892000 487320000 548287000 199682000 199985000 287638000 348302000 1860195000 1829410000 12400000 P1Y P18Y 171000000.0 P1Y P20Y 58700000 6700000 84100000 2100000 -300000 -11100000 -7900000 -22700000 -36700000 117700000 104000000.0 105000000.0 124200000 112900000 95000000.0 89400000 76800000 71100000 18600000 14800000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, for the periods indicated is as follows:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits at beginning of period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98,124</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>323,869</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,766</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions of tax positions of the current year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,819</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,804</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>252,866</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additions to tax positions of the prior years</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>751</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>558</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,049</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reductions of tax positions of the prior years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,317</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(224,878</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(668</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Settlements with taxing authorities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,847</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,285</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expiration of statutes of limitations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,382</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,859</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrecognized tax benefits at end of period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105,657</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98,124</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>323,869</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 98124000 323869000 75766000 18819000 2804000 252866000 751000 558000 1049000 10317000 224878000 668000 0 1847000 3285000 1720000 2382000 1859000 105657000 98124000 323869000 235100000 625000000.0 625000000.0 10300000 224900000 12400000 Goodwill and Other Intangible Assets<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the changes in the carrying value of goodwill, by reportable segment, for the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Pharmaceutical</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Distribution Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill as of September 30, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,270,550</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,773,731</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,044,281</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill recognized in connection with acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>641,909</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,352</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>681,261</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill impairment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(59,684</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(59,684</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,586</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,586</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill as of September 30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,852,775</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,811,497</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,664,272</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill recognized in connection with acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,418</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,418</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,183</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,183</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill as of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,852,775</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,852,732</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,705,507</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the Company's annual goodwill impairment test as of July 1, 2018, the Company recorded a goodwill impairment of </span><span style="font-family:inherit;font-size:10pt;"><span>$59.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in its Profarma reporting unit. The fair value of the reporting unit was determined based upon Profarma's publicly-traded stock price, plus an estimated purchase premium. This represents a Level 2 nonrecurring fair value measurement.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of other intangible assets:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(dollars in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Remaining Useful Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite-lived trade names</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685,324</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685,324</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685,380</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685,380</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finite-lived:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,931,212</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(489,471</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,441,741</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,549,245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(555,440</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,993,805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade names and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>271,521</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(103,750</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167,771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>397,946</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(129,303</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268,643</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,888,057</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(593,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,294,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,632,571</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(684,743</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,947,828</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization expense for finite-lived intangible assets was </span><span style="font-family:inherit;font-size:10pt;"><span>$167.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$181.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$160.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. Amortization expense for finite-lived intangible assets is estimated to be </span><span style="font-family:inherit;font-size:10pt;"><span>$134.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$130.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal </span><span style="font-family:inherit;font-size:10pt;">2021</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$128.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal </span><span style="font-family:inherit;font-size:10pt;">2022</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$127.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal </span><span style="font-family:inherit;font-size:10pt;">2023</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$126.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;">2024</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$963.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> thereafter.</span></div> <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of the changes in the carrying value of goodwill, by reportable segment, for the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Pharmaceutical</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Distribution Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill as of September 30, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,270,550</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,773,731</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,044,281</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill recognized in connection with acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>641,909</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,352</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>681,261</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill impairment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(59,684</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(59,684</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,586</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,586</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill as of September 30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,852,775</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,811,497</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,664,272</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill recognized in connection with acquisitions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,418</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,418</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,183</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,183</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill as of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,852,775</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,852,732</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,705,507</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 4270550000 1773731000 6044281000 641909000 39352000 681261000 59684000 0 59684000 0 -1586000 -1586000 4852775000 1811497000 6664272000 0 43418000 43418000 0 -2183000 -2183000 4852775000 1852732000 6705507000 59700000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of other intangible assets:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(dollars in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Remaining Useful Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite-lived trade names</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685,324</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685,324</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685,380</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685,380</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finite-lived:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,931,212</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(489,471</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,441,741</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,549,245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(555,440</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,993,805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade names and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>271,521</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(103,750</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167,771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>397,946</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(129,303</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268,643</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,888,057</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(593,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,294,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,632,571</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(684,743</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,947,828</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a summary of other intangible assets:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(dollars in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Remaining Useful Life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite-lived trade names</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685,324</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685,324</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685,380</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>685,380</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finite-lived:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;padding-left:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,931,212</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(489,471</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,441,741</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,549,245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(555,440</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,993,805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade names and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>271,521</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(103,750</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167,771</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>397,946</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(129,303</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268,643</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other intangible assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,888,057</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(593,221</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,294,836</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,632,571</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(684,743</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,947,828</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 685324000 685324000 685380000 685380000 P14Y 1931212000 489471000 1441741000 2549245000 555440000 1993805000 P13Y 271521000 103750000 167771000 397946000 129303000 268643000 2888057000 593221000 2294836000 3632571000 684743000 2947828000 167400000 181200000 160500000 134100000 130200000 128500000 127200000 126200000 963300000 Debt<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt consisted of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revolving credit note</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term loans due 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399,778</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>398,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overdraft facility due 2021 (£30,000)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,573</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,269</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receivables securitization facility due 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Multi-currency revolving credit facility due 2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$500,000, 3.50% senior notes due 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>498,908</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>498,392</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$500,000, 3.40% senior notes due 2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>497,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>497,255</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$500,000, 3.25% senior notes due 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496,311</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495,632</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$750,000, 3.45% senior notes due 2027</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>743,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>742,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$500,000, 4.25% senior notes due 2045</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>494,514</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>494,298</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$500,000, 4.30% senior notes due 2047</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>492,488</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>492,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>745</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonrecourse debt</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177,453</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,172,892</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,310,189</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less AmerisourceBergen Corporation current portion</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,573</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,976</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less nonrecourse current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total, net of current portion</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,033,880</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,158,532</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Multi-Currency Revolving Credit Facility</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> multi-currency senior unsecured revolving credit facility ("Multi-Currency Revolving Credit Facility"), which was scheduled to expire in October 2023, with a syndicate of lenders. In September 2019, the Company entered into an amendment to, among other things, extend the maturity to September 2024. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based upon the Company's debt rating and ranges from </span><span style="font-family:inherit;font-size:10pt;">70 basis points</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">112.5 basis points</span><span style="font-family:inherit;font-size:10pt;"> over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (</span><span style="font-family:inherit;font-size:10pt;">91 basis points</span><span style="font-family:inherit;font-size:10pt;"> over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">) and from </span><span style="font-family:inherit;font-size:10pt;">0 basis points</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">12.5 basis points</span><span style="font-family:inherit;font-size:10pt;"> over the alternate base rate and Canadian prime rate, as applicable. The Company pays facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on its debt rating, ranging from </span><span style="font-family:inherit;font-size:10pt;">5 basis points</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">12.5 basis points</span><span style="font-family:inherit;font-size:10pt;">, annually, of the total commitment (</span><span style="font-family:inherit;font-size:10pt;">9 basis points</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">). The Company may choose to repay or reduce its commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which the Company was compliant as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Commercial Paper Program</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a commercial paper program whereby it may from time to time issue short-term promissory notes in an aggregate amount of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase the Company's borrowing capacity as it is fully backed by the Company's Multi-Currency Revolving Credit Facility. There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> borrowings outstanding under the commercial paper program as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Receivables Securitization Facility</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a </span><span style="font-family:inherit;font-size:10pt;"><span>$1,450 million</span></span><span style="font-family:inherit;font-size:10pt;"> receivables securitization facility ("Receivables Securitization Facility"), which was scheduled to expire in October 2021. In September 2019, the Company entered into an amendment to extend the maturity to September 2022. The Company has available to it an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to </span><span style="font-family:inherit;font-size:10pt;"><span>$250 million</span></span><span style="font-family:inherit;font-size:10pt;">, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based on prevailing market rates for short-term commercial paper or LIBOR, plus a program fee. The Company pays a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the Receivables Securitization Facility, AmerisourceBergen Drug Corporation sells on a revolving basis certain accounts receivable to Amerisource Receivables Financial Corporation, a wholly-owned special purpose entity, which in turn sells a percentage ownership interest in the receivables to financial institutions and commercial paper conduits sponsored by financial institutions. AmerisourceBergen Drug Corporation is the servicer of the accounts receivable under the Receivables Securitization Facility. As sold receivables are collected, additional receivables may be sold up to the maximum amount available under the facility. The facility is a financing vehicle utilized by the Company because it generally offers an attractive interest rate relative to other financing sources. The Company securitizes its trade accounts, which are generally non-interest bearing, in transactions that are accounted for as borrowings. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which the Company was compliant as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revolving Credit Note and Overdraft Facility</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has an uncommitted, unsecured line of credit available to it pursuant to a revolving credit note ("Revolving Credit Note"). The Revolving Credit Note provides the Company with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$75 million</span></span><span style="font-family:inherit;font-size:10pt;">. The Revolving Credit Note may be decreased or terminated by the bank or the Company at any time without prior notice. The Company also has a </span><span style="font-family:inherit;font-size:10pt;"><span>£30 million</span></span><span style="font-family:inherit;font-size:10pt;"> uncommitted U.K. overdraft facility ("Overdraft Facility"), which expires in February 2021, to fund short-term normal trading cycle fluctuations related to its MWI business.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Term Loans</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2018, the Company refinanced </span><span style="font-family:inherit;font-size:10pt;"><span>$400 million</span></span><span style="font-family:inherit;font-size:10pt;"> of outstanding Term Loans by issuing a new </span><span style="font-family:inherit;font-size:10pt;"><span>$400 million</span></span><span style="font-family:inherit;font-size:10pt;"> variable-rate term loan ("October 2018 Term Loan"), which matures in October 2020. The October 2018 Term Loan bears interest at a rate equal to a base rate or LIBOR, plus a margin of </span><span style="font-family:inherit;font-size:10pt;">65</span><span style="font-family:inherit;font-size:10pt;"> basis points. The October 2018 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Senior Notes</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2017, the Company issued </span><span style="font-family:inherit;font-size:10pt;"><span>$750 million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>3.45%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due </span><span style="font-family:inherit;font-size:10pt;">December 15, 2027</span><span style="font-family:inherit;font-size:10pt;"> (the "2027 Notes") and </span><span style="font-family:inherit;font-size:10pt;"><span>$500 million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>4.30%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due </span><span style="font-family:inherit;font-size:10pt;">December 15, 2047</span><span style="font-family:inherit;font-size:10pt;"> (the "2047 Notes"). The 2027 Notes were sold at </span><span style="font-family:inherit;font-size:10pt;"><span>99.76%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal amount and have an effective yield of </span><span style="font-family:inherit;font-size:10pt;"><span>3.48%</span></span><span style="font-family:inherit;font-size:10pt;">. The 2047 Notes were sold at </span><span style="font-family:inherit;font-size:10pt;"><span>99.51%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal amount and have an effective yield of </span><span style="font-family:inherit;font-size:10pt;"><span>4.33%</span></span><span style="font-family:inherit;font-size:10pt;">. Interest on the 2027 Notes and the 2047 Notes is payable semi-annually in arrears and commenced on </span><span style="font-family:inherit;font-size:10pt;">June 15, 2018</span><span style="font-family:inherit;font-size:10pt;">. The 2027 and 2047 Notes rank pari passu to the Company's other senior notes, the Multi-Currency Revolving Credit Facility, the Revolving Credit Note, the Overdraft Facility, and the October 2018 Term Loan.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company used the proceeds from the 2027 Notes and the 2047 Notes to finance the early retirement of the </span><span style="font-family:inherit;font-size:10pt;"><span>$400 million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>4.875%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes that were due in 2019, including the payment of a </span><span style="font-family:inherit;font-size:10pt;"><span>$22.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> prepayment premium, and to finance the acquisition of H.D. Smith, which was completed in January 2018 (see </span><span style="font-weight:normal;">Note 2</span><span style="font-family:inherit;font-size:10pt;">).</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The senior notes are collectively referred to as the "Notes." Interest on the Notes is payable semiannually in arrears. The Notes were sold at small discounts to the principal amounts and, therefore, have effective yields that are greater than the stated interest rates in the table above. Costs incurred in connection with the issuance of the Notes were deferred and are being amortized over the terms of the Notes. The indentures governing the Notes contain restrictions and covenants, which include limitations on </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">additional indebtedness; distributions to stockholders; the repurchase of stock and the making of other restricted payments; issuance of preferred stock; creation of certain liens; transactions with subsidiaries and other affiliates; and certain corporate acts such as mergers, consolidations, and the sale of substantially all assets. An additional covenant requires compliance with a financial leverage ratio test, with which the Company was compliant as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Nonrecourse Debt</span></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonrecourse debt is comprised of short-term and long-term debt belonging to the Brazil subsidiaries and is repaid solely from the Brazil subsidiaries' cash flows and such debt agreements provide that the repayment of the loans (and interest thereon) is secured solely by the capital stock, physical assets, contracts, and cash flows of the Brazil subsidiaries.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Information</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Scheduled future principal payments of debt are </span><span style="font-family:inherit;font-size:10pt;"><span>$111.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal 2020, </span><span style="font-family:inherit;font-size:10pt;"><span>$450.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal 2021, </span><span style="font-family:inherit;font-size:10pt;"><span>$877.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal 2022, </span><span style="font-family:inherit;font-size:10pt;"><span>$4.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal 2023, </span><span style="font-family:inherit;font-size:10pt;"><span>$501.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal 2024, and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3 billion</span></span><span style="font-family:inherit;font-size:10pt;"> thereafter. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest paid on the above indebtedness during the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$167.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$162.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$125.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total amortization of financing fees and the accretion of original issue discounts, which are recorded as components of Interest Expense, Net on the Consolidated Statements of Operations, were </span><span style="font-family:inherit;font-size:10pt;"><span>$7.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$7.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$6.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, for the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt consisted of the following:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revolving credit note</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term loans due 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399,778</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>398,665</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overdraft facility due 2021 (£30,000)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,573</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,269</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Receivables securitization facility due 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Multi-currency revolving credit facility due 2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$500,000, 3.50% senior notes due 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>498,908</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>498,392</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$500,000, 3.40% senior notes due 2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>497,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>497,255</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$500,000, 3.25% senior notes due 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>496,311</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>495,632</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$750,000, 3.45% senior notes due 2027</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>743,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>742,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$500,000, 4.25% senior notes due 2045</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>494,514</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>494,298</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$500,000, 4.30% senior notes due 2047</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>492,488</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>492,222</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>745</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonrecourse debt</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177,453</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,172,892</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,310,189</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less AmerisourceBergen Corporation current portion</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,573</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,976</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less nonrecourse current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106,439</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>137,681</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total, net of current portion</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,033,880</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,158,532</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 0 399778000 398665000 32573000 13269000 350000000 500000000 0 0 498908000 498392000 497744000 497255000 496311000 495632000 743099000 742258000 494514000 494298000 492488000 492222000 0 745000 167477000 177453000 4172892000 4310189000 32573000 13976000 106439000 137681000 4033880000 4158532000 1400000000 1400000000 0 1450000000 250000000 75000000 30000000 400000000 400000000 750000000 0.0345 500000000 0.0430 0.9976 0.0348 0.9951 0.0433 400000000 0.04875 22300000 111200000 450300000 877800000 4700000 501400000 2300000000 167400000 162100000 125300000 7100000 7700000 6200000 Stockholders' Equity and Weighted Average Common Shares Outstanding<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The authorized capital stock of the Company consists of </span><span style="font-family:inherit;font-size:10pt;"><span>600,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock, par value </span><span style="font-family:inherit;font-size:10pt;"><span>$0.01</span></span><span style="font-family:inherit;font-size:10pt;"> per share (the "common stock"), and </span><span style="font-family:inherit;font-size:10pt;"><span>10,000,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock, par value </span><span style="font-family:inherit;font-size:10pt;"><span>$0.01</span></span><span style="font-family:inherit;font-size:10pt;"> per share (the "preferred stock").</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The board of directors is authorized to provide for the issuance of shares of preferred stock in one or more series with various designations and preferences and relative, participating, optional, or other special rights and qualifications, limitations, or restrictions. Except as required by law, or as otherwise provided by the board of directors of the Company, the holders of preferred stock will have no voting rights and will not be entitled to notice of meetings of stockholders. Holders of preferred stock will be entitled to receive, when declared by the board of directors, out of legally available funds, dividends at the rates fixed by the board of directors for the respective series of preferred stock, and no more, before any dividends will be declared and paid, or set apart for payment, on common stock with respect to the same dividend period. </span><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock have been issued as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The holders of the Company's common stock are entitled to one vote per share and have the exclusive right to vote for the board of directors and for all other purposes as provided by law. Subject to the rights of holders of the Company's preferred stock, holders of common stock are entitled to receive ratably on a per share basis such dividends and other distributions in cash, stock, or property of the Company as may be declared by the board of directors from time to time out of the legally available assets or funds of the Company.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following illustrates the components of Accumulated Other Comprehensive Loss, net of income taxes:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pension and postretirement adjustments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,344</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,065</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(107,252</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(74,811</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>631</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accumulated other comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(111,965</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(79,253</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2016, the Company entered into an Accelerated Share Repurchase ("ASR") transaction with a financial institution and paid </span><span style="font-family:inherit;font-size:10pt;"><span>$400.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the delivery of </span><span style="font-family:inherit;font-size:10pt;"><span>4.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock. The initial payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$400.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> funded stock purchases of </span><span style="font-family:inherit;font-size:10pt;"><span>$380.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and a share holdback of </span><span style="font-family:inherit;font-size:10pt;"><span>$20.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. The ASR transaction was settled in November 2016, at which time the financial institution delivered an additional </span><span style="font-family:inherit;font-size:10pt;"><span>0.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock. The number of shares ultimately received was based upon the volume-weighted average price of the Company's common stock during the term of the ASR. The Company applied the </span><span style="font-family:inherit;font-size:10pt;"><span>4.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares from the ASR to the May 2016 share repurchase program. During the fiscal year ended September 30, 2017, the Company purchased </span><span style="font-family:inherit;font-size:10pt;"><span>2.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock (included </span><span style="font-family:inherit;font-size:10pt;"><span>0.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">shares of common stock received as part of the settlement of the ASR) for a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$118.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> to complete its authorization under the May 2016 program.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2016, the Company's board of directors authorized a share repurchase program allowing the Company to purchase up to </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2017, the Company purchased </span><span style="font-family:inherit;font-size:10pt;"><span>2.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$211.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> under this program. During the fiscal year ended September 30, 2018, the Company purchased </span><span style="font-family:inherit;font-size:10pt;"><span>7.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$663.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, which included </span><span style="font-family:inherit;font-size:10pt;"><span>$24.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of September 2018 purchases that cash settled in October 2018. During the fiscal year ended September 30, 2019, the Company purchased </span><span style="font-family:inherit;font-size:10pt;"><span>1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$125.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, which excluded </span><span style="font-family:inherit;font-size:10pt;"><span>$24.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of September 2018 purchases that cash settled in October 2018, to complete its authorization under this program.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In October 2018, the Company's board of directors authorized a new share repurchase program allowing the Company to purchase up to </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of its outstanding shares of common stock, subject to market conditions. During the fiscal year ended September 30, 2019, the Company purchased </span><span style="font-family:inherit;font-size:10pt;"><span>6.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for a total of </span><span style="font-family:inherit;font-size:10pt;"><span>$538.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> under this program, which included </span><span style="font-family:inherit;font-size:10pt;"><span>$14.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> of September 2019 purchases that cash settled in October 2019. As of September 30, 2019, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$461.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of availability under this program.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Shares Outstanding</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic earnings per share is computed by dividing net income attributable to AmerisourceBergen Corporation by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed by dividing net income attributable to AmerisourceBergen Corporation by the weighted average number of shares of common stock outstanding, plus the dilutive effect of stock options and restricted stock units during the periods presented.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following illustrates the components of diluted weighted average shares outstanding:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding - basic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210,165</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>217,872</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>218,375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities - stock options and restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,675</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding - diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211,840</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220,336</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>221,602</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">The potentially dilutive stock options and restricted stock units that were antidilutive for the fiscal years ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>4.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>3.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>4.1 million</span></span>, respectively. 600000000 0.01 10000000 0.01 0 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following illustrates the components of Accumulated Other Comprehensive Loss, net of income taxes:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pension and postretirement adjustments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,344</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,065</span></span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(107,252</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(74,811</span></span></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>631</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total accumulated other comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(111,965</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(79,253</span></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -5344000 -5065000 -107252000 -74811000 631000 623000 -111965000 -79253000 -400000000.0 4500000 -400000000.0 380000000.0 20000000.0 500000 4500000 2100000 500000 118800000 1000000000.0 2700000 211100000 7700000 663100000 24000000.0 1400000 125800000 24000000.0 1000000000.0 6700000 538900000 14800000 461100000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following illustrates the components of diluted weighted average shares outstanding:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding - basic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210,165</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>217,872</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>218,375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities - stock options and restricted stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,675</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding - diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>211,840</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220,336</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>221,602</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 210165000 217872000 218375000 1675000 2464000 3227000 211840000 220336000 221602000 4600000 3200000 4100000 Related Party Transactions<div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">WBA owns more than </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company's outstanding common stock and is, therefore, considered a related party. The Company operates under various agreements and arrangements with WBA, including a pharmaceutical distribution agreement pursuant to which the Company distributes pharmaceutical products to WBA and an agreement that provides the Company the ability to access favorable economic pricing and generic products through a generic purchasing services arrangement with Walgreens Boots Alliance Development GmbH. Both of these agreements expire in 2026.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue from the various agreements and arrangements with WBA was </span><span style="font-family:inherit;font-size:10pt;"><span>$60.3 billion</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$54.7 billion</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$45.4 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. The Company's receivable from WBA, net of incentives, was </span><span style="font-family:inherit;font-size:10pt;"><span>$6.1 billion</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.6 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> 0.10 60300000000 54700000000 45400000000 6100000000 5600000000 Retirement and Other Benefit Plans<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sponsors various retirement benefit plans and a deferred compensation plan covering eligible employees. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Compensation and Succession Planning Committee ("Compensation Committee") of the Company's board of directors has delegated the administration of the Company's retirement and other benefit plans to its Benefits Committee, an internal committee, comprised of senior finance, human resources, and legal executives. The Benefits Committee is responsible for the investment options under the Company's savings plans, as well as performance of the investment advisers and plan administrators.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Defined Contribution Plans</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sponsors the AmerisourceBergen Employee Investment Plan (the "Plan"), which is a defined contribution 401(k) plan covering salaried and certain hourly employees. Eligible participants may contribute to the plan from </span><span style="font-family:inherit;font-size:10pt;"><span>1%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> of their regular compensation before taxes. Prior to January 1, 2017, the Company contributed </span><span style="font-family:inherit;font-size:10pt;"><span>$1.00</span></span><span style="font-family:inherit;font-size:10pt;"> for each $1.00 invested by the participant up to the first </span><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span><span style="font-family:inherit;font-size:10pt;"> of the participant's salary and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.50</span></span><span style="font-family:inherit;font-size:10pt;"> for each additional $1.00 invested by the participant of up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;"> of salary. Effective January 1, 2017, the Company contributed </span><span style="font-family:inherit;font-size:10pt;"><span>$1.00</span></span><span style="font-family:inherit;font-size:10pt;"> for each $1.00 invested by the participant up to the first </span><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span><span style="font-family:inherit;font-size:10pt;"> of the participant's salary. Effective January 1, 2019, the Company contributes </span><span style="font-family:inherit;font-size:10pt;"><span>$1.00</span></span><span style="font-family:inherit;font-size:10pt;"> for each $1.00 invested by the participant up to the first </span><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span><span style="font-family:inherit;font-size:10pt;"> of the participant's salary and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.50</span></span><span style="font-family:inherit;font-size:10pt;"> for each additional $1.00 invested by the participant of up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>2%</span></span><span style="font-family:inherit;font-size:10pt;"> of salary. An additional discretionary contribution, in an amount not to exceed the limits established by the Internal Revenue Code ("IRC"), may also be made depending upon the Company's performance. Based on the Company's performance in fiscal 2019 and 2018, the Company recognized an expense for a discretionary contribution to the Plan in the fiscal years ended September 30, 2019 and 2018. There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> discretionary contributions recognized in the fiscal year ended September 30, 2017. All contributions are invested at the direction of the employee in one or more funds. All contributions vest immediately except for the discretionary contributions made by the Company, which vest in full after </span><span style="font-family:inherit;font-size:10pt;"><span>five years</span></span><span style="font-family:inherit;font-size:10pt;"> of credited service.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also sponsors the AmerisourceBergen Corporation Benefit Restoration Plan. This unfunded plan provides benefits to selected key management, including all of the Company's executive officers. Prior to January 1, 2017, the Company contributed an amount equal to </span><span style="font-family:inherit;font-size:10pt;"><span>4%</span></span><span style="font-family:inherit;font-size:10pt;"> of the participant's total cash compensation to the extent that his or her compensation exceeded the annual compensation limit established by Section 401(a) (17) of the IRC. Effective January 1, 2017, this plan provided eligible participants with an annual amount equal to </span><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span><span style="font-family:inherit;font-size:10pt;"> of the participant's total cash compensation to the extent that his or her compensation exceeds the annual compensation limit established by Section 401(a) (17) of the IRC. Effective January 1, 2019, this plan provides eligible participants with an annual amount equal to </span><span style="font-family:inherit;font-size:10pt;"><span>4%</span></span><span style="font-family:inherit;font-size:10pt;"> of the participant's total cash compensation to the extent that his or her compensation exceeds the annual compensation limit established by Section 401(a) (17) of the IRC.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Costs of the defined contribution plans charged to expense for the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$51.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$37.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$28.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deferred Compensation Plan</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company sponsors the AmerisourceBergen Corporation 2001 Deferred Compensation Plan. This unfunded plan, under which </span><span style="font-family:inherit;font-size:10pt;"><span>2.96 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock are authorized for issuance, allows eligible officers, directors, and key management employees to defer a portion of their annual compensation. The amount deferred may be allocated by the employee to cash, mutual funds, or stock credits. Stock credits, including dividend equivalents, are equal to the full and fractional number of shares of common stock that could be purchased with the participant's compensation allocated to stock credits based upon the average of closing prices of common stock during each month, plus, at the discretion of the board of directors, up to one-half of a share of common stock for each full share credited. Stock credit distributions are made in shares of common stock. </span><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock have been issued under the deferred compensation plan through </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company's liability relating to its deferred compensation plan as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$28.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$27.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> 0.01 0.50 1.00 0.03 0.50 0.02 1.00 0.03 1.00 0.03 0.50 0.02 0 P5Y 0.04 0.03 0.04 51000000.0 37900000 28300000 2960000 0 28000000.0 27500000 Share-Based Compensation<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's employee stock option plans provide for the granting of incentive and nonqualified stock options to acquire shares of common stock to employees at a price not less than the fair market value of the common stock on the date the option is granted. Option terms and vesting periods are determined at the date of grant by the Compensation Committee of the board of directors. Employee options generally vest ratably, in equal amounts, over a </span><span style="font-family:inherit;font-size:10pt;">four</span><span style="font-family:inherit;font-size:10pt;">-year service period and expire in </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;"> years. The Company's non-employee director stock option plans provide for the granting of nonqualified stock options to acquire shares of common stock to non-employee directors at the fair market value of the common stock on the date of the grant. Non-employee director options vest ratably, in equal amounts, over a </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year service period and expire in </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;">. Non-employee director options have not been granted since February 2011.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, employee and non-employee director stock options for an additional </span><span style="font-family:inherit;font-size:10pt;"><span>12.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares may be granted under the AmerisourceBergen Corporation Omnibus Incentive Plan (the "Plan").</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated fair value of options granted is expensed on a straight-line basis over the requisite service periods of the awards and are net of estimated forfeitures. The Company estimates the fair values of option grants using a binomial option pricing model. Expected volatilities are based upon the historical volatility of the Company's common stock and other factors, such as implied market volatility. The Company uses historical exercise data, taking into consideration the optionees' ages at grant date, to estimate the terms for which the options are expected to be outstanding. The Company anticipates that the terms of options </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">granted in the future will be similar to those granted in the past. The risk-free rates during the terms of such options are based upon the U.S. Treasury yield curve in effect at the time of grant.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average fair values of the options granted during the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$18.60</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$14.16</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$13.57</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The following weighted average assumptions were used to estimate the fair values of options granted:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:53%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.91%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.89%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.26%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.79%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.96%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.80%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility of common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.67%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.54%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.78%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life of the options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.77 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.76 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.74 years</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized stock option expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$21.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$22.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$28.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the Company's stock option activity and related information for its option plans for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is presented below:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except exercise price and contractual term)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding as of September 30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,421</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$77</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,557</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,137</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$90</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,531</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(213</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$84</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(155</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding as of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,659</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$83</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,319</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable as of September 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,395</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$83</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,049</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected to vest after September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,162</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$83</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,010</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The intrinsic value of stock option exercises during the fiscal years ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$51.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$116.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$116.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the status of the Company's nonvested options as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and changes during the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is presented below:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except grant date fair value)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant Date</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested as of September 30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,860</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$15</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,137</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$19</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,519</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$15</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(213</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested as of September 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,265</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the total fair values of options vested were </span><span style="font-family:inherit;font-size:10pt;"><span>$22.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$25.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$25.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Expected future compensation expense relating to the </span><span style="font-family:inherit;font-size:10pt;"><span>3.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> nonvested options outstanding as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is </span><span style="font-family:inherit;font-size:10pt;"><span>$21.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, which will be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span><span style="font-family:inherit;font-size:10pt;"> years.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Units</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted stock units vest in full after </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;">. The estimated fair value of restricted stock units under the Company's restricted stock unit plans is determined by the product of the number of shares granted and the grant date market price of the Company's common stock. The estimated fair value of restricted stock units is expensed on a straight-line basis over the requisite service period, net of estimated forfeitures. During the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized restricted stock unit expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$29.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$26.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$25.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the status of the Company's nonvested restricted stock units as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and changes during the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are presented below:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except grant date fair value)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Restricted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant Date</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested as of September 30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,023</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$80</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>442</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$89</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(152</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$95</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(91</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$81</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested as of September 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,222</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$81</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the total fair values of restricted stock units vested were </span><span style="font-family:inherit;font-size:10pt;"><span>$14.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$15.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$13.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. Expected future compensation expense relating to the </span><span style="font-family:inherit;font-size:10pt;"><span>1.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> restricted stock units outstanding as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is </span><span style="font-family:inherit;font-size:10pt;"><span>$30.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, which will be recognized over a weighted average period of </span><span style="font-family:inherit;font-size:10pt;"><span>1.2</span></span><span style="font-family:inherit;font-size:10pt;"> years.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Performance Stock Units</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Performance stock units are granted to certain executive employees under the Plan and represent common stock potentially issuable in the future. Performance stock units vest at the end of a three-year performance period based upon achievement of specific performance goals. Based upon the extent to which the targets are achieved, vested shares for awards granted prior to fiscal 2018 may range from </span><span style="font-family:inherit;font-size:10pt;"><span>0%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>150%</span></span><span style="font-family:inherit;font-size:10pt;"> of the target award amount. For awards granted beginning in fiscal 2018, vested shares may range from </span><span style="font-family:inherit;font-size:10pt;"><span>0%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>200%</span></span><span style="font-family:inherit;font-size:10pt;"> of the target award amount. The fair value of performance stock units is determined by the grant date market price of the Company's common stock. Compensation expense associated with nonvested performance stock units is recognized over the requisite service period and is dependent on the Company's periodic assessment of the probability of the targets being achieved and its estimate of the number of shares that will ultimately be issued. During the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized performance stock expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$12.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$8.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the status of the Company's nonvested performance stock units as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and changes during the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is presented below (based upon target award amounts).</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except grant date fair value)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Performance</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant Date</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested as of September 30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$77</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$90</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(105</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$76</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$90</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested as of September 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>283</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$84</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares that vested over the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year performance period ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> were distributed to employees in November </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div> P10Y 12800000 18.60 14.16 13.57 The following weighted average assumptions were used to estimate the fair values of options granted:<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:53%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:15%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.91%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.89%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.26%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.79%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.96%</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.80%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Volatility of common stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.67%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.54%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.78%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life of the options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.77 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.76 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.74 years</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.0291 0.0189 0.0126 0.0179 0.0196 0.0180 0.2767 0.2654 0.2678 P3Y9M7D P3Y9M3D P3Y8M26D 21000000.0 22600000 28600000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the Company's stock option activity and related information for its option plans for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is presented below:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except exercise price and contractual term)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Price</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Intrinsic</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding as of September 30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,421</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$77</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142,557</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,137</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$90</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,531</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(213</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$84</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(155</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding as of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,659</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$83</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,319</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exercisable as of September 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,395</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$83</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,049</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected to vest after September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,162</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$83</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,010</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 8421000 77 P4Y 142557000 1137000 90 1531000 50 213000 84 155000 97 7659000 83 P4Y 35319000 4395000 83 P3Y 25049000 3162000 83 P5Y 10010000 51200000 116700000 116600000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the status of the Company's nonvested options as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and changes during the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is presented below:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except grant date fair value)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant Date</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested as of September 30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,860</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$15</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,137</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$19</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,519</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$15</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(213</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested as of September 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,265</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$16</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3860000 15 1137000 19 1519000 15 213000 16 3265000 16 22700000 25800000 25200000 3300000 21600000 P2Y P3Y 29200000 26800000 25100000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the status of the Company's nonvested restricted stock units as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and changes during the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are presented below:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except grant date fair value)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Restricted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant Date</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested as of September 30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,023</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$80</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>442</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$89</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(152</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$95</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(91</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$81</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested as of September 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,222</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$81</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1023000 80 442000 89 152000 95 91000 81 1222000 81 14500000 15800000 13800000 1200000 30100000 P1Y2M12D 0 1.50 0 2 8500000 12800000 8400000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of the status of the Company's nonvested performance stock units as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and changes during the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is presented below (based upon target award amounts).</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:72%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except grant date fair value)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Performance</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Stock</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Grant Date</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested as of September 30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$77</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$90</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(105</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$76</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$90</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested as of September 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>283</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$84</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 244000 77 147000 90 105000 76 3000 90 283000 84 Lease Commitments<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has long-term leases for facilities and equipment. In the normal course of business, leases are generally renewed or replaced by other leases. Certain leases include escalation clauses. During the fiscal years ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company recorded rental expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$108.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$114.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$80.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, in Distribution, Selling, and Administrative in the Consolidated Statements of Operations.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, future minimum rental payments under noncancelable operating leases and financing obligations were as follows:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments Due by Fiscal Year (in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Financing Obligations </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">1</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94,958</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,468</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117,426</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,002</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,790</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,792</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72,224</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,914</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109,138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,507</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,950</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99,457</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,377</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91,653</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177,267</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>270,410</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>447,677</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>548,335</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>430,808</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>979,143</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">1</sup></span><span style="font-family:inherit;font-size:8pt;"> Represents the portion of future minimum lease payments relating to facility leases where the Company was determined to be the accounting owner (see Note 1). These payments are recognized as reductions to the financing obligation and as interest expense and exclude the future non-cash termination of the financing obligation.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 108900000 114900000 80700000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, future minimum rental payments under noncancelable operating leases and financing obligations were as follows:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments Due by Fiscal Year (in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Financing Obligations </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">1</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94,958</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,468</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117,426</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,002</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,790</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,792</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72,224</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,914</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109,138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,507</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,950</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99,457</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,377</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91,653</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177,267</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>270,410</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>447,677</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>548,335</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>430,808</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>979,143</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">1</sup></span><span style="font-family:inherit;font-size:8pt;"> Represents the portion of future minimum lease payments relating to facility leases where the Company was determined to be the accounting owner (see Note 1). These payments are recognized as reductions to the financing obligation and as interest expense and exclude the future non-cash termination of the financing obligation.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, future minimum rental payments under noncancelable operating leases and financing obligations were as follows:</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments Due by Fiscal Year (in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Financing Obligations </span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">1</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94,958</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,468</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117,426</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84,002</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,790</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113,792</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>72,224</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,914</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>109,138</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,507</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,950</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99,457</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,377</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>91,653</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177,267</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>270,410</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>447,677</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>548,335</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>430,808</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>979,143</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">1</sup></span><span style="font-family:inherit;font-size:8pt;"> Represents the portion of future minimum lease payments relating to facility leases where the Company was determined to be the accounting owner (see Note 1). These payments are recognized as reductions to the financing obligation and as interest expense and exclude the future non-cash termination of the financing obligation.</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 94958000 22468000 117426000 84002000 29790000 113792000 72224000 36914000 109138000 63507000 35950000 99457000 56377000 35276000 91653000 177267000 270410000 447677000 548335000 430808000 979143000 Employee Severance, Litigation, and Other<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following illustrates the charges incurred by the Company relating to Employee Severance, Litigation, and Other for the periods indicated:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> (in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee severance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,147</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,694</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,767</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Litigation and opioid-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>185,145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,527</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>917,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition-related deal and integration costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,184</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,912</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,990</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Business transformation efforts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,437</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,963</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other restructuring initiatives</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,561</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,424</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,297</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total employee severance, litigation, and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>330,474</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183,520</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>959,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee severance in the fiscal year ended September 30, 2019 included costs primarily related to PharMEDium restructuring activities, position eliminations resulting from our business transformation efforts and the integration of H.D. Smith, and restructuring activities related to our consulting business. Employee severance in the fiscal year ended September 30, 2018 included costs primarily related to position eliminations resulting from the Company's business transformation efforts and restructuring activities related to our consulting business. Employee severance in the fiscal year ended September 30, 2017 included costs primarily related to position eliminations as the Company began to reorganize to further align the organization to its customers' needs.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Litigation and opioid-related costs in the fiscal year ended September 30, 2019 consisted of </span><span style="font-family:inherit;font-size:10pt;"><span>$116.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of legal settlements and accruals and </span><span style="font-family:inherit;font-size:10pt;"><span>$68.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of legal fees in connection with opioid lawsuits and investigations. Litigation and opioid-related costs in the fiscal year ended September 30, 2018 primarily related to opioid lawsuits, investigations, and related initiatives. Litigation and opioid-related costs in the fiscal year ended September 30, 2017 primarily related to litigation settlements and accruals.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Acquisition-related deal and integration costs in the fiscal year ended September 30, 2019 are primarily related to the integration of H.D. Smith. Integration costs primarily include costs to transition servicing legacy H.D. Smith customers to existing company distribution facilities and operating systems. Acquisition-related deal and integration costs in the fiscal year ended September 30, 2018 were primarily related to the acquisition of H.D. Smith. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Business transformation efforts in the fiscal years ended September 30, 2019 and 2018 were primarily related to costs associated with reorganizing the Company to further align the organization to its customers' needs. The majority of these costs were related to services provided by third-party consultants.</span></div> <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following illustrates the charges incurred by the Company relating to Employee Severance, Litigation, and Other for the periods indicated:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> (in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee severance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,147</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36,694</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,767</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Litigation and opioid-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>185,145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61,527</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>917,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition-related deal and integration costs</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,184</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,912</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,990</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Business transformation efforts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,437</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,963</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other restructuring initiatives</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,561</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18,424</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13,297</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total employee severance, litigation, and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>330,474</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183,520</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>959,327</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 34147000 36694000 7767000 185145000 61527000 917573000 43184000 33912000 16990000 55437000 32963000 3700000 12561000 18424000 13297000 330474000 183520000 959327000 116700000 68500000 Legal Matters and Contingencies<div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the ordinary course of its business, the Company becomes involved in lawsuits, administrative proceedings, government subpoenas, government investigations, stockholder demands, and other disputes, including antitrust, commercial, product liability, intellectual property, regulatory, employment discrimination, and other matters. Significant damages or penalties </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">may be sought from the Company in some matters, and some matters may require years for the Company to resolve. The Company records a reserve for these matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> For those matters for which the Company has not recognized a liability, the Company cannot predict the outcome of their impact on the Company as uncertainty remains with regard to whether such matters will proceed to trial, whether settlements will be reached, and the amount and terms of any such settlements. Outcomes may include settlements in significant amounts that are not currently estimable, limitations on the Company's conduct, the imposition of corporate integrity agreement obligations, consent decrees, and/or other civil and criminal penalties. From time to time, the Company is also involved in disputes with its customers, which the Company generally seeks to resolve through commercial negotiations. If negotiations are unsuccessful, the parties may litigate the dispute or otherwise attempt to settle the matter.</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Opioid Lawsuits and Investigations</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A significant number of counties, municipalities, and other governmental entities in a majority of U.S. states and Puerto Rico, as well as several states and tribes, have filed lawsuits in various federal, state and other courts against pharmaceutical wholesale distributors (including the Company and its subsidiaries AmerisourceBergen Drug Corporation ("ABDC") and H.D. Smith, which was acquired in January 2018), pharmaceutical manufacturers, retail chains, medical practices, and physicians relating to the distribution of prescription opioid pain medications. Other lawsuits regarding the distribution of prescription opioid pain medications have been filed by: third-party payors and similar entities; hospitals; hospital groups; and individuals, including cases styled as putative class actions. The lawsuits, which have been and continue to be filed in federal, state, and other courts, generally allege violations of controlled substance laws and various other statutes as well as common law claims, including negligence, public nuisance, and unjust enrichment, and seek equitable relief and monetary damages. An initial group of cases was consolidated for Multidistrict Litigation ("MDL") proceedings before the United States District Court for the Northern District of Ohio (the "Court") in December 2017. Additional cases have been, and will likely continue to be, transferred to the MDL. Further, in June 2018, the Court granted a motion permitting the United States, through the DOJ, to participate in settlement discussions and as a friend of the Court by providing information to facilitate non-monetary remedies. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2018, the Court issued an order creating a litigation track, which includes dispositive motion practice, discovery, and trials in certain bellwether jurisdictions. On December 31, 2018, the Court issued an order selecting two additional cases for a second bellwether discovery and trial track. The timing of discovery, motion practice, and trials for the second set of bellwether cases has not yet been determined.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 21, 2019, the Company announced an agreement in principle with two Ohio counties, Cuyahoga and Summit, to settle all claims brought by the two counties against the Company in the first track of the MDL. All claims against the Company were dismissed with prejudice pursuant to the settlement. As a result, the Company recorded a charge of </span><span style="font-family:inherit;font-size:10pt;"><span>$66.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the fourth quarter of the fiscal year ended September 30, 2019 within Employee Severance, Litigation and Other in its Statement of Operations and in Accrued Expenses and Other on the Company’s Consolidated Balance Sheet. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Court has continued to oversee court-ordered settlement discussions with attorneys for the plaintiffs and certain states that it instituted at the beginning of the MDL proceedings. On October 21, 2019, the Attorneys General for North Carolina, Pennsylvania, Tennessee, and Texas announced certain proposed settlement terms intended to provide a potential framework for a global resolution of the MDL and other related state court litigation, including cases currently filed and that could be filed. The attorneys general's announcement outlined that the largest U.S. pharmaceutical distributors would be expected to pay an aggregate amount of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$18.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> over </span><span style="font-family:inherit;font-size:10pt;"><span>18</span></span><span style="font-family:inherit;font-size:10pt;"> years, of which the Company's portion would be </span><span style="font-family:inherit;font-size:10pt;"><span>31%</span></span><span style="font-family:inherit;font-size:10pt;">, in addition to the development and participation in a program for free or rebated distribution of opioid-abuse medications for a period of </span><span style="font-family:inherit;font-size:10pt;"><span>10</span></span><span style="font-family:inherit;font-size:10pt;"> years and the implementation of industry-wide changes to be specified to controlled substance anti-diversion programs. The Company is currently engaged in discussions that include the four attorneys general and other parties with the objective of reaching potential terms for a global resolution. The Company is also engaged in related discussions with plaintiffs' lawyers representing local governments and other parties with the same goal of reaching a global resolution with all parties. If agreed, the potential terms for a global resolution would then need to be presented to numerous other states and local governments, and a significant number of such jurisdictions would need to accept the proposed terms in order to achieve an agreement in principle that would provide the finality that the Company requires from a global resolution. Given the large number of parties involved, the complexity and difficulty of the underlying issues, and the resulting uncertainty of achieving a potential global resolution, the Company continues to litigate and </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">prepare for trial in the cases pending in the MDL as well as in state courts where lawsuits have been filed, and intends to continue to vigorously defend itself in all such cases. A liability associated with a global resolution has not been recognized as of September 30, 2019, since the Company is unable to predict the outcome of settlement discussions with the states and local governments that will need to participate and, therefore, a global resolution cannot be considered probable. Furthermore, significant uncertainty remains with regard to whether such matters will proceed to trial, and, given the inherent uncertainty related to such litigation, the Company is not in a position to assess the likely outcome, and therefore unable to estimate the range of possible loss.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2019, attorneys for some of the plaintiffs filed a motion proposing a procedure to certify a nationwide "negotiation class" of cities and counties for the purpose of negotiating and settling with defendants engaged in the nationwide manufacturing, sale, or distribution of opioids. The attorneys subsequently withdrew the motion and refiled an amended motion on July 9, 2019. The Court granted the motion on September 11, 2019 and certain defendants, including ABDC, are appealing.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 6, 2019, a New York state court entered an order accelerating the trial date for cases brought by Nassau and Suffolk Counties and the New York Attorney General against a variety of defendants, including the Company. Pursuant to that order, the trial, which is not part of the MDL, was scheduled to begin on January 20, 2020, however during a subsequent meeting on November 13, 2019, the court amended the trial date to begin in March 2020.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Aside from those parties that have already filed suit, other entities, including additional attorneys general’s offices, counties, and cities in multiple states, have indicated their intent to sue. The Company is vigorously defending itself in the pending lawsuits and intends to vigorously defend itself against any threatened lawsuits. The Company is not in a position to assess the likely outcome or its exposure, if any, with respect to these matters.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has also received subpoenas, civil investigative demands, and other requests for information, requesting the production of documents regarding the distribution of prescription opioid pain medications from government agencies in other jurisdictions, including certain states. The Company is engaged in discussions with representatives from these government agencies regarding the requests and has been producing responsive documents.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since July 2017, the Company has received subpoenas from several U.S. Attorney's Offices. Those subpoenas request the production of a broad range of documents pertaining to ABDC's distribution of controlled substances and diversion control programs. The Company has been engaged in discussions with the various U.S. Attorney’s Offices, including the Health Care and Government Fraud Unit of the Criminal Division of the U.S. Attorney's Office for the District of New Jersey, and has been producing documents in response to the subpoenas.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2012, the Attorney General of the State of West Virginia ("West Virginia AG") filed complaints, which were amended, in the Circuit Court of Boone County, West Virginia, against a number of pharmaceutical wholesale distributors, including the Company's subsidiary ABDC, alleging, among other claims, that the distributors failed to provide effective controls and procedures to guard against diversion of controlled substances for illegitimate purposes in West Virginia, acted negligently by distributing controlled substances to pharmacies that serve individuals who abuse controlled substances, and failed to report suspicious orders of uncontrolled substances in accordance with state regulations. The West Virginia AG was seeking monetary damages and injunctive and other equitable relief. This matter was dismissed with prejudice on January 9, 2017 pursuant to a settlement agreement that provided for the payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$16.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and express denial of the allegations in the complaints and any wrongdoing. During the fiscal year ended September 30, 2017, the Company recognized the </span><span style="font-family:inherit;font-size:10pt;"><span>$16.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> settlement in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations. The Company paid the </span><span style="font-family:inherit;font-size:10pt;"><span>$16.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> settlement in fiscal 2017.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Government Enforcement and Related Litigation Matters</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Various government agencies, including the FDA, the Consumer Protection Branch of the Civil Division of the DOJ, and state boards of pharmacy, regulate the compounding of pharmaceutical products. The Company’s subsidiary, PharMEDium, operates Section 503B outsourcing facilities that must comply with current Good Manufacturing Practice ("cGMP") requirements and are inspected by the FDA periodically to determine compliance. The FDA and the DOJ have broad enforcement powers, including the authority to enjoin PharMEDium's Section 503B outsourcing facilities from distributing pharmaceutical products.</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 17, 2019, PharMEDium reached an agreement on the terms of the Consent Decree with the FDA and the DOJ that was entered by the United States District Court for the Northern District of Illinois on May 22, 2019. The Consent Decree permits commercial operations to continue at PharMEDium’s Dayton, New Jersey and Sugar Land, Texas compounding facilities and administrative operations to continue at its Lake Forest, Illinois headquarters subject to compliance with requirements set forth therein. As required by the Consent Decree, initial audit inspections were conducted by an independent cGMP expert of the Dayton and Sugar Land facilities. The cGMP expert has notified the FDA that all of the short-term corrective actions taken are </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">acceptable. The Company has submitted to the FDA several additional longer-term corrective actions, and the independent cGMP expert will assess the effectiveness of the implementation of these items in future audits. Additional audit inspections by the independent cGMP expert of the Sugar Land and Dayton facilities are required at least annually for a period of four years.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Consent Decree also establishes requirements that must be satisfied prior to the resumption of commercial operations at the Memphis, Tennessee facility. The requirements include a work plan approved by the FDA and an audit inspection and certification by an independent cGMP expert that the facilities, methods and controls at the Memphis facility and PharMEDium’s Lake Forest, Illinois headquarters comply with the Consent Decree. If PharMEDium receives written notification from the FDA of compliance with the requirements to resume operations at the Memphis facility, additional audit inspections are required for five years, during which time PharMEDium must correct any deviations from the Consent Decree observed by the independent cGMP expert.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After five years, PharMEDium may petition the district court for full relief from the Consent Decree, or for specific relief with regard to one or more facilities. If, at the time of such petition, all obligations under the Consent Decree with respect to the specific facilities for which PharMEDium is seeking relief have been satisfied, and there has been continuous compliance with the Consent Decree for at least five years, the federal government will not oppose the petition, and PharMEDium may request that the district court grant such relief.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, state boards of pharmacy may revoke, limit, or deny approval of licenses required under state law to compound or distribute pharmaceutical products. As a result of reciprocal state actions initiated due to the FDA’s inspectional observations, PharMEDium has suspended shipping of its compounded sterile preparations into several states, either voluntarily, by consent or pursuant to orders of state licensing authorities.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Subpoenas and Ongoing Investigations</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, the Company receives subpoenas or requests for information from various government agencies relating to the Company's business or to the business of a customer, supplier, or other industry participant. The Company's responses often require time and effort and can result in considerable costs being incurred. Most of these matters are resolved without incident; however, such subpoenas or requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the healthcare industry, as well as to substantial settlements.</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2017, the Company's subsidiary U.S. Bioservices Corporation ("U.S. Bio") received a subpoena for information from the U.S. Attorney's Office for the Eastern District of New York ("USAO-EDNY") relating to its activities in connection with billing for products and making returns of potential overpayments to government payers. The Company engaged in discussions with the USAO-EDNY and produced documents in response to the subpoena. In April 2019, the government informed the Company that it had filed a notice with the U.S. District Court for the Eastern District of New York that it was declining to intervene in a filed qui tam action related to its investigation. The case was unsealed in April 2019 and counsel for the relator has stated that they intend to file an amended complaint under seal, which they intend to submit to the USAO-EDNY for further consideration.</span></div><div style="line-height:120%;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company and its subsidiary AmerisourceBergen Specialty Group ("ABSG") had previously responded to subpoenas from the USAO-EDNY requesting production of documents and information relating to the pre-filled syringe program of ABSG’s subsidiary Medical Initiatives, Inc., ABSG's oncology distribution center, its group purchasing organization for oncologists, and intercompany transfers of certain oncology products. Medical Initiatives, Inc. voluntarily ceased operations in early 2014. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On September 27, 2017, pursuant to the terms of a plea agreement, ABSG entered a guilty plea to a one-count strict-liability misdemeanor violation of the Federal Food, Drug, and Cosmetic Act in the United States District Court of the Eastern District of New York. Under the terms of the agreement, which were approved by the Court, ABSG paid a total criminal fine and forfeiture of </span><span style="font-family:inherit;font-size:10pt;"><span>$260.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal 2017. The guilty plea resolves the federal criminal investigation related to the failure of Medical Initiatives, Inc. to duly register with the FDA. The Company also entered into a Compliance Agreement with the United States Department of Justice for a period of three years. During the fiscal year ended September 30, 2017, the Company recognized the </span><span style="font-family:inherit;font-size:10pt;"><span>$260.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> settlement in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The USAO-EDNY also pursued alleged civil claims under the False Claims Act. ABSG reached an agreement in principle with the USAO-EDNY during the fiscal quarter ended December 31, 2017, which the Company expected would resolve the alleged civil claims in their entirety. In the fourth quarter of the fiscal year ended September 30, 2018, the Company reached final terms of the settlement agreement with the USAO-EDNY, resolved potential administrative action by the Office of Inspector General of the U.S. Department of Health and Human Services by entering into a Corporate Integrity Agreement, and obtained dismissal </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">with prejudice of the potential civil claims. The Corporate Integrity Agreement has a five-year term, which commenced on September 28, 2018, and requires, among other things, the maintenance of a compliance program, an independent review organization and a financial recoupment program. Pursuant to the terms of the settlement agreement with the USAO-EDNY, ABSG made a payment on September 28, 2018 to resolve the civil litigation without making any admission of liability in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$625.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, plus interest from December 1, 2017. As a result of the agreement in principle, the Company had previously accrued a reserve in the amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$625.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the fiscal year ended September 30, 2017. The reserve was recognized in Employee Severance, Litigation, and Other on the Company's Statement of Operations.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:52px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s subsidiary U.S. Bio settled claims with the U.S. Attorney’s Office for the Southern District of New York ("USAO-SDNY") and with various states arising from the previously disclosed matter involving the dispensing of one product and U.S. Bio’s relationship with the manufacturer of that product. In accordance with the settlement agreements, the United States’ complaint against U.S. Bio was dismissed and the participating states agreed not to bring, and to dismiss with prejudice, any state law claims that they had the authority to bring against U.S. Bio. The Company paid the United States </span><span style="font-family:inherit;font-size:10pt;"><span>$10.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal 2017 and paid the participating states </span><span style="font-family:inherit;font-size:10pt;"><span>$2.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal 2018. During the year ended September 30, 2017, the Company recognized the </span><span style="font-family:inherit;font-size:10pt;"><span>$13.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> settlement in Employee Severance, Litigation, and Other on the Company's Consolidated Statements of Operations.</span></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Contingencies</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">New York State ("NYS") enacted the Opioid Stewardship Act ("OSA"), which went into effect on July 1, 2018. The OSA established an annual </span><span style="font-family:inherit;font-size:10pt;"><span>$100 million</span></span><span style="font-family:inherit;font-size:10pt;"> Opioid Stewardship Fund (the "Fund") and requires manufacturers, distributors, and importers licensed in NYS to ratably source the Fund. The ratable share of the assessment for each licensee was to be based upon opioids sold or distributed to or within NYS. In the fourth quarter of the fiscal year ended September 30, 2018, the Company accrued </span><span style="font-family:inherit;font-size:10pt;"><span>$22.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> as an estimate of its liability under the OSA for opioids distributed from January 1, 2017 through September 30, 2018 and recognized this reserve in Cost of Goods Sold on its Consolidated Statement of Operations and in Accrued Expenses and Other on its Consolidated Balance Sheet as of September 30, 2018. In December 2018, the OSA was ruled unconstitutional by the U.S. District Court for the Southern District of New York, and, as a result, the Company reversed the </span><span style="font-family:inherit;font-size:10pt;"><span>$22.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> accrual in the fiscal quarter ended December 31, 2018. NYS filed an appeal of the court decision on January 17, 2019; however, the Company does not believe a loss contingency is probable.</span></div> 66700000 18000000000.0 P18Y 0.31 P10Y -16000000.0 -16000000.0 16000000.0 260000000.0 260000000.0 625000000.0 625000000.0 10700000 2800000 13400000 100000000 22000000.0 -22000000.0 Litigation Settlements<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Antitrust Settlements</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Numerous lawsuits have been filed against certain brand pharmaceutical manufacturers alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. These lawsuits are generally brought as class actions. The Company has not been a named a plaintiff in any of these lawsuits, but has been a member of the direct purchasers' class (i.e., those purchasers who purchase directly from these pharmaceutical manufacturers). None of the lawsuits has gone to trial, but some have settled in the past with the Company receiving proceeds from the settlement funds. During the fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized gains of </span><span style="font-family:inherit;font-size:10pt;"><span>$145.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$35.9</span></span><span style="font-family:inherit;font-size:10pt;"> million, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, relating to these lawsuits. These gains, which are net of attorney fees and estimated payments due to other parties, were recorded as reductions to cost of goods sold in the Company's Consolidated Statements of Operations.</span></div> 145900000 35900000 1400000 Business Segment Information<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is organized based upon the products and services it provides to its customers. The Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating segments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in Other for the purpose of reportable segment presentation. Other consists of operating segments that focus on global commercialization services and animal health (MWI Animal Health). The operating segments that focus on global commercialization services include AmerisourceBergen Consulting Services ("ABCS") and World Courier.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The chief operating decision maker ("CODM") of the Company is the Chairman, President &amp; Chief Executive Officer of the Company, whose function is to allocate resources to, and assess the performance of, the Company's operating segments.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Pharmaceutical Distribution Services reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. Through a number of operating businesses, the Pharmaceutical Distribution Services </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">reportable segment provides pharmaceutical distribution (including plasma and other blood products, injectible pharmaceuticals, vaccines, and other specialty pharmaceutical products) and additional services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. Additionally, the Pharmaceutical Distribution Services reportable segment provides data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The Pharmaceutical Distribution Services reportable segment also provides pharmacy management, staffing and additional consulting services, and supply management software to a variety of retail and institutional healthcare providers. Additionally, it delivers packaging solutions to institutional and retail healthcare providers.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ABCS, through a number of operating businesses, provides a full suite of integrated manufacturer services that range from clinical trial support to product post-approval and commercialization support. World Courier, which operates in over </span><span style="font-family:inherit;font-size:10pt;"><span>50</span></span><span style="font-family:inherit;font-size:10pt;"> countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. MWI is a leading animal health distribution company in the United States and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets. Additionally, MWI offers demand-creating sales force services to manufacturers. </span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> The following illustrates reportable and operating segment revenue information for the periods indicated:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical Distribution Services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172,813,537</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161,699,343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>147,453,495</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MWI Animal Health</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,975,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,789,759</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,636,305</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Global Commercialization Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,893,109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,542,971</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,111,558</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,868,341</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,332,730</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,747,863</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intersegment eliminations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(92,757</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(92,438</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(57,532</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,589,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167,939,635</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153,143,826</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intersegment eliminations primarily represent the elimination of certain Pharmaceutical Distribution Services reportable segment sales to MWI.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following illustrates reportable segment operating income information for the periods indicated:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical Distribution Services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,671,251</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,626,748</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,643,629</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>380,660</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>355,091</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>373,797</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intersegment eliminations</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(659</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(609</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(556</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total segment operating income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,051,252</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,981,230</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,016,870</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following reconciles total segment operating income to income before income taxes for the periods indicated:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total segment operating income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,051,252</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,981,230</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,016,870</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain from antitrust litigation settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,872</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,938</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIFO credit (expense)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,544</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(67,324</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157,782</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PharMEDium remediation costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(69,423</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(66,204</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">New York State Opioid Stewardship Act</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition-related intangibles amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(159,848</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(174,751</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(156,378</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee severance, litigation, and other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(330,474</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(183,520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(959,327</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill impairment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(59,684</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impairment of long-lived assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(570,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,111,923</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,443,685</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,060,342</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,952</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,469</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,730</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157,769</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>174,699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on consolidation of equity investments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,328</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on early retirement of debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,766</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>967,106</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,177,423</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>917,887</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Segment operating income is evaluated by the CODM of the Company and excludes gain from antitrust litigation settlements; LIFO credit (expense); PharMEDium remediation costs; New York State Opioid Stewardship Act; acquisition-related intangibles amortization; employee severance, litigation, and other; goodwill impairment; and impairment of long-lived assets. Segment measures were adjusted in fiscal 2019 to exclude impairment of long-lived assets as the CODM excludes these costs in the measurement of segment performance. All corporate office expenses are allocated to the operating segment level.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company incurred remediation costs in connection with the suspended production activities at PharMEDium (see Notes 1 and 13). These remediation costs are primarily classified in Cost of Goods sold in the Consolidated Statements of Operations. Future remediation costs will also include costs related to remediation activities responsive to FDA inspectional observations generally applicable to all of PharMEDium’s 503B outsourcing facilities, including product stability studies.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded a </span><span style="font-family:inherit;font-size:10pt;"><span>$13.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> gain on the sale of an equity investment in Other (Income) Loss in the Company's Consolidated Statement of Operations in the fiscal year ended September 30, 2019.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recorded a </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> impairment of a non-customer note receivable related to a start-up venture in Other (Income) Loss in the Company's Consolidated Statement of Operations in the fiscal year ended September 30, 2018.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following illustrates total assets by reportable segment for the periods indicated:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical Distribution Services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,160,529</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,892,621</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,691,127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,011,451</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,777,217</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,625,343</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,171,980</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,669,838</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,316,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The CODM does not review assets by operating segment for the purpose of assessing performance or allocating resources.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following illustrates depreciation and amortization by reportable segment for the periods indicated:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical Distribution Services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>232,735</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225,608</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>188,065</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,824</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition-related intangibles amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,848</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>174,751</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>156,378</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>462,407</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>465,127</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>397,603</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization includes depreciation and amortization of property and equipment and intangible assets, but excludes amortization of deferred financing costs and other debt-related items, which are included in interest expense, net.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following illustrates capital expenditures by reportable segment for the periods indicated:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical Distribution Services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210,161</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>190,191</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>339,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100,061</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126,919</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total capital expenditures</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>310,222</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>336,411</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>466,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 50 The following illustrates reportable and operating segment revenue information for the periods indicated:<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical Distribution Services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>172,813,537</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161,699,343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>147,453,495</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MWI Animal Health</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,975,232</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,789,759</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,636,305</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Global Commercialization Services</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,893,109</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,542,971</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,111,558</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total Other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,868,341</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,332,730</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,747,863</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intersegment eliminations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(92,757</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(92,438</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(57,532</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,589,121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167,939,635</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153,143,826</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 172813537000 161699343000 147453495000 3975232000 3789759000 3636305000 2893109000 2542971000 2111558000 6868341000 6332730000 5747863000 -92757000 -92438000 -57532000 179589121000 167939635000 153143826000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following illustrates reportable segment operating income information for the periods indicated:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical Distribution Services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,671,251</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,626,748</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,643,629</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>380,660</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>355,091</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>373,797</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intersegment eliminations</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(659</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(609</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(556</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total segment operating income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,051,252</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,981,230</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,016,870</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following illustrates depreciation and amortization by reportable segment for the periods indicated:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical Distribution Services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>232,735</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>225,608</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>188,065</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69,824</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64,768</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53,160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition-related intangibles amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,848</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>174,751</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>156,378</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>462,407</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>465,127</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>397,603</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following illustrates capital expenditures by reportable segment for the periods indicated:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical Distribution Services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210,161</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>190,191</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>339,478</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100,061</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146,220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>126,919</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total capital expenditures</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>310,222</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>336,411</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>466,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1671251000 1626748000 1643629000 380660000 355091000 373797000 -659000 -609000 -556000 2051252000 1981230000 2016870000 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following reconciles total segment operating income to income before income taxes for the periods indicated:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total segment operating income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,051,252</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,981,230</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,016,870</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gain from antitrust litigation settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,872</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,938</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIFO credit (expense)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,544</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(67,324</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157,782</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">PharMEDium remediation costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(69,423</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(66,204</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">New York State Opioid Stewardship Act</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquisition-related intangibles amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(159,848</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(174,751</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(156,378</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee severance, litigation, and other</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(330,474</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(183,520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(959,327</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill impairment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(59,684</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impairment of long-lived assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(570,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,111,923</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,443,685</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,060,342</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other (income) loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,952</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25,469</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2,730</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>157,769</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>174,699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145,185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on consolidation of equity investments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42,328</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss on early retirement of debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,766</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>967,106</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,177,423</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>917,887</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2051252000 1981230000 2016870000 145872000 35938000 1395000 -22544000 67324000 -157782000 69423000 66204000 0 -22000000 22000000 0 159848000 174751000 156378000 330474000 183520000 959327000 0 59684000 0 570000000 0 0 1111923000 1443685000 1060342000 12952000 -25469000 2730000 -157769000 -174699000 -145185000 0 42328000 0 0 -23766000 0 967106000 1177423000 917887000 13700000 30000000.0 <div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following illustrates total assets by reportable segment for the periods indicated:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pharmaceutical Distribution Services</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33,160,529</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31,892,621</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29,691,127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,011,451</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,777,217</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,625,343</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39,171,980</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,669,838</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,316,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 33160529000 31892621000 29691127000 6011451000 5777217000 5625343000 39171980000 37669838000 35316470000 232735000 225608000 188065000 69824000 64768000 53160000 159848000 174751000 156378000 462407000 465127000 397603000 210161000 190191000 339478000 100061000 146220000 126919000 310222000 336411000 466397000 Fair Value of Financial Instruments<div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recorded amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> approximate fair value based upon the relatively short-term nature of these financial instruments. Within Cash and Cash Equivalents, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>$1,552.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1,050.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of investments in money market accounts as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. The fair value of the money market accounts was determined based upon unadjusted quoted prices in active markets for identical assets, otherwise known as Level 1 inputs.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recorded amount of long-term debt (see </span><span style="font-weight:normal;">Note 6</span><span style="font-family:inherit;font-size:10pt;">) and the corresponding fair value as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$4,033.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4,158.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The recorded amount of long-term debt and the corresponding fair value as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$4,158.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4,000.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The fair value of long-term debt was determined based upon inputs other than quoted prices, otherwise known as Level 2 inputs.</span></div> 1552000000.0 1050000000.0 4033900000 4158400000 4158500000 4000100000 Quarterly Financial Information (Unaudited)<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except per share amounts)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">First</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Second</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,392,452</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,319,602</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,239,265</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,637,802</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,589,121</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,297,580</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,424,756</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,231,239</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,184,737</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,138,312</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distribution, selling, and administrative expenses; depreciation; and amortization </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>779,085</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>751,802</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>764,539</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>830,489</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,125,915</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee severance, litigation, and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,389</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,006</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>174,407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>330,474</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impairment of long-lived assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>570,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>570,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>477,823</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,565</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>406,694</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,841</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,111,923</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (b)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>391,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,073</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>302,002</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132,307</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>854,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to AmerisourceBergen Corporation (b)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>393,652</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,135</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>301,959</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>855,365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Earnings per share operations:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.84</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:18px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">__________________________________________________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The first, second, third, and fourth quarters of the fiscal year ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> include gains from antitrust litigation settlements of </span><span style="font-family:inherit;font-size:10pt;"><span>$87.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$52.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The first, second, and third quarter of the fiscal year ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> include LIFO credits of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$66.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$9.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The fourth quarter of the fiscal year ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> includes LIFO expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$57.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. The first, second, third, and fourth quarters of the fiscal year ended September 30, 2019 include PharMEDium remediation costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$12.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$11.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$6.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The first quarter of the fiscal year ended September 30, 2019 includes a </span><span style="font-family:inherit;font-size:10pt;"><span>$22.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> reversal of a previous estimate of our liability under the New York State Opioid Stewardship Act.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The first quarter of the fiscal year ended September 30, 2019 includes a </span><span style="font-family:inherit;font-size:10pt;"><span>$37.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> income tax benefit adjustment to the one-time transition tax on historical foreign earnings and profits through December 31, 2017. The second quarter of the fiscal year ended September 30, 2019 includes a gain on the sale of an equity investment of </span><span style="font-family:inherit;font-size:10pt;"><span>$13.7 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except per share amounts)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">First </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Second </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,466,332</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,033,858</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,142,309</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,297,136</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167,939,635</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,112,652</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,255,683</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,211,341</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,032,641</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,612,317</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distribution, selling, and administrative expenses; depreciation; and amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>663,658</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>736,814</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>746,593</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>778,363</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,925,428</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee severance, litigation, and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,021</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,449</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,553</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,497</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183,520</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill impairment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,684</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,684</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>418,973</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>481,420</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>389,195</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154,097</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,443,685</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (b)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>861,853</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,160</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,875</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194,004</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,615,892</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to AmerisourceBergen Corporation (b)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>861,853</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>287,455</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>275,809</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>233,288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,658,405</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Earnings per share operations:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">__________________________________________________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The second and third quarters of the fiscal year ended September 30, 2018 include gains from antitrust litigation settlements of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$35.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The third quarter of the fiscal year ended September 30, 2018 includes a LIFO credit of </span><span style="font-family:inherit;font-size:10pt;"><span>$16.1 million</span></span><span style="font-family:inherit;font-size:10pt;">. The fourth quarter of the fiscal year ended September 30, 2018 includes LIFO expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$83.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. The second, third, and fourth quarters of the fiscal year ended September 30, 2018 include PharMEDium remediation costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$22.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$12.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$26.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The fourth quarter of the fiscal year ended September 30, 2018 includes a </span><span style="font-family:inherit;font-size:10pt;"><span>$22.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> estimate of our liability under the New York State Opioid Stewardship Act.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(b)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The first quarter of the fiscal year ended September 30, 2018 includes a loss on early retirement of debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$23.8 million</span></span><span style="font-family:inherit;font-size:10pt;">. The second quarter of the fiscal year ended September 30, 2018 includes a </span><span style="font-family:inherit;font-size:10pt;"><span>$42.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss on consolidation of equity investments and a </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> impairment of a non-customer note receivable. The first and fourth quarters of the fiscal year ended September 30, 2018 included discrete income tax benefits recognized in connection with the 2017 Tax Act of </span><span style="font-family:inherit;font-size:10pt;"><span>$587.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$25.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except per share amounts)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">First</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Second</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,392,452</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,319,602</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,239,265</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,637,802</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,589,121</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,297,580</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,424,756</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,231,239</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,184,737</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,138,312</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distribution, selling, and administrative expenses; depreciation; and amortization </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>779,085</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>751,802</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>764,539</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>830,489</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,125,915</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee severance, litigation, and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55,389</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60,006</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>174,407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>330,474</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impairment of long-lived assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>570,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>570,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>477,823</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47,565</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>406,694</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,841</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,111,923</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (b)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>391,753</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,073</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>302,002</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132,307</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>854,135</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to AmerisourceBergen Corporation (b)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>393,652</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27,135</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>301,959</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>855,365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Earnings per share operations:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.64</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.07</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.84</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:18px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">__________________________________________________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The first, second, third, and fourth quarters of the fiscal year ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> include gains from antitrust litigation settlements of </span><span style="font-family:inherit;font-size:10pt;"><span>$87.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$52.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$3.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The first, second, and third quarter of the fiscal year ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> include LIFO credits of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$66.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$9.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The fourth quarter of the fiscal year ended September 30, </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> includes LIFO expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$57.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. The first, second, third, and fourth quarters of the fiscal year ended September 30, 2019 include PharMEDium remediation costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$12.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$11.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$6.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The first quarter of the fiscal year ended September 30, 2019 includes a </span><span style="font-family:inherit;font-size:10pt;"><span>$22.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> reversal of a previous estimate of our liability under the New York State Opioid Stewardship Act.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(b)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The first quarter of the fiscal year ended September 30, 2019 includes a </span><span style="font-family:inherit;font-size:10pt;"><span>$37.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> income tax benefit adjustment to the one-time transition tax on historical foreign earnings and profits through December 31, 2017. The second quarter of the fiscal year ended September 30, 2019 includes a gain on the sale of an equity investment of </span><span style="font-family:inherit;font-size:10pt;"><span>$13.7 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal Year Ended September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except per share amounts)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">First </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Second </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Third</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fourth</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fiscal</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,466,332</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41,033,858</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,142,309</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,297,136</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167,939,635</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,112,652</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,255,683</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,211,341</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,032,641</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,612,317</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distribution, selling, and administrative expenses; depreciation; and amortization</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>663,658</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>736,814</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>746,593</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>778,363</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,925,428</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee severance, litigation, and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,021</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37,449</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,553</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,497</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183,520</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill impairment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,684</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59,684</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>418,973</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>481,420</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>389,195</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>154,097</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,443,685</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (b)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>861,853</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,160</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277,875</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194,004</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,615,892</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income attributable to AmerisourceBergen Corporation (b)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>861,853</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>287,455</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>275,809</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>233,288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,658,405</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Earnings per share operations:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.08</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.61</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.07</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:12px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">__________________________________________________________</span></div> 45392452000 43319602000 45239265000 45637802000 179589121000 1297580000 1424756000 1231239000 1184737000 5138312000 779085000 751802000 764539000 830489000 3125915000 40672000 55389000 60006000 174407000 330474000 0 570000000 0 0 570000000 477823000 47565000 406694000 179841000 1111923000 391753000 28073000 302002000 132307000 854135000 393652000 27135000 301959000 132619000 855365000 1.86 0.13 1.44 0.64 4.07 1.84 0.13 1.43 0.63 4.04 87300000 52000000.0 3500000 3100000 -3000000.0 -66800000 -9900000 57200000 17900000 12300000 11700000 6700000 -22000000.0 -37000000.0 13700000 40466332000 41033858000 43142309000 43297136000 167939635000 1112652000 1255683000 1211341000 1032641000 4612317000 663658000 736814000 746593000 778363000 2925428000 30021000 37449000 75553000 40497000 183520000 0 0 0 59684000 59684000 418973000 481420000 389195000 154097000 1443685000 861853000 282160000 277875000 194004000 1615892000 861853000 287455000 275809000 233288000 1658405000 3.95 1.31 1.26 1.08 7.61 3.90 1.29 1.25 1.07 7.53 300000 35600000 -16100000 83500000 22500000 12000000.0 26600000 22000000.0 -23800000 42300000 30000000.0 -587600000 -25000000.0 <div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:665px;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:325px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:67px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:67px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:67px;"/><td style="width:4px;"/><td style="width:5px;"/><td style="width:9px;"/><td style="width:67px;"/><td style="width:4px;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">of Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Charged to</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Costs and</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Expenses (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions-</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Describe (2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">End of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Period (3)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended September 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowances for returns and doubtful accounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,049,901</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,720,642</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,546,656</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,223,887</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowances for returns and doubtful accounts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,068,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,397,562</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,415,912</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,049,901</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended September 30, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowances for returns and doubtful accounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>926,034</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,157,960</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3,015,743</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,068,251</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">__________________________________________________________</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Represents the provision for returns and doubtful accounts.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Represents reductions to the returns allowance and accounts receivable written off during year, net of recoveries.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(3)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Includes an allowance for doubtful accounts for long-term accounts receivable within Other Assets on the Consolidated Balance Sheets of </span><span style="font-family:inherit;font-size:10pt;"><span>$981 thousand</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$13,568 thousand</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$17,890 thousand</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div> 1049901000 3720642000 3546656000 1223887000 1068251000 3397562000 3415912000 1049901000 926034000 3157960000 3015743000 1068251000 981000 13568000 17890000

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